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This thesis is primarily concerned with the pathological remodelling of 
calcium homeostasis and signalling in murine Alzheimer’s disease (AD) 
models, namely the 3xTg-AD (APPSWE/PS1M146V/TauP301L) mouse and 
TgF344-AD (APPSWE/PS1∆E9) rat models.  
The majority of data contained herein was amassed from calcium 
imaging of primary neuronal hippocampal cultures. The development of a 
new protocol for the primary culture of mouse hippocampal neurons also 
represents a major research output of this thesis (Kaar et al., 2017). In 
addition to simplifying and optimising each facet of the culturing process, we 
identified the mechanical dissociation of hippocampal tissue (trituration) as 
the critical factor in determining the success or otherwise of culture 
preparations. Furthermore, we demonstrated that successful primary mouse 
hippocampal cultures could be prepared without the need for specialised and 
expensive proprietary supplements which many researchers in the field 
propose as being essential for this purpose. As such, this method fills a niche 
in the current published literature where efficient, cost-effective and succinct 
methods for postnatal mouse cultures are lacking. 
Calcium imaging experiments were predominately conducted using 
cultures produced from three to 6-day-old mice and rats. In using animals at 
such a young age it is thought that any observed calcium dysregulation may 
reflect early pathological or perhaps even initiating AD events. In line with the 
“Calcium hypothesis of Alzheimer’s disease” (Berridge, 2010), this research 
points to cellular Ca2+ remodelling in terms of both basal Ca2+ levels and 
Ca2+ signalling as an early pathogenic event in AD. In particular, we have 
studied how the main neuronal calcium store, the endoplasmic reticulum 
(ER), functions in both maintaining calcium homeostasis and mediating 
intracellular signalling processes, and how these functions might be 
disrupted in AD. Using calcium imaging, group 1 metabotropic glutamate 
receptor (I-mGluR)-mediated somatic responses were measured under basal 
conditions and also under conditions where the ER was ‘preloaded’ with 
calcium (using a depolarising stimulus (15mM K+) which, we propose, mimics 
a ‘learning event’ in the hippocampus). In non-transgenic neurons from both 
murine models, I-mGluR activation combined with the loading stimulus-
evoked enhanced Ca2+ signals relative to I-mGluR activation alone. In 
contrast, enhanced calcium responses were not observed in 3xTg-AD mouse 
hippocampal neurons, suggesting a loss of this signalling function. Notably 
however, under basal conditions, we did observe significantly larger 
responses to I-mGluR activation as well as attenuated SOCE in 3xTg-AD 
neurons suggesting a pathological increase in resting ER calcium levels in 
these neurons relative to controls. Furthermore, in TgF344-AD neurons, 





compared with non-Tg controls. The fact that such stark alterations in 
calcium homeostasis and signalling were observed in neurons from 3xTg-AD 
mice at such a young age (≤6 days), suggests that calcium dysregulation 
may occur at a much earlier stage in the disease progression than previously 
thought and appear to greatly precede the appearance of Aβ or tau 
pathology. 
The third major theme of this thesis involved identifying the 
downstream signalling cascade(s) involved in I-mGluR activation. The 
classical understanding of I-mGluR activation involves phospholipase C β 
(PLCβ)-mediated production of IP3 and Ca2+ release from the ER via the IP3 
receptors (IP3R). However, we show here that a significant contribution 
(approximately 10 - 40%) of I-mGluR mediated Ca2+ mobilisation from the 
ER is in fact mediated by the second messenger, cyclic ADP-ribose 
(cADPR), which culminates in RyR-mediated Ca2+ release. Furthermore, the 
relative contribution of both PLCβ/IP3R and cADPR/RyR pathways to overall 
I-mGluR elicited signals is altered in transgenic neurons of both murine 
models. 
Finally, the expression of key calcium toolkit components including 
relative IP3R and RyR isoform expression, as well as the expression of Bcl-2 
and Bcl-XL, which modulate ER Ca2+ release channel function, was 
determined in hippocampal tissue from 5-, 15- and 21-day-old 3xTg-AD 
mice. It was found that there was a trend towards decreased expression of 
Bcl-2 and Bcl-XL and a trend towards increased expression of RyR and IP3R1 
with development (P5 vs P15 and P5 vs P21) regardless of transgenic 
status, however, this was significant solely in 3xTg-AD tissue and only in the 
case of Bcl-2, Bcl-XL and RyR (2) expression (and generally, solely at the 
latest stage of development tested, P21).   
In summary, the work set out in this thesis investigates neuronal Ca2+ 
homeostasis and I-mGluR/ER signalling as well as relevant protein 
expression with a particular focus on possible AD-mediated dysregulation of 
these processes. Lastly, the method of primary hippocampal culture, the 
sources of experimental units from which this data has been accrued has 





1. General introduction 
1.1. Alzheimer’s disease 
According to the ‘World Alzheimer Report 2015’ by Alzheimer’s 
Disease International the number of individuals worldwide aged 60 years and 
older will increase from the current figure of approximately 895 million to 
2022 million by 2050, a trend that is mainly fuelled by increases in average 
life expectancy in the developing world. Unfortunately, as average life 
expectancy increases so too does the prevalence of age-related diseases 
such as dementia. There were an estimated 47 million people worldwide with 
dementia in 2015, with an associated cost of US$ 818 billion (1.09% of 
global GDP). Worryingly, the number of individuals affected by dementia is 
projected to increase to 131.5 million individuals by 2050. As an indication of 
the situation in the developed world, conservative estimates predict that 5.4 
million people suffer from the most prevalent form of dementia, Alzheimer’s 
disease (AD), in the US alone, where it is currently the sixth leading cause of 
death. These figures are projected to increase to 13.8 million by 2050, 
fuelled in large part by the ageing baby boom generation (Alzheimer’s 
Association, 2016). As such, AD, is set to become one of the major public 
health concerns facing mankind in the 21st century and therefore the need for 
research into the underlying causes of the condition is more imperative than 
ever. 
AD is an inexorably progressive neurodegenerative disorder 
characterised phenotypically by progressive memory and behavioural 
impairments, and histopathologically by both the progressive deposition of 
extracellular amyloid β (Aβ) protein plaques, formed from the polymerization 
of Aβ proteins and the formation of intracellular neurofibrillary tangles 
(NFTs), consisting of hyperphosphorylated, proteolysis-resistant, aggregates 
of tau protein (Buée et al., 2000; Gendron and Petrucelli, 2009). Chronic 
neuroinflammation and frank neuronal loss, particularly in the hippocampus 
and neocortical regions of the brain, complete the disease profile (Querfurth 
and LaFerla, 2010). 
The first neuropathological changes of AD present in regions of the 
brain primarily associated with the acquisition of new memories, namely, the 
hippocampus and entorhinal cortex, and subsequently, the medial temporal 
lobe (Belleville et al., 2008; Reitz et al., 2009; Small et al., 2011). This likely 
explains the corresponding early effects of the disease, which primarily 
impair anterograde episodic memory (Ally et al., 2013; Collie and Maruff, 
2000; Selkoe, 2002). The condition spreads out to affect the neocortex in 
later stages of the disease, whilst initially affected regions worsen and 
massive neuronal cell death becomes evident, with a concurrent 





AD is somewhat arbitrarily divided into two subtypes: sporadic/late-
onset AD (LOAD) and early-onset AD (EOAD), based upon the respective 
ages of their clinically diagnosed onset. However, both types are positively 
associated with a family history of AD. The majority of cases (~ 95%) are 
classified as LOAD, which presents after 60 - 65 years (Bertram and Tanzi, 
2004a). As the name implies, EOAD is diagnosed earlier than LOAD, at 30 - 
60 years of age, and accounts for 1 – 6% of all cases. Of these, early onset 
familial AD (EOFAD), where there are multiple cases of AD within families, 
accounts for approximately 60% of cases, whilst 13% of EOFAD cases are 
inherited in an autosomal dominant manner, with at least three generations 
affected. This autosomal dominant inheritance pattern is due to mutations in 
either amyloid precursor protein (APP; on chromosome 21), presenilin 1 
(PS1; on chromosome 14) or presenilin 2 (PS2; on chromosome 1; Campion 
et al., 1999). Complicating matters further, EOAD can also occur in families 
with a history of LOAD (Brickell et al., 2006). 
Aside from these autosomal dominant cases which I will return to later 
in this Introduction, AD is generally thought to be due to the complex 
interaction of environmental and lifestyle factors combined with multiple 
susceptibility genes (Bekris et al., 2010; Bertram and Tanzi, 2004b; Kamboh, 
2004; Roses, 2006; Serretti et al., 2005). Furthermore, it has been proposed 
that approximately 60 – 80% of ‘sporadic’ AD cases may, in fact, be 
genetically determined (Gatz et al., 2006), with each of the following three 
genetic ‘risk factors’ thought to contribute significantly to this genetic 
component of LOAD (Harold et al., 2009; Lambert et al., 2009): a) 
inheritance of the ε4 allele of the polymorphic apolipoprotein E (ApoE4) gene 
(chromosome 19; Coon et al., 2007; Roses et al., 1995) which results in less 
efficient breakdown and clearance of Aβ proteins (Liu et al., 2013), b) 
mutations in Triggering Receptor Expressed on Myeloid cells 2 (TREM2), 
which regulates microglial removal of Aβ (Colonna and Wang, 2016; 
Guerreiro et al., 2013; Neumann and Daly, 2013; Yaghmoor et al., 2014)), 
and c) mutations in Clusterin (CLU/APoJ), which affects Aβ processing, 
inflammation and apoptosis (Woody and Zhao, 2016).  
The various hypotheses outlined in this general introduction to AD all 
attempt to explain the onset and progression of AD in the context of either Aβ 
proteins, Ca2+ dysregulation, tau pathology, mitochondrial impairment, 
oxidative stress and/or neuroinflammation. In reality, although establishing 
earlier versus later events in disease pathology is important for treatment 
development, focussing on any single one of these hypotheses fails to 
acknowledge the full breadth of the disease pathology. As such, it is likely 
that single or multiple components described by each of these hypotheses 
interact in a highly complex and feed forward manner to propagate the 





1.2 APP and the amyloid β cascade hypothesis 
1.2.1 APP 
APP is a type 1 transmembrane (TM) glycoprotein, with three 
isoforms: APP695 (neuron-specific isoform), APP751 and APP770 encoded for 
by an APP gene on chromosome 21 (Sandbrink et al., 1996). It consists of a 
long N-terminal ectodomain, a TM domain (within which an Aβ sequence is 
partly embedded) and a short C-terminal domain (Muller et al., 2017). APP 
expression is detectable from embryonic day 7.5 in mice (Ott and Bullock, 
2001) and expression of APP mRNA and proteins in adult rodents is 
ubiquitous (Lorent et al., 1995; Slunt et al., 1994). In the CNS, APP is 
abundantly expressed in neurons (Guo et al., 2012) which predominantly 
express the APP695 isoform (Gralle and Ferreira, 2007). APP is expressed 
particularly strongly in cortical and hippocampal excitatory neurons and in 
inhibitory gamma-aminobutyric acid (GABA)ergic interneurons (Hick et al., 
2015; Wang et al., 2014). The mammalian APP family consists of APP 
(ubiquitously expressed), the APP-like proteins (APLP) 1 (nervous system-
specific expression) and APLP 2 (ubiquitously expressed; Lorent et al., 1995; 
Slunt et al., 1994), which are all enriched at the pre-synaptic active zones 
(Laßek et al., 2013). Aside from neuronal cells, in vitro experiments indicate 
that all three APP isoforms are also expressed in microglia and astrocytes 
(LeBlanc et al., 1991). However, in vivo glial APP expression has not been 
detected (Guo et al., 2012).  
APP is synthesised in the endoplasmic reticulum (ER) and transported 
by the Golgi secretory apparatus to the trans-Golgi-network (TGN) and on to 
the plasma membrane (PM; Jiang et al., 2014). The canonical pathway of 
APP processing is carried out by α-, β- and ƴ-secretases. However, the 
cellular localisation of APP metabolism is not definite, although it appears to 
occur primarily within the ER/Golgi/TGN (Greenfield et al., 1999), the 
endolysosomal system (Haass et al., 1993a, 1993b), as well as at the PM 
(Sisodia, 1992; Fig 1.2).  
APP has wide-ranging physiological functions and numerous modes 
of action. It is beyond the scope of this thesis to describe these in detail (for 
reviews see Dawkins and Small, 2014; Müller and Zheng, 2012). Briefly, 
however, APP is known to function as both a cell surface receptor and as a 
ligand which can mediate its effects either by activating downstream 
signalling cascades or via active proteolytic fragments such as soluble APP 
fragment-α (APPsα; see below for APPsα production in the non-
amyloidogenic pathway; Muller et al., 2017). 
APP knockout (KO) mice are viable but exhibit abnormalities 
including: reactive gliosis (Burda and Sofroniew, 2014; Pekny and Pekna, 





potentiation (LTP) as well as impaired cognitive function and locomotion 
(Dawson et al., 1999; Zheng et al., 1995). Interestingly, solely expressing the 
APP metabolite APPsα in these mice can rescue these abnormalities, 
suggesting it is the primary APP effector under normal physiological 
circumstances (Ring et al., 2007).  
 
1.2.2 Amyloid β cascade hypothesis 
The central tenet of the Aβ hypothesis is that alterations in the 
processing of APP, leading to the abnormal accumulation of Aβ into Aβ 
oligomers (Aβo), insoluble fibrils and plaques and/or alterations in its 
degradation and clearance, are responsible for the onset of AD (Selkoe and 
Hardy, 2016). In addition to the deposition of Aβ plaques in AD patients’ 
brains, the strongest argument in support of the Aβ hypothesis of AD 
remains the correlation between AD susceptibility genes and Aβ production 
(Tanzi and Bertram, 2005). In this regard, there are currently 24 known 
associated pathogenic mutations of APP, which have been identified in 
several families across the world. These mutations include missense 
mutations which code for amino acid substitutions flanking, or within, the Aβ 
encoding region of APP. Most of these are near the γ-secretase cleavage 
site but there is one known double mutation which flanks the β-secretase 
site, known as the Swedish mutation (APPSWE; cleavage at both sites are 
part of the amyloidogenic processing of Aβ, as explained in Section 1.2.3 
APP processing) which is one cause of autosomal dominant EOFAD (Selkoe 
and Schenk, 2003). This APPSWE mutation is expressed in both the 3xTg-AD 
(APPSWE/PS1M146V/TauP301L) mouse and TgF344-AD (APPSWE/PS1∆E9) rat 
model of AD, both of which have been examined for the work presented in 
this thesis. Generally, these mutations either increase the overall amount of 
Aβ production or the ratio of Aβ42, the more toxic form of Aβ highly implicated 
in neuronal dysfunction, to Aβ40 (Cacace et al., 2016). Notably, in Down 
syndrome (DS) where chromosome 21 is partially or fully triplicated (which is 
why it is also known as Trisomy 21), if this triplication includes the APP gene 
region it almost inevitably results in those individuals developing AD-like 
symptoms and pathology (Margallo-Lana et al., 2004; Rumble et al., 1989). 
This DS-related AD pathology occurs 20 to 30 years earlier than in the non-
DS population (Wisniewski et al., 1985) and almost all adults over 40 with DS 
display AD neuropathology (Menéndez, 2005). The Aβ hypothesis of AD is 
further supported by the relatively recent discovery of the APPA673T mutation 
in an Icelandic population. This mutation, rather than causing AD, actually 
seems to confer an ‘immunity’ against the development of the disease as 





Although I have only provided a ‘snapshot’ here of the research 
implicating the role of APP in AD pathogenesis, this cascade has been the 
primary focus of AD research for the last 15 years (Hardy and Higgins, 1992; 
Selkoe and Hardy, 2016). As such, a large body of evidence on the 
pathological profile of APP metabolites has been generated from both human 
patients and animal models, a summary of which is provided in Section 1.2.6 
Molecular actions of Aβ. 
 
1.2.3 APP processing 
APP undergoes extensive and complex proteolytic processing, 
resulting in numerous biologically active fragments with specific and even 
opposing functions. The so-called non-amyloidogenic and amyloidogenic 
pathways comprise the canonical APP processing pathway and involve the 
sequential activity of α- and β-secretase, respectively, followed by y-
secretase activity. The δ- and η-pathways, meprin-β cleavage and caspase 
cleavage comprise non-canonical APP processing (Fig 1.1 Muller et al., 
2017). It is important to note that all of these APP processing pathways exist 
in normal healthy individuals throughout life such that Aβ proteins are 
detectable in the plasma and cerebrospinal fluid (CSF) of healthy individuals 
as well as those with AD (Selkoe and Schenk, 2003).  
APP is either cleaved at the PM by secretases or un-cleaved/partially 
cleaved APP (as well as secretases) are internalised within clathrin-coated 
vesicles where they are expressed throughout both early and late 
endosomes and the lysosome recycling system (Caporaso et al., 1994; 
Nordstedt et al., 1993). A fraction of the internalised APP is also recycled to 
the PM or retrieved back to the TGN. As such, the PM pool of APP reflects 
its secretion, internalisation and the efficiency of secretases (Jiang et al., 
2014). In overexpression studies, APP is found targeted to the endosome 
(primarily) and TGN, as well as the plasma membrane (Huse et al., 2000; 
Vassar et al., 1999; Walter et al., 2001). The components required for APP 
processing, including secretases and APP as well as the products of 
processing, including Aβ, are expressed throughout these intracellular 






Figure 1.1. APP processing  
APP can undergo canonical (a) and/or non-canonical (b) processing.  
a) Canonical processing involves either the non-amyloidogenic or amyloidogenic pathway. In the non-amyloidogenic pathway 
APP is sequentially processed by 𝛼-secretase (cutting in the Aβ region of APP) and the γ-secretase complex to form what are 
generally considered non-toxic APPsα, p3 and AICD. In the amyloidogenic pathway APP is sequentially processed by β-
secretase and the γ-secretase complex forming substances implicated in AD such as Aβ40 and Aβ42 monomers, sAPPβ and AICD. 
b) Non-canonical processing. It is proposed that δ-, meprin-β and caspase cleavage also produce toxic Aβ monomers and 
oligomers. One identified function of non-canonical APP processing is the production of AICD via δ-, meprin-β and caspase-
cleavage. Caspase cleavage can also, possibly in an isoform-specific manner, cleave within the AICD region of CTF to form the 
fragment C31 and leave a membrane bound fragment CTFα/β∆C31. This fragment is, in turn, cleaved by γ-secretase to form 
Jcasp and possibly toxic Aβ.  









Figure 1.2. APP trafficking and flux 
Newly synthesised APP, α-secretase, BACE1 (β-secretase) and γ-secretase are transported through the secretory pathway from 
the ER to the Golgi/TGN and from there to the plasma membrane (PM). This is counterbalanced by protein turnover and 
retrograde transport mechanisms directing proteins back to the PM or to the TGN. Non-amyloidogenic processing of APP 
(releasing soluble APP metabolite α (sAPPα/APPsα)) is thought to occur primarily at the PM. Conversely, un-cleaved/partially 
cleaved APP, as well as secretases, can undergo endocytosis and be expressed on early and late endosomes and lysosomes. 
Although toxic Aβ monomers can be produced in the majority of locations that APP flux occurs through, it is in these acidic 
endosomes/lysosomes where β-secretase activity is optimal and therefore amyloidogenic processing primarily occurs.  






Although toxic Aβ monomers can be produced in the majority of 
locations that APP flux occurs, including the PM, it is in acidic organelles of 
the endolysosomal system (particularly early endosomes (Das et al., 2015)) 
where β-secretase activity is optimal and therefore where amyloidogenic 
processing primarily takes place (Jiang et al., 2014; Tarassishin et al., 2004). 
Any AD-mediated redistribution of β- or γ-secretase which favours co-
expression with APP in suitable organelles could increase Aβ generation 
(Zhang et al., 2011). The cleavage of APP by β-secretase is a critical rate-
limiting step in Aβ production. Interestingly, the ‘Icelandic’ APP mutation 
mentioned earlier greatly attenuates APP-β-secretase interactions (Das et 
al., 2015). The endocytosis of APP and β-secretase to the early endosome is 
spatially segregated via targeted sorting. Manipulation of this process can 
decrease their interaction in early endosomes and therefore modulate APP 
processing and Aβ production (HeLa cells; (Sannerud et al., 2011). Neuronal 
activity is known to induce convergence of APP and β-secretase in recycling 
endosomes (Das et al., 2015, 2013) which may link the early-stage AD 
phenotypes of neuronal excitotoxicity and network hyperexcitability with Aβ 
production (Palop et al., 2007). That being said, neuronal and synaptic 
activity, including N-methyl-D-aspartate receptor (NMDAR) activation, which 
is critical for mediating forms of LTP and long-term depression (LTD; 
molecular models of learning), also stimulate the non-amyloidogenic pathway 
(Hoe et al., 2012; Hoey et al., 2009). It is possible that the latter occurs in a 
manner which is below the threshold for the induction of amyloidogenic 
processes. 
Non-amyloidogenic APP processing 
The non-amyloidogenic processing of APP occurs as a result of α-
secretase cleavage of APP. These particular -secretases appear to be 
primarily PM-bound endoproteases (Sisodia, 1992) which cleave APP at a 
point in the Aβ domain of the molecule, ensuring APP metabolism without 
the formation of β-amyloids. This proteolysis also releases the secreted 
ectodomain segment of APP, APPsα, whilst leaving a carboxy-terminal 
fragment-α (CTFα/C83; Zhang et al., 2011). It is notable that, amongst other 
activities, APPsα attenuates neuronal excitability by altering intracellular 
calcium ([Ca2+]i) responses to stimuli such as glutamate (see Section 1.2.6 
Molecular Actions of APP metabolites; Barger et al., 1995; Furukawa et al., 
1996a, 1996b; Hooper, 2005; Mattson, 1994). The other non-amyloidogenic 
pathway product, CTFα, is further hydrolysed in a series of cleavage events 
by the γ-secretase complex. Endoproteolytic ε-cleavage (near the 
cytoplasmic membrane boundary of APP) releases an APP intracellular 
domain metabolite (AICD/CTFγ), whilst sequential exoproteolytic cuts 
towards the N-terminus, termed y-cleavage, produce metabolites including 
P3 (also called P83) produced by a cut in the middle of the membrane 





degraded, has no established physiological function and does not assemble 
into stable oligomer formations which are synonymous with AD (Dulin et al., 
2008). 
The γ-secretase complex is composed of four integral membrane 
proteins; presenilins (PS1/PS2), nicastrin - a PS cofactor and scaffolding 
protein, which may have a role as an APP receptor for the complex (Luo et 
al., 2003), anterior pharynx defective 1 (APH-1) - implicated in γ-secretase 
complex assembly (Kimberly et al., 2003) and presenilin enhancer-2 (PEN-2) 
- which regulates PS endoproteolysis (Ahn et al., 2010) and genetic 
knockdown of which, is associated with increased ER calcium leak (therefore 
PEN-2 may have a role in regulating PS-mediated Ca2+ leak, discussed in 
Section 1.4 The Ca2+ hypothesis of AD; Bandara et al., 2013; Edbauer et al., 
2003; Kimberly et al., 2003; Takasugi et al., 2003). Whilst this enzyme 
complex is located primarily within the ER/Golgi/TGN network as well as the 
endocytic and intermediate compartments, γ-secretase cleavage of APP 
occurs primarily within the TGN and early endosomal domains (Cupers et al., 
2001; Kovacs et al., 1996).  
Amyloidogenic APP processing 
Processing of APP via the amyloidogenic pathway (Fig 1.1) involves 
its sequential cleavage by β- and γ-secretases, generating Aβ proteins which 
have become synonymous with AD pathology (Mattson, 2004, Shirwany et 
al., 2007).  
APP is hydrolysed by β-secretase resulting in the shedding of the N-
terminal soluble APP fragment-β (APPsβ), leaving a C-terminal fragment β 
(CTFβ/C99) on the endosomal membrane (Fig 1.1). The endogenous β-
secretases are beta-site APP cleaving enzyme (BACE) 1 and BACE2, of 
which BACE1 is more widely implicated in this process (Cai et al., 2001; Luo 
et al., 2001). For example, in transgenic mouse models of AD involving APP- 
overexpressing APPSWE mice (3 - 4-months-old) and 5xTg-AD mice 
APPSWE/I716V/V717I /PS1M146L/L286V (15 -18-months-old), BACE1 KO rescues 
cholinergic dysfunction, neuronal loss and memory deficits with 
corresponding near removal of the β-secretase metabolites Aβ40 and Aβ42 
(Luo et al., 2001; Ohno et al., 2007, 2004). Furthermore, BACE1 protein and 
activity were increased relative to healthy controls in the temporal and frontal 
cortex and hippocampal regions in human AD patients (Fukumoto et al., 
2002; Tyler et al., 2002; Yang et al., 2003). 
Following β-secretase cleavage, the γ-secretase complex further 
cleaves CTFβ in a sequential manner similar to the cleavage of CTFα. ε-
cleavage again produces AICD, whilst y-cleavage releases either monomeric 
Aβ40 (majority) or Aβ42 (minority; Suh and Checler, 2002).γ-secretase-





residues (Nunan and Small, 2000) via ζ-site (Aβ46; G. Zhao et al., 2004) and 
ε-site (Aβ49) cleavage (Sastre et al., 2001). It is well known that APPsβ, 
AICD and Aβo (especially Aβ42), as well as Aβ fibril and plaque formation, 
play significant roles in AD-associated neurodegeneration (Berridge, 2010). 
Indeed, these molecules are the primary focus of AD research in this area 
and will be discussed in more detail in subsequent sections. 
The production of AICD, previously ascribed solely to γ-secretase 
activity, may also be generated through non-canonical APP processing (Fig 
1.1), via δ-, meprin-β and/or caspase-cleavage (predominately caspase-3 
(Gervais et al., 1999)). Furthermore, whilst research into the non-canonical 
pathway is still in its relative infancy, δ- and meprin-β cleavage have also 
been implicated in AD pathogenesis (Andrew et al., 2016; Jefferson et al., 
2011) and can also produce toxic Aβ monomers and Aβos (Muller et al., 
2017). Aside from Aη, which attenuates neuronal activity (Willem et al., 
2015), the physiological roles of these cleavage mediators are currently 
unknown (Muller et al., 2017). 
Caspase cleavage, the most well characterised non-canonical 
pathway cleavage enzyme, cleaves CTFα/β at Asp664 (within the AICD 
region) yielding a C31 fragment (Fig 1.1; (Lu et al., 2003), which is implicated 
in neuronal apoptosis (Nhan et al., 2015). However, caspase cleavage has 
been implicated in both AICD production (Gervais et al., 1999) and AICD 
proteolysis (Lu et al., 2003; Muller et al., 2017), possibly in a caspase 
subtype-specific manner (Harada and Sugimoto, 1999; Marín et al., 2000; Y. 
J. Park et al., 2014; Sáez-Valero et al., 2000). A Jcasp fragment composed 
of residues located between caspase- and γ-secretase cleavage sites on 
APP is also produced via this pathway (Park et al., 2009). Jcasp fragments 
may act to inhibit pre-synaptic transmitter release via interactions with, and 
sequestering of, molecules involved in vesicle release (Fanutza et al., 2015). 
Importantly, Aβ induces caspase cleavage of APP and production of C31, 
creating an apoptosis-promoting feed-forward cycle (Lu et al., 2003; Marín et 
al., 2000). Indeed, mutation of APP at the caspase cleavage site rescues 
electrophysiological impairments, synaptic loss, dentate gyrus atrophy and 
behavioural abnormalities in APPSWE/V717F mice, despite the presence of 
Aβos and plaques(Galvan et al., 2006). It is unknown, however, whether or 
not caspase cleavage ultimately affects the production of Aβo (Gervais et al., 
1999; Soriano et al., 2001). 
In healthy individuals, Aβ formation through the amyloidogenic pathway is 
usually balanced either by its subsequent degradation, primarily by the 
enzyme neprilysin and insulin-degrading enzyme (IDE; Hersh & Rodgers, 
2008), and/or its extrusion from the brain, primarily via the efflux transporters 
LDLRs, particularly the low-density lipoprotein receptor-related protein 1 





main influx transporter is the advanced glycosylation end product-specific 
receptor (RAGE). Aβ accumulation and toxic insult, therefore, reflect an 
imbalance in the ratio of production to degradation and/or clearance 
mechanisms (Murphy and LeVine, 2010; Pearson and Peers, 2006). 
Interestingly, it is suggested that in LOAD, that impaired Aβ degradation, 
rather than increased production, underlies the disease (Saido et al., 2000). 
In support of this, neprilysin levels are decreased in AD brains, particularly in 
regions with high Aβ loads such as the hippocampus (Wang et al., 2003; 
Yasojima et al., 2001). This decreased degradation activity is likely 
exacerbated in AD by increased Aβ transport into the brain as there is a 
lower expression of LRP1 and ABC transporters and overexpression of 
RAGE (Tarasoff-Conway et al., 2015).  
Whilst the majority of Aβ is secreted out of the cell where, in AD, it 
eventually forms Aβ plaques, Aβ molecules spend a significant portion of 
time in intracellular compartments following their production as well as when 
they are internalised and/or targeted for degradation. Under such 
circumstances, Aβ can impair mitochondrial (Zhao et al., 2010) and synaptic 
function (Takahashi et al., 2002) and thus contribute directly to AD pathology 
(Zheng et al., 2012). 
Interestingly, alterations in the flux of APP itself may be involved in AD 
progression. It is thought that PM-localised APP is primarily processed via 
the non-amyloidogenic pathway. Therefore, upregulation of the 
endosomal/lysosomal recycling pathway may encourage amyloidogenic APP 
processing due to optimal β-secretase activity occurring within acidic 
organelles (Jiang et al., 2014; Muller et al., 2017). Two separate AD 
susceptibility genes illustrate the subtleties of subcellular localisations in AD 
pathology. Firstly, sortilin-related receptor 1 (SORL1), which regulates APP 
trafficking and processing, particularly anterograde and retrograde 
movement between TGN and early endosomes, is modulated by ApoE and 
tau (Yin et al., 2015). SORL1 normally functions in a neuroprotective manner 
through its targeting of APP to the recycling pathway. However, alterations in 
SORL1 expression or SORL1 mutation appear to direct APP towards 
amyloidogenic processing (Rogaeva et al., 2007). Secondly, internalisation 
of APP and Aβ can be enhanced by mutations in the gene coding for 
phosphatidylinositol binding, clathrin assembly protein (PICALM), which 
enhances Aβ40 and Aβ42 production (Kanatsu et al., 2014; Xiao et al., 2012). 
ApoE also removes Aβ molecules from the CNS by chaperoning them to 
insulin degrading enzyme (IDE) and/or by enhancing LDL receptor-related 
protein (e.g. SORL1)- mediated endosome recycling (Jiang et al., 2008). 
Increased expression of APP, partly due to the production of interleukin-1 
(IL-1), a mediator in the inflammatory response to AD, may also accelerate 






Inheritance of the ε4 allele of the apolipoprotein ApoE gene is the 
strongest known genetic risk factor for the development of LOAD (Coon et 
al., 2007; Roses et al., 1995). The most likely mechanism for this increased 
risk is due to the fact that ApoE4 expression results in decreases in the 
efficiency of Aβ breakdown and clearance (Liu et al., 2013).  
ApoE expression is highest in the liver, followed by the brain (Vance, 
2012). The highest dynamic concentrations of ApoE are found in non-
neuronal cells, primarily in astrocytes and, to some extent, in microglia 
(Grehan et al., 2001; Pitas et al., 1987). Neurons can also produce ApoE 
under certain conditions, such as in response to excitotoxicity, although it is 
present at much lower levels than in astrocytes (Grehan et al., 2001; Pitas et 
al., 1987; Xu et al., 2006). 
Astrocytes produce and secrete ApoE which acquires cholesterol and 
phospholipids, generating ApoE-containing lipoproteins (Vance, 2012). ApoE 
then functions as a ligand in LDLR family-mediated endocytosis of lipoprotein 
particles (Boyles et al., 1989; Posse De Chaves et al., 2000). Following 
endocytosis, the majority of ApoE is recycled back to the cell surface by 
retro-endocytosis, whilst minor levels of ApoE degradation also occurs 
(Rensen et al., 2000). This process enables the transport of cholesterol 
between astrocytes and neurons (Michikawa et al., 2000; Vance, 2010), 
which is essential for normal neuronal function (Vance, 2012). ApoE 
containing lipoproteins are implicated in synaptogenesis (Mauch et al., 
2001), maintenance of synaptic connections (Pfrieger, 2003) and axonal 
growth (Hayashi et al., 2004) and they prevent neuronal cell death (Hayashi 
et al., 2009). Outside of this specific cholesterol role, however, some ApoE 
receptors also function as signalling receptors (Beffert et al., 2004; Hayashi 
et al., 2007; Herz, 2001). ApoE synthesis is also increased 150-fold in 
response to nerve injury, suggesting a role for ApoE in nerve repair (Comley 
et al., 2011; Ignatius et al., 1986). Notably, ApoE also enhances the 
proteolytic breakdown of Aβ proteins, both within and between cells and thus 
regulates the clearance from and/or aggregation within the CNS of these 
proteins (Liu et al., 2013). 
The human ApoE gene exists as three polymorphic alleles, ε2, ε3 and 
ε4, with a worldwide frequency of 4%, 77.9% and 13.7%, respectively. In the 
sporadic AD population, however, the frequency of the ε4 allele is 
approximately 40% (Farrer et al., 1997). These alleles give rise to ApoE 
isoforms, ApoE2, ApoE2 and ApoE4. These isoforms differ by only one or 
two AAs, but are profoundly different in terms of their structure and function 
(Mahley et al., 2006), including their ability to bind lipids, receptors and Aβ (J. 
Chen et al., 2011; Frieden and Garai, 2012; Zhong and Weisgraber, 2009). 





genetic risk factor for the development of LOAD, whilst inheritance of the ε2 
allele is neuroprotective (Bertram et al., 2007; Corder et al., 1993; Farrer et 
al., 1997; Huang and Mucke, 2012; Strittmatter et al., 1993). For example, 
people with a single or double copy of the ε4 allele have approximately four 
and twelve- times (conservative estimates) the likelihood of developing AD, 
respectively, when compared to those with ε3 allele inheritance (Bertram et 
al., 2007; Guojun Bu, 2009). Inheritance of the ε4 allele is also associated 
with an earlier age of AD onset (Gómez-Isla et al., 1996; Roses, 1996).  
The reason why the ε4 form of ApoE leads to a decrease in the age of 
AD onset and speeds up its progression is likely due to the role that this 
lipoprotein plays in Aβ metabolism. Specifically, ApoE normally serves to 
facilitate Aβ clearance and/or degradation from/within the brain (Sanan et al., 
1994). This is illustrated by the fact that ApoE KO mice exhibited impaired Aβ 
clearance, degenerating nerves (Fagan et al., 1998) and learning deficits 
(Masliah et al., 1995; Veinbergs et al., 1998). It has also been demonstrated 
that increasing ApoE-containing lipoprotein production in the hippocampus 
and cortex of a mouse model of AD (using the retinoid X receptor agonist 
bexarotene) enhanced Aβ degradation, reduced Aβ plaque area and 
improved memory and cognition (Cramer et al., 2012). Specifically, with 
regard to ε4 allele carriers, it is known that they have lower plasma and brain 
ApoE levels (Gupta et al., 2011). This is significant as low levels of ApoE in 
the brain also correlate with an increased risk of developing AD (Bales et al., 
2009). Furthermore, in terms of ApoE4 function, it binds with less avidity to 
Aβ than ApoE3, thereby decreasing the efficiency of Aβ clearance 
(Castellano et al., 2011; Koistinaho et al., 2004; LaDu et al., 1994). 
Furthermore, ApoE2 and ApoE3, but not ApoE4, can form dimers which may 
enhance Aβ degradation (Xue et al., 2011). In support of this suggestion, 
there is increased Aβ deposition in mice expressing the ε4 allele compared 
with ε3 or ε2 (Bales et al., 2009; Castellano et al., 2011). In humans, 
inheritance of the ε4 allele acts to increase the generation and accumulation 
of Aβ proteins, particularly at early/pre-symptomatic AD stages in the cortex 
(Polvikoski et al., 1995), and decrease their removal from cerebrospinal fluid 
(Berridge, 2010). 
Aside from Aβ degradation, the cholesterol-carrying, metabolism and 
homeostatic function of ApoE may also be implicated in AD, in the context of 
Aβ clearance. As mentioned previously, when the ε4 allele is expressed in 
transgenic mice, Aβ clearance mechanisms are inefficient, in comparison to 
those animals expressing ε3 allele (Bien-Ly et al., 2011). Cholesterol levels, 
can also modulate γ-secretase activity and increase Aβ production 
(Osenkowski et al., 2008).  
Polymorphisms in the ApoE receptors, LRP and ApoER2, also appear 





Fryer et al., 2005; Kim et al., 2009b). These receptors function in both ApoE 
mediated endocytosis and signalling pathways (Beffert et al., 2004). 
Furthermore, LRP is involved in the uptake and clearance of Aβ (G. Bu, 
2009). 
ABC transporters, including ABCA1, ABCG1 and/or ABCG4 mediate 
the shuttling of cellular lipid to ApoE which contributes to the formation ApoE-
containing lipoproteins (Vance, 2012). ABCA1 has been linked to AD and to 
the regulation of ApoE and cholesterol homeostasis in the brain (Hirsch-
Reinshagen and Wellington, 2007; Vance, 2010). ABCA1 is required for the 
normal acquisition of lipids by ApoE during lipoprotein assembly (Hirsch-
Reinshagen and Wellington, 2007; Wahrle et al., 2004). Furthermore, 
ABCA1 KO mice exhibited an 80% reduction in ApoE levels, illustrating its 
importance in ApoE homeostasis (Hirsch-Reinshagen and Wellington, 2007; 
Wahrle et al., 2004). Interestingly, when ABCA1 KO mice were crossed with 
mouse models of AD, there was no effect on Aβ production. However, poorly 
lipidated ApoE lipoproteins particles were responsible for an increased Aβ 
load, suggesting, once more, that reduced ApoE function/efficiency is 
involved in reduced brain Aβ clearance in AD (Hirsch-Reinshagen and 
Wellington, 2007; Wahrle et al., 2005). Furthermore, overexpression of 
ABCA1 in transgenic AD mice decreased Aβ deposition (Wahrle et al., 
2008). Interestingly, the effect of ABCA1 may be ApoE isoform-dependent as 
the lack of one copy of ABCA1 resulted in decreased Aβ clearance, 
increased Aβ plaque deposition and memory deficits in mice carrying the ε4 
allele, but not in those carrying the ε3 allele (Fitz et al., 2012). This evidence 
suggests that alterations in the machinery regulating lipid homeostasis are 
involved in the transport, processing and clearance of Aβ proteins.  
More specific roles for ApoE in Aβ removal from the brain involve its 
transport to the systemic circulation across the BBB. ApoE4 impedes this 
process to a greater extent than both ApoE2 and ApoE3 (Deane et al., 
2008). ApoE3 is also more efficient in stimulating microglial-mediated 
degradation of Aβ when compared with ApoE4 (Jiang et al., 2008). ApoE-
lipoprotein particles may also sequester Aβ and promote its cellular uptake 
and degradation (Kim et al., 2009a). Conversely, ApoE4 enhances Aβ 
fibrillogenesis (Bales et al., 2009; Kim et al., 2009a; Liu et al., 2013).  
Thus, it is clear that that isoform-specific expression of ApoE4 is 
strongly implicated in AD pathogenesis. The effects of ApoE4 appear to be 
multi-factorial, although the strongest link connecting it to AD pathology is via 
its involvement in the Aβ cascade. This has important implications for our 
understanding of the genetic component of AD, given that ApoE has such 
diverse effects and that inheritance of the ApoE ε4 allele is the main genetic 







Presenilins (PS) are integral membrane proteins containing nine 
transmembrane domains (Spasic et al., 2006), which are primarily localised 
to ER membranes (Annaert et al., 1999) and are ubiquitously expressed 
throughout the brain and most peripheral tissues. There are two PS 
mammalian homologs (with 80% sequence homology); PS1 (located on 
chromosome 14) and PS2 (located on chromosome 1), which are recognised 
as the catalytic subunit of the γ-secretase complex (De Strooper et al., 
2012). PS undergo endoproteolytic cleavage to amino-terminal (NTF) and 
CTF fragments and it is this cleaved PS which forms a complex with 
nicastrin, aph-1, and pen-2 subunits. Together they function as the γ-
secretase complex (Zhang et al., 2010) which directly processes APP to form 
Aβ (and related molecules), and indirectly processes Notch (Wolfe, 2010). 
Indeed, cells (SH-SY5Y, HEK293 and blastocyst cells) lacking in PS do not 
exhibit γ-secretase activity and produce no Aβ or AICD (Hass and Yankner, 
2005; Zhang et al., 2000). That being said, Aβ42 production remains after 
PS1 and PS2 KO in embryonic stem cells (Wilson et al., 2003), possibly due 
to the previously mentioned non-canonical APP processing pathway.  
Mutations in human PS1, of which there have been 212 recorded to 
date, account for 2-3% of all AD cases and over half of EOFAD cases. The 
3xTg-AD mouse model and TgF344-AD rat model studied for this thesis 
express human PS1 mutations associated with EOFAD (PS1M146V and 
PS1∆E9 respectively; Clark et al., 1995; Luo et al., 2014; Riudavets et al., 
2013; Rogaeva et al., 2001). By contrast, mutations in PS2 only account for 
approximately 0.1% of AD cases (Tsai et al., 2002). Many of these known 
PS1 and PS2 mutations are implicated in Ca2+ signalling dysregulation, 
including mobilisation of calcium from the ER, ER-mitochondrial signalling 
and refilling of the ER through store-operated calcium entry (SOCE; 
Bezprozvanny and Mattson, 2008; Filadi et al., 2016; Stutzmann, 2007; 
Supnet and Bezprozvanny, 2010; Zampese et al., 2011; see Section 1.4 The 
Ca 2+ hypothesis of AD). Mutations in both PS homologs have been tangibly 
linked to altered APP processing resulting in increased Aβo and AICD 
production (Duff et al., 1996). It is likely that these roles are not independent 
as PS effects on Ca2+ dysregulation partially involves y-secretase activity 
(Akbari et al., 2004; Bojarski et al., 2009). Conversely, however, some PS1 
FAD mutations can also reduce γ-secretase activity (Bentahir et al., 2006; 
Fernandez et al., 2014; Xia et al., 2015a). 
In terms of effects on brain function, conditional PS1 and 2 KO in the 
postnatal mouse forebrain resulted in deficits in memory and hippocampal 





cortex and an increased inflammatory response (Beglopoulos et al., 2004; 
Saura et al., 2004). 
Aside from APP processing and modulation of intracellular calcium 
homeostasis however, it is worth noting that PS has numerous other 
biological substrates such as APoER2 lipoprotein receptor, the LDLR-related 
protein, ErbB4 receptor tyrosine kinase, CD44, p75 neurotrophin receptor, 
nectin-1α, syndecan-3, E- and N-cadherins and β subunits of voltage-gated 
sodium channels which are involved in functions like cell adhesion, cell 
signalling, neuronal structure and neuronal development (Koo and Kopan, 
2004; Wong et al., 2005). Although it is beyond the scope of this thesis to 
detail in depth the function of these proteins, and the possible effects that PS 
activity has on them, it is clear that due to its potentially multiple effects on a 
host of biological activities, in addition to APP processing and calcium 
homeostasis, a clear and simple elucidation of the effects of PS mutations in 
conditions such as AD is challenging. 
PS/γ-secretase mutations can also mediate cellular dysfunction via 
alterations in the processing of the integral membrane protein Notch 
(Pardossi-Piquard et al., 2005; Zhang et al., 2000). Notch functions as a 
receptor for ligands including Jagged and Delta, the binding of which results 
in Notch being proteolytically cleaved within its TM domain by PS1, resulting 
in the release of Notch Intracellular Domain (NICD). This, in turn, affects the 
expression of genes which are essential for a wide variety of development 
processes, including haematopoiesis, somitogenesis, vasculogenesis, and 
neurogenesis (for reviews see (Baron, 2003; Lasky and Wu, 2005)). In the 
brain, NICD-mediated gene expression also affects proteins involved in 
structural and functional plasticity processes of learning and memory, 
processes which also implicate Notch dysfunction in AD memory 
impairments (Lathia et al., 2008). In support of altered Notch function arising 
from PS mutation, PS1 KO mice die shortly after birth (Conlon et al., 1995; 
Swiatek et al., 1994) and exhibit skeletal and neurological development 
abnormalities, which would be expected due to altered Notch activity (Selkoe 
and Schenk, 2003). Furthermore, γ-secretase inhibition in adult mice alters 
lymphocyte development and intestinal morphology, again likely via Notch 
cleavage alterations (Wong et al., 2004).  
 
1.2.5 Types & activities of Aβ molecules 
As discussed above, the biochemical mechanisms underlying APP 
processing and the production of numerous APP fragments and Aβ 
molecules is reasonably well understood. However, how this accumulation 
might lead to the progressive development of AD remains unclear. To date, 





pathology. Indeed, AD is only definitively diagnosed following the 
identification of Aβ plaques in the brain post-mortem (Braak and Braak, 
1991; McKhann et al., 1984). However, to date, clinical trials aimed at 
targeting such plaques and/or inhibiting their formation have been 
unsuccessful as they failed to alleviate cognitive impairments or even slow 
the rate of progression of AD (Galimberti and Scarpini, 2011). Additionally, 
cognition does not correlate well with plaque density in that cognitively 
healthy people at the time of death can also have high plaque loads. For 
example, 69% of cognitively normal people at a mean age of 84 had neuritic 
plaques in the neocortex and hippocampus and at least 25% had sufficient 
numbers of plaques and NFTs to meet diagnostic criteria for a diagnosis of 
AD (Maarouf et al., 2011). Furthermore, Aβ plaques can form directly after 
brain trauma. For instance, 30% of cognitively normal people who die within 
days of severe head injury exhibit Aβ plaques (consisting of both Aβ40 and 
Aβ42) in one or more cortical areas (Roberts et al., 1994). These lines of 
evidence suggest that plaque load in and of itself does not correlate well with 
cogitation and/or with cognitive decline in AD (Berg et al., 1998; Perry et al., 
2000; Snowdon, 1997). That being the case, amyloid plaques are now 
generally regarded as ‘markers’ of AD rather than actual initiators of the 
disease process, although this does not necessarily rule out a role for them 
as the disease progresses. For instance, Ca2+ dysregulation and neuronal 
hyperexcitability occur in neurons close to Aβ plaques (Busche et al., 2008; 
Kuchibhotla et al., 2008). Thus, it is also possible that the plaques are acting 
to localise and target Aβo to extracellular/synaptic sites of action via 
‘secondary nucleation’ (i.e. the catalyses of Aβo formation from Aβ 
monomers; Fig 1.3; Verma et al., 2015). These shortcomings of Aβ plaques 
in fitting with AD pathology lead to the question of where Aβ proteins do they 
‘fit’ into the pathogenesis of AD? 
In attempting to answer this question, the general focus in Aβ 
research has shifted from the insoluble amyloid plaques to the shorter, 
soluble, oligomers of Aβ which are the precursors to plaque formation (Fig 
1.3; Deshpande et al., 2006; Haass and Selkoe, 2007; Klein et al., 2001; 
Lesné et al., 2006; McGowan et al., 2005; Näslund et al., 2000; Shankar et 






Figure 1.3. Amyloid aggregation  
(A) Amyloid beta (Aβ) monomers form heterogeneous prefibrillar oligomers (Aβo) which 
aggregate to form insoluble protofibrils. These, in turn, form mature fibrils and, eventually, 
plaques.  
(B) Mature fibrils undergo fragmentation to produce fibrillar oligomers (i.e. oligomers originating 
from fibrils) which can form protofibrils/mature fibrils again.  
(C) Mature fibrils can also catalyse the formation of oligomers from monomers via ‘secondary 
nucleation’. Such secondary nucleated oligomers are toxic, diffusible and can, in turn, contribute 
to fibril formation. 





Aβ dysregulation, as detected by alterations in CSF levels of Aβ42 
and/or PET imaging of fibrillar Aβ, occurs well before clinical diagnosis of AD 
and as such is one of the first detectable biomarkers for LOAD. This would 
suggest that these non-plaque Aβs play some role in the earlier stages of the 
disease or may even initiate the disease process (Holtzman et al., 2011). 
Non-toxic Aβ monomers can aggregate to form various toxic species (Fig 
1.3) such as heterogeneous Aβo (also referred to as Aβ–derived diffusible 
ligands (ADDLs) and prefibrillar oligomers) which are composed of between 
approximately two to fifty Aβ monomers. These oligomers form protofibrils, 
insoluble mature fibrils and, eventually, plaques. Importantly, these Aβ 
molecules are likely to exist in dynamic equilibrium (Selkoe, 2002). Indeed, 
mature fibrils which undergo fragmentation to produce fibrillar oligomers (i.e. 
oligomers originating from fibrils) can re-form protofibrils/mature fibrils again 
(Fig 1.3, B; Kayed et al., 2009; Verma et al., 2015). Furthermore, mature 
fibrils can also catalyse the formation of oligomers from diffusing monomers 
via ‘secondary nucleation’ (Fig 1.3, C). These secondary nucleated 
oligomers are toxic, diffusible and can, in turn, contribute to fibril formation 
(S. I. A. Cohen et al., 2013).  
It should be noted that although Aβo, particularly those composed of 
Aβ42 (Sakono and Zako, 2010; which is more hydrophobic, and aggregates 
more readily, than Aβ40; Burdick et al., 1992; Gu and Guo, 2013; Nunan and 
Small, 2000), are widely recognised as the most toxic form of Aβ and 
believed to be most pertinent to AD onset and progression, the dynamic 
equilibrium of Aβ molecules is not well understood. Notably, FAD mutations 
increase the ratio of Aβ42/40 (Borchelt et al., 1996; Scheuner et al., 1996), 
indicating that elevated Aβ42 levels relative to Aβ40 could be a factor in the 
disease pathogenesis. One hypothesis proposes that Aβ42 provides the core 
for the assembly of oligomers, fibrils and plaques (Iwatsubo et al., 1994; 
Jarrett et al., 1993). Other studies have found that Aβ40 maintains the 
solubility of Aβ42 (J. Kim et al., 2007) and that an increase in Aβ40 
concentration results in 60 – 90% Aβ deposition decrease in vivo (Giuffrida et 
al., 2009).  
Notably, the structure of Aβo is variously described as consisting of 
Aβo, Aβ42o, Aβ40o, ADDLs, low and high molecular weight Aβo (LMW- & 
HMW- Aβo), fibrillar oligomers, secondary nucleated oligomers, spherical 
oligomers and annular oligomers, among other components. These different 
descriptions may reflect either a difference in molecular structure, the 
specificity of the molecules for their related pathological roles and/or the 
formation of structures (such as protofibrils, fibrils, mature fibrils and plaque 
aggregates) into which these molecules tend to aggregate (Finder and 





Importantly, as discussed above, APP undergoes extensive and 
complex processing into numerous bioactive molecules. A further level of 
complexity is added to this signalling system when one also takes into 
account that the effects of one group of these molecules, Aβ monomers, 
depends upon their structure, concentration and length of exposure, all of 
which results in great difficulties modelling the behaviour of these entities in 
vivo (Deshpande et al., 2006; Glabe, 2008; Renner et al., 2010). For 
instance, when investigating the synaptic binding of Aβo, LMW-Aβo applied 
at a low concentration, it initially diffused in the manner expected of regular 
proteins, then subsequently slowed with time. This did not result in any 
detectable synaptotoxicity over a 24hr time course. However, HMW-Aβo 
acted differently, demonstrating rapid and widespread synaptic binding which 
resulted in significant synaptotoxicity within 24 hrs (Lacor et al., 2007; 
Renner et al., 2010). Furthermore, the length of incubation time with Aβo 
also alters their effects, illustrated by the fact that acute application of Aβo 
induces calcium and mitochondrial dysregulation as well as widespread cell 
death, whilst chronic application of lower concentrations of Aβo induces more 
subtle mitochondrial alterations (human cortical neurons; HCNs; Deshpande 
et al., 2006). 
The specific molecular actions of Aβ molecules, with a particular focus 
on Aβo and their Ca2+ dysregulating effects, will be described in the following 
section. 
 
1.2.6 Molecular actions of Aβo and related metabolites   
Several molecular mechanisms have been proposed to explain the 
varying and widespread effects of Aβo on neuronal physiology, including the 
formation of Ca2+ pores in the PM, modulation of membrane channel function 
and/or conductance (both PM and ER), synaptic impairment and 
mitochondrial dysfunction (Fig 1.4). A large proportion of these actions 
involve Ca2+ or act to destabilise intracellular calcium dynamics, which in turn 
can increase the amyloidogenic processing of APP (Mattson et al., 1992). It 
is this evidence that forms the basis of the Ca2+ hypothesis of AD (Section 








Figure 1.4. Molecular actions of APP metabolites  
There are several molecular mechanisms for the varying and widespread effects of amyloid beta oligomers (Aβo; formed from 
sequential cleavage by β-secretase (β) and γ-secretase (γ)) on neuronal physiology including: 
a) enhancing Ca
2+
 entry including through: i) the formation of Ca
2+ 
specific channels/pores in the PM which is enhanced by 
phosphatidylserine (PtdS) positioning on the outer leaflet of the PM, which is in turn enhanced by mitochondrial impairment ii) 









) at the PM. This results in lipid peroxidation, generating neurotoxic aldehyde 4-hydroxynonenal (HNE). 
HNE covalently modifies membrane transporters including PM Ca
2+
 ATPases (attenuating Ca
2+
 extrusion) and ion channels 
including VGCCs and NMDARs, iii) direct modulation of Ca
2+
 conductances through a plethora of PM channels including: 
NMDARs, α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptors (AMPARs) and VGCCs. 
b) Aβ causes mitochondrial oxidative stress which is exacerbated by Ca
2+
 dysregulation. Cell-wide Ca
2+
 increases result in 
mitochondrial Ca
2+
 overload (via uptake the through mitochondrial Ca
2+ 
uniporter (MCU) which results in impairment of the 
electron transport chain, increased ROS production and decreased ATP production. These effects eventually result in the 





 dysregulation also has causes stark disruption of ER Ca
2+
 dynamics, explained in Section 1.4 Calcium 





 dysregulation results in impaired synaptic plasticity (including long-term potentiation (LTP) and long-term 
depression (LTD), synaptic loss, oxidative damage, excitotoxicity and cell death. 







Modulation of Receptor Activity 
Ca2+ flux through the PM is controlled by three main transporters; the 
Na+/K+-ATPase, which serves to maintain the resting membrane potential 
and restores membrane potential following depolarisation (Stahl, 1984), the 
plasma membrane Ca2+-ATPase (PMCA), which maintains basal [Ca2+]i, and 
the Na+/Ca2+ exchanger (NCX) which rapidly removes Ca2+ following 
stimulation, but can reverse direction with membrane depolarization. 
Acute Aβo exposure (Aβ1-40 & Aβ25-35) in cultured rat hippocampal 
neurons selectively impaired Na+/K+-ATPase activity and induced an 
elevation of [Ca2+]i and apoptosis, effects which could be reversed by 
antioxidant treatment. The same acute Aβo exposure did not affect the 
activities of Mg2+-dependent ATPases or NCX (Mark et al., 1995). 
Furthermore, exposure of synaptosomes derived from post-mortem human 
hippocampus (from neurologically normal individuals aged 79-85 years) to 
Aβ also impaired Na+/K+-ATPase and PMCA activity, without affecting other 
Mg2+-dependent ATPase activities or NCX (Mark et al., 1995). Therefore, Aβ 
exposure has the potential to alter membrane potential and alter the flow of 
critical ions through the PM, all of which would have profound deleterious 
effects on neuronal activity/viability.  
Aβo can also modulate the function and expression of several plasma 
membrane-, and ER-bound channels, including those involved in Ca2+ 
signalling. Consequently, there are a number of mechanisms by which they 
can affect neuronal function and stability. The receptors upon which Aβo 
exert modulatory effects include, a) voltage-gated calcium channels (VGCCs; 
N-, T-, L-, P- & Q- VGCCs (Dursun et al., 2011; Webster et al., 2006)), b) 
nicotinic acetylcholine receptors (nAChR; Dougherty et al., 2003; Liu et al., 
2009), c) N-methyl-D-aspartic acid receptors (NMDARs; De Felice et al., 
2007; Li et al., 2011), d) α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic 
acid receptors (AMPARs; Hsieh et al., 2006; Whitehead et al., 2017), e) 
metabotropic glutamate receptors (mGluRs; Haas et al., 2014; Renner et al., 
2010; Sokol et al., 2011; Um et al., 2013), f) angiotensin II receptors (AbdAlla 
et al., 2009) and g) the ER calcium release channels, IP3R (Demuro and 
Parker, 2013) and RyR (Supnet et al., 2006). 
Aβ Pores 
It is proposed that Aβo can form Ca2+-specific channel-like structures 
which allow unregulated movement of Ca2+ into cells (Arispe et al., 1993a; 
Durell et al., 1994). These initial findings were supported by human studies in 
which electron microscopy was utilised to identified channel-like pores in 
post-mortem AD brains. Numerous Aβ oligomers, including Aβ42, Aβ40, as 





non-amyloidogenic but present in AD and DS plaques (Jang et al., 2010)), 
have been implicated in this ion channel forming ability (Bode et al., 2017; 
Huang et al., 2000; LIN et al., 2001; Sanderson et al., 1997; Sepulveda et al., 
2010). Significantly, these types of Aβ pore were not found in healthy 
controls (Inoue, 2008). 
Aβo-mediated Ca2+ entry into cells is enhanced by the presence of 
phosphatidylserine (PtdS) on the cell surface (Lee et al., 2002). However, the 
movement of PtdS to the cell surface is usually indicative of cells undergoing 
apoptosis (van den Eijnde et al., 1998). Thus, it is proposed that AD-related 
mitochondrial impairment could cause PtdS to flip from the inner to the outer 
leaflet of the plasma membrane, allowing it to come in contact with Aβ which, 
in turn, appears to induce Ca2+ influx and cell death (Simakova & Arispe, 
2006). Furthermore, neurons exhibiting increased surface PtdS are more 
vulnerable to Aβ toxicity (Simakova and Arispe, 2007).  
There is also some evidence that Aβos (both Aβ40 and Aβ42) can 
disrupt membrane lipid integrity via interactions with phospholipids and 
modulation of membrane composition, with Aβo found to bind more avidly to 
phospholipids than fibrillar Aβ (Askarova et al., 2011; Williams and Serpell, 
2011). Furthermore, Aβo may also cause an increase in membrane 
permeability in a receptor-independent fashion, through membrane thinning, 
thereby causing alterations in Ca2+, Na2+ and K+ conductance/homeostasis. 
This, in turn, would impair transporter and ion channel activity (Sokolov et al., 
2006), ultimately resulting in the induction of neurite and neuronal 
degeneration (Mattson, 2004). This disruption of membrane integrity may be 
mediated by interactions between Aβo (which is inserted in the PM) and Fe2+ 
and Cu+ to generate hydrogen peroxide and hydroxyl radicals (Morgan et al., 
2000). Indeed, antioxidants which inhibit reactive oxygen species (ROS) 
formation such as vitamin E, oestrogen and uric acid, prevented impairment 
of membrane transporters, stabilised intracellular Ca2+ levels and prevented 
cell death in Aβ-treated neurons (Ba et al., 2004; Keller et al., 1997). 
However, as mitochondria are significant generators of cellular ROS 
(Murphy, 2009), this neuroprotective effect of antioxidants may also be due 
to their ability to ‘mop up’ mitochondrially-generated ROS (Birben et al., 
2012), as opposed to that mediated by Aβo at the PM.  
Synaptic Disruption 
A key characteristic of Aβ-mediated pathology in AD is related to its 
ability to disrupt synaptic function, likely through factors such as altered Ca2+ 
homeostasis, dysregulation of PM and ER receptors, as well as more 
general cellular homeostatic and structural alterations. As an indication that 
synaptic dysfunction may be an early-stage disease event, cortical soluble 
Aβ levels correlate with the degree of synaptic loss, in mildly cognitively 





In this respect transgenic APP mice (APP695SWE and APPV717F) exhibit 
significant deficits in synaptic transmission and LTP compared with controls 
(hippocampal CA1 field; Aβ plaque independent; Hsiao et al., 1999; Larson 
et al., 1999). Failure to maintain LTP was also observed in 5-7-month-old 
APP(Val642 → Ile) mice (Moechars et al., 1999) and 15 – 17-month-old APP 
(Lys670 → Asn, Met671 → Leu double mutation) mice (Chapman et al., 1999). 
In the latter study, no alteration in basal synaptic transmission was observed. 
Conversely, in hippocampal slices taken from APPSWE mice at 12 and 18 
months, LTP was normal but there were significant alterations in basal 
synaptic transmission (Fitzjohn et al., 2001). 
Discrepancies such as these may illustrate specific alterations in 
synaptic activity as the disease progresses. For example, in work utilising 
APPV717F mice, at 1-4 months there was a 40% decrease in basal 
hippocampal SC-CA1 synaptic transmission, but no change in LTP. 
However, by 8 – 10 months, basal synaptic transmission had decreased by 
80% and LTP was inhibited. This impairment appeared to be due to reduced 
synapse number rather than a decline in the function of individual synapses 
between 2 to 10 months. Interestingly, when these results are compared to 
those derived from a mouse cell line with lower APP expression, but higher 
Aβ production (APP695SWE), impairment of synaptic transmission at 2-4 
months was exacerbated, implying that Aβ-specific effects of APP are 
involved in mediating this effect (Hsia et al., 1999). Indeed, synaptic 
dysfunction appears to be specifically dependent upon Aβ42 levels, and not 
on Aβ plaque burden or APP levels in APP transgenic mice (Hsia et al., 
1999; Mucke et al., 2000). 
The suggestion that the degenerative effects of Aβo are selectively 
targeted towards synapses, as opposed to being a generalised ‘attack’ 
across the entire neuronal surface, is supported by the fact that they 
accumulate extracellularly and selectively at hippocampal synapses (Renner 
et al., 2010). APP is also actively transported to pre-synaptic terminals and 
accumulates within synaptic regions, allowing a mechanism for mutated APP 
to cause a direct disruption of synaptic function (Bezprozvanny and Mattson, 
2008). Receptors at the post-synaptic membrane are stabilised via 
interactions with scaffolding proteins (Renner et al., 2008). However, this 
stabilisation is transient, with receptors able to diffuse into and out of the 
post-synaptic membrane in a manner dependent upon synaptic activity 
(Renner et al., 2008; Triller and Choquet, 2008). Importantly, the population 
of synaptic receptors exists in equilibrium with extrasynaptic receptors, a fact 
which can leave synapses vulnerable to disruption if receptor diffusion is 
altered (Ehlers et al., 2007). 
Such a vulnerability, specifically to the effects of Aβo, has clearly been 





synapses. These experiments showed that clusters of Aβo diffused laterally 
and accumulated at excitatory synapses. These clusters increased in 
number over time in mature cultured hippocampal neurons (21 – 27 days in 
vitro (DIV); Renner et al., 2010). Significantly, however, Aβo decreased 
(Renner et al., 2010) the ability of mGluR5 to diffuse laterally away from the 
synapses (Sergé et al., 2002). mGluR5 is primarily located on dendrites 
outside synapses, whilst any mGluR5 near the synapse is normally stabilised 
in a ring at the periphery of the post-synaptic density (Lujan et al., 1996; 
Luján et al., 1997). The decrease in mGluR5 mobility induced by Aβo is likely 
due to the formation of pathological extracellular stabilising matrices, 
resulting in their aggregation and the formation of ‘artificial signalling 
platforms’ which, in turn, results in aberrant Ca2+ signalling (neuronal Ca2+ 
signalling and that mediated by I-mGluRs is detailed in Section 1.3 Ca2+ 
signalling) that ultimately decreases synaptic NMDAR expression (Renner et 
al., 2010). The decrease in mobility induced by Aβo was specifically selective 
for mGluR5 as they had no effect on α-amino-hydroxy-5-methyl-4-
isoxazolepropionic receptor (AMPAR) and GABAR mobility (Renner et al., 
2010). These effects induced by Aβo were mimicked both by artificial 
clustering of mGluR5 (induced by crosslinking mGluR5s) and antagonists of 
mGluR5 (Renner et al., 2010). Furthermore, mGluR5 KO hippocampal 
cultures exhibited a large decrease in Aβo binding to the neuronal surface 
and a near halting of effects on synaptic NMDAR loss, revealing the 
mGluR5-dependent nature of the Aβo effects (Renner et al., 2010).  
Aβo-mGluR mediated synaptic impairment is also supported by the 
following observations: a) membrane depolarisation is evoked by Aβ42 and 
involves mGluR1 in differentiated human hNT neuronal cells and rat nerve 
growth factor-differentiated PC12 cells (Blanchard et al., 2002), b) Aβo 
suppresses hippocampal LTP and enhances LTD, actions which are 
reversed by mGluR5 agonists and antagonists, respectively (Rammes et al., 
2011; Shankar et al., 2008; Q. Wang et al., 2004), c) mGluR5 antagonism or 
antibody intervention also reversed synapse loss in hippocampal neurons in 
vitro and in vivo, as well as memory deficits (Chung et al., 2010; Haas et al., 
2014; Hu et al., 2014; Rammes et al., 2011; Renner et al., 2010; Um et al., 
2013) and d) Aβo decreased the availability of phosphatidylinositol-4,5-
bisphosphate (PIP2), the substrate for PLC which could decrease levels of 
the Ca2+ liberating second messenger IP3 following I-mGluR stimulation 
(primary cortical neurons; Berman et al., 2008). 
The evidence described in this section illustrates that mGluR5 is 
implicated in Aβo-mediated synaptic impairment. However, the nature of 
synaptic alterations, particularly with regard to NMDAR activity and 





(natural or synthetic), concentration and length of exposure or may reflect a 
progression from one type of pathology to another (Renner et al., 2010). 
Group I mGluRs (I-mGluRs) modulate NMDAR-dependent LTP and 
LTD in the hippocampus and are implicated in NMDAR-dependent learning 
(Benarroch, 2008). In agreement with the aforementioned study by Renner et 
al. (2010), research by Lacor’s group found that Aβo (high concentrations of 
synthetic oligomers) induced increases in the immediate early gene 
Arc/Arg3.1 (Lacor et al., 2007, 2004a). mGluR5-LTD is dependent upon this 
memory-related immediate early gene (Waung et al., 2008) as Arc couples 
changes in neuronal activity patterns to alterations in synaptic plasticity 
(Bramham et al., 2010). Activation of Arc is enhanced above normal levels 
by Aβo binding to mGluR5 and may contribute to the pathological effects of 
Aβo at the synapse (Lüscher and Huber, 2010; Um et al., 2013). It also 
results in altered spine morphology, decreased spine number, depletion of 
surface NMDAR and dysregulation of NMDA signalling pathways (Lacor et 
al., 2007; Shankar et al., 2007; Snyder et al., 2005). Furthermore, mGluR5 
antagonism or antibody intervention reverses synapse loss in hippocampal 
neurons in vitro and in vivo, as well as memory deficits (Chung et al., 2010; 
Haas et al., 2014; Hu et al., 2014; Rammes et al., 2011; Renner et al., 2010; 
Um et al., 2013). Interestingly, elevated Arc, mediated by mGluR5 activation, 
also stimulates Aβ production by redistributing APP and PS1 to endocytic 
vesicles (Wu et al., 2011), possibly leading to another deleterious AD feed-
forward cycle.  
An alternative mechanism of synaptic plasticity impairment by Aβo is 
proposed by Wang et al. (2004). This was adapted to include the recently 
discovered actions of Aβo mediated mGluR5 pathological signalling at the 
synapse (Renner et al., 2010). High-frequency stimulation (HFS) induces 
LTP via NMDAR activation and influx of Ca2+ (see Section 1.7). mGluR5 is 
pathologically stimulated due to cellular prion protein (PrPC)-Aβo (see below) 
mediated activation and/or activation by the neurotransmitter glutamate 
released during HFS or by glia following their activation by Aβo. This 
combined activation then stimulates kinase-mediated inhibition of LTP. 
Specifically, the kinases proposed to be involved are c-Jun N-terminal kinase 
(JNK), cyclin-dependent kinase 5 (CdK5) and p38 mitogen-activated protein 
kinase (MAPK) which have been shown to be activated by Aβo (Bolshakov et 
al., 2000; Liu et al., 2001; Rush et al., 2002).  
mGluR5 signalling can exacerbate NMDAR-induced excitotoxicity via 
activation of the Ca2+ dependent enzyme calcineurin (CN; Bruno et al., 2000, 
1995). Furthermore, mGluR5 antagonism has been shown to protect 
neurons against Aβo-induced toxicity (cortical cultures; Bruno et al., 2000). 





mechanism by which the NMDAR modulator memantine protects against 
Aβo-induced toxicity (De Felice et al., 2007; Lacor et al., 2007). 
Notably, membrane fluidity and localisation of mGluR5 to the 
aforementioned artificial signalling platforms may also be influenced by PrPC, 
which is known to localise with and form complexes together with group 1 
mGluRs (comprised of mGluR1 and mGluR5) and NMDARs (Khosravani et 
al., 2008; Perroy et al., 2008a; Renner et al., 2010; Tu et al., 1999; Um et al., 
2013).  
Role of Cellular Prion Protein (PrPC) 
PrPc is a glycosylphosphatidylinositol (GPI)-anchored protein, tethered 
to the extracellular surface of the cell membrane, which signals via complex 
formation with other TM receptors (Beraldo et al., 2016) such as mGluRs 
(Beraldo et al., 2016, 2011, Haas et al., 2016, 2014; Um et al., 2013) and 
NMDARs (Black et al., 2014). 
PrPc is of particular interest within AD research as a growing body of 
evidence suggests that it can function as a high affinity, Aβo-specific receptor 
which is essential for mediating the toxic effects of Aβo such as the 
suppression of synaptic activity (including hippocampal LTP), synapse loss, 
axonal degeneration and cell death as well as learning and memory deficits 
in transgenic APP/PS1 animals (Bate and Williams, 2011; Chen et al., 2010; 
Gimbel et al., 2010; Haas et al., 2014; Hu et al., 2014; Kudo et al., 2012; 
Larson et al., 2012; Laurén, 2014; Laurén et al., 2009; Ostapchenko et al., 
2013; Um and Strittmatter, 2013). This is evidenced by the fact that anti-PrPc 
antibodies not only reduce the binding of Aβo to the PM but also rescue Aβo 
–induced impairments such as synaptic dysfunction in hippocampal slices 
(Barry et al., 2011; Chung et al., 2010; Freir et al., 2011; Laurén et al., 2009). 
Furthermore, in support of a disease-relevant role for PrPC in AD, human AD 
brains contain PrPc- interacting Aβo and Aβ – PrPc complexes (Barry et al., 
2011; Freir et al., 2011; Laurén et al., 2009; Um et al., 2013; Zou et al., 
2011). 
At the post-synaptic density (PSD) these Aβ–PrPc complexes interact 
with intracellular Fyn kinase (Larson et al., 2012; Um et al., 2012). Indeed, 
both PrPC and Fyn are enriched in the PSD (Collins et al., 2006; Um et al., 
2012). Fyn kinase functions are diverse and in the CNS include the 
regulation of synaptic function, plasticity and myelination (for review see 
(Resh, 1998). Under normal physiological conditions, Fyn kinase can 
regulate glutamate receptor trafficking and plasticity, in part, by 
phosphorylating NMDARs (Grant et al., 1992; Prybylowski et al., 2005).To 
this end, Aβo–PrPC-Fyn complexes can evoke synaptic disruption via 
alterations in both mGluR5 (Beraldo et al., 2016) and NMDAR trafficking and 





aforementioned effects on mGluR5 stabilisation at the PSD (Um et al., 2013). 
Although mGluR1 and mGluR5 can both form PrPc-Fyn complexes, only 
mGluR5 mediates Aβo-induced calcium signalling in oocytes. These Aβo-
PrPC-mGluR5 complexes stimulate Fyn, which causes PLC-dependent 
increases in [Ca2+]i (see Section 1.3 Ca2+ signalling) in both Xenopus 
oocytes and neurons (Um et al., 2013). Notably, Fyn can also interact with 
tau to mediate potentially mGluR5-independent neurotoxic effects (Ittner et 
al., 2010; Lee et al., 2004; Roberson et al., 2011).Aβo-PrPC-mGluR5 
complexes also appear responsible for eukaryotic elongation factor 2 (eEF2) 
phosphorylation, impairments in LTP, spine loss and spatial memory 
impairments (Um et al., 2013). eEF2 is a calcium/calmodulin (CaM) -
dependent kinase which is activated physiologically by mGluR5 and 
mediates Arc translation (described previously).  
Aside from mGluR5-specific effects, synaptic accumulation of Aβo and 
fibrils could also account for the synaptic breakdown observed in AD 
(Friedlich et al., 2004; Lee et al., 2002), which may also occur via increased 
Arc transcription (Lacor et al., 2004). Furthermore, application of Aβo at very 
low concentrations results in actin-depolymerizing factor/cofilin- (involved in 
cytoskeleton plasticity) and CN - dependent decreases in NMDAR activity 
and dendritic spine number after 5 -15 days. The number of cells expressing 
NMDAR subunits (NR1 and NR2A subunits) was also lower in transgenic 
mice (APPSWE mice at 18 -22 months). Furthermore, this deficit could be 
reversed by the application of aducanumab (an anti-amyloid-β antibody; 
Sevigny et al., 2016, Shankar et al., 2007). These synaptic alterations could 
provide a mechanism for the synapse loss induced by Aβo application in 
culture (Lacor et al., 2007) and that is also observed in AD mouse models 
(Koffie et al., 2009). 
Conversely, however, Aβo have also been shown to increase NMDAR 
responses and induce excitotoxicity (De Felice et al., 2007; Szegedi et al., 
2005), effects which may mediate Aβo-stimulated oxidative stress and 
increased [Ca2+]i (Bezprozvanny and Mattson, 2008; Cullen et al., 1996), 
Furthermore, the production of Aβ at nerve terminals is regulated by synaptic 
activity and downstream signalling pathways, likely involving the transport 
and processing of Aβ in vivo (Cirrito et al., 2005; Gandy et al., 1993). This 
overlap illustrates a continual trend therefore of molecular ‘opportunities’ for 
feedforward disease progression linking to the degenerative nature of the 
condition. 
This summary provides a glimpse of the surfeit of mechanisms by 
which both APP processing and cleavage, as well as the relative 
concentrations of Aβ molecules and the assemblies that they form, can 
influence disease pathology. It is unsurprising therefore that any inherent 





overwhelmed or that pharmacological intervention targeting Aβ plaques in 
the clinical setting is unsuccessful. Crucially, both Ca2+ dysregulation and Aβ 
converge on the majority of the AD-affected processes outlined above. 
Indeed, Ca2+ may often be the mediator of Aβo toxic effects and vice versa. 
As such, both the Aβ cascade and Ca2+ hypothesis of AD are inextricably 
linked. Before moving on to explain the Ca2+ hypothesis of AD, I will first 
endeavour to provide the reader with an insight into key aspects of neuronal 
calcium signalling, particularly as it pertains to hippocampal signalling. The 
hippocampus is one of the first regions to be affected in AD and was 
therefore chosen as the area from which the primary experimental unit 
utilised in the production of data for this thesis, the cultured hippocampal 








1.3 Calcium signalling 
1.3.1 Overview 
Calcium is the central signalling molecule of neurons and is 
intrinsically associated with their vital functions (Stutzmann, 2007). This 
versatile molecule and the cytostructural and homeostatic system pertaining 
to it allows for crucial physiological roles in cellular homeostasis, intracellular 
signalling, as well as mediating and transducing responses to a wide range 
of external stimuli. As such, it is implicated in cellular activities such as the 
regulation of gene transcription (Berridge, 1998; Mellstrom & Naranjo, 2001), 
modulation of membrane excitability (Davies et al., 1996; Stutzmann et al., 
2003), enzyme/kinase activity and mitochondrial function (Supnet & 
Bezprozvanny, 2010). Ca2+ is also critical for determining synaptic activity 
such as basal synaptic transmission, synaptic plasticity (short and long-term 
forms) and dendritic spine morphology (Berridge, 2010; Chakroborty and 
Stutzmann, 2014; Fujii et al., 2000; Hayashi and Majewska, 2005; Nakamura 
et al., 1999). 
The ability of calcium to regulate such diverse activities within the cell 
is facilitated by its strict cellular compartmentalization which, in turn, is 
mediated primarily via bi-directional interactions between the plasma 
membrane and the ER, the main calcium store in neurons. Together, these 
two structures form a continuous binary membrane within cells (Berridge, 
2002). Structurally, the ER is relatively unorganised in neurons and whilst it 
spreads throughout the cell, there appears to be a division between rough 
ER in the soma, which is primarily involved in protein synthesis, but which 
transforms into smooth ER responsible for pre- and post-synaptic Ca2+ 
signalling events surrounding synaptic plasticity in the dendrites and spines 
(Berridge, 1998). The nuclear envelope, mitochondria, Golgi and lysosomes 
are also capable of Ca2+ storage and release and add a further level of 
complexity to cellular Ca2+ signalling and homeostasis which will be briefly 
touched upon in the following sections (Giorgi et al., 2009; Michelangeli et 
al., 2005; Rizzuto et al., 2009). 
 
ER 
The ER is implicitly involved in a number of signalling processes such 
as Ca2+ flux, apoptosis, arachidonic acid (AA) release and sterol biosynthesis 
(Berridge, 1998). Ca2+ homeostasis is critical for signaling-specific functions, 
but also for ER protein handling, including their synthesis, folding, trafficking, 
disaggregation and degradation. The ER, as a signalling organelle, is 
sensitive to numerous stimuli including Ca2+, IP3, cADPR, L-type channel 
inputs, ROS, sphingosine-1-phosphate S-1-P and sterols, to which the ER 





acid (AA) release, as well as activation of store-operated calcium channels 
(SOCCs; see below), stress signals and numerous transcription factors with 
wide downstream implications (including NF-κB, CHOP, ATF-6 and SREBPs; 
Berridge 2002). Disturbances of these process result in the production of 
numerous pathological phenotypes, so-called ‘calciumopathies’ (Stutzmann, 
2007). Indeed, dysregulation of calcium homeostasis at the level of the ER 
has the capacity to extensively disrupt Ca2+-dependent signalling events in a 
global manner, given the concentration gradients involved, as well as the 
extensive ER network in the neuron (Berridge, 1998). 
Resting cytosolic Ca2+ concentration ([Ca2+]cyt) is normally maintained 
between ~50-300nM (Verkhratsky et al., 2004). Thus, a large 
electrochemical gradient exists between the cytosol and the ER (the 
concentration of Ca2+ in the ER ([Ca2+]ER) ranges from 100 to 500µM; 
LaFerla, 2002), and the extracellular space, with a [Ca2+]o of 2.5mM. The 
differing Ca2+ concentrations within cells are maintained by four key 
components: 1) heterogeneous Ca2+ channels on the plasma membrane 
which allow Ca2+ entry into the cell, 2) transport to, from, and between 
organellar Ca2+ stores, including the ER, mitochondria and lysosomes, 3) 
Ca2+ release channels on the ER, including IP3R and RyR and 4) ER and PM 
Ca2+ transporters, Ca2+ ATPases and Na+/Ca2+ exchangers, which establish 
baseline concentration gradients, with respect to both intracellular and 
extracellular compartmentalisation (Berridge et al., 2003). Indeed, it is the 
intricate interplay between these four components which enables Ca2+ 
microdomain maintenance and the production of complex spatiotemporal 
Ca2+ dynamics, which ultimately allow and control the disparate functions of 
Ca2+ in the cell (Berridge, 2006; Berridge et al., 2003). 
Ca2+ ATPases and Na+/Ca2+ exchangers on the plasma membrane 
(PMCA and NCX) control Ca2+ extrusion into the extracellular space. The 
concentration gradient between the ER and cytoplasm is maintained by the 
sarco/endoplasmic reticulum Ca2+ ATPases (SERCA), which sequester Ca2+ 
into the ER. These pumps are sensitive to both [Ca2+]ER and [Ca2+]cyt, which 
affects the rate that Ca2+ is pumped into the ER (Berridge et al., 2003). 
However, once Ca2+ has been taken up by the ER, it does not remain there 
indefinitely. In the absence of further stimuli, Ca2+ leaks out into the cytosol 
over a finite time period in the order of seconds to minutes (Rae and Irving, 
2003). 
Several types of protein have been proposed to mediate this basal ER 
Ca2+ leak. These proteins include PS1 and 2 (Bezprozvanny and Mattson, 
2008; Tu et al., 2006), Ca2+ homeostasis modulator 1 (CALHM1; Dreses-
Werringloer et al., 2008), transient receptor potential (TRP) family-like 
polycystin-2 (TRPP2), members of anti-apoptotic proteins of the B-cell 





families and hemichannel-forming proteins such as pannexins (Sammels et 
al., 2010). Research concerning this ER leak function is in its infancy and 
there are numerous conflicting reports for the importance of most of the 
proteins listed above in the leak of Ca2+ from the ER. However, as described 
in Section 1.4 Ca2+ hypothesis of AD, the role of PS in ER Ca2+ leak and its 
AD-related impairment is generally accepted. 
Mitochondria are localised close to the ER at specific contact sites, 
particularly at ER Ca2+ release sites (Rizzuto et al., 1993). This factor allows 
for a triad of communication with the ER, mitochondria and lysosomes 
(Burgoyne et al., 2015), possibly enabling a role for this triad in Ca2+ 
signalling and ER refilling (Arnaudeau et al., 2001). What is known is that the 
ER-mitochondrial network is critical in cell death regulation (Decuypere et al., 
2011; Pinton et al., 2008). Ca2+ entry into the mitochondria occurs via the 
mitochondrial Ca2+ uniporter (MCU; Baughman et al., 2011) and voltage-
dependent anion channel 1 (VDAC1; Giorgi et al., 2015). Mitochondria act as 
high-capacity, low-affinity transient calcium buffers in the cytoplasm, altering 
the dynamics of intracellular Ca2+ signalling such as limiting the peak of 
[Ca2+]cyt following stimulation and broadening the time profile of the elevation 
(Nicholls, 2005). A strong driving force exists for mitochondrial Ca2+ 
accumulation due to the large negative membrane potential (approximately 
−180 mV) across the inner mitochondrial membranes (Rizzuto et al., 2012). 
This, combined with the existence of contact sites overcome the low-affinity 
Ca2+ transport characteristics of the mitochondrial uniporter (Baughman et 
al., 2011; De Stefani et al., 2011). Contact sites allow for significant localised 
Ca2+ increases (up to 20 μM) upon opening of IP3Rs which can be taken up 
efficiently by mitochondria (Csordás et al., 2010). In the recovery phase of a 
calcium response, the mitochondrially-sequestered Ca2+ is released back 
into the cytoplasm via Na+/Ca2+ and H+/Ca2+ exchangers (Palty et al., 2012; 
Scanlon et al., 2000). It is then either returned to the ER by the SERCA 
pump or extruded from the cell. Faster mechanisms (ms timescale) of Ca2+ 
entry into mitochondria are also proposed, which may enable a more 
physiologically relevant continuity between ER and mitochondrial 
membranes (Beutner et al., 2005; Sparagna et al., 1995). 
The calcium buffers BiP, calreticulin and calnexin stabilise free [Ca2+] 
in the ER, which influences the overall amount of Ca2+ that is available for 
stimulus-evoked release (Prins and Michalak, 2011). This obviously directly 
impacts upon ER-specific signalling processes, which are mediated by free 
[Ca2+] (Corbett & Michalak, 2000). The presence of ER calcium sensor 
proteins, including visinin-like protein (VILIP) and calcium-sensing processes 
such as store-operated calcium entry (see below) also allows the cell to react 





In addition to the relatively immediate regulatory and signalling roles 
described above, the ER itself is highly dynamic and can undergo longer-
term (hours to days) regulatory adaptations. These adaptations can be in 
physical size, shape and composition in response to changing demands, 
such as that experienced during development, stress and/or disease and 
ageing (Federovitch et al., 2005; Sammels et al., 2010). Pathological ER 
adaptations will, in turn, have significant effects on cellular calcium dynamics, 
including mitochondrial dysfunction (Bergner and Huber, 2008; Deniaud et 
al., 2008; Roderick and Cook, 2008). 
 
1.3.2 Extracellular calcium entry 
Ca2+ ions can enter neurons from the extracellular space through a 
variety of ion channels, with varying selectivity and permeability for calcium. 
These channels include VGCCs and ligand-gated calcium channels such as 
NMDARs, AMPARs, nicotinic receptors, ATP gated purinergic channels 
(P2XCs), SOCCs and CALHM1 (Dreses-Werringloer et al., 2008; 
Habermacher et al., 2016; Supnet and Bezprozvanny, 2010).  
Store-operated Ca2+ entry (SOCE, a.k.a. capacitative Ca2+ entry 
(CCE)) occurs through SOCCs of which the Ca2+ release-activated Ca+ 
(CRAC) channel and transient receptor potential canonical (TRPC) family of 
calcium-permeable channels have been characterised thus far (Cheng et al., 
2013; Salido et al., 2009).  
SOCE is thought to be triggered by ER Ca2+ depletion. This trigger 
threshold depletion is thought to be more likely to arise from a reduction in 
[Ca2+]ER at specific microdomains within the ER because widespread 
depletion would activate stress signalling and disrupt cellular function 
(Berridge 2002). Stromal interaction molecule (STIM) 1 is a protein located 
on the ER membrane (Liou et al., 2005; Wu et al., 2006) which acts as a 
sensor of calcium depletion (Cahalan, 2009). When this occurs, STIM1 
proteins oligomerise and migrate to the ER-PM junction (Liou et al., 2007; 
Roos et al., 2005). The oligomers then activate the PM channel Orai1 and 
induce Ca2+ influx through CRAC channels (measurable by the Ca2+ release-
activated current, ICRAC (Luik et al., 2008) and store replenishment via the ER 
SERCA pumps (LaFerla, 2002). The SOCE pathway is the principal Ca2+ 
entry pathway in non-excitable cells where it is implicated in motility, 
secretion and gene expression (Parekh and Putney, 2005). However, SOCE 
has also been observed in excitable cells of the nervous system (Putney, 
2003; Verkhratsky and Toescu, 2003), including cultured hippocampal 





There are two STIM homologs (STIM1 and STIM2) present in the ER 
of neurons (Moccia et al., 2015). Although a clear role for STIM 1 in neuronal 
SOCE has been identified, there is now considerable evidence to suggest 
that STIM2 also mediates neuronal SOCE (Gruszczynska-Biegala et al., 
2011; Gruszczynska-Biegala and Kuznicki, 2013; Sun et al., 2014; Zhang et 
al., 2015b). Interestingly, although SOCE was originally thought to be 
activated in response to ER depletion, STIM2-activated Ca2+ influx can be 
activated by small decreases in [Ca2+]ER, and may thus play an important role 
in maintaining the tight regulation of [Ca2+]cyt vs [Ca2+]ER gradients (Brandman 
et al., 2007).  
Briefly, TRPCs can be activated independently by the PLC-mediated 
production of diacylglycerol (DAG) and/or in a coordinated manner with 
CRAC channels following ER Ca2+ depletion, both of which can be mediated 
by I-mGluR stimulation (see below; Putney and Tomita, 2012). 
 
1.3.3 Intracellular calcium release 
Ca2+ release from the ER occurs primarily via activation of IP3Rs 
and/or RyRs in a highly regulated manner that is controlled by Ca2+, ATP, 
kinases and phosphatases (Ivanova et al., 2014). RyRs and IP3Rs, of which 
there are three subtypes each, differ significantly from one another in terms 
of their expression, localisation, activation mechanisms and physiological 
roles. Numerous tissues express multiple IP3R isoforms, although IP3R1 is 
enriched in neurons, IP3R2 in the heart and liver, and IP3R3 in lymphocytes 
and multiple cell lines (Ivanova et al., 2014). 
Neurons express all three subtypes of both RyRs and IP3Rs, although 
IP3R1 and RyR2 expression predominate (Berridge, 1998; Franzini-
Armstrong and Protasi, 1997; Furuichi et al., 1994; Simpson et al., 1995). 
RyR2 is distributed widely in the brain, RyR3 expression is predominant in 
the CA1 hippocampal region and RyR1 is almost exclusively expressed in 
cerebellar Purkinje cells (Furuichi et al., 1994). Generally, IP3R and RyRs co-
localise on subsurface cisternae originating from the ER and are distributed 
throughout the compartments of the neuron (Fagni et al., 2000) including 
axonal endings and dendritic spines (Berridge, 1998; Sharp et al., 1993). 
Aside from this general pattern of co-localisation, RyRs are also distinctly 
localised to the soma of neurons (Kano et al., 1995; Kuwajima et al., 1992; 
Seymour-Laurent and Barish, 1995; Sharp et al., 1993). Furthermore, in the 
CA3 and hilar hippocampal regions as well as in the cerebral cortex, RyRs 
are more prominently expressed at dendritic spines than IP3Rs (Augustine 





IP3Rs are generally activated indirectly following agonist stimulation of 
PM-bound receptors, specifically G-protein (Gq subunit)-coupled receptors 
(GPCRs) such as I-mGluRs and M1 and M3 muscarinic acetylcholine 
receptors (mAChRs; Foskett et al., 2007; Wettschureck and Offermanns, 
2005). When an agonist binds to these types of Gq-linked receptors it 
stimulates phospholipase C to cleave PIP2, forming diacylglycerol (DAG) 
and IP3 (Niswender 2010). IP3 then binds to IP3Rs on the ER membrane, 
opening them to allow Ca2+ efflux from the ER, down its concentration 
gradient into the cytosol. IP3Rs are sensitive to both cytosolic and ER Ca2+, 
with maximal stimulation occurring when both Ca2+ and IP3 are present in the 
cytosol (Missiaen et al., 1994). This relatively simplistic picture is complicated 
by the fact that I-mGluRs are part of a multi-molecular complex which 
contains NMDAR and possibly PrPc, suggesting that their signalling is 
inherently linked to these molecules and their downstream pathways and/or 
substrates (Khosravani et al., 2008; Perroy et al., 2008b; Renner et al., 2010; 
Tu et al., 1999). This is evidenced by the ability of I-mGluRs to modulate 
NMDAR-dependent LTP and LTD in the hippocampus (Benarroch, 2008). 
RyRs on the other hand, are generally activated by Ca2+-induced 
calcium release (CICR) via Ca2+ influx or ER calcium release. For example, 
CICR can be induced following membrane depolarisation and activation of 
VGCCs and following ER Ca2+ mobilisation through IP3Rs and RyRs (Zalk et 
al., 2007). Therefore, cytosolic calcium serves to enhance IP3R-and RyR-
mediated signals. However, upon reaching a threshold concentration, 
cytosolic calcium then inhibits subsequent ER calcium release by negative 
feedback (Stutzmann, 2007). This prevents an increase in cytosolic Ca2+ 
levels above a threshold which could lead to neurotoxic effects (Friel & 
Tsien, 1992). 
Although it is possible to activate IP3Rs and RyRs independently of 
each another, as demonstrated in cultured hippocampal and sensory 
neurons where receptor-stimulated- and IP3-mediated Ca2+ mobilisation was 
independent of caffeine -sensitive (i.e. RyR-mediated) Ca2+ release (Murphy 
and Miller, 1989; Thayer et al., 1988), there is evidence that both channels 
can indirectly regulate each other’s activity. This is primarily due to the fact 
that both channels are sensitive to cytoplasmic and luminal (ER) Ca2+ 
(Burdakov et al., 2005; Györke and Terentyev, 2008; Missiaen et al., 1994). 
Thus, by altering ER and cytoplasmic Ca2+ levels it is possible to create an 
excitable system whereby signals can spread throughout a cell (Berridge, 
2002) 
In support of this, cerebellar granule neurons exhibit characteristics of 
a shared Ca2+ pool, as pre-application of RyR agonists significantly reduces 
carbachol- and IP3R-mediated Ca2+ release and vice versa (Irving et al., 





RyRs access the same ER Ca2+ pool, however, is unclear, although the 
confluence or demarcation into microdomains of such Ca2+ pools could 
represent a mechanism of signal regulation in a cell type and/or intracellular 
localisation dependent manner (Berridge, 2006; Laude and Simpson, 2009). 
Notably, both of these channel types are thought to also contribute to Ca2+ 
leak currents from the ER in both health and disease (Suzuki et al., 2012; 
Szlufcik et al., 2006). 
[Ca2+]cyt can increase up to 1-5µM in response to agonist stimulation 
through the mechanisms outlined above. However, it is important to bear in 
mind that any evoked calcium increase triggers distinct spatiotemporal 
patterns of cytosolic Ca2+ release/accumulation depending on the initial 
source of Ca2+. These patterns, in turn, can also result in different Ca2+-
dependent signalling cascades being activated (Supnet & Bezprozvanny, 
2010). Due to the extensive and complex role of Ca2+ signalling in neurons, 
even minor alterations in the Ca2+ signalling apparatus could potentially have 
significant deleterious consequences at both a cellular and systems level 
over the lifetime of a cell or individual. Indeed, subtle intracellular calcium 
dysregulation has been linked to the pathogenesis of numerous proposed 
‘calciumopathies’ including AD, Parkinson’s disease (PD) and Huntington’s 








1.4 The calcium hypothesis of Alzheimer’s disease 
The central tenet of the calcium hypothesis of AD is that remodelling 
of the Ca2+ signalling system, resulting in increased basal Ca2+ levels, is 
caused by, or precedes, excessive stimulation of the amyloidogenic APP 
processing pathway. This results in early-stage disease phenotypes 
including oxidative stress, mitochondrial impairment, synaptic dysfunction, 
cognitive deficits and, ultimately, widespread neuronal cell death which 
characterises the later stages of AD (Berridge, 2010; Bezprozvanny and 
Mattson, 2008; Deshpande et al., 2006; Glabe and Kayed, 2006; Kelly and 
Ferreira, 2006; Stutzmann, 2007; Townsend et al., 2006). Importantly, it is 
thought that these phenotypic changes can be induced by small fluctuations 
in normal intracellular and/or luminal Ca2+ levels over the lifetime of a 
neuron, as was postulated for ageing and neurodegeneration, in general, 
several years previously by Khachaturian (Khachaturian, 1989).  
Ca2+ is a key factor in cytotoxicity (Kass and Orrenius, 1999) and Ca2+ 
dysregulation is seen in neurons from both human AD patients and AD 
animal models (LaFerla, 2002; Stutzmann and Mattson, 2011), as well as 
with ageing (Gant et al., 2014). The sheer number of components of the 
calcium signalling system altered in AD is staggering (Fig 1.4), as reviewed 
by Yu et al. (2009) with more recent findings reviewed by The Alzheimer's 
Association Calcium Hypothesis Workgroup (2017). The following section 
aims to provide the reader with an overview of some of these alterations, 
such as dysregulation of basal [Ca2+]i as well as Ca2+ influx and intracellular 
mobilisation, which have particular relevance to the work conducted over the 
course of this project. Such changes impact severely upon several critical 
cellular systems including mitochondria and synapses (Berridge, 2010; 
Bezprozvanny and Mattson, 2008; Smith et al., 2005; Thibault et al., 2007).  
Significantly, several studies in animal models of AD suggest that 
disruption of normal Ca2+ homeostasis occurs well in advance of any 
behavioural or synaptic deficits (Chakroborty et al., 2009; Jacobsen et al., 
2006; Oddo et al., 2003a; Smith et al., 2005; Vale et al., 2010) and/or Aβ or 
tau aggregation (Chakroborty et al., 2009; Chakroborty and Stutzmann, 
2014; Del Prete et al., 2014; Popugaeva et al., 2012; Stiller et al., 2014; 
Stutzmann et al., 2004; Zhang et al., 2010). The possibility exists therefore 
that the cognitive deficits seen in AD patients are, in fact, a result of early 
onset, chronic and insidious neurotoxic processes involving Ca2+ 
dyshomeostasis that occurs before any functional loss or amyloidogenic 
processes became apparent (Stutzmann, 2007). This calcium hypothesis is 
gaining credence within a field where scepticism continues to grow around 
the proposal that amyloid plaques are solely to blame for the pathological 






1.4.1 Remodelling of basal calcium levels 
It is known from ageing studies that decreased serum calcium levels 
correlate well with the level and rate of cognitive decline during ageing 
(Schram et al., 2007). Therefore, it is interesting to note that, AD patients 
also exhibit altered systemic calcium homeostasis in terms of decreased 
serum Ca2+ and increased urinary Ca2+ excretion, relative to age-matched 
controls (Landfield et al., 1992; Ogihara et al., 1990). Furthermore, 
alterations in the levels of proteins and genes which are directly involved in 
neuronal Ca2+ signalling are commonly observed in brain tissue samples 
from AD patients and animal models of AD (Bezprozvanny and Mattson, 
2008; Chin et al., 2007; Emilsson et al., 2006; Iritani et al., 2001; Landfield et 
al., 1992; Ogihara et al., 1990; Stutzmann, 2007). For instance, overall levels 
of both IP3 and PLC, as well as protein kinase C (PKC; important in synaptic 
plasticity and activated by calcium-dependent pathways) activation, are 
decreased relative to the degree of AD progression in the human brain 
(Kurumatani et al., 1998). 
Although there have been relatively few studies examining Ca2+ 
homeostasis in tissues and fluids from human AD patients, one study has 
shown that lymphocytes from LOAD patients did exhibit higher basal [Ca2+]i 
concentrations and an enhanced Ca2+ response to lymphocyte activation 
than controls (Sulger et al., 1999). Similarly, lymphocytes from PS1M146L mice 
also exhibited increased basal [Ca2+]i and larger Ca2+ responses to 
lymphocyte activation, as well as increased sensitivity to Ca2+- and ROS-
mediated apoptosis (Eckert et al., 2001; Mattson, 2002). Furthermore, 
double PS KO (DKO) or PS2 KO mouse embryonic fibroblasts (MEF) 
displayed increased basal [Ca2+]i. Interestingly, however, MEFs from PS1 KO 
mice only displayed modest [Ca2+]i changes relative to controls (Green et al., 
2008). In vivo studies measuring Ca2+ levels in spines and dendrites of 
pyramidal neurons from the neocortex of mature APPswe/PS1ΔE9 and 
APPSWE mice (4.5 – 5 and >17 months of age, respectively), found that 
approximately 22% of neurites located near amyloid plaques had increased 
resting [Ca2+]i above a pathological threshold. This apparently resulted in 
structural and functional neuronal network dysfunction in these animals. 
However, only about 5% of neurites from either wild-type, single transgenic 
PS1∆E9, PS1M146V and young (4.5 – 5 months of age) APPSWE mice exhibited 
similar signs of Ca2+ overload (Kuchibhotla et al., 2008), suggesting that this 
phenomenon in mice is dependent upon APP mutations and is a late, rather 
than early, stage disease effect, correlating with the appearance of plaques 
at this stage. In contrast, cultured cortical neurons from 3xTg-AD and 
APPSWE mice (8 – 12 months of age), which did not exhibit Aβ plaques but 
did have chronically elevated intracellular Aβ levels (specifically, Aβ trimers 





controls and was found to rely on both Ca2+ entry and ER mobilisation 
(Lopez et al., 2008). 
It is important to note that most of the evidence for increases in basal 
neuronal [Ca2+]i in AD comes, in fact, from indirect observations of altered 
Ca2+ transients due to Ca2+ influx or ER Ca2+ mobilisation as exemplified by 
the following data. Firstly, the PS1∆E9 mutation is associated with increased 
basal [Ca2+]i and enhanced basal phosphoinositide (PI) hydrolysis in cultured 
human SH-SY5Y neuroblastoma cells. These effects can be reversed by the 
PLC inhibitor neomycin and the IP3R inhibitor xestospongin C (Cedazo-
Mínguez et al., 2002). Secondly, in PC12 neurosecretory cells, expression of 
the human PS1L286V mutation increased their susceptibility to apoptosis 
induced by trophic factor withdrawal and synthetic Aβ25–35 (Guo et al., 1998). 
These apoptotic stimuli resulted in an oxidative stress response and 
increased [Ca2+]i levels which were much greater in PS1L286V cells than 
controls. The authors proposed that this insult was superimposed upon 
already increased basal [Ca2+]i, a suggestion that was supported by the 
finding that the SERCA pump inhibitor, thapsigargin (TPN; Lytton et al., 
1991), evoked larger elevations in [Ca2+]i in PS1L286V PC12 cells relative to 
controls, indicating that they possessed higher [Ca2+]ER (Guo et al., 1998). 
Thirdly, this Ca2+ perturbation in PC12 cells could be counteracted by 
blocking either Ca2+ influx (e.g. through VGCCs) or ER Ca2+ mobilisation 
(e.g. by blocking IP3Rs and/or RyRs, or increasing the expression of the 
constitutive IP3R modulator, Bcl-2; Guo et al., 1997, 1996). Lastly, cells from 
a neuronal cell line (CTb) derived from the cerebral cortex of APP-
overexpressing mice exhibited increased [Ca2+]i, and decay kinetics of the 
Ca2+ responses to glutamatergic and nAChR agonists, and depolarization 
(Rojas et al., 2008). These cells also displayed increased responses to the 
calcium ionophore, ionomycin (Dedkova et al., 2000; Liu and Hermann, 
1978), which causes the release of Ca2+ from most intracellular stores (into 
the cytosol) thereby indicating that the ER of these cells was overloaded 
relative to control cells (Green et al., 2008). Significantly, all of the effects 
listed previously were normalised by APP knockdown (KD) in these cTb cells 
(Rojas et al., 2008). 
Aβo are thought to increase basal [Ca2+]i via increased Ca2+ entry and 
ER mobilisation (as discussed in Section 1.3.3 Molecular actions of Aβo and 
related metabolites; Hartmann et al., 1993; Mattson et al., 1993a, 1993b, 
1992). For example, human foetal cerebral cortical cell cultures exhibited 
increased [Ca2+]i levels and an increased vulnerability to neurotoxicity 
following exposure to synthetic Aβ peptides. Conversely, chronic exposure of 
the cell to elevated [Ca2+]i levels, in turn, enhances Aβ production (Buxbaum 





These increases in [Ca2+]i likely reflect an AD-mediated enhancement 
of Ca2+ entry and impaired ER calcium release as well as the impaired 
buffering capacity of both the ER and mitochondria. The ER and 
mitochondria may either be directly impaired by Ca2+ overload or indirectly 
impaired by ROS and mitochondrial collapse, mediated by Ca2+ 
dysregulation and/or other AD-related processes (Yu et al., 2009).  
 
1.4.2 Enhanced calcium entry 
Role of Aβ oligomers 
There is a large body of evidence suggesting that APP mutations, 
including APPSWE, in single as well as multi-transgenic animal models (e.g. 
3xTg-AD mice; Lopez et al., 2008), APPSWE overexpression (Lopez et al., 
2008; Niu et al., 2009; Rojas et al., 2008), and Aβ42 aggregates, can all 
induce calcium dysregulation by, generally, enhancing Ca2+ entry and 
increasing [Ca2+]i (Arispe et al., 1993a, 1993b; Bezprozvanny and Mattson, 
2008; Demuro et al., 2010, 2005; Deshpande et al., 2006; Green and 
LaFerla, 2008; Hirakura et al., 1999; Kuchibhotla et al., 2008; Mirzabekov et 
al., 1996; Shirwany et al., 2007; Simakova and Arispe, 2007; Walsh et al., 
2002). However, the mechanism(s) underlying Aβ-mediated Ca2+ 
dysregulation remains unclear, although numerous potential mechanisms, 
including Ca2+ entry via PtdS and/or PrPc-dependent pore formation, PM 
receptor modulation and impaired Ca2+ extrusion due to PM transporter 
impairment, are postulated. This evidence is discussed in more detail in 
Section 1.3.3 Molecular actions of Aβo and related metabolites). 
CALHM1 
CALHM1 is a Ca2+ selective pore subunit of a non-selective PM 
channel which can also localise to the ER (Gallego-Sandín et al., 2011). It is 
of interest here because mutations of this protein have been associated with 
EOAD (Rubio-Moscardo et al., 2013) and LOAD (Dreses-Werringloer et al., 
2008; Lambert et al., 2010), although the latter finding is controversial 
(Beecham et al., 2009; Bertram et al., 2008; Minster et al., 2009). CALHM1 is 
expressed in neurons in all brain regions, with the highest concentrations 
being observed in the hippocampus and temporal lobes (Dreses-Werringloer 
et al., 2008; Rubio-Moscardo et al., 2013). In terms of its mechanism of 
action, CALHM1 is allosterically regulated by both membrane voltage and 
extracellular Ca2+ concentration (Dreses-Werringloer et al., 2008; Ma et al., 
2012; Moreno-Ortega et al., 2015). Indeed, CALHM1 is essential for 
controlling extracellular Ca2+-dependent excitability in primary cultured 
cortical neurons (E15) and may interact with IP3Rs in so doing (Ma et al., 
2012; Moreno-Ortega et al., 2011). Specifically, it is activated when 





frequency synaptic activity (Benninger et al., 1980; Vassilev et al., 1997). In 
CALHM1-expressing N2A cells (mouse neuroblastoma cell line), SH-SY5Y 
and HeLa cells, as well as embryonic cortical neurons (Dreses-Werringloer 
et al., 2008; Ma et al., 2012; Moreno-Ortega et al., 2015), when Ca2+ was 
subsequently re-introduced, there was a significant Ca2+ influx through 
CALHM1. This so-called ‘Ca2+ paradox’ (MacDonald et al., 2006) is observed 
in cells of the heart and neurons of the hippocampus where decreased 
[Ca2+]o leads to increased [Ca2+]i, particularly when [Ca2+]o is returned to 
normal levels, which in turn often leads to toxic insult (Deshpande et al., 
2007; Zimmerman and Hülsmann, 1966).  
Notably, a single nucleotide polymorphism in CALHM1 (CALHM1P86L), 
which has been associated with an increased risk of developing LOAD, 
decreased PM Ca2+ permeability in CHO cells and decreased [Ca2+]i in HT-
22 cells (Dreses-Werringloer et al., 2008). Furthermore, CALHM knock-down 
and CALHM1P86L transfection triggered an increase in amyloidogenic APP 
metabolism and Aβ40 and Aβ42 secretion in SH-SY5Y cells and APP695 
expressing N2a cells, respectively (Dreses-Werringloer et al., 2008). Rubio-
Moscardo et al. (2013) also found that Ca2+ entry was abolished by two 
CALHM1 mutations associated with EOAD (CALHM1G330D and 
CALHM1R154H) and diminished in CALHM1P86L -transfected HEK 293 cells 
relative to WT CALHM1. However, they did not witness any alterations in 
APP metabolism resulting from the CALHM1 mutations (Rubio-Moscardo et 
al., 2013). 
However, in spite of the evidence above implicating CALHM1P86L in 
various forms of calcium dysregulation, it remains a considerable point of 
debate as to whether (Boada et al., 2010; Dreses-Werringloer et al., 2008; 
Lambert et al., 2010; Li et al., 2008) or not CALHM1P86L on its own is a 
significant risk fact for LOAD (Beecham et al., 2009; Bertram et al., 2008; 
Lambert et al., 2010; Minster et al., 2009; Sleegers et al., 2009). Rather, it 
appears to reduce the age of LOAD onset by interacting with the effect of the 
ε4 allele of the ApoE gene on A metabolism (Lambert et al., 2010). 
Store-operated calcium entry (SOCE) 
SOCE, the process of ER Ca2+ refilling, which is triggered by the 
intraluminal depletion of Ca2+ (Berridge 2002), is also significantly disrupted 
in AD and will be discussed in more detail in following sections related to ER 
calcium remodelling and synaptic dysfunction. However, given the fact that 
SOCE is not just involved in replenishing ER Ca2+ levels but may also play a 
role in the regulation of the ER/cytoplasmic Ca2+ gradient (Brandman et al., 
2007), alterations in SOCE could have important implications for overall 





1.4.3 ER remodelling 
AD-associated Ca2+ remodelling at the level of the ER has important 
effects on both neuronal/cellular Ca2+ homeostasis and associated Ca2+ 
signalling systems, disrupting physiological signalling cascades as well as 
hijacking others to upregulate a variety of pathogenic processes. 
ER overload 
The steady-state level of Ca2+ within the ER, which will also reflect 
[Ca2+]cyto, results from the balance between the passive leak of calcium 
through PS, IP3Rs and RyRs (and potentially CALHM1), and the activity of 
SERCA pumps (Bandara et al., 2013; Das et al., 2012; Tu et al., 2006). 
However, enhanced [Ca2+]ER (relative to controls) has been observed in 
several different cell types expressing PS mutations, such as T-lymphocytes 
(PS1M146L and 5xTg-PS1 - M146L, H163R, A246E, L286V, C410Y; Eckert 
et al., 2001), fibroblasts (PS1M146V; Leissring et al., 2000) oocytes 
(PS1M146L, PS2NI121I and PS2M239V; Leissring et al., 1999a, 1999b), 
HEK293 cells, neurosecretory PC12 cells (PS1M146L, PS1M146V & 
PS1L286V; Chan et al., 2000; Guo et al., 1996) and cultured hippocampal 
neurons (PS1M146V; Chan et al., 2000). This increased [Ca2+]ER also reflects 
the broader dyshomeostasis of the intracellular environment and increased 
[Ca2+]cyto due to AD-dependent processes (Berridge, 2010; Mattson, 2002). 
The leading hypothesis concerning elevated [Ca2+]ER posits that dysfunction 
in the ability of PS1 and 2 to act as Ca2+ leak channels, due to AD-
associated mutations, causes an increase in luminal Ca2+ (Bezprozvanny 
and Mattson, 2008; Nelson et al., 2007; Tu et al., 2006; Zhang et al., 2010). 
However, the ability of PSs to form leak channels is still a contentious topic in 
the field (Bezprozvanny et al., 2012; Shilling et al., 2012). This is despite the 
fact that PSs (both PS1 and PS2) can function as low conductance, passive 
Ca2+ leak channels in planar lipid bilayers (Tu et al., 2006) and serve to 
counteract the activity of the SERCA pump (Green et al., 2008). This function 
is supported by channel structure studies, which suggest that a PS 
holoprotein structure, in particular, can allow for the movement of Ca2+ (Li et 
al., 2012; Nelson et al., 2011).  
Functional evidence in favour PSs playing a role in ER leak includes 
the fact that HEK293 cells overexpressing non-mutated PS1 have decreased 
ER Ca2+ release in response to IP3R activation relative to untreated cells 
(Honarnejad et al., 2013). Furthermore, PS2 overexpression in HEK293 cells 
decreased ER Ca2+ load relative to PS null cells (Bandara et al., 2013). 
Conversely, PS1 KO (hippocampal neurons; Herms et al., 2003), PS2 KD 
(HEK293 cells; Bandara et al., 2013) and PS DKO (cultured hippocampal 
neurons and MEFs; Zhang et al., 2010 and Nelson et al., 2006, 2010; Tu et 
al., 2006, respectively) increased [Ca2+]ER and mobilisation. Furthermore, 





of AD-associated PS mutation (e.g. ‘gain-of-leak’ vs ‘loss-of-leak’ function; 
Zhang et al., 2010). Notably, utilising PS DKO MEFs, Tu et al. (2006) 
revealed that PSs account for approximately 80% of the passive leak from 
the ER, which was independent of any γ-secretase activity (Tu et al., 2006). 
The majority of evidence for the role of PSs in mediating an ER leak 
function has been determined by measuring ER calcium release in cells 
either transfected with various PS mutations or cells from transgenic animals 
which constitutively expressed selected PS mutations. Of particular 
relevance to this thesis, increased [Ca2+]ER (as determined by robustly 
increased ionomycin responses) was measured in cultured hippocampal 
neurons from various genotypes of transgenic mice, including 3xTg-AD mice 
(which expresses the PS1M146V mutation) and PS1L166P - and PS1D385A- 
transfected hippocampal neurons, relative to controls (Zhang et al., 2010). 
Importantly, in the context of the TgF344-AD rat model which was also used 
in the current study, the PS1∆E9 mutation was associated with a ‘gain of leak 
function’ and decreased [Ca2+]ER relative to WT (Zhang et al., 2010). In 
human lymphoblast cells from FAD patients, those cells which expressed 
either PS1-M139V (in agreement with Zhang et al., 2010), M146L, K239E, 
V261F, A431E or PS2-N141I, all displayed increased [Ca2+]ER (Nelson et al., 
2010). Conversely, in cells transfected with either PS1- ΔE9, P264L, R269G, 
C410Y or A426P mutations, no differences in [Ca2+]ER relative to controls 
were observed (Nelson et al., 2010). 
Although the calcium ionophore ionomycin is a commonly used tool to 
indirectly determine ER calcium levels, it should be borne in mind that it also 
initiates the release of Ca2+ from all other intracellular organelles, which is an 
effect that effectively ‘contaminates’ the desired measurement. However, 
experiments described in the previous section which utilised ionomycin to 
determine intracellular store content were confirmed by Zhang et al. (2010) 
using the ER-targeted Ca2+ indicator D1ER (for review see McCombs and 
Palmer, 2008). A 3-fold increase in the levels of [Ca2+]ER in transgenic 
cultured hippocampal neurons, relative to controls, was determined using 
this method. Interestingly, in the same study (Zhang et al., 2010), when TPN 
was added to control and 3xTg-AD neurons (in Ca2+ free extracellular 
medium), following ER Ca2+ loading, the ER Ca2+ levels of both cell types fell 
to their respective basal levels (which were higher in 3xTg-AD mice). 
Significantly, however, it took over three times longer for the 3xTg-AD 
neurons to reach baseline compared to the control neurons, indicating the 
presence of an intact, but severely impaired, leak pathway in the transgenic 
neurons.  
PEN-2, which is a key regulatory component of the γ-secretase 
complex (Haass, 2004), may have a role in regulating PS-mediated Ca2+ 





(Bandara et al., 2013; Edbauer et al., 2003; Kimberly et al., 2003; Takasugi 
et al., 2003). Specifically, PEN-2 KD resulted in decreased PS 
endoproteolysis leading to its stabilisation and the accumulation of a 
holoprotein form of PS (Honarnejad et al., 2013; Takasugi et al., 2003; Xie et 
al., 2005). This holoprotein form appears to be responsible for PS-attributed 
ER Ca2+ leak (Tu et al., 2006) and is upregulated in human AD brain 
samples (Honarnejad et al., 2013), possibly as a compensatory mechanism 
for increased [Ca2+]ER (Popugaeva and Bezprozvanny, 2013). In support of 
this finding, PEN-2 KD increased ER Ca2+ leak rate and attenuated Ca2+ 
mobilisation following stimulation by bradykinin, TPN and carbachol in 
HEK293 cells (Bandara et al., 2013; Honarnejad et al., 2013).  
The role of PSs as leak channels is also indirectly supported by the 
observation that SOCE is attenuated in fibroblasts, SH-SY5Y and CHO cells 
expressing PS1M146V and PS1M146L, in embryonic cortical cultures expressing 
PS2N131I (Leissring et al., 2000; Yoo et al., 2000) and in 3xTg-AD and PS 
DKO mouse hippocampal neurons, in comparison to WT controls (Zhang et 
al., 2010). Such an effect makes intuitive sense as SOCE is normally 
stimulated by low ER calcium, but if the ER is overloaded with Ca2+, as 
occurs in cells/neurons derived from transgenic animals with ER leak-
inhibiting PS mutations (as described previously), relative to wild-type 
controls, then the stimulus for SOCE initiation will either be blocked or 
attenuated. This SOCE disruption also stimulates Aβ42 generation, whereas 
SOCE disruption itself is not due to Aβ-mediated effects (Herms et al., 2003; 
Leissring et al., 2000; Yoo et al., 2000). Notably, the contribution of the PS-
mediated leak to ER Ca2+ homeostasis appears to be a brain region-
dependent phenomenon as, in contrast to hippocampal neurons, ER store 
levels were unaffected by AD-associated PS1 mutations in striatal neurons 
(Zhang et al., 2010). 
Interestingly, although most researchers point to a loss of PS leak 
function as the primary factor underlying chronic increases in [Ca2+]ER due to 
PS mutations, in Xenopus oocytes the PS1M146V mutation seems to mediate 
a similar [Ca2+]ER increase via an enhancement of SERCA2b-mediated 
sequestration of cytosolic Ca2+ (Green et al., 2008). Specifically, PS1 and 
PS2 co-localise with SERCA in MEFs and PS1 or PS2 overexpression 
enhance cytosolic Ca2+ clearance (Green et al., 2008). Conversely, PS null 
fibroblasts and oocytes exhibit attenuated SERCA activity despite increased 
SERCA2b steady-state levels (SERCA2b is the SERCA isoform expressed 
in neurons; Green et al., 2008).  
It is also important to note that in contrast to the studies outlined 
previously, other studies have shown that PS DKO (or PS-null MEF and B-
cells; Leissring et al., 2002; Shilling et al., 2012; Kasri et al., 2006), PS1 KO 





seem to have decreased ER store content, including decreased TPN- and 
ionomycin-induced Ca2+ signals (Green et al., 2008). This suggests that 
SERCA filling of the ER is impaired without the normal PS regulatory input, 
resulting in an increased [Ca2+]cyt relative to controls (Green et al., 2008). 
Furthermore, FAD-PS mutations (PS2M239I - Zatti et al., 2004; PS2T122R – 
human FAD fibroblasts - Giacomello et al., 2005) also resulted in lower 
[Ca2+]ER. A noteworthy and extensive study in this regard by Zatti et al. 
(2006) utilised numerous cell models to determine the effect of PSs [Ca2+]ER 
content in human fibroblasts from controls and FAD patients as well as cell 
lines (SH-SY5Y, HeLa, HEK293, MEFs) and rat primary neurons expressing 
a number of PS mutations, i.e. P117L, M146L, L286V, and A246E in PS1 
and M239I, T122R, and N141I in PS2. Importantly, independent of the cell 
model used, agonist-stimulated Ca2+ mobilisation was either unchanged (in 
the case of PS1L286V solely), or reduced in cells expressing these PS 
mutations. ER Ca2+ content was also reduced in cells expressing PS2 
(M239I, T122R, N141I, D366A) and modestly reduced or unchanged in cells 
expressing PS1 (P117L, M146L, L286V, A246E; Zatti et al., 2006). 
Taken together then, these observations suggest that ER calcium 
dysregulation cannot be the sole explanation for the effects of all FAD PS1 
mutations. Other possible mechanisms may include the modulation of γ-
secretase and caspase activities which would have numerous important 
effects on intracellular homeostasis, including on APP metabolism and cell 
death pathway stimulation (Miyoshi et al., 2009; Shen et al., 2007; Xia et al., 
2015b).  
Alterations in receptor function 
Enhanced ER-mediated Ca2+ release has been widely reported in 
cellular systems expressing mutant PS (Cedazo-Mínguez et al., 2002; Chan 
et al., 2000; Cheung et al., 2008; Guo et al., 1996; Johnston et al., 2006; 
Leissring et al., 2001, 1999a, 1999b), transgenic AD mouse models (Barrow 
et al., 2000; Guo et al., 1996; Leissring et al., 2000; Mattson et al., 2000; 
Schneider et al., 2001; Stutzmann et al., 2006, 2004; Supnet et al., 2006; 
Supnet and Bezprozvanny, 2010) and cells from human FAD patients 
(Etcheberrigaray et al., 1998; Hirashima et al., 1996; Ito et al., 1994), which I 
will discuss in more detail below. 
IP3Rs  
 There is significant evidence, from the utilisation of murine- and 
human-derived cells as well as in vitro brain slices, to support a connection 
between PS mutation and enhanced IP3R activity. For example, fibroblasts 
from PS1 M146V mice and from FAD patients, as well as Xenopus oocytes 
expressing PS1 and PS2 mutant constructs, all had upregulated IP3R Ca2+ 





PS1M146L and PS2N141I mutations expressed in cultured non-neuronal DT-40 
(chicken B cell line) and Sf9 (insect cell line) cells (Cheung et al., 2008; 
Müller et al., 2011), cultured FAD patient B cells and cortical neurons from 
3xTg-AD and PS1M146L mice (Cheung et al., 2010, 2008) all exhibited 
increased IP3R open-probability, resulting in the generation of ROS (Müller et 
al., 2011). Ex vivo cortical brain slices from PS1M146V and 3xTg-AD mice also 
exhibited increase IP3R-stimulated Ca2+ mobilisation, accompanied by an 
increase in membrane Ca2+-evoked K+ conductance. This, in turn, decreased 
overall membrane excitability (Stutzmann et al., 2006, 2004). However, it is 
interesting to note that between 6 and 18 months of age, the enhanced 
transgenic IP3R-mediated responses observed at 6 weeks, progressively 
decrease (Stutzmann et al., 2006), possibly due to as-yet-unknown 
compensatory mechanisms. 
Somewhat surprisingly, the aforementioned increase in IP3R activity 
observed in transgenic AD models does not seem to be mediated by a 
significant increase in IP3R expression in either early or late stage transgenic 
AD animal models (Schneider et al., 2001; Stutzmann et al., 2006, 2004; 
Zhang et al., 2010). Furthermore, IP3R-mediated responses elicited by 
GPCRs are enhanced by certain PS1 mutations (Müller et al., 2011; Shilling 
et al., 2014). This has been confirmed in ex vivo brain slice pyramidal 
neurons from several AD mouse models and in fibroblasts from AD patients 
(Leissring et al., 2000; Stutzmann et al., 2006). This may be due to a PS1-
mediated increase in basal PLC (Abdul-Ghani et al., 1996; Hannan et al., 
2001) and [Ca2+]i, as has been determined in human SH-SY5Y 
neuroblastoma cells expressing the PS1∆E9 mutation (Cedazo-Mínguez et al., 
2002).  
IP3R activation specifically represents a convergence point for the 
Ca2+ and Aβ hypotheses as well as cell death pathways. This is because not 
only can the Aβ cascade influence IP3R-mediated ER Ca2+ mobilisation via 
Aβ42 enhancement of IP3 production, and subsequent Ca2+ liberation 
(Demuro and Parker, 2013), but apoptotic pathways which activate caspase-
3 can also evoke CTF cleavage of PS2 to form PS2-“loop peptide”, which 
activates IP3R and results in pathological ER Ca2+ mobilisation in NRP-154 
cells (rat prostate adenocarcinoma; Cai et al., 2006). Furthermore, AD-
mediated alterations in the Ca2+-sensitive receptor (CaR) also appear to be 
mediated by IP3Rs.  
Role of the CaR 
CaRs are Gq-protein coupled, transmembrane receptors which 
respond to, and regulate serum Ca2+ levels which may influence localised 
Ca2+ regulation in the brain (Conley et al., 2009; Kos et al., 2003). At a 
cellular level, CaRs are activated by high extracellular [Ca2+] and modulate 





specific manner (D’Souza-Li, 2006). This Gq-mediated PLC activation can be 
inhibited by the regulator of G-protein signalling 4 (RGS4; Xu et al., 1999).  
Interestingly, not only is there evidence for a mutation in the gene 
encoding CaR, being involved in human AD development (Conley et al., 
2009) but in vitro receptor activation studies have also shown that Aβ and 
ApoE can both modulate CaR function (Conley et al., 2009). Specifically, Aβ 
directly stimulates CaR on HEK293 cells (Ye et al., 1997), Cos-1 cells 
(Conley et al. 2009), cultured hippocampal neurons (Ye et al., 1997) and 
cortical astrocytes (Armato et al., 2013), which resulted in increased IP3 
levels and Ca2+ mobilisation. Importantly, RGS4 levels are decreased in 
human AD brains, which may reveal a mechanism for exacerbated IP3R 
signalling in the human condition (Emilsson et al., 2006). 
RyRs 
The RyR is also heavily implicated in mediating calcium dysregulation 
in AD, with several studies demonstrating enhanced activity and expression 
in transgenic models of AD, including 3xTg-AD and PS1M146V mice 
(Chakroborty et al., 2009; Chan et al., 2000; Guo et al., 1999; Smith et al., 
2005; Stutzmann et al., 2006; Zhang et al., 2010). Specifically, RyR activity is 
increased 2-3-fold in the soma and 10-fold in the dendrites and spines of 
cortical pyramidal neurons from young (4 – 6 week-old) transgenic models, 
including pre-symptomatic APPSWE/PS1 M146V and 3xTg-AD mice (Goussakov 
et al., 2010). Moreover, RyR-mediated Ca2+ responses were increased 
approximately 4-fold in 3xTg-AD hippocampal cultures and PS DKO 
hippocampal cultures (P0 – P1, DIV12 – 13). This suggests that either the 
PS1M146V mutation is a loss-of-function mutation (at least in terms of its 
interaction with RyRs) or that this mutation enhances RyR-mediated ER Ca2+ 
release by a separate mechanism to that resulting from DKO/loss-of-function 
mutation. Notably, in DKO neurons, the enhanced RyR signalling could be 
rescued by transfection with PS1, only when its functioning leak ability was 
intact (i.e. not by ‘loss-of-function’ leak mutant PSs such as PS1M146V) and 
the effect was not dependent on γ-secretase activity (Zhang et al., 2010). 
This study is of particular relevance to a major theme of this thesis 
investigating ER Ca2+ dynamics in young murine models of AD (Chapter 3 
and 4; P2 – 6; 2 – 20 DIV).  
RyR sensitivity to both caffeine and cytosolic Ca2+ (which can, under 
certain circumstances, induce CICR (Kong et al., 2008) is also enhanced in 
animal models expressing either single PS, APP and/or multiple AD-related 
mutations (Chakroborty et al., 2009; Chakroborty and Stutzmann, 2014; Del 
Prete et al., 2014; Hayrapetyan et al., 2008; Rybalchenko et al., 2008; Smith 
et al., 2005), possibly due to either increased ER Ca2+ loading (Koizumi et 
al., 1999; Shmigol et al., 1996) and/or PS or Aβ42-mediated increases in RyR 





RyR channel open probability and single-channel currents (Rybalchenko et 
al., 2008), whereas PS2 appears to reduce feedback inhibition of RyR2 
(Hayrapetyan et al., 2008; Payne et al., 2015).  
Increased RyR expression, particularly of the RyR2 and RyR3 
isoforms, which has been demonstrated across various models and studies 
of AD, such as pre-symptomatic or early disease stage mice - where RyR2 
was upregulated 2-5-fold (Chakroborty et al., 2009; Kelliher et al., 1999; 
Oules et al., 2012; Stutzmann et al., 2006; Zhang et al., 2010), late-stage 
murine models – where RyR3 was upregulated (Supnet et al., 2006), and in 
human AD patients and those with mild cognitive impairment (MCI), which 
displayed loss of synapses relative to age-matched controls (Bruno et al., 
2011; Kelliher et al., 1999). Not surprisingly, increased RyR expression 
enhances overall RyR activity and evokes a concomitant increase in ER Ca2+ 
release (Chan et al., 2000; Smith et al., 2005; Supnet et al., 2006). Such 
RyR upregulation may be due to the amyloidogenic production of the 
transcription factor AICD, which both stimulates RyR expression and may be 
enhanced by PS mutation (LaFerla, 2002; Leissring et al., 2002; Oules et al., 
2012). Furthermore, PS KO and/or inhibition of γ-secretase activity, which 
both inhibit AICD production (Alves da Costa et al., 2006; Zhang et al., 
2007), decrease ER Ca2+ mobilisation. 
Aβo may also play a role in RyR upregulation, as the application of 
Aβ42 to wild-type cortical neuronal cultures (E16) resulted in a 3.5-fold 
increase in RyR3 mRNA levels, but with no effect on either RyR2 or IP3R1 
expression (Supnet et al., 2006). Notably, Aβos and fibrillar Aβ (synthetic; 
Aβ42) promoted ER Ca2+ release through RyRs (and IP3Rs) and promoted 
ER stress, which resulted in glycogen synthase kinase-3 (GSK-3β)-mediated 
tau phosphorylation (Liu et al., 2003), and caspase-9-dependent apoptosis 
(Brewster et al., 2006) in cultured rat embryonic cortical neurons (Ferreiro et 
al., 2008; Resende et al., 2008). Similarly, in cultured rat embryonic 
hippocampal neurons, Aβos stimulated RyR-mediated Ca2+ mobilisation. 
This generated prolonged Ca2+ signals which induced mitochondrial 
fragmentation and attenuated BDNF/RyR-mediated dendritic spine 
remodelling (Paula-Lima et al., 2011). Critically, increased RyR- and IP3R- 
mediated Ca2+ mobilisation enhanced γ secretase-mediated formation of 
Aβ40, Aβ42, Aβo and increased Aβ42/Aβ40 ratio (Buxbaum et al., 1994; 
Cheung et al., 2008; Green et al., 2007; Pierrot et al., 2004; Querfurth et al., 
1997; Querfurth and Selkoe, 1994; Zhang et al., 2010; Zhao et al., 2010). In 
contrast to the aforementioned effects of AICD on RyR expression and 
observations from animal models of AD, RyR2 and RyR3 mRNA and RyR2 
protein expression were decreased 6 hours post-Aβo application, likely in a 
negative-feedback manner due to increased RyR-mediated signalling (Paula-





increased in hippocampal pyramidal neurons from APPSWE/PS1M146V mice 
(3–14 months of age) relative to control, this was independent of proximity to 
Aβ plaques (Briggs et al., 2013), suggesting that at this relatively later 
disease late stage, Aβ-mediated RyR modulation has peaked.  
It is also possible that the RyR upregulation, described above in 
response to ‘amyloidogenic’ stimuli and observed in animal models of AD 
may be an early compensatory mechanism to ER overload and synaptic 
deficits, including synaptic network depression (Chakroborty et al., 2012). 
Indeed, Zhang et al. (2010) showed that impaired PS-mediated ER Ca2+ leak 
resulted in increased [Ca2+]ER and RyR expression. Support for this 
suggestion lies in the fact that in cultured 3xTg-AD hippocampal neurons (0 - 
1-day-old; 12- 13 DIV), inhibition of RyRs for 6 days, either with dantrolene or 
receptor knockdown, prior to ER Ca2+ measurements, exacerbated the 
increase in [Ca2+]ER. Such an effect seems to illustrate that RyR upregulation 
and an increased RyR ‘leak’ current serves to compensate for increases in 
luminal Ca2+ (Zhang et al., 2010). A process known as store-overload-
induced Ca2+ release (SOICR), which occurs when the ER becomes 
pathologically loaded with Ca2+, may be responsible for this RyR leak ability. 
Thus, SOICR is proposed to hyper sensitise RyRs to release Ca2+ in 
response to resting levels of [Ca2+]cyt (Zhang et al., 2010). To date, however, 
SOICR has only been documented in cardiac cells (Jiang et al., 2004; 
MacLennan and Chen, 2009). 
However, compensatory or otherwise, there remains conflicting 
evidence as to whether or not the type of RyR upregulation discussed above 
in response to increased luminal Ca2+ is neuroprotective or actually 
exacerbates Ca2+ dyshomeostasis. For example, in addition to the 
normalisation of ER Ca2+ levels perturbed by impaired leak function 
mentioned above, long-term feeding of dantrolene to APPSWE/PS1L166P mice 
resulted in a 3-fold increase in amyloid load, loss of excitatory markers of 
synaptic transmission in the hippocampus and cortical and hippocampal 
neuronal atrophy, suggestive of a neuroprotective role for RyR currents 
(Zhang et al., 2010). Furthermore, the increased RyR expression exhibited in 
APPSWE/APPV717F cortical neurons was neuroprotective whereby despite 
increased Aβ deposition and RyR-mediated ER Ca2+ release, basal 
intracellular Ca2+ levels, depolarisation induced Ca2+ influx, SOCE and 
vulnerability to glutamate and H2O2-mediated stress were no different to 
control neurons. Significantly, these neuroprotective effects could be 
reversed by siRNA knockdown of RyR3 expression and culminated in the 
death of these neurons (Supnet et al., 2010). However, in complete contrast 
to the studies described above, glutamate-mediated toxicity in PS1M146V and 
3xTg-AD mouse hippocampal neurons was actually reduced by dantrolene 





A primary function of RyRs in AD is to amplify IP3-mediated ER Ca2+ 
release (Stutzmann et al., 2006). IP3-induced Ca2+ release in cortical 
neurons from non-transgenic mice was mediated predominantly through 
IP3Rs, with only a modest contribution from RyRs (Stutzmann et al., 2006). 
In cortical neurons from PS1M146V and 3xTg-AD mice, the relative 
contribution of the two channels seemed to be shifted such that RyRs (which 
were up-regulated in these transgenic mice) accounted for the exaggeration 
in IP3-induced Ca2+ release. Notably, mice expressing APPSWE and TauP301L 
mutations had no effect on the measured Ca2+ dynamics, suggesting that the 
PS1M146V mutation in the 3xTg-AD mice was the ‘calciopathic’ factor 
(Stutzmann et al., 2006). Therefore, any upregulation of RyR expression, for 
example through AICD production, RyR will amplify IP3-mediated signals, 
leading to globally enhanced ER Ca2+ mobilisation. In support of this idea, 
AICD can up-regulate IP3-mediated Ca2+ signalling (Leissring et al., 2002), 
whilst AICD itself is not associated with direct alterations in IP3R expression 
(Hamid et al., 2007). 
Taken together then, this evidence implies that the ER has the 
potential to be a devastating pathological environment, through a 
combination of Ca2+ overload and enhanced SERCA pump activity, disrupted 
leak function, increased IP3R and RyR channel sensitivity and expression, 
and altered SOCE signalling. Together, these phenomena would result in 
markedly increased ER Ca2 signals, calcium dyshomeostasis and increased 
Aβ production, providing an overwhelming feed-forward cycle. Increased 
basal cytosolic Ca2+ levels also enhance tau phosphorylation and 
aggregation (Hartigan & Johnson, 1999). This inhibits axonal transport and 
constitutes a significant toxic insult which contributes to AD-mediated 
neurodegeneration (Maccioni et al., 2010). 
Furthermore, this hypersensitive and exaggerated ER release network 
would likely result in improper coupling to many associated calcium signalling 
mechanisms including PM channels and their associated cascades. For 
instance, Ca2+ activated K+ channels and nitric oxide (NO) synthase are both 
activated via this type of ER remodelling (Bradley and Steinert, 2016; 
Chakroborty et al., 2015; Colton et al., 2006; Kakizawa et al., 2012; 
Nakamura and Lipton, 2011; Yuste et al., 2015). Under normal physiological 
conditions Ca2+ activated K+ channels are activated by calcium entry through 
L-type VGCCs and reduce membrane excitability (Chakroborty et al., 2012, 
2009; Stutzmann et al., 2006; Supnet and Bezprozvanny, 2010) whereas NO 
synthase is activated by NMDAR-mediated Ca2+ influx (Standaert, 1999) and 
modulates synaptic activity, excitotoxicity (Mehta et al., 2008; Moreno-López 
and González-Forero, 2006) and neuroprotection (Calabrese et al., 2007). 
No less important in terms of neuronal survival, Ca2+-dependent 





pathways, begin to induce neuronal cell death and modulate APP and tau 
function and metabolism in the presence of elevated neuronal Ca2+ (Lebart 
and Benyamin, 2006). They are also implicated in hippocampal and cerebral 
cortical impairments in AD (Yu et al., 2009). Numerous studies have 
illustrated the central role of calpain activation in mediating neuronal 
apoptosis (for review see Momeni, 2011; Vosler et al., 2008), all of which are 
supported by the finding that inhibition of calpains restores normal synaptic 
function in hippocampal cultures and slices from APP/PS1 mice (Trinchese 






1.5 Tau hypothesis of AD 
Although not a focus of the current thesis, for completeness sake it is 
necessary to discuss one of the other main theories underlying AD 
pathogenesis, the tau hypothesis. 
Neuronal microtubule-associated proteins (MAP) include tau 
(principally), MAP1 and MAP2. There are six tau isoforms, which exhibit 
expression profiles determined by their development in the human brain 
(Goedert et al., 1989) and which are coded for by a single gene on 
chromosome 17 (Himmler et al., 1989). Tau is a phosphoprotein which 
promotes tubulin assembly into microtubules and subsequently stabilises 
these structures (Weingarten et al., 1975). Microtubules are involved in the 
transport of nutrients, vesicles, mitochondria and chromosomes throughout 
the neuron and are necessary for the development and growth of stable 
neurites (Griffin, 2006).  
In AD, and other related neurodegenerative conditions termed 
‘tauopathies’, tau undergoes extensive post-translational modification 
processes such as hyperphosphorylation (Šimić et al., 2016) and acetylation 
(Tracy and Gan, 2017). This results in cytotoxic, self-assembling protein 
aggregates including oligomers and insoluble fibrils or NFTs. NFTs occur as 
paired helical filaments alone or combined with straight filaments which are, 
as mentioned previously, a principal neuropathological hallmark of AD (Iqbal 
et al., 2010; Noble et al., 2013). NFT formation and accumulation follow the 
predicted norms of brain regions affected in AD, i.e. formation occurs initially 
in layer II of the EC, from which emanates the performant pathway linking the 
hippocampus and cerebral cortex (Gómez-Isla et al., 1996). As the disease 
progresses, NFTs propagate throughout the limbic and associated cortices 
(Hyman and Trojanowski, 1997). Interestingly, a TauP301L mutation which 
was originally expressed in a fraction of layer II EC cells was transmitted 
along with tau pathology to other neuronal regions (de Calignon et al., 2012).  
Hyperphosphorylated tau and its accumulation are particularly evident 
within the somatodendritic compartments of AD models. This results in 
morphological alterations of the rough ER and Golgi within these regions 
(Liazoghli et al., 2005; Lin et al., 2003). Furthermore, tau accumulation as 
misfolded protein in the ER could contribute to ER stress-mediated 
neurodegeneration (I. Kim et al., 2008). In terms of neuronal composition, 
decreased mitochondria and rough ER has also been observed in TauP301S 
mice (Yoshiyama et al., 2007). 
Like the plaques which accumulate as part of the Aβ cascade, NFTs 
are largely considered the end stage of a tau cascade which starts with 
cytosolically-localised, abnormally hyperphosphorylated tau (P-tau). This P-





makes up ≥ 40% of abnormally hyperphosphorylated tau in AD brains (Iqbal 
et al., 2010). The total level of tau is four- to eight- times higher in AD brains 
relative to age-matched control brains (Khatoon et al., 1992), most likely due 
to its resistance to proteolysis (J. Z. Wang et al., 1996), decreased turnover 
(Poppek et al., 2006) and / or upregulation of tau translation via p70 s6 
kinase activation in AD (An et al., 2003).  
NFTs are inert and do not bind further tubulin or promote microtubule 
assembly (Alonso et al., 2006), whilst P-tau actively inhibits these processes 
(Alonso et al., 1994; B. Li et al., 2007) by sequestering functioning tau 
(Alonso et al., 1996) and MAP1 A/B and MAP2 (Alonso et al., 1997). 
Furthermore, the appearance of soluble P-tau correlates with cognitive 
deficiencies in mice expressing a repressible TauP301L mutation. Such mice 
also exhibit age-related NFT formation and neuronal loss (SantaCruz et al., 
2005). Cognitive deficiencies could be reversed and neuronal number 
stabilised by suppressing tau expression. These changes were independent 
of NFT load, which continued to accumulate over this period. This suggests 
that NFTs, alone, are not sufficient to cause cognitive decline or neuronal 
death. (SantaCruz et al., 2005).  
Tau phosphorylation is tightly regulated and Ca2+ dependent (Yu et 
al., 2009). For example, enzymes whose activity can be increased in the 
presence of Ca2+ and are implicated in tau phosphorylation (Ahlijanian et al., 
2000; Flaherty et al., 2000), include cyclin-dependent kinase 5 (Cdk5; Cruz 
et al., 2003; Lee et al., 2000; Lew et al., 1994) and (GSK3β; Hartigan and 
Johnson, 1999). 
Furthermore, tau phosphorylation/dephosphorylation is dependent 
upon Ca2+ influx and its rate of influx, at least in SH-SY5Y cells (Shea and 
Ekinci, 1999). In cultured neurons, membrane depolarisation results in Ca2+-
mediated transient tau phosphorylation by GSK3β and Cdk5 kinases, after 
which it is subsequently dephosphorylated by calcineurin (Pierrot et al., 
2006). Such transient and reversible phosphorylation mechanisms are 
employed by healthy neurons during development (Schmitt et al., 1977). 
Therefore, Ca2+ dysregulation associated with AD has the potential to alter 
this balance to favour tau phosphorylation via a number of mechanisms 
including basal Ca2+ increases, enhanced NMDAR-mediated Ca2+ signals (Li 
et al., 2004), CN impairment (Fleming and Johnson, 1995; Pierrot et al., 
2006), CAMKK2 activation/increased AMPK activity (Mairet-Coello et al., 
2013; Yoshimura et al., 2003), calpain activation (X. Chen et al., 2008) and 
increased transglutaminase (Miller and Johnson, 1995). Conversely, tau 
mutation can also affect the Ca2+ signalling system, including promoting 
increased VGCC Ca2+ influx (Furukawa et al., 2003) and acute ER Ca2+ 
mobilisation through RyR and IP3R as well as synaptotoxicity (Moreno et al., 





In terms of where the tau cascade fits into the progression of AD, 
TauP301S mice displayed NFTs and profound neuronal loss at 9-12 months. 
However, microglial activation, which is proposed to connect the 
neuroinflammatory and tau hypotheses, as well as supposedly inducing 
synapse dysfunction and loss, was evident from 3 months of age 
(Yoshiyama et al., 2007). Tau pathology has been observed after Aβ 
deposition in animal studies, (Hardy et al., 1998; Jack et al., 2010) 
suggesting that tau pathology is secondary to Aβ proliferation (Lewis et al., 
2001). That being said, tau deposition in the temporal lobe correlates more 
closely with dementia status in humans, and, indeed, deposition in any brain 
region correlates more closely with cognitive performance than Aβ deposition 
in early-stage AD (Brier et al., 2016). Moreover, as reviewed by (Bloom, 
2014) “a steadily accumulating body of evidence has indicated that soluble 
forms of Aβ and tau work together, independently of their accumulation into 
plaques and tangles, to drive healthy neurons into the diseased state and 







1.6 Impairment of hippocampal synaptic plasticity in AD 
1.6.1 Hippocampal anatomy and function 
Before discussing specific AD-induced alterations in synaptic 
plasticity, it is first necessary to provide the reader with a brief overview of 
the structure and function of this important brain area as all of the studies 
described within this thesis were conducted upon hippocampal tissue. 
The hippocampal formation, also referred to as the medial temporal 
lobe (MTL), is an area of the brain that is essential for the acquisition (and 
possibly storage and recall) of declarative memories (i.e. memories which 
support fact and event recollection) and includes: the hippocampus proper 
(composed of CA1, 2 and 3 fields), dentate gyrus (DG), subiculum (Sb), 
parasubiculum (ParaSb), presubiculum (PreSb) and entorhinal cortex (EC; 
which in turn is divided into medial and lateral EC (MEC and LEC; Hartley et 
al., 2013; Squire et al., 2004; Squire and Zola-Morgan, 1991; Fig 1.5). 
Interestingly, there are notable abnormalities with the myelination of 
SC-CA1 fibres in 3xTg-AD mice as young as 2-months-old (Desai et al., 
2009). Significantly, this abnormality occurs prior to the appearance of any 
Aβ or tau pathology, despite the fact that the hippocampus is a principal and 
early target for Aβ pathology (Gouras et al., 2000). Furthermore, it is possible 
that synaptic impairment precedes even these early myelination 
abnormalities, as discussed below.  
The CA1 region and Sub are the primary output structures of the 
hippocampal formation (Naber et al., 2000), whilst the EC acts as an 
interface for both incoming (via perirhinal and postrhinal cortices) and 
outgoing information from/to the surrounding cortical/subcortical association 
areas (van Groen et al., 2003). The perforant pathway (#1 in Fig 1.5) is the 
main entrance for information to the hippocampus proper and nerves 
projects from the EC to DG, CA3, CA1 and Sb. The mossy fibre projections 
from DG granule cells to CA3 pyramidal cells (#2 in Fig 1.5) and the Schaffer 
Collateral (SC) pathway from CA3 to CA1 pyramidal neurons (#3 in Fig 1.5) 
complete the hippocampal ‘tri-synaptic pathway’, with each pathway 
connected by excitatory/glutamatergic synapses (Hartley et al., 2013; Yeckel 
and Berger, 1990). The SC pathway and CA3/CA1 synapses have been 
extensively studied in terms of hippocampal LTP and are generally the sites 
from which the numerous LTP studies referred to throughout this introduction 







Figure 1.5. Hippocampal Formation Structure and Networks 
A. Schematic drawing of the neocortex and its connections with components of the hippocampal formation in primates. 
These components and networks are critical in the translation from perception to memory. Cortical regions (Ctx) receive sensory 
information, which is transmitted to the hippocampal formation via projections to the parahippocampal gyrus (PHG) and 
perirhinal cortex and from there to the entorhinal cortex (EC). The inputs are then processed through regions of the hippocampus 
proper including the dentate gyrus (DG), CA3, CA2 and CA1 regions. The main output region of the circuit is the subiculum 
(Sb) where widespread efferents return to the neocortex. 
Adapted with permission from Squire and Zola-Morgan (1991). 
B. Schematic drawing of major anatomical pathways in the hippocampal formation of the rat. Arrows indicate the 
direction of projections, whilst circles indicate cell bodies. The left-hand side of the figure illustrates the gross morphology of 
cell layers in the hippocampus and DG and their unidirectional projections. Following input from the EC, which is divided into 
lateral entorhinal cortex (LEC) and medial entorhinal cortex (MEC) to the dentate gyrus (DG; perforant pathway), nerve fibers 
project from the DG to CA3 (mossy fiber projection) and from CA3 to CA1 (Schaffer collateral pathway), completing the 
classical tri-synaptic pathway. Entorhinal input to the hippocampus proper also consists of direct LEC and MEC projections to 
CA3, to CA1, and to Sb. Other circuits within the hippocampal formation, involve projections from subiculum to presubiculum 
(PreSb) and to parasubiculum (ParaSb), and projections from PreSb to MEC, and ParaSb to both LEC and MEC.  





The output from the hippocampus can return to the surrounding 
neocortex via the deep layers of the EC and/or re-enter the formation via 
projections from the deep to superficial EC (Kloosterman et al., 2004, 2003). 
This ‘re-entrance’ process is believed to be critical for memory formation and 
may act as a way to compare processed input with new information and/or 
be involved in memory consolidation during sleep (Egorov et al., 2002; 
Gerrard et al., 2008; Naber et al., 2000; Ribeiro et al., 2004).  
The importance of the entire hippocampal formation in memory 
processes (including spatial learning and memory) is evident in the profound 
disruption of these regions within the MTL (Backman et al., 2001; Becker et 
al., 1980; Buckmaster et al., 2004; Gouras et al., 2000; Jarrard, 1993; Olton 
and Papas, 1979; Reed and Squire, 1997; Zola-Morgan et al., 1986). 
Furthermore, it is well documented that this region is targeted early in AD, 
which explains the characteristic concomitant learning and memory deficits 
associated with the disease (Golby et al., 2005). 
The ventral hippocampus is directly connected to the medial prefrontal 
cortex (Ctx), both functionally and anatomically (Degenetais et al., 2003; 
Tripathi et al., 2016) and exhibits prominent early tissue loss in AD 
pathogenesis (Frisoni et al., 2008; Qiu et al., 2009). Aβ plaques and tau-
containing dystrophic neurites appear primarily in the terminal zone of the 
perforant pathway (Hyman et al., 1988, 1986) which is responsible for the 
majority of cortico-hippocampal afferents (Van Hoesen and Pandya, 1975). 
Tau pathology affects areas of the hippocampal formation responsible for 
cortical and subcortical efferent projections, most notably in the Sb and CA1 
regions and layer IV of the EC. Hippocampal input is also impaired by NFT 
formation, particularly in stellate cells of the EC layer II, causing a 
degenerative alteration in the perforant path (Van Hoesen and Hyman, 
1990). Such changes disrupt the structural and/or functional circuitry of the 
hippocampus on many levels, impairing efferent and afferent connections 
with cortical and subcortical structures that are important for memory (Van 
Hoesen and Hyman, 1990) and which may play a role in early AD cognitive 
deficits (Davis et al., 2014).  
 
1.6.2 Synaptic plasticity and its impairment in AD 
Long-term potentiation (LTP) and long-term depression (LTD) are 
enduring changes in synaptic strength and efficacy that are induced by 
specific patterns of synaptic activity, (Bear and Malenka, 1994), and which 
are proposed to be cellular models of memory storage and erasure, 
respectively, that have been discovered to occur within the hippocampus and 
numerous other brain regions (for reviews see Bliss and Cooke, 2011; 





In the context of the work conducted for this thesis and its specific 
focus on neuronal calcium signalling, it is notable that the induction of almost 
all forms of LTP and LTD so far investigated (and indeed synaptic 
transmission itself; Malenka and Bear, 2004) are contingent on an initial 
increase in intracellular Ca2+ (Lynch et al., 1983; Mulkey and Malenka, 1992). 
However, it is the manner in which LTP or LTD is induced, in conjunction 
with the different magnitudes and locations of calcium elevations, as well as 
specific co-requirements of LTP/LTD for second messengers, which 
determines if one or the other is induced (Cummings et al., 1996; Malenka et 
al., 1988), e.g. high frequency, large amplitude Ca2+ influx generally evokes 
LTP, whereas low frequency, prolonged, low-level Ca2+ influx and/or 
mobilisation generally evokes LTD (Connor et al., 1999). Indeed, as 
described previously, the calcium signalling system is replete with subtleties 
and complexities which could allow for the selective, localised and 
magnitude-specific increases of both pre-synaptic and post-synaptic [Ca2+] 
required for the induction of different forms of plasticity. Molecular entities 
specifically implicated in synaptic plasticity-induced Ca2+ signalling include; 
glutamate-gated receptors (e.g. NMDAR and I-mGluRs), depolarisation-
activated channels (e.g. VGCCs), and ER Ca2+ release via IP3Rs and RyRs 
(Reyes-Harde et al., 1999b). Each of these signalling components has been 
investigated in the context of an induced ‘learning event’ in control and AD-
transgenic hippocampal neurons (Chapters 3, 4 and 5). Given the proposed 
chronic disruption of intracellular calcium homeostasis and signalling and its 
effects on synaptic function, it becomes clear how AD pathology may 
correlate with deficits in learning and memory.  
As alluded to above, both LTP and LTD rely upon similar molecular 
mediators such as NMDARs and I-mGluRs in a manner that is not yet fully 
understood. Additionally, interpreting exactly how pathological signals 
mediated by such receptors equates to deficits in plasticity is difficult. 
However, what is clear is that Ca2+ remodelling, the Aβ cascade and altered 
CN levels may upset the normal delicate balance between the induction of 
LTP and LTD (Deshpande et al., 2008). Indeed, as will be discussed next, 
disruptions in plasticity that correlate with memory impairments and Aβ 
proteins have been observed across disease stages in several murine AD 
models (Jang and Chung, 2016; Marchetti and Marie, 2011; Oddo et al., 
2003b). 
Impairments in NMDAR-dependent LTP and spatial working memory 
have been noted in 3 and 8-month-old 3xTg-AD mice (Chakroborty et al., 
2015; Clark et al., 2015). Notably, non-NMDAR LTP appears to be dominant 
at both 3 and 8 months of age in 3xTg-AD mice, possibly due to Aβ-mediated 
upregulation of this LTP pathway in order to compensate for the deficits in 





LTP at CA1 synapses in vitro has also been reported in APPSWE, APPINDIANA 
(Tozzi et al., 2015) and PS1M146V (Y. Wang et al., 2009) mutant mice at 2 
months and 9 – 12 month-old, respectively. However, APPSWE/PS1M146L) and 
Tg2576 mutant mice (APPLys670 → Asn, Met671 → Leu) at 10 months and 24 months 
of age, respectively, exhibited decreased Na2+ currents, proportional to Aβo 
load, which contributed to decreased VGCC activation (Brown et al., 2011). It 
is possible then, that a failure of this compensatory upregulation of non-
NMDAR LTP (which is mediated by L-type VGCCs and/or I-mGluRs) in 
transgenic AD mice due to reduced VGCC activity, underpins a total 
impairment of LTP observed at 8 months in the 3xTg-AD mouse (Clark et al., 
2015). 
With regard to the Aβ cascade, intracellular Aβo and/or extracellular 
Aβ accumulation can disrupt neuronal plasticity in vitro and in vivo in both the 
hippocampus and dentate gyrus, as has been shown in numerous murine 
models of AD (Hsiao et al., 1999; Larson et al., 1999; Li et al., 2009; 
Moechars et al., 1999; Shankar et al., 2008; Tyszkiewicz and Yan, 2005; Q. 
Wang et al., 2004). Generally, the appearance (due to transgene expression) 
or acute administration of Aβo in various murine AD models results in a 
decline in LTP (Oddo et al., 2003a; Townsend et al., 2006; Walsh et al., 
2002). Interestingly, at least in terms of adult rat hippocampal slices, 
application of ‘natural’ Aβo with abundant monomers, but not solely 
monomers or fibrils, mediated this effect on LTP (Walsh et al., 2002). 
Synthetic Aβ peptides can induce similar deficits in LTP, but greater, possibly 
non-physiological micromolar, as opposed to picomolar, concentrations are 
required for them to exert this effect (Hartley et al., 1999; Lambert et al., 
1998). Furthermore, synthetic Aβ40 and Aβ43 application results in their in 
vivo aggregation into amyloid deposits, the formation of which was 
associated with impaired basal synaptic transmission and LTP maintenance 
in rat hippocampal slices and which correlated with short-term working 
memory deficits (Stéphan et al., 2001). Aβo-induced impairment of LTP may 
be due to an inhibition of AMPAR mediated signalling (Palop et al., 2003; 
Snyder et al., 2005) or via inhibition of calcium/calmodulin-dependent protein 
kinase II (CAMKII; D. Zhao et al., 2004).  
Consistent with the theory of the deleterious effects of Aβo on 
synaptic plasticity being mediated by Ca2+ dysregulation, Aβ25-35-induced 
depression of LTP could be reversed by applying an L-type VGCC 
antagonist in vitro and in vivo (Freir et al., 2003). Furthermore, Aβo-induced 
inhibition of LTP in the dentate gyrus is reversed by CN inhibition (Chen et 
al., 2002). Ca2+ dyshomeostasis itself also appears to favour LTD whilst 
increasing the threshold frequency required for LTP induction, at least in 
aged neurons (Foster, 2007). Interestingly, supporting the theory that subtle 





suggest that short-term plasticity deficits are a function of the emergent stage 
of the disease (where compensatory mechanisms can likely act) before 
widespread synaptic deficits take hold. Indeed, 3-month-old 3xTg-AD mice 
exhibit LTP characteristics which are very similar to age-matched controls. At 
this stage in the disease early pre- and post-synaptic Ca2+ signalling 
abnormalities, namely increases in pre-synaptic spontaneous vesicle 
release, altered probability of vesicle release, and upregulated post-synaptic 
small conductance calcium-activated potassium channels (SK) channel 
activity, are masked by increased RyR-mediated Ca2+ mobilisation in 
transgenic hippocampal neurons. However, progressive calcium 
dysregulation, manifesting as increased [Ca2+]i, in these AD mice produces a 
profound enhancement of LTD (Chakroborty et al., 2012; Chakroborty and 
Stutzmann, 2014). Furthermore, short-term LTP is impaired in young and old 
3xTg-AD models which are proposed to be reflective of alterations in pre-
synaptic Ca2+ signalling via RyR (Chakroborty et al., 2012, 2009; Clark et al., 
2015; Unni et al., 2004). Aberrant RyR activation and subsequent excessive 
Ca2+ release via NMDAR (Goussakov et al., 2010; Y. Wang et al., 1996), 
AMPAR (Rossi et al., 2008) and VGCCs (Thibault et al., 2007) have all been 
recorded in AD models. Although this increased calcium would logically 
stimulate LTP, conversely, it will also activate small conductance calcium-
activated potassium (SK) channels. This, in turn, will inhibit synaptic 
depolarisation, thereby limiting Ca2+ influx via NMDAR which may act to 
impede LTP and impair the post-excitation stabilisation of dendritic spines 
(Faber et al., 2005; Zhang et al., 2015a). Furthermore, the transcription 
factor Lim-only domain protein 4 (LMO4), a positive regulator of RyR2 
expression, is upregulated by Aβ42 (Barucker et al., 2015) in the entorhinal 
cortex and hippocampus in AD (Leuba et al., 2004). Knockout of LMO4 also 
reduced RyR-mediated Ca2+ signalling and, of particular relevance to this 
project, it also reduced the facilitation of glutamatergic synaptic transmission 
and LTP (Qin et al., 2012).  
CN is upregulated in aged rats and APP Tg mice which display related 
defects in cognition (Dineley et al., 2007; Ferguson, 2001). The importance 
of this fact is illustrated by the finding that the CN inhibitor, FK506, improved 
memory function in APP transgenic mice as determined by fear conditioning 





It is proposed then that the above effects, in particular, those driven by 
increases in basal Ca2+, result in LTD being continuously enhanced, 
preventing memory consolidation which ultimately may lead to severe 
memory loss (Fig 1.6; Berridge, 2014a, 2014b). 
  
Figure 1.6. The LTD hypothesis of Alzheimer's disease  
During the day, the formation of memories and their ‘temporary’ storage relies on brief high concentration (approximately 1000 
nm) Ca2+ spikes which activate long-term potentiation (LTP). These memories are consolidated to a ‘permanent memory store’ 
at night. Also during sleep, relatively long and low concentration (approximately 300 nM) Ca2+ signals stimulate long-term 
depression (LTD) and erasure of the temporary store. 
In Alzheimer’s disease, LTD is chronically stimulated due to increased basal levels of intracellular Ca2+. This causes deletion of 
new memories in the temporary store before consolidation during sleep can occur. 






Functionally and Structurally intact synapses are absolutely essential 
for functioning memory systems (Harris and Weinberg, 2012; Mayford et al., 
2012). It is perhaps no surprise then that synaptic loss is the best known 
correlate of cognitive impairment that we are aware of in human AD (as 
opposed to, for example, the accumulation of plaques or NFTs, neuronal cell 
death or cortical gliosis; Coleman and Yao, 2003; DeKosky and Scheff, 
1990; Hamos et al., 1989; Robinson et al., 2014; Terry, 2000; Terry et al., 
1991). Therefore, it is significant that both APP mutations and the Aβ 
cascade, as well as PS mutations, have all been implicated in disrupting 
synaptic function (for review see; Koffie et al., 2011; Sheng et al., 2012). For 
example, post-mortem cortical human AD brain samples exhibit a decrease 
in synaptic density and a compensatory increase in synapse size, relative to 
age-matched controls (Arnold et al., 2013; DeKosky and Scheff, 1990; Scheff 
et al., 1990). Furthermore, biopsies performed 2 - 4 years after AD diagnosis 
(mild to moderate AD patients) revealed a 25 – 35% decrease in synapse 
density and 15 – 35% decrease in the number of synapses per neuron 
(DeKosky and Scheff, 1990). Notably, a novel method which allows for the 
imaging of synaptic density in living human brain has the potential to 
extensively examine differences in synaptic density between control and AD 
brains in situ (Finnema et al., 2016) 
In terms of which specific aspects of synaptic physiology may be 
affected by AD-related cognitive decline, studies have revealed a correlation 
with loss of the presynaptic vesicle protein, synaptophysin in the 
hippocampus and associated cortices (Dickson et al., 1995; Sze et al., 1997; 
Terry et al., 1991). This is supported by the fact that synaptophysin 
immunoreactivity was decreased by approximately 25% in the frontal cortex 
in MCI and early AD patients (Masliah et al., 2001). This decrease was 
mirrored by a 30% decrease in synaptophysin-containing pre-synaptic 
terminals as well as decreased microtubule-associated protein (MAP) 2 
(which promotes assembly and stability of the microtubule network; for 
review see; Dehmelt and Halpain, 2005) positive neurons, in APP717V-->F and 
APPSWE mice at 2-3 months of age, before any plaque formation (Hsia et al., 
1999).  
It is also worth noting that pre-synaptic nerve terminals are particularly 
vulnerable to Ca2+-mediated degeneration as they experience repeated 
bouts of Ca2+ influx and have an unusually high energy demand to maintain 
ion homeostasis and signalling systems. As such, the Ca2+- and/or ROS-
mediated pathological effects of mitochondrial dysregulation have the 
potential to be particularly severe in these regions. Similarly, pre-synaptic 
nerve terminals and post-synaptic dendritic spines are both also particularly 
vulnerable to dysregulated Ca2+ signalling mediated by RyRs (Briggs et al., 





structure, function and NT release, and in so doing influences both short- 
and long-term plasticity (Briggs et al., 2017).  
There are also numerous lines of evidence implicating PS mutations 
in synaptic impairment. For instance, PS DKO in both hippocampal cultures 
and acute hippocampal slices results in synaptic deficits (Saura et al., 2004; 
Zhang et al., 2009). Hippocampal neurons from PS1A246E mice also exhibit a 
reduction in the amplitude of evoked AMPAR- and NMDAR-mediated 
excitatory currents and reduced frequency of spontaneous miniature synaptic 
currents suggesting a decrease in synaptic activity and a reduction in the 
number of functional synapses. These impairments could be rescued in 
transgenic neurons with the application of a γ-secretase blocker (suggesting 
involvement of PSs and/or APP processing) and could be replicated in WT 
neurons with the application of monomeric Aβ42, suggesting APP processing 
mediates the actions of PS1A246E mutation (Priller et al., 2007). 
It is also postulated that PS-mediated synaptic deficits in AD are 
mediated by dysregulated neuronal SOCE (Bezprozvanny et al., 2013; 
Popugaeva et al., 2012; Tong et al., 2016) and/or synaptic vesicle recycling 
(Zhang et al., 2009; D. Zhang et al., 2010). SOCE- mediated calcium entry 
can stabilise dendritic mushroom spine synapses of pyramidal neurons via 
CAMKII (Briggs et al., 2017). Conversely, STIM2 (ER Ca2+ sensor involved in 
SOCE (Moccia et al., 2015) upregulation and SOCE enhancement in a 
Huntington’s disease model results in dendritic spine disruption (Wu et al., 
2016). As such, SOCE- mediated effects on synaptic function appears to be 
circumstance specific, i.e. it is likely to be dependent upon disease state, cell 
type and a variety of other confounding factors. 
Endogenous PS1 and STIM1 interact allowing γ-secretase cleavage 
of STIM1, reducing its activity in human neuroblastoma SH-SY5Y cells, 
human fibroblasts, and mouse primary cortical neurons (Tong et al., 2016). 
On the other hand, PS1KO in SH-SY5Y cells (Tong et al., 2016) or cultured 
cortical neurons as well as SH-SY5Y cells expressing loss-of-y-secretase-
function PS mutations (PS1D257A and PS1D385A; Yoo et al., 2000b) exhibit 
enhanced SOCE. Moreover, PS-deficient MEFs and human FAD patient B 
lymphocytes as well as PS1M146V mouse hippocampal neurons have 
significantly elevated STIM1 protein levels and decreased STIM2 levels 
(Bojarski et al., 2009; Sun et al., 2014). Conversely, SOCE is attenuated in 
SH-SY5Y cells expressing PS1M146L which, specifically, exhibited impaired 
STIM1 oligomerisation as well as impaired STIM1-ORAI1 interaction. 
Furthermore, cultured hippocampal neurons expressing the PS1M146L 
mutation exhibited destabilisation of dendritic spines which is rescued by 





The study by Tong et al. (2016) proposes that PS-mediated SOCE 
impairment is γ-secretase dependent (Shideman et al., 2009; Yoo et al., 
2000), a statement which is supported by studies utilising cells expressing 
PS mutations (PS1M146L, V97L, A136G or A246E) which confer enhanced γ-
secretase activity (Bentahir et al., 2006; Fang et al., 2006) and exhibit 
impaired SOCE (Bojarski et al., 2009; Tong et al., 2016). However, at least 
one of the y-secretase enhancing PS mutations utilised in the study by Tong 
et al. (2016) also confers impaired ER leak function (Nelson et al., 2010; 
Zhang et al., 2010). Therefore, PS-mediated SOCE impairment may also 
result from an indirect increase in [Ca2+]ER due to impaired leak function (as 








1.7 Transgenic murine models 
The well characterised 3xTg-AD mouse model and the novel TgF344-
AD rat model of AD were utilised for the completion of this study. 
1.7.1. 3xTg-AD mouse model 
The well characterised ‘triple transgenic’ model of AD expresses three 
human transgenes: PS1M146V, APPSWE (or APPKM670/671NL) and TauP301L (Oddo 
et al., 2003b). Whilst in humans the presence of either PS1 or APP 
mutations results in EOFAD, in mice, knock-in of all three mutations is 
required in order to recapitulate the main hallmarks of the disease: Aβ 
oligomers and plaques, NFTs and calcium dysregulation. These primary 
hallmarks likely underlie the appearance of a larger number of AD-related 
phenotypes in this model including impairment of neuronal signalling, 
synaptic efficacy, synaptic plasticity and behaviour and memory (Oddo et al., 
2003b; Selkoe, 2002; Sterniczuk et al., 2010a; Stover et al., 2015). 
Importantly, Aβ and tau pathology has a similar temporal and spatial 
pathological progression through the hippocampus and other MTL structures 
as that seen in human AD, with concomitant cognitive decline (Mastrangelo 
and Bowers, 2008; Oddo et al., 2003b). 
Aβ is first detectable (in terms of immunoreactivity) in CA fields of the 
hippocampus by 3 weeks of age (Billings et al., 2005; Oh et al., 2010, Kazim 
2017) and has been independently documented to be present at 2 months in 
the entorhinal cortex (both Aβ40 and Aβ42; Duffy et al., 2015) and at 3-5 
months in the neocortex (Oddo et al., 2003b). Furthermore, soluble Aβ42 
levels remain constant from 2-6 months of age in 3xTg-AD mice (Brown et 
al., 2011), but increase by 8 months (Clark et al., 2015). Interestingly, there 
appears to be a correlation between Aβ42 levels and spatial working memory 
performance deficits at 3 months. However, exaggerated Aβ42 levels at 8 
months of age do not correlate with exaggerated performance deficits, 
perhaps because of the fact that deficits due to soluble Aβ42 have already 
reached a pathological ‘threshold’ by 3 months of age (Clark et al., 2015; 
Oddo et al., 2003a). In humans, elevated Aβ42 levels in the cortex are 
correlated with mild clinical dementia prior to tau pathology (Näslund et al., 
2000). Similarly, transgenic AD mice with high levels of Aβ42 exhibited 
synaptic loss and behavioural impairments in the absence of plaques or tau 
pathology (Koistinaho et al., 2001; Mucke et al., 2000). Conversely, in 
APPSWE/PS1M146L mice, Aβ42 burden appeared to only correlate with spatial 
reference memory performance (tested using a Morris water maze (MWM)) 
when amyloid plaques were also present (Brown et al., 2011). Total Aβ load 
may also be important, as in a behavioural study analysing 4 different 
transgenic mouse lines with differing Aβ deposition profiles, it was concluded 





with “diffuse” and “compact” Aβ deposition in the brain, respectively (Leighty 
et al., 2004). 
Neurotransmission and synaptic plasticity at CA1 synapses, as well as 
spatial working memory, are impaired in 3xTg-AD mice from 3 months of age 
(Clark et al., 2015). In vitro, abnormalities in synaptic transmission and 
profound LTP deficits were also apparent in CA1 regions by 6 months of age 
(LaFerla and Oddo, 2005; Oddo et al., 2003b). 
The earliest cognitive deficits in this model appear by 2-3 months 
(Davis et al., 2013b; Stevens and Brown, 2015). Specifically, there is a 
decline in episodic-like memory which progresses to a complete deficit by 6 
months (Davis et al., 2013a, 2013b). By 4 months of age, performance in 
long-term retention, a hippocampal-dependent behavioural task Is impaired, 
coinciding with the appearance of intraneuronal Aβ (Billings et al., 2005). By 
7.5 – 11 months of age, behavioural alterations, including increased fear, 
anxiety and restlessness, can also be observed (Sterniczuk et al., 2010b). 
More subtle alterations are seen in the Ca2+ signalling toolkit well 
before these overt cognitive or synaptic deficits, in accordance with the 
proposal that AD may be a form of lifelong ‘calciumopathy’ (Stutzmann, 
2007). Alterations in the Ca2+ signalling toolkit in the 3xTg-AD mouse are 
well documented throughout Section 1.4 The Calcium Hypothesis of AD, 
although of particular note are the following early-stage observations.  
1) Reduced Kv2.1 potassium channel function, which likely contributes 
to synaptic disruption, as it increased excitability in cultured hippocampal 
neurons from embryonic 3xTg-AD mice (Frazzini et al., 2016).  
2) 3xTg-AD primary neuronal hippocampal cultures exhibited impaired 
leak function and altered ER Ca2+ release (Zhang et al., 2010). Importantly, 
Zhang et al. (2010) concluded from reverse transcription PCR experiments 
that APPSWE and tauP301L transgenes were not expressed in hippocampal 
cultures from 3xTg-AD mice before DIV18 and therefore Ca2+ dysregulation 
was most likely due to the PS1 mutation alone.  
3) Enhanced ER mobilisation at 6 weeks in ex vivo hippocampal 
slices, stimulated by IP3R stimulation is primarily via increased CICR due to 
RyR expression upregulation (Stutzmann et al., 2006, 2004).  
4) Increased coupling of [Ca2+]CYT with K+ channels to enhance 
hyperpolarisation mediated by ER Ca2+ release (Stutzmann et al., 2006).  
5) An increase in RyR-mediated Ca2+ responses (by 2-3-fold in the 
soma and 10-fold in the dendrites and spines) in young (4 - 6-weeks-old), 





6) Aberrant network activity, specifically CA3 network hyperexcitability 
and enhanced seizure susceptibility, likely due to intraneuronal Aβ, is evident 
at 3-weeks-old and is reversible with mGluR5 blockade (Kazim et al., 2017). 
This increased excitability appeared to be a chronic process as increased 
entorhinal cortex excitability was also observed in Tg2576 mice (APPSWE 
mutation) at 2-4 months (Duffy et al., 2015) and has also been observed in 
the hippocampal formation at 3-6 months after the appearance of episodic 
memory deficits in the 3xTg-AD mouse (Davis et al., 2014).  
7) Ca2+ dysregulation worsens with disease progression, as 
evidenced by the fact that in the 3xTg-AD mouse, basal [Ca2+]i in cultured 
cortical neurons (produced from 8 – 12 month-old mice) was double that of 
age-matched controls and was found to rely on both Ca2+ entry and ER 
mobilisation (Lopez et al., 2008).  
Tau pathology was evident in 3xTg-AD mice by 9 to 12 months of age, 
which is significantly later than previously mentioned pathology (Billings et 
al., 2005; Oddo et al., 2003b, 2003a). Tau accumulates in an age-dependent 
manner starting in the hippocampus, progressing to the cortex (Oddo et al., 
2003a). Taking these observations into account, this transgenic animal 
model would appear to follow the generally accepted pathological cascade of 
AD, namely calcium dysregulation and/or Aβ oligomer production followed by 
tauopathy (Karran et al., 2011; Oh et al., 2010; Selkoe and Hardy, 2016). 
However, an extensive immunohistochemical study investigating the 
presence of a plethora of tau isoforms found pathological tau formations from 
3 weeks of age in the hippocampus and Sb (Oh et al., 2010). 
 
1.7.2 TgF344-AD rat model 
The TgF344-AD rat model used in this study, which expresses two 
human mutant genes, APPSWE and PS1ΔE9, was recently developed and 
characterised by Cohen et al. (2013) and displays the full spectrum of AD 
hallmarks, including the sequential appearance of cerebral amyloidosis, 
tauopathy, gliosis and frank hippocampal and cortical neuronal loss. More 
specifically, this AD rat model displays the following characteristics:  
1) Robust and progressive accumulation of intraneuronal Aβ, Aβ40, 
Aβ42, soluble Aβo and Aβ plaques. Interestingly, cerebral Aβ abundance was 
large enough in this model to be within the clinicopathological range of the 
human syndrome.  
2) Intraneuronal Aβ42 and Aβo, but not Aβ40, appeared by 16 months 
of age. Aβ40 is robustly increased by 6 months, which was well before plaque 
formation. Furthermore, with increasing age (but beginning at 16 months of 





Aβo (which first appeared at 6 months of age) and CTFβ levels, also 
increased in an age-dependent manner in the cerebral cortex and 
hippocampus. 
3) Despite having no specific tau mutation, this model displays 
increased hyperphosphorylated tau (ptau) at 6 months of age, which is 
before Aβ deposition but coincides with increases in Aβo. Furthermore, NFT-
like structures form by 16 months of age. A possible reason for this unique 
observation may lie in the fact that rats, unlike mice, but like humans, all 
express six tau isoforms, making rats more physiologically comparable to 
humans than mice (Breunig et al., 2013; R. M. Cohen et al., 2013). 
4) Outside of these major AD hallmarks, this model is characterised 
by progressive microgliosis and astrogliosis in the cerebral cortex and 
hippocampus. Although activated astrocytes and microglia appeared in close 
proximity to Aβ plaques, activation also occurred by 6 months of age, which 
was before robust Aβ deposition and coincided with the appearance of Aβo.  
5) Amyloidosis and tauopathy are accompanied by frank neuronal loss 
(ranging from 23 – 45%) in the cerebral cortex and hippocampus at 16 and 
26 months.  
6) Behaviourally, amyloidosis was associated with hyperactivity in 
open-field as well as age-related deficits in spatial learning and memory.  
7) Finally, it is worth noting that although tauopathy and neuronal loss 
were observed in close proximity to Aβ plaques, this pathology was also 
evident in brain areas devoid of Aβ deposits but where Aβo were present. 
Indeed, Aβo and Aβ42 levels were most strongly correlated with neuronal loss 
in the cerebral cortex and hippocampus. A correlation between Aβ deposition 






2. Primary hippocampal neuronal culture 
Abstract 
This chapter centres on a publication by Kaar et al. (2017) entitled ‘An 
efficient and cost-effective method of generating postnatal (P2–5) mouse 
primary hippocampal neuronal cultures’ in The Journal of Neuroscience 
Methods (Appendix 1). 
Primary culture of postnatal central neurons is a widely used 
methodology for applications such as the investigation of neuronal 
development, protein trafficking/distribution and cellular signalling. However, 
successful production and maintenance of such cultures, particularly from 
postnatal animals, can be challenging. In attempting to surmount these 
difficulties, several disparate culturing methodologies have been developed. 
Such methodologies are centred upon the identification and optimisation of 
critical steps and, therefore, the techniques and reagents utilised can differ 
quite markedly from protocol to protocol. Often, it is suggested that the use of 
a proprietary reagent, lengthy substrate preparation and/or cell isolation 
techniques are necessary for successful culture preparation. These 
invariably lead to increased costs of research. 
Herein, we present a simple and inexpensive protocol for the 
preparation of primary hippocampal neurons from postnatal (2 - 5-day-old) 
mice, which remain viable for experimental use for over one month. Neurons 
cultured using this method follow well-established developmental norms and 
display typical responses to standard physiological stimuli such as 
depolarisation and pharmacological agents.  
By using a novel trituration technique, simplified methodology and 
non-proprietary reagents, we have developed a reliable protocol that enables 
the cost-effective and efficient production of high-quality postnatal mouse 
hippocampal cultures. This method, if required, can also be utilised to 
prepare neurons both from other regions of the brain and from other species 







2.1.1 Uses of primary neuronal culture 
Primary neuronal culture enables the conversion of complex, three-
dimensional brain tissue, which is difficult to study in vivo, into a two-
dimensional monolayer of cells, thus allowing easy access to, and 
visualisation of, individual neurons and synapses (Nunez, 2008). Primary 
neuronal cultures are also advantageous over continuous cell lines (CCLs) 
as they exhibit important markers of physiologically-relevant neuronal 
networks such as well-defined axons and dendrites, dendritic spine formation 
and synapse formation, which are absent in CCLs (Kaech and Banker, 
2006). Consequently, the technique is routinely utilised for a wide variety of 
applications in neuroscience including, inter alia pharmacological, 
electrophysiological, immunohistochemical, neurotoxicological, 
developmental and cell signalling studies (Beaudoin et al., 2012; Brewer and 
Torricelli, 2007; Nunez, 2008).  
However, in addition to ease of access to, and visualisation of, 
neurons and synapses, this simplified monolayer system is also of use for 
several other purposes. For example, neuronal cell culture eliminates, or at 
least reduces, potential hormonal, vascular and/or inflammatory confounding 
influences that one might encounter when using intact or whole brain tissue 
systems (Brewer and Torricelli, 2007). Such a feature may be important 
when investigating phenomena such as the subcellular localisation and 
trafficking of neuronal proteins such as neurotransmitter receptors (Y. Chen 
et al., 2008). To further reduce intercellular interactions, so-called “low-
density” cultures can also be prepared (Kaech and Banker, 2006). 
Conversely, one can easily and very specifically manipulate the cellular 
environment of cultured neurons/glia to determine the effect of a particular 
pharmacological or hormonal intervention in the absence of any other 
confounding factors. Thus, careful and selective manipulation of the cellular 
environment in this way provides more specific and reproducible information 
than could be achieved by using whole-tissue or in vivo animal studies in the 
same way (Zhang et al., 2006). 
Neuronal culturing also enables the preparation of multiple, separate 
neuronal ‘populations’ which can be considered as identical experimental 
replicates (Brewer and Torricelli, 2007). As it is usually possible to seed a 
relatively large number of identical neuronal populations from a single piece 
of brain tissue, this technique represents a highly efficient method of 
increasing sample size, whilst reducing variability. Finally, but no less 
important, given the relative long-term viability of cultured cells compared to, 
for example, intact tissue such as brain slices, cell culture also allows for 
longer-term studies investigating toxicology and neuronal development (Y. 





2.1.2 Embryonic versus postnatal brain tissue 
The possible advantages of using cultured neurons/glia over intact 
brain tissue notwithstanding, there can be significant practical limitations to 
producing viable neuronal cultures, as the technique itself is technically 
demanding and can be hampered by a lack of reproducibility. 
Variation in the quality of neuronal cultures can be ameliorated to 
some extent by utilising embryonic, rather than postnatal, tissue. This is most 
likely due to the increased plasticity of embryonic, relative to postnatal, 
neurons. As such, they have fewer complex neurites, lower interneuronal 
connectivity and a decreased reliance on trophic support (Brewer and 
Torricelli, 2007; Kivell et al., 2000; Zhang et al., 2006). Taken together, these 
factors are likely to bestow upon embryonic cultures a higher resistance to, 
and higher survival rate following, chemical and mechanical tissue 
dissociation. This is evidenced by the fact that the use of brainstem tissue 
from postnatal (P) rat (P6) resulted in an increase in unattached cells and 
debris on the day of dissection in comparison to embryonic (E) tissue (E14 – 
20). Furthermore, when the same protocol was applied utilising P15 tissue, 
few neurons survived after 1 day (Kivell et al., 2000). In a separate study, rat 
hippocampal cultures produced from E18 and E19 tissue were compared in 
terms of neurite length (multiple measurements during weeks in culture), an 
indicator of neuronal survival and active growth. Neurite length was more 
than twice as long in younger cultures, despite a difference of only one day in 
the age of animals (Kaneko and Sankai, 2014). This technical advantage has 
led to the widespread use of embryonic tissue, particularly that of mice, for 
the preparation of neuronal cultures. 
Although, the use of embryonic neuronal culture may be relevant for 
studies concerned with, for example, neuronal/glial development, disease 
aetiology, or where, due to genetic mutation, animals die at, or soon after 
birth, it would often be more appropriate to use more physiologically-relevant 
postnatal tissue in other situations. The investigation of the function and role 
of developed neurons and studies of age-developed pathology such as 
Alzheimer’s disease are two examples where it would be more appropriate to 
use such postnatal tissue.  
The developmental stage of the animal used for culture preparation 
also influences the cellular composition of a given culture. For example, late-
stage embryonic tissue has an abundance of pyramidal neurons, whilst 
dentate gyrus neuron production has not begun at this stage (Banker and 
Cowan, 1977; Kaech and Banker, 2006).  
It is also recognised that embryonic neurons display a different 
phenotype to that of adult neurons in terms of their pharmacology, 





Importantly, in the context of the research that is described in this thesis, 
embryonic neurons display different calcium dynamics (Brewer et al., 2006), 
mitochondrial function (Parihar and Brewer, 2007) and responses to 
glutamate and A (Brewer, 1998) when compared to postnatal neurons. 
Specifically, in terms of Ca2+ dynamics, inhibitory circuitry in the 
hippocampus and NMDAR-mediated signalling is not fully developed until 1 - 
2 weeks after birth in rat hippocampal cultures (Corradetti et al., 1988; 
Swann et al., 1989; Wyss and van Groen, 1989).  
Unfortunately, however, in contrast to embryonic tissue, postnatal 
brain tissue is relatively sensitive to the culturing process. This is thought to 
be due to the fact that as neurons develop, they become more susceptible to 
glutamate-mediated excitotoxicity (Brewer, 1998) and exhibit enhanced 
caspase activation and apoptosis (Brewer et al., 2005). Physical degradation 
of neurons also removes intra-neuronal trophic support, thereby decreasing 
cell viability still further (Brewer and Torricelli, 2007). 
This susceptibility to culturing seems to be particularly true when one 
considers the culturing of hippocampal and other central neurons derived 
from postnatal mice, where there are limited documented successful 
culturing methodologies for either very early postnatal (P0 - 1; Ahlemeyer 
and Baumgart-Vogt, 2005; Beaudoin et al., 2012) or adult mice (Brewer and 
Torricelli, 2007; Eide and McMurray, 2005), relative to protocols published for 
producing postnatal rat neuronal cultures (e.g. (Brewer, 1997; Drysdale et 
al., 2006; Edwards et al., 2010; Hogins et al., 2011; Irving et al., 2000; Kivell 
et al., 2000; Nunez, 2008; Pozzi et al., 2017; Rae et al., 2000; Rao and 
Sikdar, 2004; Stoppelkamp et al., 2010; Ternaux and Portalier, 1993; Zhang 
et al., 2006). Given that the vast majority of transgenic animal models that 
have been developed to date are mice, this is a very significant issue. Thus, 
a reliable and cost-effective postnatal mouse primary hippocampal culturing 
protocol could have widespread applications, particularly in the fields of 
learning and memory, and neurodegeneration. 
 
2.1.3 Limitations of the culturing method 
Despite the numerous advantages of using primary neuronal cultures 
for experimental research, their limitations do also, however, need to be 
acknowledged. Firstly, the physiological relevance of a monolayer of 
dispersed cells is debatable. The removal of environmental, hormonal and 
ageing influences could result in an altered cellular phenotype, which may 
include factors such as a different epigenetic response to transgenes in 
culture. That being said, even so-called monolayer systems, in reality, have 





could be up to 18 μm thick, at least in high-density rat cortical cultures (3000 
– 4500 neurons/mm2; E18; 21 days in vitro (DIV); Cullen et al., 2010).  
Secondly, it is standard practice to maintain neurons at 5% CO2 and 
ambient O2 (approximately 20%). At sea level, the partial pressure of O2 is 
approximately 150 mmHg whilst the arterial partial pressure of O2 is 
approximately 75 – 100 mmHg (Chernecky and Berger, 2013; Trulock, 1990; 
Weinberger et al., 2014). The partial pressure of O2 in the brain, however, is 
low (24 – 33 ± 13 mmHg; human brain at a range of probe depths) and non-
uniform (Dings et al., 1998; Erecińska and Silver, 2001). Ambient O2 is 
unphysiological and inhibits neurite growth, resulting in processes which are 
half the length of those in 9% O2 at 3 DIV. Indeed, 9% is considered to be an 
optimal O2 tension, in terms of neuronal survival and neurofilament 
synthesis, in culture (Brewer and Cotman, 1989; Kaplan et al., 1986), which 
tallies with average in vivo oxygen levels of between 1 and 11% (Tiede et al., 
2011). Importantly, neurons cultured under controlled O2 conditions (at 9%) 
had higher anatomical polarisation, lower ROS production rates, larger 
mitochondrial networks, an increased number of mitochondria and an 
increased susceptibility to cell death induction, relative to those cultured in 
ambient O2 (Tiede et al., 2011).  
Thirdly, the culturing process, by its very nature, saturates neurons 
with supplements and growth factors. This nutritional state does not reflect 
the nutrient profile arising from normal animal/human behaviour and/or the 
physiological process of nutrient assimilation and distribution.  
However, despite these limitations, neurons in primary culture develop 
in an anatomically relevant manner, exhibiting numerous dendrites with 
spines, branched and extended axons and synapses (Kaech and Banker, 
2006). Furthermore, the physiological relevance of primary cultures has been 
verified by Ca2+ signalling studies (e.g. Chakroborty et al., 2012; Kaar et al., 
2017; Kaar and Rae, 2014; Rae et al., 2000; Rae and Irving, 2004; Zhang et 
al., 2010). 
In reality, results accrued from cultured cells are generally further 
investigated utilising more intact three-dimensional tissue environments, 
such as acute hippocampal slice and organotypic cell culture systems or in 
vivo studies. Previous work by this lab group suggested that results 
generated using cultured rat hippocampal cells were generally similar to 
those in rat hippocampal slices (Rae et al., 2000; Rae and Irving, 2004). 
Conversely, however, electrophysiological measurements have been shown 
to vary between in vitro slices and cultured cells and are also modulated 
depending on culture conditions (Mynlieff, 1997). Where this culture 





biological replicates where hypothesis testing can be carried out efficiently 
and on an extensive number of experimental units. 
 
2.1.4 Characteristics of hippocampal cultures 
The primary advantage of using hippocampal tissue for the work 
detailed within this thesis was its relevance to the aetiology of AD, in that it is 
one of the first regions to be targeted by the disease (Belleville et al., 2008; 
Reitz et al., 2009; Small et al., 2011). Furthermore, there is a large body of 
research which has utilised cultured hippocampal neurons and this both aids 
in directing hypotheses and forms a large data pool which novel data can be 
compared to. The neuronal population of the hippocampus is also 
comparatively simple with pyramidal neurons composing the majority of the 
tissue, with only a relatively small number of interneurons (Benson et al., 
1994).  
The development of neurons in hippocampal culture is well defined 
and appears to be relatively consistent across most research groups. Thus, 
neurons develop polarity during the first two days in vitro (DIV), during 
developmental stage one. This begins soon after cell plating onto coverslips, 
whereby hippocampal neurons extend a lamella around the cell body. In 
developmental stage two, this lamella then collects at distinct regions of the 
cell periphery and it is at these points that minor neurites, of approximately 
20 – 30 μM in length, begin to extend. Growth cones (GC) and their filopodia 
at neurite tips show characteristic motility and the neurites intermittently 
extend and retract short distances (Craig and Banker, 1994; Dotti et al., 
1988). Although little is known about in vivo GC morphology with which to 
compare the in vitro situation, there is evidence to suggest that they are 
elaborate structures with numerous filopodia, especially in the early stages of 
development (Hossain et al., 2012). However, there is little net growth at this 
stage and the cell maintains a symmetrical appearance (Craig and Banker, 
1994; Dotti et al., 1988; Kaech and Banker, 2006). Notably, at this point in 
development, most axonal and dendritic markers will stain all neurites and, 
indeed, any neurite appears to be able to form either an axon or a dendrite 
(Jacobson et al., 2006; Kaech and Banker, 2006). Cells remain in 
developmental stage two for 12 – 36 hours, after which a rapid 
transformation to phase three occurs.  
During phase three, a single neurite continues to elongate rapidly and 
continuously for 2 – 3 hours and acquires axonal characteristics (Dotti et al., 
1988; Kaneko and Sankai, 2014). Such a neurite will eventually extend for 
many hundreds to thousands of micrometres (Dotti et al., 1988; Kaneko and 
Sankai, 2014). Notably, transitions from phase to phase do not occur 





neurons reach stage three by 1 DIV, with 80% reaching this stage by 1.5 – 2 
DIV (Kaech and Banker, 2006). This is fuelled by specific and targeted 
signalling events which emphasise the growth of this single neurite (Arimura 
and Kaibuchi, 2005; Wiggin et al., 2005). The other neurites grow 5 – 10 
times slower (Kaneko and Sankai, 2014) and form dendrites, normally 
between 3 - 4 DIV (Craig and Banker, 1994; Dotti et al., 1988). It is within this 
time frame that the first synapses also begin to form (Fletcher and Banker, 
1989), which is known as developmental stage four.  
Stage five is a relatively slowly progressing phase, normally observed 
between 1 and 4 weeks in vitro, and comprises the following events: 
dendrites become highly developed and branched, a synaptic network forms, 
spines form on the dendrites of pyramidal neurons and, finally, synaptic 
plasticity is evident (Kaech and Banker, 2006). As an example of cell 
appearance at this developmental stage, by 13 DIV nerve bodies have grown 
significantly larger and an extensive network of intertwined axons and 
dendrites forms in hippocampal cultures (E18; Kaech and Banker, 2006). 
Dendrites emerge gradually, and project radially, from and around the cell 
body, taper with distance and are between approximately 20 – 300 μM in 
length. Axons are thinner at their point of origin and are less tapered. In fact, 
an axonal diameter is generally uniform over long distances (Kaech and 
Banker, 2006). Axons also extend along a more meandering course, 
including several branches, for millimetres of distance. Often, axons will also 
loop back on themselves (Kaech and Banker, 2006). 
 
2.1.5 Previous studies 
To date, opting to use postnatal tissue to prepare primary neuronal 
cultures has often meant ‘accepting the fact that there will be some bad 
culture days’ (Banker et al., 2007). Such ‘bad cultures’ and lack of 
reproducibility are likely to arise from subtle variations in the reagents used 
(Beaudoin et al., 2012) and/or techniques employed between labs. This has 
resulted in the utilisation and publication of several distinct culturing 
protocols, with each containing highly specific, often very different, and 
sometimes even conflicting, advice for each facet of the culturing protocol.  
However, differences in protocol notwithstanding, a review of recent 
literature reveals the widely held belief that the preparation of postnatal 
mouse cultures specifically necessitates the use of expensive, defined media 
and supplements, namely, Neurobasal®-A (NB-A) and the HEPES-based 
Hibernate® A, which are utilised in combination with a proprietary serum-free 
supplement solution, B-27® (see inter alia, Ahlemeyer and Baumgart-Vogt, 
2005; Beaudoin et al., 2012; Brewer, 1997; Brewer and Torricelli, 2007; 





2000; Nunez, 2008; Rao and Sikdar, 2004; Stoppelkamp et al., 2010; Xie et 
al., 2000; Zhang et al., 2006). Indeed, their use is so prevalent that one 
would be forgiven for thinking that it is nigh on impossible to prepare 
postnatal cultures without using these proprietary reagents and supplements 
(as well as lengthy protocols such as gradient separation to further optimise 
the procedure; Brewer and Torricelli, 2007). However, not only are these 
proprietary media and supplements much more expensive than standard, 
non-proprietary, media preparations such as Dulbecco’s modified Eagle’s 
medium (DMEM), there is also a concern in some quarters about variable 
quality and uniformity between batches of B-27 (Y. Chen et al., 2008) and 
certain, possibly neurotoxic, ingredients contained within NB-A (Hogins et al., 
2011). 
Therefore, it was the aim of the present study to determine the 
possibility of producing consistent, successful postnatal primary mouse 
hippocampal neuronal cultures utilising non-proprietary solutions and 
supplements. Further, we also wanted to simplify the overall culturing 
protocol relative those published in recent times (e.g. Brewer and Torricelli, 
2007, Beaudoin et al., 2012; Table 1 provides a comparison of the main 
components of previously published postnatal mouse hippocampal culture 
methods with our method). 
Therefore, with these goals in mind, in this section, I will describe a 
simplified, technically straightforward and reliable method for the production 
of postnatal (P2 - P5) mouse hippocampal cultures of consistently high 
quality that remain viable and responsive to normal physiological stimuli for 
















































































































































































































































































2.2 Materials and methods 
2.2.1 Chemicals and reagents 
• Mice (2 - 5-days-old) 
• Serum replacement 2 (SR2; 50×; Sigma, cat. no. S9388). 
• GlutaMAX™ supplement (ThermoFisher Scientific, cat. no. 35050038). 
• L-glutamic acid (Sigma, cat. no. G1251). 
• Penicillin-streptomycin (P-S; Sigma, cat. No. P4333). 
• Foetal bovine serum (FBS; Sigma, cat. no. F7524).  
Optimisation: Storage limitations, as described by Beaudoin et al., 
2012, were adhered to, namely storage at -80ºC and limit freeze-thaw 
cycles to one. 
• Dulbecco’s Modified Eagle’s Medium-low glucose (Sigma, cat. no. 
D5546). 
• Papain (Worthington, cat. no. 3119) (see Reagent Setup). 
• Poly-D-lysine hydrobromide (Sigma, cat. no. P6407) (see Reagent 
Setup). 
• Dissection, trituration, plating and culture solutions (see Reagent Setup). 
• Trypan blue solution (Sigma, cat. no. T8154). 
• 70% ethanol solution for sterilisation of surfaces and hands. 
• Deionised water (dH2O). 
• Immunocytochemistry reagents: Triton™ X-100 (Sigma, cat. no. X100), 
paraformaldehyde (Sigma, cat. no. P6148), sucrose (Sigma, cat. no. 
S7903), glycine (e.g., Sigma, cat. no. G7126), bovine serum albumin 
(BSA; Sigma, cat. no. 05470), mounting medium (Sigma, cat. no. F6182), 
microscope slides (25 x 75 mm; Sigma, cat. no. S8400). Primary 
antibodies: pan-neuronal marker (mouse monoclonal, Millipore, cat. no. 
MAB2300, Antibody Registry: AB_1587299), anti-glial fibrillary acidic 
protein (GFAP; rabbit monoclonal, Cell Signalling, cat. no. 12389, 
Antibody Registry: AB_2631098), anti-Synapsin I (rabbit polyclonal, 
Millipore, cat. no. AB1543, Antibody Registry: AB_2200400). Secondary 
antibodies: FITC goat anti-mouse (Jackson, cat. no. 115-095-003, 
Antibody Registry: AB_2338589), Cy5 goat anti-rabbit (Abcam, cat. no. 
ab97077, Antibody Registry: AB_10679461), TRITC donkey anti-rabbit 
(Jackson, cat. no. 711-025-152, Antibody Registry: AB_2340588). 
• Compounds used for calcium imaging: (S)-3, 5-dihydroxyphenylglyccine 
(DHPG; Tocris, cat. no. 0805), caffeine (Sigma, cat. no. C0750), carbachol 








• 35 mm cell culture dish (untreated; Sigma, cat. no. CLS430588).  
Optimisation: Previous studies have suggested “cell culture treated” 
dishes (i.e. those pre-treated with a cell-adherent substrate) give rise 
to altered neuronal morphology (W. S. Chen et al., 2011). 
Implementing the use of untreated dishes ensured normal neuronal 
development with no negative effects on culture success.  
• 145 mm cell culture dish (Sigma, cat. no. Z652539) 
• 13 mm glass coverslips, other sizes can be used as desired (TAAB, cat. 
no. M160/1). 
Optimisation: A thickness measurement of both 0 and 1 (as defined 
by manufacturer) can be used, indicating that a relatively thin glass is 
conducive to cell development in an inverted culture system. There 
are recommended providers of coverslips with proven reliability, 
without which cells will initially grow but detach soon after, such as 
Type “D” glass from Schott Desag (Kaech and Banker, 2006). In our 
hands, coverslips provided by TAAB have also been conducive to 
long-term reliable culturing. 
• 15- and 50-ml sterile polypropylene (PP) centrifuge tubes (Fisher 
Scientific, cat. no. 11849650 and 11512303 respectively).  
Optimisation: Previous studies have recommended the routine use 
of polystyrene or polyethylene terephthalate (PET) tubes given reports 
of toxicity from PP tubes (Brewer and Torricelli, 2007), but we did not 
find any adverse effects using PP tubes. 
• 15 ml and 30 ml syringes (Fisher Scientific, cat. no. 12931031 and 
10313015 respectively) 
• Haemocytometer. 
• Sterile syringe filter, 0.2 µm pore size (Sigma, cat. no. CLS431229). 
• 150 mm Pasteur pipette (VWR, cat. no. 612-1701) (see Equipment 
Setup). 
• 3.5 ml Plastic transfer pipette (Sarstedt, cat. no. 86.1171). 
Optimisation: Pipette material, shape and size were selected based 
upon numerous optimisation procedures using both glass and plastic 
pipettes of different shapes and end aperture sizes. 
• Incubator, controlled 5% CO2, humidified. Other studies have 
recommended the use of an O2 regulated incubator (Brewer and Torricelli, 
2007). However, in our experience, these costlier incubators are not 
necessary for producing successful cultures. 
• Inverted microscope, phase contrast, with a long working distance 
objective.  
• Sterile laminar flow hood, HEPA-filtered air. 





• Swinging bucket centrifuge compatible with the use of 15 ml tubes, 
ambient room temperature, capable of speeds of 258 g. 
• Water bath. 
• Temperature-regulated orbital shaker, capable of incubating at 37ºC. 
• Fine and course dissection tools. 
• Osmometer. 
 
2.2.3 Reagent setup 
• HEPES-buffered saline solution (HBSS) of the following composition (in 
mM): NaCl 130, HEPES 10, KCl 5.4, MgCl2 2, D-glucose 2 and CaCl2 0.5, 
pH 7.4, 310 mOsm. 
• Dissection solution. Prepare 8 ml of HBSS solution containing 0.5 mM 
GlutaMAX, 0.025 mM L-glutamic acid and 1% P-S.  
Optimisation: All solutions were supplemented with L-glutamic acid 
and GlutaMAX as detailed in the discussion section. 
• Trituration solution. Prepare 15 ml of HBSS solution containing 10% 
FBS, 5 mM GlutaMAX, 0.025 mM L-glutamic acid and 1% P-S. Place in 
an incubator at 37ºC. 
Optimisation: Hibernate A and HBSS, with and without Ca2+ and 
Mg2+, were compared for use in the dissection and trituration 
solutions, with Hibernate A providing no obvious advantage on culture 
quality. Therefore, due to its greater cost-effectiveness, lab-made 
HBSS was routinely used in preference to Hibernate A. Furthermore, 
no advantage was observed with the use of Ca2+-and Mg2+ -free 
HBSS over normal HBSS in the trituration solution. 
• Plating solution. Prepare 2 ml of DMEM solution containing 10% FBS, 5 
mM GlutaMAX, 0.025 mM L-glutamic acid and 1% P-S. Place in the 
incubator and allow CO2 to buffer solution. 
• Culture solution. Prepare 35 ml of DMEM solution containing 2% SR2, 5 
mM GlutaMAX, 0.025 mM L-glutamic acid and 1% P-S. Place in the 
incubator and allow CO2 to buffer solution. 
Optimisation: As mentioned previously, almost all methodologies in 
this field utilise a combination of NB and B27 for maintenance media. 
We found that using non-proprietary DMEM and a basic SR2 was 
equally conducive to successful and cost-effective culture production. 
Subjectively, we found that using another alternative proprietary 
supplement, NeuroPlexTM (Gemini Bio-Products), provided no 
advantage over either SR2 or B27 on neuronal quality. 
Practical Use: Numerous published methods provide guidelines on 
the time culture solutions can be prepared in advance of the actual 
dissection, as well as the number of temperature changes which these 





et al., 2012; Brewer and Torricelli, 2007; Eide and McMurray, 2005). 
However, we felt that it was more beneficial to negate such variables 
by making solutions fresh each day and to keep them at a stable 
temperature, dependent upon their temperature of use. 
• Poly-D-lysine solution. Dissolve at 0.1 g/ml in dH2O. Store as frozen 2 
ml aliquots in 15 ml tubes. 
• Papain solution. Immediately prior to beginning the dissection, dissolve 
2.5 mg/ml papain in Dissection solution with a total volume of 2 ml 
(approximately 25 U ml-1). To ensure full dissolution of papain, the solution 
should be placed in a water bath at 37°C for approximately four minutes. 
Filter sterilise the solution into a 15 ml tube and store on ice.  
Note: Papain has been found to be the most suitable protease for cell 
culture (Brewer, 1997). The supplier, Worthington Scientific, is 
reported as being superior for papain than Sigma (Brewer and 
Torricelli, 2007). The merits of dissolving papain in Ca2+- and Mg2+- 
free solution, to aid tissue digestion (Copray and Liem, 1993; Harris et 
al., 2007; McDonough et al., 2012) are debated, due to the damage 
that an absence of these cations may have directly on cells. It is 
recommended that papain is stored on ice for no longer than three 
hours (Brewer and Torricelli, 2007).  
Optimisation: In our hands, papain from Worthington Scientific was 
superior to that purchased from Sigma, but the specific supplier does 
not appear to be crucial to culture success. No advantage was 
observed using Ca2+- and Mg2+- free HBSS over normal HBSS for the 
trituration solution. In contrast to Brewer and Torricelli (2007), who 
suggest that papain treatment of tissue is improved at 30ºC in 
comparison to 25ºC or 37ºC, in our hands, tissue breakup was optimal 
after incubation at 37ºC. We tried various tissue incubation periods of 
30-60 minutes at 37ºC, with 45 minutes incubation, combined with 
light tissue agitation, proving to be optimal for tissue dissociation. 
• Phosphate buffered saline (PBS) of the following composition (in mM): 
NaCl 137, KCl 2.7, Na2HPO4 10, KH2PO4 2, pH 7.4. 
• Mice (2 - 5-days-old). The volumes provided in this protocol are designed 
for hippocampi from three to four mice aged between 2 - 5-days-old and 
would have to be adjusted accordingly if one wished to use older animals. 
Animals were euthanised in accordance with European Directive 2010/63/EU 
and experiments approved by the Animal Experimentation Ethics Committee 
of University College of Cork. 
Optimisation: The culture of rat hippocampal tissue results in a 
greater proportion of successful cultures. However, with care and 
significant optimisation, mouse hippocampal cultures could also be 
routinely and reliably produced. Although mice from 2 - 5-days-old 





of concept of the effectiveness of our culture protocol, mice up to 14-





2.2.4 Equipment setup 
150 mm Pasteur pipette 
 Glass pipettes were flame polished briefly (approximately two seconds) to 
smooth off any sharp edges, but not to significantly reduce aperture size. 
These polished pipettes were used to transfer small volumes of the plating 
solution to coverslips and to transfer the enzyme-treated hippocampal tissue 
into the trituration solution. 
Note: The use of siliconised glass is recommended by some in the 
field for ease of trituration and transfer due to the viscous nature of the 
dissociated cell suspension (Brewer and Torricelli, 2007). However, in 
our hands, standard glass pipettes were sufficient. 
Preparation of coverslips 
 In a laminar flow hood, coverslips were transferred to a 35 mm cell culture 
dish containing 2 ml of 70% ethanol for sterilisation. Two coverslips were 
then removed and placed upright in each of sixteen 35 mm cell culture 
dishes and allowed to air dry. Once dried, coverslips were placed flat on the 
base of each 35 mm dish.  
Note: Substrate cleaning and coating are key steps in the culture 
process as they ensure neuronal attachment and survival, as well as 
their standard development and maturation (Kaech and Banker, 
2006). As such, neurons are highly sensitive to the cleaning methods 
and coatings which are utilised (Beaudoin et al., 2012). In terms of 
substrate material, adult neurons do not grow well on plastic (Brewer 
and Torricelli, 2007) and, therefore, glass coverslips are routinely 
used. ‘Etching’ of these substrates with nitric acid is discouraged by 
some (Brewer, 1997), but recommended by others, in combination 
with subsequent cleaning and heat and/or radiation sterilization 
(Beaudoin et al., 2012; Kaech and Banker, 2006). 
Optimisation: In our hands, brief prior sterilisation in 70% ethanol 
followed by air drying was sufficient to allow for poly-D-lysine 
attachment and subsequent cell adherence, without any adverse 
effects on neuronal survival, despite the assertion that solvents leave 
a ruinous toxic residue (Brewer and Torricelli, 2007). Although the use 
of nitric acid etching and heat sterilisation were both trialled, 
improvements in terms of poly-D-lysine coating, cell adherence or cell 
survival were not observed 
Poly-D-lysine coating of coverslips 
One drop of sterile filtered poly-D-lysine solution was added to the 
centre of each coverslip. The 35 mm cell culture dishes were then placed 





temperature. After one hour, the poly-D-lysine was aspirated and the 
coverslips rinsed twice with dH2O.  
Timing: This step can be conducted during the tissue incubation with 
papain.  
Note: Poly-D-lysine is superior in terms of consistent cell attachment 
and neurite outgrowth when compared with poly-L-lysine (Kivell et al., 
2000). Alternative substrates used in the field include the following: a) 
poly-ornithi-nylated coated substrates which are reported as being 
conducive to rapid cell adhesion (Eide and McMurray, 2005; it is 
unclear however how this adhesion compares to that facilitated by 
poly-D-lysine), b) Polyethyleneimine, which is reported to initially 
result in good neuron attachment, survival and process outgrowth but 
thereafter is “unstable”, giving rise to inconsistent cultures. However, 
the specific manner of this instability and inconsistency was not 
elaborated upon by the authors (Eide and McMurray, 2005). The 
benefit of subsequently treating substrates with laminin (10mg ml-1) is 
debated and was found to have no benefit in hippocampal culture 
(Brewer and Torricelli, 2007). However, laminin does provide an 
extracellular matrix/scaffold and enhances cell growth in culture 
systems in general (Hall et al., 2008; Manthorpe et al., 1983). 
Optimisation: Evidence for the superiority of poly-D-lysine over other 
substrates for cell attachment, its widespread use and its low cost 
resulted in its selection for use in this method. We did not use laminin 
to reduce any unnecessary procedures and increase the efficiency of 
the method. Although serum pre-treatment of coverslips is reported as 
being essential for cell attachment, presumably due to an initial 
stimulus for neurite growth that it provides, thereby facilitating 
neuronal attachment (Kivell et al., 2000), we opted to provide this 
stimulus through a serum-containing plating medium.  
Storage: In the interest of efficiency, we opted not to prepare poly-D-
lysine fresh for each dissection as recommended by Kaech and 
Banker (2006) and instead used frozen stocks, whilst limiting freeze-
thaw cycles to no more than two (Brewer and Torricelli, 2007).  
Practical use: Poly-D-lysine was generally reconstituted at 100mg ml-
1 in sterile water (Brewer and Torricelli, 2007; Kaar et al., 2017) or 
borate buffer (Kaech and Banker, 2006). In terms of physically coating 
the coverslips, 0.1ml of poly-D-lysine per cm2 of the glass substrate to 
be covered is recommended (Brewer and Torricelli, 2007). In our 
hands, an objective measurement of one drop per coverslip was 
sufficient, whereas other protocols recommend enough to coat the 
entire coverslip (Beaudoin et al., 2012; Kaech and Banker, 2006). 
Indeed, the ability of poly-D-lysine to spread over the area of the 
coverslip, without signs of visible aggregation, is regarded as a 





2006). Once applied, poly-D-lysine is stable for between 3 d (Brewer 
and Torricelli, 2007) and 7 d at 4ºC (Beaudoin et al., 2012). To 
prevent any issues concerning poly-D-Lysine stability, our method 
recommends substrate treatment with poly-D-Lysine on the day of 
culture preparation. 
Troubleshooting: In preparation and after thawing, it is 
recommended that poly-D-lysine is thoroughly dissolved. The 
appearance of bubbles, which stick to the side of holding tubes, is a 
sign of undissolved poly-D-lysine. Applied poly-D-lysine should not be 
allowed to dry out on the coverslip prior to washing. Although some 
authors identify this as a critical step, no reason is given for its 
importance (Kaech and Banker, 2006). As a precaution, this 
recommendation is adhered to for the protocol described here. If 
unbound poly-D-lysine is not rinsed away thoroughly, cell attachment 
is compromised and cell death occurs (Brewer and Torricelli, 2007). In 




Unless otherwise stated, all procedures were carried out in a sterile 
laminar flow hood, using equipment and reagents which, if not already 
contained in sterile packaging, were sterilised with 70% ethanol. Strict 
aseptic technique was adhered to at all times in order to avoid contamination 
of the culture. 
Solution preparation 
Approximately 3 ml of dissection solution was sterile filtered into each 
of two 35 mm dishes which were then placed on ice in a dissection hood. 
Tissue isolation and treatment 
Hippocampi were isolated as described previously (Beaudoin 2012) 
and placed in the 35 mm dish on ice. Any extraneous tissue was cleaned 
from the hippocampi before they were transferred to the second 35 mm dish 
on ice. The tissue was then chopped into smaller pieces with fine scissors 
and then transferred to a 15ml tube using a Pasteur pipette. This tube was 
placed in a water bath at 37ºC with the papain solution, separately, and both 
were allowed to equilibrate at this temperature for five minutes. The tissue 
was then carefully transferred into the papain solution and placed onto an 
orbital shaker at 100 rpm at 37ºC for 45 minutes. The tissue was then gently 
removed from the papain solution and placed into another 15 ml tube 
containing 2 ml HBSS. This step was repeated two more times (to remove 





at this stage. The tissue was then transferred into another 15 ml tube 
containing approximately 6 ml of trituration solution. 
Trituration 
The tissue was allowed to settle to the bottom of the 15 ml tube 
containing the trituration solution. The tip of a plastic transfer pipette, with the 
bulb fully depressed, was firmly pushed against the bottom of the 15 ml tube 
(Fig 2.1). The solution containing the tissue was then aspirated into the 
pipette such that the tissue experienced a certain degree of friction as it 
moved between the edges of the bottom of the tube and the pipette itself. 
This friction helped to dissociate individual hippocampal neurons from the 
larger pieces. When all the tissue had been aspirated into the pipette, the tip 
of the pipette was then placed under the meniscus of the trituration solution 
and forcefully expelled. Depending on the resulting tissue break up, this 
procedure was repeated up to an absolute maximum of four times, allowing 
the tissue to settle to the bottom of the tube between each aspiration. The 
supernatant was then placed into another 15 ml tube, leaving behind as 
much as possible of the un-triturated tissue. This whole procedure took no 
more than five minutes. The supernatant was then centrifuged at 258 xg for 
two minutes at room temperature. A video illustrating this trituration 
procedure is published at https://doi.org/10.1016/j.jneumeth.2017.05.020. 
Practical use: A practical measure of the suitability of one’s trituration 
technique can be garnered by observing the consistency of the trituration 
solution. A sticky accumulate of floating tissue pieces indicates DNA release 





Optimisation: See discussion section for trituration optimisation  
information. Centrifugation parameters were optimised to allow for the 
formation of a relatively cohesive pellet, without compromising cell viability 
due to sheer stress or compression of cells. 
 
Cell seeding and culture 
After centrifugation, the supernatant was carefully poured out of the 
tube without disturbing the pellet of cells. Two drops of plating solution were 
then gently added and subsequently removed to dilute any residual 
supernatant. The volume of plating solution added (0.6 - 1 ml) is determined 
subjectively, depending on the size of the pellet which, in turn, is dependent 
upon the effectiveness of trituration. This resulted in a plating density of 
approximately 1 – 1.5 x 105 cells/cm2, which was optimal for cell survival and 
our subsequent calcium imaging experiments. The pellet was carefully 
dislodged from the bottom of the 15 ml tube using a Pasteur pipette, and the 
cells re-suspended by firmly finger vortexing 2 - 3 times, depending upon the 
level of re-suspension. An indication of successful technique up to this point 
Figure 2.1. Trituration method 
The trituration procedure is the most critical step in determining the success of a culture. The 
following procedure is considered optimal: 
1) The pipette bulb is fully depressed. 2) The pipette tip is then pushed firmly against the bottom 
of the tube and the bulb is released whilst maintaining downward pressure. 3) This results in tissue 
being “sieved” between the bottom of the tube and pipette tip. 4) Firmly dispel contents of pipette 
into the tissue solution. The majority of tissue will be dissociated following 2 – 3 repetitions. 
Video still, taken from a video illustrating the trituration method in full, is published by Kaar et al. 





was routinely determined by employing a trypan blue staining and cell 
counting protocol (see below). 
Optimisation: Cells undergo considerable mechanical stress during 
pellet re-suspension. Optimisation of this technique was achieved by 
observing the extent of cell dispersion by either mixing with a glass 
transfer pipette or “finger vortexing” using various forces and a 
number of repetitions. Whether these processes resulted in culture 
success or failure was noted. Careful dislodging of the pellet with a 
glass transfer pipette followed by relatively forceful finger vortexing (2 
– 3 times) was determined to be optimal. 
A drop (approximately 25 μl) of the final plating solution was then 
added to each coverslip using a Pasteur pipette. The coverslips were then 
placed in an incubator, where the cells were allowed to adhere to the 
coverslips for one hour. 2 ml of the culture solution was then very gently 
added to each 35 mm dish (to prevent damaging the cells through sheer 
stress), before returning the dishes to the incubator. 
Note: Limiting exposure of cells to ambient air during plating to 3 
minutes is recommended (Brewer and Torricelli, 2007). In practical 
terms, this was achieved through competence and the speed at which 
the protocol is carried out. Furthermore, the splitting of culture dishes 
into larger “holding dishes” reduced the number of dishes which were 
exposed to ambient air at any given time and made this process 
logistically easier. Measurement of culture success at this point could 
subjectively be determined by noting neuronal morphology soon after 
plating. Cells tend to start as isolated spheres and quickly grow 
neurites and processes. Such processes are regarded as being 
important for neuronal attachment to the substrate (Eide and 
McMurray, 2005) and their appearance can be taken as initial markers 
of success from 1 hour to several days post-culture (Kivell et al., 2000; 
Zhang et al., 2006). Previous studies have shown that cell viability 
immediately before plating is approximately 65 – 80% (rat brainstem 
cultures between E14 and P6). Neuron maturity is inversely 
proportional to viability at this stage (Kivell et al., 2000).  
Trypan blue exclusion 
100 μl of the cell suspension solution was gently mixed with 200μl of 
trypan blue. Approximately 10 μl of this mixture was then added to each side 
of a haemocytometer. A 1 ml pipette was used for this purpose as a narrow-
tip pipette excludes cell clusters and results in an underestimation of cell 
numbers (Brewer and Torricelli, 2007). The field of view was observed under 
a 10x phase contrast microscope. Phase-bright (dye-excluding) spherical 





haemocytometer. This count was averaged and multiplied by 104 to 
determine cell concentration per millilitre. 
Coverslip inversion 
Three hours after the culture medium was added to the 35mm dishes, 
the coverslips were inverted using sterile forceps. To prevent cross-
contamination, forceps were flame sterilised between each dish. 
Note: It has been shown previously that neurite growth, neuron 
survival and long-term neuronal maintenance is improved by the 
sandwiching of cells between the substrate and a coverslip (Brewer 
and Cotman, 1989; W. S. Chen et al., 2011; Kaneko and Sankai, 
2014; Lucius and Mentlein, 1995). The proposed mechanism 
underlying this improvement is thought to be the creation of a 
microenvironment where the diffusion of various growth factors and 
nutrients from neurons and glia into the surrounding media is limited, 
and extracellular [O2] is also reduced to more physiological levels 
(Brewer and Cotman, 1989; Kaech and Banker, 2006). 
Optimisation: In agreement with the findings described above, by 
subjective observation, we determined that neuron morphology and 
survival was improved upon coverslip inversion. Previous studies 
have shown that maximum neurite length, an indicator of neuronal 
viability and active growth, is highest with coverslip sandwich at 1 or 3 
hours when compared to 22 hours at 3 - 8 DIV. For longer-term 
maintenance (14 – 38 DIV), 3 or 22 hours inversion induced the 
greatest extent of neurite length. Therefore, 3 hours post-plating 
would appear to be a practical compromise for both short- and long-
term viability (Kaneko and Sankai, 2014). In line with this study, in our 
protocol cells were generally left to adhere to coverslips for 3 hours 
prior to coverslip inversion. However, an incubation ranging from 
between 2 – 4 hours does not appear to alter culture success.  
Immunocytochemistry 
Wash steps consisted of three changes of PBS, each lasting five 
minutes. Cells were fixed with paraformaldehyde (4%) and sucrose (4%) 
prepared in PBS and warmed to 37ºC for ten minutes. All subsequent steps, 
unless otherwise stated, were carried out at room temperature. After 
washing, a permeabilisation solution (0.25% Triton™X-100 in PBS) was 
added to the cells for ten minutes. Cells were washed once more with PBS 
and a blocking buffer (BSA 5% and glycine 0.3 M in PBS) was added for one 
hour. Primary antibody incubation was carried out overnight at 4ºC, using the 
following antibodies: pan-neuronal marker (1: 100), GFAP (1: 500) and 
Synapsin I (1: 200). The pan-neuronal marker is an antibody cocktail 
containing NeuN, βii-tubulin, NF-H and microtubule-associated protein 2 
(MAP-2). MAP-2 is only present on dendritic microtubules (Kaech and 





BSA (1%) in PBS. After washing, cells were incubated with the 
corresponding secondary antibody at 1: 200 dilution for one hour. Cells were 
again washed before being mounted on microscope slides.  
Determining the neuron versus glial cell composition of cultures 
The ratio of neurons to glia was determined by counting the number of 
pan-neuronal and GFAP-positive cells, respectively, under a confocal 
fluorescent microscope. As described previously, when cells were initially 
added to coverslips following their dispersal, a drop was placed in the centre 
of each coverslip. As a result, there is a non-uniform distribution and density 
of cells, with the highest density of cells appearing in the centre of the 
coverslip and receding outwards towards the perimeter of the initial cell 
droplet (Fig 2.2). Consequently, to obtain an accurate representation of 
overall cell numbers, a central point was chosen and three randomised 
points radiating from the middle to the edge of the immunostained region of 
each coverslip were selected for counting (such regions contained an 
average of 16 cells in an area of approximately 200 μm2). Compositional 
analysis was conducted upon coverslips fixed at 2, 5, 8, 11, 14, 17 and 20 
days in vitro and from three separate culture preparations (from three 











Figure 2.2. Global image of an immunostained coverslip 
Representative image displaying the non - uniformity of cell density and distribution of mouse hippocampal cultures. Neuronal 
marker, pan-neuronal stain containing NeuN, βii-tubulin, NF-H and MAP-2 (green). Glial marker, GFAP (blue). Image captured at 






Intracellular calcium measurements from neuronal somata were 
conducted as previously described (Rae et al., 2000). Briefly, using a 
conventional fluorescence imaging system consisting of a bright light source 
(Olympus TH4-200), monochromator (Cairn Optoscan), integrating camera 
(Hamamatsu ORCA-ER), DAQ device (USB6229) and frame grabber, 
neurons that had been preloaded for one hour in an incubator with the single 
wavelength, intensity modulating calcium indicator, fluo-2 AM (4 µM 
dissolved in a solution of HBSS with 0.1% pluronic) were imaged (excitation 
at 488 nm, emission at 550 nm; no neutral density filters were used) under 
both 20x and 40x magnification, where appropriate. The intensity of 
excitation light was minimised using neutral density filters. Under these 
conditions, there was no discernible bleaching or phototoxicity. 
Once loaded, washed and mounted on the microscope stage, neurons 
were continuously superfused with HBSS (2 ml/min) and all drugs were 
added to the superfusate. In so doing, we reduced the risk of inducing 
experimental artefacts which may have been caused by the pipetting of 
compounds directly onto cells within the field of view. However, this method 
of drug application also meant that it took a finite ‘lag time’ for the drug to 
reach the neurons (~30s). 
To block indirect actions of I-mGluR activation via synaptically driven 
Ca2+ transients/action potential-mediated release of neurotransmitter, all 
experiments were performed in the presence of the voltage-gated sodium 
channel (VGSC) antagonist tetrodotoxin (TTx; 1 M). Experiments involving 
NMDA were performed in Mg2+-free HBSS supplemented with 10 M glycine. 
Images were acquired at one-second intervals using the open source 
imaging software, Winfluor (John Dempster, University of Strathclyde, 
Scotland) via an Olympus BX50 WI microscope. Pixel binning (2-times) was 
applied to images. Winfluor calculated fluorescence values for each pixel in 
the frame after subtraction of background fluorescence intensities. Data files 
with time (seconds) vs fluorescence values (arbitrary units) for each region of 
interest (ROI) were exported from Winfluor as standard text files. This 
information was then imported into GraphPad Prism where XY line graphs 







2.3.1 Production and optimisation of postnatal primary mouse 
hippocampal cultures 
We have consistently produced postnatal hippocampal mouse 
cultures from animals between 3 - 5-days-old, which are routinely used for 
calcium imaging experiments. The ability to produce such cultures reliably 
and in a cost-effective manner is a result of optimising almost all facets of the 
culturing procedure. These optimisation steps are described in the materials 
and methods section and are also displayed in Table 2.2 Critical steps, 
including trituration, which we have identified as a primary determinant of 
culture success will be elaborated upon in Section 2.4 Discussion. 
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2.3.2 Characterisation of Hippocampal Cultures 
Hippocampal cultures produced using this new method contained 
healthy, functional cells which responded appropriately to physiological 
stimuli (see 2.3.3 Calcium imaging experiments). Cultures displayed normal 
neuronal morphology, arborisation, synaptic connections and intercellular 
associations from 2 DIV onwards, as evidenced by both bright field images 
(Fig 2.3 and 2.4) and from immunocytochemical images of neurons that had 
been stained with both a pan-neuronal marker, GFAP, and synapsin I 
antibodies (Fig 2.5 and 2.6).  
In order to characterise the development and composition of such 
cultures in vitro, we examined the neuron to glial cell ratio after fixing cultures 
at 2, 5, 8, 11, 14, 17 and 20 DIV (Fig 2.7). Although there is a steady decline 
in the numbers of both glia and neurons with increasing DIV, the neurons 
which do remain respond to standard physiological stimuli for up to one 
month after initial culturing (e.g. Fig 2.9).  































































































































































































Figure 2.4. Development of neurons in vitro 
Bright field (DIC) images of cultured mouse hippocampal neurons taken at progressively older days in vitro, 2 (a), 4 (b), 10 







Figure 2.5. Immunocytochemical visualisation of culture composition with progressive time in vitro 
Immunostaining of hippocampal cultures for neuronal and glial markers with corresponding phase - contrast images. Images were 
captured of cultures fixed at progressively older days in vitro 2 (a), 5 (b), 8 (c), 11 (d), 14 (e), 17 (f) and 20 (g). Neuronal marker, 
pan-neuronal stain containing NeuN, βii-tubulin, NF-H and MAP-2 (green). Glial marker, GFAP (blue). All cultures were 





























































































































































































































































































































































































































































2.3.3 Calcium imaging experiments 
Cultured neurons harvested from 3 - 5-day-old mice were usually 
utilised for up to fourteen days in vitro for calcium imaging experiments (Kaar 
and Rae, 2016, 2014). However, some experiments were also carried out 
using neurons which had been cultured for approximately one month to test 
long-term cell function (e.g. Fig 2.9). In the course of our calcium imaging 
investigations, we have utilised various compounds which healthy and 
functional cultured hippocampal neurons would be expected to respond to. 
For example, we have conducted experiments in which these neurons have 
responded to physiologically relevant stimuli such as 15 mM and 50 mM K+-
containing HBSS (Fig 2.8 a and b; which depolarise neurons and thereby 
activate VGCCs on the neuronal plasma membrane); the specific I-mGluR 
agonist, (S)-DHPG (50 µM), the muscarinic acetylcholine receptor agonist, 
carbachol (10 µM) and the RyR agonist, caffeine (20 mM), which all evoke 
calcium release from the endoplasmic reticulum (ER; Fig 2.8 c, d and f, 
respectively); as well as the ionotropic glutamate receptor agonist, NMDA (1 
µM; Fig 2.8 e). All compounds were added to the superfusate. 
 
 
Figure 2.8. Representative traces showing changes in somatic [Ca2+] levels within a cultured 
mouse hippocampal neuron in response to selected physiological stimuli 
Representative traces display responses to the application of: K+ (15 mM) (a), K+ (50 mM) (b), 
(S)-DHPG (50 µM) (c), carbachol (10 µM) (d), NMDA (1 µM) (e) and Caffeine (20 mM) (f). All 
compounds were added to the superfusate. All neurons were generated from 3 - 5-day-old mice 






Figure 2.9. Aged cultured hippocampal neurons remain viable for up to 1 month 




 levels within an aged (29 days in vitro) 
cultured mouse hippocampal neuron in response to perfusion of a physiological solution (HBSS) 
containing 50 mM K
+






The study and use of postnatal neurons and cultures are important for 
the investigation of chronic and/or age-dependent conditions such as 
neurodegeneration. Furthermore, as mentioned earlier, the importance and 
widespread use of transgenic mouse models, but the inherent difficulty in 
culturing postnatal mouse neurons relative to embryonic tissues (Brewer and 
Torricelli, 2007), or those of the rat (Beaudoin et al., 2012), underpins the 
need for an easily applicable and effective postnatal mouse culture protocol. 
Herein, we have described a novel, simplified protocol for the cost-
effective production of primary cultured neurons from postnatal mouse 
hippocampal tissue that remains viable for up to one-month post-culture. 
Hippocampal neurons within such cultures display normal development and 
arborisation, observable cellular interconnection (including synapses) and 
association with glial cells. 
The optimisation of almost all facets of the culturing procedure is 
outlined in Section 2.3 Results. Decisions on optimisation were developed 
out of practical and objective measurements of neuronal survival and 
morphology. These results led to an incremental improvement of current 
practices and omission of unnecessary steps/procedures as discussed in the 
Methods and Results sections. Optimisation steps which warrant a more 
thorough discussion, as well as key considerations in the design of our 







Contrary to previous studies such as that of Eide and McMurray 
(2005), we found that the manner in which the tissue is treated following 
incubation with tissue proteases, specifically the steps of trituration and 
subsequent resuspension after supernatant centrifugation, is absolutely 
critical to ensuring the production of consistent and successful cultures. In 
this respect, mouse neurons seem to be much more vulnerable and 
susceptible to mechanical stress than postnatal rat and embryonic neurons 
at this stage in the protocol.  
Of these two phases of major mechanical stress, the trituration 
procedure is the most critical step in determining the success of a culture. 
Thus, a balance is required between reaching optimal cell yield by sufficient 
tissue dissociation, whilst minimising cell lysis. Such lysis and debris 
production can both directly and indirectly, by altering the pH of the trituration 
solution and releasing cytotoxic agents such as glutamate, hinder cell 
attachment, sprouting and viability (Brewer, 1997; Eide and McMurray, 
2005).  
Trituration pipette tip diameter is crucial in determining overall cell 
yield, with too small a tip diameter causing cell damage, but too large a 
diameter resulting in the insufficient tissue breakdown. We found that a 
plastic, wide tip diameter (drop size 35 – 55 µl) transfer pipette (see 
equipment) was optimal for reaching this compromise. Using such a plastic 
pipette allowed us to abandon using flame polished glass pipettes, which are 
routinely utilised for this purpose in the field. Thus, the requirement to create 
smooth tipped glass pipettes through flame polishing, which is inherently 
unreliable and can result in such a small a tip diameter that it damages cells, 
is circumvented (Beaudoin et al., 2012).  
When the triturated cell suspension is expelled from the pipette and 
returned to the residual supernatant, it is done so relatively forcefully but with 
the pipette tip under the liquid surface (see video). This results in minimal 
bubble production. The production of such bubbles during trituration is 
actively discouraged by other research groups (Brewer and Torricelli, 2007). 
However, we have found that this relatively forceful expulsion from the 
pipette allows for improved tissue dissociation. Furthermore, it does not 
significantly affect the quality of our cultures in comparison to, say, over 
trituration which is much more damaging to the neurons. 
Specific protocols can be utilised to reduce the production of cellular 
debris during trituration. These protocols include: the use of cell strainers 
(Beaudoin et al., 2012; Kaneko and Sankai, 2014), “washing” plated neurons 





of neurons to remove both contaminating glia and debris (Brewer and 
Torricelli, 2007).  
The process of washing adhered neurons (i.e. removing the cell 
suspension) increased cell sprouting by 7-fold at 5 DIV in adult rat 
hippocampal neurons (Brewer, 1997), suggesting that cellular debris 
contains factors which inhibit sprouting (Faissner and Steindler, 1995). 
However, it is proposed that because neurons depend upon their processes 
for adherence to the substrate, and because such processes are slow to 
develop, washing could remove healthy neurons which have not had 
sufficient time to attach (Eide and McMurray, 2005). This influences the 
period of time within which cells are allowed to adhere before the plating 
solution is washed off and/or culture medium is added. Experiments on cell 
attachment (using poly-L-ornithine substrates) by Eide et al. (2005) illustrated 
the importance of the length of plating incubation to culture success. 
Specifically, cell attachment to the substrate occurred within the first 10 
minutes and a 15-minute incubation prior to washing was optimal whereas a 
2-hour incubation resulted in complete culture failure (Eide and McMurray, 
2005). We determined that a plating time of 1 hour was optimum for cell 
survival and for consistent culture success using poly-D-lysine-coated 
coverslips. This is within the time frame of 2 hours, which has previously 
been reported as allowing the majority of cells attach to poly-D-lysine 
(Brewer, 1997). A specific wash step was not employed in our method in an 
effort to reduce the time cells spend in unfavourable conditions outside of the 
incubator. Instead, any debris that was present was effectively diluted to 
apparently negligible amounts through the addition of a large volume of 
culture medium (~2.5 ml). 
Debris removal using cell strainers (Chen et al., 2013) of various pore 
diameters or neuronal enrichment by gradient centrifugation (Brewer and 
Torricelli, 2007) did not yield significant improvements in culture quality to 
warrant their utilisation. Furthermore, these techniques increase the 
exposure of cells to ambient conditions, decrease the efficiency of protocol 
and add to the overall costs of the method. 
By using the novel trituration technique described herein, combined 
with limiting the number of triturations to an absolute maximum of four, we 
effectively minimised the main mechanical stress experienced by neurons 
and also significantly reduced the amount of debris that would be produced 
under normal circumstances. The production of debris was further limited by 
implementing a gentle re-suspension of triturated cells by finger-vortexing 
rather than further trituration. In turn, this resulted not only in the production 
of very little potentially contaminating cellular debris but also, more 
importantly, a cell suspension containing a very high percentage of viable 





represents a significant improvement on previous studies, which have 
typically shown approximately 75-85% cell viability post-trituration in 
hippocampal prenatal mouse culture (E19; Seibenhener and Wooten, 2012) 
and 65–80% in rat brainstem culture (E14 – P6; Kivell et al., 2000). 
 
2.4.2 Glial cells in culture 
The utilisation of either “pure” neuronal cultures, mixed cultures 
(composed of neurons and glia) or removable glial feeder layers is 
dependent upon the suitability of these particular environments to specific 
experimental requirements. “Pure” neuronal cultures (e.g. Chen et al., 2011; 
Brewer 1995) exhibit minimal glial proliferation and represent a means of 
reducing the confounding factor of glial influence on neuronal physiology. 
However, this simplification in terms cellular environment must be balanced 
with physiological relevance.  
Glia play a critical role in supporting neuronal function and 
development, including roles in signalling, synaptic plasticity and network 
formation (Allen and Barres, 2009; Araque and Navarrete, 2010; Auld and 
Robitaille, 2003; Banker, 1980; Barker and Ullian, 2008; Bazargani and 
Attwell, 2016; Nedergaard et al., 2003; Shaham, 2005). These functions are 
achieved, primarily, via the release of soluble factors, including growth 
factors, signalling molecules and lipids (Ebrahimi et al., 2016; Hassanpoor et 
al., 2013; Mauch et al., 2001). Therefore, the presence, or otherwise, of glial 
cells in neuronal cultures will almost certainly influence both culture 
development and phenotype.  
With this evidence in mind, we opted not to use glial inhibitors such 
as -D-cytosine arabinofuranoside (Beaudoin et al., 2012; Mao and Wang, 
2001; Rae et al., 2000; Seibenhener and Wooten, 2012) and 5-fluro-2X-
deoxyuridine (Oorschot, 1989). These inhibitors negatively impact upon 
culture viability and synaptic development and, indeed, can actually enhance 
neuronal cell death (Beaudoin et al., 2012; Kivell et al., 2000; Pfrieger and 
Barres, 1997; Seibenhener and Wooten, 2012; Ullian et al., 2001; Wallace 
and Johnson, 1989). Furthermore, we feel that the presence of glia is more 
reflective of the in vivo environment, which we are striving to model in these 
cultures as accurately as possible. Although some proponents of pure 
cultures point to cytotoxic factors which are produced and released during 
the lifespan of glia (Price and Brewer, 2001) as a reason not to include these 
cells (Seibenhener and Wooten, 2012), we believe that the benefits of glial-
containing cultures far outweigh this negative aspect.  
Numerous studies have characterised the interaction between 





brainstem cultures (E14 – P6, 4 – 9 DIV) associated with glia (Kivell et al., 
2000; Miller and Azmitia, 1999). Furthermore, rat hippocampal cultures (P2 - 
P3, 7 DIV) also contained glia which had complex shapes and several 
processes and which were also closely associated with neurons (Pozzi et al., 
2017). Other types of cultured neurons (e.g. brainstem and cerebellum) can 
grow on top of a naturally occurring layer of type 1 astrocytes, although there 
were also viable neurons on the same coverslips which were not in proximity 
to glia (Kivell et al., 2000; Trenkner, 1992).  
The positive effects of such interactions are evidenced by the 
following observations: i) glial proliferation in hippocampal cultures has been 
shown to be protective against excitatory amino acid-induced degeneration 
of hippocampal neurons (Mattson et al., 1995; Mattson and Rychlik, 1990), ii) 
the use of astroglial-conditioned media (ACM) increased long-term neuronal 
survival (up to 60 DIV) in rat embryonic hippocampal (P0 – 3) and 
hypothalamic (P21) cultures (Pozzi et al., 2017; Todd et al., 2013; Yamashita 
et al., 1992), and iii) we have observed (albeit unquantified) a positive 
association between neuron and glia interaction, where long-term viability 
and responsiveness of neurons in Ca2+ imaging experiments is increased in 
those cultures where neurons and glia are in proximity to each other. 
The importance of neuron-glia interactions is also illustrated by the 
number of recently published primary culture methods which specifically 
seek to foster glial support through the utilisation of, a) astroglial monolayers 
which are used as a substrate on which to plate hippocampal neurons 
(Ivenshitz and Segal, 2010; Segal et al., 1998), b) glia feeder layers which, 
although time-consuming to implement, resulted in high-quality primary 
neurons (Beaudoin et al., 2012; Boraso and Viviani, 2011; Kaech and 
Banker, 2006; Shimizu et al., 2011) and, c) culturing neurons in ACM (Pozzi 
et al., 2017). However, the simplicity and effectiveness of our mixed culture 
method make the use of these technically demanding protocols redundant, at 
least for our particular application of subsequent Ca2+ imaging between 2 – 
14 DIV. Depending upon the specific research question one wishes to 
investigate however, the components of the various media suggested herein 








2.4.3 Culture density 
Paracrine support from glia and other neurons can also be fostered 
using a relatively high plating density. However, above a threshold density, 
cells and debris can clump into large aggregates. Although such aggregates 
are oftentimes viable it would be almost impossible to accurately visualise 
individual cells contained within them (e.g. during Ca2+ imaging 
experiments). Furthermore, in our experience at least, such high-density 
cultures are not amenable to long-term maintenance. 
In line with previous reports (Kaneko and Sankai, 2014), in our hands, 
utilising a plating density which is below a certain threshold also resulted in 
the complete failure of our cultures. Specifically, rat hippocampal cultures at 
a density below 104 cells/cm2 die within days (Banker and Cowan, 1979, 
1977; Banker, 1980; Brewer et al., 1993; Brewer and Cotman, 1989; Lucius 
and Mentlein, 1995). This may be due to the relatively lower concentrations 
of trophic factors such as nerve growth factor, brain-derived neurotrophic 
factor and basic and acidic fibroblast growth factor (bFGF and aFGF), that 
are released from neurons and glia (Kaech and Banker, 2006), and which 
are important for neuronal survival (Barde, 1989; Kaech and Banker, 2006; 
Levi-Montalcini, 1966; Varon and Adler, 1980). Interestingly, mature neurons 
may be more dependent upon such trophic support, relative to embryonic 
tissue (Kivell et al., 2000). That there may be a so-called “sweet-spot” for 
culture density is illustrated in work by Kaneko et al. (2014), where rat 
hippocampal cultures (E18 – 19) were plated at the following concentrations: 
3 × 103, 1 – 1.25 × 104, 2.5 – 3 × 104 and 105 cells ml-1. Maximum neurite 
length was measured in these cultures as an indication of neuronal survival 
and active neurite growth, When this range of densities was investigated, it 
was determined that 3 × 104 cells ml-1 or 8.9 × 103 cells/cm2 were the optimal 
plating density for survival of the culture (Kaneko and Sankai, 2014). 
Plating density also has important implications for synapse formation 
and, therefore, the generation of neuronal networks in culture. In rat cortical 
cultures (E18), the mean number of synapses per neuron at 7 DIV was less 
than five and did not vary significantly between lower, medium and higher 
density cultures (ranging from 10 – 50,000 neurons/mm2; Cullen et al., 
2010). Conversely, at 21 DIV, culture density was inversely proportional to 
synapse density (Cullen et al., 2010). Synapse-to-neuron ratio was greatest 
at lower neuronal densities (< 500 neurons/mm2), with an average of 400 
synapses per neuron, whereas mid to higher neuronal densities (500 - 4500 
neurons/mm2) had an average of approximately 150 synapses per neuron 
(Cullen et al., 2010). It is possible therefore, that if one wanted to investigate 






2.4.4 Choice of medium 
Aside from the desired cell-type composition of one's culture, other 
factors which determine the choice of the medium one chooses to utilise 
include the age of the animal from which the culture is produced, evidence of 
the medium’s reliability in fostering healthy cell growth, previous 
characterisation of cell development and phenotype in the medium and 
financial considerations. Each plating and culture medium has its own 
advantages and the composition of each can be altered depending upon the 
desired specific application. Investing time in researching optimum medium 
composition, to ensure that there are no pharmacological conflicts with one’s 
experimental design, is suggested by Nunez et al. (2008). With respect to 
our subsequent calcium imaging experiments, DMEM/SR2 did not contain 
any compounds of concern. Related to this, the use of fully defined media 
and supplements, as opposed to undefined biological supplements such as 
FBS during culture maintenance, reduces confounding factors in 
experimental design (Kaneko and Sankai, 2014). Some common media and 
supplement combinations are listed below: 
NB combined with B27. NB is widely used and is generally reported 
upon positively in the field (Kivell et al., 2000). It is a commercial formulation 
based upon DMEM, which is usually supplemented with B27. NB-A is 
formulated for postnatal use and has a higher osmolarity than media 
designed for foetal cultures. It is optimised for neuronal survival and growth, 
and when supplemented with B27 results in approximately 80% neuronal 
survival after 7 DIV for hippocampal cultures plated at 100 cells/mm2 (Xie et 
al., 2000). NB/B27 also suppresses glial survival and growth (Zhang et al., 
2006). Specifically, NB/B27 prevents the growth of astrocytes but not 
oligodendrocytes (Brewer et al., 1993; Svendsen et al., 1995).  
The use of NB is however associated with the appearance of vacuoles 
and increased clumping, postulated to result from increased neuronal 
projections (Banker and Cowan, 1977; Brewer et al., 1993), when compared 
to an alternative medium, NM-2 (composed of 70% MEM and 30% NB; Xie 
et al., 2000). Furthermore, there is evidence that a component of NB, L-
cysteine, causes NMDA receptor-mediated excitotoxicity in mature neuronal 
cultures (12 -14 DIV; Brewer, 1997). As a consequence of this feature, its 
use may be limited to maintaining neurons from 1-11 DIV (Hogins et al., 
2011). Furthermore, NB may not be suitable for hippocampal neurons, which 
are particularly susceptible to NMDA receptor-mediated excitotoxicity 
(Hogins et al., 2011). 
B27. In terms of supplementing the base media, serum or a “serum 
replacement” supplement is generally used. There are a wide variety of 





commonly used for a wide array culture protocols (Chen et al., 2008) 
probably because it contains a high proportion of antioxidants and promotes 
neuronal survival, whilst inhibiting glial growth (Brewer, 1997; Brewer et al., 
1993; Kivell et al., 2000; Marriott et al., 1995). B27 supplementation has 
been used for culturing of embryonic neurons from multiple brain regions 
(Brewer, 1995) and for the culture of adult rat hippocampal neurons (24 - 36-
months-old) which remained viable for several months without glial feeder 
layers (Brewer and Torricelli, 2007).  
However, Chen et al. (2008), reported issues of reliability surrounding 
B27. The biological nature and differing procedures for the isolation of 
several components in this media, such as BSA and transferrin, results in 
variations in product quality. As a solution, this group altered 21 ingredients 
of an early published formula of B27, to produce NS21 (Y. Chen et al., 2008). 
Key differences between it and NB which increased reliability were the use of 
specific product vendors for certain key ingredients and the use of holo-
transferrin instead of apo-transferrin. This supplement enabled the 
production of high quality, reliable cultures, exhibiting normal neuronal 
morphology, synapse formation and post-synaptic responses. For instance, 
NS21 facilitated the growth of up to five times more filopodia-like structures 
during neuronal development than B27 (Y. Chen et al., 2008). We did not 
measure the effectiveness of this supplement using our protocol as we did 
not feel it was necessary given our success using less expensive SR2. 
However, again depending upon individual labs’ requirements/preferences, 
this, or any other supplement, could be utilised instead of SR2. 
NbActiv4 is described as a recent improvement on the NB/B27 
combination, developed by the same group that formulated this classical 
medium (Brewer et al., 2008). Its use is associated with improved 
measurements of developed synapses in rat hippocampal neurons (E18), 
such as increased neuronal spike rates (4- to 8-fold) when compared with 
cultures prepared using NB/B27. However, this new proprietary medium 
combination is significantly more expensive than NB. Furthermore, aside 
from synaptic measurements, whether or not this formulation is a significant 
improvement, in terms of culture viability and cellular physiology, on classical 
formulations such as that presented herein, is unknown. 
Hibernate A (Brewer and Price, 1996) is a form of NB (Brewer et al., 
1993) which has the advantage of maintaining a stable pH out of the CO2 
buffering environment of the incubator. It has been used with B27 
supplementation during the trituration and cell isolation procedures in 
numerous previously published hippocampal culture protocols (Brewer, 
1997; Brewer and Torricelli, 2007; Todd et al., 2013). In our hands, Hibernate 





cell survival (determined subjectively) when compared with the use of 
standard lab-made HBSS during the trituration and cell isolation procedures. 
DMEM and SR2. DMEM is referred to as a basal medium as it 
contains no proteins or growth promoting agents and therefore requires 
supplementation with specific additives. CO2 regulation is essential to 
maintain a pH of 7.4 (Arora, 2013). In our hands, DMEM medium 
supplemented with a generic serum replacement supplement, SR-2, 
produced reliable and high-quality hippocampal cultures. Therefore, this 
combination was used as a replacement for the more expensive NB/B27 
combination. 
The choice of media becomes more complex when one studies 
protocols which utilise blends of currently available media. For example, Xie 
et al. (1999) compared the effectiveness of supplemented NB, MEM and 
various blends composed of different relative contributions of these two 
media such as “NM-2”. This study illustrated that one could tailor and 
balance culture solutions to suit one's desired outcomes, such as cell density 
and neuron-to-glial ratio. 
Importantly, the preparation and long-term survival of our neuronal 
cultures was independent of any requirement for either proprietary media 
and/or supplements (Ahlemeyer and Baumgart-Vogt, 2005; Beaudoin et al., 
2012; Brewer and Torricelli, 2007; Kivell et al., 2000; Nunez, 2008; Zhang et 
al., 2006). To the best of our knowledge, only three other papers have 
demonstrated viable mouse postnatal neuronal cultures from central nervous 
system tissue, but all utilised the aforementioned proprietary media and 
supplements. The method described by Eide and McMurray (2005), using 
striatal and cortical mouse tissue, is particularly impressive given the age of 
the animals involved, 1 – 1.5-years-old. Unfortunately, it is unclear how these 
researchers achieved this outcome as the paper in question lacks 
methodological detail about the protocol that was employed to prepare the 
neurons. Although the methods employed by both Beaudoin et al. (2012) and 
Brewer et al. (2007), using early postnatal (P0 – P1) and adult mouse 
hippocampal tissue, respectively, are well described and imply that good 
quality cultures can be produced, they are much more laborious and 
expensive than the protocol described here. Therefore, our technique would 
appear to offer several advantages over these aforementioned studies, in 
that the methodology is simple and efficient, cultures can be produced from 
older animals (routinely 3 - 6 day-old mice, but several cultures have been 
produced up to day 14) and the protocol has relatively lower costs of 






2.4.5 Inclusion of glutamine and glutamate 
The amino acid glutamine is essential for the survival and growth of 
cells in culture (Eagle et al., 1956). L-glutamine (L-Gln) and GlutaMAX / L-
alanyl-L-glutamine, which is a stable form of L-Gln, are commonly used 
media supplements. The use of GlutaMAX is recommended over L-Gln as 
the latter degrades with time to produce ammonia and carboxylic acid, which 
are both toxic substances (Seibenhener and Wooten, 2012). According to 
the manufacturer’s guidelines, the use of GlutaMAX increases cell viability 
and growth reduces or removes the need for medium change (due to the 
decreased build-up of ammonia in comparison to L-glutamine) and remains 
stable across a wide range of temperatures. Subjectively, we found that 
there were more successful cultures when using GlutaMAX over L-Gln and 
so this supplement was used routinely.  
Another reason for the routine use in the field of GlutaMAX over L-Gln 
is that above 4ºC L-Gln deaminates to glutamate which builds up over time 
and is excitotoxic to neurons (Choi et al., 1987; Zhang and Bhavnani, 2005). 
That being said, when we replaced half the culture media every three days in 
an effort to prevent the cytotoxic build-up of glutamate and other toxic 
metabolites there were no observable benefits in terms of viability or 
development of the neurons. Furthermore, the addition of glutamate to 
neuronal cultures may actually be beneficial. 
Glutamate plays a key role in CNS neurons where it acts as the 
principal fast excitatory transmitter (Verderio et al., 1999) and regulates 
neuronal differentiation, cell proliferation, CNS development, cell survival and 
synaptic plasticity (Balazs, 2006; Edwards et al., 2010; Verderio et al., 1999). 
Indeed, micromolar glutamate concentrations have been used to culture 
embryonic neurons, with the aim of facilitating glutamate-dependent 
developmental processes (Brewer et al., 1993). Similarly, in adult 
hippocampal neurons, glutamate was removed after 4 DIV, presumably after 
allowing for its positive developmental effects on plated neurons before 
glutamate toxicity occurred (Brewer, 1998, 1997; Brewer et al., 2005). 
Furthermore, incubation of adult hippocampal cultures (3 - 6-month-old; rat) 
with very low concentrations of glutamate (25 μM; 1 – 7 DIV), promoted a 
persistent enhancement of physiological neuronal activity and produced 
minimal excitotoxicity, relative to controls (Edwards et al., 2010). Therefore, 
we too utilised this low glutamate concentration in all our culture solutions to 








Kaech and Banker (2007) noted that “only the most resolute attempt 
to work with cultures beyond 4 weeks.” Indeed, typically with hippocampal 
cultures, widespread cell death occurs within 3 – 4 weeks in vitro (Kaech and 
Banker, 2006). “Replenishment”/replacement of the maintenance medium is 
routinely used in the field, with the aim of removing and diluting waste 
products of metabolism and supplying fresh nutrients, in order to maintain 
neuronal viability (see below). 
However, medium changes are not without their disadvantages. For 
example, they risk infecting the culture medium and cell death through 
exposure of cells to ambient temperatures and CO2. Furthermore, given the 
importance of trophic factors to mature neurons, if replacement is to be 
carried out it must be to an extent where these trophic factors are not diluted 
to the detriment of cell viability. Attempts to balance these advantages and 
disadvantages has resulted in quite varied recommended protocols for 
medium replacement, ranging from every 2 to 5 days (Beaudoin et al., 2012; 
Hilgenberg and Smith, 2007; Hogins et al., 2011; Lee et al., 2009; Srinivas et 
al., 2007), every week (Brewer and Torricelli, 2007; Chen et al., 2008; Kaech 
and Banker, 2006b; Kivell et al., 2000; Nunez, 2008; Potter and DeMarse, 
2001; Zhang et al., 2006) or leaving it entirely unchanged (Ahlemeyer and 
Baumgart-Vogt, 2005; Eide and McMurray, 2005; Xie et al., 2000). 
Interestingly Potter et al. (2001) could maintain neuronal viability by 
replenishing evaporated water alone. Although in the early stages of the 
development of our protocol we did investigate the effects of replacing 50% 
of the culture medium every 3 days, we did not observe any significant 
difference in the quality or responsiveness of neurons relative to those in 
which the medium remained unchanged. Because of this and the fact that 
our cultures remain viable for up to one month without medium replacement 
(which is well within our needs for subsequent experimental use) we chose 
not to include this replacement step in the protocol described herein. 
In terms of the upper limits of long-term maintenance in culture, we 
have observed sparse but viable cells in our cultures past 100 DIV. This is 
significant as the reported upper limit of survival in current mouse 
hippocampal culture protocols ranges from 6 – 60 DIV (Table 2.1; early 
postnatal and adult mice). As an indication of more long-term viability, Fig 2.9 
displays a Ca2+ response from a neuron at approximately 1 month in vitro. In 
practice, and as previously mentioned, we generally utilised cultures within 2 







2.4.7 Culture characterisation 
Methodology 
The determination of culture composition requires anatomical analysis 
of cell type as identification based on morphology alone is relatively 
unreliable (Raff et al., 1979). This is due, in part, to the morphological 
similarities between multipolar neurons and stellate-shaped type II astrocytes 
under phase contrast microscopy (Kivell et al., 2000). Therefore, 
immunocytochemistry-based identification, in tandem with morphological 
analysis (Kivell et al., 2000) is widely believed to be preferable. For instance, 
Kivell et al. (2000) utilised MAP-2 and GFAP positive immunoreactivity, for 
neuron and glia identification, respectively. Other cells were assumed to 
include fibroblasts, macrophages, oligodendrocytes, and endothelial cells 
(Magistretti et al., 1996). The protocol utilised herein adopts a similar 
identification protocol based on this method by utilising a pan-neuronal 
cocktail which contained MAP-2 and the glial marker, GFAP. Use of the pan-
neuronal cocktail had the added advantage of illuminating, more 
comprehensively, the neuronal cytoarchitectural structure. This identification 
protocol allowed us to determine the composition, in terms of neuron and 
glial cells, of our cultures. In the next section, I will detail how this 
composition compares to that obtained using alternative methodologies to 
ours. 
Culture composition of previous studies 
Methods published by Kivell et al. (2000), utilising E14 – P6 rat 
brainstem tissue (B27/NB), contain the most extensive cell characterisation 
in the field. They presented the following findings:  
1. Culture composition was dependent upon the age of the animal, with type 
I astrocytes constituting a greater proportion of total cells in older, (P6; 50 
- 72%) relative to younger cultures (E14; 17 - 20%). 
 
2. E14 cultures contained a higher proportion of glia than neurons (61% vs 
35%) and most neurons were bipolar as opposed to multipolar (40% 
versus 21%). 
 
3. Late embryonic (E16 and E20) and early postnatal (P3 and P6) cultures 
also contained a higher proportion of glia than neurons (67-73% versus 
25-31%) and, as would be expected with a more developed nervous 
system, had an increased proportion of multipolar neurons (18-25%) 
compared with bipolar (5-9%) neurons with developmental age.  
 
4. Type I astrocytes were more abundant than type II at all development 





The majority of studies have displayed hippocampal culture 
composition as a percentage of neurons and glia present. These studies 
include, a) mouse hippocampal cultures (P0.5, 6 DIV, NB/B27) which 
contained 7% astrocytes and fewer than 1% oligodendrocytes (Ahlemeyer 
and Baumgart-Vogt, 2005), b) mouse hippocampal cultures (P0 - 1, DIV 5, 
NB/B27), which contained 6 – 8% glia (Beaudoin et al., 2012), and c) rat 
hippocampal cultures (P2 -P3, 7 DIV), which contained 23% glia, when 
cultures were maintained in NB/B27, and 32% when maintained in FBS 
(Pozzi et al., 2017).  
These findings illustrate that before attempting to find correlations 
between our work and previous studies one must bear in mind the caveat 
that other studies may have utilised different animal species, brain regions, 
culture media and/or methods, which will undoubtedly affect the final culture 
composition. However, that said, such comparisons are still worthwhile in 
terms of identifying general trends in culture characterisation. 
The majority of studies measured culture composition in vitro at one 
specific point in time or commented generally using subjective observational 
evidence. However, there are some exceptions, such as the work of Kivell et 
al. (2000), which showed that the proportion of glia in brainstem cultures 
(E14 – P6, rat) remained constant from 4 – 9 DIV. Although these cells did 
not proliferate and overgrow, they still remained viable. Serum-free culture 
conditions, such as the B27/NB medium used in the aforementioned study, 
are known to inhibit astrocytic cell division and proliferation in culture (Brewer 
et al., 1993; Kivell et al., 2000; Marriott et al., 1995).  
Conversely, in our study we showed that by using our DMEM/SR2 
medium combination without replacement, there was a steady increase in 
the percentage of glial cells (ranging from 25% to 60%), out of the total 
number of viable cells, from 2 – 20 DIV (Figs 2.5 and 2.7). Despite this 
increase, glial cells did not proliferate to an extent which hindered Ca2+ 
imaging experiments. The difference in glial composition between our 
protocol and that of Kivell et al. (2000) is likely due to the use of FBS to 
supplement plating media. Whilst FBS causes glial proliferation (and 
potentially enhances their trophic support of neurons), it also encourages 
neuronal attachment and survival during this critical plating period (Kivell et 
al., 2000; Pozzi et al., 2017). For instance, when rat hippocampal neurons 
(P2 – P3) were plated in serum-free NB/B27 media, neuronal death 
increased and there was an absence of electrical activity. When the same 
culturing procedure was repeated with ACM medium or plating medium 
supplemented with FBS, it produced viable hippocampal cultures with normal 
physiology which could be maintained for over one month (Pozzi et al., 
2017). Therefore, the dilution of FBS after 1 hour of plating as opposed to the 





survival, maintenance and practical use of the experimental units. The ratio 
of glia to neurons in our cultures between 2 – 20 DIV could be altered, 
should a researcher desire a more neuron-enriched culture. This could be 
achieved, for example, by the removal of FBS after plating, instead of diluting 
it as we have done.  
 
Measurement of Culture Quality 
The immunocytochemical studies which allow culture composition to 
be determined also have the advantage of allowing us to study neuron 
morphology. A physiologically-relevant temporal change in neuron 
morphology is indicative of healthy and maturing neurons, as discussed in 
Section 2.1.4 Characteristics of hippocampal cultures. Such temporally 
determined observations include an increase in process length, the 
development of multiple well-arborised dendrites (Y. Chen et al., 2008) and 
increased neuron-neuron and neuron-glial (depending on the desired purity 
of culture) connections and synapses (Zhang et al., 2006).  
With respect to glia, immature astrocytes have relatively simple and 
undifferentiated morphology with a low degree of arborisation. In contrast, 
mature astrocytes have highly branched and complex arborisation, observed 
after 2 months in vitro in rat hippocampal neurons (P2 - 3, NB/ACM; Pozzi et 
al., 2017), which is similar to their structure in vivo (Cerbai et al., 2012; 
Puschmann et al., 2013). If astrocytes have a fibroblast-like morphology, it is 
likely to be an artefact of serum being included in the culture medium (Foo et 
al., 2011; Landis et al., 1990). The fact that neurons and glia in our cultures 
clearly exhibit evidence of maturation (by 2 and 5 DIV, respectively), 
connectedness (Fig 2.5), and markers of functional synapses (Fig 2.6), is an 
indication of the usefulness of this protocol in modelling physiologically-
relevant neurons, glia and neuronal networks. Notably, cultures produced by 
this method appear to mature much more rapidly than the relatively slow 
process outlined for previous methods in Section 1.4. Of particular note is the 
formation of mature axons, dendrites and synapses by 2 DIV, indicating 
stage five development, in comparison to previous cultures exhibiting such 
developmental markers at 3 – 4 DIV (Craig and Banker, 1994; Dotti et al., 
1988; Fletcher and Banker, 1989).  
Moreover, cultures produced using our method have been utilised 
routinely for hundreds of Ca2+ imaging experiments, including those 
presented in Chapters 3 and 4. These hippocampal cultures displayed 
physiological characteristics and responses which were similar to those 
previously presented using other hippocampal culture methods (e.g. Zhang 





such as membrane depolarisation and stimulation of ACh, NMDA and 
glutamate receptors are presented in Fig 8. 
Alteration of phenotype in vitro 
Related to the anatomical changes of cells that occur during 
development in vitro, the question arises; does cellular physiology change in 
a similar temporal manner to development in vitro and, if so, what is the 
extent of these changes? Such physiological changes may be related to 
natural developmental and/or ageing processes and/or unnatural 
environmental influences generated by the particular culture methodology 
that was employed. Such unnatural influences include altered O2 
dependency, saturated nutritional state and/or the build-up of waste 
products, metabolites and signalling factors which may be processed and 
regulated differently in vivo. As an indication of how phenotype can be 
altered in vitro, to counterbalance the use of embryonic tissue as a proxy for 
‘mature’ tissue, some methods recommend “maturing” cells in vitro before 
use. For example, Xenopus spinal neurons and rat superior cervical ganglia 
cells begin to exhibit “mature” action potentials after 14 DIV (Baccaglini and 
Spitzer, 1977; Nerbonne and Gurney, 1989). Conversely, when measuring 
Ca2+ currents in response to depolarising membrane potentials, no 
differences were detected in neurons between 1 - 7 DIV (Zhang et al., 2006). 
In our own Ca2+ imaging experiments, there is limited evidence that 
hippocampal neurons exhibit developmental differences, dependent on in 
vitro development (2 – 20 DIV), in depolarisation-induced Ca2+ influx 
(appendix figure 1 (Fig A.1), B, ii & iv; Fig A.2, B, ii; Fig A.7, F, ii) and I-
mGluR-mediated signalling (Fig 3.6). 
 
2.4.8 Improvement on methods 
Increasing viability  
The addition of neuroprotective mediators throughout the culture 
protocol may be one feasible means of increasing neuronal viability. Such 
neuroprotective strategies include using, a) the NMDAR antagonist ifenprodil 
(Graham et al., 1992), b) the caspase inhibitor carbobenzoxy-valyl-alanyl-
aspartyl-[O-methyl]- fluoromethylketone (z-VAD-FMK; Han et al., 2002), c) 3-
aminobenzamide to suppress oxidative stress-induced cell death (Zingarelli 
et al., 1997), d) deoxyribonuclease (DNase) inhibition of DNA-mediated 
neuron-debris clumping (Kaneko and Sankai, 2014), and e) cholesterol 
addition compensating for the lack of cholesterol released by glia (only 
relevant to pure cultures), a process which is essential for synaptogenesis 
(Mauch et al., 2001). However, Eide et al. (2005) found that no significant 
advantage was gained by exposing neurons to any of the factors mentioned 





survival. However, it should be noted that in this particular case, the 
hippocampal tissue was incubated with these compounds prior to cell 
dispersal (papain treatment and trituration), rather than the substances being 
added to the culture medium. It would be worthwhile repeating these 
experiments with compounds added during, or after, papain treatment, 
and/or trituration as they are the primary stress events that the neurons 
experience during the culturing process.  
A role for bFGF in the development and viability of cultured neurons 
has been well established. bFGF is known to activate anti-apoptotic 
pathways (König et al., 1997; Miho et al., 1999) and promotes neurogenesis 
(Sun et al., 2009; Tao et al., 1996; Yoshimura et al., 2001). In culture, it 
facilitates the proliferation and differentiation of rat brainstem neurons (P3 – 
5; Zhang et al., 2006). Furthermore, it can increase neuronal survival up to 
threefold, independent of age, in rat hippocampal (11 - 36-months-old) and 
brainstem cultures (Brewer, 1997; Zhang et al., 2006). Therefore, the 
inclusion of bFGF during plating and in the maintenance media could be 
investigated as further optimisation of the current method. 
Use of an oxygen controlled incubator 
The rationale behind the utilisation of controlled oxygen incubators 
has been outlined previously (Section 2.1.3 Limitations of the culturing 
method). It would be of interest to investigate whether or not the use of such 
an incubator has similar positive effects on neurite growth in our cultures as 
that described previously (Brewer and Torricelli, 2007; Genetos et al., 2010). 
However, as mentioned previously, the inverted coverslip method and the 
resulting creation of a more physiological microenvironment may also reduce 
the partial pressure of O2 which cultured cells are exposed to (Brewer and 
Cotman, 1989). Alternatively, a reducing agent, such as 2-mercaptoethanol 
(a thiol), which causes the chemical reduction of numerous substances, 
could also be used to replicate the low oxygen conditions in vivo (Grill and 






2.5. Conclusions  
In summary, we present here a simplified, economical and reliable 
method for the consistent production of primary hippocampal cultures from 
postnatal mouse hippocampal tissue. Furthermore, the neurons within these 
cultures, in addition to displaying characteristics of normal, healthy neurons, 
also exhibit consistent and reproducible responses to physiological stimuli 
which have been investigated in Chapters 3 and 4. We propose that this 









3. mGluR Signalling 
3.1 Introduction 
Glutamate is the primary excitatory neurotransmitter (NT) in the 
mammalian CNS and thus is essential for a wide range of neuronal and glial 
functions (Niswender and Conn, 2010). In the context of Ca2+ signalling, the 
primary pathways of glutamate signalling are: a) a rapid entry of Ca2+ 
through Ca2+ permeable PM bound ionotropic glutamate receptors (iGluRs), 
namely NMDARs (Sommer and Seeburg, 1992) and AMPARs (Wiltgen et al., 
2010) which enables their modulation of cellular excitability (Niswender and 
Conn, 2010) and b) a relatively slower mobilisation of Ca2+ from intracellular 
stores following mGluR stimulation (specifically group I mGluRs; Morikawa et 
al., 2003) and activation of downstream signalling pathways, processes 
which are generally mediated by guanine nucleotide-binding regulatory 
proteins (G-proteins; Fagni et al., 2000). Stimulation of mGluRs, specifically 
I-mGluRs, and the subsequent downstream signalling pathways involved, 
comprise a central theme running through this PhD thesis. 
The eight mGluR subtypes (mGluR1 - 8) are widely distributed 
throughout the CNS and are divided into three functional groups: group I 
(mGluR1 and 5), group II (mGluR2 and 3) and group III (mGluR4, 6, 7 and 8) 
mGluRs, based upon their sequence homology, structure, ligand selectivity, 
pharmacology, G-protein coupling and downstream signalling similarities 
(Conn and Pin, 1997; Nakanishi, 1992). 
mGluR subtypes are differentially expressed in a cell type-dependent 
manner and display distinct distributions in particular brain regions, as well 
as at pre- and post-synaptic localisations in neurons (Nomura et al., 1994; 
Ottersen and Landsend, 1997; Shigemoto et al., 1997; Tamaru et al., 2001) 
and glia (Biber et al., 1999). I-mGluRs are expressed in both neurons and 
glia, including microglia and astrocytes (Bernstein et al., 1998; Biber et al., 
1999). In the hippocampus, the tissue where the experimental unit of this 
study was produced from, I-mGluR immunostaining is dense in post-synaptic 
membranes and densities as well as in perisynaptic and extrasynaptic 
membranes (Baude et al., 1993; Lujan et al., 1996; Luján et al., 1997; 
Nusser et al., 1994; Petralia et al., 1997). Immunoreactivity of a splice variant 
of mGluR, mGluR1a, is particularly strong in interneurons of the CA1 region 
and some CA3 pyramidal neurons. Conversely, mGluR1a staining is weak in 
hippocampal CA1 pyramidal cells and granule cells of the dentate gyrus 
(Baude et al., 1993; Chuang et al., 2002; Lu et al., 1997; Lujan et al., 1996; 
Petralia et al., 1997). mGluR5 staining is prominent in hippocampal CA1 
pyramidal neurons (Chuang et al., 2002; Lu et al., 1997; Lujan et al., 1996; 
Luján et al., 1997). Such differential expression of I-mGluR splice variants 





downstream signalling targets in different cell types and/or localisations 
(Fagni et al., 2000). 
Indeed, often the role of specific mGluR sub-groups and subtypes is 
determined by their expression in a neuronal population and/or subcellular 
localisation (Niswender and Conn, 2010). For instance, I-mGluR mediated 
Ca2+ signalling can generate slow EPSPs in hippocampal pyramidal neurons 
(Congar et al., 1997) and cerebellar Purkinje cells (Batchelor and Garthwaite, 
1997), whilst it generates IPSPs in dopaminergic neurons (of the ventral 
tegmental area; Williams and Fiorillo, 1998). Furthermore, I-mGluRs located 
pre-synaptically or post-synaptically can either increase or decrease NT 
release (Anwyl, 1999; Bellone et al., 2008; Pinheiro and Mulle, 2008). 
Importantly, there is also significant functional interaction between mGluRs at 
different localisations, evidenced by the fact that glutamate acting post-
synaptically can exert positive feedback to increase NT release in the 
hippocampus (Hu and Storm, 1991), cerebral cortex (Herrero et al., 1992) 
and hypothalamus (Schrader and Tasker, 1997). 
 As mentioned previously, mGluRs are members of the G-protein-
coupled receptor (GPCR) superfamily (Morikawa et al., 2003) and as such 
are membrane-bound and activated by a diverse range of extracellular 
ligands including hormones, peptides and NTs (Pierce et al., 2002). Ligand 
binding induces a conformational change in the GPCR which activates 
specific G-protein(s) associated with it (Niswender and Conn, 2010) 
I-mGluRs canonically couple to Gq protein/PLC-mediated signalling 
resulting in Ca2+ mobilisation from intracellular stores (for reviews see Conn 
and Pin, 1997; Fagni et al., 2000; Krause et al., 2002; Valenti et al., 2002) 
such as those within hippocampal neurons (Rae et al., 2000; Rae and Irving, 
2004; Sohn et al., 2011). More specifically, activated PLC catalyses the 
formation of inositol (1, 4, 5) trisphosphate (IP3) and diacylglycerol (DAG; 
from phosphatidylinositol‑4, 5‑bisphosphate (PIP2)). IP3 activates IP3-
dependent receptor channels (IP3Rs) on the endoplasmic reticulum (ER), 
resulting in Ca2+ release into the cytosol (Li et al., 2002; Niswender and 
Conn, 2010). This has critically important consequences for cellular 
signalling (described in more detail in section 1.7 Learning and Memory). 
However, despite the widely accepted view that this type of I-mGluR 
signalling is PLC-dependent, it is well documented in both overexpression 
and recombinant systems, as well as more physiological cellular models, that 
these receptors are promiscuous, in that they appear to be capable of 
coupling to multiple intracellular signalling cascades (Hermans and Challiss, 
2001). For example, several reports have suggested that certain downstream 
effects of I-mGluR activation on membrane currents and intracellular Ca2+ 
release can occur independently of either PLC (Chavis et al., 1998; del Río 





and/or IP3R activation (Chavis et al., 1996; Currie et al., 1995; del Río et al., 
1999; Gafni et al., 1997). In this context, one possible explanation for these 
findings, and a key element to this thesis (discussed in Chapter 4 mGluR-
ARC Signalling) is the coupling of I-mGluRs to the enzyme ADP-ribosyl 
cyclase (ARC; Sohn et al., 2011), which catalyses the production of cyclic 
ADP ribose (cADPR). cADPR, in turn, stimulates Ca2+ mobilisation through 
RyRs on the ER (Kaar and Rae, 2015). 
Neuronal SOCE is considered essential to maintaining I-mGluR-driven 
Ca2+ signals, at least in cultured cortical neurons (González-Sánchez et al., 
2017). Subsequently, this increased [Ca2+]i combines with the actions of 
synthesised DAG to activate protein kinase C (PKC) which, in turn, 
determines the activation state of I-mGluRs and is intertwined with the 
activities of the downstream components of mGluR-stimulated signalling 
cascades (Conn and Pin, 1997; Hisatsune et al., 2005; Murphy and Miller, 
1988; Sorrentino et al., 1996). It is also worth noting that [Ca2+]i levels can 
also enhance the activity of PLC and thereby regulate intracellular Ca2+ 
mobilisation in a feedforward manner (Nakamura and Fukami, 2017; Suh et 
al., 2008). 
Numerous downstream signalling cascades are modulated by the 
activity of G-proteins. For instance, depending upon cell type or neuronal 
population, Gq activates ion channels and protein kinase pathways including 
casein kinase 1, cyclin-dependent protein kinase 5 and c-Jun N-terminal 
kinase (JNK; Yin and Niswender, 2014). Two further kinase pathways, the 
mitogen-activated protein kinase/extracellular receptor kinase (MAPK/ERK) 
and the mammalian target of rapamycin (mTOR)/p70 S6 kinase pathway, are 
particularly important for the regulation of synaptic plasticity by mGluRs (Hou 
and Klann, 2004; Li et al., 2007; Page et al., 2006). I-mGluR activation also 
enhances the expression of the c-fos gene, an indicator of calcium-induced 
transcription of various genes (Mao and Wang, 2003). 
 Numerous roles specific for I-mGluRs have been revealed within the 
CNS, including the regulation of synaptic transmission and neuronal 
excitability, as well as the induction of long-lasting forms of synaptic plasticity 
including LTD and LTP (Anwyl, 1999; Bashir, 2003; Bellone et al., 2008; 
Bortolotto et al., 1999; Conquet et al., 1994; Ichise et al., 2000; Jia et al., 
1998; Kullmann and Lamsa, 2008; Lu et al., 1997). This modulation of 
neuronal excitability is a function of an underlying modulation of a number of 
ion channel conductances and can result in robust excitation as well as more 
subtle effects, such as changes in the pattern of cell firing, synchronisation of 
network activity and cellular responses to excitatory input (Anwyl, 1999; 
Chuang et al., 2001; Cobb et al., 2000; Conn and Pin, 1997; Coutinho and 
Knöpfel, 2002; Valenti et al., 2002; Woodhall et al., 1999). This range of 





by I-mGluRs in both a G protein-dependent and - independent manner, as 
will be discussed in subsequent sections.  
 
3.1.1 Downstream Signalling 
Depolarisation 
Stimulation of I-mGluRs depolarises hippocampal cells (Bianchi et al., 
1999; Bortolotto and Collingridge, 1995; Davies et al., 1995). In this respect, 
within hippocampal neurons at least, mGluR1 is more effective at mediating 
depolarising responses than mGluR5. As such, the degree of depolarisation 
induced by I-mGluR activation will be dependent upon the expression of 
mGluR subtype which, in turn, differs according to cell type (Chuang et al., 
2002). Mechanistically, I-mGluR mediated ion channel modulation can occur 
directly via G-proteins as well as downstream of second messenger 
formation. Furthermore, there are numerous conductance mechanisms 
proposed to underlie such I-mGluR mediated depolarisation (Chuang et al., 
2002), as outlined below. 
a) I-mGluRs decrease both voltage-dependent and -independent K+ 
conductances (Chuang et al., 2001, 2000; Guérineau et al., 1994; Lüthi et 
al., 1996; Wu and Barish, 1999). Inhibition of this K+ current results in an 
excitatory response manifesting as either a slowly developing depolarisation 
and inward current and/or an inhibition of action potential firing 
accommodation (Fagni et al., 2000).  
b) I-mGluRs modulate Ca2+ -sensitive K+ channel conductances 
(Bianchi et al., 1999; Charpak et al., 1990; Jaffe and Brown, 1997; Rae and 
Irving, 2004; Shirasaki et al., 1994). This modulation primarily results in 
decreased conductance, although variable results have been found, as 
discussed in greater detail below. 
c) I-mGluRs activate the Na+/Ca2+ exchanger resulting in 
depolarisation in neurons of the amygdala (Keele et al., 1997), striatum 
(Dumuis et al., 1993), melanin-concentrating hormone (MCH) neurons of the 
hypothalamus (Huang and van den Pol, 2007) and cerebellar Purkinje 
neurons; Linden et al., 1994; Staub et al., 1992). 
d) I-mGluRs initiate a Ca2+ -activated non-selective cationic (CAN) 
current (ICAN) through intracellular CAN channels (Partridge et al., 1994) in 
hippocampal CA1 pyramidal neurons. In CA3 neurons (rat; organotypic slice 
cultures) this excitatory current is characterised as a transient receptor 
potential (TRP)- like conductance which can be activated in a G-protein -
independent (possibly by an Src-family protein tyrosine kinase, in a [Ca2+]i 
dependent manner (Heuss et al., 1999)) and G-protein-dependent manner 





from intracellular stores (Congar et al., 1997; Crepel et al., 1994). These 
conductances can be activated synaptically and may be involved in 
regulating synaptic plasticity (Batchelor and Garthwaite, 1997). 
e) I-mGluRs activate a PLCβ/ER-dependent, voltage-gated inward 
current (ImGluR(V)) which may have a role in loading intracellular stores. This I-
mGluR-mediated increase in [Ca2+]ER could occur directly, via activation of 
VGCCs (Rae et al., 2000) or indirectly via an “intrinsic Ca2+ permeability” 
through linking I-mGluR signalling with TRP channels (Kim et al., 2003; Tozzi 
et al., 2003). Although this current has been investigated across numerous 
neuronal cell types it likely reflects a mixture of currents dependent upon 
differing underlying conductances in the cell being investigated (Anwyl, 
1999). ImGluR is activated in CA3 pyramidal cells (where it is critical in 
generating prolonged rhythmic bursts in these cells (Chuang et al., 2001, 
2000; W. Zhao et al., 2001)) but not CA1 cells, and as such the overall I-
mGluR mediated response is decreased in CA1 cells, due most likely to a 
functional deficit in mGluR1 expression (Bortolotto and Collingridge, 1995; 
Chuang et al., 2002; Lu et al., 1997). It is also worth noting that such a 
functional deficit in mGluR1-mediated signalling in CA1 cells is dependent 
upon murine species (i.e. mouse vs rat), developmental stage and/or 
differences in experimental protocols (Chuang et al., 2002; Ireland et al., 
2002; Mannaioni et al., 2001). However, a role for mGluR1 in CA1 pyramidal 
neuronal signalling (both [Ca2+]i and ImGluR) has been observed in numerous 
studies (Ireland et al., 2002; Mannaioni et al., 2001; Nakamura et al., 2000). 
With regard to ImGluR specifically, functional studies utilising hippocampal 
neurons show that either mGluR5 alone (Rae et al., 2000) or both mGluR1 
and 5 are critical in mediating this current (Gee et al., 2003; Rae and Irving, 
2004). In CA1 pyramidal neurons, ImGluR is thought to reflect a mixture of 
inhibition of certain K+ conductances, and activation of a ICAN (Chuang et al., 
2002; Congar et al., 1997; Crepel et al., 1994; Ireland et al., 2002; Mannaioni 
et al., 2001). Specifically, in CA1 pyramidal neurons this inward current 
exhibits the following characteristics; a) prolonged time course (ranging from 
9 – 30 minutes), b) a decrease in membrane conductance, c) it is temporally 
distinct from the brief increase in [Ca2+]i following I-mGluR activation (Rae 
and Irving, 2004) and, d) is facilitated by neuronal depolarisation (Chuang et 
al., 2000; Lüthi et al., 1996; Rae and Irving, 2004). This depolarisation results 
in an increase in ionic driving force for K+ efflux which, along with removal of 
Mg2+ block from cationic NMDAR-mediated currents (Congar et al., 1997; 
Guerineau et al., 1995), or increased [Ca2+]i (Gee et al., 2003), may further 
potentiate this ImGluR (Rae and Irving, 2004). 
However, the dependence of this I-mGluR-activated inward current on 
intracellular Ca2+, possibly generated via ER Ca2+ mobilisation (Congar et al., 





et al., 1999) is debatable (Bianchi et al., 1999; Guerineau et al., 1995; Ireland 
et al., 2002; Nakamura et al., 2000). Indeed, Rae and Irving (2004) 
demonstrated that although the I-mGluR activated inward current evoked in 
rat CA1 pyramidal neurons by DHPG (I-mGluR agonist) did display some 
dependence on Ca2+ (only being significantly reduced in amplitude with 
either prolonged, high intracellular concentrations of the Ca2+ buffer BAPTA 
or perfusion with Ca2+-free/EGTA (calcium chelator; 1 mM) aCSF, it was 
much less sensitive to alterations in cytosolic Ca2+ than the release of Ca2+ 
from the ER.  
Regulation of VGCCs and iGluRs 
Aside from the mechanisms of ion channel modulation and 
depolarisation listed above, I-mGluRs also possess numerous means of 
modulating VGCC and iGluR activity. 
Direct G-protein mediated modulation of P/Q- and N-type VGCC-
mediated Ca2+ conductances by mGluR1 and 5 has been observed in both 
neurons and recombinant cell systems (Choi and Lovinger, 1996; 
Kammermeier and Ikeda, 1999; McCool et al., 1998). Glutamate-induced 
depolarisation by either mGluRs (as discussed in the previous section) or 
iGluRs can activate VGCCs and also evoke Ca2+ influx indirectly. This results 
in a significant degree of physiologically relevant cross-talk between these 
receptors and their related signalling pathways (Fagni et al., 2000). In acutely 
dissociated hippocampal neurons, for example, glutamate-mediated Ca2+ 
influx was due to both AMPAR-mediated depolarisation which subsequently 
activated L-type VGCCs, but did not involve NMDAR activation (Sohn et al., 
2011). The fact that this was an NMDAR-independent effect may be due to 
where the NMDARs are localised. Thus, NMDAR-mediated Ca2+ entry 
occurs primarily in neuronal spines which tend to be more concentrated at 
oblique dendrites in vivo and in acute brain slices (Bannister and Larkman, 
1995; Kovalchuk et al., 2000; Migliore et al., 2005; Nakamura et al., 2002). 
However, acutely dissociated neurons generally lack this type of ‘oblique’ 
dendrite which would therefore reduce, or eliminate, the role of NMDARs in 
glutamatergic signalling in these cells (Sohn et al., 2011). Interestingly, Sohn 
and colleagues (2011) also demonstrated that the contribution of the 
AMPAR/L-type VGCC -mediated calcium influx to glutamate-induced somatic 
Ca2+ signalling in acutely dissociated hippocampal neurons was larger than 
the contribution of Ca2+ release from intracellular stores mediated by I-
mGluRs, illustrating the potential importance of this Ca2+ entry pathway to 
overall glutamatergic signalling (Sohn et al., 2011). 
On the other hand, I-mGluRs modulate synaptic transmission by 
potentiating NMDAR-, but not AMPAR-, mediated currents in striatal and 
spinal cord neurons (Krieger et al., 2000; Pisani et al., 1997). The 





of CaM at NMDARs due to CaM buffering of I-mGluR/PLC-mediated 
increases in intracellular Ca2+ (Ehlers et al., 1996). Furthermore, I-mGluRs 
enhance NMDAR activity in rat hippocampal slices, in a manner independent 
of Ca2+ release from stores (Enokido et al., 1996; Harvey and Collingridge, 
1993). This mechanism helps to explain the potentiating effect of mGluR 
agonists on NMDAR-mediated LTP induction in the hippocampus 
(McGuinness et al., 1991; Otani and Ben-Ari, 1991). Conversely however, 
one study has shown that NMDAR-mediated whole-cell currents were 
reversibly attenuated by I-mGluR stimulation in cultured mouse cortical 
neurons (Yu et al., 1997). The reason for these contradictory findings 
remains unclear, however. 
Interestingly, NMDAR activation can also enhance I-mGluR activity. 
For example, NMDAR-mediated Ca2+ influx in cultured rat hippocampal 
neurons and hippocampal CA1 pyramidal neurons (Luthi et al., 1994, Rae et 
al., 2000), and L-type VGCCs in apical dendrites of hippocampal CA1 
neurons; (Emptage 1999, Nakamura et al., 2000, 1999), cultured mouse and 
rat hippocampal neurons, and CA1 pyramidal neurons from rat hippocampal 
slices, potentiates I-mGluR mediated ER Ca2+ signals, to evoke enhanced or 
“supralinear” intracellular calcium responses (Rae et al., 2000; Rae and 
Irving, 2004). These findings are supported by similar results showing that 
ER-mediated Ca2+ release in hippocampal cultures, acutely dissociated adult 
mouse DRG neurons and PC12 cells (via muscarinic receptor or RyR 
activation) is potentiated by increased Ca2+ influx (via depolarisation and/or 
NMDAR activation; Friel and Tsien, 1992; Garaschuk et al., 1997; Irving and 
Collingridge, 1998; Koizumi et al., 1999; Shmigol et al., 1996). 
So-called supralinear Ca2+ signals are a signalling paradigm of 
synaptic activation (Nakamura et al., 1999; Rae et al., 2000) and proposed to 
be a rough correlate of in vivo “learning events” (Magee and Johnston, 1997; 
Markram et al., 1997). Supralinear responses are proposed to arise from the 
Hebbian pairing of I-mGluR stimulation with a depolarisation stimulus to 
produce a Ca2+ response that is greater than that generated by the sum of 
each individual stimulus, i.e. the summation of the Ca2+ response due to 
depolarisation and that due to I-mGluR stimulation (Rae et al., 2000). Similar 
types of enhanced responses were also observed when NMDAR activation 
was paired with membrane depolarisation (Koester and Sakmann, 1998; Rae 
et al., 2000; Schiller et al., 1998; Yuste and Denk, 1995). 
I-mGluR-mediated Ca2+ release also enhances action potential/L-type 
VGCC-mediated pre-synaptic Ca2+ transients, which can, in turn, enhance 
both NT release (Atlas, 2013) and synaptically-evoked EPSCs (Nakamura et 
al., 2015). These effects are blocked by ryanodine in the lamprey spinal cord, 
suggesting RyR involvement (Cochilla and Alford, 1998). mGluR5 stimulation 





of the hippocampus, with L-type VGCC currents also being potentiated by 
RyR-mediated Ca2+ mobilisation and PKC in the same cells (Topolnik et al., 
2009). Similarly, mGluR1 mediates a large, oscillatory increase in L-type 
VGCC conductance in cerebellar granule cells that is RyR-dependent, but 
IP3-independent (Chavis et al., 1996). This particular study differs from those 
mentioned before it in that the proposed mechanism underlying the 
enhanced I-mGluR signalling is unaffected by calcium chelation (using 
BAPTA) or block of IP3Rs (using heparin) and is not mimicked by intracellular 
IP3 dialysis. Instead, this enhancement arises from the promotion of physical 
and functional coupling between I-mGluRs, RyRs and L-type VGCCs (Chavis 
et al., 1996; Fagni et al., 2000). Furthermore, it is proposed that I-mGluR 
coupling to L-type VGCCs occurs in the proximity of Ca2+ mobilisation sites. 
In so doing, this may allow for the replenishment of ER stores following I-
mGluR stimulation (Irving et al., 1992a; Murphy and Miller, 1989). Lastly, 
cADPR may also play have a role in I-mGluR mediated L-type VGCC signal 
potentiation seen within NG108-15 cells (Hashii et al., 2000).  
In contrast to the evidence listed above illustrating the numerous 
means of I-mGluR – mediated neuronal excitation, I-mGluR evoked Ca2+ 
elevations can also inhibit VGCC opening in numerous brain regions 
including the hippocampal formation (Anwyl, 1999; Ikeda et al., 1995; Shen 
and Slaughter, 1998) by activating/modulating Ca2+ -sensitive K+ channel 
activity, as discussed next. 
 
3.1.2 I-mGluR signalling and the Ca2+ hypothesis of AD 
ER channels 
As outlined in Section 1.4 Ca2+ Hypothesis, ER Ca2+ dyshomeostasis and 
signalling dysregulation are hallmarks of AD. However, at this point, it is 
worthwhile summarising the aspects of ER Ca2+ dysregulation which are of 
particular relevance to this thesis section. 
• RyRs and IP3Rs are heavily implicated in mediating neuronal calcium 
dysregulation in murine transgenic models of AD (including 3xTg-AD 
mice and PS1 mutant mice; Chakroborty et al., 2009; Chan et al., 
2000; Guo et al., 1999b; Smith et al., 2005; Stutzmann et al., 2006; 
Supnet et al., 2006; Zhang et al., 2010). 
• Significant differences are evident in Ca2+ signalling and 
electrophysiological parameters when 3xTg-AD neurons are 
compared with controls in response to direct activation of IP3Rs and 
RyRs (Chakroborty et al., 2009; Kuchibhotla et al., 2008; Rae et al., 
2000; Rae and Irving, 2004; Stutzmann et al., 2007). For instance, of 
particular relevance to the results contained herein, direct IP3R 
stimulation with caged IP3 results in somatic Ca2+ responses which 





as that of 3xTg-AD mice) and 3xTg-AD mice than in control neurons 
(Stutzman et al. 2007). Similarly, RyR-mediated [Ca2+]i responses 
were also much larger (approximately 400%) in cultured 3xTg-AD 
hippocampal neurons in comparison to non-Tg neurons (Zhang et al. 
2010). 
• Ca2+ responses mediated by SOCE are much larger in non-Tg 
neurons relative to 3xTg-AD and PS DKO neurons (2-fold increase; 
cultured hippocampal neurons; 0 - 1-days-old; 12 - 13 DIV) and in 
vitro in cells expressing PS FAD mutations, possibly reflecting PS 
mutation-dependent increases in [Ca2+]ER (Akbari et al., 2004; Herms 
et al., 2003; Leissring et al., 2000; Yoo et al., 2000) 
mGluRs 
There are limited lines of evidence specifically implicating mGluR-
mediated Ca2+ signalling, depolarisation-induced Ca2+ entry and/or ER Ca2+ 
mobilisation in AD, most of which are concerned with APP-related proteins. 
For example, 
a) I-mGluR-mediated PLC activation is impaired in the cerebral cortex of AD 
patients (Albasanz et al., 2005).  
b) Previous work from our lab group demonstrated that there are clear 
differences in hippocampal I-mGluR mediated Ca2+ signals from young 3xTg-
AD mice (cultured hippocampal neurons; 3 - 5-days-old; 7-14 DIV) relative to 
age-matched control neurons (Morley et al., 2012, 2011). 
c) mGluR5 inhibition suppressed early-stage (3-weeks-old) network 
hyperexcitability in 3xTg-AD mice (Kazim et al., 2017). 
d) Depolarisation of cortical synaptoneurosomes (containing vesicularised 
elements of the pre-synapse and post-synapse which are used to study 
synaptic transmission, see Johnson et al., 1997; Westmark et al., 2011) from 
APPSWE/V717F mice (10 - 14-days-old; extracellular application of K+ (40 mM)) 
resulted in Ca2+ influx via L-type VGCCs. This rapidly decreased levels of 
αCTF and βCTF, suggesting that ƴ-secretase was being rapidly activated 
(Kim et al., 2010). Depolarisation also activated α-, β- secretases and 
resulted in rapid Aβ40 and Aβ42 generation and release into the extracellular 
environment (Kim et al., 2010).  
e) Stimulation of synaptoneurosomes with the I-mGluR agonist DHPG 
produced very different effects and resulted in αCTF and βCTF accumulation 
and Aβ40 release, but not the release of Aβ42. This suggests that activation of 
I-mGluRs and the subsequent profile of Ca2+ mobilisation, as opposed to that 
due to extracellular Ca2+ entry, results in activation of α- and β- secretases 
without significant activation of γ-secretase (Kim et al., 2010). Non-subtype-





neuroprotective and Ca2+ stabilising APPsα in cultured hippocampal neurons 
(Lee et al., 1995) and cortical rat brain slices (Kirazov et al., 1997) likely via 
an enhancement of α-secretase activity (i.e. the non-amyloidogenic APP 
processing pathway). Furthermore, inhibition of either mGluRs or PKC 
prevented sAPP release, which suggests that PKC was the mediator of 
mGluR effects on α-secretase (Lee et al., 1995). Similarly, mGluR-mediated 
sAPP production was observed in HEK293 cells transfected with mGluR1α 
(Lee et al., 1995). In these cells, a more detailed mechanism of APP 
processing was proposed whereby protein kinases, phospholipase A2 
(PLA2) and melittin (a peptide that stimulates PLA2; Nitsch et al., 2002) 
mediate mGluR1α-stimulated sAPP production. In rat cerebral cortical slices, 
APP cleavage and sAPPα formation are primarily mediated by mGluRs, 
whilst AMPAR activation suppressed the processing of APP to sAPP 
(Kirazov et al., 1997). Therefore, AD-dependent impairment of mGluR-
mediated signalling (Albasanz et al., 2005) may reduce the overall levels of 
non-amyloidogenic APP processing within the CNS. Conversely, however, 
mGluR5 activation can also lead to rapid APP mRNA translation in the 
synapse, which has the potential to increase the levels of its toxic 
metabolites (Sokol et al., 2011; Westmark, 2013; Westmark and Malter, 
2007). 
f) As discussed in Section 1.2.6 Molecular actions of APP metabolites, 
clustered Aβo accumulate at excitatory hippocampal synapses where they 
interact with mGluR5 via PrPC to prevent mGluR5 diffusion over the post-
synaptic membrane (Um et al., 2013). This stabilises mGluR5 clusters at 
these sites and creates so-called ‘artificial signalling platforms’ (ASPs). 
These ASPs lead to aberrant neuronal Ca2+ signalling, increased [Ca2+]i and 
Arc activation (Um et al., 2013). Arc activation ultimately results in altered 
spine morphology, decreased spine number, depletion of surface NMDAR 
and dysregulation of NMDAR-mediated signalling pathways (Lacor et al., 
2007; Shankar et al., 2007; Snyder et al., 2005). Indeed, these synaptic 
deficits are observed in an Aβo-mGluR5 signalling dependent manner in 
models of AD (Haas et al., 2014; Renner et al., 2010; Sokol et al., 2011; Um 
et al., 2013).  
g) Antagonists of mGluR5 prevent Aβo-mediated LTP disruption (Q. Wang et 
al., 2004) and genetic deletion of mGluR5 reduces circulating levels of Aβos, 
plaque deposition and cognitive decline in APPswe/PS1ΔE9 mice (9-12 months 
of age; Hamilton et al., 2014). Chronic inhibition of mGluR5 using MTEP, 
which is a negative allosteric modulator of mGluR5 in 9-month-old APPswe-
/PS1ΔE9 mice also rescued spatial memory deficits as well as deficits in 
episodic and recognition memory, the latter of which both developed earlier 
in the disease progression in this mouse model (Hamilton et al., 





spatial memory and synapse density in APPswe/PS1ΔE9 mice (9-10 months of 
age), as well as object recognition in 3xTg-AD mice (8-9 months of age; Um 
et al., 2013). 
iGluRs 
The function and expression of iGluRs also appear to be modified in 
AD (De Felice et al., 2007; Li et al., 2011). Examples of this include: 
a) A reduction in the amplitude of evoked AMPAR- and NMDAR-
mediated excitatory currents, in a -secretase dependent manner, in 
hippocampal neurons from PS1A246E mice relative to non-transgenic controls 
(Priller et al., 2007). 
b) Evidence utilising prefrontal cortical brain slices from 4-6 week old 
3xTg-AD and APPSWE/PS1M146V mice suggest that although NMDAR-
mediated currents are not measurably different amongst mouse strains 
(including when compared to non-Tg controls), dendritic spine Ca2+ 
transients are larger in both AD strains relative to age-matched controls. This 
effect was mediated by NMDAR-mediated activation of RyRs via CICR, 
which occurred in transgenic animals only. This abbarent NMDAR-mediated 
CICR activation is hypothesised to be due to increased intracellular calcium 
and therefore hypersensitisation of RyRs within spines and dendrites of 
transgenic neurons  (Goussakov et al., 2010). Similarly, in experiments 
utilising hippocampal slices from 3-month-old PS1M146V mice, the magnitude 
of NMDAR-dependent field EPSPs was significantly increased relative to 
non-transgenic controls (Auffret et al., 2010).  
c) As mentioned previously, Aβo-PrPC mediates disruption of mGluR5 
Ca2+ signalling at synapses and activates Arc. This leads to a decrease in 
NMDAR expression (Renner et al., 2010) and dysregulation of NMDAR-
mediated signalling pathways (Lacor et al., 2007; Shankar et al., 2007; 
Snyder et al., 2005). 
d) Aβo–PrPC-Fyn complexes cause synaptic disruption mediated via 
alterations in NMDAR trafficking and activation (Larson et al., 2012; Um et 
al., 2012). 
e) Application of very low concentrations of Aβo to organotypic 
hippocampal slices results in actin-depolymerizing factor/cofilin- (involved in 
cytoskeleton plasticity) and CN-dependent decreases in NMDAR activity and 
dendritic spine number after 5 -15 days (Shankar et al., 2007). The number 
of cells expressing NR1 and NR2A subunits of NMDAR were also lower in 
APPSWE mice at 18 - 22 months relative to controls. Furthermore, this deficit 
could be reversed by administering the anti-amyloid-β antibody, aducanumab 





loss induced by Aβo application in vitro in neuronal cultures (Lacor et al., 
2007) and in vivo in AD mouse models (Koffie et al., 2009).  
f) Conversely, however, Aβo have also been shown to increase 
NMDAR-mediated responses and induce excitotoxicity (De Felice et al., 
2007; Szegedi et al., 2005), effects which may mediate Aβo-stimulated 
oxidative stress and increased [Ca2+]i (Bezprozvanny and Mattson, 2008; 







The primary aim of the work covered in this chapter was to expand 
upon initial studies (including work I was involved with during my 
undergraduate project; Morley et al., 2012) within Dr M.G. Rae’s lab group, 
investigating the molecular basis of the altered neuronal calcium handling 
observed in the 3xTg-AD mouse. The same experimental approaches were 
also applied to a novel model of AD, the TgF344-AD rat which was acquired 
part of the way through my PhD studies. The specific aims of this part of my 
project were:  
 
1. To build upon initial findings of this lab group, which found that 
enhanced responses were observed in non-Tg cultured hippocampal 
neurons (3 - 6-days-old; ≥12 DIV) following I-mGluR stimulation under 
depolarisation conditions relative to basal conditions. These types of 
enhanced calcium signals were not observed in 3xTg-AD mouse 
neurons (Morley et al., 2011, 2012). Specifically, neurons in this study 
were utilised over a wider range of in vitro development (2 – 20 DIV) in 
order to determine how early this calcium dysregulation occurred and to 
determine the robustness of the previous findings during early-postnatal 
development.  
 
2. Furthermore, this experimental approach was extended to Sprague 
Dawley (SD), non-Tg F344 and TgF344-AD rat hippocampal cultures. 
Not only would this allow us to determine whether this effect was 
replicated across species but also whether such calcium signalling 
alterations existed in an alternative AD model. We hypothesised that it 
was likely that neurons of this TgF344-AD rat might display ER-
mediated calcium dysregulation but that it would occur through a 
different mechanism as these animals expressed a “gain-of leak” PS1 
mutation rather than the “loss-of-leak” PS1 mutation expressed in 3xTg-
AD mice (Zhang et al., 2010). 
 
3. Aside from paired measurements comparing the magnitude of I-mGluR 
responses under depolarisation conditions relative to basal conditions 
within a single murine strain, we also wanted to determine whether 
responses to depolarisation and I-mGluR stimulation (under basal and 
depolarisation conditions) were different between 3xTg-AD and 
TgF344-AD neurons relative to non-Tg age-matched controls. 
 
 
4. In addition to excitation-mediated Ca2+ entry, one of the primary means 
of loading the neuronal ER with Ca2+ is via SOCE. This process is 





of Ca2+ directly through plasma membrane-located channels into the 
ER. However, to date, little is known about how this Ca2+ entry pathway 
is affected by mutations which predispose to the development of AD. 
Therefore, we wished to a) determine if SOCE was present in mouse 
primary cultured hippocampal neurons and, if so, b) to investigate if it 







3.3. Materials and methods 
3.3.1 Materials  
 
• All materials and methods related to the production of hippocampal 
cultures are outlined in Section 2 Primary Hippocampal Neuronal 
Culture and the publication by Kaar et al. (2017). 
• Fluo-2 High Affinity (AM; TEFLABS, cat. no. 0220) 
• Fura-2 (AM; ThermoFisher scientific, cat no. F-1201) 
• HEPES-buffered saline solution (HBSS) of the following composition 
(in mM): NaCl 130, HEPES 10, KCl 5.4, MgCl2 2, D-glucose 2 and 
CaCl2 2, pH 7.4, 310 – 340 mOsm. HBSS K+ replaced NaCl with KCl 
to increase the concentration of K+ to 10 – 15 mM. 
• Pluronic F127 (TEFLABS, cat. no. 2510) 
• (S)-3,5-dihydroxyphenylglycine (DHPG; Tocris, cat. no. 0805/5) 
• Tetrodotoxin (TTx; Tocris, cat. no. 1078/1) 
• Thapsigargin (TPN; Sigma, cat. no. T9033) 




Calcium imaging was carried out as described in Section 2.2.5 Calcium 
imaging. Where possible, data in studies presented were collated from at 
least 4 different experiments/coverslips and derived from at least four 
separate cultures. Throughout this results section, instead of solely using n 
numbers, collated data are presented as follows: (x number of cells – from y 
number of experiments/coverslips – from z separate cultures; e.g. (115 – 12 
– 8) - Fig 3.5, B). Wild-type (WT) refers to neurons harvested from SD rat 
neurons. Non-transgenic (non-Tg) refers to neurons harvested from either 
the same background strain as the 3xTg-AD mice used (C57BL6/129sv) or 
non-Tg littermates of TgF344-AD rats (as determined by genotyping). 
“Transgenic” (Tg) is also used throughout this results section to describe 
neurons harvested from 3xTg-AD mice or TgF344-AD rats (as determined by 
genotyping). 
 
“DHPG” refers to (S) 3, 5-dihydroxyphenylglycine and was always 
applied at a concentration of 50 μM and superfused for 120 s (See Fig 3.1 for 
a general timeline of experiments). The term “basal conditions” refers to the 
application of compounds in normal physiological solution (HBSS) as 
opposed to “depolarisation conditions” where a physiological solution with an 
elevated concentration of K+ was used (HBSS K+; 5.4 vs 15mM K+). and 
applied for 120 s prior to DHPG application, for the period of DHPG 





3.1). These measures were taken in an effort to standardise experiments and 
reduce variability.  
In order to determine the potential effects of tachyphylaxis in our 
experimental protocol across in each neuronal population we determined that 
utilisation of a 50-minute washout period between DHPG applications was 
optimal for the production of statistically reproducible responses in SD rat, 
non-Tg rat and 3xTg-AD mouse neurons (when compared to 15, 30 and 40 
minutes; data not shown). However, in non-Tg mouse neurons a significantly 
decreased peak amplitude (38 ± 4 vs 31 ± 3 a.u.; first application vs second; 
p = 0.002; n = 58)  but not duration or AUC of the second DHPG response 
was observed and this desensitisation effect should be factored into any 
results obtained from these neurons. 
For SOCE experiments (completed under my co-supervision by M. P. 
Wier), an initial baseline was determined in normal (i.e. Ca2+-containing) 
HBSS for 4 mins after which the SOCE process was “primed” by depleting 
the ER using the SERCA pump inhibitor TPN (1 µM) in Ca2+-free HBSS for 
20 mins. SOCE was then subsequently triggered by adding Ca2+ “back in” by 
perfusing the neurons with normal HBSS (5 - 10 mins; Chauvet et al., 2016). 
We also utilised the non-specific SOCE antagonist Gd3+ (50 M; added 5 min 
after Ca2+ “add back”, for 20 mins) (Yeromin et al., 2004) to determine the 
susceptibility of the SOCE process to this antagonist in the two mouse 
genotypes. As we were unable to use the time taken for the calcium 
response to return to baseline in the presence of Gd3+ (50 M) as our 
measure of the antagonist’s effectiveness against SOCE, simply because the 
calcium signal did not return to baseline following its application in the 
continued presence of normal HBSS (e.g. see Fig 3.12), we instead 
measured the percentage drop in calcium signal amplitude (from peak 
SOCE) after 4 minutes in the presence of Gd3+. 
Representative traces were generated offline using GraphPad Prism 
where amplitude, duration and area under the curve (A.U.C.) of responses 
were measured. Baselines for amplitude and A.U.C. measurements were 
chosen based on the average fluorescence of either 120 s before or after a 
given response, depending on which baseline was higher. Cells were utilised 
after 2 - 20 days in culture. Following segregation of data into groups based 
on in vitro development (0 – 5, 6 – 10, 11 – 15 and 16 – 20 DIV) there were 
no significant differences between such groups within non-Tg mouse and rat, 
TgF344-AD rat and SD rat populations used in this study (data not shown). 
Conversely, 3xTg-AD mouse populations appeared (based on a single 
experiment; 33 – 1 – 1; 4 DIV) not to express a transgenic phenotype and 
rather responded in the same manner as non-Tg mouse neurons between 0 
- 5 DIV and as such data for 3xTg-AD neurons (Fig 3.5) are pooled from  6 – 





region as drawn by the experimenter for each neuron individually. Regions of 
interest (ROIs) were manually traced around the somata of cells subjectively 
observed to be neurons. Such identification was aided by comparison to 
bright field (DIC) images which were acquired for each individual experiment. 
At this stage neurons which had obviously deteriorated and/or were dead 
(e.g. those that were granular, misshapen, extremely bright or dark under 
excitation light or were obviously non-vital in any other way) were removed 
from the analysis. Furthermore, at the analysis stage, certain neurons were 
removed due to artefacts arising from debris moving over the field of view 
(FOV) and/or due to spontaneous activity, where the frequency or magnitude 
of spontaneous activity impacted upon genuine agonist-specific responses. 
All data are presented as mean ± SEM. As described in 3.4.1 General 
I-mGluR response characteristics, there is generally (across the different 
murine populations utilised in this study) an increased proportion of neurons 
which exhibit detectable responses to DHPG under depolarisation conditions 
relative to basal conditions (control). This most likely due to the fact that 
cultured hippocampal neurons appear to have an ER which is “functionally 
empty” under basal conditions (see inter alia Rae et al., 2000; Zhang et al., 
2010). Cells which only displayed DHPG-evoked responses following 
depolarisation are included in data displayed in histograms (i.e. peak 
amplitude (arbitrary units (a.u.)), duration (s) and A.U.C (a.u.; e.g. Fig 3.5 – B 
– i, iii, iv)), where changes in intracellular calcium are displayed in absolute 
numbers (i.e. as opposed to data which have been normalised). For the 
subset of cells that displayed responses to DHPG under both basal and 
depolarised conditions, we were able to normalise the data to determine the 
percentage change in response amplitude and magnitude (e.g. Fig 3.5 – B - 
ii). Only these cells were included for such analysis as it was impossible to 
determine the magnitude of the DHPG-evoked calcium increase in cells 
where there had been no basal response as one would have to divide the 
numerator by 0 (i.e. the value would be infinity). Statistical analyses were 
performed using a paired Student’s t-test or Wilcoxon matched paired signed 
rank test (for normalised data) for paired observations or repeated measures 
ANOVA with Tukey's multiple comparison test or Dunnett's multiple 
comparison test (normalised AUC data only) for group data on repeated 
measures. Unpaired t-tests and one-way analysis of variance with Tukey's 
multiple comparison test or Dunnett's multiple comparison test (for 
normalised AUC data only) were utilised for unpaired observations and 
grouped data, respectively. Unpaired t-test was utilised for comparing the 
frequency of observations between neuronal populations. P value (p) of < 
0.05 was considered significant. Degree of significance was displayed as 
follows: *p < 0.05, **p < 0.01 and ***p < 0.001. Pearson correlation (data 
assumed from Gaussian populations) was used to measure the correlation 












































































































































































































































































































































































































































































































































































































Figure 3.2 Glial [Ca2+]i dynamics in culture 
Representative somatic intracellular Ca
2+
 response (SD rat; 3-days-old; 13 
DIV) illustrating distinctive Ca
2+
 oscillations associated with glia which 
facilitates their identification in culture.  
Neuron identification 
During the analysis process, neuronal identification was carried out 
primarily based on the morphological characteristics of cultured cells. 
However, identification of cultured neurons based solely on morphology (as 
opposed to immunohistochemical identification) has been shown to be 
unreliable (Raff et al., 1979). This is, in part, due to the morphological 
similarities between multipolar neurons and stellate-shaped type II astrocytes 
(Kivell et al., 2000). With this in mind, functional Ca2+ imaging data can also 
aid in the categorisation of cells because neurons are selectively sensitive to 
depolarisation stimuli via application of elevated extracellular K+ (Rae et al., 
2000). Aside from visual identification, glial and neuronal identification can 
also be clarified by examining their spontaneous activity as outlined by Pozzi 
et al. (2017). Briefly, according to their protocol, spontaneous calcium 
transients are defined as beginning when the fluorescence signal exceeds, 
by at least by three times, the standard deviation of the noise. When TTx 
was added, such transients disappear from the majority of cells in culture, 
which are considered to be neurons whilst the remaining cells are deduced 
to be astrocytes and can, therefore, be removed from the analysis (Pozzi et 
al., 2017). This exclusion is based upon the fact that astrocytes display Ca2+ 
signals even after TTx addition in the typical form of calcium waves (Scemes 
and Giaume, 2006). In practical terms, using our imaging and data analysis 
protocol, each ROI was individually screened by the user and, as such, cells 
which exhibited this glial-type oscillatory wave activity were removed from 
the analysis (Fig 3.2).  
With this in mind, there were a small number of cells in the neuronal 
populations (outlined in Fig 3.3 & 3.4) which responded to DHPG under 
basal conditions but not in the presence of depolarisation (< 1%). As these 
cells did not display Ca2+ ‘waves’, they may reflect a sub-population of 
neurons which are relatively insensitive to these mechanisms of 
depolarisation, or they may be glial cells which were atypical in that they did 









3.4.1 I–mGluR response characteristics  
  
 Figure 3.3 displays the percentage of cultured hippocampal neurons 
harvested from non-Tg and Tg mouse (3xTg-AD model) and rat (TgF344-AD 
model) as well as WT rat (SD rat) populations which exhibited detectable 
responses to a) DHPG under basal and depolarisation conditions (including 
those which responded solely under depolarisation conditions) and b) the 
depolarisation stimulus itself. The percentage of neurons which exhibited 
spontaneous activity under basal and depolarisation conditions is also 
shown. There were no significant differences between proportions of 
responding neurons with respect to any parameter measured between non-
Tg and 3xTg-AD mouse, WT rat and non-Tg rat or non-Tg rat and TgF344-
AD rat with one exception, namely that a greater proportion of TgF344-AD 
neurons per experiment responded to the depolarisation stimulus (K+; 15mM) 
than non-Tg age-matched controls (p = 0.02; 79% vs 39%; n = 2 vs n = 4 
experiments; TgF344-AD vs non-Tg rat). The quantitative data accrued from 
Figure 3.3 Response characteristics of neuronal populations 
The percentage of cultured hippocampal neurons which exhibited detectable responses to I-mGluR stimulation (DHPG) under: 
basal (K
+
 5.4 mM), depolarisation conditions (K
+ 
15 mM) and depolarisation conditions alone as well as to the depolarisation 
stimulus itself is shown for each population utilised in this study: non-transgenic (non-Tg; 3 – 20 DIV; 237 – 12 – 8; white 
boxes) and 3xTg-AD mouse (138 – 9 – 6; grey boxes), wild-type rat (SD rat; 406 – 14 – 7; white spotted boxes) and non-Tg 
(372 – 9 – 4; white dashed boxes) and TgF344-AD rat (95 – 2 – 1; grey dashed boxes). The percentage of neurons which 






these responses (peak amplitude, normalised peak amplitude, duration and 
A.U.C.) across these populations are presented in Fig 3.5 – 3.10.  
Once DHPG reached the tissue bath, all of the responding cells on the 
coverslip were activated in a synchronised manner. Regardless of species or 
strain (no significant differences between proportions of neuronal populations 
responding monophasically when comparing non-Tg and 3xTg-AD mouse, 
WT rat and non-Tg rat or non-Tg rat and TgF344-AD rat), DHPG-mediated 
responses were predominately monophasic under basal (Fig 3.4; 84 ± 3%; n 
= 41 experiments) and depolarisation conditions (Fig 3.2; 89 ± 2%; n = 41 
experiments). Monophasic responses consisted of a rapid rising phase and a 
slower decay phase, as reported previously in rat hippocampal cultures (Rae 
et al., 2000). Multiphasic responses were observed in a manner typical of 
that illustrated in Fig 3.3 (ii). Ca2+ responses, generally, were variable both in 
amplitude and duration.  
Application of a depolarisation stimulus of K+ (15 mM) evoked a rapid 
increase in somatic [Ca2+]i, which we attributed to activation of VGCCs. 
When this depolarisation stimulus was applied prior to DHPG application, a 
small number of neurons (generally, across species and strains) responded 
to the depolarisation stimulus alone (and not DHPG; < 1%; Fig 3.2, iii; n = 41 
experiments). This response consisted of a rapid rising phase, which 
plateaued and remained at a steady level until the depolarisation stimulus 
was removed. Those cells which responded to both the depolarisation 
stimulus and DHPG exhibited a DHPG response that was superimposed 
upon this depolarisation- mediated plateau (59 ± 3; Fig 3.2, iv; n = 41 
experiments). 12 ± 2% (n = 41 experiments) of neurons which did not 
produce a measurable DHPG-evoked Ca2+ signal under basal conditions did, 
subsequently, under depolarisation conditions. There is a significant 
correlation between the increase in amplitude mediated by the depolarisation 
stimulus and the amplitude of DHPG responses exhibited by non-Tg mouse 
(p = < 0.0001; n = 92), 3xTg-AD mouse (p = < 0.0001; n = 14), SD rat (p = < 
0.0001; n = 143) and non-Tg rat neurons (p = < 0.0001; n = 34). Conversely, 
TgF344-AD rat neurons do not exhibit a significant correlation (p = 0.99; n = 
34) between these measurements. 
Neurons frequently exhibited spontaneous activity across species, 
strains and experimental conditions (i.e. basal 35 ± 4% and depolarisation 
conditions 37 ± 4% of neurons in each experiment; n = 41 experiments) and 
these responses varied markedly in both their frequency, amplitude and 
duration. Numbers of spontaneously active cells increased with time in 
culture and as such we considered this a sign of cell deterioration as it 
coincided with the appearance of other Ca2+ signalling attributes that we felt 
were markers of cell deterioration such as steadily increasing or decreasing 





membrane which is collapsing) and rapid drops in fluorescence (possibly due 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This series of experiments investigated neuronal DHPG-mediated [Ca2+]i 
responses under basal and depolarisation conditions. Note: These data are 
pooled from experiments with washout times between DHPG applications 
ranging from 15 - 50 minutes (15, 30, 40 and 50 minutes). This reflects the 
fact that as the experimental protocol was optimised (see methods) the 
washout time between DHPG additions was increased from 15 mins to a 
standard 50 mins in order to minimise tachyphylaxis. Therefore, data pooled 
from experiments utilising a washout period of fewer than 50 minutes should 
be interpreted with the caveat that a slight temporal decrease in DHPG-
mediated calcium response magnitude influences the displayed result and as 
such, any increased are likely under-emphasised in the data. Unlike all other 
murine species and strains utilised in this study, in the case of non-Tg mouse 
neurons a small but significant degree of tachyphylaxis was still evident 
when utilising a 50 minute washout (peak amplitude = 38 ± 4 vs 31 ± 3 a.u.; 
first application vs second; p = 0.002; n = 58).  
Data resulting from DHPG-mediated calcium responses, in the 
absence and presence of depolarisation, in non-Tg mouse cells were pooled 
(3 - 5-days-old; 3 – 20 DIV; Fig 3.5; B) and were consistent with previous 
data from our lab (Morley et al., 2012, 2011; Rae et al., 2000), where 
significantly enhanced amplitude, normalised amplitude, duration and AUC of 
DHPG-mediated responses were observed under depolarisation conditions 
relative to basal conditions (Figs 3.5, B; amplitude = 8 ± 1 vs 14 ± 1 a.u., p = 
<0.0001, n = 115; normalised amplitude. = 100 vs 233 ± 40%, p = 0.0016, n 
= 62; duration = 47 ± 6 s vs 79 ± 7 s, p = <0.0001, n = 115; AUC =  322 ± 56 
































































































































































































































































































































































































































































































































































































































The experiments presented in Fig 3.5 which utilised cultured non-Tg 
hippocampal neurons were also conducted on cultured hippocampal neurons 
derived from 3xTg-AD mice (3 - 5-days-old; 6 - 18 DIV), the results of which 
are presented in Fig 3.6. As reported in previous studies undertaken by Dr 
Rae’s lab group (Morley et al., 2011, 2012), but unlike findings obtained 
using cultured non-Tg hippocampal neurons (Fig 3.5), there was no 
enhancement in the any of the DHPG-mediated [Ca2+]i signalling parameters 
(amplitude, normalised amplitude, duration and A.U.C.) under depolarisation 
conditions, relative to basal conditions, in these 3xTg-AD neurons (Fig 3.6; 
amplitude = 22 ± 3 a.u. vs 18 ± 2 a.u., p = 0.07, n = 104; normalised 
amplitude = 100% vs 109 ± 13%, p = 0.31, n = 79; basal vs depolarisation 
conditions). In fact, duration and AUC were significantly decreased in Tg 
neurons from 6 – 18 DIV under depolarisation conditions relative to basal 
conditions (duration = 122 ± 10 s vs 95 ± 8 s, p = 0.0004, n = 104; A.U.C. = 
1973 ± 335 a.u. vs 1248 ± 247 a.u., p = 0.0002, n = 104; basal vs 
depolarisation conditions). Thus, the transgenic genotype has a particularly 
striking effect on attenuating the magnitude (AUC) of I-mGluR-mediated 
responses under depolarisation conditions relative to basal conditions when 










Figure 3.7. Somatic calcium dynamics of non-transgenic (non-Tg; 3 – 20 DIV) and 3xTg-AD (Tg; 6 - 18 DIV) cultured 
mouse hippocampal neurons (3 - 5-days-old) under basal conditions (DHPG (50 μM); 5.4 mM K
+
) or depolarisation 




Histograms illustrating the amplitude (arbitrary units) (i), duration (s) (ii) and area under the curve of (A.U.C.; arbitrary units) (iii) 
of intracellular calcium responses from 3 – 5-day-old non-Tg (white bars) and Tg (grey bars) mouse neurons between 2 – 20 DIV. 
These responses were measured under basal conditions (A) or depolarisation conditions (B). The response due to depolarisation 
(K+; 15 mM) alone (i.e. in the absence of DHPG-elicited responses or minus the superimposed DHPG-elicited component) is 







When DHPG-mediated calcium responses evoked under basal 
conditions in non-Tg and 3xTg-AD neurons were compared (non-Tg = 3 - 20 
DIV, n = 115; 3xTg-AD = 6 - 18 DIV, n = 104 ; Fig 3.7; A) peak amplitude, 
duration and A.U.C. of responses were significantly increased in 3xTg-AD 
neurons relative to non-Tg neurons (amplitude = 25 ± 4 vs 8 ± 1 a.u., p = 
<0.0001; duration = 122 ± 10 s vs 48 ± 6s, p = < 0.0001; A.U.C. 1973 ± 335 
a.u. vs 476 ± 88 a.u., p = 0.0001; Tg vs non-Tg). 
Under depolarisation conditions (Fig 3.7; B), the amplitude (19 ± 2 vs 
14 ± 1 a.u., p = 0.0492; Tg vs non-Tg) and AUC (1248 ± 247 vs 528 ± 57 
a.u., p = 0.0054; Tg vs non-Tg) of DHPG responses were increased in Tg 
neurons relative to non-Tg controls, whereas duration was unchanged (95 ± 
8 vs 79 ± 7 a.u., p = 0.13; Tg vs non-Tg) 
When responses to depolarisation alone were analysed (Fig 3.7; C), 
the peak amplitude (54 ± 11 vs 28 ± 3 a.u., p = 0.0299; Tg vs non-Tg) was 
significantly increased in Tg neurons relative to non-Tg controls, whereas 
duration and AUC were unchanged (duration = 500 ± 26 s vs 482 ± 14s, p = 




































































































































































































































































































































































































































































































































































































































This study was next extended to the use of WT/SD rat neurons (2 - 5-
days-old; 3 – 13 DIV) as a way of validating the data gathered from the 
utilisation of non-Tg mouse neurons (Fig 3.7), in an alternative species (Fig 
3.8). Similar to data from non-Tg mouse neurons, in SD rat neurons, the 
amplitude and normalised amplitude of I-mGluR-mediated responses were 
significantly increased under depolarisation conditions relative to basal 
conditions (amplitude = 27 ± 2 a.u. vs 34 ± 2 a.u., p = < 0.0001, n = 193; 
normalised amplitude = 100% vs 177 ± 11%, p = < 0.0001, n = 169; basal vs 
depolarisation conditions).  
In contrast to non-Tg mouse neurons where both duration and AUC 
were significantly increased under depolarisation conditions relative to basal 
conditions, in SD rat neurons there were no differences in these parameters 
(duration = 93.8 ± 5 s vs 92.6 ± 5 a.u., p = 0.80, n = 193, n = 193; A.U.C. = 






















































































































































































































































































































































































































































































































































































































Enhanced calcium signalling was also investigated in an alternative 
and novel AD model, the TgF344-AD rat. This work comprises the first Ca2+ 
signalling research in this animal model. Notably, whilst previous data was 
accrued from cultures produced from mice and rats from between two and 
five-days-old, cultures were produced from non-Tg and Tg F344 rats from 
three to nine-days-old. This difference reflects a practical limitation in that 
F344 litters had to be individually genotyped to allow for separation of pups 
into non-Tg or Tg sub-groups before a culture could be produced. 
Pooled data from experiments between 3 and 12 DIV showed that the 
amplitude, normalised amplitude, duration and A.U.C. were all significantly 
increased under depolarisation conditions relative to control in non-Tg F344 
neurons (amplitude = 1.8 ± 0.3 a.u. vs 4.6 ± 0.6 a.u., p = <0.0001, n = 76; 
normalised A.U.C. = 100% vs 171 ± 25%, p = 0.004, n = 42; duration = 79 ± 
11 s vs 129 ± 8 s, p = <0.0001, n = 76; A.U.C. = 114 ± 26 a.u. vs 299 ± 58 
a.u., p = 0.0007, n = 76; basal vs depolarisation conditions). Notably, the 
signalling phenotype expressed in non-Tg F344 rats is closer to the profile 
expressed in non-Tg mouse neurons (Fig 3.5) than that of SD rat neurons 
(Fig 3.6) where in the latter, duration and AUC of DHPG responses were not 



























































































































































































































































































































































































































































































































































































































































TgF344-AD rat hippocampal neurons (7-days-old; 3 – 7 DIV) 
exhibit a significant enhancement in the amplitude and normalised 
amplitude of DHPG-mediated calcium responses under depolarisation 
conditions relative to basal conditions (amplitude= 4 ± 0.6 vs 9 ± 0.8 
a.u.; p = <0.0001; n = 53; normalised amplitude = 100% vs 178 ± 
20%, p = 0.0008, n = 31; basal vs depolarisation conditions). 
Therefore, in terms of these two parameters there is little difference 
between Tg and non-Tg F344 neurons with in both populations (both 
parameters approximately doubled under depolarisation conditions 
relative to basal conditions; for non-Tg see Fig 3.9).  
Conversely, unlike in non-Tg F344 rat neurons where duration 
and AUC are significantly enhanced under depolarisation conditions, 
these parameters are unchanged in TgF344-AD neurons (Fig 3.10; 
A.U.C. = 305 ± 62 a.u. vs 503 ± 105 a.u., p = 0.09; duration = 83 ± 13 






3.4.3 Store-operated calcium entry (SOCE) 















































































































































































































































































































































































































































































































































































































































































































































Comparison of ER Ca2+ levels using the SERCA inhibitor TPN between 




































































































































































































































































































































































The peak amplitude of SOCE-mediated Ca2+ influx (following Ca2+ 
“add back”) in 3xTg-AD neurons was significantly reduced compared to that 
evoked in non-Tg neurons (Fig 3.11; by 46 ± 10%, p < 0.0001; non-Tg, n=65; 
3xTg-AD, n = 57). Gd3+ (50 M) significantly inhibited SOCE in both non-Tg 
and 3xTg-AD hippocampal neurons but the degree of SOCE inhibition was 
significantly greater in non-Tg neurons (Fig 3.12; by 21 ± 5% (% decrease 
from peak SOCE-mediated amplitude); p < 0.001; non-Tg, n = 35; 3xTg-AD, 
n = 29). However, it should be noted that this effect may simply have been 
due to the fact that the peak amplitude of SOCE was significantly smaller in 
3xTg-AD than in non-Tg neurons, and therefore there was already a reduced 
driving force for calcium entry in 3xTg-AD neurons relative to the non-Tg 
neurons. Additionally, the intracellular Ca2+ elevation evoked by TPN (1 µM) 
was significantly reduced in 3xTg-AD neurons relative to non-Tg neurons 







3.5.1 General characteristics of I-mGluR responses 
Previously established mechanism of depolarisation- and DHPG- 
mediated responses 
This chapter centres on the intracellular Ca2+ responses of 
hippocampal neurons to I-mGluR stimulation under basal and depolarisation 
conditions. The mechanistic understanding of the intracellular processes 
occurring during these protocols has been extensively characterised in 
similar cells and as such was not a focus of investigation in the current study. 
Briefly, neuronal depolarisation results in the influx of Ca2+ through L-type 
VGCCs. This Ca2+ is then actively transported into the ER by SERCA such 
that it enhances I-mGluR-mediated Ca2+ mobilisation from this store, relative 
to basal conditions (e.g. Rae et al., 2000; Rae and Irving, 2004). As 
mentioned previously, L-type VGCC and I-mGluR co-activation produce 
supralinear/additive [Ca2+]i responses (e.g. Rae and Irving, 2004). However, 
as the Ca2+ imaging technique used in the current study cannot accurately 
determine supralinearity, we will discuss similarly evoked responses in terms 
of whether they are simply “enhanced” under depolarisation conditions 
relative to control. 
A notable difference between the current study and previous research 
was evident in the responses of hippocampal neurons to depolarisation. Rae 
and Irving (2004) showed that depolarisation of rat CA1 hippocampal 
pyramidal neurons in acute slices (by 30 mV from an initial holding potential 
of -60 mV) evoked only a ‘modest’ increase in [Ca2+]i. Rae et al. (2000) also 
showed, utilising cultured rat hippocampal neurons, that depolarisation 
(extracellular application of K+ 10.8 mM (~18 mV depolarisation) or 
depolarisation of 10 ± 1 mV from a mean resting potential of −52 ± 2 mV) 
resulted in a ‘small’ increase in [Ca2+]i. In contrast to these studies, in the 
current experiments, application of the depolarisation stimulus (15 mM K+ = 
~28 mV depolarisation) caused a large intracellular calcium response and a 
characteristic plateau, in cultured hippocampal neurons (across species and 
strains; Fig 3.4; iii & iv). We had concerns that such a relatively large 
increase in [Ca2+]i produced by the depolarisation stimulus may interfere in 
some way with the cells’ ability to handle Ca2+ and produce DHPG-mediated 
increases in [Ca2+]i. The degree of depolarisation will primarily alter Ca2+ 
influx but may also alter more subtle intracellular signalling dynamics. For 
instance, a difference in holding potential (-30 mV (Rae and Irving, 2004) vs -
70 mV (Mannaioni et al. 2001) was proposed as a possible explanation as to 
why signs of both mGluR1- and mGluR5-mediated signalling could be 
detected at -30 mV (Rae and Irving, 2004), but only signs of mGluR1-
mediated signalling could be detected at around resting potentials 





level of depolarisation may also allow for the activation of G protein-
independent I-mGluR-mediated signalling pathways (Gee et al., 2003). In 
this context, we compared paired responses of neurons to I-mGluR 
stimulation following depolarisation with either 10 mM or 15 mM K+ and 
found that although responses were increased with the utilisation of either 
depolarisation stimulus, relative to basal conditions, this was significant 
solely when utilising 15 mM K+ (data not shown).  
Rae et al. (2000) also utilised a 5 – 10 min equilibration period after 
depolarisation and prior to DHPG application. However, given the rapid 
increase and stable plateau of [Ca2+]i (as long as the K+ stimulus was 
present) following K+ -mediated depolarisation (Fig 3.4, B, iii & iv; 3.5, A), we 
reduced this period to 2 minutes in our study. However, although time did not 
permit me to conduct such experiments, it would be interesting to determine 
how long the depolarisation-mediated enhancement of I-mGluR signalling 
persists for after removing the depolarisation stimulus, as depolarisation-
mediated increases in [Ca2+]ER have been proposed as a mechanism for 
recency detection of neuronal activity (Rae et al., 2000). In cultured rat 
hippocampal neurons and CA1 neurons from acute hippocampal slices, this 
facilitation persisted for up to 8 - 10 minutes following removal of the store 
loading stimulus (Rae and Irving, 2003; Rae et al., 2000). This supports the 
suggestion that the extent to which DHPG-mediated calcium responses are 
enhanced following depolarisation (relative to basal conditions) is a direct 
reflection of the state of loading of the Ca2+ stores and that leak from these 
stores occurs relatively slowly (Rae et al., 2000). The persistence of the ER-
mediated calcium signals (and that seen by other groups; Garaschuk et al., 
1997; Irving and Collingridge, 1998) also suggests that the enhancement of 
I–mGluR evoked [Ca2+ ]i responses by depolarisation occurs independently 
of cytosolic Ca2+, which returns to baseline within this persistence window, 
and thus may reflect [Ca2+]ER solely.  
We were also interested in how extracellular Ca2+ could modify I-
mGluR signals in our cultured hippocampal neurons. Indeed, [Ca2+]o 
modulates glutamate-stimulated mGluR1 responses in a variety of 
recombinant systems (Gabellini et al., 1993; Kubo et al., 1998; Kubokawa et 
al., 1996; Nash et al., 2001). In rat hippocampal CA1 neurons, the removal of 
Ca2+ from the external media (or removal of [Ca2+]o combined with the 
inclusion of EGTA in the external media) for 20 mins prior to I-mGluR 
stimulation markedly decreased [Ca2+]i responses (by 80.2 ± 6.9 and 95.6 ± 
1.3% respectively; Rae and Irving, 2004). When we attempted to replicate 
this experiment utilising cultured non-Tg mouse neurons, albeit without the 
electrophysiological component, we also found that there was a trend 
towards decreased DHPG-evoked [Ca2+]i signals under depolarisation 





decrease was not statistically significant (67 ± 22% reduction; p = 0.17; n = 
9; 3-days-old/13 DIV). Notably, several previous studies have suggested that 
calcium is required for receptor-ligand interactions in I-mGluR signalling 
(Mutel et al., 2008; Nash et al., 2001; Thomsen et al., 1993). Therefore, the 
fact we continued to observe DHPG-evoked [Ca2+]i signals under “0” mM 
Ca2+ conditions could indicate that there was still sufficient residual Ca2+ in 
the perfusion system following the period of washout used (50 mins). On the 
other hand, the fact that Rae & Irving (2004) could still evoke I-mGluR-
mediated [Ca2+]i responses when removal of external Ca2+ from media was 
combined with EGTA calls this Ca2+ dependence suggestion into question.  
Characterisation of I-mGluR responses in cultured mouse and rat 
hippocampal neurons 
Previous research by Rae et al. (2000) found that under basal 
conditions DHPG (R, S-DHPG; 100M) application to cultured SD rat 
hippocampal neurons evoked little or no increase in intracellular Ca2+ levels 
in the majority of neurons tested (45% and 23%, respectively). However, in 
acute hippocampal slices from the same group (Rae and Irving, 2004) found 
that the same concentration of DHPG (again under basal conditions) evoked 
a small increase in somatic Ca2+ in the majority (81%) of SD rat CA1 
pyramidal neurons (Rae and Irving, 2004) which may reflect a fundamental 
difference in the nature of ER calcium signals between neurons that have 
been cultured compared to neurons in situ in a brain slice. In the current 
investigation, I conducted a similar but extended analysis of several 
genotypes of neurons, the results of which are presented in Figure 3.3. From 
this work, numerous notable differences in the nature of DHPG-elicited 
responses between the current study and previous research were identified.  
Firstly, the aforementioned relatively small magnitude of DHPG-
evoked [Ca2+ ]i responses generated under basal conditions either in cultured 
neurons or in hippocampal slices suggests that in the majority of non-
transgenic neurons, across numerous studies, species and cell types, ER 
Ca2+ stores are functionally depleted (Garaschuk et al., 1997; Irving and 
Collingridge, 1998; Koizumi et al., 1999; Rae et al., 2000; Rae and Irving, 
2004; Shmigol et al., 1996). Although it is difficult make direct comparisons 
between the magnitude of calcium responses generated across studies (as 
they are not routinely quantified in terms of calcium concentration), DHPG-
mediated responses of cultured SD rat hippocampal neurons under basal 
conditions were robust and not fundamentally dissimilar from responses 
under depolarisation conditions, in the current study (Fig 3.8). Such robust 
responses under basal conditions were also observed in neurons from non-
Tg F344 rats (Fig 3.9) and non-Tg mice (Figs 3.5). One possible explanation 
for this finding is that the relatively small responses observed in previous 





current study (personal communication comparing the nature of responses 
recorded in previous studies with those in the current study with one of the 
original authors, Dr M.G. Rae). 
In terms of the proportion of neurons which responded under basal 
conditions, a response rate of 68 ± 5% for cultured SD rat neurons, (and 
indeed of 54 ± 5% and 27 ± 18% for non-Tg mouse and non-Tg rat neurons, 
respectively; Figure 3.3), is considerably lower than that seen by Rae et al. 
(2004) in SD rat intact slices (81%). This may reflect advantages in the 
function and/or health of the overall cell population utilising intact tissues as 
opposed to cultured cells. That being said, the total number of responding 
neurons under basal conditions was also slightly lower in our study relative to 
that of Rae et al. (2000) in similarly cultured SD rat hippocampal cells (68 ± 
5% in this study vs 77%). However, this observation may simply reflect the 
aforementioned potential difference in the detection threshold of our 
equipment. Differences between these studies may also reflect the fact that 
“SD rats” are an outbred, genetically diverse group of animals which would 
likely lead to significant phenotypic variability in the rats held by different lab 
groups and possibly even between different litters (Brower et al., 2015; 
Jensen et al., 2016). Aside from phenotypic differences arising from the 
utilisation of acute hippocampal slices compared with cultured hippocampal 
neurons, differences in culturing techniques between groups may also 
increase phenotypic variability. For example, in contrast to the current study 
which utilised 2% SR2 to supplement culture media (in order to inhibit glial 
cell growth Kaar et al., 2017), Rae et al. (2000) supplemented their media 
with 10% FBS, which would almost certainly increase glial growth which, in 
turn, could alter the excitability and/or survival of cultured neurons (Igelhorst 
et al., 2015; Vezzani et al., 2008), as discussed previously (Chapter 2). 
In agreement with Rae et al. (2004), DHPG-mediated calcium 
responses were monophasic (across species and under both depolarisation 
(89 ± 2%) and basal conditions (84 ± 3%) in this study vs 81% under basal 
conditions in the Rae et al. (2004) study) and consisted of a rapid rising 
phase and slower decay. Multi-phasic and/or oscillatory responses to DHPG 
were also observed across species and under both depolarisation and basal 
conditions in this study and, as noted by Rae et al. (2004), may reflect the 
initiation of CICR (Berridge et al., 2000).  
The duration of DHPG-mediated calcium responses in SD rat 
hippocampal cultures observed in the current study was significantly longer 
than that observed in SD rat hippocampal slices (101 - 108 ± 6 s (basal and 
depolarisation conditions) vs 21 ± 4 s; current study vs Rae et al. (2004)). 
Moreover, the duration of DHPG-elicited calcium responses was in the range 
of 82 - 162 ± 11 s across the species and models utilised in this study and 





DHPG is dramatically longer in the current study with respect to previous 
work is unknown but a possible explanation may be that the specific culturing 
method used in the current study in some way confers a phenotype which is 
less efficient at cytoplasmic Ca2+ clearance. Alternatively, and perhaps less 
likely, the equipment used in the current study may have been more 
sensitive to calcium elevations than earlier studies and so may have 
captured a greater duration of responses. 
In contrast to our results with non-Tg mouse, non-Tg rat and SD rat 
neurons for which there was no significant difference in the temporal profile 
of I-mGluR responses, previous studies demonstrated that this parameter 
was increased under depolarisation conditions relative to basal conditions in 
SD rat hippocampal cultures and pyramidal neurons in intact tissue 
(unspecified and 72 ± 12 s increase, respectively; Rae et al., 2000, Rae and 
Irving, 2004). Why this aspect of I-mGluR responses was altered previously 
but not in the current study is unknown but may again reflect the genetic 
heterogeneity of “SD rats”. Although not investigated in this study, the 
latency between agonist exposure and the subsequent response was also 
reduced under depolarisation conditions in SD rat neurons, suggesting that 
neurons are primed for activation in some manner, possibly due to 
depolarisation-mediated increases in IP3 formation (Rae et al., 2000).  
 
3.5.2 WT and non-Tg neurons 
Enhanced neuronal calcium responses 
The experiments carried out in this current study were largely guided 
by two previous studies which both utilised similar experimental protocols. In 
agreement with the first such study of Rae et al. (2000), the peak amplitude 
(370% vs approx. 126% (see Fig 3.8); Rae et al. (2000) vs current study) of 
DHPG-mediated calcium signals were significantly increased under 
depolarisation conditions relative to basal conditions (K+ mM = 5.4 to 10.8 vs 
5.4 to 15; Rae et al. (2000) vs current study)  in cultured SD rat neurons (2-
days-old, 6 – 21 DIV vs 2 - 5-days-old, 3 - 13 DIV; Rae et al. (2000) vs 
current study). Furthermore, in the sub-population of neurons which exhibited 
detectable responses under both basal and depolarisation conditions the 
normalised amplitude of the responses was increased by 77 ± 11% under 
depolarisation conditions in the current study (Fig 3.8).  
The second guiding study by Rae and Irving (2004), using whole-cell 
patch-clamp recording, found that under depolarisation conditions (-70 mV to 
-30 mV), DHPG evoked enhanced [Ca2+]i responses in SD rat CA1 
hippocampal neurons in acute slices (743 ± 135% increase in normalised 





under basal conditions. (-70mV). In contrast to this study, we observed no 
statistically significant differences in the A.U.C. of responses when 
comparing depolarisation to basal conditions (Fig 3.8). Differences in the 
methodology used in each study, such as the use of cultured neurons over 
intact slices, the method utilised to produce cultured neurons, the age and/or 
development of neurons (previous studies utilised older/more developed 
cells in vitro), the degree of depolarisation used, as well as possible 
differences in analytical method, may explain these disparities. Furthermore, 
the aforementioned genetic diversity amongst SD rats may also play a role in 
the variable responses observed between studies. 
The slightly less robust depolarisation-enhanced I-mGluR evoked 
calcium responses seen in the SD rats notwithstanding, the fact that these 
types of significantly enhanced calcium signals were also observed in non-Tg 
mouse neurons (Fig 3.5) and non-Tg F344 rat neurons (Fig 3.9), suggests 
that enhanced responses under depolarisation conditions may be a universal 
neuronal phenomenon, possibly acting a means of recency detection and/or 
triggering gene transcription (Rae et al. 2000). 
 
3.5.3 Transgenic neurons 
Neuronal calcium signalling under basal conditions 
ER Ca2+ receptors are heavily implicated as mediators of neuronal 
calcium dysregulation in murine transgenic models of AD (including 3xTg-AD 
mice) and PS1 mutant mice (including PS1M146V; cortical and hippocampal 
neurons; Chakroborty et al., 2009; Chan et al., 2000; Guo et al., 1999; Smith 
et al., 2005; Stutzmann et al., 2006; Supnet et al., 2006; Zhang et al., 2010). 
The observation in the current study that DHPG-mediated [Ca2+ ]i 
responses (amplitude, duration and A.U.C.) are dramatically and significantly 
larger in 3xTg-AD neurons when compared with non-Tg controls under basal 
conditions (Fig 3.7, A) is in agreement with preliminary observations by this 
group (which I was involved in) comparing non-Tg and 3xTg-AD cultured 
mouse hippocampal neurons (Morley et al., 2012). Furthermore, the findings 
are also in agreement with subsequent studies in my lab examining dentate 
gyrus neurons in ex vivo hippocampal slices (A.U.C. = 1558 ± 189 a.u. vs 
700 ± 66 a.u.; P < 0.05, n = 20; 19 ± 10 days-old; Vaughan et al., 2018). 
These data were generated using similar experimental protocols, which have 
since been optimised with regard to the culture method employed (Kaar et al. 
2017) and DHPG washout time (as previously described, see methods). 
Furthermore, it has been shown previously that direct stimulation of IP3Rs 
(with caged IP3) resulted in somatic [Ca2+ ]i responses which were up to 





mutation as that of 3xTg-AD mice) relative to age-matched controls 
(Stutzman et al. 2007). Similarly, RyR-mediated [Ca2+]i responses were also 
much larger (approximately 400%) in cultured 3xTg-AD hippocampal 
neurons in comparison to non-Tg neurons (Zhang et al. 2010).  
As discussed in Section 1.3 Ca2+ signalling and investigated in 
Chapter 4, I-mGluR [Ca2+]i responses are mediated primarily by Ca2+ release 
from the ER through IP3Rs in hippocampal neurons. Thus, the enhanced ER 
Ca2+ mobilisation through IP3Rs (and RyRs) is likely to be due to a 
pathological increase in [Ca2+]i throughout the neuron, but particularly within 
the ER which is consistent with the Ca2+ hypothesis of AD (Section 1.4). In 
attempting to explain the elevated [Ca2+]i caused by certain AD-linked 
mutations, Zhang et al. (2010) proposed that the PS1M146V mutation 
expressed in 3xTg-AD mice was the principal underlying cause of the 
enhanced [Ca2+]ER as it impairs the normal constitutive calcium leak function 
of PS1. Specifically, ER Ca2+ leak was approximately 2.5 times less efficient 
in 3xTg-AD neurons relative to non-Tg neurons and, as a result, ER Ca2+ 
levels were 3-fold higher in 3xTg-AD neurons (Zhang et al. 2010). 
Interestingly, in these neurons, Ca2+ appeared to specifically accumulate in 
an ER pool which, in contrast to non-Tg neurons, was not depleted following 
TPN treatment. The authors suggested that the existence of this “TPN-
insensitive” calcium pool was compensatory in nature and arose due to 
impaired PS1 leak function (Zhang et al., 2010). In agreement with this study 
and others (Leissring et al., 2000; Yoo et al., 2000), and with the proposal of 
increased ER Ca2+ levels in neurons from PS1M146V (specifically 3xTg-AD) 
mice, in the current study SOCE-mediated Ca2+ influx in 3xTg-AD neurons is 
significantly dampened (Fig 3.11) as is the effect of SOCE inhibition (Fig 
3.12) relative to non-Tg neurons. Such an effect makes intuitive sense as 
SOCE is normally stimulated by low ER calcium, but if the ER is overloaded 
with Ca2+ then the stimulus for SOCE initiation may be blocked or attenuated. 
In further agreement with Zhang et al. (2010), the intracellular Ca2+ elevation 
evoked by TPN was significantly reduced in 3xTg-AD neurons relative to 
non-Tg neurons (Fig 3.13) suggesting a PS1M146V-dependent impairment in 
the passive leak of Ca2+ from the ER leading to a hyper-loaded ER state. 
Aside from utilising differences in SOCE-elicited signals as an indirect 
comparison of ER Ca2+ levels between non-Tg and 3xTg-AD neurons, the 
fact that SOCE is not just involved in replenishing ER Ca2+ levels but may 
also play a role in the regulation of the ER/cytoplasmic Ca2+ gradient 
(Brandman et al., 2007) could have important implications for differences in 
Ca2+ homeostasis and signalling between these two populations. Indeed, 
PS-mediated synaptic deficits in AD are thought to be mediated by 
dysregulated SOCE (Bezprozvanny et al., 2013; Popugaeva et al., 2012; 





SOCE disruption stimulates Aβ42 generation, whereas SOCE disruption itself 
is not due to Aβ-mediated effects (Herms et al., 2003; Leissring et al., 2000; 
Yoo et al., 2000). 
Aside from the possibility of increased ER store content of Tg neurons 
being responsible for increased IP3R- and/or RyR-mediated Ca2+ 
mobilisation, relative to non-Tg controls, it is also possible that increased 
RyR and IP3R expression plays a role (Chakroborty et al., 2009; Chan et al., 
2000; Smith et al., 2005; Stutzmann et al., 2007, 2006; Zhang et al., 2010). 
We investigated this possibility in 3xTg-AD, TgF344-AD hippocampal lysates 
and age-matched non-Tg controls in Chapter 5.  
Unfortunately, it was not possible to carry out similar comparisons to 
those carried out utilising the 3xTg-AD model, between non-Tg and TgF344-
AD rat neurons, due to the relatively low numbers of experiments that I was 
able to conduct using these animals. This was primarily due to the fact that, 
whilst conducting these experiments, and for reasons outside of my control, 
this animal model became unavailable. 
Neuronal calcium signalling under depolarisation conditions 
Unlike data obtained from non-Tg mouse neurons (Fig 3.5; and from 
non-Tg rat (Fig 3.9) and SD rat neurons (Fig 3.8)), the amplitude and 
normalised amplitude of DHPG-evoked responses were not enhanced under 
depolarisation conditions in 3xTg-AD neurons, relative to basal conditions 
(Fig 3.6). In fact, interestingly, duration and A.U.C. of DHPG-evoked 
responses were decreased in 3xTg-AD neurons under depolarisation relative 
to basal conditions (Fig 3.6) which is in stark contrast to non-Tg mouse and 
rat neurons (Fig 3.5 & Fig 3.9) which exhibited a significant increase in both 
parameters under depolarisation conditions relative to basal conditions, as 
well as in contrast to SD rat neurons where duration and A.U.C. were 
unchanged between the two experimental conditions (Fig 3.8). A similar 
significant decrease under depolarisation conditions, relative to basal 
conditions, has also been observed in subsequent studies utilising 3xTg-AD 
dentate gyrus neurons in ex vivo hippocampal slices (37 ± 7% a.u. decrease 
in A.U.C.; n = 20; 19 ± 10-days-old; Vaughan et al., 2018).In the context of 
our hypothesis of both an intracellular environment and ER which are 
overloaded with Ca2+ under basal conditions, it is logical that a depolarisation 
stimulus (which loads the ER with Ca2+; Rae and Irving, 2003) does not 
facilitate a significant enhancement of subsequent DHPG-evoked calcium 
signals in 3xTg-AD neurons relative to basal conditions.  
A decrease in the duration and A.U.C. of calcium responses upon 
depolarisation in 3xTg-AD neurons is more difficult to explain. It could be 
possible that the first exposure of cells to DHPG alleviates a chronic increase 
in ER Ca2+, such that even with the Ca2+ influx and efficient uptake by the ER 





smaller than that observed under chronically elevated conditions. As this 
decrease is only evident in the parameters of duration and A.U.C. and not 
amplitude (unchanged), it may suggest that the initial response to DHPG is 
not enhanced in 3xTg-neurons, whereas the maintenance of the response is 
reduced. A potential mechanism underlying such a reduction in response 
persistence could be increased coupling between L-type VGCC-dependent 
Ca2+ entry (or the signal produced in combination with I-mGluR stimulation) 
and molecular mechanisms which return intracellular and ER Ca2+ levels to 
baseline in 3xTg-AD neurons, i.e. extrusion mediated by PMCA (Berrocal et 
al., 2015, 2012; Mata et al., 2011) and NCX (Kessete Afewerky, 2016; Magi 
et al., 2016) and ER sequestration mediated by SERCA (Green et al., 2008) 
which are impaired in AD, in a manner dependent on [Ca2+]i and Aβ42. 
Alternatively, depolarisation-mediated Ca2+ influxes into a cytosol which is 
already overburdened with Ca2+ could negatively regulate the production of 
subsequent I-mGluR/ER Ca2+ transients, possibly as a means of 
neuroprotection. A candidate mediator of such neuroprotective modulation 
would have to negatively regulate IP3Rs and/or RyRs, be upregulated by 
chronic increases in [Ca2+]i, but also be activated by acute (possibly VGCC 
micro domain-dependent) increases in [Ca2+]i. Possible mediators of such an 
effect are outlined in Chapter 5 and include proteins such as Bcl-2, which 
suppresses Ca2+ release through both IP3Rs, RyRs (Vervliet et al., 2016) and 
calcineurin, which is activated by Ca2+ and suppresses IP3R-mediated Ca2+ 
release via receptor dephosphorylation (Cameron et al., 1997, 1995a, 
1995b). Conversely, it may simply indicate that there was a deterioration of 
cells as experiments progressed, although this suggestion seems to be 
contradicted by the finding that repeated DHPG application controls in the 
same cells evoked reproducible responses (50 minute washout; data not 
shown), and by the fact that there was no decrease in the proportion of 3xTg-
AD neurons responding to DHPG nor was there an increase in 
spontaneously active neurons (which we used as an indirect measurement of 
deterioration in a given population of cultured cells) between experimental 
phases (Fig 3.3). 
Furthermore, under depolarisation conditions, the amplitude and 
A.U.C. of DHPG-evoked calcium responses were significantly increased in 
3xTg-AD neurons, relative to non-Tg (Fig 3.7, B). This suggested that 
although 3xTg-AD neurons were unable to produce enhanced responses 
under depolarisation conditions relative to basal conditions (Fig 3.6), the 
magnitude of their responses in K+ HBSS was increased when compared to 
those produced by non-Tg neurons under identical conditions (Fig 3.7; B). 
This could simply be due to the previously described generally enhanced 
levels of [Ca2+]i in 3xTg-AD/PS1M146 neurons, which could negate the effect 
of the depolarisation stimulus, despite its amplitude being enhanced in 3xTg-





TgF344-AD rat neurons (Fig 3.10) exhibited a different phenotype to 
that observed for 3xTg-AD neurons (Fig 3.6) when compared with age-
matched non-Tg controls. Specifically, the amplitude and normalised 
amplitude of I-mGluR responses were not different when TgF344-AD 
neurons were compared with non-Tg control (Fig 3.9), i.e. both parameters 
were enhanced under depolarisation relative conditions to basal regardless 
of transgenic status. This suggests that there is no overt dysregulation in I-
mGluR-mediated signalling in TgF344-AD neurons relative to non-Tg control 
at this age (7-days-old) and this development in vitro (3 – 7 DIV). In contrast, 
in 3xTg-AD neurons, amplitude and normalised amplitude were not 
enhanced under depolarisation relative to basal conditions. 
Where the TgF344-AD phenotype did differ from that of the non-Tg 
F344 neurons was with respect to duration and A.U.C. of DHPG-elicited 
responses which were not significantly different under depolarisation 
conditions relative to basal conditions in TgF344-AD neurons (Fig 3.10) but 
which were enhanced in non-Tg F344 neurons (Fig 3.9). Possible factors 
underlying such an observation are outlined above in the context of the 
significant decrease observed in both duration and A.U.C. under 
depolarisation conditions relative to basal conditions in 3xTg-AD mouse 
neurons (Fig 3.6).  
These differences in phenotype between the 3xTg-AD mouse and 
TgF344-AD rat models suggest that Ca2+ dysregulation at this early stage of 
development with respect to amplitude and normalised amplitude is 
determined by PS1 mutation (i.e. PS1∆E9 vs PS1M146V; TgF344-AD rat vs 
3xTg-AD mouse) or the fact that the 3xTg-AD mice also express a mutation 
in tau. Where both mutations could converge in terms of pathogenic effects 
is with respect to attenuation of I-mGluR-mediated response persistence. 
Work by Zhang et al. (2010) suggests that the PS1∆E9 mutation, 
expressed by the TgF344-AD rats, resulted in a gain-of-leak-function of Ca2+ 
from the ER. Furthermore, at least in MEF cells, transfection with PS1∆E9 
normalised [Ca2+]ER to WT levels despite the fact that in lipid bilayer studies, 
PS∆E9 exhibits an approximately 2-fold increase in the rate of Ca2+ 
conductance when compared with WT PS1 (Tu et al., 2011). However, this 
gain-of leak function is not supported in the current study as the amplitude of 
I-mGluR-mediated responses under basal conditions (an indirect 
measurement of resting ER Ca2+ levels) was unchanged in TgF344-AD 
neurons relative to non-Tg controls (data not shown). Indeed, unlike 
comparisons between non-Tg and 3xTg-AD neurons (Fig 3.7), there were no 
differences between non-Tg and TgF344-AD neurons with regard to 
amplitude, duration or A.U.C. of DHPG-mediated responses under basal or 
depolarisation conditions, or to the depolarisation stimulus itself (data not 





not evident, at least at this early developmental time point in TgF344-AD rat 
hippocampal neurons, or that it does not operate at a fast-enough rate to 
minimise the effects of depolarisation-induced ER loading and subsequent 
stimulation of enhanced responses under depolarisation conditions in 
TgF344-AD neurons (Fig 3.10).  
The fact that there was a significant correlation between the increase 
in amplitude mediated by the depolarisation stimulus and the amplitude of 
DHPG responses exhibited by non-Tg mouse, 3xTg-AD mouse, SD rat and 
non-Tg rat neurons, whereas TgF344-AD rat neurons did not exhibit a 
significant correlation between these measurements (see 3.4.1 I-mGluR 
response characteristics), does however suggest a difference in the coupling 
of depolarisation and/or intracellular Ca2+ influx with ER Ca2+ release 
between these models. Interestingly, this is despite the fact that the 
proportion of TgF344-AD neurons which responded to depolarisation was 
significantly higher than non-Tg controls, suggesting they were in some way 
more sensitive to L-type VGCCs activation as a population (Fig 3.3). In 
circumstances where there is normal cellular calcium homeostasis, an 
increase in Ca2+ influx due to depolarisation and the opening of L-type 
VGCCs could logically cause larger I-mGluR-mediated Ca2+ responses, due 
to the Ca2+ uptake by SERCA into the ER. However, this would not 
necessarily be expected in 3xTg-AD or TgF344-AD neurons at this age and 
development in vitro where PS-dependent ER Ca2+ dysregulation is likely 
(Zhang et al., 2010). Alterations in, for example, L-type VGCC, SERCA, RyR, 
IP3R and PS regulation, expression and/or stability could influence whether 
or not the amount of Ca2+ influx due to depolarisation correlates with the 
amount released from the ER following I-mGluR mediated stimulation. In the 
context of the Ca2+ hypothesis of AD, if the ER was chronically hyper-loaded 
with Ca2+, one would expect that a further influx of Ca2+ would not correlate 
with an increased I-mGluR elicited Ca2+ release relative to basal conditions 
as this additional calcium could not be taken up by the ER. However, such a 
correlation is observed in data from 3xTg-AD neurons and suggests that the 
ER may not be loaded to capacity in 3xTg-AD neurons under basal 
conditions. Alternatively, the initial application of DHPG under basal 
conditions could alleviate the hypothesised chronic increase in ER Ca2+ 
levels (Popugaeva and Bezprozvanny, 2013), such that when DHPG was 
subsequently applied under depolarisation conditions, this Ca2+ influx 
stimulus is able to increase ER Ca2+ levels and, as such, the nature of 
responses to DHPG. Although there are fundamental differences between 
TgF344-AD rats and 3xTg-AD mice, including the facts that they are different 
species, express different PS1 genes (which have opposite effects on ER 
Ca2+ levels; enhanced leak (TgF344-AD) vs impaired leak (3xTg-AD); Zhang 
et al. 2010) and that the 3xTg-AD mice alone express a tau mutation, the 





mediated responses observed in TgF344-AD neurons is puzzling given that 
the profile (at least in terms of amplitude and duration) of I-mGluR-mediated 
responses is not different in transgenic neurons relative to control. As 
described previously, if the proposed gain-of-leak PS∆E9 mutation were active 
at this developmental timepoint the rate of calcium leak may not outcompete 
the rate of ER loading by SERCA over such an acute time period (Tu et al., 
2011, Zhang et al., 2010) and prevent the stimulation of enhanced responses 
under depolarisation conditions, but its effects may be significant enough to 
alter the correlation between the amplitude of depolarisation- and I-mGluR-
stimulated responses.  
It also worth noting, however, that the correlation statistics described 
above reflect activity only within a subpopulation of neurons which exhibited 
measurable responses to depolarisation and may not capture the subtleties 
of store loading following depolarisation. Indeed, previous research has 
shown that store loading/depolarisation stimuli can enhance I-mGluR-
mediated Ca2+ responses without any detectable increase in [Ca2+]i arising 
from the depolarisation stimulus itself (cultured rat hippocampal neurons, 
dentate gyrus neurons from ex vivo intact hippocampal slices and pancreatic 
acinar cells; Mogami et al., 1997, Rae et al., 2000, Vaughan et al., 2018)). 
Finally, it is worth noting that aside from the aforementioned increase 
in the proportion of TgF344-AD neurons which responded to the 
depolarisation stimulus relative to non-Tg controls, there were no differences 
in a) the proportions of neurons which exhibited detectable responses to 
DHPG under basal and depolarisation conditions (including those which 
responded solely under depolarisation conditions) or the depolarisation 
stimulus itself and b) the percentage of neurons which exhibited 
spontaneous activity under basal and depolarisation conditions between non-
Tg and 3xTg-AD mouse, WT rat and non-Tg rat or non-Tg rat and TgF344-
AD rat. This suggests that at the population level, there is nothing inherently 
different between these murine strains with regards to responsiveness to I-
mGluR or L-type VGCC stimulation or spontaneous activity rather it is in the 
profile and magnitude of the responses themselves where differences 
between strains occur.  
 
3.5.4 Limitations 
Somatic Calcium Responses 
The decision to measure somatic calcium responses was, in part, a 
pragmatic one due to the limitations of our imaging system. Depending on 
the focal plane, some neuronal processes could be discerned; however, this 





been possible to view dendrites and spines in our hippocampal cultures, the 
optical resolution of our imaging system was of insufficient quality to 
accurately measure calcium transients in these microscopic structures. 
Ideally, it would have been preferable to employ two-photon confocal 
microscopy for these studies. Unfortunately, significant financial constraints 
aside, there are no confocal microscopes available at University College 
Cork that are configured to allow continuous perfusion of living tissue. 
Global I-mGluR stimulation 
I-mGluRs are prominently expressed in CA1 pyramidal neurons (Conn 
and Pin, 1997) and indeed, are widely distributed on pyramidal neurons 
(Lujan et al., 1996). Given that we were ‘globally’ superfusing an I-mGluR 
agonist onto neurons, the magnitude of the calcium responses was 
presumably determined largely by the expression and localisation of the 
neuronal I-mGluRs. Such global application results in activation of I-mGluRs 
throughout the neuron, a situation which is unlikely to replicate in vivo 
glutamate-mediated stimulation. 
 
3.5.5 General discussion 
Use of young animals 
The use of young animals follows the “road map” for the direction of 
AD research proposed by Selkoe (2002) who, with regard to investigating the 
aetiology of AD, stated that “The earlier one looks, the better”. The findings 
presented within this thesis support such an assertion as they demonstrate 
that clear mechanistic changes in calcium signalling occur at early stages of 
development in AD gene-expressing hippocampal neurons prior to, and 
apparently independently of, structural changes and or/protein aggregation. 
These changes, which could be responsible for an early, subtle memory loss 
syndrome, are likely to be underpinned by eventual synaptic deficits and loss 
at a much earlier stage than other late-stage and commonly investigated AD-
related proteins/mechanisms such as Aβ plaques and tangles. 
 
The physiological relevance of I-mGluR evoked hippocampal enhanced 
[Ca2+]i signals  
Intracellular calcium homeostasis and signalling are universally 
recognised as being essential to normal neuronal function and health (see 
Section 1.3; e.g. Stutzmann, 2007). Given the possibility that dysregulated 
calcium may also be a primary element in initiating and propagating AD, 
understanding intracellular Ca2+ dynamics in both health and disease states 
may be key to developing a treatment for the disease (Berridge, 2010). As 





neuronal calcium handling but also provides important information about how 
neuronal intracellular Ca2+ dynamics can be dramatically altered by specific 
gene mutations that are associated with FAD. 
Specifically, with regard to the enhanced I-mGluR mediated Ca2+ 
signals observed in hippocampal neurons described here, similar types of 
responses (supralinear responses) may serve as a means of translating 
changes in neuronal activity (e.g. membrane depolarisation) into a 
physiological response, via the loading state of the ER. The Ca2+ loading 
state of the ER could serve as a means of coincidence detection following 
prior excitatory input to the neuron (e.g. which may, under certain 
circumstances generate back-propagating APs; Nakamura et al., 1999). The 
fact that these enhanced ER-mediated Ca2+ signals can be activated for a 
relatively long time period following Ca2+ loading of the organelle means that 
they could serve as a memory of recent synaptic activity (i.e. a recency 
detector; Rae et al., 2000). By enhancing the state of ER Ca2+ loading, 
phenomena such as membrane depolarisation and/or NMDAR activation can 
also increase the frequency and coupling between elementary release sites 
(Koizumi et al., 1999). This increased coupling could, in turn, lead to the 
generation of global Ca2+ signals which may ultimately convey Ca2+ signals 
from neurites and spines to the nucleus, leading to alterations in gene 
expression (Berridge, 1998; Nakamura et al., 1999). Indeed, supralinear 
calcium signalling via activation of NMDARs and I-mGluRs may be involved 
in the modulation of synaptic plasticity in CA1 hippocampal cells during weak 
stimulation paradigms (Rae et al., 2000), whereas NMDAR activation alone 
may be sufficient for modulation of synaptic plasticity when stimulation is 
sufficiently robust (Wilsch et al., 1998). The magnitude of such calcium 
signals generated by ER calcium release can also be further modulated due 
to the sensitivity of ER Ca2+ release channels to both luminal (Koizumi et al., 
1999; Missiaen et al., 1992) and cytosolic [Ca2+]i (Bezprozvanny et al., 1991; 
Nakamura et al., 1999). The loss of such physiological function and nuance 
due to AD-dependent Ca2+ dysregulation has the potential to contribute to 
memory impairments that are characteristic of the disease. 
More pertinent to our understanding of the Ca2+ hypothesis of AD 
however, this work adds to the evidence that Ca2+ dysregulation is an early-
stage event in the pathogenesis of at least certain forms of FAD which are 
likely caused by neuronal expression of specific PS1 mutations (Guo et al., 
1998; Zhang et al., 2010). As discussed, this Ca2+ dysregulation takes the 
form of altered [Ca2+]i and [Ca2+]ER, the former of which is dependent upon 
the activity of PLC, IP3R, RyR and/or L-type VGCCs in PC12 and SH-SY5Y 
cells (Cedazo-Mínguez et al., 2002; Guo et al., 1998, 1997, 1996). In 
agreement with this, I-mGluR-mediated calcium signalling under basal and 
depolarisation conditions, likely involving a contribution from, to varying 





hippocampal neurons (3xTg-AD and TgF344-AD) expressing PS1 mutations 
relative to non-Tg controls, from a very early age (2 - 5-days-old/2 – 20 DIV; 
Fig 3.5 – 3.10) and this effect was particularly evident (across all parameters 
measured) in 3xTg-AD mouse neurons relative to non-Tg control (Fig 3.5 – 
3.7). 
[Ca2+]i and [Ca2+]ER are inextricably linked (Bandara et al., 2013; Das 
et al., 2012; Tu et al., 2006) and in AD, normal homeostatic mechanisms 
which would return increases in [Ca2+]i back to baseline are overwhelmed, 
due in large part to the impaired buffering capacity of the ER. This, in turn, is 
primarily due to the fact that the ER is pathologically loaded with Ca2+ 
(Berridge, 2010; Mattson, 2002), a statement which the current study 
supports (see Fig 3.7, 3.11, 3.12 & 3.13). There are numerous lines of 
evidence that this is a PS1 mutation-dependent effect across a plethora of 
transgenic cell types (e.g. Leissring et al., 2000; see Section 1.4.4 ER 
remodelling) whereas in the context of LOAD, there is a surfeit of evidence 
for Aβo-mediated Ca2+ dysregulation (e.g. see Yu et al. 2009; see Section 
1.2.6 Molecular actions of Aβo and related metabolites). Moreover, the ratio 
of [Ca2+]i to [Ca2+]ER in animal models of AD will be determined by which 
particular PS1 mutation is expressed, i.e. whether a mutation increases 
(including the PS∆E9) or impairs (including PS1M146V) ER Ca2+ leak (Zhang et 
al., 2010), given that 80% of the Ca2+ leak from the ER is mediated by PS1 
(Tu et al., 2006). In both cases, PS1 mutation could result in chronically 
increased [Ca2+]cyt. In the case of PS1M146V, this could occur due to the 
impaired buffering capacity of a hyper-loaded ER, whereas the PS1∆E9 
mutation could result in a chronically enhanced leak of Ca2+ into the 
cytoplasm. Our experiments in 3xTg-AD neurons which express the 
proposed impaired leak PS1M146V mutation support these hypotheses as I-
mGluR stimulation, the primary consequence of which was to evoke ER Ca2+ 
mobilisation, is enhanced under basal conditions. Furthermore, as described 
previously, this study suggests an impairment in the passive leak of Ca2+ 
from the ER of 3xTg-AD neurons (Fig 3.13) relative to non-Tg controls, likely 
in a PS1M146V-dependent manner which could lead to a hyper-loaded ER in 
these cells. 
The relative contributions of RyR- and IP3R- dependent Ca2+ signals 
to I-mGluR-mediated responses aside (see Chapter 4 & Kaar and Rae 
(2015)), this work also supports the extensive evidence that ER Ca2+ 
mobilisation through both IP3Rs and RyRs is enhanced in AD models in a 
PS1-dependent manner (see Section 1.4.4 - Alterations in receptor function; 
e.g. Stutzman et al. 2007, Zhang et al., 2010).  
Basal increases in ER Ca2+ levels such as that seen in 3xTg-AD 
neurons will also have critical implications for SOCE, for which low ER Ca2+ 





mediated by SOCE are much larger in non-Tg neurons relative to 3xTg-AD 
and PS DKO neurons (2-fold increase; cultured hippocampal neurons; 0 - 1-
days-old; 12 - 13 DIV) and in vitro in cells expressing PS FAD mutations 
(Akbari et al., 2004; Herms et al., 2003; Leissring et al., 2000; Yoo et al., 
2000). In agreement with these studies, we have also found that SOCE 
stimulation and its inhibition was significantly attenuated in 3xTg-AD cultured 
hippocampal neurons, relative to non-Tg controls (Fig 3.11 & 3.12). Crucially, 
in the context of AD pathogenesis, Ca2+ dyshomeostasis, including that 
specifically due to impaired SOCE (Herms et al., 2003; Leissring et al., 2000; 
Yoo et al., 2000), increases the production of pathological Aβo (Hartigan & 
Johnson, 1999). 
Although I have proposed that I believe that the primary modulator of 
Ca2+ homeostasis observed in transgenic AD neurons used in this study is 
mutations in PS1, alterations in the levels of APP metabolites, including Aβo, 
could also contribute to the transgenic phenotype. This, in turn, will likely 
result in further modulation/dysregulation of the neuronal Ca2+ signalling 
system, including mGluR-mediated signalling, as described in Section 3.1.4 - 
I-mGluR signalling and the Ca2+ Hypothesis of AD. Notably, there is 
conflicting evidence for (Leissring et al., 2002; Lopez et al., 2008; Rojas et 
al., 2008) and against (Stieren et al., 2010) the ability of APP mutations 
(independently of PS1 mutations or Aβ production, which have both been 
definitively determined to cause increased [Ca2+]i; see Section 1.3.3 
Molecular actions of Aβo and related metabolites and Section 1.4 The 
calcium hypothesis of AD) to cause neuronal Ca2+ dysregulation in animal 
models of AD. However, the FAD-linked APP mutants such as the Swedish, 
London, Indiana, Flemish and V717L mutations, had no effect on basal 
[Ca2+]i, [Ca2+]ER or IP3R-mediated Ca2+ mobilisation in neurosecretory PC12 
cells (Stieren et al., 2010). As disparate types of Ca2+ dyshomeostasis were 
induced in our rat and mouse models of AD in spite of the fact that they 
expressed the same APPSWE mutation, it suggests that this mutation is not 
the critical factor inducing the early Ca2+ dysregulation observed here. 
Support for this suggestion has been provided by the finding that the 3xTg-
AD mutant APP and tau gene products are not expressed in cultured 
hippocampal neurons before DIV 18 (Zhang et al. 2010). However, that said, 
the levels of expression of these transgenes was not determined in this 
particular study so we are unable to state conclusively that they did not play 






There are numerous differences in the nature of responses to 
depolarisation and I-mGluR stimulation under basal and depolarisation 
conditions when comparing cultured transgenic hippocampal neurons to non-
transgenic controls. As I-mGluR-elicited calcium responses are mediated 
primarily by ER Ca2+ mobilisation, the differences in the responses observed 
with the transgenic phenotypes are likely due to alterations in ER Ca2+ 
handling. Under depolarisation conditions, differences in the influx of Ca2+ 
through VGCCs and its uptake by the ER may also influence this transgenic 
phenotype. Furthermore, the nature of dysregulated I-mGluR-mediated 
signalling is different when comparing responses from 3xTg-AD mouse or 
TgF344-AD rat tissue. The most likely candidate underlying Ca2+ 
dysregulation, in general, and also differences in the transgenic phenotype 
between models are leak-specific mutations in PS1 (i.e. y-secretase and 
APP processing-independent functions of PS1; Zhang et al., 2010). 
Together, these data suggest that Ca2+ dysregulation is an early-stage 
phenotype of these particular transgenic models of Alzheimer’s disease, i.e. 
PS1-linked FAD could result from chronic Ca2+ dysregulation, beginning at 
very early stages of development.  
Moreover, this illustrates the potential effect Ca2+ dysregulation could 
have in the pathogenesis of LOAD. In this case, the cause of Ca2+ 
dysregulation is less clear (see Chapter 1) and could arise indirectly from 
mutations in genes related to APP processing or Aβo removal such as ApoE 
(Coon et al., 2007; Roses et al., 1995), CLU/APoJ (Woody and Zhao, 2016), 
SORL1 (Rogaeva et al., 2007) and TREM2 (Colonna and Wang, 2016; 
Guerreiro et al., 2013; Neumann and Daly, 2013; Yaghmoor et al., 2014) as 
well as from mutations in genes directly implicated in Ca2+ homeostasis such 
as CALHM1 (Dreses-Werringloer et al., 2008). That being said, current 
understanding of AD suggests that subtle Ca2+ dysregulation (Khachaturian, 
1989), which may precede excessive activation of the amyloidogenic APP 
processing pathway (Stutzmann, 2007), can induce degenerative pathology 
involving oxidative stress, mitochondrial impairment, synaptic dysfunction, 
cognitive deficits and, ultimately, widespread neuronal cell death which 
characterises the later stages of the disease (Berridge, 2010; Bezprozvanny 
and Mattson, 2008; Deshpande et al., 2006; Glabe and Kayed, 2006; Kelly 






4 ADP-ribosyl cyclase-mediated signalling 
4.1 Introduction 
Sections of this chapter are taken from a review publication by Kaar 
and Rae (2015) entitled ‘Metabotropic glutamate receptor-mediated cyclic 
ADP ribose signalling’ which is published in Biochemical Society 
Transactions (Appendix 2). 
In Chapter 3 I discussed the classical PLC/IP3R pathway, which is 
stimulated following I-mGluR activation. However, as mentioned there, 
several reports have indicated that certain downstream effects of I-mGluR 
activation, on membrane currents and intracellular Ca2+ release, occur 
independently of either PLC (Chavis et al., 1998; del Río et al., 1999; Ireland 
et al., 2004, 2002; Sohn et al., 2007; Young et al., 2004) and/or IP3R 
activation (Currie et al., 1995; Gafni et al., 1997; Ireland et al., 2002).  
These findings led to the suggestion that I-mGluR-mediated calcium 
signals could, under certain conditions, be mediated by activation of the 
other main ER calcium release channel, the RyR (Sohn et al., 2011). This 
was based upon the finding that the plant alkaloid, ryanodine, which can both 
activate and inhibit RyRs in a concentration-dependent manner, attenuated I-
mGluR-evoked responses in rat cerebellar granule neurons and dorsal root 
ganglion (DRG) neurons (Crawford et al., 1997a; Irving et al., 1992). 
Furthermore, in dopaminergic neurons of the ventral midbrain, mGluR-
mediated Ca2+ mobilisation occurs via activation of both IP3R and RyRs 
(Higashida et al., 2003). Moreover, in “acutely dissociated” (i.e. cells which 
are dissociated and adhered to a substrate for immediate Ca2+ imaging (Min 
et al., 1996), as opposed to the use of cultured cells which are maintained in 
vitro prior to utilisation) rat CA1 hippocampal neurons it is proposed that I-
mGluR-mediated Ca2+ mobilization was generated in its entirety by activation 
of the RyRs (Sohn et al., 2011). 
The Ca2+-mobilising second messenger cADPR was a prime 
candidate mediator of I-mGluR-mediated RyR activation as thousands of 
studies support the model of cADPR mobilisation from a RyR-sensitive ER 
source (see Morgan et al., 2005) and its activity is established in a plethora 
of neuronal and neuron-like cells (Currie et al., 1992; Empson and Galione, 
1997; Hachisuka et al., 2007; Higashida et al., 2012, 2003; Hua et al., 1994; 
Jin et al., 2007; Lopatina et al., 2010; Sohn et al., 2011; Yue et al., 
2009)(Currie et al., 1992).  However, the exact means by which this 
interaction occurs has yet to be clearly delineated as cADPR does not 
appear to regulate RyR activity by directly binding to the channel itself 
(Morgan et al., 2005; Sitsapesan and Williams, 1995). Rather, it is 
hypothesized that cADPR activates some sort of molecular ‘intermediary’ 





Williams, 1995). As such, several cytosolic proteins including FKPB12.6 
(Hashii et al., 2000b; Noguchi et al., 1997; Tang et al., 2002; Y. X. Wang et 
al., 2004), CaM (Lee et al., 1995; Thomas et al., 2001), CaMKII and PKA 
(Wehrens et al., 2005b) have been proposed as putative ‘missing links’ 
between cADPR generation and RyR activation. 
cADPR sensitises RyRs to activation by CICR and increases their 
open probability, as opposed to a direct ligand-induced gating (Empson and 
Galione, 1997; Galione et al., 1991; Guo and Becker, 1997; Hachisuka et al., 
2007; Lee, 1993). In terms of the modulation of this activity, at submaximal 
cADPR concentrations, there are synergistic interactions at the same site on 
RyRs between Ca2+, Sr2+, caffeine and cADPR, which are all known CICR 
enhancing molecules (Guo and Becker, 1997; Lee, 1993). It is also known 
that cADPR binding to RyR is unaffected by most CICR modulators (both 
endogenous and pharmacological), aside from high levels of Ca2+ which causes 
a minor inhibition of cADPR binding (Lee, 1991; Thomas et al., 2001), 
suggesting that these compounds modulate the CICR response rather than 
cADPR receptor binding. cADPR can sensitise RyRs to such an extent that 
they begin to respond to basal [Ca2+]i and can also potentiate release 
activated by other signalling processes (Lee et al., 1993). Specifically, 
cADPR enhances CICR by orthograde signalling, i.e. that triggered by 
calcium influx, in neurons (Empson and Galione, 1997; Hashii et al., 2000b; 
Pollock et al., 1999). This, in turn, produces a retrograde signal, whereby 
cADPR-mediated Ca2+ mobilisation indirectly primes other RyRs an IP3Rs 
(Chavis et al., 1996; Empson and Galione, 1997; Hashii et al., 2000b). Aside 
from the well-documented ability of cADPR to mobilise Ca2+ from intracellular 
stores, in 3T3 fibroblasts, it can also regulate basal [Ca2+]i(Bruzzone et al., 
2003a; Franco et al., 2001a; Zocchi et al., 1998).  
cADPR is abundant in the brain (Partida-Sánchez et al., 2001; 
Walseth et al., 1997) and ARC activity has been detected from 1 week of age 
in rat hippocampal tissue homogenates (Higashida et al., 2003; Reyes-Harde 
et al., 1999a). In the brain, cADPR plays a role in numerous calcium-
dependent aspects of neuronal and glial signalling (Bruzzone et al., 2004; 
Lee, 2001) such as neurotransmitter release (Mothet et al., 1998; Verderio et 
al., 2001), excitability (Budde et al., 2000; Ceni et al., 2006), plasticity 
(Linden et al., 1995; Morikawa et al., 2003; Pollock et al., 1999; Reyes-Harde 
et al., 1999a) and neuron-glia signalling (Higashida et al., 2001a). It also 
plays an important role in regulating inflammation and repair processes in the 
brain (and other tissues) through the modulation of Ca2+ signalling and 





4.1.1 ARC enzymes 
cADPR is catalysed from β-nicotinamide adenine dinucleotide (NAD+) 
by ADP ribosyl cyclase (ARC; Morgan et al., 2005). Currently, an “Aplysia 
cyclase” (Glick et al., 1991; Mothet et al., 1998) and two mammalian 
cyclases - CD38 and CD157 are well characterised which are homologous 
and structurally similar (Liu et al., 2005; Malavasi et al., 2008; Morgan et al., 
2005; Prasad et al., 1996; States et al., 1992; Yamamoto-Katayama et al., 
2002). Numerous studies suggest that CD157 does not play a critical role in 
brain ARC activity (Hirata et al., 1994; Hussain et al., 1998; Itoh et al., 1994; 
Kaisho et al., 1994; Kajimoto et al., 1996; Lopatina et al., 2014) and 
therefore, it will not be discussed in any further detail. CD38 is widely 
expressed in vertebrate cells (Zocchi et al., 1999), including neurons (human 
cerebral and cerebellar cortical lysates and cultured mouse hippocampal 
neurons; Ceni et al., 2003b; Mizuguchi et al., 1995), astrocytes (Banerjee et 
al., 2008; Ma et al., 2014) and microglia (Ceni et al., 2003a; Jin et al., 2007; 
Mayo et al., 2008), where it is known to influence Ca2+ homeostasis 
(Bruzzone et al., 2004; Higashida et al., 2007; Verderio et al., 2001) and cell 
survival (Ma et al., 2014). In the mouse, ARC activity was primarily mediated 
by CD38 and was highest in the hypothalamus with activity also detectable in 
the cerebellum, cerebrum and posterior pituitary (Jin et al., 2007). CD38 
exhibits developmental dependent CNS expression with activity detectable 
from E15 in mouse (Choe et al., 2011; Higashida et al., 2007). CD38 staining 
is dense in the soma and dendrites of murine and human neurons (Ceni et 
al., 2003a; Jin et al., 2007; Mizuguchi et al., 1995) and is expressed on 
synaptosomes (Durnin et al., 2012) supporting a role for cADPR in synaptic 
transmission and plasticity (Linden et al., 1995; Morikawa et al., 2003; 
Pollock et al., 1999; Reyes-Harde et al., 1999a). In human neuronal cultures, 
co-culture of neurons with astrocytes resulted in astrocytic CD38 
overexpression (both plasma membrane and intracellularly) in a glutamate-
mediated fashion. It is suggested, therefore, that CD38 may also have a role 
in glutamate-mediated neuronal-glial communication (Bruzzone et al., 2004). 
ARC enzymes have three known catalytic activities (Fig 4.1), the 
products of which stimulate distinct Ca2+ signalling pathways (Fig 4.1 & Fig 
4.2; see (Berridge, 2014a; Fliegert et al., 2007): 
 
1. Cyclisation of NAD+ and nicotinamide guanine dinucleotide (NGD) to 
cADPR and cGDPR respectively. CD38 exhibits cyclase activity (Ceni 
et al., 2003b; Deshpande et al., 2003; Howard et al., 1993; Itoh et al., 
1994; Quarona et al., 2013) producing a relatively small amount of 
cADPR (2% of products arising from the application of NAD+ vs 98% 





(Ceni et al., 2003a; Schuber and Lund, 2004; Takasawa et al., 1993; 
Ziegler, 2000). 
 
2. Hydrolysation of NAD+ and cADPR to ADPR, an enzymatic activity 
which is solely exhibited by CD38 and is its predominant mode of 
action (Hirata et al., 1994; Howard et al., 1993; Snell et al., 1984; 
Takasawa et al., 1993). ADPR is also involved in Ca2+ signalling 
(Ayub and Hallett, 2004) and homeostasis (Perraud et al., 2001; Sano 
et al., 2001) and activates RyR1 when micromolar [Ca2+]i levels are 
also present (Bastide et al., 2002). The majority of investigations of 
ADPR-mediated Ca2+ signalling are concerned with the stimulation of 
Ca2+ entry into cells through TRPM2, a non-selective cation channel 
that is expressed in a variety of tissues, with highest levels in the brain 
and immune cells (for review of ADPR signalling see Ernst et al., 
2013). ADPR-mediated activation of TRPM2 is synergised by [Ca2+]i, 
cADPR, NAADP and ROS (Sumoza-Toledo and Penner, 2011).  
 
3. The production of nicotinamide and NAADP+ by catalysing a base 
exchange reaction, i.e. catalysing the exchange of the NADP+ 
nicotinamide group with free nicotinic acid (Aarhus et al., 1995; 
Fliegert et al., 2007). The substrate NADP+ which is required for this 
reaction is formed from NAD+ by NAD+ kinase (Pollak et al., 2007). 
NAADP is a Ca2+ mobiliser (for reviews see Fliegert et al., 2007 and 
Galione, 2011) which is considered to be critical for the development 
of global Ca2+ signals and the regulation of membrane excitability 
(Galione, 2011; Schmid et al., 2011). In different cell types it mediates 
its effects via IP3Rs (Singaravelu and Deitmer, 2006), RyRs 
(Dammermann and Guse, 2005; Gerasimenko et al., 2006; 
Hohenegger et al., 2002; Langhorst et al., 2004) and two-pore 
channels (TPCs; expressed on endolysosomes; for review see 
Morgan et al., 2015; Patel et al., 2010)  and from both ER and 








Figure 4.1 Formation of cADPR, ADPR and NAADP 
There is a close metabolic relationship between these compounds that are formed from the three 
main enzymatic functions of ADP-ribosyl cyclases (ARCs): 
1) cADPR is primarily formed from the cyclisation of the substrate NAD+ (also producing 
nicAmide). cADPR mediates Ca2+ mobilisation through RyRs. 
2) NAD+ and cADPR are hydrolysed to ADPR (also producing nicAmide). ADPR activates Ca2+ 
and/or Na+ entry through TRPM2.  
3) NAD+ is converted to NADP+ by NAD+ kinase. NADP is then converted by a base-exchange 
reaction to NAADP+ and nicAmide. NAADP+ activates RyRs and/or a proposed NAADP 
receptor (NAADP-R; which we now know is either RyRs, IP3Rs or endolysosomal TPCs, 
dependent on cell type) resulting in intracellular Ca2+ mobilization.  
Abbreviations used: ADP-ribose (ADPR), cyclic adenosine 5'-diphosphoribose (cADPR), 
nicotinamide adenine dinucleotide (NAD), nicotinate adenine dinucleotide phosphate (NAADP), 
the proposed NAADP receptor (NAADP-R), nicotinamide (NicAmide), nicotinic acid (NicAcid), 
two pore channel (TPC) and transient receptor potential (TRP) melastatin 2. 








Figure 4.2 ADP ribosyl cyclase activation and associated intracellular signalling 
ADP ribosyl cyclase (ARC) is activated by exogenous plasma membrane-bound receptors 
including GPCRs such as mGluRs. This produces three Ca2+ mobilising second messengers 
cADPR, ADPR and NAADP (from NAD, cADPR and NADP, respectively).  
There are multiple proposed mechanism which result in cADPR-mediated Ca2+ mobilisation from 
ER, such as enhancing the activity of SERCA and by activation of RyRs.  
ADPR activates TRPM2 channels causing Ca2+ influx whereas NAADP activates TPC channels 
on lysosome related organelles stimulating Ca2+ mobilisation resulting in an intracellular Ca2+ 
response, possibly in a co-operative manner with other relevant receptors such as VGCCs. 
Note: ARC activity is also influenced by cellular metabolism and the levels of intracellular ATP 
and NADH. 
Abbreviations used: ADP-ribose (ADPR), cyclic adenosine 5'-diphosphoribose (cADPR), G-
protein-coupled receptor (GPCR), metabotropic glutamate receptor (mGluR) nicotinamide 
adenine dinucleotide (NAD), nicotinate adenine dinucleotide phosphate (NADP), nicotinic acid 
adenine dinucleotide phosphate (NAADP), sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA), transient receptor potential (TRP) melastatin 2 and voltage-gated Ca2+ channels 
(VOC) 





Notably, evidence supporting ARC (including CD38) regulation of basal 
and/or stimulus-induced (Aarhus et al., 1995; Cosker et al., 2010) NAADP 
levels in a manner that is physiologically relevant is conflicting (Aarhus et al., 
1995; Gul et al., 2016; Schmid et al., 2011) and has been shown in non-CNS 
cells, in vitro and in a cell-type specific manner. In fact, there is evidence 
from non-CNS cells and tissue that CD38 may degrade NAADP(Aarhus et 
al., 1995; Schmid et al., 2011; Soares et al., 2007). Alternatively, however, 
the degradation of NAADP to 2′-phospho-ADPR may also occur in these 
cells via nucleotide pyrophosphatases (Graeff et al., 2006).  
Importantly, ARC preference for the production of either cADPR or 
NAADP can be altered with pH (Aarhus et al., 1995; Bacher et al., 2004; 
Graeff et al., 1998; Howard et al., 1993). When placed in an acidic 
environment (approximately pH 4.5 - 5) and with excess nicotinic acid, CD38 
exhibited a preference for base-exchange activity and NAADP generation 
which outweighed its hydrolysis (Aarhus et al., 1995). However, when 
conditions were more neutral (both pH 7 and pH 7.4) with low nicotinic acid 
concentrations, base-exchange did not occur and degradation to 2′-phospho-
ADPR was enhanced. cADPR was also produced at this more neutral pH. 
Given the importance of pH on ARC function, the location of the enzyme 
within the cell may be a primary determinant of enzyme activity. 
The catalytic domains of membrane-bound ARC, including CD38 
which is predominately a transmembrane ectoenzyme (Schuber and Lund, 
2004), have been demonstrated as acting extracellularly, as measured by 
the extracellular production of ADPR, cADPR and NAADP utilising numerous 
cell types including rat cortical astrocytes (Gelman et al., 1993; Hirata et al., 
1994; Hotta et al., 2000; Hussain et al., 1998; Ishihara and Hirano, 2000; Itoh 
et al., 1994; Kajimoto et al., 1996; Malavasi et al., 2008; Pawlikowska et al., 
1996; Yamamoto-Katayama et al., 2002). This leads to the “topological 
paradox” of cADPR production (De Flora et al., 2004), i.e. that extracellular 
synthesis of cADPR conflicts with intracellular activity. However, there are 
numerous ways in which this paradox could be satisfied physiologically. 
Firstly, NAD+ efflux and availability may be enabled via the gap junction 
protein connexin 43 (Cx43; Bruzzone et al., 2001a) and connexin 43 (Cx43)-
independent transporters, including P2X, ligand-gated ion channel, 7 
(P2X7R)-mediated NADH / NAD+ symport (Lu et al., 2007; Romanello et al., 
2002; Salmina et al., 2014). Cx43-mediated NAD+ efflux is hypothesised to 
be negatively regulated by Ca2+-dependent (Zocchi et al., 1999) and PKC-
mediated phosphorylation of Cx43. This decreases the open probability of 
Cx43 connexon, preventing NAD+ delivery to the proposed extracellular 
active site of CD38, thereby inhibiting CD38-mediated Ca2+ increases 
(Bruzzone et al., 2001). There are also three potential mechanisms for 





signalling molecule (De Flora et al., 2004; Franco et al., 2001). Namely, 
CD38-mediated concentrative cADPR transport (De Flora et al., 2004; 
Franco et al., 1998; Jin et al., 2007), co-internalisation with CD38 possibly in 
a ligand (Zumaquero et al., 2010) and-or NAD+-induced manner (McCarthy 
et al., 2003) which may be balanced with lysosomal degradation of CD38 at 
least during periods of prolonged RyR1 activation (Chidambaram and 
Chang, 1999; Franco et al., 1998; M.-K. Han et al., 2002; McCarthy et al., 
2003; Zocchi et al., 1999) and CD38-independent transport (both 
concentrative and equilibrative) of cADPR (Bruzzone et al., 2003b; De Flora 
et al., 2004; Franco et al., 2001; Guida et al., 2002) by nucleoside 
transporters (Guida et al., 2004, 2002). These discussions centre upon the 
assumption that CD38 is an ectoenzyme. However, extra-plasma membrane 
expression of CD38 and the presence of non-CD38 ARC enzymes (see 
below) may negate the issues surrounding the topological paradox in certain 
cell types. In more detail, CD38 expression has been detected in the cytosol 
(Durnin et al., 2012) and in ER, mitochondrial, nuclear and exosome 
membranes in numerous non-neuronal cell types (Adebanjo et al., 1999; 
Khoo et al., 2000; Khoo and Chang, 2002, 1999; Matsumura and Tanuma, 
1998; Orciani et al., 2008; Sternfeld et al., 2003; Sun et al., 2002; 
Zumaquero et al., 2010). Furthermore, in addition to the type I conformation, 
where the CD38 active site is extracellular, CD38 has been observed in type 
II (intracellular) conformation, allowing for cADPR and ADPR production in 
the cytosol (Zhao et al., 2012). 
Importantly, in the context of this thesis, CD38 and RyRs were 
colocalised in osteoblastic MC3T3-E1 cells and NIH3T3 cells, suggesting a 
functional coupling of CD38 to intracellular Ca2+ mobilisation (Sun et al., 
2002). Furthermore, mitochondrial CD38 expression (Liang et al., 1999) has 
potential relevance to both the upregulated Ca2+ signalling and activation of 
cell death pathways evident in AD (Celsi et al., 2009). In more detail, 
mitochondrial impermeability to NAD+ (Stein and Imai, 2012) is compromised 
following MPT-opening which, aside from depleting mitochondrial NAD+, also 
perturbs cellular levels of NAD+ and NADH. This culminates in the activation 
of NAD+-glycohydrolases, which alters cellular bioenergetics (Kristian et al., 
2011). The localisation of Cx43 in the mitochondrial compartment is critical in 
mPTP-opening (Azarashvili et al., 2011). Given the association of CD38 with 
Cx43, this provides a mechanism by which NAD+ released from mitochondria 
in damaged cells could be rapidly utilised (Salmina et al., 2008), with 
subsequent metabolite formation and downstream Ca2+ signalling.  
Other ARC isoforms 
Due to the relatively small rates of cADPR production by CD38 
discussed previously, and the fact that the cADPR content of certain tissues 





physiological importance of CD38 in cADPR-mediated signalling has been 
questioned (Ceni et al., 2003a). The necessity of CD38 for cADPR 
production seems to be variable across tissues and between studies. For 
instance, CD38 KO either slightly decreases (Partida-Sánchez et al., 2001), 
drastically decreases (Ceni et al., 2003a; Jin et al., 2007), or has no effect 
on, brain cADPR levels relative to controls (Soares et al., 2007). An 
alternative CNS ARC enzyme, with cyclase (10% of products formed; 
hypothesised to be able to replenish brain cell cADPR levels within 1 min) 
and NAD-glycohydrolase activity (1000-fold lower than CD38 activity) 
activities was detected in a PM and ER-enriched fraction from CD38 KO total 
brains harvested from either neonate and adult tissue (Ceni et al., 2006). 
This novel enzyme is membrane localised, but with an intracellular active site 
regulated by G-proteins. Furthermore, this enzyme was functional at both pH 
6 (optimal) and pH 7 and inhibited by Zn2+. Interestingly, this enzyme 
differentiates itself from other known ARCs as it appears to not possess 
NGD cyclization activity (Ceni et al., 2006). Such lack of NGD utilisation has 
been recorded previously for a lymphocyte ARC which was observed to have 
a physiological role in signalling following T-cell receptor activation (Guse et 
al., 1999).  
Aside from the cyclase identified by Ceni et al. (2006), it is 
hypothesised that numerous, as yet molecularly unidentified, ARC isoforms 
exist (Morgan et al., 2005). This suggestion is based upon the detection of 
ARCs (including in CD38 KO cells) which have characteristics unlike CD157 
and CD38, such as different mechanisms of regulation (e.g. sensitivity to 
inhibition by Cu2+), agonist specificity (e.g. to ACh, cholecystokinin (CCK) 
and a membrane-permeant analogue of cGMP) and different intracellular 
localisations (including soluble). Such ARCs have been detected in a 
plethora of non-CNS cell types (Bacher et al., 2004; Bruzzone et al., 2003b; 
de Toledo et al., 2000; Graeff et al., 1998; Gul et al., 2008; Guse et al., 1999; 
B.-J. Kim et al., 2008; Matsumura and Tanuma, 1998; Nam et al., 2006; Park 
et al., 2011; Soares et al., 2007; Sternfeld et al., 2003; Wilson and Galione, 
1998; Xie et al., 2003) and brain homogenates (Matsumura and Tanuma, 
1998). 
 
4.1.2 Downstream effects of cADPR  
cADPR has numerous molecular targets, but in the context of 
neuronal signalling, the most interesting of these are RyRs, TRPM ion 
channels and purinergic P2X7 receptors. The primary effect of cADPR 
production is Ca2+ mobilisation and as such the processes outlined in 





modulation of membrane excitability are also pertinent to the ultimate effects 
of cADPR on cellular physiology. 
RyR 
In general, cADPR-mediated activation of RyR1 and RyR3 is quite 
variable across cell types and preparations, ranging from inactive to robust 
and potentially allowing for a degree of redundancy in the system (Copello et 
al., 2001; Fulceri et al., 2001; Kunerth et al., 2004; Mészáros et al., 1993; 
Morrissette et al., 1993; Murayama and Ogawa, 2002; Sitsapesan and 
Williams, 1995; Sonnleitner et al., 1998). Conversely, cADPR activates RyR2 
across numerous cell types (Barone et al., 2002; Rakovic et al., 1996; 
Sitsapesan and Williams, 1995; Takasawa et al., 1998; Y. X. Wang et al., 
2004).  
cADPR-mediated calcium release is generally considered to be 
independent of IP3- and NAADP-mediated Ca2+ release processes. This is 
due to the fact that each receptor homologously desensitises, i.e. 
desensitisation of one receptor system does not influence the ability of either 
of the other systems to be activated (Churchill et al., 2002; Clapper et al., 
1987; Galione et al., 1991; Lee and Aarhus, 1997; Masgrau et al., 2003). 
Furthermore, antagonists of IP3Rs do not generally affect cADPR-mediated 
signalling (Cancela et al., 1999; Lee, 1993) with the exception of experiments 
in bone marrow mesenchymal stem cells (Tao et al., 2011). However, this 
does not preclude these alternative intracellular Ca2+ mobilisation sources 
from acting in a sequential and/or contributing manner to propagate 
response to stimuli.  
Indeed, T-cell signalling provides an interesting case study of how 
related signalling pathways, particularly those stimulated by other NAD+ 
metabolites, can work in tandem during physiological responses. Thus, 
TCR/CD3 ligation by an antigenic peptide results in the intracellular formation 
of NAADP within 10 – 20 seconds (Gasser et al., 2006a). A rapid decrease in 
NAADP levels occurs within the first minute, although they remain elevated 
for 5 – 20 minutes. At the same time, a smaller rise in intracellular Ca2+ 
occurs over several minutes (Gasser et al., 2006b). It is hypothesised that 
NAADP produces a local Ca2+ signal, which sensitises IP3Rs and RyRs, 
thereby facilitating global amplification of the initial NAADP signal (Ernst et 
al., 2013). IP3 is formed soon after the initial NAADP peak (Guse et al., 1995) 
resulting in IP3R-mediated Ca2+ mobilisation (Guse et al., 1992). Lastly, 
cADPR levels increase and cause RyR-mediated Ca2+ mobilisation (Guse et 
al., 1999) which is likely facilitated by Ca2+ release arising from both NAADP 
and IP3 stimulation (Ernst et al., 2013). This continuous Ca2+ mobilisation 
decreases [Ca2+]ER and activates SOCE (Ernst et al., 2013; Guse, 1999). 
This amplification and propagation of Ca2+ signals by cADPR has also been 





Kunerth et al., 2004). Furthermore, intracellular Ca2+ mobilisation and 
resulting cellular motility following IL-8 application in natural killer cells result 
from the activities of cGMP, cADPR and PLCβ (Rah et al., 2005). Aside from 
RyRs, cADPR also interacts with Ca2+-ATPases, IP3Rs, FKBPs, TRP 
channels and P2XY7Rs (outlined in subsequent sections). RyR-independent 
modulatory effects of cADPR may add an even greater degree of complexity 
to cADPR- mediated signalling, in terms of increasing specificity or 
redundancy to its processes.   
IP3R 
The presence of a regulatory site for cADPR in the ligand-binding 
domain of IP3R1 and IP3R2, but not IP3R3, has been identified in 
permeabilised A7r5 smooth-muscle cells (Vanlingen et al., 2001). 
Furthermore, cADPR increased the binding of IP3 to IP3R1 (rabbit cerebellar 
microsomes), IP3R2 (RBL-2H3 rat mucosal mast cells) and IP3R3 
(16HBE14o- human bronchial epithelial cells; Vanlingen et al., 1999) 
However, cADPR can also inhibit IP3R-mediated calcium signals in 
16HBE14o-cells (Missiaen et al., 1998). Aside from direct regulation via the 
aforementioned regulatory site, cADPR could also mediate these effects via 
interaction with the IP3R regulatory protein FK506 binding protein 12.6 
(FKBP12.6; Noguchi et al., 1997). 
 
FKBP12.6  
FKBP12.6 acts to stabilize and suppress RyR- and IP3R-mediated 
Ca2+ release (Ahern et al., 1997; Chelu et al., 2004; Patterson et al., 2004) 
and is a regulator of hippocampal LTP as well as learning, memory and 
behaviour (Hoeffer et al., 2008; Yuan et al., 2016). FKBP12.6 disassociation 
from RyRs is enhanced by PKA phosphorylation (Marx et al., 2000) as well 
as oxidation and nitrosylation resulting in Ca2+ leak which is implicated in 
numerous pathologies (Shan et al., 2010; Wehrens et al., 2006, 2005b).  
cADPR has also been shown to bind to FKBP12.6, resulting in its 
dissociation from RyRs and IP3R, priming these channels for activation 
and/or delaying their inactivation (Hashii et al., 2000b; Noguchi et al., 1997). 
Furthermore, in airway smooth muscle cells of FKBP12.6 null mice (Y. X. 
Wang et al., 2004) and arterial preparations functionally or physically 
stripped of FKBP12.6, cADPR failed to elicit calcium release (Tang et al., 
2002). Conversely, cADPR did not modulate the association between 
recombinant FKBP isoforms and RyR3 (Bultynck et al., 2001), suggesting a 






Additional modulators of cADPR-mediated calcium release include 
CaM (Lee et al., 1994), CaM-Kinase II and PKA (potentially via the 
aforementioned phosphorylation of RyRs and FKBP12.6 dissociation; 
Wehrens et al., 2005). In more detail, CaM binds to RyRs (Wagenknecht et 
al., 1997) and sensitises them to CICR (Fruen et al., 2000; Lee et al., 1995; 
Tripathy et al., 1995). When a threshold intracellular level of cADPR is 
reached, CAM dissociates from RyRs, resulting in a refractory period until 
cADPR levels are decreased, allowing for negative feedback regulation 
(Thomas et al., 2002). 
 
4.1.3 CD38 regulation 
So far, I have discussed how cADPR is formed by ARC, its 
mechanism of action and its effects at both the cellular and systems level. 
However, a fundamental question which also remains unanswered some 30 
years after the initial discovery of cADPR as a Ca2+ signalling molecule is 
exactly how ARC itself is activated following activation of exogenous plasma 
membrane-bound receptors? Although, as discussed below, there are 
numerous lines of evidence to suggest that I-mGluR-elicited ARC activation 
may be mediated by a cholera toxin (CTx; Gs activator and inhibitor of 
GTPase activity (Mangmool and Kurose, 2011) sensitive G-protein. 
Regulation at the enzyme level includes its ultrastructural organisation 
where it can exist in either a monomeric (Terhorst et al., 1981) and/or 
dimeric/multimeric form (Mallone et al., 1998). It is also proposed by Zhao et 
al. (2012) that CD38 can alter its cell surface positioning to expose an active 
site either intracellularly or extracellularly. Modulation of the structure of its 
catalytic centre (Salmina et al., 2014), as well as the targeting of its 
expression on numerous intracellular organelles, reveals further mechanisms 
of regulation (Quarona et al., 2013). Indirect regulation includes that dictated 
by the intracellular levels of substrates and modulators, including NADH, 
NAD+, cADPR, NADP, ADPR, ATP and the non-substrate ligand CD31 
(Salmina et al., 2014).  
The end result of ARC activation is increased [Ca2+]i which can, at 
least following cholinergic agonist stimulation in chromaffin cell membranes 
(Morita et al., 1997) and adult cardiomyocytes (Xie et al., 2003) in turn, 
activate ARC via adenylyl cyclase/ cAMP/ PKA-dependent phosphorylation. 
Fukushi et al., 2001; Higashida et al., 2007, 1997; Sternfeld et al., 2003; 
Zhang et al., 2005). 
A plethora of physiological mediators regulate ARC expression and 
activity (including CD38 specific studies) in a variety of cell types including 





a significant body of evidence in support of G-protein (Gi and Gq) 
involvement in ARC activation across these different cell types and different 
molecular pathways (Barisione et al., 2010; Fukushi et al., 2001; Higashida 
et al., 2007, 2003, 2001b, 2000, 1999, 1997; Hotta et al., 2000; Shi et al., 
2007; Sternfeld et al., 2003; Zhang et al., 2005). 
Those of which are particularly relevant to neuronal ARC activation include: 
Angiotensin II (Higashida et al., 2000), non-specific beta-adrenergic receptor 
stimulation (Barisione et al., 2010; Higashida et al., 2003, 2001b, 1999, 
1997; Hotta et al., 2000), endothelin receptors (Barone et al., 2002), 
mAChRs - M1 & M3 (Fukushi et al., 2001; Higashida et al., 2007, 2001b, 
1999, 1997; Sternfeld et al., 2003; Zhang et al., 2005), mGluR1, 3, 5 & 6 
(Higashida et al., 2003; Morita et al., 1997; Xie et al., 2003), Nitric oxide (NO) 
(Clementi et al., 1996; Galione et al., 1993; Reyes-Harde et al., 1999a; 
Willmott et al., 1996), oxytocin (Kim et al., 2016), VGCCs (possibly via NO; 
Morita et al., 1997; Xie et al., 2003) and inflammatory mediators such as 
bradykinin, histamine (Deshpande et al., 2005; Higashida et al., 2006), TNF-
α, IL-1β, interferon gamma (Deshpande et al., 2003), IL-8 (Rah et al., 2005) 
and lipopolysaccharide (LPS; implicating ARC activity in LPS-mediated 
microglial activation; Barone et al., 2002; Higashida et al., 2007; Mayo et al., 
2008). Notably, mGluR2, M2, M4 and NMDA receptor stimulation inhibits 
ARC activity (Higashida, 1997; Higashida et al., 2003, 1997; Salmina et al., 
2011). As the focus of this chapter is on I-mGluR mediated ARC activation, 
this will now be discussed in greater detail.   
Activation of ARC by mGluRs is mediated by specific mGluR subtypes 
in a cell-specific manner. For instance, ARC activation occurs via mGluR6 
stimulation in crude rat and mouse retinal membranes and via I-mGluRs in 
rat superior cervical ganglion (SCG) membranes. Notably, however, 
glutamate had little effect on ARC activity in membranes from rat and mouse 
olfactory bulb, cerebral cortex, hippocampus, and cerebellum (Higashida et 
al., 2003). Activation of transiently overexpressed mGluR subtypes in 
NG108-15 cells with glutamate also differentially modulated ARC activity, 
with cells expressing mGluR1, 3, 5 and 6 increasing ARC activity (CTx 
sensitive), cells expressing mGluR2 decreasing activity (PTx sensitive) and 
with no change in activity being observed in mGluR4 and 7 expressing cells 
(Higashida et al., 2003). Mechanistically, in retinal and SCG membranes and 
NG108-15 cells (Higashida et al., 1997) cADP-ribose hydrolase activity was 
barely detectable and unchanged in the presence or absence of glutamate 
respectively, suggesting glutamate-induced cADPR accumulation was due to 
increases in production rather than the inhibition of hydrolysis. Notably, I-
mGluR agonists can reverse NMDAR-mediated ARC inhibition, suggesting a 





This evidence clearly supports a role for mGluRs in the G-protein 
mediated activation of ARC, in a cell type-dependent manner. Notably, as 
mentioned previously, RyR-mediated Ca2+ mobilisation following I-mGluR 
stimulation also supports the suggestions of a role for cADPR in this 
signalling pathway as observed in hippocampal, cerebellar granule, midbrain 
dopaminergic and DRG neurons (Crawford et al., 1997a; Higashida et al., 
2003; Irving et al., 1992; Morikawa et al., 2003; Sohn et al., 2011).  
It is clear though that across different tissues, and even within the 
same tissue, where evidence of I-mGluR – induced RyR - evoked calcium 
signals have been provided, the contribution, or otherwise, of cADPR to the 
generation of those signals is highly variable. For example, in studies on 
whole labyrinth preparations, Hendricson and Guth (2002), demonstrated 
that although I-mGluR stimulation did activate RyRs, this was induced by 
calcium-induced calcium release (CICR), initiated by calcium release through 
IP3Rs, rather than being due to ARC - mediated cADPR production. Indeed, 
RyR function was necessary for IP3R-mediated Ca2+ release, at least in rat 
cerebellar granule cells where RyR antagonism inhibited mAChR/IP3- 
mediated Ca2+ responses (Irving et al., 1992a). In this scenario, it is 
proposed that an initial Ca2+ release via IP3R triggers a major regenerative 
Ca2+ response component through CICR (Berridge, 1998; Crawford et al., 
1997; Irving et al., 1992a, 1992b; Simpson et al., 1995). However, when the 
contribution of RyR-mediated Ca2+ mobilisation to IP3R-stimulated responses 
in mouse cortical neurons was quantified by Stutzmann et al. (2007), it was 
found to be relatively modest (caged IP3 = 20 ± 7%; AP-evoked = 15 ± 5%; 4 
- 6 weeks of age).  
In contrast, within cultured rat DRG neurons, I-mGluR activation did 
evoke cADPR - dependent calcium release via RyR activation. However, 
because the potential contribution of IP3R - mediated signalling to the overall 
I-mGluR - evoked calcium signal was not measured, it is unclear what the 
net relative contributions of the two calcium signalling pathways to the overall 
calcium response were (Crawford et al., 1997b). Of particular interest in this 
respect was the study of Sohn et al. (2011) which, using acutely dissociated 
rat hippocampal neurons, indicated that I-mGluR-mediated Ca2+ mobilization 
was generated in its entirety by activation of the cADPR/RyR pathway. This 
finding was supported by the fact that I-mGluR-mediated Ca2+ signals were 
evoked in hippocampal neurons derived from PLCβ1 and PLCβ4 knockout 
mice (Sohn et al., 2011). The nature of this Ca2+ mobilisation in cultured 
hippocampal neurons, in terms of the involvement of IP3Rs and RyRs and 







4.1.4 Implication of ARCs/cADPR signalling in AD 
There is considerable overlap between processes regulated by CD38 
and those implicated in AD pathology, including Ca2+ signalling and 
regulation of inflammatory processes such as microglial activation (Franco et 
al., 2006; Mayo et al., 2008). However, the ARC signalling system has not 
been investigated in any great depth in the context of AD aside from the 
observations that, a) the percentage of CD38 positive PBMCs was 
upregulated in samples from AD patients (Kassner et al., 2008), b) CD38 has 
been observed to accumulate in NFTs (Otsuka et al., 1994) and, c) 
intracerebral injection of Aβ increased CD38 and Cx43 expression in the 
cortex and hippocampus, which could lead to Ca2+ dysregulation, but 
decreased expression in the amygdala (Salmina et al., 2014). 
Blacher et al. (2015) conducted the most extensive study with regard 
to CD38 in the context of AD published to date. When CD38 KO 
APPSWE/PS1∆E9 mice were compared with controls (8- and 14-month-old), 
KO mice displayed significant reductions in both soluble and insoluble Aβ 
levels and total brain plaque load which correlated with improved spatial 
learning. Furthermore, the reduction in Aβ42 levels observed in mice brain 
samples was also mirrored in cerebral cortical cultures from CD38 KO mice 
and in APP/PS cultures treated with a CD38 enzyme inhibitor or a 
competitive antagonist of cADPR-dependent Ca2+ signalling, relative to 
control. This suggested that the pathological effects of this enzyme were 
mediated, partly at least, by cADPR. Indeed, cADPR is implicated directly in 
AD with respect to P2X7 purinergic receptor (P2X7Rs) and TRP activity. 
P2X7 in the brain are expressed primarily on microglia and astrocytes 
(Kamatsuka et al., 2014; Yamamoto et al., 2013) where they transport NAD+, 
NADH and ions across the PM in both neuronal and glial cells (Lu et al., 
2007; Salmina et al., 2014). Moreover, cADPR is implicated in P2XYR-
dependent Ca2+ influx, mitochondrial activity and cell death (Bruzzone et al., 
2010, 2007). In mice, expression of P2X7R was required for Aβ-mediated 
microglial activation and neuroinflammation (Sanz et al., 2009) resulting in 
ROS production and synaptotoxicity in APPSWE/PS1∆E9 mice (Lee et al., 
2011). Furthermore, inhibition of native or overexpressed P2X7R inhibited 
glycogen synthase kinase 3β (GSK3β)-mediated increases α-secretase 
activity, in cell lines (Diaz-Hernandez et al., 2012) and reduced Aβ plaque 
number in APPSWE/V717F(Indiana) mice (Diaz-Hernandez et al., 2012). 
TRP ion channels are expressed abundantly in the brain including on 
neurons (Okada et al., 1998; Tóth et al., 2010), astroglia (Verkhratsky et al., 
2013) and microglia (Kraft et al., 2003) where their modulation of Ca2+ influx 
is regulated by cADPR and [Ca2+]i (Starkus et al., 2007; Tao et al., 2011). 





and neurotoxicity in AD (Fonfria et al., 2005; L. Park et al., 2014) and is 
implicated in the development of oxidative stress in brain cells (Bai and 
Lipski, 2010). Interestingly in T-lymphocytes and neutrophils, although 
TRPM2 is activated by micromolar concentrations of NAADP, this activation 
is significantly synergised by cADPR (Beck et al., 2006; Lange et al., 2008). 
Conversely however, cADPR modulation of TRPM2 signalling was not 
observed in HEK293 cells overexpressing TRPM2 (Tóth and Csanády, 
2010). However, the active molecule at TRPM2 may also be ADPR (Ernst et 
al., 2013), which is a common contaminant of commercial cADPR 
preparations (Kirchberger et al., 2009). 
It is also possible that the “anti-amyloid” effects of CD38 KO in AD 
models are mediated by increases in its substrate, NAD+ (Aksoy et al., 
2006b; Blacher et al., 2015). This is supported by the finding that application 
of NAD+ to APPSWE mouse neocortical cultures as well as to APP/PS and/or 
CD38 KO cerebral cortical cultures reduced Aβ levels (Aksoy et al., 2006b; 
Blacher et al., 2015; Qin et al., 2006). Furthermore, treatment of APPSWE 
mice with an NAD+ precursor, attenuated cognitive deficits (Gong et al., 
2013). The process underlying these observations likely involves a reduction 
in Aβ production and/or secretion on the basis that CD38 KO reduced the 
number but not the size of plaques, reduced both soluble and insoluble Aβ 
levels, decreased β- secretase and γ-secretase activity and did not alter 
expression of genes known to be involved in microglia/macrophage-
mediated Aβ phagocytosis or degradation (Blacher et al., 2015).   
NAD+ levels decrease with ageing (Imai and Guarente, 2014) which 
impairs cellular respiration, decreases mitochondrial ATP and contribute to 
cell death (Yao et al., 2017). As such, NAD+ depletion and the resulting 
cellular energy deficits attributed to the effects of neurodegeneration are 
proposed as a potential therapeutic target (Liu et al., 2008). In order to 
increase NAD+ levels, one of four NAD+ synthesising pathways present in 
mammals would need to be enhanced. The principal route of NAD+ 
production is via the salvage pathway where nicotinamide, nicotinic acid, 
nicotinamide riboside are utilised (Yao et al., 2017). There is also an 
additional de novo NAD+ synthesis pathway which utilises tryptophan 
(Yamamoto et al., 2014).  
NAD+ also seems to interact with the JNK family of protein kinases 
which, in addition to being involved in regulating brain development, repair 
and memory formation, are also mediators of neuroinflammation and 
neuronal death, and as such are implicated in neurodegenerative conditions 
including AD (Mehan et al., 2011; Yarza et al., 2016). Indeed, JNK is 
abnormally activated in transgenic models of AD and in AD patients 
(Braithwaite et al., 2010; Sclip et al., 2011; Thakur et al., 2007). Interestingly 





mononucleotide (NMN), inhibits JNK and decreases Aβ production, Aβ 
plaque burden, synaptic loss, inflammatory responses and cognitive 
impairments in APPSWE/PS1∆E9 mice. Aside from the effects mediated by the 
inhibition of JNK activation, NMN also upregulates the non-amyloidogenic 
processing of APP (Yao et al., 2017). 
The aforementioned potential decrease in NAD+ levels in AD models 
could subsequently alter metabolic activity, by decreasing glycolysis and 
glycolysis-associated NAD+ regeneration (Salmina et al., 2014). Astrocytes 
are particularly sensitive to NAD+ depletion compared to neurons (Alano et 
al., 2010; Ying et al., 2005a) as they are highly dependent on glycolysis 
(Hertz et al., 2007). Furthermore, astrocytic NAD+ depletion also decreases 
astrocytic lactate production which, in turn, impacts upon neuronal 
metabolism as lactate is a major energy source for neurons (Bouzier-Sore et 
al., 2003; Wyss et al., 2011) and is shuttled from glia-neurons by Cx (Bennett 
et al., 2012) for use in oxidative metabolism (Pellerin et al., 1998; Pellerin 
and Magistretti, 1994). 
Aside from ARCs, numerous other enzymes, including poly-ADP-
ribose polymerases (PARP), ADP-ribosyltransferases (ART) and SIRTs, use 
NAD+ and its metabolites as substrates (Haigis and Sinclair, 2010; Hassa 
and Hottiger, 2008). PARP and ART activity regulate cell signalling, DNA 
repair and apoptosis (Haag et al., 2007). It is proposed that ARCs/CD38 
(CD38 is the principal mammalian ARC; Bruzzone et al., 2004) regulate 
NAD+ homeostasis under normal physiological conditions. Conversely, in 
pathological conditions, where significant DNA damage has occurred, it is 
proposed that PARPs principally regulate NAD+ levels (Ying et al., 2005b). In 
AD, astrocytic PARP-1 activation by Aβ indirectly mediates neuronal cell 
death (Abeti and Duchen, 2012). PARP-1 is a DNA repair enzyme which is 
activated by single strand breaks associated with oxidative stress (de Murcia 
and de Murcia, 1994). This catalyses the formation of poly ADP-ribose 
polymers from NAD+. Pathological activation of PARP-1 by Aβ leads to NAD+ 
depletion and cell death (Abeti and Duchen, 2012; Ying et al., 2003). As 
such, prevention of NAD+ depletion is a proposed therapeutic approach for 
AD (Braidy et al., 2008). 
NAD+ also interacts with the NAD-dependent deacetylase, SIRT1, the 
activity of which is increased in the brains of CD38KO mice (Barbosa et al., 
2007; Blacher et al., 2015), likely due to decreased nuclear CD38 expression 
(Aksoy et al., 2006a). Aside from their role in energy metabolism (Haag et 
al., 2007; Malavasi et al., 2010), in the brain SIRTs are critical for normal 
learning, memory, and synaptic plasticity, at least in mice (Michan et al., 
2010). They are also implicated in ageing (Haag et al., 2007; Malavasi et al., 
2010) and neurodegeneration (Outeiro et al., 2008), including AD (Braidy et 





expression which decreases Aβ levels in APPSWE mice (Qin et al., 2006). 
The SIRT1/PGC-1a pathway has also been shown to promote BACE1 
degradation resulting in a reduction in β-secretase activity (Gong et al., 
2013). That being said, in the study by Blacher et al. (2015) utilising 
APP/PS/CD38KO mice, α-secretase and ADAM10 activity were not 
increased, nor were BACE1 levels decreased, suggesting that the effect of 
CD38KO on Aβ dynamics and neuroprotection was not due to SIRT1-
mediated reduction in α- secretase and/or β- secretase expression and/or 







Based primarily upon the finding that I-mGluR mediated Ca2+ signals 
were cADPR-dependent (and PLC-independent) in pyramidal neurons from 
acutely dissociated SD rat CA1 hippocampal tissue (Sohn et al., 2011), the 
aim of this chapter was to determine the proportion, if any, of I-mGluR-
mediated responses which were mediated by the ARC/cADPR/RyR 
signalling pathway in cultured rat hippocampal neurons. Specifically, to add 
weight to any determination of the importance of this pathway to I-mGluR-
mediated signals, I wished to compare results from the inhibition of both the 
enzyme which produces cADPR, ARC (utilising nicotinamide and NGD), as 
well as the primary target of cADPR-mediated Ca2+ mobilisation, RyRs 
(utilising dantrolene).  
I also sought to determine if any observed results were reproducible 
across different murine across species (comparing data from SD rat with that 
from non-Tg mouse). Moreover, I also wished to determine whether or not 
the contribution of the ARC/RyR pathway was altered in 3xTg-AD neurons 






4.3 Materials and Methods 
4.3.1 Ca2+ imaging  
Ca2+ imaging experiments and data analysis were carried out as 
described in Section 3.3. Materials and methods. For experiments which 
compared the percentage increase from baseline between two unpaired 
nonparametric populations (See Fig 4.3) the Mann Whitney test was utilised. 
This set of experiments differs from those presented in Chapter 3 in that 
application of DHPG under depolarisation conditions served as the control 
responses which were then compared with DHPG-evoked responses under 
depolarisation conditions but in the presence of, and subsequent to 
incubation (4 mins) with, antagonists of either ARC (nicotinamide; 5 mM) and 
NGD; 100 µM) or RyRs (dantrolene; 10 µM). Negative control experiments 
for nicotinamide were conducted using an analogue, benzamide (5 mM) 
(Martino Carpi et al., 2018) but does not inhibit of CD38 (Migaud et al., 
1999a). 
 
4.3.2 Applied compounds  
• Benzamide (Sigma, cat. no. 135828) 
• DMSO (Sigma, cat. no. W387520) 
• Nicotinamide (Sigma, cat. no. 72340) 
• Nicotinamide guanine dinucleotide (NGD) sodium salt (Sigma, cat. no. 
N5131) 
• Dantrolene (Sigma, cat. no. 1163140) dissolved in DMSO 







4.4 Results  


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































When DHPG-mediated responses under depolarisation conditions 
were compared with and without prior incubation with nicotinamide, we found 
that nicotinamide produced a significant decrease in the amplitude, 
normalised amplitude and A.U.C. (amplitude = 43 ± 5 vs 32 ± 4 a.u., p = 
0.003; normalised amplitude = 100 vs 80 ± 6%, p = 0.001; A.U.C. = 2216 ± 
394 vs 1659 ± 348 a.u.; p = 0.01; n = 44; control vs nicotinamide) of 
responses in SD rat neurons (Fig 4.3, A; 3 days-old; 6 – 13 DIV). These 
results are likely under-represented, given that the off-target effects of the 
nicotinamide analogue benzamide modified I-mGluR signals in a significantly 
different manner to nicotinamide, (p = 0.01; n = 44 vs 22; nicotinamide vs 
benzamide), namely, benzamide significantly enhanced I-mGluR signals, at 
least in data normalised to the control phase of the experiment (100 vs 149 ± 
24%; p = 0.0001; n = 22; 4 days old 2 – 6 DIV; Fig 4.3, A, ii, dashed bars). 
Conversely, the amplitude (raw a.u.) and A.U.C. of I-mGluR signals were 
unchanged by benzamide (amplitude = 17 ± 2 vs 21 ± 3 a.u., p = 0.27; 
A.U.C. = 2526 ± 479 vs 2328 ± 552 a.u.; p = 0.74; n = 22; control vs 
benzamide). 
In contrast to the nicotinamide experiments carried out in SD rat 
neurons, in non-Tg neurons (Fig 4.3, B; 3 - 4 days-old; 2 DIV), prior 
incubation with nicotinamide increased amplitude, normalised amplitude and 
A.U.C. of I-mGluR-mediated responses relative to I-mGluR stimulation alone 
(amplitude = 13 ± 2 vs 19 ± 2 a.u., p = <0.0001; normalised amplitude = 100 
vs 177 ± 11%, p = <0.0001; A.U.C. = 1144 ± 247 vs 1439 ± 247 a.u.; p = 
0.05; n = 61; control vs nicotinamide). These effects are likely due to extra-
ARC nicotinamide side effects given that the amplitude and normalised 
amplitude (but not A.U.C.) of I-mGluR responses was also increased with 
benzamide co-application (amplitude = 9 ± 1 vs 13 ± 2 a.u., p = 0.007; 
normalised amplitude = 100 vs 139 ± 9%, p = 0.0001; A.U.C. = 572 ± 119 vs 
660 ± 134 a.u., p = 0.35; n = 34; control vs benzamide). Furthermore, the 
effect of nicotinamide and benzamide on I-mGluR signals was statistically 
similar (p = 0.06; n = 61 vs 32; nicotinamide vs benzamide) 
In 3xTg-AD mouse neurons (Fig 4.3, C; 4 - 5 days-old; 3 - 9 DIV), co-
application of nicotinamide and DHPG had no effect on amplitude, 
normalised amplitude or A.U.C. relative to DHPG application alone 
(amplitude = 12 ± 1 vs 11 ± 2 a.u., p = 0.07; normalised amplitude = 100 vs 
91 ± 10%, p = 0.29; A.U.C. = 738 ± 130 vs 652 ± 136 a.u.; p = 0.40; n = 33; 
control vs nicotinamide). Again, these figures are likely under-represented (p 
< 0.0001; n = 33 vs 41; nicotinamide vs benzamide) given that the amplitude 
and normalised amplitude (but not A.U.C.) of I-mGluR responses were both 
enhanced in 3xTg-AD neurons with benzamide co-application (amplitude = 6 





0.0001; A.U.C. = 358 ± 87 vs 431 ± 62 a.u., p = 0.33; n = 41; control vs 
benzamide). 
Duration was unchanged between these experimental conditions in all 
animal models used in nicotinamide (SD rat = 98 ± 11 vs 96 ± 10 s, p = 0.8; 
non-Tg mouse = 120 ± 12 vs 124 ± 11 s, p = 0.63; 3xTg-AD mouse = 98 ± 11 
vs 98 ± 12 s, p = 0.98; control vs nicotinamide) and benzamide experiments 
(SD rat = 257 ± 24 vs 196 ± 28 s, p = 0.08; non-Tg mouse = 97 ± 14 vs 89 ± 







4.4.2 Effect of NGD on I-mGluR-evoked neuronal calcium signals 
 
  
Figure 4.4. Somatic I-mGluR-mediated (DHPG = 50 μM) Ca2+ responses of SD rat (A), non-transgenic mouse (B) and 3xTg-
AD mouse (C) cultured hippocampal neurons (3 – 5-days-old) under depolarisation conditions (K+ = 15 mM) with and without 
prior incubation with the ARC inhibitor nicotinamide guanine dinucleotide (NGD; 100 μM) which prevents the formation of 
cyclic ADP-ribose (cADPR). 
Representative traces illustrate somatic intracellular DHPG-mediated Ca
2+
 responses of cultured hippocampal neurons under 
depolarisation conditions (DHPG = 50 μM; K+ = 15 mM) with (grey dashed line) and without (control; solid black line) prior 
incubation with the ARC antagonist NGD (4 mins; 100 μM; a 50 minute agonist washout period separates both experimental phases). 
A = SD rat; 5-days-old / 2 - 6 DIV, B = non-transgenic mouse; 2-days-old / 11 DIV and C = 3xTg-AD mouse; 4-days-old / 9 DIV. 
The horizontal axis represents 120 seconds (s) and the vertical axis represents 25 arbitrary units (a.u.) of fluorescence. 
Histograms illustrate the amplitude (a.u.; i) , normalised amplitude (% change; ii), duration (s; iii) and area under the curve (A.U.C.; 
measured in a.u.; iv) of DHPG-mediated calcium responses under depolarisation conditions (control; DHPG = 50 μM; K+ = 15 mM; 
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Experiments to determine the effect of inhibiting cADPR production on 
I-mGluR-mediated Ca2+ signals were repeated utilising an alternative ARC 
antagonist, NGD (100 μM). In experiments utilising SD rat neurons, prior 
incubation with NGD resulted in a significant decrease in all I-mGluR 
mediated response parameters measured (amplitude = 13 ± 1 vs  8 ± 1 a.u., 
p = < 0.0001; normalised amplitude = 100 vs 67 ± 4%, p = < 0.0001; duration 
=  159 ± 9 vs 129 ± 8 s, p = 0.009; A.U.C. = 159 ± 9 vs 129 ± 8 a.u.; p = 
0.0009; n = 49; control vs NGD; Fig 4.4, A), relative to I-mGluR application 
alone. 
In contrast, in non-Tg neurons NGD significantly, but slightly, 
increased the amplitude (amplitude = 30 ± 2 vs 33 ± 2 a.u., p = 0.03; 
normalised amplitude = 100 vs 114 ± 6%, p = 0.01; control vs NGD) of 
DHPG-mediated Ca2+ responses, relative to control (Fig 4.4, B; n = 40), 
whereas the duration and A.U.C. were decreased with NGD and DHPG co-
application (duration =  178 ± 9 vs 138 ± 21 s, p = 0.02; A.U.C. = 2667 ± 221 
vs 2056 ± 304 a.u.; p = 0.02; control vs NGD).  
In experiments utilising 3xTg-AD mouse neurons (4 days old; 9 DIV), 
NGD had no significant effect (albeit in a single experiment) on the 
amplitude, duration or A.U.C. of DHPG-responses, relative to DHPG 
application alone (amplitude = 18 ± 3 vs 19 ± 3 a.u., p = 0.63; normalised 
amplitude = 100 vs 140 ± 22%, p = 0.22; duration = 76 ± 12 vs 78 ± 9 s, p = 
0.75; A.U.C. = 591 ± 135 vs 727 ± 170 a.u.; p = 0.16; n = 18; control vs NGD; 












Figure 4.5. Somatic I-mGluR-mediated (DHPG = 50 μM) Ca2+ responses of SD rat (A), non-transgenic mouse (B) and 3xTg-AD 
mouse (C) cultured hippocampal neurons (3 – 4-days-old) under depolarisation conditions (K+ = 15 mM) with and without prior 
incubation with the ryanodine receptor (RyR) antagonist dantrolene (10 μM). 
Representative traces illustrate somatic intracellular DHPG-mediated Ca
2+
 responses of cultured hippocampal neurons under 
depolarisation conditions (DHPG = 50 μM; K+ = 15 mM) with (grey dashed line) and without (control; solid black line) prior incubation 
with the RyR antagonist dantrolene (4 mins; 10 μM; a 50 minute agonist washout period separates both experimental phases). A = SD 
rat; 3-days-old / 7 - 13 DIV, B = non-transgenic mouse; 3 - 4-days-old/3 – 9 DIV and C = 3xTg-AD mouse; 3 - 4-days-old / 5 - 14 DIV. 
The horizontal axis represents 120 seconds (s) and the vertical axis represents 25 arbitrary units (a.u.) of fluorescence. 
Histograms illustrate the amplitude (a.u. ; i) , normalised amplitude (% change; ii), duration (s; iii) and area under the curve (A.U.C.; 
measured in a.u.; iv) of DHPG-mediated calcium responses under depolarisation conditions (control; DHPG = 50 μM; K+ = 15 mM; 
white bars) and following prior incubation with the RyR antagonist dantrolene (4 mins; 10 μM; grey bars). 
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The RyR antagonist dantrolene (10 μM) significantly decreased the 
amplitude and A.U.C. (amplitude = 74 ± 8 vs 46 ± 4 a.u., p = < 0.0001; 
normalised amplitude = 100 vs 73 ± 6%, p = 0.0002; A.U.C. = 5658 ± 1052 
vs 3302 ± 555 a.u.; p = 0.0004), but not duration (76 ± 12 vs 78 ± 9 s, p = 
0.75; n = 29; control vs dantrolene; Fig 4.5, A) of I-mGluR-mediated calcium 
responses under depolarisation conditions in SD rat neurons.  
When these experiments were repeated with non-Tg mouse neurons, 
the normalised amplitude of I-mGluR responses were significantly enhanced 
following prior incubation with dantrolene relative to I-mGluR responses 
alone (100 vs 116 ± 7%, p = 0.02; n = 36; control vs dantrolene; Fig 4.5, B, 
ii). Conversely, amplitude (measured in a.u.), duration and A.U.C. of I-mGuR 
responses were unchanged by dantrolene (amplitude = 11 ± 1 vs 11 ± 1 a.u., 
p = 0.96; duration = 168 ± 17 vs 152 ± 21 s, p = 0.19; A.U.C. = 1107 ± 166 
vs 1111 ± 209 a.u.; p = 0.97; control vs dantrolene; Fig 4.5, B). 
Dantrolene had no effect on any I-mGluR response parameters 
measured in neurons from 3xTg-AD mice (albeit from one experiment; 
amplitude = 18 ± 4 vs 13 ± 3 a.u., p = 0.09; normalised amplitude = 100 vs 
78 ± 15%, p = 0.19; duration = 68 ± 8 vs 59 ± 7 s, p = 0.15; A.U.C. = 648 ± 
151 vs 459 ± 135 a.u.; p = 0.14; n = 15; control vs dantrolene; Fig 4.5, C).  
Notably, there were no significant differences between the levels of 
inhibition of the amplitude of the I-mGluR signal between any of the 
antagonists used (i.e. nicotinamide, NGD or dantrolene) in SD rat neurons 
(one-way ANOVA with Tukey’s multiple comparison test; ns). Conversely, in 
non-Tg mouse experiments, the level of I-mGluR response agonism was 
significantly less with NGD co-application relative to nicotinamide (14 ± 6% 
vs 177 ± 11%; n = 40 vs 61; p = < 0.0001). In 3xTg-AD experiments 
(although there was no significant effect of nicotinamide, NGD or dantrolene 
on DHPG responses relative to DHPG responses alone) NGD application (n 
= 18) resulted in a significantly different effect on DHPG responses 
compared with nicotinamide or dantrolene whereas there were no significant 
differences between co-application of nicotinamide or dantrolene with DHPG 









4.5.1 Contribution of ARC/RyR pathway to I-mGluR signalling 
The central aim of this study was to add to the limited experimental 
data investigating whether cADPR is a second messenger downstream of 
neuronal I-mGluR stimulation. In order to determine if a given drug can be 
related to its proposed effect, in this case; DHPG / I-mGluR-mediated 
stimulation of the ARC/cADPR/RyR system, it needs to satisfy the five 
characteristics of second messengers as proposed by Sutherland and 
Robison (1966; and expanded upon by others (Gao and Vanhoutte, 2014; 
Hardman et al., 1971; Schultz and Rosenthal, 1985)). 
Two of these characteristics are concerned with established effects 
downstream of cADPR production, i.e. that the cADPR signal can be 
terminated and that cADPR can act as a cellular effector (controlling a 
biological function in cells, organs or tissues), which have been explained 
previously in both this chapter and in reviews covering the status of cADPR 
as a bona fide second messenger (Guse, 2004; Lee, 2011). Of note, with 
respect to glutamate signalling, ARC may be regulated in a hierarchical 
manner (at least in cerebellar granule cells), whereby NMDAR activation 
inhibits ARC activity which, in turn, can be reversed by I-mGluR and II-
mGluR activation (Salmina et al., 2011). The remaining three characteristics 
are more relevant to the proposed coupling of I-mGluR signalling with 
ARC/cADPR and will be discussed in more detail below. 
Firstly, does ARC respond to I-mGluR-stimulation in broken cell 
preparations as might be expected in results with intact tissues? I-mGluR-
mediated ARC stimulation in broken cell preparations exhibits significant 
variability across cell types and/or brain regions. For instance, glutamate-
stimulated ARC on NG108-15 cell membranes overexpressing mGluR1 and 
5 only and I-mGluR stimulation activated ARC in SCG membrane 
preparations. Conversely, glutamate or DHPG had little effect on ARC 
activity in membranes from rat and mouse retina, olfactory bulb, cerebral 
cortex, hippocampus, and cerebellum (Higashida et al., 2003). 
Secondly, with regard to regulation, does the concentration of cADPR 
in intact cells change when I-mGluRs are stimulated and does this 
generation occur rapidly enough to accompany or precede the known 
physiological effect? The precise intracellular concentration of cADPR cannot 
yet be visualised directly in intact cells. However, there are indirect methods 
of measuring cADPR levels in intact cells including Ca2+ imaging following 
intracellular injection of cADPR, as well as an indirect determination of ARC 
activity using a fluorogenic substrate nicotinamide guanine dinucleotide (see 
Morgan et al., 2005). It is known that extracellular stimuli, generally, cause a 





Yamasaki et al., 2005). Evidence for I-mGluR stimulation, specifically, is 
lacking although ARC activity is increased (rate was not measured) in 
cerebellar granule cells following I-mGluR stimulation (Salmina et al., 2011). 
Furthermore, within cultured rat DRG neurons, I-mGluR and II-mGluR co-
activation (with a non-specific agonist) evoked calcium release via RyR 
activation which was mimicked by extracellular application of the cADPR 
precursor NAD+. This observation suggests cADPR generation could occur 
rapidly enough to be involved in I-mGluR-mediated neuronal signalling. 
However, as mentioned previously, this study contains a major flaw in that 
the potential contribution of IP3R - mediated signalling to the overall I-mGluR 
- evoked calcium signal was not measured (Crawford et al., 1997b).  
Thirdly, can the physiological effect of I-mGluR stimulation be 
mimicked by cADPR (not membrane permeable; Morgan, 2005), a cADPR 
derivative or a membrane-permeable cADPR analogue? The major 
downstream physiological effect, at least with respect to this project, of 
DHPG / I-mGluR stimulation is RyR-(and/or IP3R-) mediated Ca2+ signalling 
as a potential molecular mechanism for synaptic plasticity (Futagi and 
Kitano, 2015; Rose and Konnerth, 2001; Sajikumar et al., 2009). Although 
ARC is implicated in mediating such I-mGluR signals, and cADPR can 
certainly mimic ER Ca2+ release (Crawford et al., 1997a; Higashida et al., 
2003; Irving et al., 1992; Morikawa et al., 2003; Sohn et al., 2011), little is 
known about ARC/cADPR involvement in synaptic plasticity (Reyes-Harde et 
al., 1999a) or in I-mGluR-mediated enhanced signals proposed to correlate 
to “learning events” (Nakamura et al., 1999; Rae et al., 2000). It is in this 
context that the current project sought to determine cADPR involvement, 
albeit not specifically by utilising cADPR analogues, but instead indirectly by 
way of ARC inhibition and/or cADPR antagonism.  
This approach was utilised previously by Sohn et al. (2011) who 
proposed that I-mGluR-mediated Ca2+ mobilization in acutely dissociated SD 
rat CA1 pyramidal neurons was generated in its entirety by activation of the 
cADPR/RyR pathway. Although this finding was supported by the 
demonstration that I-mGluR-mediated Ca2+ signals were still evoked in 
neurons derived from PLCβ1- and PLCβ4-knockout mice, the investigators 
failed to either quantify how large these signals were relative to those evoked 
in control neurons or, indeed, to demonstrate that these calcium signals were 
blocked by their chosen cADPR antagonists (Sohn et al., 2011). This is a 
particularly important distinction given the aforementioned canonical coupling 
of I-mGluRs to IP3Rs. Furthermore, in whole labyrinth preparations at least, I-
mGluR-mediated RyR activation occurred via IP3R-initiated CICR and not 
due to ARC-mediated cADPR production (Hendricson and Guth, 2002). 
When we attempted to replicate the findings of Sohn et al. (2011), 





SD rat CA1 pyramidal neurons, we found that the cADPR/RyR calcium 
signalling pathway was indeed responsible for a significant proportion of the 
overall I-mGluR-mediated calcium signal (Fig 4.3 - 4.5; Kaar and Rae, 2014). 
However, this portion comprised a much lower proportion of the total I-
mGluR mediated response (ARC inhibition = 20 ± 6% (nicotinamide) and 33 
± 4% (NGD); RyR inhibition = 17 ± 6% (dantrolene); % decrease in 
amplitude; Fig 4.3 – 4.5, A, ii) in comparison to the entirety of the signal 
proposed by Sohn et al. (2011). However, as detailed below, the effect of 
nicotinamide is likely underrepresented given the opposing effects of 
negative controls used in these experiments (Fig 4.3). Interestingly, our 
finding of potential redundancy in the IP3/IP3R and cADPR/RyR pathways 
activated by I-mGluR stimulation was mirrored by findings from rat midbrain 
dopaminergic neurons. Here, both the IP3/IP3R and cADPR/RyR pathways 
were necessary to mediate maximum magnitude intracellular calcium 
responses to I-mGluR activation, but both ‘arms’ of the calcium signalling 
cascade evoked intracellular calcium release independently of one another 
(Morikawa et al., 2003). 
By using dantrolene I was able to determine the role of the putative 
cADPR target, RyR, in I-mGluR mediated Ca2+ signals with the caveat that 
there are question marks regarding its isoform specificity (see Section 4.5 - 
Limitations). There were no significant differences in the level of I-mGluR-
mediated calcium signal reduction following inhibition of the synaptosomal 
cyclase (with NGD) or RyRs. This suggests that the entirety of the 
dantrolene- sensitive RyR-evoked signal (potentially through RyR1 and 3 
subtypes, solely (F. Zhao et al., 2001)) downstream of I-mGluR activation is 
stimulated by cADPR derived from this synaptosomal cyclase.  
Conversely, when negative control experiments are factored in for 
nicotinamide inhibition of CD38 (likely meaning that levels of I-mGluR 
inhibition are much greater in reality with this antagonist; Fig 3.4; A; ii) it 
suggests that, a) both the synaptosomal cyclase and CD38 are mediators of 
I-mGluR stimulated ER Ca2+ mobilisation and that, b) there is a RyR- 
accessible Ca2+ pool which is not inhibited by dantrolene (possibly through 
RyR2; F. Zhao et al., 2001) in SD rat hippocampal neurons. Conversely, if 
dantrolene is an effective pan-RyR inhibitor, it suggests that the effects of the 
proposed cADPR binding to, and enhancement of, IP3R1-3 Ca2+ mobilisation 
(Vanlingen et al., 1999) and/or SERCA activation (Bradley et al., 2003; 
Lukyanenko et al., 2001; Yamasaki-Mann et al., 2009) also contribute to this 
I-mGluR-elicited signal. Notably, NGD at high concentrations (2 mM) is also 
considered to be a general ARC (including CD38) inhibitor. However, it is 
unknown if the 100 μM concentrations used in this study inhibited other 





circumstances permitted them, experiments in which these antagonists were 
co-applied would have been useful in determining this definitively.  
Although ARC-mediated I-mGluR signalling appears under-
represented in this study, it is still markedly lower than the entirety of the 
signal suggested by Sohn et al. (2011). The reason(s) for such a marked 
difference in results between the two studies is unclear but one obvious 
suggestion is that the culturing process itself might somehow alter the 
phenotype of intracellular calcium signals evoked by I-mGluR stimulation, 
relative to those observed in acutely dissociated cells. A similar discrepancy 
in IP3-mediated calcium mobilisation between cultured, compared to acutely 
dissociated, cells has been noted when utilising rat DRG neurons, although 
overall responsiveness to I-mGluR stimulation appeared to also be a function 
of DRG soma size (Pollock et al., 1999; Svichar et al., 1997a). In order to 
determine, in a relatively definitive manner, if the culturing process did 
indeed induce a rapid alteration in I-mGluR-activated calcium signalling 
pathways relative to more ‘physiological’ preparations, experiments which 
examined the contribution of the cADPR/RyR pathway to I-mGluR-mediated 
signals in dentate gyrus neurons within intact hippocampal slices using “bulk-
loading” calcium imaging have also been carried out by Dr Rae’s lab group. 
Thus far only the effects of nicotinamide on I-mGluR-mediated Ca2+ signals 
have been investigated. It caused a significant decrease in I-mGluR-
mediated Ca2+ signals in both non-Tg mouse (11 ± 5%; n = 30 from 5 
experiments) and 3xTg-AD mouse neurons (23 ± 6; n = 22 from 3 
experiments; Vaughan et al., 2018). Alternatively, hippocampal neurons can 
exhibit differences in mGluR expression, localisation and activity in a manner 
dependent on postnatal development (2 – 3 weeks vs 6 – 8 weeks; CA1 
pyramidal neurons; intact hippocampal slices; Ireland and Abraham, 2002; 
Mannaioni et al., 2001). This factors may be relevant to differences in 
phenotype between acutely dissociated neurons in the Sohn et al. (2011) 
study (7 to 14-days-old) and cultured hippocampal neurons (3 days-old; 6 - 
13 DIV) in the present study.  
Caution must be taken when making comparisons between the results 
of Sohn et al. (2011) utilising acutely dissociated rat neurons, results from 
Vaughan et al. (2018) utilising dentate gyrus mouse neurons from intact 
hippocampal slices and my own research utilising cultured mouse and rat 
hippocampal neurons, as the role of cADPR signalling in I-mGluR-evoked 
calcium responses may vary between species and neuronal populations and 
may even be dependent on I-mGluR localisation within the same cell. For 
example, dendritic I-mGluR mediated Ca2+ signalling within hippocampal 
neurons appears to be mediated solely by the IP3R pathway (Nakamura et 
al., 2000, 1999), whereas, as discussed above, cADPR appears to mediate 





the somata of both hippocampal (Kaar and Rae, 2014; Sohn et al., 2011) 
and adult DRG neurons (Svichar et al., 1997b), with or without additional 
involvement of IP3-evoked signalling. Importantly, in the current study, 
species differences were evident between SD rat and non-Tg mouse 
neurons. Specifically, ARC inhibition with nicotinamide prior to and during I-
mGluR stimulation enhanced Ca2+ signals (77 ± 11% increase; Fig 4.3, A, ii) 
in non-Tg mouse neurons. This is in direct contrast to the decrease we saw 
using nicotinamide in SD rat experiments (reduced amplitude and A.U.C.; 
duration unchanged). The fact that our benzamide experiments mirrored the 
results of our nicotinamide experiments in non-Tg mouse neurons (Fig 4.3; 
B; ii) suggests that the effects we witnessed were due to off-target effects of 
nicotinamide and (unlike in SD rat, where the effects observed in control 
conditions and in the presence of nicotinamide were opposed) may suggest 
that CD38 does not play a role in I-mGluR-evoked signals in these mouse 
neurons. Potential off-target effects of both the synaptosomal cyclase 
inhibitor, NGD, and nicotinamide may occur by enhanced ER Ca2+ release 
as cADPR can stimulate SERCAs (Bradley et al., 2003; Lukyanenko et al., 
2001; Yamasaki-Mann et al., 2009) and IP3Rs (Tao et al., 2011; Vanlingen et 
al., 1999). However, conversely, Missiaen et al. (1998) presented evidence 
of the exact opposite effect, i.e. cADPR-mediated inhibition of SERCA and 
IP3Rs. 
Similar to our nicotinamide experiments, NGD caused a small but 
significant increase in the amplitude of I-mGluR-evoked signals in non-Tg 
mouse experiments (14 ± 6% increase; Fig 4.4, B, ii) which could also be 
due to off-target effects of this antagonist (although to significantly lower 
levels than observed with nicotinamide; 14 ± 6% and 77 ± 11% increase 
respectively). Aside from off-target effects perhaps explaining the 
enhancement of I-mGluR-mediated signals we observed following ARC 
inhibition, another possibility is that an I-mGluR-mediated persistent (>20 
minutes) suppression of sAHP, similar to that described by Ireland and 
Abraham (2002) following application of a I- and II-mGluR agonist (Ireland 
and Abraham, 2002), may result in a greater activation of L-type VGCCs 
upon the second depolarisation stimulus, potentially allowing greater uptake 
of Ca2+ by the ER and its subsequent mobilisation by DHPG. However, in 
control experiments (repeated DHPG applications under depolarisation 
conditions) there was a decrease in the amplitude of I-mGluR-evoked 
responses in non-Tg mouse neurons over time (16 ± 5%; p = 0.006; n = 58).  
To complicate matters further, however, the duration and A.U.C. of 
DHPG-mediated responses were decreased in the presence of NGD in both 
non-Tg mouse and SD rat neurons (Fig 4.4; A & B, iii & iv). This could 
suggest that potential off-target effects of this antagonist in non-Tg mouse 





amplitude, but not with respect to signal A.U.C. (Fig 4.4; B; I & ii vs iii & iv). 
Furthermore, despite response size differences between non-Tg mouse and 
SD rat neurons in the initial I-mGluR mediated ER Ca2+ release following 
inhibition of the synaptosomal cyclase (amplitude), the magnitude (A.U.C.) of 
the resultant sustained somatic Ca2+ signals were not different and 
decreased in both models when DHPG and NGD were co-applied. Could it 
be that in non-Tg neurons, inhibition of the synaptosomal cyclase (and a 
rapid decrease in cADPR) relieves a negative regulation of IP3Rs, causing 
an initial increase (amplitude) of the I-mGluR response, whereas a reduction 
in cADPR ultimately results in less CICR and a decrease in the sustained I-
mGluR response? However, if this were the case, quite why it would be a 
signalling algorithm in non-Tg mouse but not SD rat neurons is unclear. 
Furthermore, if this was the case one would expect the RyR antagonist 
dantrolene to have the same effect on the A.U.C. of I-mGluR responses as 
the ARC inhibitors, which is not the case (Fig 4.5, B, iv). In fact, dantrolene 
did not alter I-mGluR responses in non-Tg neurons, suggesting a lack of 
involvement of RyR1 and 3 (and potentially 2) in this signalling system. It is 
also a possibility that these unique differences between enhanced amplitude 
but inhibited duration and A.U.C. of I-mGluR responses with NGD co-
application (Fig 4.4; B) reflect that this single non-Tg mouse experiment was 
an outlier.  
This large inter-species variability is in contrast to the work of 
Higashida et al. (2003) which found consensus between mouse (“adult WT”) 
and Wistar rat (1 – 12 weeks-old) in that mGluR or I-mGluR stimulation did 
not affect ARC activity in membranes from the retina, olfactory bulb, cerebral 
cortex, hippocampus, and cerebellum. Aside from species differences, an 
added layer of variability could also arise from the fact that SD rats are a 
genetically heterogeneous outbred strain in comparison to our inbred strain 
of non-Tg mice (C57BL6/129sv).  
An added layer of complexity to this story comes from the finding that 
in NG108-15 cells and rat cerebellar granule neurons, cADPR signalling 
seems to be dependent upon the excitation state of the cell as well as the 
loading state of the ER. For example, under resting conditions, intracellularly 
applied cADPR failed to evoke any form of Ca2+ mobilisation, but did amplify 
both depolarization-induced Ca2+ mobilisation (by acting as an agonist of 
RyRs at the ER) as well as Ca2+ influx through L-type VGCCs (De Flora et 
al., 1996; Empson and Galione, 1997; Hashii et al., 2000b). These findings 
support previous research which showed that the loading state of the ER had 
an important bearing on the magnitude of signals evoked by ER stimulation 
(Rae et al., 2000; Rae and Irving, 2004). Similarly, oxytocin release in 
hypothalamic neurons in response to depolarization was decreased in CD38 





interest to investigate whether the contribution of the ARC/RyR pathway to I-
mGluR-evoked calcium signals displayed a similar modulation under basal 
conditions, relative to depolarisation conditions, in our model of cultured 
hippocampal neurons. 
Another consideration that must be borne in mind when interpreting 
putative cADPR-evoked Ca2+ signalling data is the possibility that RyR-
mediated CICR can be induced both by cADPR alone (Ayar and Scott, 1999; 
Crawford et al., 1997b; Empson and Galione, 1997; Hua et al., 1994) and by 
amplification of local signals following IP3R activation (Morgan and Cyclic, 
2002; Stutzmann et al., 2007). Thus, one may show the sensitivity of one's 
Ca2+ signals to RyR blockade, but it may be that the responses are mediated 
via IP3R-evoked CICR, rather than cADPR activation of RyRs per se. This 
might explain why I-mGluR evoked responses which can be inhibited by IP3R 
and/or PLC antagonists are also sensitive to inhibition by RyR antagonists 
(Abdul-Ghani et al., 1996). However, in the case of hippocampal neurons at 
least, I-mGluR mediated calcium signals can still be evoked even following 
putative IP3R blockade with heparin in acutely dissociated hippocampal CA1 
neurons (Sohn et al., 2011) and cultured SD rat hippocampal neurons (150 
μM 2-APB; no effect on DHPG-evoked Ca2+ signals; p = 0.97; n = 17; Kaar 
and Rae, 2013), although this finding is absolutely contingent upon the 
antagonists being specific for IP3Rs, which is less than certain in some cases 
(Bootman et al., 2002; Chung et al., 2004; Dasso and Taylor, 1991; 
Lemonnier et al., 2004; Peppiatt et al., 2003; Rae et al., 2012). Indeed, this 
last point highlights a problem which continues to beset this field of study: the 
lack of specific antagonists and agonists for IP3Rs, RyRs and ARC with 
which to pharmacologically dissect out the relative contributions of IP3-
mediated versus cADPR/RyR-mediated I-mGluR-evoked Ca2+ signals (as 
discussed below - Limitations). This usually necessitates the requirement for 
multiple approaches to establish a single datum piece which, in addition to 
being both costly and time-consuming, may still be regarded with some 
suspicion by others in the field. 
Finally, there is evidence to suggest that both I-mGluR subtypes, 
mGluR1 and mGluR5, may mediate cADPR/RyR-activated Ca2+ signals. For 
example, Higashida et al. (2003) showed that activation of I-mGluRs 
stimulated ARC activity and increased cADPR concentration in rat SCG 
membranes. Interestingly, they also demonstrated that both mGluR1 and 
mGluR5 were relatively equally effective in stimulating ARC activity when 
these receptors were overexpressed in NG108-15 cells (Higashida et al., 
2003). Conversely, mGluR-mediated cADPR responses in rat DRG neurons 
and acutely dissociated CA1 hippocampal neurons were proposed to be 
mediated solely by mGluR5 (Pollock et al., 1999; Sohn et al., 2011). This 





subtypes are expressed, such as rat CA1 hippocampal neurons, as has been 
shown in other studies with regard to I-mGluR-evoked Ca2+ signals 
previously ascribed to activation of IP3Rs (e.g. Rae and Irving, 2004). 
 
4.5.2 ARC/RyR-mediated signalling in AD 
The final aim of the work detailed in this chapter was to determine 
whether or not the contribution of the ARC/RyR pathway was altered in 
3xTg-AD neurons relative to non-Tg controls. This investigation was 
predicated upon the results of Stutzmann et al. (2007) who found that the 
contribution of RyR-mediated Ca2+ mobilisation to IP3R-stimulated responses 
in non-Tg cortical neurons was relatively modest (caged IP3 = 20 ± 7%; 
action potential-evoked = 15 ± 5%). This was replicated in the current study 
as the RyR antagonist dantrolene had no effect on the amplitude, duration or 
A.U.C. of I-mGluR mediated responses (Fig 5.5; B). However, as evidenced 
by the aforementioned apparent enhanced inhibition of I-mGluR signals with 
nicotinamide, compared with dantrolene there appears to be a dantrolene 
insensitive RyR pool accessed by I-mGluRs, at least at the concentration 
used in these experiments. 
The contribution of RyRs to caged IP3 induced signals (i.e. due to 
CICR) was increased in PS1M146V and 3xTg-AD neurons (which also express 
PS1M146V) to 59 ± 11% and 71 ± 9%, respectively, suggesting an 
upregulation of RyRs in these models (Stutzmann et al., 2007). This 
apparent increase in the amplitude of RyR-mediated Ca2+ responses in 
3xTg-AD neurons, relative to PS1M146V neurons, suggested an additive effect 
of either APPSWE or TauP301L to PS1 M146V-mediated Ca2+ dysregulation. 
When compared to the experiments contained herein, there was no 
significant difference in the amplitude, duration or A.U.C. of I-mGluR 
responses following dantrolene incubation. However, the caveat of a low n 
number (15 cells) used in these experiments should be considered in this 
case as well as the fact there is a trend towards an inhibitory effect of 
dantrolene on I-mGluR responses (Fig 4.5; C). 
Interestingly however, unlike in non-Tg mouse where the 
synaptosomal cyclase appears to modify I-mGluR-mediated signals (Fig 4.4; 
B) in 3xTg-AD mouse neurons NGD did not alter I-mGluR signals (albeit in 
one experiment; n = 18; Fig 4.4, C), suggesting an alteration in I-mGluR 
coupling to this enzyme. Furthermore, when negative control experiments 
are factored in to CD38 inhibition experiments and results are compared 
between non-Tg and 3xTg-AD mouse experiments (Fig 4.3; B vs C) it 
appears that CD38 does not modulate the amplitude of I-mGluR responses 
(although off-target effects of nicotinamide do; Fig 4.3, B, ii) in non-Tg 





have the effect of upregulating ER Ca2+ signals which is a proposed 
characteristic of a neuron affected by AD pathology (Berridge, 2010). 
 In summary, these results suggest that FAD mutations, most likely in 
PS1, can alter the dynamics of I-mGluR-mediated ER Ca2+ mobilisation in 
terms of the relative contributions of IP3Rs and RyRs to overall stimulated 
Ca2+ mobilisation. As discussed previously and investigated in Chapter 5, 
this transgenic phenotype could be underpinned by increased RyR 
expression in transgenic cultured neurons (Chakroborty et al., 2009; Kelliher 
et al., 1999; Oules et al., 2012; Stutzmann et al., 2006; see Fig 5.3) and/or a 
more general increase in ER Ca2+ levels due to impaired PS1-mediated Ca2+ 
leak (Zhang et al., 2010). With regard to ARC, there is tentative evidence 




Morgan et al. (2005) outline common problems surrounding Ca2+ 
imaging experiments which may influence the results presented herein. 
These include the “questionable pharmacology” of antagonists targeting 
proteins relevant to this field and fluorimetry issues (such as an antagonist 
which absorbs the exciting light or is auto-fluorescent).  
To address the first issue, we utilised two ARC antagonists (nicotinamide 
and NGD) as well as an antagonist of RyRs (the most likely downstream 
mediator of ARC-dependent Ca2+ mobilisation; RyRs) in order to reduce the 
likelihood that the effects of these compounds on I-mGluR evoked calcium 
signals was not completely due to non-specific or unwanted modulation of 
other Ca2+ signalling pathways. Evidence for the effectiveness of these 
compounds as inhibitors of ARC/RyR signalling is as follows:  
 
1. Nicotinamide is a cell-membrane permeant (possibly in a non-passive 
manner; Olsson et al., 1993) inhibitor of ARC activity, which prevents 
the formation of cADPR (Bruzzone et al., 2003a; Geiger et al., 2000; 
Liang et al., 1999; Migaud et al., 1999b; Sethi et al., 1996). There is also 
limited evidence that nicotinamide inhibits PARP1 (Namazi, 2003; Woon 
and Threadgill, 2005). Of particular relevance to this study, it has been 
utilised in acutely dissociated rat hippocampal neurons to antagonise I-
mGluR/ARC-mediated Ca2+ responses (5 mM; 5 mins pre-treatment; 
Sohn et al., 2011). 
 
2. NGD is catalysed by CD38, CD157 and Aplysia cyclase to produce 





Guse et al., 2001; Lee et al., 1999; Zocchi et al., 2001). cGDPR does not 
evoke Ca2+ mobilisation and as such is often used to measure ARC 
activity in cell homogenates (Graeff et al., 1996). The use of NGD, in this 
context, is based upon the assumption that the active ARC enzyme(s) in 
one’s cell(s) of choice can utilise this substrate. However, as mentioned 
previously, Ceni et al. (2003) have identified a non-CD38 synaptosomal 
ARC in mouse whole brain tissue enriched in a PM and ER-fraction which 
can bind NGD but cannot utilise it as a substrate. Indeed, NGD acts as a 
competitive antagonist of NAD+ at the cyclase active site (Ki = 24 μM; 
Ceni et al., 2006, 2003a). Similarly, high concentrations of NGD (2 mM) 
inhibited ACch-mediated Ca2+ responses and the number of oscillatory 
responses in permeabilised myocytes (resulting from RyR-mediated 
CICR). Ach-mediated Ca2+ responses in these cells are dependent on a 
signalling cascade involving muscarinic M2 receptors, ARC (likely CD38), 
FKBP12.6 and RyR2 (Fritz et al., 2005). Therefore, the use of NGD (in 
excess) as an ARC inhibitor can also be extended to non-synaptosomal 
ARCs such as CD38, which do utilise NGD as a substrate. Previous 
studies have characterised its function mostly in homogenised or 
permeabilised cells, however its use as an antagonist in this study is 
dependent upon either the presence of an extracellular active site on the 
constitutively active ARC(s) in cultured hippocampal neurons or the 
transport of NGD across the plasma membrane. To the best of our 
knowledge such transport has not yet been described but may involve 
similar mechanisms to the transport of cADPR (including that by NTRs or 
concomitant with CD38 internalisation; Guida et al., 2004, Zumaquero et 
al., 2010) or its analogue NAD+ (including that by P2X7Rs; Salmina et al., 
2014), as described previously in Section 4.1 - Transport of 
NAD+/cADPR.  
 
3. Dantrolene has been characterised as a membrane-permeable RyR 
antagonist. However, there are still numerous questions surrounding its 
molecular action and binding sites on RyRs (Krause et al., 2004). 
Although it has been established that dantrolene inhibits RyR1 (in a CaM-
dependent manner; native SR vesicles; Zhao et al., 2001) and RyR3 
(expressed in HEK-293 cells; Zhao et al., 2001), its activity at RyR2 is 
less clear. In this particular context, although dantrolene has inhibits 
RyR2 in CHO cells, a finding which is supported by an abundance of 
literature on cardiac tissue where RyR2 is predominately expressed (for 
review see Wehrens and Marks, 2005), it failed to inhibit RyR2 in native 
cardiac SR vesicles or when they were expressed in HEK-293 and CHO 
cells (F. Zhao et al., 2001). As all three RyR isoforms are expressed in 
mouse, rat and human brain (Bennett et al., 1996), it is possible that a 
component of the I-mGluR-mediated Ca2+ signals in hippocampal 





would not have been blocked by dantrolene (S. Kim et al., 2007). This 
suggestion is all the more pertinent given that cADPR-mediated activation 
of RyR1 and RyR3 is variable across cell types (Copello et al., 2001; 
Fulceri et al., 2001; Kunerth et al., 2004; Morrissette et al., 1993; 
Murayama and Ogawa, 2002; Sitsapesan and Williams, 1995; 
Sonnleitner et al., 1998), whereas it universally activates RyR2 (Barone 
et al., 2002; Rakovic et al., 1996; Sitsapesan and Williams, 1995; 
Takasawa et al., 1998; Y. X. Wang et al., 2004). 
 
4. U73122 has been utilised in numerous previous studies as an irreversible 
cell membrane permeant inhibitor of PLC (Bleasdale et al., 1990) and 
PLC-dependent Ca2+ mobilisation. As such, this compound was utilised 
by Jin et al., (1994) to study PLC function in neuronal NG108-15 cells and 
rat DRG neurons where they found that it inhibited bradykinin-induced 
increases in [Ca2+]i (IC50 of 1 μM after 3 mins incubation and 200 nM after 
a 20-minute incubation). However, U73122 also inhibited VGCCs, 
preventing depolarisation-induced Ca2+ influx in both NG108-15 cells and 
DRG neurons (Jin et al., 1994). U73122 also stimulated a slight Ca2+ 
mobilisation in NG108-15 cells, DRG neurons and MDCK cells (Jin et al., 
1994) and Ca2+ influx in MDCK cells (Jan et al., 1998). Furthermore, in 
myocytes, U73122 (10 μM) inhibited SERCA, increased steady-state 
[Ca2+]cyto and sensitised IP3Rs and RyRs to stimulated Ca2+ release 
(Macmillan and McCarron, 2010). Notably, in a cell-free system, human 
PLCβ was, in fact, activated by U73122 (EC50 = 13.6 ± 5 μM; (Klein et al., 
2011). Therefore, caution clearly needs to be exercised when interpreting 
experiments utilising this compound. In our hands, U73122 (10 μM; 8 
mins) induced widespread death of our cultured hippocampal neurons as 
evidenced by phenomena such as cell lysis, cell shrinkage or rapidly 
increasing or decreasing [Ca2+]i baselines (unpublished observations). 
These findings are in agreement with other studies which showed that 
U73122 (10 μM) was pro-apoptotic in cultured human umbilical vein 
endothelial cells (Miao et al., 1997) and PC12 cells where it resulted in 
decreased Bcl-2 expression and activation of caspase-2, at least 
following hydrogen peroxide-induced cell insult mediated by PLC-ƴ1 
(Yuan et al., 2009). 
 
The choice of antagonists and agonists of both the ARC/RyR and 
PLC/IP3 systems in this study was limited by the commercial availability of 
membrane-permeable compounds. To add weight to the proposal that I-
mGluR signalling is mediated in part by the ARC/RyR pathway, it would have 
been useful to have employed several more alternative agonists, antagonists 





constraints did not allow for such experiments to be undertaken in this period 
of study. These compounds include: 
 
1. Membrane-permeant cADPR competitive-antagonists 8-Br-cADPR and 
7-deaza-8-Br-cADPR (Barone et al., 2002; Lukyanenko et al., 2001; Sethi 
et al., 1997; Walseth et al., 1993). 
2. cADPR mimetics (agonists). A large number of cADPR derivatives have 
been developed of which N1-cyclic inosine diphosphoribose (N1-cIDPR) 
has an almost-identical biological activity to cADPR (Wagner et al., 2005) 
and its derivatives are membrane permeant (Guse et al., 2005; Jianfeng 
Xu et al., 2006; Xianfeng Gu et al., 2004).  
3. ARC antagonists. Flavonoids, including luteolinidin, inhibit CD38 
(membrane permeant; Kellenberger et al., 2011) and mirror results from 
CD38 KO mice (Blacher et al., 2015). 
4. IP3R antagonists. Heparin (non-cell permeant), xestospongin C and 2-
APB are utilised as IP3Rs blockers but have numerous side-effects 
(Morgan et al., 2005). For instance, heparin uncouples GPCRs from G-
proteins (Dasso and Taylor, 1991), xestospongin C inhibits SERCA 
(Castonguay and Robitaille, 2002; De Smet et al., 1999; Solovyova et al., 
2002), and 2-APB inhibits SERCA, SOCCs, GABAA and TRPV3 
(Bootman et al., 2002; Chung et al., 2004; Lemonnier et al., 2004; 
Peppiatt et al., 2003; Rae et al., 2012). For this reason, preliminary 
experiments utilising 2-APB in cultured SD rat neurons, which did not 
inhibit I-mGluR-mediated signals (described previously; Kaar and Rae, 
2013) were not expanded upon further.  
5. RyR antagonists. Ruthenium red inhibits RyRs but is also a potent 
blocker of the MCU (Matlib et al., 1998). Although ryanodine is 
recognised as a concentration-dependent RyR agonist/antagonist, the 
precise concentration ranges which have to be utilised vary between 
experimental preparations. Furthermore, it binds to the open-state of 
RyRs only and therefore its effectiveness is determined by the activation 
state of the receptor (Morgan et al., 2005).  
 
Lastly, with regard to fluorimetry issues, dantrolene exhibits 
fluorescent properties with an excitation at 395 nm and emission at 530 nm 
(Dehpour et al., 1982; Hollifield and Conklin, 1968). However, although this is 
of concern when utilising fura-2 (excitation = 340/380 nm (high/low Ca2+); 
emission = 505 nm; Coleman, 2005), given that fluo-2 has markedly different 
excitation (491 nm) and emission (515 nm) properties to dantrolene, the 
auto-fluorescent effects of dantrolene were likely to be negligible in our 
protocol. Indeed, this was tested by recording baseline fluorescence before 
and after dantrolene application in basal and high K+ HBSS and was found to 






In conclusion, nearly 30 years after its initial discovery, much work still 
remains to be done to characterise neuronal cADPR /RyR signalling both in 
terms of its fundamental mechanics and interactions with other calcium 
signalling systems. Although this work informs the proposal of cADPR acting 
as a second messenger downstream of I-mGluR stimulation, at least in SD 
rat neurons, much further characterisation needs to be done. As outlined by 
Seifert et al. (2015), the harnessing of technologies including high-
performance liquid chromatography (HPLC), mass spectrometry (MS), 
combined LC-MS, dynamic mass redistribution (DMR) and the creation of 
membrane permeable cADPR-AM dyes may be pivotal in answering this 
question. 
Crucially, the possible role for, or alteration of, cADPR / RyR signalling 
in human pathology has yet to be investigated to any significant degree. This 
is surprising given the putative role that dysregulation of normal cellular 
calcium homeostasis and/or calcium signalling pathways are proposed to 
play in several major human diseases such as cardiac disease, 
schizophrenia, bipolar disorder and AD.  
Specifically with regard to AD, there is now substantial evidence, 
gleaned from both human and animal studies, that alterations in neuronal 
calcium homeostasis, with the knock-on effect that this has on both IP3 - and 
RyR - mediated signalling (including that mediated by I-mGluRs), may be the 
key underlying factor in the disease pathogenesis. In transgenic models of 
AD, these alterations occur long before any behavioural changes or overt 
histopathology appears (Berridge, 2014b, 2012; Stutzmann, 2007). 
Therefore, it is not inconceivable that one may also detect alterations in 
cADPR - mediated signalling within these animals, and in the process, 
uncover a hithertofore unrecognised novel therapeutic target. Given that AD 
is currently one of the greatest public health threats facing mankind in the 






5. Bcl-2 Superfamily 
5.1.1 Introduction 
The superfamily of Bcl-2 proteins are critical regulators of cell death 
and survival by virtue of the fact that they are primary regulators of 
apoptosis, the major mode of programmed cell death (for review see: 
Czabotar et al., 2013; Youle and Strasser, 2008), necrosis (Tsujimoto et al., 
1997) and, indeed, the balance between these two forms of cell death (Du et 
al., 2006; Meilhac et al., 1999).  
Bcl-2 family proteins contain blocks of sequence homology called 
Bcl-2 Homology (BH) domains (Fig 5.1).  
 
  
Figure 5.1 Structures of the three main classes of BCl-2 family proteins 
Anti-apoptotic Bcl-2 proteins contain four α-helical Bcl-2 homology (BH) domains. BH1 2 and 3 
form a hydrophobic cleft which binds to the hydrophobic surface of pro-apoptotic BH3 proteins. 
These include multi-domain pro-apoptotic proteins and BH3-only pro-apoptotic proteins. 
Acronyms used: Bcl-2 antagonist of cell death (BAD), Bcl-2 antagonist of cell death (BAK), Bcl-
2-associated X protein (BAX), B-cell lymphoma 2 (BCL2), Bcl-2 homology (BH) domain, BH3-
interacting domain death agonist (BID), Bcl-2-interacting killer (BIK), Bcl-2-modifying factor 
(BMF), Bcl-2-related ovarian killer (BOK), myeloid cell leukaemia sequence 1 (MCL1), 
transmembrane domain (TM). 






The anti-apoptotic Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1 (BFL1) and Bcl-B 
and pro-apoptotic multi-domain effector proteins BAX, BAK and BOK, all 
share three BH domains (BH 1 – 3; Fig 5.1; Kvansakul et al., 2008) which 
give these proteins a common structure (Muchmore et al., 1996) including a 
cleft which allows for interactions with BH3-containing proteins (i.e. all known 
Bcl-2 family proteins; Czabotar et al., 2013; Letai, 2008). Anti-apoptotic Bcl-2 
family proteins also have a BH4 domain (Letai, 2008) that is critical for 
binding to ER Ca2+ release channels (Rong et al., 2009). 
Of these proteins, the focus of this particular investigation was on the 
relative expression of Bcl-2 and Bcl-XL in postnatal hippocampal tissue from 
3xTg-AD mice (P5, 15 and 21) in comparison to non-transgenic age-matched 
controls. These proteins were chosen for investigation as increases in their 
expression and activity correlate with increased neuronal resistance to 
apoptotic and oxidative stresses both in vitro and in vivo (for reviews see 
Merry and Korsmeyer, 1997; Shacka and Roth, 2006) which, as discussed in 
Section 1, are processes of significant relevance to AD.  
Bcl-2 and Bcl-XL also reversibly inhibit IP3R and RyR gating. This 
process is itself anti-apoptotic, at least with regard to IP3Rs, as it reduces 
Ca2+-dependent apoptosis, but also has important implications for 
intracellular Ca2+ signalling (Hanson et al., 2008; Rong et al., 2008; Vervliet 
et al., 2014). Furthermore, these Bcl-2 family proteins are of significant 
interest in early AD pathology due to the fact that there is a growing body of 
evidence implicating them in almost all aspects of cell death, intracellular 
Ca2+ homeostasis and signalling, as well as ER organelle remodelling 
(Vervliet et al., 2016), all of which are affected by AD. In the subsequent 
sections of this chapter, the physiological functions of various Bcl-2 family 
members, particularly Bcl-2 and Bcl-XL, will be discussed, with a specific 
emphasis on Ca2+ homeostasis and signalling.  
The expression of the ER Ca2+ release channels, IP3Rs and RyRs, 
which Bcl-2 family members interact with, will also be assessed in this 
chapter. As these have been discussed thoroughly in Section 1.3 Ca2+ 
Signalling and 1.4 Ca2+ Hypothesis the reader is directed to these sections 
for introductory information relating to these receptors, whereas their 
relevance to Bcl-2 family members, specifically, can be found throughout the 
following sections and in Section 5.4 Discussion. 
Bcl-2 
Bcl-2 is predominately expressed as an integral membrane protein 
which localises to mitochondria, ER and nuclear membranes (Hockenbery et 
al., 1990; Krajewski et al., 1993; Monaghan et al., 1992; Shimohama et al., 
1998), although cytosolic expression of splice variants has also been 





1996). Notably, it is a characteristic of Bcl-2 family members to be directed 
by a C-terminal hydrophobic transmembrane domain to intracellular 
membranes, resulting in the majority of their interactions occurring at these 
sites(Czabotar et al., 2013).  
In rodents, Bcl-2 expression in the CNS begins at the early prenatal 
period and peaks during embryonic development, where high levels of Bcl-2 
mRNA and protein are widespread in the developing brain (Abe-Dohmae et 
al., 1993; Castrén et al., 1994; Ferrer et al., 1994b; González-García et al., 
1995; Hockenbery et al., 1991; Krajewska et al., 2002; LeBrun et al., 1993; 
Martinou et al., 1994b; Merry et al., 1994; Shimohama et al., 1998). Bcl-2 
mRNA levels decrease slightly in adult mouse brain (8- to 20-week-old; 
including hippocampal tissue) relative to embryonic and neonatal samples 
(Castrén et al., 1994; González-García et al., 1995; Vyas et al., 1997). In the 
adult human brain, Bcl-2 mRNA remains readily detectable (85 – 89 ± 7 
years of age; Castrén et al., 1994). Bcl-2 protein is robustly expressed in 
adult mouse (including in the hippocampus; Karlnoski et al., 2007) and 
human brain samples (85 – 89 ± 7 years of age; Vyas et al., 1997). There 
are however conflicting reports showing that Bcl-2 mRNA and protein 
expression in the adult human brain occurs solely in neurons (Hockenbery et 
al., 1991; Vyas et al., 1997) or solely in microglia (Merry et al., 1994).  
Bcl-X 
Bcl-X mRNA and protein is found almost exclusively within neuronal 
tissue where it is widely expressed during human, rat and mouse 
development (González-García et al., 1995), as well as in adult brains. It is 
localised primarily to the soma, although it has also been detected in axons, 
dendrites and peripheral nerve fibres (Frankowski et al., 1995; González-
García et al., 1995, 1994; Krajewski et al., 1994; Parsadanian et al., 1995).  
Bcl-XL is the major form of Bcl-X expressed in the murine nervous 
system and its expression (RNA and protein) begins early in neurogenesis 
and increases postnatally until it peaks either at an early prenatal stage (E14; 
mice; Krajewska et al., 2002), early postnatal stage (P14; rat; Shimohama et 
al. 1998) or at adulthood (mouse; Frankowski et al., 1995; González-García 
et al., 1995; Krajewski et al., 1994). In more detail, Shimohama et al. (1998) 
found that Bcl-XL protein levels remained high in embryonic and adult rat 
cerebral cortex lysates over a wide range of ages from E19 days to 96 weeks 
but found that Bcl-XL levels peaked at P14. Another detailed study by 
Krajewska et al. (2002) found that relative Bcl-XL immunoreactivity, including  
in hippocampal CA3 pyramidal neurons, increased from E15.5 – E17.5, 
where levels were maintained postnatally (P0 to 3-months-old) These 
findings were supported by immunoblot data which demonstrated that Bcl-XL 
protein declined only slightly in adult brain (cerebrum and cerebellum) and 





and postnatally when compared to early embryonic stages (defined as 
<E15.5; Krajewska et al., 2002)  
Bcl-XL is primarily found in the membrane-associated, as opposed to 
the cytosolic,  fraction where the other Bcl-X isoform, Bcl-Xβ (also called Bcl-
Xs), is primarily detected (rat cerebral cortex; E19 – “adult”; Shimohama et 
al., 1998). Notably, Bcl-XL has the highest sequence homology of pro-
survival Bcl-2 family members with Bcl-2 (Boise et al., 1993). Krajewska et 
al. (2002) showed that Bcl-Xβ expression begins in the CNS at E8.5 - E11.5 
and in subsequent embryonic stages, expression is confined to post-mitotic 
neurons (which are also Bcl-2 and Bcl-XL positive) but becomes 
undetectable by later foetal life (E15.5 - 17.5 mice; Krajewska et al., 2002). 
Thus, this study questions the relevance of Bcl-Xβ expression in the tissue 
harvested postnatally in these studies. Conversely, Shimohama et al., (1998) 
showed that Bcl-Xβ expression mirrors that of Bcl-XL postnatally, except that 
its levels are lower than Bcl-XL at 4 weeks of age and are maintained at 
moderately high levels thereafter.  
In summary, the documented localisation, expression and activity of 
Bcl-2 and Bcl-X in mouse and human CNS tissue is such that they can be 
considered candidate modulators of IP3R and RyR signalling within the 
hippocampal tissue utilised in this project and their levels could, therefore, be 
relevant to interpreting the Ca2+ signalling experiments outlined in Chapter 3 






5.1.2 Bcl-2 family members and Ca2+ regulation 
Aside from the aforementioned neuroprotective interactions of anti-
apoptotic Bcl-2 family members such as Bcl-2 and Bcl-XL with proapoptotic 
Bcl-2 family members at the mitochondria, activity at the ER also contributes 
to their anti-apoptotic effects (Akl et al., 2014; Annis et al., 2001; Thomenius 
et al., 2003) via modulation of ER Ca2+ signals and intracellular Ca2+ 
homeostasis (Baffy et al., 1993; Lam et al., 1994; Magnelli et al., 1994). For 
example, Bcl-2 mediated dampening of ER Ca2+ signals prevents excessive 
Ca2+ transfer to the mitochondria and therefore, indirectly, prevents 
mitochondrial outer membrane permeabilisation (MOMP; (Giorgi et al., 2012; 
Marchi et al., 2014; Pinton et al., 2008). 
There are two proposed mechanisms underlying such Bcl-2 
mediated dampening of ER Ca2+ signals: either Bcl-2 lowers steady-state 
[Ca2+]ER (Pinton et al., 2000), or Bcl-2 directly suppresses ER Ca2+ 
mobilisation (He et al., 1997; Thomenius and Distelhorst, 2003). Although, 
this question remains a provocative one in the field (e.g. "Bcl-2 and calcium: 
controversy beneath the surface"; Distelhorst and Shore, 2004), Vervliet et 
al. (2016) posit that rather than being an “either/or” scenario, the two 
proposed mechanisms likely reflect the complex and diverse regulation of 
Ca2+ signalling by Bcl-2 family members. Regardless of which hypothesis is 
correct, it is worth noting that a decrease in [Ca2+]ER (Scorrano et al., 2003), 
mediated by either anti-apoptotic Bcl-2 (Pinton et al., 2000) or BAX/BAK KO 
will, on the one hand, limit pro-apoptotic ER Ca2+ transfer to the mitochondria 
(Pinton and Rizzuto, 2006) but, on the other, also have the potential 
(perhaps at a certain threshold) to trigger ER stress and ER-mediated 
apoptosis via the unfolded protein response (UPR; (Kiviluoto et al., 2013; 
Mekahli et al., 2011; Urra et al., 2013). 
Importantly, there are also examples of Ca2+ regulation by Bcl-2 
family members which are independent (at least directly) of cell death 
regulation, such as the fine-tuning of IP3R signals (Bonneau et al., 2013; 
Parys, 2014). Indeed, Bcl-2 family members interact with the majority of the 
known Ca2+ signalling toolkit proteins including IP3Rs (Bcl-2, Bcl-XL , Mcl-1), 
RyRs (Bcl-2, Bcl-XL), SERCA (Bcl-2), PMCA (Bcl-2), mitochondrial VDAC 
(Bcl-2, Bcl-XL , Mcl-1) and mitochondrial Na+/Ca2+ exchanger (Bcl-2; for 
review see Vervliet et al., 2016) as will be discussed next. 
IP3R 
Bcl-2 binds to the central modulatory domain of all IP3R isoforms to 
inhibit Ca2+ release producing an anti-apoptotic effect (Chen et al., 2004; 
Hanson et al., 2008; Monaco et al., 2013, 2012b; Rong et al., 2009) 
Conversely, Bcl-XL binds to IP3Rs with significantly lower affinity than that of 





Bcl-XL overexpression does, however, produce anti-apoptotic effects 
via negative regulation of the expression of IP3R1 and 3 (in an interleukin-3-
dependent lymphoid cell line FL5.12; Li et al., 2002). In line with this, T cell 
receptor-stimulated Ca2+ signals, which are mediated by IP3Rs, were 
suppressed in Bcl-XL overexpressing cells (Jayaraman et al., 1995).  
In addition to binding to the central modulatory domain of IP3Rs, Bcl-
2 and Bcl-XL can also bind to an alternative IP3R site at the C-terminal region 
(Eckenrode et al., 2010; Monaco et al., 2012a; White et al., 2005). Binding at 
this region sensitises IP3Rs to low/basal levels of IP3 and promotes Ca2+ 
oscillations regulating mitochondrial bioenergetics and cell survival 
(Eckenrode et al., 2010; Monaco et al., 2012a; Palmer et al., 2004; White et 
al., 2005). Binding of Bcl-XL at the C-terminal region sensitises all three IP3R 
isoforms and, notably, binding to the IP3R3 isoform alone causes a reduction 
in [Ca2+]ER (C. Li et al., 2007).  
Bcl-2 can also act as a docking protein for, a) DARPP-32 (a 32kDa 
phosphoprotein) which is regulated by dopamine cAMP and PKA, and, b) the 
Ca2+-activated phosphatase, calcineurin (CN). The combined activities of 
both proteins dynamically control IP3R1 phosphorylation and activity (Chang 
et al., 2014).  
RyR 
The characterisation of the Bcl-2-IP3R binding site also revealed a 
homologous region in the central domain of all three RyR isoforms (Vervliet 
et al., 2015b, 2014) and subsequent co-immunoprecipitation studies 
demonstrated that RyR1 and RyR3 form complexes with Bcl-2 (full length) 
and the BH4 domain of Bcl-2 in both HEK293 cells and 21-day-old rat 
hippocampal lysates. Furthermore, endogenous Bcl-2 expression or 
application of its BH4 domain both suppressed RyR-mediated Ca2+ release 
in HEK293 cells. Application of the BH4 domain in hippocampal neurons also 
decreased RyR-mediated Ca2+ release (E18; 14 – 18 DIV; Vervliet et al., 
2014). 
Bcl-XL also binds to RyR3 via its BH4 domain, although with a lower 
affinity than Bcl-2. Furthermore, caffeine-induced Ca2+ release was inhibited 
by Bcl-XL-BH4 domain in both RyR3-overexpressing HEK293 cells and 
dissociated hippocampal neurons (E18; 14 – 18 DIV; Vervliet et al., 2015a). 
 
5.1.3 Bcl-2 family members and AD 
Support for the involvement of Bcl-2 family members in AD 
pathogenesis comes from research utilising murine models of AD and human 





is still in its infancy, where Bcl-2 is, so far, the only anti-apoptotic protein 
characterised to any great extent. The majority of these studies has indicated 
that Bcl-2 expression generally decreases from around 3 months of age 
compared to non-transgenic controls (Table 5.1; Giuliani et al., 2013; 
Karlnoski et al., 2007; Stein and Johnson, 2002; X. Wang et al., 2009). 
Furthermore, Bcl-2 expression correlates with a reduction in the formation of 
APP (Poon et al., 2010) and tau pathology via caspase cleavage inhibition 
(Rohn et al., 2008). Bcl-2 expression also protects cells from Aβ-induced 
toxicity (Deng et al., 1999; Saillé et al., 1999; Song et al., 2004). Conversely, 
Aβ peptides generally downregulate Bcl-2 (and Bcl-XL and Bcl-w (Yao et al., 
2005)) expression (Clementi et al., 2006; Lee et al., 2015; Paradis et al., 
1996). Later stage pathology Aβ plaques increase Bcl-2 and BAX 
immunoreactivity in human AD brain samples, including in reactive glia 
surrounding Aβ plaques (Kitamura et al., 1998; Satou et al., 1995; Tortosa et 
al., 1998), whereas NFTs either have no effect (Tortosa et al., 1998), or 
actually decrease Bcl-2 immunoreactivity (Satou et al., 1995; Su et al., 
1996). 
Finally, Bcl-XL and Bcl-2 interact with PS1 and PS2, which may 
modulate the threshold for induction of apoptosis (Passer et al., 1999; 
Schellenberg et al., 1992). These findings are elaborated upon in the 
following sections. 
Bcl-2 protein family expression 
At mRNA and protein level, the expression of Bcl-2 in the CNS is 
altered in animal models of AD relative to controls (Table 5.1). In a study 
utilising young 3xTg-AD mice (3 months of age), hippocampal levels of Bcl-2 
(lower), BAX (higher) and caspase-3 (higher) protein were altered to a more 
pro-apoptotic phenotype (Giuliani et al., 2013). Similarly, Bcl-2 expression 
was decreased in the cerebral cortex of 3 – 6-month-old APPSWE/PS1∆E9 
mice (X. Wang et al., 2009). Interestingly, microRNA (miR)-34a was found to 
be highly expressed in the cerebral cortex of APPSWE/PS1∆E9 mice (3 – 6 
months of age) when compared with age-matched controls (X. Wang et al., 
2009). miR-34a interacts with Bcl-2 mRNA to inhibit its translation, such that 
miR-34a expression is inversely correlated with Bcl-2 protein levels (Lin et 
al., 2014). Conversely, miR-34a knockdown increased Bcl-2 protein levels 
and decreased active caspase-3 in SH-SY5Y cells (X. Wang et al., 2009). In 
line with the known mediators of Bcl-2 function, APPSWE/PS1∆E9 mice and 
miR-34a transfected cell lines exhibited higher levels of active caspase-3 (X. 
Wang et al., 2009) which is an important apoptotic mediator involved in DNA 
fragmentation (Friedlander, 2003). Similarly, Bcl-2 mRNA is upregulated by 
approximately 25% in the hippocampus and Bcl-2 expression is increased 2-
fold in the cortex and hippocampus of “middle-aged”/16-18-month-old mice 





al., 2007). This increase in Bcl-2 expression is also primarily localised to 
neuronal cells (Karlnoski et al., 2007).  The authors of this study speculate 
that amyloid deposition was a key stimulus for Bcl-2 upregulation based on a 
correlation between the two in tissue of the posterior cortex and cerebellum 
from both APPSWE and APPSWE/PS1M146L mice, although transgene effects 
independent of amyloid deposition are also possible. This lack of an Aβ 
“deposition stimulus” could explain currently limited observations whereby 
Bcl-2 levels decrease at early stages of the disease and increase thereafter. 
That being said, more generally, neuroprotective genes such as IGF-2, Akt, 
Erk1/2, and TTR are upregulated in AD, as is a protective pathway which 
results in the phosphorylation of the proapoptotic Bcl-2 antagonist of cell 
death (BAD) at both pre-plaque (6 months of age) and post-plaque (12 
months of age) stages in “Aβ containing” hippocampi and cerebellums of 
APPSWE mice. This suggests that Aβ plaques may not be the determining 




Table 5.1 Bcl-2, BAX and BAD expression and activity in animal models of AD from 3 - 18-
months-old. 
The expression or activity of the anti-apoptotic Bcl-2 and the pro-apoptotic BAX and BAD in 
mouse models of Alzheimer’s disease (AD) are displayed in sequential order based on age 
(relative to non-transgenic controls).  
Abbreviations used: amyloid precursor protein (APP), Bcl-2 antagonist of cell death (BAD), Bcl-





Recorded expression levels of Bcl-2 in adult human AD brain tissue, 
compared with age-matched controls, is limited and exhibits significant 
variability (see Table 5.2). 
 
 Taken together, these studies suggest that AD does affect the 
expression of certain Bcl-2 family members in either membrane or cytosolic 
fractions of the human brain. Specifically with regard to Bcl-2, it is generally 
increased in AD, most notably of the membrane, rather than the cytosolic, 
fraction (Karlnoski et al., 2007). There is a paucity of studies investigating 
Bcl-2 family members in animal models of AD, particularly at early 
developmental stages. From the limited number of studies in the field, APP 
Table 5.2 Expression of pro- and anti-apoptotic Bcl-2 family members in human tissue from 
Alzheimer’s disease patients relative to age-matched controls.  
 The activity or expression of the anti-apoptotic Bcl-2, Bcl-XL and Bcl-Xβ as well as the pro-
apoptotic BAK and BAD in Alzheimer’s disease (AD) human brain tissue (from numerous brain 
regions) is displayed, relative to age-matched controls. 
Numbers following references refer to their explanation in the preceding list 
Abbreviations used: Bcl-2 antagonist of cell death (BAD), Bcl-2 antagonist of cell death (BAK), 





and/or PS1 mutations appear to suppress Bcl-2 expression relative to non-
Tg controls.  
Bcl-2 and Aβ 
There are now numerous studies which have identified a specific 
connection between Bcl-2 expression and Aβ pathology. In terms of cell 
death, which is intertwined with Bcl-2 family member expression and 
function, I have already discussed how Aβo promote cell death pathways 
and thereby contribute to neurodegeneration in AD (Section 1.2 Amyloid 
Cascade Hypothesis; e.g. Demuro et al., 2005; Simakova and Arispe, 2007). 
Notably, the expression levels of Bcl-XL are variably altered in 
studies, depending upon the profile of Aβ exposure utilised. For instance, 
exposure of SH-SY5Y neuroblastoma cells to “sub-toxic” levels of Aβ40 and 
Aβ25-35 up-regulated Bcl-XL (Luetjens et al., 2001), whereas toxic Aβ 
exposure using aggregated Aβ40, Aβ42 and Aβ25-35, dramatically reduced Bcl-
XL (Yao et al., 2005). However, regarding Bcl-2, specifically, according to the 
current research, Aβo appear to reduce its expression regardless of the 
severity of the insult.  
Aβ25-35 and Aβ42 application resulted in dissipation of mitochondrial 
transmembrane potential (MMP), decreased Bcl-2/Bax ratio, increased 
caspase-3 expression and activation and time-dependent decreases in cell 
viability in SH-SY5Y cells and human neuroblastoma cells (IMR-32) (Lee et 
al., 2015). Interestingly, the redox state of the Aβ peptides modulated the 
expression profiles of the aforementioned proteins, revealing yet another AD 
disease process which can be affected by ROS (Clementi et al., 2006). 
Similarly, sub-apoptotic inducing levels of Aβ40 and Aβ42 peptides 
downregulated Bcl-2 expression, increased neuronal susceptibility to low 
levels of oxidative stress and, in the case of Aβ42 alone, increased BAX 
expression after 3 DIV in human foetal (13 – 17 week) cerebrum cultures 
(Paradis et al., 1996). 
Logically, increased levels of anti-apoptotic Bcl-2 family members 
including Bcl-2 (in PC12 cells and cortical neurons; Deng et al., 1999; Saillé 
et al., 1999; Song et al., 2004), Bcl-XL (in PC12 cells and SH-SY5Y 
neuroblastoma cells; Luetjens et al., 2001; Tan et al., 1999) and Bcl-w (in 
cortical neurons and M17 neuroblastoma cells; Yao et al., 2005; Zhu et al., 
2004) protect cells from Aβ-induced toxicity, including apoptosis and 
necrosis, in vitro. Furthermore, in APPSWE/APPV717F(INDIANA) mice, Bcl-2 
overexpression decreased plaque pathology and reduced Aβ42 levels in the 
hippocampi of aged mice (Poon et al., 2010). In the most comprehensive 
study conducted to date investigating the links between AD pathology and 
Bcl-2 family-related signalling, Rohn et al. (2008) found that Bcl-2 





Specifically, Bcl-2 overexpression limited caspase-3 and -9 activations and 
translocation in the neocortex and hippocampus of these animals at 6-, 12- 
and 18- months of age, resulting in an attenuation of APP and tau cleavage 
by caspases relative to untreated animals (Rohn et al., 2008). This factor 
likely attenuated Aβo- and tau-mediated pathology in these animals (Gamblin 
et al., 2003; Gervais et al., 1999; Rissman et al., 2004; Rohn et al., 2002). 
Indeed, these Bcl-2 overexpressing mice exhibited; a) reduced caspase-
mediated cleavage of tau (6 – 18 months of age), b) reduced “total 
pathological tau”, c) an absence of NFTs (12 months of age) d) reduced Aβ42 
and Aβ40 levels and accumulation (12-18 months of age) and, e) improved 
place recognition memory (24 months of age; Rohn et al., 2008). 
Oxidative stress 
Oxidative stress, which is proposed to be of considerable importance 
in contributing to AD pathogenesis (Gella and Durany, 2009; Huang et al., 
2016; Perry et al., 2002), can also increase the expression of Bcl-2 family 
members, including Bcl-XL in PC12 cells (Luetjens et al., 2001) and Bcl-2 in 
the hippocampus and cerebellum of 3- and 24-month-old rats (Kaufmann et 
al., 2001). Although outside the remit of this general introduction, the reader 
should note that the activities of other apoptotic regulators such as pro-
apoptotic caspases and neuroprotective NFB can also be altered by AD-








1) To determine the expression of the anti-apoptotic proteins Bcl-2 and 
Bcl-XL in total hippocampal lysates from 3xTg-AD mice (P5, 15 and 21) and 
to compare these with non-transgenic controls. 
2) The expression of IP3Rs and RyRs, which Bcl-2 and Bcl-XL are 
reported to regulate, was also investigated in transgenic and non-transgenic 
control hippocampal tissue in the same age groups as in aim 1. 
The expression profiles of each these Ca2+ interacting proteins may 
elucidate underlying mechanisms responsible for altered Ca2+ signalling 






5.3 Materials and methods 
5.3.1 Statement of collaboration 
The majority of work presented in this chapter was undertaken in the 
lab of Dr Geert Bultynck in K.U. Leuven (Belgium), in collaboration with, and 
under the supervision and expert guidance of, Dr Tim Vervliet. Specifically, 
animals were sacrificed and hippocampi harvested in University College 
Cork (UCC; Ireland), as described in Chapter 2. I then travelled to Dr 
Bultynck’s lab in Belgium to conduct the actual western blot experiments 
outlined herein. The data presented in the results section of this chapter 
investigating BCL-2, Bcl-XL, IP3R and RyR expression arise from work 
carried out during this period of study (1 biological replicate) combined with 
data that Dr Vervliet subsequently generated independently using additional 
samples which were harvested by me in UCC (4 biological replicates). I 
would like to express mine and my lab’s sincere gratitude to both Dr Bultynck 
and Dr Vervliet for their time, expertise and stimulating discussions during 
this aspect of my doctoral work.  
5.3.2 Chemicals, antibodies, peptides 
Unless otherwise stated all chemicals were obtained from Sigma–
Aldrich. Antibodies used in this study were: mouse monoclonal anti-Bcl-2 
(C2; 1:1000: Santa Cruz Biotechnology cat no. sc-7382, Antibody Registry: 
AB_626736), mouse monoclonal anti-Bcl-XL antibody (YTH-2H12; 1:1000; 
Trevigen, cat no. 2300-MC-100, Antibody Registry: AB_2064868), rabbit 
polyclonal anti-IP3R1 (Rbt03; 1:1000; made “in-house” as published 
previously in Parys et al. (1995)), mouse monoclonal anti-RyR (1-3) antibody 
(34C; 1:2000; Thermo Scientific, cat no. MA3-925, Antibody Registry: 
AB_2254138), mouse monoclonal anti-RyR (2) antibody (C3:33; 1:2000; 
Thermo Scientific, cat no. MA3-916, Antibody Registry: AB_2183054), 
mouse monoclonal anti-actin antibody (AC-74; 1:2000; Sigma Aldrich, cat. 
no. A222, Antibody Registry: AB_476697), mouse monoclonal anti-GAPDH 
antibody (GAPDH-71.1; 1:50000; Sigma Aldrich, cat. no. G8795, Antibody 
Registry: AB_1078991), mouse monoclonal anti-vinculin (VIN-11-5; 1:1000; 
Sigma Aldrich, cat. no. V4505, Antibody Registry: AB_477617). 
5.3.3 Brain samples 
3xTg-AD mice and non-transgenic controls at 5-, 15- and 21-days-
old were euthanized in accordance with European Directive 2010/63/EU and 
experiments approved by the Animal Experimentation Ethics Committee of 
University College of Cork. Hippocampi were removed as described 
previously (Beaudoin et al., 2012). For experiments comparing the effect of 
elevated extracellular potassium concentration on Bcl-2 family member 
expression utilising 5-day-old mice, whole brains were either dissected in the 





HBSS (15mM K+) while the hippocampus was being removed. Hippocampi 
were frozen in liquid nitrogen before storage at -80oC. 
5.3.4 Immunoblots 
Samples were prepared and used as described previously (Monaco 
et al., 2012b). Briefly, tissue was taken from storage at -80oC and placed in 
iced extraction buffer (pH7.5; 100mM NaCl, 50mM Tris-HCl, 50mM NaF, 
2mM EDTA, 1mM Na3VO4, Chaps 1%, 2 x protease inhibitor cocktail tablets 
(Roche, Basel, Switzerland) for tissue homogenisation. Depending upon the 
size of hippocampal tissue, an appropriate volume of buffer was added 
(approximate values of 175ul, 250ul and 500ul were used for 5, 15 and 21 
DIV mouse samples, respectively, whereas 375ul and 1ml were used for 5 
and 21 DIV rat samples, respectively). The hippocampi were incubated in 
extraction buffer for 30 mins, vortexing at 10-minute intervals, before being 
centrifuged (4000 xg; 5 mins; 4oC). The protein concentration of samples 
was determined by Bradford assay (Sigma-Aldrich) using bovine serum 
albumin (BSA) as standard. Samples containing protein levels of 300 μg, 
50ul Lithium Dodecyl Sulfate (LDS) and the remaining volume H2O up to 
200ul were boiled (95°C; 5 min) immediately prior to running on either 
NuPAGE 4 - 12% Bis-Tris SDS-polyacrylamide gels (180V; 55min; RT) or 
NuPAGE 3 - 8% Tris-Acetate gels (180V; 1hr30; 4oC; both from Life 
Technologies). Transfer (100V; 1hr; 4oC) was carried out onto a 
polyvinylidene fluoride (PVDF) membrane.  
After blocking with Tris-buffered saline (TBS) containing 0.1% Tween 
and 5% non-fat dry milk powder, the membrane was incubated with the 
primary antibody overnight (1% non-fat dry milk powder 0.1% Tween/TBS 
was used for all antibody incubations). After washing (3 x 5 mins in 0.1% 
Tween/TBS), membranes were incubated for 1 hour with a secondary 
horseradish peroxidase (HRP)-conjugated antibody (dilution 1: 2000 in 0.1% 
Tween/TBS). After washing (3 x 5 mins in 0.1% Tween/TBS), detection was 
performed using Pierce ECL Western Blotting Substrate (Thermo 
Scientific) and the Chemidoc™ MP system (Bio-Rad, Nazareth Eke, 
Belgium). Band quantification was performed using Image Lab™ software 
(Bio-Rad). 
5.3.5 Statistical analysis 
Two-tailed unpaired Student's t-tests were performed when two 
conditions were compared. When comparing three conditions, a one-way 
ANOVA with Tukey’s multiple comparison test was utilised. * indicates 








5.4.1 Bcl-2 and Bcl-XL  
  
Figure 5.2. Western blot analysis of non-transgenic (non-Tg) and 3xTg-AD (Tg) hippocampal lysates, harvested from 
animals at 5-, 15- and 21-days-old, with antibodies against Bcl-2 (A) and Bcl-X
L 
(B). 
i) Representative images from five independent experiments (n = 5) are shown. GAPDH was used as a loading control. 
ii) Graphical representation of protein expression after densitometric analysis. Data normalised to GAPDH and shown relative 





Western blot analysis of Bcl-2 expression in hippocampal lysates 
prepared from P5, 15 and 21 non-Tg and 3xTg-AD animals is displayed in 
Fig 5.2. All data are presented in arbitrary units, normalised to expression of 
a control protein (either GAPDH, vinculin or actin; see corresponding graphs) 
and displayed relative to non-Tg P5 expression levels.  
Interestingly, and although not significant, there was a trend towards 
greater Bcl-2 expression in P5 3xTg-AD tissue relative to age-matched 
controls (1.24 ± 0.07 vs 1; Tg P5 vs non-Tg P5; p = 0.25, n = 5). It is notable 
that Bcl-2 expression decreased in both control and Tg tissue with increasing 
age (significantly in controls when comparing P5 to P15 (p = 0.008) and in Tg 
when comparing P5 with P15 and P21 (p = < 0.0001; n = 5). However, this 
decrease was even more dramatic in Tg tissue at P21 relative to age-
matched controls (0.41 ± 0.09 vs 0.83 ± 0.13; p = 0.03; n = 5; Tg P21 vs non-
Tg P21). 
Bcl-XL expression followed a similar trend to that of Bcl-2 whereby 
expression appeared to be greater in Tg tissue at P5, relative to non-Tg 
tissue (although not significantly so; 1.23 ± 0.22 vs 1; Tg P5 vs non-Tg P5; p 
= 0.93, n = 5) and decreased thereafter in both non-Tg and Tg tissue 
although only  significantly so in Tg tissue, when comparing P5 with P21 
animals; 1.23 ± 0.22 vs 0.43 ± 0.11; Tg P5 vs Tg P21; p = 0.01, n = 5). There 
was also a non-significant trend towards a greater decrease in Bcl-XL levels 
in Tg tissue with increasing postnatal development, relative to non-Tg tissue 
(0.79 ± 0.20 vs 0.63 ± 0.14, non-Tg P15 vs Tg P15, p = 0.5, n = 5; 0.82 ± 




















































































































































































































































































































































































































 We found that there were no significant differences in RyR (2), RyR 
(3) or IP3R1 expression levels between non-Tg and 3xTg-AD samples at 
either P5, P15 or P21 (n = 4; Fig 5.3). That being said there were some 
notable trends. At P5, transgenic tissue had a trend towards increased RyR 
(2) (2.09 ± 0.28 vs 1; p = 0.37; Tg P5 vs non-Tg P5), RyR (3) (1.83 ± 0.44 vs 
1; p = 0.99; Tg P5 vs non-Tg P5) and IP3R1 (2.05 ± 0.39 vs 1; p = 0.18; Tg 
P5 vs non-Tg P5), relative to non-Tg controls. At P15 the levels of all three 
ER release channels were similar between non-Tg and Tg tissue. However, 
differences between phenotype were observable again at P21, where RyR 
(3) expression increased in Tg tissue to a greater extent than in controls 
(4.37 ± 0.27 vs 3.4 ± 0.49; p = 0.14; Tg P21 vs non-Tg P21), whereas IP3R1 
expression decreased relative to that in non-Tg tissue (5.63 ± 0.9 vs 6.04 ± 
1.27; p = 0.79; Tg P21 vs non-Tg P21). 
Both non-Tg and Tg samples followed similar trends of 
developmental-dependent expression for RyR (2 and 3), which increased 
with increasing age (although the extent of this increase was quite variable 
between biological units) and was significant only for the expression of non-
Tg RyR (2) (1 vs 5.61 ± 1.49 vs 6.04 ± 1.27; non-Tg P5 vs P15 vs P21; p = 
0.04 and 0.02, respectively), non-Tg RyR (3) (1 vs 3.48 ± 0.63 vs 3.4 ± 0.49; 
non-Tg P5 vs P15 vs P21; p = 0.003 and 0.004, respectively) and Tg RyR (3) 
(2.09 ± 0.28 vs 4.37 ± 0.27; p = 0.001; Tg P5 vs Tg P21).  
In immunoblot experiments measuring IP3R1 expression, there was 
no significant difference between groups (non-Tg vs Tg) or between ages 
within groups. In non-Tg tissue, there was a trend towards greater IP3R1 
expression with increasing age, but this was not significant. In Tg tissue, 
IP3R1 expression trended towards an increase at P15 but then decreased to 







Bcl-2 and Bcl-XL expression correlate with resistance to apoptotic 
and oxidative stresses, two highly relevant processes in AD pathology, in 
vitro and in vivo (for reviews see Merry and Korsmeyer, 1997; Shacka and 
Roth, 2006). However, whether the apparent decreased expression of either 
Bcl-XL or Bcl-2 in transgenic tissue relative to controls would have a 
significant impact upon cell death in these animals at this early time point (P5 
– 21) is unknown and was not measured. Instead, the focus of this 
discussion relates to the ability of Bcl-2 and Bcl-XL to reversibly inhibit IP3R- 
and RyR-gating which, aside from being an important mechanism employed 
by these proteins to prevent Ca2+-dependent apoptosis (Giorgi et al., 2012; 
Marchi et al., 2014; Pinton et al., 2008), also has important implications for 
intracellular Ca2+ signalling (Hanson et al., 2008; Rong et al., 2008; Vervliet 
et al., 2014).  
It was our hypothesis that in animal models of AD (such as the 3xTg-
AD mouse) which display robust Ca2+ dyshomeostasis, including that 
mediated by ER Ca2+-release channels (see Chapter 4), Bcl-2 expression 
would be increased in a compensatory manner to dampen pathologically 
increased IP3R- and RyR- mediated ER signals (Morley et al., 2012). 
However, the expression levels of Bcl-2 family proteins and/or the activity of 
their downstream effectors (including caspases) are generally reduced in 
transgenic models of AD and/or following exposure to Aβ proteins in vitro 
(discussed previously). That being said, as is the norm in the field of AD, 
these investigations were solely concerned with later stages of the disease 
and comparisons between Tg and non-Tg brain tissue are lacking at earlier 
disease stages. We were also aware that if murine models of AD displayed 
upregulation of Bcl-2 relative to controls, the resulting hypothetical Bcl-2 
mediated inhibition of IP3Rs could be counteracted indirectly, by AD-initiated 
mitochondrial impairment (dependent upon the appearance of mitochondrial 
impairment in the chronology of the disease). This would induce cytochrome 
c translocation to the ER where it binds to, and blocks, Ca2+-dependent 
inhibition of IP3Rs. This results in sustained, oscillatory increases in [Ca2+]i 
levels and amplification of Ca2+-dependent apoptosis (Boehning et al., 2003).  
The expression of the anti-apoptotic Bcl-2 and Bcl-XL as well as two 
Ca2+ release channels with which Bcl-2 and Bcl-XL interact, IP3Rs and RyRs, 
were investigated in whole hippocampal lysates using immunoblot analysis. 
In summary, although there was a trend towards decreased expression of 
Bcl-2 and Bcl-XL and a trend towards increased expression of RyR and IP3R1 
with development (P5 vs P15 and P5 vs P21) regardless of transgenic 
status, this was only significant in 3xTg-AD tissue only in the case of Bcl-2, 
Bcl-XL and RyR (2) expression, and generally, solely at the latest stage of 





5.5.1 Characterisation of postnatal Bcl-2 and Bcl-XL expression 
As detailed previously, Bcl-2 expression peaks in the CNS during 
embryonic development and declines postnatally (Krajewska et al., 2002; 
Shimohama et al., 1998). In line with these data, we found that Bcl-2 
expression decreased with increasing postnatal development (P15 and 21 vs 
P5) in hippocampal lysates from non-Tg and 3xTg-AD mice (19 of 20 
samples (regardless of transgenic status) exhibited lower expression when 
compared to control (non-Tg; P5); group analysis was significant for the 
following comparisons: non-Tg P5 vs P15 and Tg P5 vs P15 and P5 vs P21; 
Fig 5.2)  
It is worth noting that in agreement with relatively recently observed 
Bcl-2 protein expression in adult mouse and human brain (Karlnoski et al., 
2007, Vyas et al., 1997), as opposed to an absence of Bcl-2 protein 
expression in older studies (González-García et al., 1995; Merry et al., 
1994), Bcl-2 protein was readily detectable in 28 separate postnatal mouse 
and rat whole hippocampal lysates (data not shown), suggesting that despite 
a relative decline postnatally, Bcl-2 may still be physiologically relevant for 
both the regulation of Ca2+ signalling and neuroprotection. However, whether 
or not this Bcl-2 signal was derived from neurons or glia, or a combination of 
both, was not determined in this study. Indeed, there are conflicting reports 
of Bcl-2 mRNA and protein expression occurring either solely in neurons 
(Hockenbery et al., 1991; Vyas et al., 1997) or solely in glia (Merry et al., 
1994), at least in human CNS tissue.  
The physiological process(es) underlying this change in Bcl-2 
expression is likely the developmentally-regulated mechanism of naturally 
occurring cell death (NOCD). NOCD is enhanced during the first postnatal 
week and decreases thereafter (Ferrer et al., 1994a), in tandem with Bcl-2 
expression (Shimohama et al., 1998). Moreover, it is likely that Bcl-2 plays a 
role in dictating which neurons undergo NOCD, as Bcl-2 overexpression 
protects neurons from this process (Martinou et al., 1994a). Lower levels of 
Bcl-2 found in numerous brain regions postnatally (as described previously) 
may help to protect neurons from more subtle toxic insults such as oxidative 
stress (Shimohama et al., 1998). Conversely, such low levels may simply 
indicate that Bcl-X proteins, which are highly expressed postnatally, are the 
principal anti-apoptotic regulators of neuronal cell death in adult brain 
(González-García et al., 1995; Shimohama et al., 1998; Yachnis et al., 
1998). 
Previous research suggests that Bcl-XL expression (both RNA and 
protein) begins early in neurogenesis and increases postnatally, peaking 
either at an early prenatal stage (E14 mouse; Krajewska et al., 2002), early 





Frankowski et al., 1995; González-García et al., 1995; Krajewski et al., 
1994). Conversely, the current research suggests that Bcl-XL expression 
actually trended towards a decrease in the early postnatal stages of 
development in tissue from both non-Tg and 3xTg-AD mice (18 of 20 
samples (regardless of transgenic status) exhibited lower expression when 
compared to control (non-Tg; P5); group analysis was significant only for Tg 
P5 vs P21; Fig 5.2). However, there are some notable differences between 
our work and that undertaken previously, which may explain this 
discrepancy. Firstly, Shimohama et al. (1998) showed that Bcl-XL expression 
peaked at P14 and remained elevated thereafter (P14 – 96 weeks of age) 
but this investigation utilised cortical lysates which may have had a different 
Bcl-XL expression profile to hippocampal lysates. Secondly, the Krajewska et 
al. (2002) study also showed that although hippocampal Bcl-XL 
immunoreactivity (immunohistochemistry), was maintained at a high level 
postnatally (mice between P0 – 3 months), this was predominately evident 
only in CA3 hippocampal pyramidal neurons. Although staining may have 
been strong in this specific region, the overall expression levels may have 
actually been relatively low when lysates were analysed from whole 
hippocampi, as utilised in the current study. Furthermore, although protein 
expression was found to increase postnatally (compared to early embryonic 
stages; immunoblot) and reduced only slightly in adult tissue in the study by 
Krajewska et al. (2002), this work was carried out utilising lysates from the 
cerebrum and cerebellum, not the hippocampus. 
Interestingly, two further publications which are often cited as 
correlating increased Bcl-XL expression with development, in fact, lack the 
required evidence to support such a statement. For example, González-
García et al. (1995) presented an image of RNA analysis which showed a 
comparison of Bcl-XL mRNA levels between E13 – 19, neonatal and adult 
mouse brain sections (from undefined brain regions) which were not 
quantified. This lack of quantification was repeated for another image in the 
same paper which showed that there was elevated Bcl-XL expression (in 
comparison to Bcl-2 and Bcl-Xβ) in all regions tested in the adult CNS, 
including the hippocampus. The same study also presented a single western 
blot showing Bcl-XL protein expression in lysates from various embryonic 
(E17; cerebral cortex and cerebellum) and adult (20 weeks-old; cerebral 
cortex, basal ganglia, cerebellum, spinal cord) brain regions. In said blot, Bcl-
XL protein expression differences are not objectively clear, as no loading 
control has been used and the blot was not densitometrically analysed 
(González-García et al., 1995). The study by Krajewski et al., (1994) 
presented “graded/arbitrary” immunohistochemical staining intensity of Bcl-
XL in the CNS from a range of 4 - 12-week-old mice as well as human biopsy 
and autopsy samples, but with no analysis of how this changed with 





therefore, argue that Bcl-XL expression in the CNS in the early postnatal 
stages, which I have investigated herein, has not previously been well 
characterised, particularly in hippocampal tissue. The increase in Bcl-XL 
expression established as a trend in the literature may also occur at a later 
developmental stage than that investigated in this study (post-P21).  
 
5.5.2 Effects on Ca2+ signalling 
Bcl-2 family members interact with the majority of cellular Ca2+ 
signalling toolkit components such as IP3Rs, RyRs, SERCAs, PMCAs, 
mitochondrial VDACs and mitochondrial Na+/Ca2+ exchangers (see Section 
5.1 and for review see Vervliet et al., 2016). The expression and activity of 
this family are therefore of great relevance to neuronal mechanisms of Ca2+ 
homeostasis, Ca2+ signalling (including I-mGluR-IP3R/RyR mediated 
signalling outlined in Chapter 3 and 4) and putative ‘calciumopathies’ such as 
AD.  
Specifically, given our investigations into ER Ca2+ dynamics, the 
mechanisms through which Bcl-2 is proposed to alter Ca2+ signalling are 
particularly relevant. As described previously, these mechanisms include the 
suppression of ER Ca2+ mobilisation through IP3Rs (binding to all three 
isoforms; Monaco et al., 2012) and RyRs (He et al., 1997; Thomenius and 
Distelhorst, 2003), the lowering of steady-state [Ca2+]ER (Pinton et al., 2000) 
or a combination of all aforementioned forms of regulation (Vervliet et al., 
2016). Bcl-XL also suppresses ER Ca2+ release. However, aside from one 
study which utilised supra-physiological Bcl-XL concentrations (Yang et al., 
2016), this occurs solely via RyRs (Monaco et al., 2012b; Vervliet et al., 
2015a). Importantly though, Bcl-XL also indirectly modulates IP3R-mediated 
Ca2+ release as its expression (at least in overexpression studies) negatively 
regulates IP3R1 and 3 expression in an interleukin-3-dependent lymphoid 
cell line (FL5.12; Li et al., 2002). However, the subtleties of Bcl-XL 
expression-mediated regulation of IP3R expression may be lost amongst the 
overall developmentally-dependent expression patterns of Bcl-XL and IP3R 
proteins and therefore may not be physiologically relevant during this period 
of development. 
Any changes in the functional activity and/or expression of Bcl-2 
and/or Bcl-XL within neurons will almost certainly modulate I-mGluR 
mediated signalling. Such modulation could occur by direct regulation of 
IP3R- and RyR-mediated Ca2+ mobilisation, steady-state [Ca2+]ER, IP3R 
expression, and/or modulation of the plethora of Ca2+ signalosome proteins 
with which Bcl-2 proteins interact (including FKBPs, SERCA and PMCA; 





Our results suggest that in the hippocampi of 3xTg-AD mice (non-
significant trend; Fig 5.2) expression of Bcl-2 may be increased (by 
approximately 25%) at P5 relative to age-matched controls. Hypothetically, 
an elevation in Tg tissue at such an early postnatal stage could occur as a 
compensatory response to either increased AD-related susceptibility to cell 
death or  dysregulated intracellular Ca2+ homeostasis such as that which has 
been observed in 3xTg-AD mice at this stage of development (Morley et al., 
2012; Zhang et al., 2010). As mentioned previously, in mice,  levels of Bcl-2 
and Bcl-XL generally decrease in the hippocampus with increasing postnatal 
age irrespective of transgenic status. Notably, this decrease in Bcl-2 
expression with postnatal developments exaggerated in transgenic 
hippocampi (significantly solely when comparing Bcl-2 expression in 
hippocampi from 3xTg-AD mice at P21 to non-Tg age-matched controls), a 
finding which suggests that transgenic neurons are, by an as yet unknown 
mechanism, unable to maintain protective Bcl-2 protein expression to the 
same extent as age-matched controls.  
Given its roles as a suppressor of ER Ca2+ release (Vervliet et al., 
2016), lower levels of Bcl- expression in hippocampi from 3xTg-AD mice may 
contribute to the enhancement of I-mGluR-mediated Ca2+ responses in Tg 
neurons under basal and depolarisation conditions, relative to non-Tg 
neurons (see Chapter 3; Fig 3.7). Furthermore, the fact that RyR (3) 
expression is significantly increased solely when comparing Tg tissue at P21 
vs P5 and is unaltered in the same developmental timeline in non-Tg 
neurons (Fig 5.2) suggests RyR upregulation may further enhance the 
magnitude of ER Ca2+ release in Tg neurons. Indeed, Zhang et al. (2010) 
showed that RyR expression increased approximately 2-fold in cultured 
3xTg-AD hippocampal neurons relative to non-Tg controls at P0-1 (13 DIV). 
Whether this increase in RyR expression was due to regulation by Bcl-2 
family proteins and/or by separate AD-driven process (including, for 
example, general disruption of normal of ER Ca2+ homeostasis, see Chapter 
3), is not clear.  
Interestingly, Bcl-2 expression and activity correlated with a 
reduction in the formation of APP (Poon et al., 2010), protects cells from Aβ-
induced toxicity (Deng et al., 1999; Saillé et al., 1999; Song et al., 2004), and 
reduces  tau-related pathology via caspase cleavage inhibition (Rohn et al., 
2008). Whether these effects occur in a manner that is dependent upon the 
previously described modulation of intracellular Ca2+ dynamics by Bcl-2 is 
however currently not clear. The exaggerated decrease of Bcl-2 expression 
observed in 3xTg-AD hippocampi (Fig 5.2) may leave this region more 
vulnerable to amyloid- and tau-related pathological insults. Furthermore, Aβo 
decrease Bcl-2 expression (Clementi et al., 2006; Lee et al., 2015; Paradis et 





expression in transgenic animal models of AD and enhance ER Ca2+ signals 
further at later stages of the disease (if the appearance of Aβo in these 
models is subsequent to diminished Bcl-2 expression). Importantly, this work 
provides entirely novel evidence of altered Bcl-2 expression in the 
hippocampus of 3xTg-AD mice in early postnatal development (P21). The 
decrease in Bcl-2 expression that we describe here is in agreement with 
previous work utilising hippocampi of 3-month-old 3xTg-AD mice (Giuliani et 
al., 2013) and the cerebral cortex of 3 - 6-month-old APPSWE and PS1∆E9 
mice (Wang et al., 2009). The relevance of this evidence of decreased Bcl-2 
and Bcl-XL expression collected from animal models to the human condition 
of AD becomes difficult to determine given that, as discussed previously (see 
table 5.2), Bcl-2 expression (which is the only Bcl-2 family member studied to 
any degree in human samples) is generally increased in brain samples from 
AD patients. It could be possible that enhanced Bcl-2 expression in the 
human brains of AD patients is an end-stage protective mechanism which 
does not reflect the early response to the disease. Alternatively, the opposite 




In summary, the data we present here suggest that in the 3xTg-AD 
model of AD, the expression profiles of Bcl-2, Bcl-XL and RyRs, combined 
with the known regulatory effects of Bcl-2 and Bcl-XL at these ER Ca2+ 
release channels, could promote dysregulated hippocampal ER Ca2+ 























































































Aarhus, R., Graeff, R.M., Dickey, D.M., Walseth, T.F., Lee, H.C., 1995. ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-
mobilizing metabolite from NADP. J. Biol. Chem. 270, 30327–30333. 
AbdAlla, S., Lother, H., el Missiry, A., Langer, A., Sergeev, P., el Faramawy, Y., Quitterer, U., 2009. Angiotensin II AT2 Receptor Oligomers 
Mediate G-protein Dysfunction in an Animal Model of Alzheimer Disease. J. Biol. Chem. 284, 6554–6565. 
Abdul-Ghani, M.A., Valiante, T.A., Carlen, P.L., Pennefather, P.S., 1996. Metabotropic glutamate receptors coupled to IP3 production mediate 
inhibition of IAHP in rat dentate granule neurons. J. Neurophysiol. 76, 2691–2700. 
Abe-Dohmae, S., Harada, N., Yamada, K., Tanaka, R., 1993. Bcl-2 gene is highly expressed during neurogenesis in the central nervous system. 
Biochem. Biophys. Res. Commun. 191, 915–21. 
Abeti, R., Duchen, M.R., 2012. Activation of PARP by Oxidative Stress Induced by ?-Amyloid: Implications for Alzheimer?s Disease. 
Neurochem. Res. 37, 2589–2596. 
Adebanjo, O.A., Anandatheerthavarada, H.K., Koval, A.P., Moonga, B.S., Biswas, G., Sun, L., Sodam, B.R., Bevis, P.J., Huang, C.L., Epstein, 
S., Lai, F.A., Avadhani, N.G., Zaidi, M., 1999. A new function for CD38/ADP-ribosyl cyclase in nuclear Ca2+ homeostasis. Nat. Cell 
Biol. 1, 409–414. 
Ahern, G.P., Junankar, P.R., Dulhunty, A.F., 1997. Subconductance states in single-channel activity of skeletal muscle ryanodine receptors after 
removal of FKBP12. Biophys. J. 72, 146–162. 
Ahlemeyer, B., Baumgart-Vogt, E., 2005. Optimized protocols for the simultaneous preparation of primary neuronal cultures of the neocortex, 
hippocampus and cerebellum from individual newborn (P0.5) C57Bl/6J mice. J. Neurosci. Methods 149, 110–20. 
Ahlijanian, M.K., Barrezueta, N.X., Williams, R.D., Jakowski, A., Kowsz, K.P., McCarthy, S., Coskran, T., Carlo, A., Seymour, P.A., Burkhardt, 
J.E., Nelson, R.B., McNeish, J.D., 2000. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing 
human p25, an activator of cdk5. Proc. Natl. Acad. Sci. U. S. A. 97. 
Ahn, K., Shelton, C.C., Tian, Y., Zhang, X., Gilchrist, M.L., Sisodia, S.S., Li, Y.-M., 2010. Activation and intrinsic gamma-secretase activity of 
presenilin 1. Proc. Natl. Acad. Sci. U. S. A. 107, 21435–40. 
Akbari, Y., Hitt, B.D., Murphy, M.P., Dagher, N.N., Tseng, B.P., Green, K.N., Golde, T.E., LaFerla, F.M., 2004. Presenilin regulates capacitative 
calcium entry dependently and independently of γ-secretase activity. Biochem. Biophys. Res. Commun. 322, 1145–1152. 
Akl, H., Vervloessem, T., Kiviluoto, S., Bittremieux, M., Parys, J.B., De Smedt, H., Bultynck, G., 2014. A dual role for the anti-apoptotic Bcl-2 
protein in cancer: Mitochondria versus endoplasmic reticulum. Biochim. Biophys. Acta - Mol. Cell Res. 1843, 2240–2252. 
Aksoy, P., Escande, C., White, T.A., Thompson, M., Soares, S., Benech, J.C., Chini, E.N., 2006a. Regulation of SIRT 1 mediated NAD 
dependent deacetylation: A novel role for the multifunctional enzyme CD38. Biochem. Biophys. Res. Commun. 349, 353–359. 
Aksoy, P., White, T.A., Thompson, M., Chini, E.N., 2006b. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem. Biophys. 
Res. Commun. 345, 1386–92. 
Alano, C.C., Garnier, P., Ying, W., Higashi, Y., Kauppinen, T.M., Swanson, R.A., 2010. NAD+ depletion is necessary and sufficient for 
poly(ADP-ribose) polymerase-1-mediated neuronal death. J. Neurosci. 30, 2967–78. 
Albasanz, J.L., Dalfó, E., Ferrer, I., Martín, M., 2005. Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the 
cerebral cortex in Alzheimer’s disease and dementia with Lewy bodies correlates with stage of Alzheimer’s-disease-related changes. 
Neurobiol. Dis. 20, 685–693. 
Allen, N.J., Barres, B.A., 2009. Neuroscience: Glia - more than just brain glue. Nature 457. 
Ally, B.A., Hussey, E.P., Ko, P.C., Molitor, R.J., 2013. Pattern separation and pattern completion in Alzheimer’s disease: Evidence of rapid 
forgetting in amnestic mild cognitive impairment. Hippocampus 23, 1246–1258. 
Alonso, A. d. C., Li, B., Grundke-Iqbal, I., Iqbal, K., 2006. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory 
activity. Proc. Natl. Acad. Sci. 103, 8864–8869. 
Alonso, A.C., Grundke-Iqbal, I., Iqbal, K., 1996. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments 
and disassembles microtubules. Nat. Med. 2, 783–7. 
Alonso, A.C., Zaidi, T., Grundke-Iqbal, I., Iqbal, K., 1994. Role of abnormally phosphorylated tau in the breakdown of microtubules in 
Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91, 5562–6. 
Alonso, A.D., Grundke-Iqbal, I., Barra, H.S., Iqbal, K., 1997. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary 
degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. 
Natl. Acad. Sci. U. S. A. 94, 298–303. 
Alves da Costa, C., Sunyach, C., Pardossi-Piquard, R., Sevalle, J., Vincent, B., Boyer, N., Kawarai, T., Girardot, N., St. George-Hyslop, P., 
Checler, F., 2006. Presenilin-Dependent  -Secretase-Mediated Control of p53-Associated Cell Death in Alzheimer’s Disease. J. Neurosci. 
26, 6377–6385. 
Alzheimer’s Association, 2016. 2016 Alzheimer’s disease facts and figures. Alzheimers. Dement. 12, 459–509. 
An, W.-L., Cowburn, R.F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.-G., Winblad, B., Pei, J.-J., 2003. Up-Regulation of 
Phosphorylated/Activated p70 S6 Kinase and Its Relationship to Neurofibrillary Pathology in Alzheimer’s Disease. Am. J. Pathol. 163, 
591–607. 
Andrew, R.J., Kellett, K.A.B., Thinakaran, G., Hooper, N.M., 2016. A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid 
Precursor Protein Proteolysis. J. Biol. Chem. 291, 19235–19244. 
Annaert, W.G., Levesque, L., Craessaerts, K., Dierinck, I., Snellings, G., Westaway, D., St. George-Hyslop, P., Cordell, B., Fraser, P., De 
Strooper, B., 1999. Presenilin 1 controls γ-secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal 
neurons. J. Cell Biol. 147. 
Annis, M.G., Zamzami, N., Zhu, W., Penn, L.Z., Kroemer, G., Leber, B., Andrews, D.W., 2001. Endoplasmic reticulum localized Bcl-2 prevents 
apoptosis when redistribution of cytochrome c is a late event. Oncogene 20, 1939–1952. 
Anwyl, R., 1999. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res. Brain Res. Rev. 29, 83–120. 
Araque, A., Navarrete, M., 2010. Glial cells in neuronal network function. Philos. Trans. R. Soc. B Biol. Sci. 365. 
Arimura, N., Kaibuchi, K., 2005. Key Regulators in Neuronal Polarity. Neuron 48, 881–884. 
Arispe, N., Pollard, H.B., Rojas, E., 1993a. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] 
in bilayer membranes. Proc. Natl. Acad. Sci. U. S. A. 90, 10573–7. 
Arispe, N., Rojas, E., Pollard, H.B., 1993b. Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: Blockade by 





Armato, U., Chiarini, A., Chakravarthy, B., Chioffi, F., Pacchiana, R., Colarusso, E., Whitfield, J.F., Dal Prà, I., 2013. Calcium-sensing receptor 
antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Aβ42 prompted by exogenous fibrillary or 
soluble Aβ25–35 in human cortical astrocytes and neurons—Therapeutic relevance to Alzheimer’s disease. Biochim. Biophys. Acta - 
Mol. Basis Dis. 1832, 1634–1652. 
Arnaudeau, S., Kelley, W.L., Walsh Jr., J.V., Demaurex, N., 2001. Mitochondria Recycle Ca2+ to the Endoplasmic Reticulum and Prevent the 
Depletion of Neighboring Endoplasmic Reticulum Regions. J. Biol. Chem. 276. 
Arnold, S.E., Louneva, N., Cao, K., Wang, L.-S., Han, L.-Y., Wolk, D.A., Negash, S., Leurgans, S.E., Schneider, J.A., Buchman, A.S., Wilson, 
R.S., Bennett, D.A., 2013. Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer’s disease. Neurobiol. Aging 
34, 157–168. 
Arora, M., 2013. Cell Culture Media: A Review. Mater. Methods 3. 
Askarova, S., Yang, X., Lee, J.C.-M., 2011. Impacts of Membrane Biophysics in Alzheimer’s Disease: From Amyloid Precursor Protein 
Processing to A β Peptide-Induced Membrane Changes. Int. J. Alzheimers. Dis. 2011, 1–12. 
Atlas, D., 2013. The Voltage-Gated Calcium Channel Functions as the Molecular Switch of Synaptic Transmission. Annu. Rev. Biochem. 82, 
607–635. 
Auffret, A., Gautheron, V., Mattson, M.P., Mariani, J., Rovira, C., 2010. Progressive age-related impairment of the late long-term potentiation in 
Alzheimer’s disease presenilin-1 mutant knock-in mice. J. Alzheimers. Dis. 19, 1021–33. 
Augustine, G.J., Finch, E.A., 1998. Local calcium signalling by inositol-1,4,5-trisphosphate in Purkinje cell dendrites. Nature 396, 753–756. 
Auld, D.S., Robitaille, R., 2003. Glial cells and neurotransmission: an inclusive view of synaptic function. Neuron 40, 389–400. 
Ayar, A., Scott, R.H., 1999. The actions of ryanodine on Ca2+-activated conductances in rat cultured DRG neurones; evidence for Ca2+-induced 
Ca2+ release. Naunyn-Schmiedeberg’s archives of pharmacology. 359, 81–91. 
Ayub, K., Hallett, M.B., 2004. The mitochondrial ADPR link between Ca2+ store release and Ca2+ influx channel opening in immune cells. 
FASEB J. 18, 1335–1338. 
Azarashvili, T., Baburina, Y., Grachev, D., Krestinina, O., Evtodienko, Y., Stricker, R., Reiser, G., 2011. Calcium-induced permeability transition 
in rat brain mitochondria is promoted by carbenoxolone through targeting connexin43. AJP Cell Physiol. 300, C707–C720. 
Ba, F., Pang, P.K.T., Benishin, C.G., 2004. The role of Ca2+ channel modulation in the neuroprotective actions of estrogen in β-amyloid protein 
and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) cytotoxic models. Neurochem. Int. 45. 
Baba, A., Yasui, T., Fujisawa, S., Yamada, R.X., Yamada, M.K., Nishiyama, N., Matsuki, N., Ikegaya, Y., 2003. Activity-evoked capacitative 
Ca2+ entry: implications in synaptic plasticity. J. Neurosci. 23, 7737–41. 
Baccaglini, P.I., Spitzer, N.C., 1977. Developmental changes in the inward current of the action potential of Rohon-Beard neurones. J. Physiol. 
271, 93–117. 
Bacher, I., Zidar, A., Kratzel, M., Hohenegger, M., 2004. Channelling of substrate promiscuity of the skeletal-muscle ADP-ribosyl cyclase 
isoform. Biochem. J. 381, 147–154. 
Backman, L., Small, B.J., Fratiglioni, L., 2001. Stability of the preclinical episodic memory deficit in Alzheimer’s disease. Brain 124, 96–102. 
Baffy, G., Miyashita, T., Williamson, J.R., Reed, J.C., 1993. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent 
hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. 
J. Biol. Chem. 268, 6511–9. 
Bai, J.-Z., Lipski, J., 2010. Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death 
in organotypic hippocampal culture. Neurotoxicology 31, 204–214. 
Balazs, R., 2006. Trophic effect of glutamate. Curr. Top. Med. Chem. 6, 961–8. 
Bales, K.R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J.C., Sullivan, P.M., Paul, S.M., 2009. Human APOE Isoform-Dependent 
Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice. J. Neurosci. 29. 
Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., Wisniewski, H.M., 
1989. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain 
Res. 477, 90–9. 
Bandara, S., Malmersjö, S., Meyer, T., 2013. Regulators of Calcium Homeostasis Identified by Inference of Kinetic Model Parameters from Live 
Single Cells Perturbed by siRNA. Sci. Signal. 6. 
Banerjee, S., Walseth, T.F., Borgmann, K., Wu, L., Bidasee, K.R., Kannan, M.S., Ghorpade, A., 2008. CD38/cyclic ADP-ribose regulates 
astrocyte calcium signaling: implications for neuroinflammation and HIV-1-associated dementia. J. Neuroimmune Pharmacol. 3, 154–64. 
Banker, G. a, Cowan, W.M., 1979. Further observations on hippocampal neurons in dispersed cell culture. J. Comp. Neurol. 187, 469–93. 
Banker, G.A., 1980. Trophic interactions between astroglial cells and hippocampal neurons in culture. Science (80-. ). 209. 
Banker, G.A., Cowan, W.M., 1977. Rat hippocampal neurons in dispersed cell culture. Brain Res. 126, 397–42. 
Bannister, N.J., Larkman, A.U., 1995. Dendritic morphology of CA1 pyramidal neurones from the rat hippocampus: II. Spine distributions. J. 
Comp. Neurol. 360, 161–171. 
Barbosa, M.T.P., Soares, S.M., Novak, C.M., Sinclair, D., Levine, J.A., Aksoy, P., Chini, E.N., 2007. The enzyme CD38 (a NAD glycohydrolase, 
EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J. 21, 3629–39. 
Barde, Y.A., 1989. Trophic factors and neuronal survival. Neuron 2, 1525–34. 
Barisione, G., Baroffio, M., Crimi, E., Brusasco, V., 2010. Beta-Adrenergic Agonists. Pharmaceuticals (Basel). 3, 1016–1044. 
Barker, A.J., Ullian, E.M., 2008. New roles for astrocytes in developing synaptic circuits. Commun. Integr. Biol. 1, 207–11. 
Baron, M., 2003. An overview of the Notch signalling pathway. Semin. Cell Dev. Biol. 14, 113–9. 
Barone, F., Genazzani, A.A., Conti, A., Churchill, G.C., Palombi, F., Ziparo, E., Sorrentino, V., Galione, A., Filippini, A., 2002. A pivotal role 
for cADPR-mediated Ca2+ signaling: regulation of endothelin-induced contraction in peritubular smooth muscle cells. FASEB J. 16, 
697–705. 
Barrow, P.A., Empson, R.M., Gladwell, S.J., Anderson, C.M., Killick, R., Yu, X., Jefferys, J.G.R., Duff, K., 2000. Functional Phenotype in 
Transgenic Mice Expressing Mutant Human Presenilin-1. Neurobiol. Dis. 7, 119–126. 
Barry, A.E., Klyubin, I., McDonald, J.M., Mably, A.J., Farrell, M.A., Scott, M., Walsh, D.M., Rowan, M.J., 2011. Alzheimer’s disease brain-
derived amyloid-β-mediated inhibition of LTP In Vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 31. 
Barucker, C., Sommer, A., Beckmann, G., Eravci, M., Harmeier, A., Schipke, C.G., Brockschnieder, D., Dyrks, T., Althoff, V., Fraser, P.E., 





Expression of Transcription and Growth Factors. J. Alzheimer’s Dis. 44, 613–624. 
Bashir, Z.I., 2003. On long-term depression induced by activation of G-protein coupled receptors. Neurosci. Res. 45, 363–367. 
Bastide, B., Snoeckx, K., Mounier, Y., 2002. ADP-ribose stimulates the calcium release channel RyR1 in skeletal muscle of rat. Biochem. 
Biophys. Res. Commun. 296, 1267–71. 
Batchelor, A.M., Garthwaite, J., 1997. Frequency detection and temporally dispersed synaptic signal association through a metabotropic 
glutamate receptor pathway. Nature 385, 74–77. 
Bate, C., Williams, A., 2011. Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J. Biol. Chem. 286, 
37955–63. 
Baude, A., Nusser, Z., Roberts, J.D.B., Mulvihill, E., Jeffrey Mcllhinney, R.A., Somogyi, P., 1993. The metabotropic glutamate receptor 
(mGluRlα) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction. Neuron 11, 771–
787. 
Baughman, J.M., Perocchi, F., Girgis, H.S., Plovanich, M., Belcher-Timme, C.A., Sancak, Y., Bao, X.R., Strittmatter, L., Goldberger, O., 
Bogorad, R.L., Koteliansky, V., Mootha, V.K., 2011. Integrative genomics identifies MCU as an essential component of the 
mitochondrial calcium uniporter. Nature 476, 341–345. 
Bazargani, N., Attwell, D., 2016. Astrocyte calcium signaling: the third wave. Nat. Neurosci. 19, 182–189. 
Bear, M.F., Malenka, R.C., 1994. Synaptic plasticity: LTP and LTD. Curr. Opin. Neurobiol. 4, 389–399. 
Beaudoin, G.M.J., Lee, S.-H., Singh, D., Yuan, Y., Ng, Y.-G., Reichardt, L.F., Arikkath, J., Beaudoin III, G.M.J., Seung-Hye L, D.S., Yang Y, 
Y.-G.N., Reichardt L.F, A.J., Beaudoin, G.M.J., Lee, S.-H., Singh, D., Yuan, Y., Ng, Y.-G., Reichardt, L.F., Arikkath, J., 2012. 
Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat. Protoc. 7, 1741–1754. 
Becker, J.T., Walker, J.A., Olton, D.S., 1980. Neuroanatomical bases of spatial memory. Brain Res. 200, 307–320. 
Beecham, G.W., Schnetz-Boutaud, N., Haines, J.L., Pericak-Vance, M.A., 2009. CALHM1 polymorphism is not associated with late-onset 
Alzheimer disease. Ann. Hum. Genet. 73, 379–81. 
Beffert, U., Stolt, P.C., Herz, J., 2004. Functions of lipoprotein receptors in neurons. J. Lipid Res. 45, 403–9. 
Beglopoulos, V., Sun, X., Saura, C.A., Lemere, C.A., Kim, R.D., Shen, J., 2004. Reduced β-amyloid production and increased inflammatory 
responses in presenilin conditional knock-out mice. J. Biol. Chem. 279. 
Bekris, L.M., Yu, C.-E., Bird, T.D., Tsuang, D.W., 2010. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 23, 213–27. 
Belleville, S., Sylvain-Roy, S., de Boysson, C., Ménard, M.-C., 2008. Chapter 23 Characterizing the memory changes in persons with mild 
cognitive impairment. In: Progress in Brain Research. pp. 365–375. 
Bellone, C., Lüscher, C., Mameli, M., 2008. Mechanisms of synaptic depression triggered by metabotropic glutamate receptors. Cell. Mol. Life 
Sci. 65, 2913–2923. 
Benarroch, E.E., 2008. Metabotropic glutamate receptors: synaptic modulators and therapeutic targets for neurologic disease. Neurology 70, 964–
8. 
Bennett, D.L., Cheek, T.R., Berridge, M.J., De Smedt, H., Parys, J.B., Missiaen, L., Bootman, M.D., 1996. Expression and function of ryanodine 
receptors in nonexcitable cells. J. Biol. Chem. 271, 6356–62. 
Bennett, M.V.L., Garr?, J.M., Orellana, J.A., Bukauskas, F.F., Nedergaard, M., Giaume, C., S?ez, J.C., 2012. Connexin and pannexin 
hemichannels in inflammatory responses of glia and neurons. Brain Res. 1487, 3–15. 
Benninger, C., Kadis, J., Prince, D.A., 1980. Extracellular calcium and potassium changes in hippocampal slices. Brain Res. 187, 165–82. 
Benson, D.L., Watkins, F.H., Steward, O., Banker, G., 1994. Characterization of GABAergic neurons in hippocampal cell cultures. J. Neurocytol. 
23, 279–95. 
Bentahir, M., Nyabi, O., Verhamme, J., Tolia, A., Horre, K., Wiltfang, J., Esselmann, H., Strooper, B., 2006. Presenilin clinical mutations can 
affect gamma-secretase activity by different mechanisms. J. Neurochem. 96, 732–742. 
Beraldo, F.H., Arantes, C.P., Santos, T.G., Machado, C.F., Roffe, M., Hajj, G.N., Lee, K.S., Magalhães, A.C., Caetano, F.A., Mancini, G.L., 
Lopes, M.H., Américo, T.A., Magdesian, M.H., Ferguson, S.S.G., Linden, R., Prado, M.A., Martins, V.R., 2011. Metabotropic glutamate 
receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin $γ$1 chain. FASEB J 25. 
Beraldo, F.H., Ostapchenko, V.G., Caetano, F.A., Guimaraes, A.L.S., Ferretti, G.D.S., Daude, N., Bertram, L., Nogueira, K.O.P.C., Silva, J.L., 
Westaway, D., Cashman, N.R., Martins, V.R., Prado, V.F., Prado, M.A.M., 2016. Regulation of Amyloid β Oligomer Binding to 
Neurons and Neurotoxicity by the Prion Protein-mGluR5 Complex. J. Biol. Chem. 291, 21945–21955. 
Berg, L., McKeel, D.W., Miller, J.P., Storandt, M., Rubin, E.H., Morris, J.C., Baty, J., Coats, M., Norton, J., Goate, A.M., Price, J.L., Gearing, 
M., Mirra, S.S., Saunders, A.M., 1998. Clinicopathologic studies in cognitively healthy aging and Alzheimer’s disease: relation of 
histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55, 326–35. 
Bergner, A., Huber, R.M., 2008. Regulation of the endoplasmic reticulum Ca(2+)-store in cancer. Anticancer. Agents Med. Chem. 8. 
Berna-Erro, A., Braun, A., Kraft, R., Kleinschnitz, C., Schuhmann, M.K., Stegner, D., Wultsch, T., Eilers, J., Meuth, S.G., Stoll, G., Nieswandt, 
B., 2009. STIM2 Regulates Capacitive Ca2+ Entry in Neurons and Plays a Key Role in Hypoxic Neuronal Cell Death. Sci. Signal. 2, 
ra67-ra67. 
Bernstein, M., Behnisch, T., Balschun, D., Reymann, K.G., Reiser, G., 1998. Pharmacological characterisation of metabotropic glutamatergic and 
purinergic receptors linked to Ca2+ signalling in hippocampal astrocytes. Neuropharmacology 37, 169–78. 
Berridge, M.J., 1998. Neuronal calcium signaling. Neuron 21, 13–26. 
Berridge, M.J., 2002. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 32, 235–249. 
Berridge, M.J., 2006. Calcium microdomains: Organization and function. Cell Calcium 40, 405–412. 
Berridge, M.J., 2010. Calcium hypothesis of Alzheimer’s disease. Pflügers Arch. - Eur. J. Physiol. 459, 441–449. 
Berridge, M.J., 2012. Calcium signalling remodelling and disease. Biochem. Soc. Trans. 40, 297–309. 
Berridge, M.J., 2014a. Module 2: Cell Signalling Pathways. Cell Signal. Biol. 6, csb0001002. 
Berridge, M.J., 2014b. Calcium regulation of neural rhythms, memory and Alzheimer’s disease. J. Physiol. 592, 281–293. 
Berridge, M.J., Bootman, M.D., Roderick, H.L., 2003. Calcium: Calcium signalling: dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell 
Biol. 4, 517–529. 
Berridge, M.J., Lipp, P., Bootman, M.D., 2000. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 1, 11–21. 





function of aging and Alzheimer’s neuropathology. Biochim. Biophys. Acta - Mol. Basis Dis. 1852, 1465–1476. 
Berrocal, M., Sepulveda, M.R., Vazquez-Hernandez, M., Mata, A.M., 2012. Calmodulin antagonizes amyloid-β peptides-mediated inhibition of 
brain plasma membrane Ca2+-ATPase. Biochim. Biophys. Acta - Mol. Basis Dis. 1822, 961–969. 
Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., Tanzi, R.E., 2007. Systematic meta-analyses of Alzheimer disease genetic association 
studies: the AlzGene database. Nat. Genet. 39, 17–23. 
Bertram, L., Schjeide, B.-M.M., Hooli, B., Mullin, K., Hiltunen, M., Soininen, H., Ingelsson, M., Lannfelt, L., Blacker, D., Tanzi, R.E., 2008. No 
association between CALHM1 and Alzheimer’s disease risk. Cell 135, 993-4; author reply 994-6. 
Bertram, L., Tanzi, R.E., 2004a. Alzheimer’s disease: one disorder, too many genes? Hum. Mol. Genet. 13, 135R–141. 
Bertram, L., Tanzi, R.E., 2004b. The current status of Alzheimer?s disease genetics: what do we tell the patients? Pharmacol. Res. 50, 385–396. 
Beutner, G., Sharma, V.K., Lin, L., Ryu, S.-Y., Dirksen, R.T., Sheu, S.-S., 2005. Type 1 ryanodine receptor in cardiac mitochondria: Transducer 
of excitation-metabolism coupling. Biochim. Biophys. Acta - Biomembr. 1717. 
Bezprozvanny,  llya, Watras, J., Ehrlich, B.E., 1991. Bell-shaped calcium-response curves of lns(l,4,5)P3- and calcium-gated channels from 
endoplasmic reticulum of cerebellum. Nature 351, 751–754. 
Bezprozvanny, I., Hiesinger, P., Andre, V., Cummings, D., Levine, M., Shen, J., Sudhof, T., Shen, J., Xia, W., Tesco, G., Abeliovich, A., 2013. 
The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration. Mol. Neurodegener. 8, 23. 
Bezprozvanny, I., Mattson, M.P.M.P., 2008. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci. 31, 
454–463. 
Bezprozvanny, I., Supnet, C., Sun, S., Zhang, H., De Strooper, B., 2012. Response to Shilling et al. (10.1074/jbc.M111.300491). J. Biol. Chem. 
287, 20469; author reply 20470. 
Bianchi, R., Young, S.R., Wong, R.K., 1999. Group I mGluR activation causes voltage-dependent and -independent Ca2+ rises in hippocampal 
pyramidal cells. J. Neurophysiol. 81, 2903–13. 
Biber, K., Laurie, D.J., Berthele, A., Sommer, B., Tölle, T.R., Gebicke-Härter, P.J., van Calker, D., Boddeke, H.W., 1999. Expression and 
signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem. 72, 1671–80. 
Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Wang, C., Huang, Y., 2011. C-terminal-truncated apolipoprotein (apo) E4 inefficiently 
clears amyloid-β (Aβ) and acts in concert with Aβ to elicit neuronal and behavioral deficits in mice. Proc. Natl. Acad. Sci. U. S. A. 108. 
Billings, L.M., Oddo, S., Green, K.N., McGaugh, J.L., LaFerla, F.M., 2005. Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-
Related Cognitive Deficits in Transgenic Mice. Neuron 45, 675–688. 
Birben, E., Sahiner, U.M., Sackesen, C., Erzurum, S., Kalayci, O., 2012. Oxidative stress and antioxidant defense. World Allergy Organ. J. 5, 9–
19. 
Blacher, E., Dadali, T., Bespalko, A., Haupenthal, V.J., Grimm, M.O.W., Hartmann, T., Lund, F.E., Stein, R., Levy, A., 2015. Alzheimer’s 
disease pathology is attenuated in a CD38-deficient mouse model. Ann. Neurol. 78, 88–103. 
Black, S.A.G., Stys, P.K., Zamponi, G.W., Tsutsui, S., 2014. Cellular prion protein and NMDA receptor modulation: protecting against 
excitotoxicity. Front. cell Dev. Biol. 2, 45. 
Blanchard, B.J., Thomas, V.L., Ingram, V.M., 2002. Mechanism of membrane depolarization caused by the Alzheimer Aβ1–42 peptide. 
Biochem. Biophys. Res. Commun. 293, 1197–1203. 
Bleasdale, J.E., Thakur, N.R., Gremban, R.S., Bundy, G.L., Fitzpatrick, F.A., Smith, R.J., Bunting, S., 1990. Selective inhibition of receptor-
coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J. Pharmacol. Exp. Ther. 255, 
756–68. 
Bliss, T.V.P., Cooke, S.F., 2011. Long-term potentiation and long-term depression: a clinical perspective. Clinics 66, 3–17. 
Bloom, G.S., 2014. Amyloid-$β$ and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71. 
Boada, M., Antúnez, C., López-Arrieta, J., Galán, J.J., Morón, F.J., Hernández, I., Marín, J., Martínez-Lage, P., Alegret, M., Carrasco, J.M., 
Moreno, C., Real, L.M., González-Pérez, A., Tárraga, L., Ruiz, A., 2010. CALHM1 P86L Polymorphism is Associated with Late-Onset 
Alzheimer’s Disease in a Recessive Model. J. Alzheimer’s Dis. 20, 247–251. 
Bode, D.C., Baker, M.D., Viles, J.H., 2017. Ion Channel Formation by Amyloid-β42 Oligomers but Not Amyloid-β40 in Cellular Membranes. J. 
Biol. Chem. 292, 1404–1413. 
Boehning, D., Patterson, R.L., Sedaghat, L., Glebova, N.O., Kurosaki, T., Snyder, S.H., 2003. Cytochrome c binds to inositol (1,4,5) 
trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat. Cell Biol. 5, 1051–1061. 
Boise, L.H., González-García, M., Postema, C.E., Ding, L., Lindsten, T., Turka, L.A., Mao, X., Nuñez, G., Thompson, C.B., 1993. bcl-x, a bcl-2-
related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597–608. 
Bojarski, L., Pomorski, P., Szybinska, A., Drab, M., Skibinska-Kijek, A., Gruszczynska-Biegala, J., Kuznicki, J., 2009. Presenilin-dependent 
expression of STIM proteins and dysregulation of capacitative Ca2+ entry in familial Alzheimer’s disease. Biochim. Biophys. Acta - 
Mol. Cell Res. 1793, 1050–1057. 
Bolshakov, V.Y., Carboni, L., Cobb, M.H., Siegelbaum, S.A., Belardetti, F., 2000. Dual MAP kinase pathways mediate opposing forms of long-
term plasticity at CA3–CA1 synapses. Nat. Neurosci. 3, 1107–1112. 
Bonneau, B., Prudent, J., Popgeorgiev, N., Gillet, G., 2013. Non-apoptotic roles of Bcl-2 family: The calcium connection. Biochim. Biophys. 
Acta - Mol. Cell Res. 1833, 1755–1765. 
Bootman, M.D., Collins, T.J., Mackenzie, L., Roderick, H.L., Berridge, M.J., Peppiatt, C.M., 2002. 2-Aminoethoxydiphenyl borate (2-APB) is a 
reliable blocker of store-operated Ca2+ entry but an inconsistent inhibitor of InsP3-induced Ca2+ release. FASEB J. 16, 1145–1150. 
Boraso, M., Viviani, B., 2011. Glia-neuron sandwich cocultures: An in vitro approach to evaluate cell-to-cell communication in 
neuroinflammation and neurotoxicity. Methods Mol. Biol. 758, 135–152. 
Borchelt, D.R., Thinakaran, G., Eckman, C.B., Lee, M.K., Davenport, F., Ratovitsky, T., Prada, C.M., Kim, G., Seekins, S., Yager, D., Slunt, 
H.H., Wang, R., Seeger, M., Levey, A.I., Gandy, S.E., Copeland, N.G., Jenkins, N.A., Price, D.L., Younkin, S.G., Sisodia, S.S., 1996. 
Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005–13. 
Bortolotto, Z.A., Collingridge, G.L., 1995. On the mechanism of long-term potentiation induced by (1S,3R)-1-aminocyclopentane-1,3-
dicarboxylic acid (ACPD) in rat hippocampal slices. Neuropharmacology 34, 1003–14. 
Bortolotto, Z.A., Fitzjohn, S.M., Collingridge, G.L., 1999. Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Curr. 
Opin. Neurobiol. 9, 299–304. 
Bouzier-Sore, A.-K., Voisin, P., Canioni, P., Magistretti, P.J., Pellerin, L., 2003. Lactate Is a Preferential Oxidative Energy Substrate Over 





Boyles, J.K., Zoellner, C.D., Anderson, L.J., Kosik, L.M., Pitas, R.E., Weisgraber, K.H., Hui, D.Y., Mahley, R.W., Gebicke-Haerter, P.J., 
Ignatius, M.J., 1989. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during 
regeneration and remyelination of the rat sciatic nerve. J. Clin. Invest. 83, 1015–1031. 
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., Tredici, K., 2006. Staging of Alzheimer disease-associated neurofibrillary pathology 
using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389–404. 
Braak, H., Braak, E., 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–59. 
Bradley, K.N., Currie, S., MacMillan, D., Muir, T.C., McCarron, J.G., 2003. Cyclic ADP-ribose increases Ca2+ removal in smooth muscle. J. 
Cell Sci. 116, 4291–306. 
Bradley, S.A., Steinert, J.R., 2016. Nitric Oxide-Mediated Posttranslational Modifications: Impacts at the Synapse. Oxid. Med. Cell. Longev. 
2016, 1–9. 
Braidy, N., Guillemin, G., Grant, R., 2008. Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and 
Alzheimer’s disease. Neurotox. Res. 13, 173–84. 
Braidy, N., Jayasena, T., Poljak, A., Sachdev, P.S., 2012. Sirtuins in cognitive ageing and Alzheimer?s disease. Curr. Opin. Psychiatry 25, 226–
230. 
Braithwaite, S.P., Schmid, R.S., He, D.N., Sung, M.L.A., Cho, S., Resnick, L., Monaghan, M.M., Hirst, W.D., Essrich, C., Reinhart, P.H., Lo, 
D.C., 2010. Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer’s disease. Neurobiol. Dis. 39. 
Bramham, C.R., Alme, M.N., Bittins, M., Kuipers, S.D., Nair, R.R., Pai, B., Panja, D., Schubert, M., Soule, J., Tiron, A., Wibrand, K., 2010. The 
Arc of synaptic memory. Exp. brain Res. 200, 125–40. 
Brandman, O., Liou, J., Park, W.S., Meyer, T., 2007. STIM2 Is a Feedback Regulator that Stabilizes Basal Cytosolic and Endoplasmic Reticulum 
Ca2+ Levels. Cell 131. 
Breunig, J.J., Guillot-Sestier, M.-V., Town, T., 2013. Brain injury, neuroinflammation and Alzheimer’s disease. Front. Aging Neurosci. 5, 26. 
Brewer, G.J., 1997. Isolation and culture of adult rat hippocampal neurons. J. Neurosci. Methods 71, 143–55. 
Brewer, G.J., 1998. Age-related toxicity to lactate, glutamate, and beta-amyloid in cultured adult neurons. Neurobiol. Aging 19, 561–568. 
Brewer, G.J., Boehler, M.D., Jones, T.T., Wheeler, B.C., 2008. NbActiv4 medium improvement to Neurobasal/B27 increases neuron synapse 
densities and network spike rates on multielectrode arrays. J. Neurosci. Methods 170, 181–7. 
Brewer, G.J., Cotman, C.W., 1989. Survival and growth of hippocampal neurons in defined medium at low density: advantages of a sandwich 
culture technique or low oxygen. Brain Res. 494, 65–74. 
Brewer, G.J., Lim, A., Capps, N.G., Torricelli, J.R., 2005. Age-related calcium changes, oxyradical damage, caspase activation and nuclear 
condensation in hippocampal neurons in response to glutamate and beta-amyloid. Exp. Gerontol. 40, 426–437. 
Brewer, G.J., Reichensperger, J.D., Brinton, R.D., 2006. Prevention of age-related dysregulation of calcium dynamics by estrogen in neurons. 
Neurobiol. Aging 27, 306–17. 
Brewer, G.J., Torricelli, J.R., 2007. Isolation and culture of adult neurons and neurospheres. Nat. Protoc. 2, 1490–8. 
Brewer, G.J., Torricelli, J.R., Evege, E.K., Price, P.J., 1993. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new 
serum-free medium combination. J. Neurosci. Res. 35, 567–76. 
Brewster, J.L., Linseman, D.A., Bouchard, R.J., Loucks, F.A., Precht, T.A., Esch, E.A., Heidenreich, K.A., 2006. Endoplasmic reticulum stress 
and trophic factor withdrawal activate distinct signaling cascades that induce glycogen synthase kinase-3β and a caspase-9-dependent 
apoptosis in cerebellar granule neurons. Mol. Cell. Neurosci. 32, 242–253. 
Brickell, K.L., Steinbart, E.J., Rumbaugh, M., Payami, H., Schellenberg, G.D., Van Deerlin, V., Yuan, W., Bird, T.D., 2006. Early-Onset 
Alzheimer Disease in Families With Late-Onset Alzheimer Disease. Arch. Neurol. 63, 1307. 
Brier, M.R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N.J., 
Holtzman, D.M., Fagan, A.M., Morris, J.C., Benzinger, T.L.S., Ances, B.M., 2016. Tau and Aβ imaging, CSF measures, and cognition in 
Alzheimer’s disease. Sci. Transl. Med. 8. 
Briggs, C.A., Chakroborty, S., Stutzmann, G.E., 2017. Emerging pathways driving early synaptic pathology in Alzheimer’s disease. Biochem. 
Biophys. Res. Commun. 483, 988–997. 
Briggs, C.A., Schneider, C., Richardson, J.C., Stutzmann, G.E., 2013. Beta amyloid peptide plaques fail to alter evoked neuronal calcium signals 
in APP/PS1 Alzheimer’s disease mice. Neurobiol. Aging 34, 1632–1643. 
Brower, M., Grace, M., Kotz, C.M., Koya, V., 2015. Comparative analysis of growth characteristics of Sprague Dawley rats obtained from 
different sources. Lab. Anim. Res. 31, 166–73. 
Brown, J.T., Chin, J., Leiser, S.C., Pangalos, M.N., Randall, A.D., 2011. Altered intrinsic neuronal excitability and reduced Na+ currents in a 
mouse model of Alzheimer’s disease. Neurobiol. Aging 32, 2109.e1-2109.e14. 
Bruno, A.M., Huang, J.Y., Bennett, D.A., Marr, R.A., Hastings, M.L., Stutzmann, G.E., 2011. Altered ryanodine receptor expression in mild 
cognitive impairment and Alzheimer’s disease. Neurobiol. Aging 33, 1001.e1-1001.e6. 
Bruno, V., Ksiazek, I., Battaglia, G., Lukic, S., Leonhardt, T., Sauer, D., Gasparini, F., Kuhn, R., Nicoletti, F., Flor, P.J., 2000. Selective blockade 
of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39, 2223–30. 
Bruzzone, S., Basile, G., Chothi, M.P., Nobbio, L., Usai, C., Jacchetti, E., Schenone, A., Guse, A.H., Di Virgilio, F., De Flora, A., Zocchi, E., 
2010. Diadenosine homodinucleotide products of ADP-ribosyl cyclases behave as modulators of the purinergic receptor P2X7. J. Biol. 
Chem. 285, 21165–74. 
Bruzzone, S., De Flora, A., Usai, C., Graeff, R., Lee, H.C., 2003a. Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated 
proliferation of human peripheral blood mononuclear cells. Biochem. J. 375, 395–403. 
Bruzzone, S., Dodoni, G., Kaludercic, N., Basile, G., Millo, E., De Flora, A., Di Lisa, F., Zocchi, E., 2007. Mitochondrial dysfunction induced by 
a cytotoxic adenine dinucleotide produced by ADP-ribosyl cyclases from cADPR. J. Biol. Chem. 282, 5045–52. 
Bruzzone, S., Franco, L., Guida, L., Zocchi, E., Contini, P., Bisso, A., Usai, C., De Flora, A., 2001. A self-restricted CD38-connexin 43 cross-talk 
affects NAD+ and cyclic ADP-ribose metabolism and regulates intracellular calcium in 3T3 fibroblasts. J. Biol. Chem. 276, 48300–8. 
Bruzzone, S., Kunerth, S., Zocchi, E., De Flora, A., Guse, A.H., 2003b. Spatio-temporal propagation of Ca2+ signals by cyclic ADP-ribose in 
3T3 cells stimulated via purinergic P2Y receptors. J. Cell Biol. 163, 837–45. 
Bruzzone, S., Verderio, C., Schenk, U., Fedele, E., Zocchi, E., Matteoli, M., De Flora, A., 2004. Glutamate-mediated overexpression of CD38 in 
astrocytes cultured with neurones. J. Neurochem. 89, 264–272. 
Bu, G., 2009. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333–344. 





Buckmaster, C.A., Eichenbaum, H., Amaral, D.G., Suzuki, W.A., Rapp, P.R., 2004. Entorhinal cortex lesions disrupt the relational organization 
of memory in monkeys. J. Neurosci. 24, 9811–25. 
Budde, T., Sieg, F., Braunewell, K.H., Gundelfinger, E.D., Pape, H.C., 2000. Ca2+-induced Ca2+ release supports the relay mode of activity in 
thalamocortical cells. Neuron 26, 483–92. 
Bultynck, G., Rossi, D., Callewaert, G., Missiaen, L., Sorrentino, V., Parys, J.B., De Smedt, H., 2001. The conserved sites for the FK506-binding 
proteins in ryanodine receptors and inositol 1,4,5-trisphosphate receptors are structurally and functionally different. J. Biol. Chem. 276, 
47715–24. 
Burda, J.E., Sofroniew, M. V, 2014. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229–48. 
Burdakov, D., Petersen, O.H., Verkhratsky, A., 2005. Intraluminal calcium as a primary regulator of endoplasmic reticulum function. Cell 
Calcium 38. 
Burgoyne, T., Patel, S., Eden, E.R., 2015. Calcium signaling at ER membrane contact sites. Biochim. Biophys. Acta - Mol. Cell Res. 1853, 2012–
2017. 
Busche, M.A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K.-H., Haass, C., Staufenbiel, M., Konnerth, A., Garaschuk, O., 
2008. Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer’s Disease. Science (80-. ). 321. 
Buxbaum, J.D., Ruefli, A.A., Parker, C.A., Cypess, A.M., Greengard, P., 1994. Calcium regulates processing of the Alzheimer amyloid protein 
precursor in a protein kinase C-independent manner. Proc. Natl. Acad. Sci. U. S. A. 91. 
Cacace, R., Sleegers, K., Van Broeckhoven, C., 2016. Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimer’s Dement. 12, 
733–748. 
Cahalan, M.D., 2009. STIMulating store-operated Ca2+ entry. Nat. Cell Biol. 11, 669–677. 
Cai, C., Lin, P., Cheung, K.-H., Li, N., Levchook, C., Pan, Z., Ferrante, C., Boulianne, G.L., Foskett, J.K., Danielpour, D., Ma, J., 2006. The 
presenilin-2 loop peptide perturbs intracellular Ca2+ homeostasis and accelerates apoptosis. J. Biol. Chem. 281, 16649–55. 
Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., Wong, P.C., 2001. BACE1 is the major beta-secretase for generation of 
Abeta peptides by neurons. Nat. Neurosci. 4, 233–234. 
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D.A., Giuffrida Stella, A.M., 2007. Nitric oxide in the central nervous 
system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 8, 766–775. 
Cameron, A.M., Nucifora, F.C., Fung, E.T., Livingston, D.J., Aldape, R.A., Ross, C.A., Snyder, S.H., 1997. FKBP12 binds the inositol 1,4,5-
trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. J. Biol. Chem. 272, 27582–8. 
Cameron, A.M., Steiner, J.P., Roskams, A.J., Ali, S.M., Ronnett, G. V, Snyder, S.H., 1995a. Calcineurin associated with the inositol 1,4,5-
trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. Cell 83, 463–72. 
Cameron, A.M., Steiner, J.P., Sabatini, D.M., Kaplin, A.I., Walensky, L.D., Snyder, S.H., 1995b. Immunophilin FK506 binding protein 
associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. Proc. Natl. Acad. Sci. U. S. A. 92, 1784–8. 
Cancela, J.M., Churchill, G.C., Galione, A., 1999. Coordination of agonist-induced Ca2+-signalling patterns by NAADP in pancreatic acinar 
cells. Nature 398, 74–6. 
Caporaso, G.L., Takei, K., Gandy, S.E., Matteoli, M., Mundigl, O., Greengard, P., De Camilli, P., 1994. Morphologic and biochemical analysis of 
the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein. J. Neurosci. 14, 3122–38. 
Castellani, R.J., Smith, M.A., 2011. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail.’ J. Pathol. 
224, 147–152. 
Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., DeMattos, R.B., Patterson, B.W., Fagan, A.M., Morris, J.C., Mawuenyega, K.G., Cruchaga, C., 
Goate, A.M., Bales, K.R., Paul, S.M., Bateman, R.J., Holtzman, D.M., 2011. Human apoE Isoforms Differentially Regulate Brain 
Amyloid-β Peptide Clearance. Sci. Transl. Med. 3. 
Castello, M.A., Jeppson, J.D., Soriano, S., 2014. Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease. 
BMC Neurol. 14, 169. 
Castonguay, A., Robitaille, R., 2002. Xestospongin C is a potent inhibitor of SERCA at a vertebrate synapse. Cell Calcium 32, 39–47. 
Castrén, E., Ohga, Y., Berzaghi, M.P., Tzimagiorgis, G., Thoenen, H., Lindholm, D., 1994. bcl-2 messenger RNA is localized in neurons of the 
developing and adult rat brain. Neuroscience 61, 165–77. 
Cedazo-Mínguez, A., Popescu, B.O., Ankarcrona, M., Nishimura, T., Cowburn, R.F., 2002. The presenilin 1 ΔE9 mutation gives enhanced basal 
phospholipase C activity and a resultant increase in intracellular calcium concentrations. J. Biol. Chem. 277. 
Celsi, F., Pizzo, P., Brini, M., Leo, S., Fotino, C., Pinton, P., Rizzuto, R., 2009. Mitochondria, calcium and cell death: A deadly triad in 
neurodegeneration. Biochim. Biophys. Acta - Bioenerg. 1787, 335–344. 
Ceni, C., Muller-Steffner, H., Lund, F., Pochon, N., Schweitzer, A., De Waard, M., Schuber, F., Villaz, M., Moutin, M.-J.J., 2003a. Evidence for 
an intracellular ADP-ribosyl cyclase/NAD+-glycohydrolase in brain from CD38-deficient mice. J. Biol. Chem. 278, 40670–40678. 
Ceni, C., Pochon, N., Brun, V., Muller-Steffner, H., Andrieux, A., Grunwald, D., Schuber, F., De Waard, M., Lund, F., Villaz, M., Moutin, M.-J., 
2003b. CD38-dependent ADP-ribosyl cyclase activity in developing and adult mouse brain. Biochem. J. 370, 175–83. 
Ceni, C., Pochon, N., Villaz, M., Muller-Steffner, H., Schuber, F., Baratier, J., De Waard, M., Ronjat, M., Moutin, M.-J., 2006. The CD38-
independent ADP-ribosyl cyclase from mouse brain synaptosomes: a comparative study of neonate and adult brain. Biochem. J. 395, 
417–426. 
Cerbai, F., Lana, D., Nosi, D., Petkova-Kirova, P., Zecchi, S., Brothers, H.M., Wenk, G.L., Giovannini, M.G., 2012. The Neuron-Astrocyte-
Microglia Triad in Normal Brain Ageing and in a Model of Neuroinflammation in the Rat Hippocampus. PLoS One 7, e45250. 
Chakroborty, S., Goussakov, I., Miller, M.B., Stutzmann, G.E., 2009. Deviant Ryanodine Receptor-Mediated Calcium Release Resets Synaptic 
Homeostasis in Presymptomatic 3xTg-AD Mice. J. Neurosci. 29, 9458–9470. 
Chakroborty, S., Kim, J., Schneider, C., Jacobson, C., Molgó, J., Stutzmann, G.E., 2012. Early Presynaptic and Postsynaptic Calcium Signaling 
Abnormalities Mask Underlying Synaptic Depression in Presymptomatic Alzheimer’s Disease Mice. J. Neurosci. 32. 
Chakroborty, S., Kim, J., Schneider, C., West, A.R., Stutzmann, G.E., 2015. Nitric Oxide Signaling Is Recruited As a Compensatory Mechanism 
for Sustaining Synaptic Plasticity in Alzheimer’s Disease Mice. J. Neurosci. 35. 
Chakroborty, S., Stutzmann, G.E., 2014. Calcium channelopathies and Alzheimer’s disease: Insight into therapeutic success and failures. Eur. J. 
Pharmacol. 739, 83–95. 
Chan, S.L., Mayne, M., Holden, C.P., Geiger, J.D., Mattson, M.P., 2000. Presenilin-1 mutations increase levels of ryanodine receptors and 
calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 275, 18195–200. 





endometrial hyperplasia and adenocarcinoma. J. Pathol. 177, 241–246. 
Chang, M.-J., Zhong, F., Lavik, A.R., Parys, J.B., Berridge, M.J., Distelhorst, C.W., 2014. Feedback regulation mediated by Bcl-2 and DARPP-
32 regulates inositol 1,4,5-trisphosphate receptor phosphorylation and promotes cell survival. Proc. Natl. Acad. Sci. 111, 1186–1191. 
Chapman, P.F., White, G.L., Jones, M.W., Cooper-Blacketer, D., Marshall, V.J., Irizarry, M., Younkin, L., Good, M.A., Bliss, T.V.P., Hyman, 
B.T., Younkin, S.G., Hsiao, K.K., 1999. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. 
Nat. Neurosci. 2, 271–276. 
Charpak, S., Gähwiler, B.H., Do, K.Q., Knöpfel, T., 1990. Potassium conductances in hippocampal neurons blocked by excitatory amino-acid 
transmitters. Nature 347, 765–767. 
Chauvet, S., Jarvis, L., Chevallet, M., Shrestha, N., Groschner, K., Bouron, A., 2016. Pharmacological Characterization of the Native Store-
Operated Calcium Channels of Cortical Neurons from Embryonic Mouse Brain. Front. Pharmacol. 7, 486. 
Chavis, P., Ango, F., Michel, J.M., Bockaert, J., Fagni, L., 1998. Modulation of big K+ channel activity by ryanodine receptors and L-type Ca2+ 
channels in neurons. Eur. J. Neurosci. 10, 2322–7. 
Chavis, P., Fagni, L., Lansman, J.B., Bockaert, J., 1996. Functional coupling between ryanodine receptors and L-type calcium channels in 
neurons. Nature 382, 719–722. 
Chelu, M.G., Danila, C.I., Gilman, C.P., Hamilton, S.L., 2004. Regulation of Ryanodine Receptors by FK506 Binding Proteins. Trends 
Cardiovasc. Med. 14, 227–234. 
Chen, J., Li, Q., Wang, J., 2011. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc. Natl. Acad. Sci. 
108, 14813–14818. 
Chen, Q.-S., Wei, W.-Z., Shimahara, T., Xie, C.-W., 2002. Alzheimer amyloid β-peptide inhibits the late phase of long-term potentiation through 
calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol. Learn. Mem. 77. 
Chen, R., Valencia, I., Zhong, F., McColl, K.S., Roderick, H.L., Bootman, M.D., Berridge, M.J., Conway, S.J., Holmes, A.B., Mignery, G.A., 
Velez, P., Distelhorst, C.W., 2004. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release 
from the ER in response to inositol 1,4,5-trisphosphate. J. Cell Biol. 166, 193–203. 
Chen, S.-H., Oyarzabal, E.A., Hong, J.-S., 2013. Preparation of rodent primary cultures for neuron-glia, mixed glia, enriched microglia, and 
reconstituted cultures with microglia. Methods Mol. Biol. 1041, 231–40. 
Chen, S., Yadav, S.P., Surewicz, W.K., 2010. Interaction between human prion protein and amyloid-β (Aβ) oligomers: Role of N-terminal 
residues. J. Biol. Chem. 285. 
Chen, W.S., Yueh, C.Y., Huang, Y.A., Hwang, E., 2011. An inverted method for culturing dissociated mouse hippocampal neurons. Neurosci. 
Res. 70, 118–123. 
Chen, X., Huang, T., Zhang, J., Song, J., Chen, L., Zhu, Y., 2008. Involvement of calpain and p25 of CDK5 pathway in ginsenoside Rb1’s 
attenuation of β-amyloid peptide25-35-induced tau hyperphosphorylation in cortical neurons. Brain Res. 1200. 
Chen, Y., Stevens, B., Chang, J., Milbrandt, J., Barres, B.A., Hell, J.W., 2008. NS21: Re-defined and modified supplement B27 for neuronal 
cultures. J. Neurosci. Methods 171, 239–247. 
Cheng, K.T., Ong, H.L., Liu, X., Ambudkar, I.S., 2013. Contribution and regulation of TRPC channels in store-operated Ca2+ entry. Curr. Top. 
Membr. 71, 149–79. 
Chernecky, C.C., Berger, B.J., 2013. Blood gases, arterial (ABG) - blood. In: Laboratory Tests and Diagnostic Procedures. Elsevier/Saunders, 
Philadelphia, PA, pp. 208–213. 
Cheung, K.-H., Mei, L., Mak, D.-O.D., Hayashi, I., Iwatsubo, T., Kang, D.E., Foskett, J.K., 2010. Gain-of-Function Enhancement of IP3 
Receptor Modal Gating by Familial Alzheimer’s Disease-Linked Presenilin Mutants in Human Cells and Mouse Neurons. Sci. Signal. 3, 
ra22-ra22. 
Cheung, K.-H., Shineman, D., Müller, M., Cárdenas, C., Mei, L., Yang, J., Tomita, T., Iwatsubo, T., Lee, V.M.-Y.V.M.-Y., Foskett, J.K.K., 2008. 
Mechanism of Ca2+ Disruption in Alzheimer’s Disease by Presenilin Regulation of InsP3 Receptor Channel Gating. Neuron 58, 871–
883. 
Chidambaram, N., Chang, C.F., 1999. NADP+-Dependent internalization of recombinant CD38 in CHO cells. Arch. Biochem. Biophys. 363, 
267–272. 
Chin, J., Massaro, C.M., Palop, J.J., Thwin, M.T., Yu, G.-Q., Bien-Ly, N., Bender, A., Mucke, L., 2007. Reelin Depletion in the Entorhinal 
Cortex of Human Amyloid Precursor Protein Transgenic Mice and Humans with Alzheimer’s Disease. J. Neurosci. 27, 2727–2733. 
Choe, C., Lardong, K., Gelderblom, M., Ludewig, P., Leypoldt, F., Koch-Nolte, F., Gerloff, C., Magnus, T., 2011. CD38 Exacerbates Focal 
Cytokine Production, Postischemic Inflammation and Brain Injury after Focal Cerebral Ischemia. PLoS One 6, e19046. 
Choi, D.W., Maulucci-Gedde, M., Kriegstein, A.R., 1987. Glutamate Neurotoxicity in Cortical Cell Culture. J. Neurosci. 7, 357–388. 
Choi, S., Lovinger, D.M., 1996. Metabotropic glutamate receptor modulation of voltage-gated Ca2+ channels involves multiple receptor subtypes 
in cortical neurons. J. Neurosci. 16, 36–45. 
Chuang, S.-C., Zhao, W., Young, S.R., Conquet, F., Bianchi, R., Wong, R.K.S., 2002. Activation of group I mGluRs elicits different responses in 
murine CA1 and CA3 pyramidal cells. J. Physiol. 541, 113–21. 
Chuang, S.C., Bianchi, R., Kim, D., Shin, H.S., Wong, R.K., Group, I., 2001. metabotropic glutamate receptors elicit epileptiform discharges in 
the hippocampus through PLCbeta1 signaling. J. Neurosci. Off. J. Soc. Neurosci. 21, 6387–6394. 
Chuang, S.C., Bianchi, R., Wong, R.K., 2000. Group I mGluR activation turns on a voltage-gated inward current in hippocampal pyramidal cells. 
J. Neurophysiol. 83, 2844–53. 
Chung, E., Ji, Y., Sun, Y., Kascsak, R.J., Kascsak, R.B., Mehta, P.D., Strittmatter, S.M., Wisniewski, T., 2010. Anti-PrPC monoclonal antibody 
infusion as a novel treatment for cognitive deficits in an alzheimer’s disease model mouse. BMC Neurosci. 11, 130. 
Chung, M.-K., Lee, H., Mizuno, A., Suzuki, M., Caterina, M.J., 2004. 2-Aminoethoxydiphenyl Borate Activates and Sensitizes the Heat-Gated 
Ion Channel TRPV3. J. Neurosci. 24, 5177–5182. 
Churchill, G.C., Okada, Y., Thomas, J.M., Genazzani, A.A., Patel, S., Galione, A., 2002. NAADP mobilizes Ca(2+) from reserve granules, 
lysosome-related organelles, in sea urchin eggs. Cell 111, 703–8. 
Cirrito, J.R., Yamada, K.A., Finn, M.B., Sloviter, R.S., Bales, K.R., May, P.C., Schoepp, D.D., Paul, S.M., Mennerick, S., Holtzman, D.M., 2005. 
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo. Neuron 48, 913–922. 
Clapper, D.L., Walseth, T.F., Dargie, P.J., Lee, H.C., 1987. Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg 
microsomes desensitized to inositol trisphosphate. J. Biol. Chem. 262, 9561–8. 
Clark, J.K., Furgerson, M., Crystal, J.D., Fechheimer, M., Furukawa, R., Wagner, J.J., 2015. Alterations in synaptic plasticity coincide with 





Clementi, E., Riccio, M., Sciorati, C., Nisticò, G., Meldolesi, J., 1996. The type 2 ryanodine receptor of neurosecretory PC12 cells is activated by 
cyclic ADP-ribose - Role of the nitric oxide cGMP pathway. J. Biol. Chem. 271, 17739–17745. 
Clementi, M.E., Pezzotti, M., Orsini, F., Sampaolese, B., Mezzogori, D., Grassi, C., Giardina, B., Misiti, F., 2006. Alzheimer’s amyloid β-peptide 
(1–42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: An intriguing role for methionine 35. Biochem. Biophys. 
Res. Commun. 342, 206–213. 
Cobb, S.R., Bulters, D.O., Davies, C.H., 2000. Coincident activation of mGluRs and mAChRs imposes theta frequency patterning on 
synchronised network activity in the hippocampal CA3 region. Neuropharmacology 39, 1933–42. 
Cochilla, A.J., Alford, S., 1998. Metabotropic Glutamate Receptor–Mediated Control of Neurotransmitter Release. Neuron 20, 1007–1016. 
Cohen, R.M., Rezai-zadeh, K., Weitz, T.M., Rentsendorj, A., Gate, D., Spivak, I., Bholat, Y., Vasilevko, V., Glabe, C.G., Breunig, J.J., Rakic, P., 
Davtyan, H., Agadjanyan, M.G., Kepe, V., Barrio, J.R., Bannykh, S., Szekely, C.A., Pechnick, R.N., Town, T., 2013. Neurobiology of 
Disease A Transgenic Alzheimer Rat with Plaques , Tau Pathology , Behavioral Impairment , Oligomeric A ␤ , and Frank Neuronal 
Loss. J. Neurosci. 33, 6245–6256. 
Cohen, S.I.A., Linse, S., Luheshi, L.M., Hellstrand, E., White, D.A., Rajah, L., Otzen, D.E., Vendruscolo, M., Dobson, C.M., Knowles, T.P.J., 
2013. Proliferation of amyloid- 42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. 110, 9758–9763. 
Coleman, P.D., Yao, P.J., 2003. Synaptic slaughter in Alzheimer’s disease. Neurobiol. Aging 24. 
Coleman, R.M. (Robert M., 2005. Trends in neurochemistry research. Nova Science Publishers. 
Collie, A., Maruff, P., 2000. The neuropsychology of preclinical Alzheimer’s disease and mild cognitive impairment. Neurosci. Biobehav. Rev. 
24, 365–74. 
Collins, M.O., Husi, H., Yu, L., Brandon, J.M., Anderson, C.N., Blackstock, W.P., Choudhary, J.S., Grant, S.G., 2006. Molecular 
characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J. Neurochem. 97 Suppl 1. 
Colonna, M., Wang, Y., 2016. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 17, 201–207. 
Colton, C.A., Vitek, M.P., Wink, D.A., Xu, Q., Cantillana, V., Previti, M.L., Van Nostrand, W.E., Weinberg, J.B., Weinberg, B., Dawson, H., 
2006. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U. 
S. A. 103, 12867–72. 
Comley, L.H., Fuller, H.R., Wishart, T.M., Mutsaers, C.A., Thomson, D., Wright, A.K., Ribchester, R.R., Morris, G.E., Parson, S.H., Horsburgh, 
K., Gillingwater, T.H., 2011. ApoE isoform-specific regulation of regeneration in the peripheral nervous system. Hum. Mol. Genet. 20, 
2406–2421. 
Congar, P., Leinekugel, X., Ben-Ari, Y., Crépel, V., 1997. A Long-Lasting Calcium-Activated Nonselective Cationic Current Is Generated by 
Synaptic Stimulation or Exogenous Activation of Group I Metabotropic Glutamate Receptors in CA1 Pyramidal Neurons. J. Neurosci. 
17. 
Conley, Y.P., Mukherjee, A., Kammerer, C., DeKosky, S.T., Kamboh, M.I., Finegold, D.N., Ferrell, R.E., 2009. Evidence supporting a role for 
the calcium-sensing receptor in Alzheimer disease. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 150B, 703–709. 
Conlon, R.A., Reaume, A.G., Rossant, J., 1995. Notch1 is required for the coordinate segmentation of somites. Development 121, 1533–45. 
Conn, P.J., Pin, J.P., 1997. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205–237. 
Connor, J.A., Petrozzino, J., Pozzo-Miller, L.D., Otani, S., 1999. Calcium signals in long-term potentiation and long-term depression. Can. J. 
Physiol. Pharmacol. 77, 722–34. 
Conquet, F., Bashir, Z.I., Davies, C.H., Daniel, H., Ferraguti, F., Bordi, F., Franz-Bacon, K., Reggiani, A., Matarese, V., Condé, F., Collingridge, 
G.L., Crépel, F., 1994. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature 372, 237–243. 
Coon, K.D., Myers, A.J., Craig, D.W., Webster, J.A., Pearson, J. V, Lince, D.H., Zismann, V.L., Beach, T.G., Leung, D., Bryden, L., Halperin, 
R.F., Marlowe, L., Kaleem, M., Walker, D.G., Ravid, R., Heward, C.B., Rogers, J., Papassotiropoulos, A., Reiman, E.M., Hardy, J., 
Stephan, D.A., 2007. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic 
late-onset Alzheimer’s disease. J. Clin. Psychiatry 68, 613–8. 
Copello, J.A., Qi, Y., Jeyakumar, L.H., Ogunbunmi, E., Fleischer, S., 2001. Lack of effect of cADP-ribose and NAADP on the activity of skeletal 
muscle and heart ryanodine receptors. Cell Calcium 30, 269–84. 
Copray, J.C., Liem, R.S., 1993. Survival and neurite formation of mesencephalic trigeminal neurones of the rat in vitro. Arch. Oral Biol. 38, 547–
57. 
Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A., 
1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–3. 
Corradetti, R., Gaïarsa, J.L., Ben-Ari, Y., 1988. D-aminophosphonovaleric acid-sensitive spontaneous giant EPSPs in immature rat hippocampal 
neurones. Eur. J. Pharmacol. 154, 221–2. 
Cosker, F., Cheviron, N., Yamasaki, M., Menteyne, A., Lund, F.E., Moutin, M.J.M.-J.M.J., Galione, A., Cancela, J.M.J.-M., 2010. The ecto-
enzyme CD38 is a Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) synthase that couples receptor activation to Ca2+ 
mobilization from lysosomes in pancreatic acinar cells. J. Biol. Chem. 285, 38251–38259. 
Coutinho, V., Knöpfel, T., 2002. Book Review: Metabotropic Glutamate Receptors: Electrical and Chemical Signaling Properties. Neurosci. 8, 
551–561. 
Craig, A.M., Banker, G., 1994. Neuronal Polarity. Annu. Rev. Neurosci. 17, 267–310. 
Cramer, P.E., Cirrito, J.R., Wesson, D.W., Lee, C.Y.D., Karlo, J.C., Zinn, A.E., Casali, B.T., Restivo, J.L., Goebel, W.D., James, M.J., Brunden, 
K.R., Wilson, D.A., Landreth, G.E., 2012. ApoE-Directed Therapeutics Rapidly Clear  -Amyloid and Reverse Deficits in AD Mouse 
Models. Science (80-. ). 335, 1503–1506. 
Crawford, J.H., Wootton, J.F., Seabrook, G.R., Scott, R.H., 1997a. Activation of Ca2+-dependent currents in dorsal root ganglion neurons by 
metabotropic glutamate receptors and cyclic ADP-ribose precursors. J. Neurophysiol. 77, 2573–2584. 
Crawford, J.H., Wootton, J.F., Seabrook, G.R., Scott, R.H., 1997b. Activation of Ca 2+ -dependent currents in dorsal root ganglion neurons by 
metabotropic glutamate receptors and cyclic ADP- ribose precursors. J. Neurophysiol. 77, 2573–2584. 
Crepel, V., Aniksztejn, L., Ben-Ari, Y., Hammond, C., 1994. Glutamate metabotropic receptors increase a Ca(2+)-activated nonspecific cationic 
current in CA1 hippocampal neurons. J. Neurophysiol. 72. 
Csordás, G., Várnai, P., Golenár, T., Roy, S., Purkins, G., Schneider, T.G., Balla, T., Hajnóczky, G., 2010. Imaging Interorganelle Contacts and 
Local Calcium Dynamics at the ER-Mitochondrial Interface. Mol. Cell 39, 121–132. 
Cullen, D.K., Gilroy, M.E., Irons, H.R., LaPlaca, M.C., 2010. Synapse-to-neuron ratio is inversely related to neuronal density in mature neuronal 
cultures. Brain Res. 1359, 44–55. 





transmission in rat hippocampus. Neuroreport 8, 87–92. 
Cummings, J.A., Mulkey, R.M., Nicoll, R.A., Malenka, R.C., 1996. Ca2+ signaling requirements for long-term depression in the hippocampus. 
Neuron 16. 
Cupers, P., Bentahir, M., Craessaerts, K., Orlans, I., Vanderstichele, H., Saftig, P., De Strooper, B., Annaert, W., 2001. The discrepancy between 
presenilin subcellular localization and γ -secretase processing of amyloid precursor protein. J. Cell Biol. 154, 731–740. 
Currie, K.P., Swann, K., Galione, A., Scott, R.H., 1992. Activation of Ca(2+)-dependent currents in cultured rat dorsal root ganglion neurones by 
a sperm factor and cyclic ADP-ribose. Mol. Biol. Cell 3, 1415–1425. 
Currie, K.P., Wootton, J.F., Scott, R.H., 1995. Activation of Ca(2+)-dependent Cl-currents in cultured rat sensory neurones by flash photolysis of 
DM-nitrophen. J. Physiol. 482 Pt 2 291–307. 
Czabotar, P.E., Lessene, G., Strasser, A., Adams, J.M., 2013. Control of apoptosis by the BCL-2 protein family: implications for physiology and 
therapy. Nat. Rev. Mol. Cell Biol. 15, 49–63. 
D’Souza-Li, L., 2006. The calcium-sensing receptor and related diseases. Arq. Bras. Endocrinol. Metabol. 50, 628–39. 
Dammermann, W., Guse, A.H., 2005. Functional ryanodine receptor expression is required for NAADP-mediated local Ca2+ signaling in T-
lymphocytes. J. Biol. Chem. 280, 21394–21399. 
Das, H.K., Tchedre, K., Mueller, B., 2012. Repression of transcription of presenilin-1 inhibits γ-secretase independent ER Ca2+ leak that is 
impaired by FAD mutations. J. Neurochem. 122, 487–500. 
Das, U., Scott, D.A., Ganguly, A., Koo, E.H., Tang, Y., Roy, S., 2013. Activity-Induced Convergence of APP and BACE-1 in Acidic 
Microdomains via an Endocytosis-Dependent Pathway. Neuron 79, 447–460. 
Das, U., Wang, L., Ganguly, A., Saikia, J.M., Wagner, S.L., Koo, E.H., Roy, S., 2015. Visualizing APP and BACE-1 approximation in neurons 
yields insight into the amyloidogenic pathway. Nat. Neurosci. 19, 55–64. 
Dasso, L.L., Taylor, C.W., 1991. Heparin and other polyanions uncouple alpha 1-adrenoceptors from G-proteins. Biochem. J. 280 ( Pt 3), 791–5. 
Davies, C.H., Clarke, V.R., Jane, D.E., Collingridge, G.L., 1995. Pharmacology of postsynaptic metabotropic glutamate receptors in rat 
hippocampal CA1 pyramidal neurones. Br. J. Pharmacol. 116, 1859–69. 
Davis, K.E., Eacott, M.J., Easton, A., Gigg, J., 2013a. Episodic-like memory is sensitive to both Alzheimer’s-like pathological accumulation and 
normal ageing processes in mice. Behav. Brain Res. 254, 73–82. 
Davis, K.E., Easton, A., Eacott, M.J., Gigg, J., 2013b. Episodic-like memory for what-where-which occasion is selectively impaired in the 
3xTgAD mouse model of Alzheimer’s disease. J. Alzheimers. Dis. 33, 681–98. 
Davis, K.E., Fox, S., Gigg, J., Waldvogel, H., Faull, R., 2014. Increased Hippocampal Excitability in the 3xTgAD Mouse Model for Alzheimer’s 
Disease In Vivo. PLoS One 9, e91203. 
Dawkins, E., Small, D.H., 2014. Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer’s disease. J. 
Neurochem. 129, 756–769. 
Dawson, G.R., Seabrook, G.R., Zheng, H., Smith, D.W., Graham, S., O’Dowd, G., Bowery, B.J., Boyce, S., Trumbauer, M.E., Chen, H.Y., Van 
der Ploeg, L.H., Sirinathsinghji, D.J., 1999. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic 
marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90, 1–13. 
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D.H., Kopeikina, K.J., Pitstick, R., Sahara, N., Ashe, K.H., Carlson, 
G.A., Spires-Jones, T.L., Hyman, B.T., 2012. Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73, 685–97. 
De Felice, F.G., Velasco, P.T., Lambert, M.P., Viola, K., Fernandez, S.J., Ferreira, S.T., Klein, W.L., 2007. Aβ oligomers induce neuronal 
oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. 
Biol. Chem. 282. 
De Flora, A., Guida, L., Franco, L., Zocchi, E., Pestarino, M., Usai, C., Marchetti, C., Fedele, E., Fontana, G., Raiteri, M., 1996. Ectocellular in 
vitro and in vivo metabolism of cADP-ribose in cerebellum. Biochem. J 320, 665–672. 
De Flora, A., Zocchi, E., Guida, L., Franco, L., Bruzzone, S., 2004. Autocrine and paracrine calcium signaling by the CD38/NAD+/cyclic ADP-
ribose system. Ann. N. Y. Acad. Sci. 1028, 176–91. 
de Murcia, G., de Murcia, J.M., 1994. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 19, 172–176. 
De Smet, P., Parys, J.B., Callewaert, G., Weidema, A.F., Hill, E., De Smedt, H., Erneux, C., Sorrentino, V., Missiaen, L., 1999. Xestospongin C 
is an equally potent inhibitor of the inositol 1,4,5-trisphosphate receptor and the endoplasmic-reticulum Ca(2+) pumps. Cell Calcium 26, 
9–13. 
De Stefani, D., Raffaello, A., Teardo, E., Szabò, I., Rizzuto, R., 2011. A forty-kilodalton protein of the inner membrane is the mitochondrial 
calcium uniporter. Nature 476, 336–340. 
De Strooper, B., Iwatsubo, T., Wolfe, M.S., 2012. Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring 
Harb. Perspect. Med. 2, a006304. 
de Toledo, F.G., Cheng, J., Liang, M., Chini, E.N., Dousa, T.P., 2000. ADP-Ribosyl cyclase in rat vascular smooth muscle cells: properties and 
regulation. Circ. Res. 86, 1153–9. 
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M.B., Holtzman, D.M., Zlokovic, B. V., 2008. apoE isoform–specific disruption of 
amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118, 4002–4013. 
Decuypere, J.-P., Monaco, G., Bultynck, G., Missiaen, L., De Smedt, H., Parys, J.B., 2011. The IP3 receptor–mitochondria connection in 
apoptosis and autophagy. Biochim. Biophys. Acta - Mol. Cell Res. 1813, 1003–1013. 
Dedkova, E.N., Sigova, A.A., Zinchenko, V.P., 2000. Mechanism of action of calcium ionophores on intact cells: ionophore-resistant cells. 
Membr. Cell Biol. 13, 357–68. 
Degenetais, E., Thierry, A.-M., Glowinski, J., Gioanni, Y., 2003. Synaptic Influence of Hippocampus on Pyramidal Cells of the Rat Prefrontal 
Cortex: An In Vivo Intracellular Recording Study. Cereb. Cortex 13, 782–792. 
Dehmelt, L., Halpain, S., 2005. The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 6, 204. 
Dehpour, A.R., Mofakham, S., Mahmoudian, M., 1982. In vitro binding of dantrolene to sarcoplasmic reticulum of rabbit skeletal muscle. 
Biochem. Pharmacol. 31, 965–8. 
DeKosky, S.T., Scheff, S.W., 1990. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity. Ann. 
Neurol. 27, 457–464. 
Del Prete, D., Checler, F., Chami, M., Kriegstein, A., Nicoll, R., Takao, K., Takeshima, H., Miyakawa, T., Mikoshiba, K., Reed, J., Arancio, O., 
Bush, A., Nakai, A., Nishida, K., Kurihara, S., Donoviel, D., Bernstein, A., Tomita, T., Iwatsubo, T., Hori, M., Otsu, K., 2014. 





del Río, E., McLaughlin, M., Downes, C.P., Nicholls, D.G., 1999. Differential coupling of G-protein-linked receptors to Ca2+ mobilization 
through inositol(1,4,5)trisphosphate or ryanodine receptors in cerebellar granule cells in primary culture. Eur. J. Neurosci. 11, 3015–22. 
Demuro, A., Mina, E., Kayed, R., Milton, S.C., Parker, I., Glabe, C.G., 2005. Calcium Dysregulation and Membrane Disruption as a Ubiquitous 
Neurotoxic Mechanism of Soluble Amyloid Oligomers. J. Biol. Chem. 280, 17294–17300. 
Demuro, A., Parker, I., 2013. Cytotoxicity of intracellular aβ42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by 
stimulated production of inositol trisphosphate. J. Neurosci. 33, 3824–33. 
Demuro, A., Parker, I., Stutzmann, G.E., 2010. Calcium Signaling and Amyloid Toxicity in Alzheimer Disease. J. Biol. Chem. 285, 12463–
12468. 
Deng, G., Su, J.H., Ivins, K.J., Van Houten, B., Cotman, C.W., 1999. Bcl-2 Facilitates Recovery from DNA Damage after Oxidative Stress. Exp. 
Neurol. 159, 309–318. 
Deniaud, A., Sharaf El Dein, O., Maillier, E., Poncet, D., Kroemer, G., Lemaire, C., Brenner, C., 2008. Endoplasmic reticulum stress induces 
calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 27. 
Desai, M.K., Sudol, K.L., Janelsins, M.C., Mastrangelo, M.A., Frazer, M.E., Bowers, W.J., 2009. Triple-transgenic Alzheimer’s disease mice 
exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 57, 54–65. 
Deshpande, A., Mina, E., Glabe, C., Busciglio, J., 2006. Different Conformations of Amyloid β Induce Neurotoxicity by Distinct Mechanisms in 
Human Cortical Neurons. J. Neurosci. 26, 6011–6018. 
Deshpande, D.A., Walseth, T.F., Panettieri, R.A., Kannan, M.S., 2003. CD38-cyclic ADP-ribose-mediated Ca2+ signaling contributes to airway 
smooth muscle hyperresponsiveness. FASEB J. 17, 452–4. 
Deshpande, D.A., White, T.A., Dogan, S., Walseth, T.F., Panettieri, R.A., Kannan, M.S., 2005. CD38/cyclic ADP-ribose signaling: role in the 
regulation of calcium homeostasis in airway smooth muscle. AJP Lung Cell. Mol. Physiol. 288, L773–L788. 
Deshpande, L.S., Limbrick, D.D., Sombati, S., DeLorenzo, R.J., 2007. Activation of a Novel Injury-Induced Calcium-Permeable Channel That 
Plays a Key Role in Causing Extended Neuronal Depolarization and Initiating Neuronal Death in Excitotoxic Neuronal Injury. J. 
Pharmacol. Exp. Ther. 322, 443–452. 
Deshpande, L.S., Sun, D.A., Sombati, S., Baranova, A., Wilson, M.S., Attkisson, E., Hamm, R.J., DeLorenzo, R.J., 2008. Alterations in neuronal 
calcium levels are associated with cognitive deficits after traumatic brain injury. Neurosci. Lett. 441, 115–119. 
Diaz-Hernandez, J.I., Gomez-Villafuertes, R., Le?n-Otegui, M., Hontecillas-Prieto, L., del Puerto, A., Trejo, J.L., Lucas, J.J., Garrido, J.J., 
Gualix, J., Miras-Portugal, M.T., Diaz-Hernandez, M., 2012. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease 
through GSK3? and secretases. Neurobiol. Aging 33, 1816–1828. 
Dickson, D.W., Crystal, H.A., Bevona, C., Honer, W., Vincent, I., Davies, P., 1995. Correlations of synaptic and pathological markers with 
cognition of the elderly. Neurobiol. Aging 16, 285-98; discussion 298-304. 
Dineley, K.T., Hogan, D., Zhang, W.-R., Taglialatela, G., 2007. Acute inhibition of calcineurin restores associative learning and memory in 
Tg2576 APP transgenic mice. Neurobiol. Learn. Mem. 88. 
Dings, J., Meixensberger, J., Jäger, A., Roosen, K., 1998. Clinical Experience with 118 Brain Tissue Oxygen Partial Pressure Catheter Probes. 
Neurosurgery 43, 1082–1094. 
Distelhorst, C.W., Shore, G.C., 2004. Bcl-2 and calcium: controversy beneath the surface. Oncogene 23, 2875–2880. 
Dotti, C.G., Sullivan, C.A., Banker, G.A., 1988. The establishment of polarity by hippocampal neurons in culture. J. Neurosci. 8, 1454–68. 
Dreses-Werringloer, U., Lambert, J.-C., Vingtdeux, V., Zhao, H., Vais, H., Siebert, A., Jain, A., Koppel, J., Rovelet-Lecrux, A., Hannequin, D., 
Pasquier, F., Galimberti, D., Scarpini, E., Mann, D., Lendon, C., Campion, D., Amouyel, P., Davies, P., Foskett, J.K., Campagne, F., 
Marambaud, P., 2008. A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Aβ Levels, and Alzheimer’s Disease Risk. Cell 133. 
Drysdale, A.J., Ryan, D., Pertwee, R.G., Platt, B., 2006. Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. 
Neuropharmacology 50, 621–631. 
Du, G.-J., Lin, H.-H., Xu, Q.-T., Wang, M.-W., 2006. Bcl-2 switches the type of demise from apoptosis to necrosis via cyclooxygenase-2 
upregulation in HeLa cell induced by hydrogen peroxide. Cancer Lett. 232, 179–188. 
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Perez-Tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M.N., 
Holcomb, L., Refolo, L., Zenk, B., Hardy, J., Younkin, S., 1996. Increased amyloid-β42(43) in brains of mice expressing mutant 
presenilin 1. Nature 383. 
Duffy, Á.M., Morales-Corraliza, J., Bermudez-Hernandez, K.M., Schaner, M.J., Magagna-Poveda, A., Mathews, P.M., Scharfman, H.E., 2015. 
Entorhinal cortical defects in Tg2576 mice are present as early as 2–4 months of age. Neurobiol. Aging 36, 134–148. 
Dulin, F., Léveillé, F., Ortega, J.B., Mornon, J.-P., Buisson, A., Callebaut, I., Colloc’h, N., 2008. p3 peptide, a truncated form of Aβ devoid of 
synaptotoxic effect, does not assemble into soluble oligomers, FEBS Letters. 
Dumuis, A., Sebben, M., Fagni, L., Prézeau, L., Manzoni, O., Cragoe, E.J., Bockaert, J., 1993. Stimulation by glutamate receptors of arachidonic 
acid release depends on the Na+/Ca2+ exchanger in neuronal cells. Mol. Pharmacol. 43, 976–81. 
Durell, S.R., Guy, H.R., Arispe, N., Rojas, E., Pollard, H.B., 1994. Theoretical models of the ion channel structure of amyloid beta-protein. 
Biophys. J. 67, 2137–2145. 
Durnin, L., Dai, Y., Aiba, I., Shuttleworth, C.W., Yamboliev, I.A., Mutafova-Yambolieva, V.N., 2012. Release, neuronal effects and removal of 
extracellular ??-nicotinamide adenine dinucleotide (??-NAD +) in the rat brain. Eur. J. Neurosci. 35, 423–435. 
Dursun, E., Gezen-Ak, D., Yilmazer, S., 2011. A novel perspective for Alzheimer’s disease: vitamin D receptor suppression by amyloid-β and 
preventing the amyloid-β induced alterations by vitamin D in cortical neurons. J. Alzheimers. Dis. 23, 207–19. 
Eagle, H., Oyama, V.I., Levy, M., Horton, C.L., Fleischman, R., 1956. The growth response of mammalian cells in tissue culture to L-glutamine 
and L-glutamic acid. J. Biol. Chem. 218, 607–16. 
Ebrahimi, M., Yamamoto, Y., Sharifi, K., Kida, H., Kagawa, Y., Yasumoto, Y., Islam, A., Miyazaki, H., Shimamoto, C., Maekawa, M., 
Mitsushima, D., Yoshikawa, T., Owada, Y., 2016. Astrocyte-expressed FABP7 regulates dendritic morphology and excitatory synaptic 
function of cortical neurons. Glia 64. 
Eckenrode, E.F., Yang, J., Velmurugan, G. V., Foskett, J.K., White, C., 2010. Apoptosis Protection by Mcl-1 and Bcl-2 Modulation of Inositol 
1,4,5-Trisphosphate Receptor-dependent Ca 2+ Signaling. J. Biol. Chem. 285, 13678–13684. 
Eckert, A., Schindowski, K., Leutner, S., Luckhaus, C., Touchet, N., Czech, C., Müller, W.E., 2001. Alzheimer’s Disease-like Alterations in 
Peripheral Cells from Presenilin-1 Transgenic Mice. Neurobiol. Dis. 8, 331–342. 
Edbauer, D., Winkler, E., Regula, J.T., Pesold, B., Steiner, H., Haass, C., 2003. Reconstitution of γ-secretase activity. Nat. Cell Biol. 5, 486–488. 
Edwards, D., Das, M., Molnar, P., Hickman, J.J., 2010. Addition of glutamate to serum-free culture promotes recovery of electrical activity in 





Egorov, A. V, Hamam, B.N., Fransén, E., Hasselmo, M.E., Alonso, A.A., 2002. Graded persistent activity in entorhinal cortex neurons. Nature 
420, 173–8. 
Ehlers, M.D., Heine, M., Groc, L., Lee, M.-C., Choquet, D., 2007. Diffusional Trapping of GluR1 AMPA Receptors by Input-Specific Synaptic 
Activity. Neuron 54. 
Ehlers, M.D., Zhang, S., Bernhardt, J.P., Huganir, R.L., 1996. Inactivation of NMDA Receptors by Direct Interaction of Calmodulin with the 
NR1 Subunit. Cell 84, 745–755. 
Eide, L., McMurray, C.T., 2005. Culture of adult mouse neurons. Biotechniques 38, 99–104. 
Elder, G.A., Cho, J.Y., English, D.F., Franciosi, S., Schmeidler, J., Sosa, M.A.G., Gasperi, R. De, Fisher, E.A., Mathews, P.M., Haroutunian, V., 
Buxbaum, J.D., 2007. Elevated plasma cholesterol does not affect brain A? in mice lacking the low-density lipoprotein receptor. J. 
Neurochem. 102, 1220–1231. 
Emilsson, L., Saetre, P., Jazin, E., 2006. Alzheimer’s disease: mRNA expression profiles of multiple patients show alterations of genes involved 
with calcium signaling. Neurobiol. Dis. 21, 618–625. 
Empson, R.M., Galione, A., 1997. Cyclic ADP-ribose enhances coupling between voltage-gated Ca2+ entry and intracellular Ca2+ release. J. 
Biol. Chem. 272, 20967–70. 
Enokido, Y., Araki, T., Aizawa, S., Hatanaka, H., 1996. p53 involves cytosine arabinoside-induced apoptosis in cultured cerebellar granule 
neurons. Neurosci. Lett. 203, 1–4. 
Erecińska, M., Silver, I.A., 2001. Tissue oxygen tension and brain sensitivity to hypoxia. Respir. Physiol. 128, 263–276. 
Ernst, I.M.A., Fliegert, R., Guse, A.H., 2013. Adenine Dinucleotide Second Messengers and T-lymphocyte Calcium Signaling. Front. Immunol. 
4, 259. 
Etcheberrigaray, R., Hirashima, N., Nee, L., Prince, J., Govoni, S., Racchi, M., Tanzi, R.E., Alkon, D.L., 1998. Calcium responses in fibroblasts 
from asymptomatic members of Alzheimer’s disease families. Neurobiol. Dis. 5. 
Faber, E.S.L., Delaney, A.J., Sah, P., 2005. SK channels regulate excitatory synaptic transmission and plasticity in the lateral amygdala. Nat. 
Neurosci. 8, 635–641. 
Fagan, A.M., Murphy, B.A., Patel, S.N., Kilbridge, J.F., Mobley, W.C., Bu, G., Holtzman, D.M., 1998. Evidence for Normal Aging of the Septo-
Hippocampal Cholinergic System in apoE (?/?) Mice but Impaired Clearance of Axonal Degeneration Products Following Injury. Exp. 
Neurol. 151, 314–325. 
Fagni, L., Chavis, P., Ango, F., Bockaert, J., 2000. Complex interactions between mGluRs, intracellular Ca2+ stores and ion channels in neurons. 
Trends Neurosci. 23, 80–8. 
Faissner, A., Steindler, D., 1995. Boundaries and inhibitory molecules in developing neural tissues. Glia 13, 233–254. 
Fanutza, T., Del Prete, D., Ford, M.J., Castillo, P.E., D’Adamio, L., 2015. APP and APLP2 interact with the synaptic release machinery and 
facilitate transmitter release at hippocampal synapses. Elife 4, e09743. 
Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., Pericak-Vance, M.A., Risch, N., van Duijn, C.M., 
1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. 
APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349–56. 
Federovitch, C.M., Ron, D., Hampton, R.Y., 2005. The dynamic ER: Experimental approaches and current questions. Curr. Opin. Cell Biol. 17. 
Ferguson, S.S., 2001. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. 
Rev. 53, 1–24. 
Fernàndez, J.E., Deaglio, S., Donati, D., Beusan, I.S., Corno, F., Aranega, A., Forni, M., Falini, B., Malavasi, F., 1998. Analysis of the 
distribution of human CD38 and of its ligand CD31 in normal tissues. J. Biol. Regul. Homeost. Agents 12, 81–91. 
Fernandez, M.A., Klutkowski, J.A., Freret, T., Wolfe, M.S., 2014. Alzheimer Presenilin-1 Mutations Dramatically Reduce Trimming of Long 
Amyloid  -Peptides (A ) by  -Secretase to Increase 42-to-40-Residue A. J. Biol. Chem. 289, 31043–31052. 
Ferreiro, E., Oliveira, C.R., Pereira, C.M.F., 2008. The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion 
peptides activates the mitochondrial apoptotic pathway. Neurobiol. Dis. 30. 
Ferrer, I., Tortosa, A., Blanco, R., Martín, F., Serrano, T., Planas, A., Macaya, A., 1994a. Naturally occurring cell death in the developing 
cerebral cortex of the rat. Evidence of apoptosis-associated internucleosomal DNA fragmentation. Neurosci. Lett. 182. 
Ferrer, I., Tortosa, A., Condom, E., Blanco, R., Macaya, A., Planas, A., 1994b. Increased expression of bcl-2 immunoreactivity in the developing 
cerebral cortex of the rat. Neurosci. Lett. 179, 13–6. 
Finder, V.H., Glockshuber, R., 2007. Amyloid-beta aggregation. Neurodegener. Dis. 4, 13–27. 
Finnema, S.J., Nabulsi, N.B., Eid, T., Detyniecki, K., Lin, S. -f., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, D.D., 
Mercier, J., Hannestad, J., Huang, Y., Carson, R.E., 2016. Imaging synaptic density in the living human brain. Sci. Transl. Med. 8, 
348ra96-348ra96. 
Fitz, N.F., Cronican, A.A., Saleem, M., Fauq, A.H., Chapman, R., Lefterov, I., Koldamova, R., 2012. Abca1 Deficiency Affects Alzheimer’s 
Disease-Like Phenotype in Human ApoE4 But Not in ApoE3-Targeted Replacement Mice. J. Neurosci. 32, 13125–13136. 
Fitzjohn, S.M., Morton, R.A., Kuenzi, F., Rosahl, T.W., Shearman, M., Lewis, H., Smith, D., Reynolds, D.S., Davies, C.H., Collingridge, G.L., 
Seabrook, G.R., 2001. Age-Related Impairment of Synaptic Transmission But Normal Long-Term Potentiation in Transgenic Mice that 
Overexpress the Human APP695SWE Mutant Form of Amyloid Precursor Protein. J. Neurosci. 21. 
Flaherty, D.B., Soria, J.P., Tomasiewicz, H.G., Wood, J.G., 2000. Phosphorylation of human tau protein by microtubule-associated kinases: 
GSK3β and cdk5 are key participants. J. Neurosci. Res. 62. 
Fleming, L.M., Johnson, G.V.W., 1995. Modulation of the phosphorylation state of tau in situ: The roles of calcium and cyclic AMP. Biochem. J. 
309. 
Fletcher, T.L., Banker, G.A., 1989. The establishment of polarity by hippocampal neurons: the relationship between the stage of a cell’s 
development in situ and its subsequent development in culture. Dev. Biol. 136, 446–54. 
Fliegert, R., Gasser, A., Guse, A.H., 2007. Regulation of calcium signalling by adenine-based second messengers. Biochem. Soc. Trans. 35, 109–
114. 
Fonfria, E., Marshall, I.C.B., Boyfield, I., Skaper, S.D., Hughes, J.P., Owen, D.E., Zhang, W., Miller, B.A., Benham, C.D., McNulty, S., 2005. 
Amyloid beta-peptide(1-42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. J. 
Neurochem. 95, 715–723. 
Foo, L., Allen, N., Bushong, E., Ventura, P., Chung, W.-S., Zhou, L., Cahoy, J., Daneman, R., Zong, H., Ellisman, M., Barres, B., 2011. 





Foster, T.C.T.C., 2007. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 6, 319–325. 
Franco, L., Bodrato, N., Moreschi, I., Usai, C., Bruzzone, S., Scarf ì, S., Zocchi, E., De Flora, A., 2006. Cyclic ADP-ribose is a second messenger 
in the lipopolysaccharide-stimulated activation of murine N9 microglial cell line. J. Neurochem. 99, 165–76. 
Franco, L., Guida, L., Bruzzone, S., Zocchi, E., Usai, C., De Flora, A., 1998. The transmembrane glycoprotein CD38 is a catalytically active 
transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes. FASEB J. 12, 1507–20. 
Franco, L., Zocchi, E., Usai, C., Guida, L., Bruzzone, S., Costa, A., De Flora, A., 2001. Paracrine Roles of NAD+ and Cyclic ADP-ribose in 
Increasing Intracellular Calcium and Enhancing Cell Proliferation of 3T3 Fibroblasts. J. Biol. Chem. 276, 21642–21648. 
Frankowski, H., Missotten, M., Fernandez, P.A., Martinou, I., Michel, P., Sadoul, R., Martinou, J.C., 1995. Function and expression of the Bcl-x 
gene in the developing and adult nervous system. Neuroreport 6, 1917–21. 
Franzini-Armstrong, C., Protasi, F., 1997. Ryanodine receptors of striated muscles: a complex channel capable of multiple interactions. Physiol. 
Rev. 77, 699–729. 
Frazzini, V., Guarnieri, S., Bomba, M., Navarra, R., Morabito, C., Mariggiò, M.A., Sensi, S.L., 2016. Altered Kv2.1 functioning promotes 
increased excitability in hippocampal neurons of an Alzheimer’s disease mouse model. Cell Death Dis. 7, e2100. 
Freir, D.B., Costello, D.A., Herron, C.E., 2003. Aβ25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is 
attenuated by verapamil. J. Neurophysiol. 89. 
Freir, D.B., Nicoll, A.J., Klyubin, I., Panico, S., Mc Donald, J.M., Risse, E., Asante, E.A., Farrow, M.A., Sessions, R.B., Saibil, H.R., Clarke, 
A.R., Rowan, M.J., Walsh, D.M., Collinge, J., 2011. Interaction between prion protein and toxic amyloid β assemblies can be 
therapeutically targeted at multiple sites. Nat. Commun. 2, 336. 
Frieden, C., Garai, K., 2012. Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer’s 
disease. Proc. Natl. Acad. Sci. 109, 8913–8918. 
Friedlander, R.M., 2003. Apoptosis and Caspases in Neurodegenerative Diseases. N. Engl. J. Med. 348, 1365–1375. 
Friedlich, A.L., Lee, J.-Y., van Groen, T., Cherny, R.A., Volitakis, I., Cole, T.B., Palmiter, R.D., Koh, J.-Y., Bush, A.I., 2004. Neuronal Zinc 
Exchange with the Blood Vessel Wall Promotes Cerebral Amyloid Angiopathy in an Animal Model of Alzheimer’s Disease. J. Neurosci. 
24, 3453–3459. 
Frisoni, G.B., Ganzola, R., Canu, E., Rub, U., Pizzini, F.B., Alessandrini, F., Zoccatelli, G., Beltramello, A., Caltagirone, C., Thompson, P.M., 
2008. Mapping local hippocampal changes in Alzheimer’s disease and normal ageing with MRI at 3 Tesla. Brain 131, 3266–3276. 
Fritz, N., Macrez, N., Mironneau, J., Jeyakumar, L.H., Fleischer, S., Morel, J.-L., 2005. Ryanodine receptor subtype 2 encodes Ca2+ oscillations 
activated by acetylcholine via the M2 muscarinic receptor/cADP-ribose signalling pathway in duodenum myocytes. J. Cell Sci. 118, 
2261–70. 
Fruen, B.R., Bardy, J.M., Byrem, T.M., Strasburg, G.M., Louis, C.F., 2000. Differential Ca(2+) sensitivity of skeletal and cardiac muscle 
ryanodine receptors in the presence of calmodulin. Am. J. Physiol. Cell Physiol. 279, C724-33. 
Fryer, J.D., Demattos, R.B., McCormick, L.M., O’Dell, M.A., Spinner, M.L., Bales, K.R., Paul, S.M., Sullivan, P.M., Parsadanian, M., Bu, G., 
Holtzman, D.M., 2005. The low density lipoprotein receptor regulates the level of central nervous system human and murine 
apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 280, 25754–9. 
Fujii, S., Matsumoto, M., Igarashi, K., Kato, H., Mikoshiba, K., 2000. Synaptic plasticity in hippocampal CA1 neurons of mice lacking type 1 
inositol-1,4,5-trisphosphate receptors. Learn. Mem. 7, 312–20. 
Fukumoto, H., Cheung, B.S., Hyman, B.T., Irizarry, M.C., 2002. Beta-secretase protein and activity are increased in the neocortex in Alzheimer 
disease. Arch. Neurol. 59, 1381–9. 
Fukushi, Y., Kato, I., Takasawa, S., Sasaki, T., Ong, B.H., Sato, M., Ohsaga, A., Sato, K., Shirato, K., Okamoto, H., Maruyama, Y., 2001. 
Identification of cyclic ADP-ribose-dependent mechanisms in pancreatic muscarinic Ca(2+) signaling using CD38 knockout mice. J. 
Biol. Chem. 276, 649–55. 
Fulceri, R., Rossi, R., Bottinelli, R., Conti, A., Intravaia, E., Galione, A., Benedetti, A., Sorrentino, V., Reggiani, C., 2001. Ca2+ release induced 
by cyclic ADP ribose in mice lacking type 3 ryanodine receptor. Biochem. Biophys. Res. Commun. 288, 697–702. 
Furuichi, T., Kohda, K., Miyawaki, A., Mikoshiba, K., 1994. Intracellular channels. Curr. Opin. Neurobiol. 4, 294–303. 
Furukawa, K., Wang, Y., Yao, P.J., Fu, W., Mattson, M.P., Itoyama, Y., Onodera, H., D’Souza, I., Poorkaj, P.H., Bird, T.D., Schellenberg, G.D., 
2003. Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau 
mutation. J. Neurochem. 87. 
Futagi, D., Kitano, K., 2015. Ryanodine-receptor-driven intracellular calcium dynamics underlying spatial association of synaptic plasticity. J. 
Comput. Neurosci. 39, 329–347. 
Gabellini, N., Manev, R.M., Candeo, P., Favaron, M., Manev, H., 1993. Carboxyl domain of glutamate receptor directs its coupling to metabolic 
pathways. Neuroreport 4, 531–4. 
Gafni, J., Munsch, J.A., Lam, T.H., Catlin, M.C., Costa, L.G., Molinski, T.F., Pessah, I.N., 1997. Xestospongins: Potent Membrane Permeable 
Blockers of the Inositol 1,4,5-Trisphosphate Receptor. Neuron 19, 723–733. 
Galimberti, D., Scarpini, E., 2011. Behavioral Genetics of Neurodegenerative Disorders. In: Current Topics in Behavioral Neurosciences. pp. 
615–631. 
Galione, A., 2011. NAADP Receptors. Cold Spring Harb. Perspect. Biol. 3, a004036–a004036. 
Galione, A., Lee, H.C., Busa, W.B., 1991. Ca(2+)-induced Ca2+ release in sea urchin egg homogenates: modulation by cyclic ADP-ribose. 
Science 253, 1143–6. 
Galione, A., White, A., Willmott, N., Turner, M., Potter, B.V.L., Watson, S.P., 1993. cGMP mobilizes intracellular Ca2+ in sea urchin eggs by 
stimulating cyclic ADP-ribose synthesis. Nature 365, 456–459. 
Gallego-Sandín, S., Alonso, M.T., García-Sancho, J., 2011. Calcium homoeostasis modulator 1 (CALHM1) reduces the calcium content of the 
endoplasmic reticulum (ER) and triggers ER stress. Biochem. J. 437. 
Galvan, V., Gorostiza, O.F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson, E., Sagi, S.A., Chevallier, N., Jin, K., Greenberg, 
D.A., Bredesen, D.E., 2006. Reversal of Alzheimer’s-like pathology and behavior in human APP transgenic mice by mutation of 
Asp664. Proc. Natl. Acad. Sci. 103, 7130–7135. 
Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., Miller, R., 
Berry, R.W., Binder, L.I., Cryns, V.L., 2003. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s 
disease. Proc. Natl. Acad. Sci. U. S. A. 100, 10032–7. 
Gandy, S.E., Caporaso, G.L., Buxbaum, J.D., de Cruz Silva, O., Iverfeldt, K., Nordstedt, C., Suzuki, T., Czernik, A.J., Nairn, A.C., Greengard, P., 





Ann. N. Y. Acad. Sci. 695, 117–21. 
Gant, J.C., Blalock, E.M., Chen, K.-. C., Kadish, I., Porter, N.M., Norris, C.M., Thibault, O., Landfield, P.W., 2014. FK506-binding protein 
1b/12.6: A key to aging-related hippocampal Ca2+ dysregulation? Eur. J. Pharmacol. 739, 74–82. 
Gao, Y., Vanhoutte, P.M., 2014. Tissues cIMPly do not lie. Naunyn. Schmiedebergs. Arch. Pharmacol. 387, 901–903. 
Garaschuk, O., Yaari, Y., Konnerth, A., 1997. Release and sequestration of calcium by ryanodine-sensitive stores in rat hippocampal neurones. J. 
Physiol. 502 ( Pt 1), 13–30. 
Gasser, A., Bruhn, S., Guse, A.H., 2006a. Second messenger function of nicotinic acid adenine dinucleotide phosphate revealed by an improved 
enzymatic cycling assay. J. Biol. Chem. 281, 16906–16913. 
Gasser, A., Glassmeier, G., Fliegert, R., Langhorst, M.F., Meinke, S., Hein, D., Krüger, S., Weber, K., Heiner, I., Oppenheimer, N., Schwarz, 
J.R., Guse, A.H., 2006b. Activation of T Cell Calcium Influx by the Second Messenger ADP-ribose. J. Biol. Chem. 281, 2489–2496. 
Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B., Mortimer, J.A., Berg, S., Fiske, A., Pedersen, N.L., 2006. Role of genes and 
environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63, 168–74. 
Gee, C.E., Benquet, P., Gerber, U., 2003. Group I metabotropic glutamate receptors activate a calcium-sensitive transient receptor potential-like 
conductance in rat hippocampus. J. Physiol. 546, 655–64. 
Geiger, J., Zou, A.P., Campbell, W.B., Li, P.L., 2000. Inhibition of cADP-ribose formation produces vasodilation in bovine coronary arteries. 
Hypertens. (Dallas, Tex.  1979) 35, 397–402. 
Gella, A., Durany, N., 2009. Oxidative stress in Alzheimer disease. Cell Adh. Migr. 3, 88–93. 
Gelman, L., Deterre, P., Gouy, H., Boumsell, L., Debré, P., Bismuth, G., 1993. The lymphocyte surface antigen CD38 acts as a nicotinamide 
adenine dinucleotide glycohydrolase in human T lymphocytes. Eur. J. Immunol. 23, 3361–4. 
Genetos, D.C., Cheung, W.K., Decaris, M.L., Leach, J.K., 2010. Oxygen tension modulates neurite outgrowth in PC12 cells through a mechanism 
involving HIF and VEGF. J. Mol. Neurosci. 40, 360–6. 
Gerasimenko, J. V., Maruyama, Y., Yano, K., Dolman, N.J., Tepikin, A. V., Petersen, O.H., Gerasimenko, O. V., 2003. NAADP mobilizes Ca2+ 
from a thapsigargin-sensitive store in the nuclear envelope by activating ryanodine receptors. J. Cell Biol. 163, 271–282. 
Gerasimenko, J. V., Sherwood, M., Tepikin, A. V., Petersen, O.H., Gerasimenko, O. V., 2006. NAADP, cADPR and IP3 all release Ca2+ from 
the endoplasmic reticulum and an acidic store in the secretory granule area. J. Cell Sci. 119. 
Gerrard, J.L., Burke, S.N., McNaughton, B.L., Barnes, C.A., 2008. Sequence reactivation in the hippocampus is impaired in aged rats. J. 
Neurosci. 28, 7883–90. 
Gervais, F.G., Xu, D., Robertson, G.S., Vaillancourt, J.P., Zhu, Y., Huang, J., LeBlanc, A., Smith, D., Rigby, M., Shearman, M.S., Clarke, E.E., 
Zheng, H., Van Der Ploeg, L.H., Ruffolo, S.C., Thornberry, N.A., Xanthoudakis, S., Zamboni, R.J., Roy, S., Nicholson, D.W., 1999. 
Involvement of caspases in proteolytic cleavage of Alzheimer’s amyloid-beta precursor protein and amyloidogenic A beta peptide 
formation. Cell 97, 395–406. 
Gimbel, D.A., Nygaard, H.B., Coffey, E.E., Gunther, E.C., Laurén, J., Gimbel, Z.A., Strittmatter, S.M., 2010. Memory Impairment in Transgenic 
Alzheimer Mice Requires Cellular Prion Protein. J. Neurosci. 30. 
Giorgi, C., Baldassari, F., Bononi, A., Bonora, M., De Marchi, E., Marchi, S., Missiroli, S., Patergnani, S., Rimessi, A., Suski, J.M., Wieckowski, 
M.R., Pinton, P., 2012. Mitochondrial Ca2+ and apoptosis. Cell Calcium 52, 36–43. 
Giorgi, C., De Stefani, D., Bononi, A., Rizzuto, R., Pinton, P., 2009. Structural and functional link between the mitochondrial network and the 
endoplasmic reticulum. Int. J. Biochem. Cell Biol. 41. 
Giuffrida, M.L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., 
Garozzo, D., Nicoletti, F., Rizzarelli, E., Copani, A., 2009. β-Amyloid Monomers Are Neuroprotective. J. Neurosci. 29. 
Giuliani, D., Ottani, A., Zaffe, D., Galantucci, M., Strinati, F., Lodi, R., Guarini, S., 2013. Hydrogen sulfide slows down progression of 
experimental Alzheimer’s disease by targeting multiple pathophysiological mechanisms. Neurobiol. Learn. Mem. 104, 82–91. 
Glabe, C.G., 2008. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283. 
Glabe, C.G., Kayed, R., 2006. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. 
Neurology 66, S74–S78. 
Glick, D.L., Hellmich, M.R., Beushausen, S., Tempst, P., Bayley, H., Strumwasser, F., 1991. Primary structure of a molluscan egg-specific 
NADase, a second-messenger enzyme. Cell Regul. 2, 211–8. 
Goedert, M., Spillantini, M.G., Jakes, R., Rutherford, D., Crowther, R.A., 1989. Multiple isoforms of human microtubule-associated protein tau: 
sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3, 519–26. 
Golby, A., Silverberg, G., Race, E., Gabrieli, S., O’Shea, J., Knierim, K., Stebbins, G., Gabrieli, J., 2005. Memory encoding in Alzheimer’s 
disease: an fMRI study of explicit and implicit memory. Brain 128, 773–787. 
Gómez-Isla, T., Price, J.L., McKeel, D.W., Morris, J.C., Growdon, J.H., Hyman, B.T., 1996. Profound loss of layer II entorhinal cortex neurons 
occurs in very mild Alzheimer’s disease. J. Neurosci. 16, 4491–500. 
Gong, B., Pan, Y., Vempati, P., Zhao, W., Knable, L., Ho, L., Wang, J., Sastre, M., Ono, K., Sauve, A.A., Pasinetti, G.M., 2013. Nicotinamide 
riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation 
and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol. Aging 34, 1581–8. 
González-García, M., García, I., Ding, L., O’Shea, S., Boise, L.H., Thompson, C.B., Núñez, G., 1995. bcl-x is expressed in embryonic and 
postnatal neural tissues and functions to prevent neuronal cell death. Proc. Natl. Acad. Sci. U. S. A. 92, 4304–8. 
González-García, M., Pérez-Ballestero, R., Ding, L., Duan, L., Boise, L.H., Thompson, C.B., Núñez, G., 1994. bcl-XL is the major bcl-x mRNA 
form expressed during murine development and its product localizes to mitochondria. Development 120, 3033–42. 
González-Sánchez, P., del Arco, A., Esteban, J.A., Satrústegui, J., 2017. Store-Operated Calcium Entry Is Required for mGluR-Dependent Long 
Term Depression in Cortical Neurons. Front. Cell. Neurosci. 11, 363. 
Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., Greengard, P., 
Relkin, N.R., 2000. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 156, 15–20. 
Goussakov, I., Miller, M.B., Stutzmann, G.E., 2010. NMDA-Mediated Ca 2 ϩ Influx Drives Aberrant Ryanodine Receptor Activation in 
Dendrites of Young Alzheimer ’ s Disease Mice. J Neurosci 30, 12128–12137. 
Graeff, R., Liu, Q., Kriksunov, I.A., Hao, Q., Lee, H.C., 2006. Acidic Residues at the Active Sites of CD38 and ADP-ribosyl Cyclase Determine 
Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Synthesis and Hydrolysis Activities. J. Biol. Chem. 281, 28951–28957. 
Graeff, R.M., Franco, L., De Flora, A., Lee, H.C., 1998. Cyclic GMP-dependent and -independent effects on the synthesis of the calcium 





Graeff, R.M., Walseth, T.F., Fryxell, K., Branton, W.D., Lee, H.C., 1994. Enzymatic synthesis and characterizations of cyclic GDP-ribose. A 
procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. J. Biol. Chem. 269, 30260–7. 
Graeff, R.M., Walseth, T.F., Hill, H.K., Lee, H.C., 1996. Fluorescent Analogs of Cyclic ADP-Ribose:  Synthesis, Spectral Characterization, and 
Use †. Biochemistry 35, 379–386. 
Graham, D., Darles, G., Langer, S.Z., 1992. The neuroprotective properties of ifenprodil, a novel NMDA receptor antagonist, in neuronal cell 
culture toxicity studies. Eur. J. Pharmacol. 226, 373–6. 
Gralle, M., Ferreira, S.T., 2007. Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. 
Prog. Neurobiol. 82, 11–32. 
Grant, S.G.N., O’Dell, T.J., Karl, K.A., Stein, P.L., Soriano, P., Kandel, E.R., 1992. Impaired long-term potentiation, spatial learning, and 
hippocampal development in fyn mutant mice. Science (80-. ). 258. 
Green, K.N., LaFerla, F.M., 2008. Linking Calcium to Aβ and Alzheimer’s Disease. Neuron 59, 190–194. 
Green, K.N., Smith, I.F., Laferla, F.M., 2007. Role of calcium in the pathogenesis of Alzheimer’s disease and transgenic models. Subcell. 
Biochem. 45. 
Green, K.N.K.N., Demuro, A., Akbari, Y., Hitt, B.D.B.D., Smith, I.F.I.F., Parker, I., LaFerla, F.M.F.M., 2008. SERCA pump activity is 
physiologically regulated by presenilin and regulates amyloid β production 181. 
Greenfield, J.P., Tsai, J., Gouras, G.K., Hai, B., Thinakaran, G., Checler, F., Sisodia, S.S., Greengard, P., Xu, H., 1999. Endoplasmic reticulum 
and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc. Natl. Acad. Sci. U. S. A. 96, 742–7. 
Grehan, S., Tse, E., Taylor, J.M., 2001. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in 
the brain. J. Neurosci. 21, 812–22. 
Griffin, W.S.T., 2006. Inflammation and neurodegenerative diseases 1 – 4. Am. J. Clin. Nutr. 83(suppl), 470S–4S. 
Grill, R.J., Pixley, S.K., 1993. 2-Mercaptoethanol is a survival factor for olfactory, cortical and hippocampal neurons in short-term dissociated 
cell culture. Brain Res. 613, 168–72. 
Gruszczynska-Biegala, J., Kuznicki, J., 2013. Native STIM2 and ORAI1 proteins form a calcium-sensitive and thapsigargin-insensitive complex 
in cortical neurons. J. Neurochem. 126, 727–738. 
Gruszczynska-Biegala, J., Pomorski, P., Wisniewska, M.B., Kuznicki, J., Chu, G., 2011. Differential Roles for STIM1 and STIM2 in Store-
Operated Calcium Entry in Rat Neurons. PLoS One 6, e19285. 
Guerineau, N., Bossu, J., Gahwiler, B., Gerber, U., 1995. Activation of a nonselective cationic conductance by metabotropic glutamatergic and 
muscarinic agonists in CA3 pyramidal neurons of the rat hippocampus. J. Neurosci. 15. 
Guérineau, N.C., Gähwiler, B.H., Gerber, U., 1994. Reduction of resting K+ current by metabotropic glutamate and muscarinic receptors in rat 
CA3 cells: mediation by G-proteins. J. Physiol. 474, 27–33. 
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J.S.K., Younkin, S., Hazrati, L., 
Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J.-C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St. 
George-Hyslop, P., Singleton, A., Hardy, J., Alzheimer Genetic Analysis Group, 2013. TREM2 Variants in Alzheimer’s Disease. N. 
Engl. J. Med. 368, 117–127. 
Guida, L., Bruzzone, S., Sturla, L., Franco, L., Zocchi, E., De Flora, A., 2002. Equilibrative and concentrative nucleoside transporters mediate 
influx of extracellular cyclic ADP-ribose into 3T3 murine fibroblasts. J. Biol. Chem. 277, 47097–105. 
Guida, L., Franco, L., Bruzzone, S., Sturla, L., Zocchi, E., Basile, G., Usai, C., De Flora, A., 2004. Concentrative influx of functionally active 
cyclic ADP-ribose in dimethyl sulfoxide-differentiated HL-60 cells. J. Biol. Chem. 279, 22066–75. 
Gul, R., Kim, S.-J.S.-Y.S.-J.S.-Y., Park, K.-H.K.-H., Kim, B.-J.B.-J., Kim, S.-J.S.-Y.S.-J.S.-Y., Im, M.-J.M.-J.M.-J., Kim, U.-H., 2008. A novel 
signaling pathway of ADP-ribosyl cyclase activation by angiotensin II in adult rat cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 
295, H77–H88. 
Gul, R., Park, D.-R., Shawl, A.I., Im, S.-Y., Nam, T.-S., Lee, S.-H., Ko, J.-K., Jang, K.Y., Kim, D., Kim, U.-H., 2016. Nicotinic Acid Adenine 
Dinucleotide Phosphate (NAADP) and Cyclic ADP-Ribose (cADPR) Mediate Ca2+ Signaling in Cardiac Hypertrophy Induced by β-
Adrenergic Stimulation. PLoS One 11, e0149125. 
Guo, Q., Christakos, S., Robinson, N., Mattson, M.P., 1998. Calbindin D28K blocks the proapoptotic actions of mutant presenilin 1: Reduced 
oxidative stress and preserved mitochondrial function. Proc. Natl. Acad. Sci. U. S. A. 95. 
Guo, Q., Fu, W., Sopher, B.L., Miller, M.W., Ware, C.B., Martin, G.M., Mattson, M.P., 1999. Increased vulnerability of hippocampal neurons to 
excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat. Med. 5, 101–107. 
Guo, Q., Furukawa, K., Sopher, B.L., Pham, D.G., Xie, J., Robinson, N., Martin, G.M., Mattson, M.P., 1996. Alzheimer’s PS-1 mutation perturbs 
calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport 8, 379–83. 
Guo, Q., Li, H., Gaddam, S.S.K., Justice, N.J., Robertson, C.S., Zheng, H., 2012. Amyloid Precursor Protein Revisited: Neuron-specific 
expression and highly stable nature of soluble derivatives. J. Biol. Chem. 287, 2437–2445. 
Guo, Q., Sopher, B.L., Furukawa, K., Pham, D.G., Robinson, N., Martin, G.M., Mattson, M.P., 1997. Alzheimer’s Presenilin Mutation Sensitizes 
Neural Cells to Apoptosis Induced by Trophic Factor Withdrawal and Amyloid β-Peptide: Involvement of Calcium and Oxyradicals. J. 
Neurosci. 17. 
Guo, X., Becker, P.L., 1997. Cyclic ADP-ribose-gated Ca2+ release in sea urchin eggs requires an elevated [Ca2+]i. J. Biol. Chem. 272, 16984–
9. 
Gupta, V.B., Laws, S.M., Villemagne, V.L., Ames, D., Bush, A.I., Ellis, K.A., Lui, J.K., Masters, C., Rowe, C.C., Szoeke, C., Taddei, K., 
Martins, R.N., AIBL Research Group, 2011. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 
76, 1091–8. 
Guse, A.H., 1999. Cyclic ADP-ribose: A Novel Ca2+-Mobilising Second Messenger. Cell. Signal. 11, 309–316. 
Guse, A.H., 2004. Regulation of calcium signaling by the second messenger cyclic adenosine diphosphoribose (cADPR). Curr. Mol. Med. 4, 
239–48. 
Guse, A.H., da Silva, C.P., Berg, I., Skapenko, A.L., Weber, K., Heyer, P., Hohenegger, M., Ashamu, G.A., Schulze-Koops, H., Potter, B. V, 
Mayr, G.W., 1999. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature 398, 70–3. 
Guse, A.H., Goldwich, A., Weber, K., Mayr, G.W., 1995. Non-radioactive, isomer-specific inositol phosphate mass determinations: high-
performance liquid chromatography-micro-metal-dye detection strongly improves speed and sensitivity of analyses from cells and micro-
enzyme assays. J. Chromatogr. B Biomed. Sci. Appl. 672, 189–198. 
Guse, A.H., Gu, X., Zhang, L.L., Weber, K., Krämer, E., Yang, Z., Jin, H., Li, Q., Carrier, L., Zhang, L.L., 2005. A minimal structural analogue 





Guse, A.H., Roth, E., Emmrich, F., 1992. d-myo-inositol 1,3,4,5-tetrakisphosphate releases Ca2+ from crude microsomes and enriched vesicular 
plasma membranes, but not from intracellular stores of permeabilized T-lymphocytes and monocytes. Biochem. J. 288. 
Guse, A.H., Tsygankov, A.Y., Weber, K., Mayr, G.W., 2001. Transient tyrosine phosphorylation of human ryanodine receptor upon T cell 
stimulation. J. Biol. Chem. 276, 34722–7. 
Györke, S., Terentyev, D., 2008. Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. 
Cardiovasc. Res. 77. 
Haag, F., Adriouch, S., Bra?, A., Jung, C., M?ller, S., Scheuplein, F., Bannas, P., Seman, M., Koch-Nolte, F., 2007. Extracellular NAD and ATP: 
Partners in immune cell modulation. Purinergic Signal. 3, 71–81. 
Haas, L.T., Kostylev, M.A., Strittmatter, S.M., 2014. Therapeutic molecules and endogenous ligands regulate the interaction between brain 
cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). J. Biol. Chem. 289. 
Haas, L.T., Salazar, S. V., Kostylev, M.A., Um, J.W., Kaufman, A.C., Strittmatter, S.M., 2016. Metabotropic glutamate receptor 5 couples 
cellular prion protein to intracellular signalling in Alzheimer’s disease. Brain 139, 526–546. 
Haass, C., 2004. Take five—BACE and the γ-secretase quartet conduct Alzheimer’s amyloid β-peptide generation. EMBO J. 23, 483–488. 
Haass, C., Hung, A.Y., Schlossmacher, M.G., Oltersdorf, T., Teplow, D.B., Selkoe, D.J., 1993a. Normal cellular processing of the beta-amyloid 
precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann. N. Y. Acad. Sci. 695, 109–16. 
Haass, C., Hung, A.Y., Schlossmacher, M.G., Teplow, D.B., Selkoe, D.J., 1993b. beta-Amyloid peptide and a 3-kDa fragment are derived by 
distinct cellular mechanisms. J. Biol. Chem. 268, 3021–4. 
Habermacher, C., Dunning, K., Chataigneau, T., Grutter, T., 2016. Molecular structure and function of P2X receptors. Neuropharmacology 104, 
18–30. 
Hachisuka, J., Soga-Sakakibara, S., Kubota, M., Narita, K., Kuba, K., 2007. Enhancement of Ca2+-induced Ca2+ release by cyclic ADP-ribose in 
frog motor nerve terminals. Neuroscience 146, 123–34. 
Haigis, M.C., Sinclair, D.A., 2010. Mammalian Sirtuins: Biological Insights and Disease Relevance. Annu. Rev. Pathol. Mech. Dis. 5, 253–295. 
Hall, P.E., Lathia, J.D., Caldwell, M.A., Ffrench-Constant, C., 2008. Laminin enhances the growth of human neural stem cells in defined culture 
media. BMC Neurosci. 9, 71. 
Hamid, R., Kilger, E., Willem, M., Vassallo, N., Kostka, M., Bornhövd, C., Reichert, A.S., Kretzschmar, H.A., Haass, C., Herms, J., 2007. 
Amyloid precursor protein intracellular domain modulates cellular calcium homeostasis and ATP content. J. Neurochem. 102, 1264–
1275. 
Hamilton, A., Vasefi, M., Vander Tuin, C., McQuaid, R.J.J., Anisman, H., Ferguson, S.S.G.S.G., Vander Tuin, C., McQuaid, R.J.J., Anisman, H., 
Ferguson, S.S.G.S.G., 2016. Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in 
an Alzheimer Disease Mouse Model. Cell Rep. 15, 1859–1865. 
Hamos, J.E., DeGennaro, L.J., Drachman, D.A., 1989. Synaptic loss in Alzheimer’s disease and other dementias. Neurology 39, 355–61. 
Han, B.H., Xu, D., Choi, J., Han, Y., Xanthoudakis, S., Roy, S., Tam, J., Vaillancourt, J., Colucci, J., Siman, R., Giroux, A., Robertson, G.S., 
Zamboni, R., Nicholson, D.W., Holtzman, D.M., 2002. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct 
pathways of cell death after neonatal hypoxic-ischemic brain injury. J. Biol. Chem. 277, 30128–36. 
Han, M.-K., Kim, S.-J., Park, Y.-R., Shin, Y.-M., Park, H.-J., Park, K.-J., Park, K.-H., Kim, H.-K., Jang, S.-I., An, N.-H., Kim, U.-H., 2002. 
Antidiabetic effect of a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, through CD38 dimerization and internalization. J. 
Biol. Chem. 277, 5315–5321. 
Hannan, A.J., Blakemore, C., Katsnelson, A., Vitalis, T., Huber, K.M., Bear, M., Roder, J., Kim, D., Shin, H.-S., Kind, P.C., 2001. PLC-β1, 
activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex. Nat. Neurosci. 4, 282–288. 
Hanson, C.J., Bootman, M.D., Distelhorst, C.W., Wojcikiewicz, R.J.H., Roderick, H.L., 2008. Bcl-2 suppresses Ca2+ release through inositol 
1,4,5-trisphosphate receptors and inhibits Ca2+ uptake by mitochondria without affecting ER calcium store content. Cell Calcium 44, 
324–338. 
Harada, J., Sugimoto, M., 1999. Activation of caspase-3 in beta-amyloid-induced apoptosis of cultured rat cortical neurons. Brain Res. 842, 311–
23. 
Hardman, J.G., Robison, G.A., Sutherland, E.W., 1971. Cyclic Nucleotides. Annu. Rev. Physiol. 33, 311–336. 
Hardy, J., Duff, K., Hardy, K.G., Perez-Tur, J., Hutton, M., 1998. Genetic dissection of Alzheimer’s disease and related dementias: amyloid and 
its relationship to tau. Nat. Neurosci. 1, 355–358. 
Hardy, J.A., Higgins, G.A., 1992. Alzheimer’s disease: the amyloid cascade hypothesis. Science (80-. ). 256. 
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Hamshere, M., Pahwa, J.S., Moskvina, V., Williams, A., Jones, N., Thomas, C., Stretton, 
A., Lovestone, S., Powell, J., Proitsi, P., Lupton, M.K., Rubinsztein, D.C., Gill, M., Lawlor, B., Lynch, A., Brown, K., Passmore, P., 
Craig, D., Mcguinness, B., Todd, S., Holmes, C., Mann, D., Smith,  a D., Love, S., Patrick, G., Hardy, J., Mead, S., Fox, N., Rossor, M., 
Collinge, J., Wichmann, H., Carrasquillo, M.M., Pankratz, V.S., 2009. Genome-Wide Association Study Identifies Variants at CLU and 
PICALM Associated with Alzheimer’s Disease, and Shows Evidence for Additional Susceptibility Genes. Nat. Genet. 41, 1088–1093. 
Harris, J., Lee, H., Tu, C.T., Cribbs, D., Cotman, C., Jeon, N.L., 2007. Preparing E18 Cortical Rat Neurons for Compartmentalization in a 
Microfluidic Device. J. Vis. Exp. e305–e305. 
Harris, K.M., Weinberg, R.J., 2012. Ultrastructure of synapses in the mammalian brain. Cold Spring Harb. Perspect. Biol. 4, a005587. 
Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., Teplow, D.B., Selkoe, D.J., 1999. Protofibrillar Intermediates of 
Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons. J. Neurosci. 19. 
Hartley, T., Lever, C., Burgess, N., O’Keefe, J., 2013. Space in the brain: how the hippocampal formation supports spatial cognition. Philos. 
Trans. R. Soc. B Biol. Sci. 369, 20120510–20120510. 
Harvey, J., Collingridge, G.L., 1993. Signal transduction pathways involved in the acute potentiation of NMDA responses by 1S,3R-ACPD in rat 
hippocampal slices. Br. J. Pharmacol. 109, 1085–90. 
Hashii, M., Minabe, Y., Higashida, H., 2000a. voltage-activated Ca 2 + channels in NG108-15 neuronal cells. Society 215, 207–215. 
Hashii, M., Minabe, Y., Higashida, H., 2000b. cADP-ribose potentiates cytosolic Ca2+ elevation and Ca2+ entry via L-type voltage-activated 
Ca2+ channels in NG108-15 neuronal cells. Biochem. J. 345 Pt 2, 207–15. 
Hass, M.R., Yankner, B.A., 2005. A {gamma}-secretase-independent mechanism of signal transduction by the amyloid precursor protein. J. Biol. 
Chem. 280, 36895–904. 
Hassa, P.O., Hottiger, M.O., 2008. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose 





Hassanpoor, H., Fallah, A., Raza, M., 2013. Effect of BDNF secretion by astrocyte on learning and memory: A modeling approach. In: 2013 2nd 
International Conference on Advances in Biomedical Engineering, ICABME 2013. 
Hayashi, H., Campenot, R.B., Vance, D.E., Vance, J.E., 2004. Glial lipoproteins stimulate axon growth of central nervous system neurons in 
compartmented cultures. J. Biol. Chem. 279, 14009–15. 
Hayashi, H., Campenot, R.B., Vance, D.E., Vance, J.E., 2007. Apolipoprotein E-Containing Lipoproteins Protect Neurons from Apoptosis via a 
Signaling Pathway Involving Low-Density Lipoprotein Receptor-Related Protein-1. J. Neurosci. 27. 
Hayashi, H., Campenot, R.B., Vance, D.E., Vance, J.E., 2009. Protection of neurons from apoptosis by apolipoprotein E-containing lipoproteins 
does not require lipoprotein uptake and involves activation of phospholipase Cgamma1 and inhibition of calcineurin. J. Biol. Chem. 284, 
29605–13. 
Hayashi, Y., Majewska, A.K., 2005. Dendritic Spine Geometry: Functional Implication and Regulation. Neuron 46, 529–532. 
Hayrapetyan, V., Rybalchenko, V., Rybalchenko, N., Koulen, P., 2008. The N-terminus of presenilin-2 increases single channel activity of brain 
ryanodine receptors through direct protein–protein interaction. Cell Calcium 44, 507–518. 
He, H., Lam, M., McCormick, T.S., Distelhorst, C.W., 1997. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. J. Cell 
Biol. 138, 1219–28. 
Hermans, E., Challiss, R.A., 2001. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic 
family C G-protein-coupled receptors. Biochem. J. 359, 465–84. 
Herms, J., Schneider, I., Dewachter, I., Caluwaerts, N., Kretzschmar, H., Van Leuven, F., 2003. Capacitive Calcium Entry Is Directly Attenuated 
by Mutant Presenilin-1, Independent of the Expression of the Amyloid Precursor Protein. J. Biol. Chem. 278, 2484–2489. 
Herrero, I., Miras-, Portugal, M., 1992. Positive feedback of glutamate exocytosis by metabotropic presynaptic receptor stimulation. J SÃ¡nchez-
Prieto Nat. 360. 
Herrup, K., 2015. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 18, 794–9. 
Hertz, L., Peng, L., Dienel, G.A., 2007. Energy Metabolism in Astrocytes: High Rate of Oxidative Metabolism and Spatiotemporal Dependence 
on Glycolysis/Glycogenolysis. J. Cereb. Blood Flow Metab. 27, 219–249. 
Herz, J., 2001. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 29, 571–81. 
Heuss, C., Scanziani, M., Gähwiler, B.H., Gerber, U., 1999. G-protein-independent signaling mediated by metabotropic glutamate receptors. Nat. 
Neurosci. 2, 1070–1077. 
Hick, M., Herrmann, U., Weyer, S.W., Mallm, J.-P., Tschäpe, J.-A., Borgers, M., Mercken, M., Roth, F.C., Draguhn, A., Slomianka, L., Wolfer, 
D.P., Korte, M., Müller, U.C., 2015. Acute function of secreted amyloid precursor protein fragment APPsα in synaptic plasticity. Acta 
Neuropathol. 129, 21–37. 
Higashida, H., 1997. ADP-ribosyl cyclase coupled with receptors via G protiens. FEBS Lett. 418, 355–356. 
Higashida, H., Egorova, A., Higashida, C., Zhong, Z.G., Yokoyama, S., Noda, M., Zhang, J.S., 1999. Sympathetic potentiation of cyclic ADP-
ribose formation in rat cardiac myocytes. J. Biol. Chem. 274, 33348–54. 
Higashida, H., Hashii, M., Yokoyama, S., Hoshi, N., Asai, K., Kato, T., 2001a. Cyclic ADP-ribose as a potential second messenger for neuronal 
Ca2+ signaling. J. Neurochem. 76, 321–31. 
Higashida, H., Salmina, A., Hashii, M., Yokoyama, S., Zhang, J.-S., Noda, M., Zhong, Z.-G., Jin, D., 2006. Bradykinin activates ADP-ribosyl 
cyclase in neuroblastoma cells: intracellular concentration decrease in NAD and increase in cyclic ADP-ribose. FEBS Lett. 580, 4857–
60. 
Higashida, H., Salmina, A.B., Olovyannikova, R.Y., Hashii, M., Yokoyama, S., Koizumi, K., Jin, D., Liu, H.-X., Lopatina, O., Amina, S., Islam, 
M.S., Huang, J.-J., Noda, M., 2007. Cyclic ADP-ribose as a universal calcium signal molecule in the nervous system. Neurochem. Int. 
51, 192–199. 
Higashida, H., Yokoyama, S., Hashii, M., Taketo, M., Higashida, M., Takayasu, T., Ohshima, T., Takasawa, S., Okamoto, H., Noda, M., 1997. 
Muscarinic receptor-mediated dual regulation of ADP-ribosyl cyclase in NG108-15 neuronal cell membranes. J. Biol. Chem. 272, 
31272–7. 
Higashida, H., Yokoyama, S., Hoshi, N., Hashii, M., Egorova, A., Zhong, Z.-G., Noda, M., Shahidullah, M., Taketo, M., Knijnik, R., Kimura, Y., 
Takahashi, H., Chen, X.-L., Shin, Y., Zhang, J.-S., 2001b. Signal Transduction from Bradykinin, Angiotensin, Adrenergic and 
Muscarinic Receptors to Effector Enzymes, Including ADP-Ribosyl Cyclase. Biol. Chem. 382, 23–30. 
Higashida, H., Yokoyama, S., Kikuchi, M., Munesue, T., 2012. CD38 and its role in oxytocin secretion and social behavior. Horm. Behav. 61, 
351–358. 
Higashida, H., Zhang, J.-S.S., Mochida, S., Chen, X.-L.L., Shin, Y., Noda, M., Hossain, K.Z., Hoshi, N., Hashii, M., Shigemoto, R., Nakanishi, 
S., Fukuda, Y., Yokoyama, S., 2003. Subtype-specific coupling with ADP-ribosyl cyclase of metabotropic glutamate receptors in retina, 
cervical superior ganglion and cells. J. Neurochem. 11481158 85, NG108-15. 
Higashida, H., Zhang, J., Hashii, M., Shintaku, M., Higashida, C., Takeda, Y., 2000. Angiotensin II stimulates cyclic ADP-ribose formation in 
neonatal rat cardiac myocytes. Biochem J Nov 15, 197–202. 
Himmler, A., Drechsel, D., Kirschner, M.W., Martin, D.W., 1989. Tau consists of a set of proteins with repeated C-terminal microtubule-binding 
domains and variable N-terminal domains. Mol. Cell. Biol. 9, 1381–8. 
Hirakura, Y., Lin, M.-C., Kagan, B.L., 1999. Alzheimer amyloid Aβ1-42 channels: Effects of solvent, pH, and Congo Red. J. Neurosci. Res. 57. 
Hirashima, N., Etcheberrigaray, R., Bergamaschi, S., Racchi, M., Battaini, F., Binetti, G., Govoni, S., Alkon, D.L., 1996. Calcium responses in 
human fibroblasts: A diagnostic molecular profile for Alzheimer’s disease. Neurobiol. Aging 17. 
Hirata, Y., Kimura, N., Sato, K., Ohsugi, Y., Takasawa, S., Okamoto, H., Ishikawa, J., Kaisho, T., Ishihara, K., Hirano, T., 1994. ADP ribosyl 
cyclase activity of a novel bone marrow stromal cell surface molecule, BST-1. FEBS Lett. 356, 244–8. 
Hirsch-Reinshagen, V., Wellington, C.L., 2007. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, 
and Alzheimer?s disease. Curr. Opin. Lipidol. 18, 325–332. 
Hisatsune, C., Nakamura, K., Kuroda, Y., Nakamura, T., Mikoshiba, K., 2005. Amplification of Ca2+ Signaling by Diacylglycerol-mediated 
Inositol 1,4,5-Trisphosphate Production. J. Biol. Chem. 280, 11723–11730. 
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R.D., Korsmeyer, S.J., 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks 
programmed cell death. Nature 348, 334–336. 
Hockenbery, D.M., Zutter, M., Hickeyt, W., Korsmeyer, S.J., 1991. BCL2 protein is topographically restricted in tissues characterized by 
apoptotic cell death. Cell Biol. 88, 6961–6. 





Hoeffer, C.A., Tang, W., Wong, H., Santillan, A., Patterson, R.J., Martinez, L.A., Tejada-Simon, M. V., Paylor, R., Hamilton, S.L., Klann, E., 
2008. Removal of FKBP12 Enhances mTOR-Raptor Interactions, LTP, Memory, and Perseverative/Repetitive Behavior. Neuron 60, 
832–845. 
Hoey, S.E., Williams, R.J., Perkinton, M.S., 2009. Synaptic NMDA Receptor Activation Stimulates  -Secretase Amyloid Precursor Protein 
Processing and Inhibits Amyloid-  Production. J. Neurosci. 29, 4442–4460. 
Hogins, J., Crawford, D.C., Zorumski, C.F., Mennerick, S., 2011. Excitotoxicity triggered by Neurobasal culture medium. PLoS One 6, e25633. 
Hohenegger, M., Suko, J., Gscheidlinger, R., Drobny, H., Zidar, A., 2002. Nicotinic acid-adenine dinucleotide phosphate activates the skeletal 
muscle ryanodine receptor. Biochem. J. 367, 423–431. 
Hollifield, R.D., Conklin, J.D., 1968. A spectrophotofluorometric procedure for the determination oxidase of dantrolene in blood and urine. Arch. 
Int. Pharmacod 174, 333–341. 
Holtzman, D.M., Morris, J.C., Goate, A.M., 2011. Alzheimer’s Disease: The Challenge of the Second Century. Sci. Transl. Med. 3, 77sr1-77sr1. 
Honarnejad, K., Jung, C.K.E., Lammich, S., Arzberger, T., Kretzschmar, H., Herms, J., 2013. Involvement of presenilin holoprotein upregulation 
in calcium dyshomeostasis of Alzheimer’s disease. J. Cell. Mol. Med. 17, 293–302. 
Hossain, S., Sesath Hewapathirane, D., Haas, K., 2012. Dynamic morphometrics reveals contributions of dendritic growth cones and filopodia to 
dendritogenesis in the intact and awake embryonic brain. Dev. Neurobiol. 72. 
Hotta, T., Asai, K., Fujita, K., Kato, T., Higashida, H., 2000. Membrane-bound form of ADP-ribosyl cyclase in rat cortical astrocytes in culture. J. 
Neurochem. 74, 669–75. 
Hou, L., Klann, E., 2004. Activation of the Phosphoinositide 3-Kinase-Akt-Mammalian Target of Rapamycin Signaling Pathway Is Required for 
Metabotropic Glutamate Receptor-Dependent Long-Term Depression. J. Neurosci. 24, 6352–6361. 
Howard, M., Grimaldi, J.C., Bazan, J.F., Lund, F.E., Santos-Argumedo, L., Parkhouse, R.M., Walseth, T.F., Lee, H.C., 1993. Formation and 
hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 262, 1056–1059. 
Hsia, A.Y., Masliah, E., McConlogue, L., Yu, G.Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R.C., Nicoll, R.A., Mucke, L., 1999. Plaque-
independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 96, 3228–33. 
Hsiao, K.K., Chapman, P.F., White, G.L., Jones, M.W., Cooper-Blacketer, D., Marshall, V.J., Irizarry, M., Younkin, L., Good, M.A., Bliss, 
T.V.P., Hyman, B.T., Younkin, S.G., 1999. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. 
Nat. Neurosci. 2, 271–276. 
Hu, G.-Y., Storm, J.F., 1991. Excitatory amino acids acting on metabotropic glutamate receptors broaden the action potential in hippocampal 
neurons, Brain Research. 
Hu, N.-W., Nicoll, A.J., Zhang, D., Mably, A.J., O’Malley, T., Purro, S.A., Terry, C., Collinge, J., Walsh, D.M., Rowan, M.J., 2014.  mGlu5 
receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo. Nat. Commun. 5, 3374. 
Hua, S.Y., Tokimasa, T., Takasawa, S., Furuya, Y., Nohmi, M., Okamoto, H., Kuba, K., Cyclic, A.D.P., 1994. ribose modulates Ca2+ release 
channels for activation by physiological Ca2+ entry in bullfrog sympathetic neurons. Neuron 12, 1073–1079. 
Huang, H., van den Pol, A.N., 2007. Rapid direct excitation and long-lasting enhancement of NMDA response by group I metabotropic glutamate 
receptor activation of hypothalamic melanin-concentrating hormone neurons. J. Neurosci. 27, 11560–72. 
Huang, H.M., Ou, H.C., Hsieh, S.J., 2000. Antioxidants prevent amyloid peptide-induced apoptosis and alteration of calcium homeostasis in 
cultured cortical neurons. Life Sci. 66, 1879–92. 
Huang, W.-J., Zhang, X., Chen, W.-W., 2016. Role of oxidative stress in Alzheimer’s disease. Biomed. reports 4, 519–522. 
Huang, Y., Mucke, L., 2012. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204–22. 
Hui, L., Geiger, N.H., Bloor-Young, D., Churchill, G.C., Geiger, J.D., Chen, X., 2015. Release of calcium from endolysosomes increases calcium 
influx through N-type calcium channels: Evidence for acidic store-operated calcium entry in neurons. Cell Calcium 58, 617–27. 
Huse, J.T., Pijak, D.S., Leslie, G.J., Lee, V.M.-Y., Doms, R.W., 2000. Maturation and Endosomal Targeting of  -Site Amyloid Precursor Protein-
cleaving Enzyme: THE ALZHEIMER’S DISEASE  -SECRETASE. J. Biol. Chem. 275, 33729–33737. 
Hussain, A.M.M., Lee, H.C., Chang, C.F., 1998. Functional Expression of Secreted Mouse BST-1 in Yeast. Protein Expr. Purif. 12, 133–137. 
Hyman, B.T., Kromer, L.J., Van Hoesen, G.W., 1988. A direct demonstration of the perforant pathway terminal zone in Alzheimer’s disease 
using the monoclonal antibody Alz-50. Brain Res. 450, 392–7. 
Hyman, B.T., Trojanowski, J.Q., 1997. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National 
Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer 
disease. J. Neuropathol. Exp. Neurol. 56, 1095–7. 
Hyman, B.T., Van Hoesen, G.W., Kromer, L.J., Damasio, A.R., 1986. Perforant pathway changes and the memory impairment of Alzheimer’s 
disease. Ann. Neurol. 20, 472–481. 
Ichise, T., Kano, M., Hashimoto, K., Yanagihara, D., Nakao, K., Shigemoto, R., Katsuki, M., Aiba, A., 2000. mGluR1 in cerebellar Purkinje cells 
essential for long-term depression, synapse elimination, and motor coordination. Science 288, 1832–5. 
Igelhorst, B.A., Niederkinkhaus, V., Karus, C., Lange, M.D., Dietzel, I.D., 2015. Regulation of neuronal excitability by release of proteins from 
glial cells. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 370. 
Ignatius, M.J., Gebicke-Härter, P.J., Skene, J.H., Schilling, J.W., Weisgraber, K.H., Mahley, R.W., Shooter, E.M., 1986. Expression of 
apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. U. S. A. 83, 1125–9. 
Ikeda, S.R., Lovinger, D.M., McCool, B.A., Lewis, D.L., 1995. Heterologous expression of metabotropic glutamate receptors in adult rat 
sympathetic neurons: subtype-specific coupling to ion channels. Neuron 14, 1029–38. 
Imai, S.-I., Guarente, L., 2014. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24. 
Inoue, S., 2008. In situ A beta pores in AD brain are cylindrical assembly of A beta protofilaments. Amyloid 15, 223–233. 
Iqbal, K., Grundke-Iqbal, I., Zaidi, T., Merz, P.A., Wen, G.Y., Shaikh, S.S., Wisniewski, H.M., Alafuzoff, I., Winblad, B., 1986. Defective brain 
microtubule assembly in Alzheimer’s disease. Lancet (London, England) 2, 421–6. 
Iqbal, K., Liu, F., Gong, C.X., Grundke-Iqbal, I., 2010. Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7. 
Ireland, D.R., Abraham, W.C., Group, I., 2002. mGluRs increase excitability of hippocampal CA1 pyramidal neurons by a PLC-independent 
mechanism. J. Neurophysiol. 88, 107–116. 
Ireland, D.R., Guevremont, D., Williams, J.M., Abraham, W.C., 2004. Metabotropic glutamate receptor-mediated depression of the slow 
afterhyperpolarization is gated by tyrosine phosphatases in hippocampal CA1 pyramidal neurons. J. Neurophysiol. 92, 2811–2819. 





hippocampal formation of Alzheimer’s disease. Neuropathology 21, 162–7. 
Irving, A.J., Collingridge, G.L., 1998. A characterization of muscarinic receptor-mediated intracellular Ca2+ mobilization in cultured rat 
hippocampal neurones. J. Physiol. 511 ( Pt 3), 747–59. 
Irving, A.J., Collingridge, G.L., Schofield, J.G., 1992. Interactions between Ca2+ mobilizing mechanisms in cultured rat cerebellar granule cells. 
J. Physiol. 456, 667–680. 
Irving, A.J., Coutts, A.A., Harvey, J., Rae, M.G., Mackie, K., Bewick, G.S., Pertwee, R.G., 2000. Functional expression of cell surface 
cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience 98, 253–62. 
Ishihara, K., Hirano, T., 2000. BST-1&amp;sol;CD157 Regulates the Humoral Immune Responses in vivo. In: Human CD38 and Related 
Molecules. KARGER, Basel, pp. 235–255. 
Ishii, K., Katayama, M., Hori, K., Yodoi, J., Nakanishi, T., 1993. Effects of 2-mercaptoethanol on survival and differentiation of fetal mouse 
brain neurons cultured in vitro. Neurosci. Lett. 163, 159–62. 
Ito, E., Oka, K., Etcheberrigaray, R., Nelson, T.J., McPhie, D.L., Tofel-Grehl, B., Gibson, G.E., Alkon, D.L., 1994. Internal Ca2+ mobilization is 
altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91, 534–8. 
Itoh, M., Ishihara, K., Tomizawa, H., Tanaka, H., Kobune, Y., Ishikawa, J., Kaisho, T., Hirano, T., 1994. Molecular cloning of murine BST-1 
having homology with CD38 and Aplysia ADP-ribosyl cyclase. Biochem. Biophys. Res. Commun. 203, 1309–17. 
Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B.C., Christie, M.J., Napier, I.A., Eckert, A., 
Staufenbiel, M., Hardeman, E., Götz, J., 2010. Dendritic function of tau mediates amyloid-β toxicity in alzheimer’s disease mouse 
models. Cell 142. 
Ivanova, H., Vervliet, T., Missiaen, L., Parys, J.B., De Smedt, H., Bultynck, G., 2014. Inositol 1,4,5-trisphosphate receptor-isoform diversity in 
cell death and survival. Biochim. Biophys. Acta - Mol. Cell Res. 1843, 2164–83. 
Ivenshitz, M., Segal, M., 2010. Neuronal density determines network connectivity and spontaneous activity in cultured hippocampus. J. 
Neurophysiol. 104. 
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y., 1994. Visualization of A beta 42(43) and A beta 40 in senile plaques 
with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45–53. 
Jack, C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., 2010. Hypothetical model of 
dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119–128. 
Jacobsen, J.S., Wu, C.-C., Redwine, J.M., Comery, T.A., Arias, R., Bowlby, M., Martone, R., Morrison, J.H., Pangalos, M.N., Reinhart, P.H., 
Bloom, F.E., 2006. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 
103, 5161–6. 
Jacobson, C., Schnapp, B., Banker, G.A., 2006. A Change in the Selective Translocation of the Kinesin-1 Motor Domain Marks the Initial 
Specification of the Axon. Neuron 49, 797–804. 
Jaffe, D.B., Brown, T.H., 1997. Calcium dynamics in thorny excrescences of CA3 pyramidal neurons. J. Neurophysiol. 78, 10–18. 
Jan, C.R., Ho, C.M., Wu, S.N., Tseng, C.J., 1998. The phospholipase C inhibitor U73122 increases cytosolic calcium in MDCK cells by 
activating calcium influx and releasing stored calcium. Life Sci. 63, 895–908. 
Jang, H., Arce, F.T., Ramachandran, S., Capone, R., Azimova, R., Kagan, B.L., Nussinov, R., Lal, R., 2010. Truncated beta-amyloid peptide 
channels provide an alternative mechanism for Alzheimer’s Disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 107, 6538–43. 
Jang, S.-S., Chung, H.J., 2016. Emerging Link between Alzheimer’s Disease and Homeostatic Synaptic Plasticity. Neural Plast. 2016, 1–19. 
Jarrard, L.E., 1993. On the role of the hippocampus in learning and memory in the rat. Behav. Neural Biol. 60, 9–26. 
Jarrett, J.T., Berger, E.P., Lansbury, P.T., 1993. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: 
implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32, 4693–7. 
Jayaraman, T., Ondriasová, E., Ondrias, K., Harnick, D.J., Marks, A.R., 1995. The inositol 1,4,5-trisphosphate receptor is essential for T-cell 
receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 92, 6007–11. 
Jefferson, T., Causevic, M., auf dem Keller, U., Schilling, O., Isbert, S., Geyer, R., Maier, W., Tschickardt, S., Jumpertz, T., Weggen, S., Bond, 
J.S., Overall, C.M., Pietrzik, C.U., Becker-Pauly, C., 2011. Metalloprotease Meprin   Generates Nontoxic N-terminal Amyloid Precursor 
Protein Fragments in Vivo. J. Biol. Chem. 286, 27741–27750. 
Jensen, V.S., Porsgaard, T., Lykkesfeldt, J., Hvid, H., 2016. Rodent model choice has major impact on variability of standard preclinical readouts 
associated with diabetes and obesity research. Am. J. Transl. Res. 8, 3574–84. 
Jia, Z., Lu, Y., Henderson, J., Taverna, F., Romano, C., Abramow-Newerly, W., Wojtowicz, J.M., Roder, J., 1998. Selective abolition of the 
NMDA component of long-term potentiation in mice lacking mGluR5. Learn. Mem. 5, 331–43. 
Jianfeng Xu, #, Zhenjun Yang, #, Werner Dammermann, †, Liangren Zhang, *,#, Andreas H. Guse, † and, Li-he Zhang*, #, 2006. Synthesis and 
Agonist Activity of Cyclic ADP-Ribose Analogues with Substitution of the Northern Ribose by Ether or Alkane Chains. 
Jiang, D., Xiao, B., Yang, D., Wang, R., Choi, P., Zhang, L., Cheng, H., Chen, S.R.W., 2004. RyR2 mutations linked to ventricular tachycardia 
and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). Proc. Natl. Acad. Sci. 101, 13062–13067. 
Jiang, Q., Lee, C.Y.D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T.M., Collins, J.L., Richardson, J.C., 
Smith, J.D., Comery, T.A., Riddell, D., Holtzman, D.M., Tontonoz, P., Landreth, G.E., 2008. ApoE Promotes the Proteolytic 
Degradation of A? Neuron 58, 681–693. 
Jiang, S., Li, Y., Zhang, X., Bu, G., Xu, H., Zhang, Y., 2014. Trafficking regulation of proteins in Alzheimer’s disease. Mol. Neurodegener. 9, 6. 
Jin, D., Liu, H.-X., Hirai, H., Torashima, T., Nagai, T., Lopatina, O., Shnayder, N.A., Yamada, K., Noda, M., Seike, T., Fujita, K., Takasawa, S., 
Yokoyama, S., Koizumi, K., Shiraishi, Y., Tanaka, S., Hashii, M., Yoshihara, T., Higashida, K., Islam, M.S., Yamada, N., Hayashi, K., 
Noguchi, N., Kato, I., Okamoto, H., Matsushima, A., Salmina, A., Munesue, T., Shimizu, N., Mochida, S., Asano, M., Higashida, H., 
2007. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446, 41–45. 
Jin, W., Lo, T.-M., Loh, H.H., Thayer, S.A., 1994. U73122 inhibits phospholipase C-dependent calcium mobilization in neuronal cells. Brain 
Res. 642, 237–243. 
Joensuu, H., Pylkkänen, L., Toikkanen, S., 1994. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 145, 1191–8. 
Johnson, M.W., Chotiner, J.K., Watson, J.B., 1997. Isolation and characterization of synaptoneurosomes from single rat hippocampal slices. J. 
Neurosci. Methods 77, 151–6. 
Johnston, J.M., Burnett, P., Thomas, A.P., Tezapsidis, N., 2006. Calcium oscillations in type-1 astrocytes, the effect of a presenilin 1 (PS1) 
mutation. Neurosci. Lett. 395. 





K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R.R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O.A., Jonsson, E.G., 
Palotie, A., Behrens, T.W., Magnusson, O.T., Kong, A., Thorsteinsdottir, U., Watts, R.J., Stefansson, K., 2012. A mutation in APP 
protects against Alzheimer‘s disease and age-related cognitive decline. Nature 488. 
Kaar, A., Morley, S.J., Rae, M.G., 2017. An efficient and cost-effective method of generating postnatal (P2–5) mouse primary hippocampal 
neuronal cultures. J. Neurosci. Methods 286, 69–77. 
Kaar, A., Rae, M.G., 2013. Proceedings of the 8th Neuroscience Ireland Conference; September 12-13; Cork, Ireland. Neuroscience Ireland. 
Kaar, A., Rae, M.G., 2014. Investigating the role of the cyclic ADP ribose/RyR pathway in Group I mGluR mediated calcium signalling in 
cultured rat hippocampal neurones. F1000Research 5, 26625. 
Kaar, A., Rae, M.G., 2016. Proceedings of the RAMI Section of Biomedical Sciences Annual Meetings, 2013- 2015, Irish Journal of Medical 
Science. Springer London. 
Kaar, A., Rae, M.G.M.G., 2015. Metabotropic glutamate receptor-mediated cyclic ADP ribose signalling. Biochem. Soc. Trans. 43, 405–409. 
Kaech, S., Banker, G., 2006. Culturing hippocampal neurons. Nat. Protoc. 1, 2406–2415. 
Kajimoto, Y., Miyagawa, J., Ishihara, K., Okuyama, Y., Fujitani, Y., Itoh, M., Yoshida, H., Kaisho, T., Matsuoka, T., Watada, H., Hanafusa, T., 
Yamasaki, Y., Kamada, T., Matsuzawa, Y., Hirano, T., 1996. Pancreatic Islet Cells Express BST-1, a CD38-like Surface Molecule 
Having ADP-Ribosyl Cyclase Activity. Biochem. Biophys. Res. Commun. 219, 941–946. 
Kakizawa, S., Takeshima, H., Iino, M., 2012. Nitric Oxide-Induced Calcium Release: A Novel Calcium-Mobilizing Mechanism Mediated by S-
nitrosylation-Dependent Modulation of Ryanodine Receptor. Messenger 1, 133–140. 
Kamatsuka, Y., Fukagawa, M., Furuta, T., Ohishi, A., Nishida, K., Nagasawa, K., 2014. Astrocytes, but not neurons, exhibit constitutive 
activation of P2X7 receptors in mouse acute cortical slices under non-stimulated resting conditions. Biol. Pharm. Bull. 37, 1958–62. 
Kamboh, M.I., 2004. Molecular Genetics of Late-Onset Alzheimer’s Disease. Ann. Hum. Genet. 68, 381–404. 
Kammermeier, P.J., Ikeda, S.R., 1999. Expression of RGS2 Alters the Coupling of Metabotropic Glutamate Receptor 1a to M-Type K+ and N-
Type Ca2+ Channels. Neuron 22, 819–829. 
Kanatsu, K., Morohashi, Y., Suzuki, M., Kuroda, H., Watanabe, T., Tomita, T., Iwatsubo, T., 2014. Decreased CALM expression reduces Aβ42 
to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase. Nat. Commun. 5, 3386. 
Kaneko, A., Sankai, Y., 2014. Long-Term Culture of Rat Hippocampal Neurons at Low Density in Serum-Free Medium: Combination of the 
Sandwich Culture Technique with the Three-Dimensional Nanofibrous Hydrogel PuraMatrix. PLoS One 9, e102703. 
Kano, M., Garaschuk, O., Verkhratsky, A., Konnerth, A., 1995. Ryanodine receptor-mediated intracellular calcium release in rat cerebellar 
Purkinje neurones. J. Physiol. 
Karlnoski, R., Wilcock, D., Dickey, C., Ronan, V., Gordon, M.N., Zhang, W., Morgan, D., Taglialatela, G., 2007. Up-regulation of Bcl-2 in APP 
transgenic mice is associated with neuroprotection. Neurobiol. Dis. 25, 179–188. 
Karran, E., Mercken, M., Strooper, B. De, 2011. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of 
therapeutics. Nat. Rev. Drug Discov. 10, 698–712. 
Kass, G.E., Orrenius, S., 1999. Calcium signaling and cytotoxicity. Environ. Health Perspect. 107 Suppl 1, 25–35. 
Kassner, S.S., Bonaterra, G.A., Kaiser, E., Hildebrandt, W., Metz, J., Schröder, J., Kinscherf, R., 2008. Novel systemic markers for patients with 
Alzheimer disease? - a pilot study. Curr. Alzheimer Res. 5, 358–66. 
Kaufmann, J.A., Bickford, P.C., Taglialatela, G., 2001. Oxidative-stress-dependent up-regulation of Bcl-2 expression in the central nervous 
system of aged Fisher-344 rats. J. Neurochem. 76, 1099–108. 
Kazim, S.F., Chuang, S.-C., Zhao, W., Wong, R.K.S., Bianchi, R., Iqbal, K., 2017. Early-Onset Network Hyperexcitability in Presymptomatic 
Alzheimer’s Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Aβ Antibody and by mGluR5 
Blockade. Front. Aging Neurosci. 9, 71. 
Keele, N.B., Arvanov, V.L., Shinnick-Gallagher, P., 1997. Quisqualate-preferring metabotropic glutamate receptor activates Na(+)-Ca2+ 
exchange in rat basolateral amygdala neurones. J. Physiol. 499 ( Pt 1), 87–104. 
Kellenberger, E., Kuhn, I., Schuber, F., Muller-Steffner, H., 2011. Flavonoids as inhibitors of human CD38, Bioorganic & Medicinal Chemistry 
Letters. 
Keller, J.N., Germeyer, A., Begley, J.G., Mattson, M.P., 1997. 17β-Estradiol attenuates oxidative impairment of synaptic Na+/K+- ATPase 
activity, glucose transport, and glutamate transport induced by amyloid β-peptide and iron. J. Neurosci. Res. 50. 
Kelliher, M., Fastbom, J., Cowburn, R.F., Bonkale, W., Ohm, T.G., Ravid, R., Sorrentino, V., O’Neill, C., 1999. Alterations in the ryanodine 
receptor calcium release channel correlate with Alzheimer’s disease neurofibrillary and beta-amyloid pathologies. Neuroscience 92, 499–
513. 
Kelly, B.L., Ferreira, A., 2006. beta-Amyloid-induced Dynamin 1 Degradation Is Mediated by N-Methyl-D-Aspartate Receptors in Hippocampal 
Neurons. J. Biol. Chem. 281, 28079–28089. 
Kessete Afewerky, H., 2016. Roles of Sodium-Calcium Exchanger Isoform-3 toward Calcium Ion Regulation in Alzheimers Disease. 
Kettunen, P., Hess, D., El Manira, A., 2003. mGluR1, But Not mGluR5, Mediates Depolarization of Spinal Cord Neurons by Blocking a Leak 
Current. J. Neurophysiol. 90, 2341–2348. 
Khachaturian, Z.S., 1989. Calcium, membranes, aging, and Alzheimer’s disease. Introduction and overview. Ann. N. Y. Acad. Sci. 568, 1–4. 
Khatoon, S., Grundke-Iqbal, I., Iqbal, K., 1992. Brain levels of microtubule-associated protein tau are elevated in Alzheimer’s disease: a 
radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem. 59, 750–3. 
Khoo, K.M., Chang, C.F., 1999. Characterization and localization of CD38 in the vertebrate eye. Brain Res. 821, 17–25. 
Khoo, K.M., Chang, C.F., 2002. Identification and characterization of nuclear CD38 in the rat spleen. Int. J. Biochem. Cell Biol. 34, 43–54. 
Khoo, K.M., Han, M.K., Park, J.B., Chae, S.W., Kim, U.H., Lee, H.C., Bay, B.H., Chang, C.F., 2000. Localization of the cyclic ADP-ribose-
dependent calcium signaling pathway in hepatocyte nucleus. J. Biol. Chem. 275, 24807–24817. 
Khosravani, H., Zhang, Y., Tsutsui, S., Hameed, S., Altier, C., Hamid, J., Chen, L., Villemaire, M., Ali, Z., Jirik, F.R., Zamponi, G.W., 2008. 
Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J. Cell Biol. 181, 551–565. 
Kim, B.-J., Park, K.-H., Yim, C.-Y., Takasawa, S., Okamoto, H., Im, M.-J., Kim, U.-H., 2008. Generation of Nicotinic Acid Adenine 
Dinucleotide Phosphate and Cyclic ADP-Ribose by Glucagon-Like Peptide-1 Evokes Ca2+ Signal That Is Essential for Insulin Secretion 
in Mouse Pancreatic Islets. Diabetes 57, 868–878. 
Kim, I., Xu, W., Reed, J.C., 2008. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug 





Kim, J., Basak, J.M., Holtzman, D.M., 2009a. The role of apolipoprotein E in Alzheimer’s disease. Neuron 63, 287–303. 
Kim, J., Castellano, J.M., Jiang, H., Basak, J.M., Parsadanian, M., Pham, V., Mason, S.M., Paul, S.M., Holtzman, D.M., 2009b. Overexpression 
of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular A? Clearance. 
Neuron 64, 632–644. 
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D.W., Golde, T., McGowan, E., 2007. Aβ40 Inhibits Amyloid 
Deposition In Vivo. J. Neurosci. 27. 
Kim, S., Yun, H.-M., Baik, J.-H., Chung, K.C., Nah, S.-Y., Rhim, H., 2007. Functional interaction of neuronal Cav1.3 L-type calcium channel 
with ryanodine receptor type 2 in the rat hippocampus. J. Biol. Chem. 282, 32877–89. 
Kim, S.H., Fraser, P.E., Westaway, D., St. George-Hyslop, P.H., Ehrlich, M.E., Gandy, S., 2010. Group II Metabotropic Glutamate Receptor 
Stimulation Triggers Production and Release of Alzheimer’s Amyloid  42 from Isolated Intact Nerve Terminals. J. Neurosci. 30, 3870–
3875. 
Kim, S.J., Kim, Y.S., Yuan, J.P., Petralia, R.S., Worley, P.F., Linden, D.J., 2003. Activation of the TRPC1 cation channel by metabotropic 
glutamate receptor mGluR1. Nature 426, 285–291. 
Kim, S.S.J.S.S.J.S., Kim, T., Lee, H.-R., Jang, E.-H., Ryu, H.-H., Kang, M., Rah, S.-Y., Yoo, J., Lee, B., Kim, J.-I., Lim, C.S., Kim, 
S.S.J.S.S.J.S., Kim, U.-H., Lee, Y.-S., Kaang, B.-K., 2016. Impaired learning and memory in CD38 null mutant mice. Mol. Brain 9, 16. 
Kimberly, W.T., LaVoie, M.J., Ostaszewski, B.L., Ye, W., Wolfe, M.S., Selkoe, D.J., 2003. -Secretase is a membrane protein complex comprised 
of presenilin, nicastrin, aph-1, and pen-2. Proc. Natl. Acad. Sci. 100, 6382–6387. 
Kinnear, N.P., Boittin, F.-X., Thomas, J.M., Galione, A., Evans, A.M., 2004. Lysosome-sarcoplasmic reticulum junctions. A trigger zone for 
calcium signaling by nicotinic acid adenine dinucleotide phosphate and endothelin-1. J. Biol. Chem. 279, 54319–26. 
Kirazov, L., Löffler, T., Schliebs, R., Bigl, V., 1997. Glutamate-stimulated secretion of amyloid precursor protein from cortical rat brain slices. 
Neurochem. Int. 30, 557–63. 
Kitamura, Y., Shimohama, S., Kamoshima, W., Ota, T., Matsuoka, Y., Nomura, Y., Smith, M.A., Perry, G., Whitehouse, P.J., Taniguchi, T., 
1998. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer’s disease. Brain Res. 
780, 260–9. 
Kivell, B.M., McDonald, F.J., Miller, J.H., 2000. Serum-free culture of rat post-natal and fetal brainstem neurons. Dev. Brain Res. 120, 199–210. 
Kiviluoto, S., Vervliet, T., Ivanova, H., Decuypere, J.-P., De Smedt, H., Missiaen, L., Bultynck, G., Parys, J.B., 2013. Regulation of inositol 
1,4,5-trisphosphate receptors during endoplasmic reticulum stress. Biochim. Biophys. Acta - Mol. Cell Res. 1833, 1612–1624. 
Klein, R.R., Bourdon, D.M., Costales, C.L., Wagner, C.D., White, W.L., Williams, J.D., Hicks, S.N., Sondek, J., Thakker, D.R., 2011. Direct 
activation of human phospholipase C by its well known inhibitor u73122. J. Biol. Chem. 286, 12407–16. 
Kloosterman, F., van Haeften, T., Lopes da Silva, F.H., 2004. Two reentrant pathways in the hippocampal-entorhinal system. Hippocampus 14, 
1026–39. 
Kloosterman, F., Van Haeften, T., Witter, M.P., Lopes Da Silva, F.H., 2003. Electrophysiological characterization of interlaminar entorhinal 
connections: an essential link for re-entrance in the hippocampal-entorhinal system. Eur. J. Neurosci. 18, 3037–52. 
Koester, H.J., Sakmann, B., 1998. Calcium dynamics in single spines during coincident pre- and postsynaptic activity depend on relative timing 
of back-propagating action potentials and subthreshold excitatory postsynaptic potentials. Proc. Natl. Acad. Sci. U. S. A. 95, 9596–601. 
Koffie, R.M., Hyman, B.T., Spires-Jones, T.L., 2011. Alzheimer’s disease: synapses gone cold. Mol. Neurodegener. 6, 63. 
Koffie, R.M., Meyer-Luehmann, M., Hashimoto, T., Adams, K.W., Mielke, M.L., Garcia-Alloza, M., Micheva, K.D., Smith, S.J., Kim, M.L., 
Lee, V.M., Hyman, B.T., Spires-Jones, T.L., 2009. Oligomeric amyloid β associates with postsynaptic densities and correlates with 
excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U. S. A. 106. 
Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K.R., Paul, S.M., 2004. 
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-? peptides. Nat. Med. 10, 719–726. 
Koistinaho, M., Ort, M., Cimadevilla, J.M., Vondrous, R., Cordell, B., Koistinaho, J., Bures, J., Higgins, L.S., 2001. Specific spatial learning 
deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not 
form plaques. Proc. Natl. Acad. Sci. U. S. A. 98, 14675–80. 
Koizumi, S., Bootman, M.D., Bobanović, L.K., Schell, M.J., Berridge, M.J., Lipp, P., 1999. Characterization of elementary Ca2+ release signals 
in NGF-differentiated PC12 cells and hippocampal neurons. Neuron 22, 125–37. 
Kong, H., Jones, P.P., Koop, A., Zhang, L., Duff, H.J., Chen, S.R.W., 2008. Caffeine induces Ca2+ release by reducing the threshold for luminal 
Ca2+ activation of the ryanodine receptor. Biochem. J. 414, 441–52. 
König, A., Menzel, T., Lynen, S., Wrazel, L., Rosén, A., Al-Katib, A., Raveche, E., Gabrilove, J.L., 1997. Basic fibroblast growth factor (bFGF) 
upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11, 258–
65. 
Koo, E.H., Kopan, R., 2004. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat. Med. 10. 
Kos, C.H., Karaplis, A.C., Peng, J.-B., Hediger, M.A., Goltzman, D., Mohammad, K.S., Guise, T.A., Pollak, M.R., 2003. The calcium-sensing 
receptor is required for normal calcium homeostasis independent of parathyroid hormone. J. Clin. Invest. 111, 1021–1028. 
Kotler, S.A., Walsh, P., Brender, J.R., Ramamoorthy, A., 2014. Differences between amyloid-β aggregation in solution and on the membrane: 
insights into elucidation of the mechanistic details of Alzheimer’s disease. Chem. Soc. Rev. 43, 6692–6700. 
Kovacs, D.M., Fausett, H.J., Page, K.J., Kim, T.W., Moir, R.D., Merriam, D.E., Hollister, R.D., Hallmark, O.G., Mancini, R., Felsenstein, K.M., 
Hyman, B.T., Tanzi, R.E., Wasco, W., 1996. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to 
intracellular membranes in mammalian cells. Nat. Med. 2, 224–9. 
Kovalchuk, Y., Eilers, J., Lisman, J., Konnerth, A., 2000. NMDA receptor-mediated subthreshold Ca(2+) signals in spines of hippocampal 
neurons. J. Neurosci. 20, 1791–9. 
Kraft, R., Grimm, C., Grosse, K., Hoffmann, A., Sauerbruch, S., Kettenmann, H., Schultz, G., Harteneck, C., 2003. Hydrogen peroxide and ADP-
ribose induce TRPM2-mediated calcium influx and cation currents in microglia. Am. J. Physiol. - Cell Physiol. 286. 
Krajewska, M., Mai, J.K., Zapata, J.M., Ashwell, K.W., Schendel, S.L., Reed, J.C., Krajewski, S., 2002. Dynamics of expression of apoptosis-
regulatory proteins Bid, Bcl-2, Bcl-X, Bax and Bak during development of murine nervous system. Cell Death Differ. 9, 145–157. 
Krajewski, S., Krajewska, M., Shabaik, A., Wang, H.G., Irie, S., Fong, L., Reed, J.C., 1994. Immunohistochemical analysis of in vivo patterns of 
Bcl-X expression. Cancer Res. 54, 5501–7. 
Krajewski, S., Tanaka, S., Takayama, S., Schibler, M.J., Fenton, W., Reed, J.C., 1993. Investigation of the subcellular distribution of the bcl-2 
oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53, 4701–14. 





glutamatergic modulation of potassium currents and excitability in hippocampal neurons. J. Neurosci. 22, 666–73. 
Krause, T., Gerbershagen, M.U., Fiege, M., Weisshorn, R., Wappler, F., 2004. Dantrolene--a review of its pharmacology, therapeutic use and 
new developments. Anaesthesia 59, 364–73. 
Krieger, P., Hellgren-Kotaleski, J., Kettunen, P., El Manira, A.J., 2000. Interaction between metabotropic and ionotropic glutamate receptors 
regulates neuronal network activity. J. Neurosci. 20, 5382–91. 
Kristian, T., Balan, I., Schuh, R., Onken, M., 2011. Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell 
death and promising targets for neuroprotection. J. Neurosci. Res. 89, 1946–1955. 
Kubo, Y., Miyashita, T., Murata, Y., 1998. Structural basis for a Ca2+-sensing function of the metabotropic glutamate receptors. Science 279, 
1722–5. 
Kubokawa, K., Miyashita, T., Nagasawa, H., Kubo, Y., 1996. Cloning and characterization of a bifunctional metabotropic receptor activated by 
both extracellular calcium and glutamate. FEBS Lett. 392, 71–76. 
Kuchibhotla, K. V, Goldman, S.T., Lattarulo, C.R., Wu, H.-Y., Hyman, B.T., Bacskai, B.J., 2008. Abeta plaques lead to aberrant regulation of 
calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214–25. 
Kudo, W., Lee, H.-P., Zou, W.-Q., Wang, X., Perry, G., Zhu, X., Smith, M.A., Petersen, R.B., Lee, H. -g., 2012. Cellular prion protein is essential 
for oligomeric amyloid- -induced neuronal cell death. Hum. Mol. Genet. 21, 1138–1144. 
Kullmann, D.M., Lamsa, K., 2008. Roles of distinct glutamate receptors in induction of anti-Hebbian long-term potentiation. J. Physiol. 586, 
1481–1486. 
Kumar, A., 2011. Long-Term Potentiation at CA3-CA1 Hippocampal Synapses with Special Emphasis on Aging, Disease, and Stress. Front. 
Aging Neurosci. 3, 7. 
Kunerth, S., Langhorst, M.F., Schwarzmann, N., Gu, X., Huang, L., Yang, Z., Zhang, L., Mills, S.J., Zhang, L.-H., Potter, B.V.L., Guse, A.H., 
2004. Amplification and propagation of pacemaker Ca2+ signals by cyclic ADP-ribose and the type 3 ryanodine receptor in T cells. J. 
Cell Sci. 117, 2141–9. 
Kurumatani, T., Fastbom, J., Bonkale, W.L., Bogdanovic, N., Winblad, B., Ohm, T.G., Cowburn, R.F., 1998. Loss of inositol 1,4,5-trisphosphate 
receptor sites and decreased PKC levels correlate with staging of Alzheimer’s disease neurofibrillary pathology. Brain Res. 796, 209–21. 
Kuwajima, G., Futatsugi, A., Niinobe, M., Nakanishi, S., Mikoshiba, K., 1992. Two types of ryanodine receptors in mouse brain: Skeletal muscle 
type exclusively in Purkinje cells and cardiac muscle type in various neurons. Neuron 9, 1133–1142. 
Kvansakul, M., Yang, H., Fairlie, W.D., Czabotar, P.E., Fischer, S.F., Perugini, M.A., Huang, D.C.S., Colman, P.M., 2008. Vaccinia virus anti-
apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell 
Death Differ. 15, 1564–1571. 
Lacor, Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., 
Klein, W.L., 2004a. Synaptic targeting by Alzheimer’s-related amyloid β oligomers. J. Neurosci. 24. 
Lacor, Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., 
Klein, W.L., 2004b. Synaptic Targeting by Alzheimer’s-Related Amyloid Oligomers. J. Neurosci. 24, 10191–10200. 
Lacor, Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., Viola, K.L., Klein, W.L., 2007. Aβ oligomer-induced aberrations 
in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J. Neurosci. 27. 
LaDu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, G.S., Frail, D.E., 1994. Isoform-specific binding of apolipoprotein E to beta-
amyloid. J. Biol. Chem. 269, 23403–6. 
LaFerla, F.M., 2002. Calcium dyshomeostasis and intracellular signalling in alzheimer’s disease. Nat. Rev. Neurosci. 3, 862–872. 
LaFerla, F.M., Oddo, S., 2005. Alzheimer’s disease: Aβ, tau and synaptic dysfunction. Trends Mol. Med. 11, 170–176. 
Lam, M., Dubyakt, G., Chent, L., Nufiez, G., Miesfeldt, R.L., Distelhorst, C.W., 1994. Evidence that BCL-2 represses apoptosis by regulating 
endoplasmic reticulum-associated Ca2+ fluxes (pogammed cel death/gucocorlcosteroid/mouse lymphoma cell/calcium. Med. Sci. 91, 
6569–6573. 
Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M.J., Tavernier, B., 
Letenneur, L., Bettens, K., Berr, C., Pasquier, F., Fiévet, N., Barberger-Gateau, P., Engelborghs, S., De Deyn, P., Mateo, I., Franck, A., 
Helisalmi, S., Porcellini, E., Hanon, O., European Alzheimer’s Disease Initiative Investigators, M.M., de Pancorbo, M.M., Lendon, C., 
Dufouil, C., Jaillard, C., Leveillard, T., Alvarez, V., Bosco, P., Mancuso, M., Panza, F., Nacmias, B., Bossù, P., Piccardi, P., Annoni, G., 
Seripa, D., Galimberti, D., Hannequin, D., Licastro, F., Soininen, H., Ritchie, K., Blanché, H., Dartigues, J.-F., Tzourio, C., Gut, I., Van 
Broeckhoven, C., Alpérovitch, A., Lathrop, M., Amouyel, P., 2009. Genome-wide association study identifies variants at CLU and CR1 
associated with Alzheimer’s disease. Nat. Genet. 41, 1094–9. 
Lambert, J.-C., Sleegers, K., González-Pérez, A., Ingelsson, M., Beecham, G.W., Hiltunen, M., Combarros, O., Bullido, M.J., Brouwers, N., 
Bettens, K., Berr, C., Pasquier, F., Richard, F., DeKosky, S.T., Hannequin, D., Haines, J.L., Tognoni, G., Fiévet, N., Dartigues, J.-F., 
Tzourio, C., Engelborghs, S., Arosio, B., Coto, E., De Deyn, P., Del Zompo, M., Mateo, I., Boada, M., Antunez, C., Lopez-Arrieta, J., 
Epelbaum, J., Schjeide, B.-M.M., Frank-Garcia, A., Giedraitis, V., Helisalmi, S., Porcellini, E., Pilotto, A., Forti, P., Ferri, R., Delepine, 
M., Zelenika, D., Lathrop, M., Scarpini, E., Siciliano, G., Solfrizzi, V., Sorbi, S., Spalletta, G., Ravaglia, G., Valdivieso, F., Vepsäläinen, 
S., Alvarez, V., Bosco, P., Mancuso, M., Panza, F., Nacmias, B., Bossù, P., Hanon, O., Piccardi, P., Annoni, G., Mann, D., Marambaud, 
P., Seripa, D., Galimberti, D., Tanzi, R.E., Bertram, L., Lendon, C., Lannfelt, L., Licastro, F., Campion, D., Pericak-Vance, M.A., 
Soininen, H., Van Broeckhoven, C., Alpérovitch, A., Ruiz, A., Kamboh, M.I., Amouyel, P., 2010. The CALHM1 P86L Polymorphism is 
a Genetic Modifier of Age at Onset in Alzheimer’s Disease: a Meta-Analysis Study. J. Alzheimer’s Dis. 22, 247–255. 
Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., Wals, 
P., Zhang, C., Finch, C.E., Krafft, G.A., Klein, W.L., 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central 
nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95, 6448–53. 
Landfield, P.W., Thibault, O., Mazzanti, M.L., Porter, N.M., Kerr, D.S., 1992. Mechanisms of neuronal death in brain aging and alzheimer’s 
disease: Role of endocrine-mediated calcium dyshomeostasis. J. Neurobiol. 23, 1247–1260. 
Landis, D.M.D., Weinstein, L.A., Skordeles, C.J., 1990. Serum influences the differentiation of membrane structure in cultured astrocytes. Glia 3. 
Langhorst, M.F., Schwarzmann, N., Guse, A.H., 2004. Ca2+ release via ryanodine receptors and Ca2+ entry: major mechanisms in NAADP-
mediated Ca2+ signaling in T-lymphocytes. Cell. Signal. 16, 1283–1289. 
Larson, J., Lynch, G., Games, D., Seubert, P., 1999. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from 
young and aged PDAPP mice. Brain Res. 840, 23–35. 
Larson, M., Sherman, M.A., Amar, F., Nuvolone, M., Schneider, J.A., Bennett, D.A., Aguzzi, A., Lesne, S.E., 2012. The Complex PrPc-Fyn 
Couples Human Oligomeric A  with Pathological Tau Changes in Alzheimer’s Disease. J. Neurosci. 32, 16857–16871. 





Laßek, M., Weingarten, J., Einsfelder, U., Brendel, P., Müller, U., Volknandt, W., 2013. Amyloid precursor proteins are constituents of the 
presynaptic active zone. J. Neurochem. 127, n/a-n/a. 
Lathia, J.D., Mattson, M.P., Cheng, A., 2008. Notch: from neural development to neurological disorders. J. Neurochem. 107, 1471–81. 
Laude, A.J., Simpson, A.W.M., 2009. Compartmentalized signalling: Ca2+ compartments, microdomains and the many facets of Ca2+ signalling. 
FEBS J. 276, 1800–1816. 
Laurén, J., 2014. Cellular Prion Protein as a Therapeutic Target in Alzheimer’s Disease. J. Alzheimer’s Dis. 38, 227–244. 
Laurén, J., Gimbel, D.A., Nygaard, H.B., Gilbert, J.W., Strittmatter, S.M., 2009. Cellular prion protein mediates impairment of synaptic plasticity 
by amyloid-Β oligomers. Nature 457. 
Lebart, M.-C., Benyamin, Y., 2006. Calpain involvement in the remodeling of cytoskeletal anchorage complexes. FEBS J. 273. 
LeBlanc, A.C., Chen, H.Y., Autilio-Gambetti, L., Gambetti, P., 1991. Differential APP gene expression in rat cerebral cortex, meninges, and 
primary astroglial, microglial and neuronal cultures. FEBS Lett. 292, 171–8. 
LeBrun, D.P., Warnke, R.A., Cleary, M.L., 1993. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am. J. Pathol. 142, 743–
53. 
Leckie, C., Empson, R., Becchetti, A., Thomas, J., Galione, A., Whitaker, M., 2003. The NO pathway acts late during the fertilization response in 
sea urchin eggs. J. Biol. Chem. 278, 12247–12254. 
Lee, C., Park, G.-H., Lee, J.-W., Jang, J.-H., 2015. Protective Effect of Wheat Bran Extract against β-Amyloid-induced Cell Death and Memory 
Impairment. Kor. J. Herbol. 30, 67–75. 
Lee, G., Thangavel, R., Sharma, V.M., Litersky, J.M., Bhaskar, K., Fang, S.M., Do, L.H., Andreadis, A., Van Hoesen, G., Ksiezak-Reding, H., 
2004. Phosphorylation of Tau by Fyn: Implications for Alzheimer’s Disease. J. Neurosci. 24. 
Lee, H.C., 1991. Specific binding of cyclic ADP-ribose to calcium-storing microsomes from sea urchin eggs. J. Biol. Chem. 266, 2276–81. 
Lee, H.C., 1993. Potentiation of calcium- and caffeine-induced calcium release by cyclic ADP-ribose. J. Biol. Chem. 268, 293–9. 
Lee, H.C., 2001. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol. 41, 317–45. 
Lee, H.C., 2011. Cyclic ADP-ribose and NAADP: fraternal twin messengers for calcium signaling. Sci. China Life Sci. 54, 699–711. 
Lee, H.C., Aarhus, R., 1997. Structural determinants of nicotinic acid adenine dinucleotide phosphate important for its calcium-mobilizing 
activity. J. Biol. Chem. 272, 20378–83. 
Lee, H.C., Aarhus, R., Graeff, R., Gurnack, M.E., Walseth, T.F., 1994. Cyclic ADP ribose activation of the ryanodine receptor is mediated by 
calmodulin. Nature 370, 307–309. 
Lee, H.C., Aarhus, R., Graeff, R.M., 1995. Sensitization of calcium-induced calcium release by cyclic ADP-ribose and calmodulin. J. Biol. 
Chem. 270, 9060–9066. 
Lee, H.C., Aarhus, R., Walseth, T.F., 1993. Calcium mobilization by dual receptors during fertilization of sea urchin eggs. Science 261, 352–5. 
Lee, H.C., Munshi, C., Graeff, R., 1999. Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes. Mol. Cell. 
Biochem. 193, 89–98. 
Lee, H.G., Won, S.M., Gwag, B.J., Lee, Y.B., 2011. Microglial P2X 7 receptor expression is accompanied by neuronal damage in the cerebral 
cortex of the APP swe /PS1dE9 mouse model of Alzheimer’s disease. Exp. Mol. Med. 43, 7. 
Lee, J.-Y., Cole, T.B., Palmiter, R.D., Suh, S.W., Koh, J.-Y., 2002. Contribution by synaptic zinc to the gender-disparate plaque formation in 
human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. 99, 7705–7710. 
Leighty, R.E., Nilsson, L.N.., Potter, H., Costa, D.A., Low, M.A., Bales, K.R., Paul, S.M., Arendash, G.W., 2004. Use of multimetric statistical 
analysis to characterize and discriminate between the performance of four Alzheimer’s transgenic mouse lines differing in Aβ deposition. 
Behav. Brain Res. 153, 107–121. 
Leissring, M.A., Akbari, Y., Fanger, C.M., Cahalan, M.D., Mattson, M.P., LaFerla, F.M., 2000. Capacitative calcium entry deficits and elevated 
luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 149, 793–797. 
Leissring, M.A., LaFerla, F.M., Callamaras, N., Parker, I., 2001. Subcellular mechanisms of presenilin-mediated enhancement of calcium 
signaling. Neurobiol. Dis. 8. 
Leissring, M.A., Murphy, M.P., Mead, T.R., Akbari, Y., Sugarman, M.C., Jannatipour, M., Anliker, B., Müller, U., Saftig, P., De Strooper, B., 
Wolfe, M.S., Golde, T.E., LaFerla, F.M., 2002. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of 
APP. Proc. Natl. Acad. Sci. U. S. A. 99, 4697–702. 
Leissring, M.A., Parker, I., LaFerla, F.M., 1999a. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-
mediated calcium signals. J. Biol. Chem. 274, 32535–8. 
Leissring, M.A., Paul, B.A., Parker, I., Cotman, C.W., LaFerla, F.M., 1999b. Alzheimer’s presenilin-1 mutation potentiates inositol 1,4,5-
trisphosphate-mediated calcium signaling in Xenopus oocytes. J. Neurochem. 72, 1061–8. 
Lemonnier, L., Prevarskaya, N., Mazurier, J., Shuba, Y., Skryma, R., 2004. 2-APB inhibits volume-regulated anion channels independently from 
intracellular calcium signaling modulation. FEBS Lett. 556, 121–6. 
Lesné, S.E., Sherman, M.A., Grant, M., Kuskowski, M., Schneider, J.A., Bennett, D.A., Ashe, K.H., 2013. Brain amyloid-β oligomers in ageing 
and Alzheimer’s disease. Brain 136, 1383–98. 
Letai, A.G., 2008. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat. Rev. Cancer 8, 121–132. 
Leuba, G., Vernay, A., Vu, D., Walzer, C., Belloir, B., Kraftsik, R., Bouras, C., Savioz, A., 2004. Differential expression of LMO4 protein in 
Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 30, 57–69. 
Levi-Montalcini, R., 1966. The nerve growth factor: its mode of action on sensory and sympathetic nerve cells. Harvey Lect. 60, 217–59. 
Lewis, J., Dickson, D.W., Lin, W.L., Chisholm, L., Corral, A., Jones, G., Yen, S.H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., 
Hutton, M., McGowan, E., 2001. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP. Science 
(80-. ). 293, 1487–1491. 
Li, B., Chohan, M.O., Grundke-Iqbal, I., Iqbal, K., 2007. Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. 
Acta Neuropathol. 113, 501–511. 
Li, C., Wang, X., Vais, H., Thompson, C.B., Foskett, J.K., White, C., 2007. Apoptosis regulation by Bcl-xL modulation of mammalian inositol 
1,4,5-trisphosphate receptor channel isoform gating. Proc. Natl. Acad. Sci. 104, 12565–12570. 
Li, H., Wetten, S., Li, L., St. Jean, P.L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M.R., Briley, J.D., Borrie, M., Coletta, N., Delisle, R., 
Dhalla, D., Ehm, M.G., Feldman, H.H., Fornazzari, L., Gauthier, S., Goodgame, N., Guzman, D., Hammond, S., Hollingworth, P., 





Plumpton, M., Pryse-Phillips, W., Prinjha, R.K., Richardson, J.C., Saunders, A., Slater, A.J., St. George-Hyslop, P.H., Stinnett, S.W., 
Swartz, J.E., Taylor, R.L., Wherrett, J., Williams, J., Yarnall, D.P., Gibson, R.A., Irizarry, M.C., Middleton, L.T., Roses, A.D., 2008. 
Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease. Arch. Neurol. 65, 45–53. 
Li, J., Ning, Y., Hedley, W., Saunders, B., Chen, Y., Tindill, N., Hannay, T., Subramaniam, S., 2002. The Molecule Pages database. Nature 420, 
716–717. 
Li, L., Sengupta, A., Haque, N., Grundke-Iqbal, I., Iqbal, K., 2004. Memantine inhibits and reverses the Alzheimer type abnormal 
hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 566. 
Li, S., Hong, S., Shepardson, N.E., Walsh, D.M., Shankar, G.M., Selkoe, D., 2009. Soluble Oligomers of Amyloid β Protein Facilitate 
Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake. Neuron 62, 788–801. 
Li, S., Jin, M., Koeglsperger, T., Shepardson, N.E., Shankar, G.M., Selkoe, D.J., 2011. Soluble Aβ oligomers inhibit long-term potentiation 
through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 31, 6627–38. 
Li, X.-M., Li, C.-C., Yu, S.-S., Chen, J.-T., Sabapathy, K., Ruan, D.-Y., 2007. JNK1 contributes to metabotropic glutamate receptor-dependent 
long-term depression and short-term synaptic plasticity in the mice area hippocampal CA1. Eur. J. Neurosci. 25, 391–396. 
Li, X., Dang, S., Yan, C., Gong, X., Wang, J., Shi, Y., 2012. Structure of a presenilin family intramembrane aspartate protease. Nature 493, 56–
61. 
Liang, M., Chini, E.N., Cheng, J., Dousa, T.P., 1999. Synthesis of NAADP and cADPR in Mitochondria. Arch. Biochem. Biophys. 371, 317–
325. 
Liazoghli, D., Perreault, S., Micheva, K.D., Desjardins, M., Leclerc, N., 2005. Fragmentation of the Golgi Apparatus Induced by the 
Overexpression of Wild-Type and Mutant Human Tau Forms in Neurons. Am. J. Pathol. 166, 1499–1514. 
LIN, H., Bhatia, R., Lal, R., 2001. Amyloid beta protein forms ion channels: implications for Alzheimer’s disease pathophysiology. FASEB J. 15, 
2433–2444. 
Lin, W.-L., Lewis, J., Yen, S.-H., Hutton, M., Dickson, D.W., 2003. Ultrastructural neuronal pathology in transgenic mice expressing mutant 
(P301L) human tau. J. Neurocytol. 32, 1091–1105. 
Lin, X., Guan, H., Huang, Z., Liu, J., Li, H., Wei, G., Cao, X., Li, Y., 2014. Downregulation of Bcl-2 expression by miR-34a mediates palmitate-
induced Min6 cells apoptosis. J. Diabetes Res. 2014, 258695. 
Linden, D.J., Dawson, T.M., Dawson, V.L., 1995. An evaluation of the nitric oxide/cGMP/cGMP-dependent protein kinase cascade in the 
induction of cerebellar long-term depression in culture. J. Neurosci. 15, 5098–105. 
Linden, D.J., Smeyne, M., Connor, J.A., 1994. Trans-ACPD, a metabotropic receptor agonist, produces calcium mobilization and an inward 
current in cultured cerebellar Purkinje neurons. J. Neurophysiol. 71, 1992–8. 
Liou, J., Fivaz, M., Inoue, T., Meyer, T., 2007. Live-cell imaging reveals sequential oligomerization and local plasma membrane targeting of 
stromal interaction molecule 1 after Ca2+ store depletion. Proc. Natl. Acad. Sci. U. S. A. 104, 9301–6. 
Liou, J., Kim, M.L., Do Heo, W., Jones, J.T., Myers, J.W., Ferrell, J.E., Meyer, T., 2005. STIM Is a Ca2+ Sensor Essential for Ca2+-Store-
Depletion-Triggered Ca2+ Influx, Current Biology. 
Liu, C.-C., Kanekiyo, T., Xu, H., Bu, G., 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 
106–118. 
Liu, C., Hermann, T.E., 1978. Characterization of ionomycin as a calcium ionophore. J. Biol. Chem. 253, 5892–4. 
Liu, D., Pitta, M., Mattson, M.P., 2008. Preventing NAD+ depletion protects neurons against excitotoxicity: Bioenergetic effects of mild 
mitochondrial uncoupling and caloric restriction, Annals of the New York Academy of Sciences. 
Liu, F., Ma, X.H., Ule, J., Bibb, J.A., Nishi, A., DeMaggio, A.J., Yan, Z., Nairn, A.C., Greengard, P., 2001. Regulation of cyclin-dependent 
kinase 5 and casein kinase 1 by metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U. S. A. 98, 11062–8. 
Liu, Q., Kriksunov, I.A., Graeff, R., Munshi, C., Lee, H.C., Hao, Q., 2005. Crystal Structure of Human CD38 Extracellular Domain. Structure 13, 
1331–1339. 
Liu, S.J., Zhang, A.H., Li, H.L., Wang, Q., Deng, H.M., Netzer, W.J., Xu, H., Wang, J.Z., 2003. Overactivation of glycogen synthase kinase-3 by 
inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. 
Neurochem. 87, 1333–44. 
Lopatina, O., Liu, H.-X., Amina, S., Hashii, M., Higashida, H., 2010. Oxytocin-induced elevation of ADP-ribosyl cyclase activity, cyclic ADP-
ribose or Ca(2+) concentrations is involved in autoregulation of oxytocin secretion in the hypothalamus and posterior pituitary in male 
mice. Neuropharmacology 58, 50–5. 
Lopez, J.R., Lyckman, A., Oddo, S., LaFerla, F.M., Querfurth, H.W., Shtifman, A., 2008. Increased intraneuronal resting [Ca2+] in adult 
Alzheimer’s disease mice. J. Neurochem. 105, 262–271. 
Lorent, K., Overbergh, L., Moechars, D., De Strooper, B., Van Leuven, F., Van den Berghe, H., 1995. Expression in mouse embryos and in adult 
mouse brain of three members of the amyloid precursor protein family, of the alpha-2-macroglobulin receptor/low density lipoprotein 
receptor-related protein and of its ligands apolipoprotein E, lipoprotein lipase, alpha-2-macroglobulin and the 40,000 molecular weight 
receptor-associated protein. Neuroscience 65, 1009–25. 
Lu, D.C., Soriano, S., Bredesen, D.E., Koo, E.H., 2003. Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein 
toxicity. J. Neurochem. 87, 733–41. 
Lu, H., Burns, D., Garnier, P., Wei, G., Zhu, K., Ying, W., 2007. P2X7 receptors mediate NADH transport across the plasma membranes of 
astrocytes. Biochem. Biophys. Res. Commun. 362, 946–950. 
Lu, Y.M., Jia, Z., Janus, C., Gerlai, R., Wojtowicz, J.M., Roder, J.C., 1997. Mice lacking metabotropic glutamate receptor 5 show impaired 
learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17. 
Lucius, R., Mentlein, R., 1995. Development of a culture system for pure rat neurons: advantages of a sandwich technique. Ann. Anat. 177, 447–
54. 
Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E., Rogers, J., 1999. Soluble amyloid beta 
peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am. J. Pathol. 155, 853–62. 
Luetjens, C.M., Lankiewicz, S., Bui, N.T., Krohn, A.J., Poppe, M., Prehn, J.H., 2001. Up-regulation of Bcl-xL in response to subtoxic beta-
amyloid: role in neuronal resistance against apoptotic and oxidative injury. Neuroscience 102, 139–50. 
Luik, R.M., Wang, B., Prakriya, M., Wu, M.M., Lewis, R.S., 2008. Oligomerization of STIM1 couples ER calcium depletion to CRAC channel 
activation. Nature 454, 538–542. 
Lujan, R., Nusser, Z., Roberts, J.D., Shigemoto, R., Somogyi, P., 1996. Perisynaptic location of metabotropic glutamate receptors mGluR1 and 





Luján, R., Roberts, J.D.B., Shigemoto, R., Ohishi, H., Somogyi, P., 1997. Differential plasma membrane distribution of metabotropic glutamate 
receptors mGluR1α, mGluR2 and mGluR5, relative to neurotransmitter release sites. J. Chem. Neuroanat. 13. 
Lukyanenko, V., Györke, I., Wiesner, T.F., Györke, S., 2001. Potentiation of Ca(2+) release by cADP-ribose in the heart is mediated by enhanced 
SR Ca(2+) uptake into the sarcoplasmic reticulum. Circ. Res. 89, 614–22. 
Luo, W. -j., Wang, H., Li, H., Kim, B.S., Shah, S., Lee, H.-J., Thinakaran, G., Kim, T.-W., Yu, G., Xu, H., 2003. PEN-2 and APH-1 Coordinately 
Regulate Proteolytic Processing of Presenilin 1. J. Biol. Chem. 278, 7850–7854. 
Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J.-C., Yan, Q., 
Richards, W.G., Citron, M., Vassar, R., 2001. Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and 
abolished beta-amyloid generation. Nat. Neurosci. 4, 231–232. 
Lüscher, C., Huber, K.M., 2010. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and 
disease. Neuron 65, 445–59. 
Lüthi, A., Gähwiler, B.H., Gerber, U., 1996. A slowly inactivating potassium current in CA3 pyramidal cells of rat hippocampus in vitro. J. 
Neurosci. 16, 586–94. 
Lynch, G., Larson, J., Kelso, S., Barrionuevo, G., Schottler, F., 1983. Intracellular injections of EGTA block induction of hippocampal long-term 
potentiation. Nature 305, 719–21. 
Lytton, J., Westlin, M., Hanley, M.R., 1991. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium 
pumps. J. Biol. Chem. 266, 17067–71. 
Ma, Y., Wu, D., Ding, X., Ying, W., 2014. CD38 plays key roles in both antioxidation and cell survival of H2O2-treated primary rodent 
astrocytes. Int. J. Physiol. Pathophysiol. Pharmacol. 6, 102–8. 
Ma, Z., Siebert, A.P., Cheung, K.-H., Lee, R.J., Johnson, B., Cohen, A.S., Vingtdeux, V., Marambaud, P., Foskett, J.K., 2012. Calcium 
homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca2+ regulation of 
neuronal excitability. Proc. Natl. Acad. Sci. 109, E1963–E1971. 
Maarouf, C.L., Daugs, I.D., Kokjohn, T.A., Walker, D.G., Hunter, J.M., Kruchowsky, J.C., Woltjer, R., Kaye, J., Castaño, E.M., Sabbagh, M.N., 
Beach, T.G., Roher, A.E., 2011. Alzheimer’s Disease and Non-Demented High Pathology Control Nonagenarians: Comparing and 
Contrasting the Biochemistry of Cognitively Successful Aging. PLoS One 6, e27291. 
Maccioni, R.B., Farías, G., Morales, I., Navarrete, L., 2010. The Revitalized Tau Hypothesis on Alzheimer’s Disease. Arch. Med. Res. 41, 226–
231. 
MacDonald, J.F., Xiong, Z.-G., Jackson, M.F., 2006. Paradox of Ca2+ signaling, cell death and stroke. Trends Neurosci. 29, 75–81. 
MacLennan, D.H., Chen, S.R.W., 2009. Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by 
mutations in RYR and CASQ genes. J. Physiol. 587, 3113–5. 
Macmillan, D., McCarron, J.G., 2010. The phospholipase C inhibitor U-73122 inhibits Ca(2+) release from the intracellular sarcoplasmic 
reticulum Ca(2+) store by inhibiting Ca(2+) pumps in smooth muscle. Br. J. Pharmacol. 160, 1295–301. 
Magee, J.C., Johnston, D., 1997. A Synaptically Controlled, Associative Signal for Hebbian Plasticity in Hippocampal Neurons. Science (80-. ). 
275. 
Magi, S., Castaldo, P., Macrì, M.L., Maiolino, M., Matteucci, A., Bastioli, G., Gratteri, S., Amoroso, S., Lariccia, V., 2016. Intracellular Calcium 
Dysregulation: Implications for Alzheimer’s Disease. Biomed Res. Int. 2016, 1–14. 
Magistretti, J., de Curtis, M., Vescovi, A., Galli, R., Gritti, A., 1996. Long-term survival of cortical neurones from adult guinea-pig maintained in 
low-density cultures. Neuroreport 7, 1559–64. 
Magnelli, L., Cinelli, M., Turchetti, A., Chiarugi, V.P., 1994. Bcl-2 Overexpression Abolishes Early Calcium Waving Preceding Apoptosis in 
NIH-3T3 Murine Fibroblasts. Biochem. Biophys. Res. Commun. 204, 84–90. 
Mahley, R.W., Weisgraber, K.H., Huang, Y., 2006. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including 
Alzheimer’s disease. Proc. Natl. Acad. Sci. 103, 5644–5651. 
Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., Polleux, F., 2013. The CAMKK2-AMPK Kinase Pathway Mediates the 
Synaptotoxic Effects of Aβ Oligomers through Tau Phosphorylation. Neuron 78, 94–108. 
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A.L., Ortolan, E., Vaisitti, T., Aydin, S., 2008. Evolution and Function of the ADP 
Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology. Physiol. Rev. 88. 
Malavasi, F., Deaglio, S., Zaccarello, G., Horenstein, A.L., Chillemi, A., Audrito, V., Serra, S., Gandione, M., Zitella, A., Tizzani, A., 2010. The 
hidden life of NAD+-consuming ectoenzymes in the endocrine system. J. Mol. Endocrinol. 45, 183–91. 
Malenka, R.C., Bear, M.F., 2004. LTP and LTD. Neuron 44, 5–21. 
Malenka, R.C., Kauer, J.A., Zucker, R.S., Nicoll, R.A., 1988. Postsynaptic calcium is sufficient for potentiation of hippocampal synaptic 
transmission. Science 242, 81–4. 
Mallone, R., Ferrua, S., Morra, M., Zocchi, E., Mehta, K., Notarangelo, L.D., Malavasi, F., 1998. Characterization of a CD38-like 78-kilodalton 
soluble protein released from B cell lines derived from patients with X-linked agammaglobulinemia. J. Clin. Invest. 101, 2821–2830. 
Mangmool, S., Kurose, H., 2011. G(i/o) protein-dependent and -independent actions of Pertussis Toxin (PTX). Toxins (Basel). 3, 884–99. 
Mannaioni, G., Marino, M.J., Valenti, O., Traynelis, S.F., Conn, P.J., 2001. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 
pyramidal cell function. J. Neurosci. 21, 5925–34. 
Manthorpe, M., Engvall, E., Ruoslahti, E., Longo, F.M., Davis, G.E., Varon, S., 1983. Laminin Promotes Neuritic Regeneration from Cultured 
Peripheral and Central Neurons. J. Cell Biol. 97, 1882–90. 
Mao, L., Wang, J.Q., 2001. Gliogenesis in the striatum of the adult rat: alteration in neural progenitor population after psychostimulant exposure. 
Brain Res. Dev. Brain Res. 130, 41–51. 
Mao, L., Wang, J.Q., 2003. Group I metabotropic glutamate receptor-mediated calcium signalling and immediate early gene expression in 
cultured rat striatal neurons. Eur. J. Neurosci. 17, 741–50. 
Marchetti, C., Marie, H., 2011. Hippocampal synaptic plasticity in Alzheimer’s disease: what have we learned so far from transgenic models? 
Rev. Neurosci. 22, 373–402. 
Marchi, S., Patergnani, S., Pinton, P., 2014. The endoplasmic reticulum–mitochondria connection: One touch, multiple functions. Biochim. 
Biophys. Acta - Bioenerg. 1837, 461–469. 
Margallo-Lana, M., Morris, C.M., Gibson, A.M., Tan, A.L., Kay, D.W.K., Tyrer, S.P., Moore, B.P., Ballard, C.G., 2004. Influence of the amyloid 
precursor protein locus on dementia in Down syndrome. Neurology 62, 1996–8. 





in primary cultures of rat neurons. Mech. Ageing Dev. 119, 63–7. 
Mark, R.J., Hensley, K., Butterfield, D.A., Mattson, M.P., 1995. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role 
in loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci. 15, 6239–49. 
Markram, H., Lübke, J., Frotscher, M., Sakmann, B., 1997. Regulation of Synaptic Efficacy by Coincidence of Postsynaptic APs and EPSPs. 
Science (80-. ). 275. 
Marriott, D.R., Hirst, W.D., Ljunberg, C.M., 1995. Astrocytes. In: Cohen, J., Wilkin (Eds.), Neural Cell Culture. Oxford Univ. Press, NY, pp. 85–
96. 
Martino Carpi, F., Cortese, M., Orsomando, G., Polzonetti, V., Vincenzetti, S., Moreschini, B., Coleman, M., Magni, G., Pucciarelli, S., 2018. 
Simultaneous quantification of nicotinamide mononucleotide and related pyridine compounds in mouse tissues by UHPLC-MS/MS. Sep. 
Sci. Plus 1, 22–30. 
Martinou, J.C., Dubois-Dauphin, M., Staple, J.K., Rodriguez, I., Frankowski, H., Missotten, M., Albertini, P., Talabot, D., Catsicas, S., Pietra, C., 
1994a. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. 
Neuron 13, 1017–30. 
Martinou, J.C., Frankowski, H., Missotten, M., Martinou, I., Potier, L., Dubois-Dauphin, M., 1994b. Bcl-2 and neuronal selection during 
development of the nervous system. J. Physiol. Paris 88, 209–11. 
Marx, S.O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosemblit, N., Marks, A.R., 2000. PKA phosphorylation dissociates 
FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365–76. 
Masgrau, R., Churchill, G.C., Morgan, A.J., Ashcroft, S.J.H., Galione, A., 2003. NAADP: a new second messenger for glucose-induced Ca2+ 
responses in clonal pancreatic beta cells. Curr. Biol. 13, 247–51. 
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L.A., McKeel, D.W., Morris, J.C., 2001. Altered expression of synaptic proteins 
occurs early during progression of Alzheimer’s disease. Neurology 56, 127–9. 
Masliah, E., Mallory, M., Ge, N., Alford, M., Veinbergs, I., Roses, A.D., 1995. Neurodegeneration in the Central Nervous System of apoE-
Deficient Mice. Exp. Neurol. 136, 107–122. 
Mastrangelo, M.A., Bowers, W.J., 2008. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer’s 
disease-related pathologies in male triple-transgenic mice. BMC Neurosci. 9, 81. 
Mata, A.M., Berrocal, M., Sepúlveda, M.R., 2011. Impairment of the activity of the plasma membrane Ca 2+ -ATPase in Alzheimer’s disease. 
Biochem. Soc. Trans. 39, 819–822. 
Matlib, M.A., Zhou, Z., Knight, S., Ahmed, S., Choi, K.M., Krause-Bauer, J., Phillips, R., Altschuld, R., Katsube, Y., Sperelakis, N., Bers, D.M., 
1998. Oxygen-bridged dinuclear ruthenium amine complex specifically inhibits Ca2+ uptake into mitochondria in vitro and in situ in 
single cardiac myocytes. J. Biol. Chem. 273, 10223–31. 
Matsumura, N., Tanuma, S., 1998. Involvement of cytosolic NAD+ glycohydrolase in cyclic ADP-ribose metabolism. Biochem. Biophys. Res. 
Commun. 253, 246–252. 
Mattson, M.P., 2002. Oxidative Stress, Perturbed Calcium Homeostasis, and Immune Dysfunction in Alzheimer’s Disease. J. Neurovirol. 8, 539–
550. 
Mattson, M.P., 2004. Pathwyas Towards and Away from Alzheimer’s Disease. Nature 430, 631–639. 
Mattson, M.P., 2007. Calcium and neurodegeneration. Aging Cell 6, 337–350. 
Mattson, M.P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., Rydel, R.E., 1992. beta-Amyloid peptides destabilize calcium homeostasis and 
render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376–89. 
Mattson, M.P., LaFerla, F.M., Chan, S.L., Leissring, M.A., Shepel, P.N., Geiger, J.D., 2000. Calcium signaling in the ER: its role in neuronal 
plasticity and neurodegenerative disorders. Trends Neurosci. 23, 222–229. 
Mauch, D.H.H., Nägier, K., Schumacher, S., Göritz, C., Müller, E.-C.C., Otto, A., Pfrieger, F.W.W., Nägler, K., Schumacher, S., Göritz, C., 
Müller, E.-C.C., Otto, A., Pfrieger, F.W.W., 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354–7. 
Mayford, M., Siegelbaum, S.A., Kandel, E.R., 2012. Synapses and memory storage. Cold Spring Harb. Perspect. Biol. 4, a005751. 
Mayo, L., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., Moutin, M.-J., Lund, F.E., Stein, R., 2008. Dual role of CD38 in microglial activation and 
activation-induced cell death. J. Immunol. 181, 92–103. 
McCarthy, T. V, Datar, S., Mackrill, J.J., 2003. Activation of ryanodine receptor/Ca2+ release channels downregulates CD38 in the Namalwa B 
lymphoma. FEBS Lett. 554, 133–7. 
McCombs, J.E., Palmer, A.E., 2008. Measuring calcium dynamics in living cells with genetically encodable calcium indicators. Methods 46, 
152–159. 
McCool, B.A., Pin, J.P., Harpold, M.M., Brust, P.F., Stauderman, K.A., Lovinger, D.M., 1998. Rat group I metabotropic glutamate receptors 
inhibit neuronal Ca2+ channels via multiple signal transduction pathways in HEK 293 cells. J. Neurophysiol. 79, 379–91. 
McDonough, M.J., Allen, C.E., Ng-Sui-Hing, N.-K.-L.A., Rabe, B.A., Lewis, B.B., Saha, M.S., 2012. Dissection, culture, and analysis of 
Xenopus laevis embryonic retinal tissue. J. Vis. Exp. 
McGuinness, N., Anwyl, R., Rowan, M., 1991. Trans-ACPD enhances long-term potentiation in the hippocampus. Eur. J. Pharmacol. 197, 231–
232. 
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., 1984. Clinical diagnosis of Alzheimer’s disease: report of the 
NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. 
Neurology 34, 939–44. 
Mehan, S., Meena, H., Sharma, D., Sankhla, R., 2011. JNK: A stress-activated protein kinase therapeutic strategies and involvement in 
Alzheimer’s and various neurodegenerative abnormalities. J. Mol. Neurosci. 43. 
Mehta, B., Begum, G., Joshi, N.B., Joshi, P.G., 2008. Nitric oxide-mediated modulation of synaptic activity by astrocytic P2Y receptors. J. Gen. 
Physiol. 132, 339–49. 
Meilhac, O., Escargueil-Blanc, I., Thiers, J.C., Salvayre, R., Négre-Salvayre, A., 1999. Bcl-2 alters the balance between apoptosis and necrosis, 
but does not prevent cell death induced by oxidized low density lipoproteins. FASEB J. 13, 485–94. 
Mekahli, D., Bultynck, G., Parys, J.B., De Smedt, H., Missiaen, L., 2011. Endoplasmic-Reticulum Calcium Depletion and Disease. Cold Spring 
Harb. Perspect. Biol. 3, a004317–a004317. 
Menéndez, M., 2005. Down syndrome, Alzheimer’s disease and seizures. Brain Dev. 27, 246–252. 
Merry, D.E., Veis, D.J., Hickey, W.F., Korsmeyer, S.J., 1994. bcl-2 protein expression is widespread in the developing nervous system and 





Mészáros, L.G., Bak, J., Chu, A., 1993. Cyclic ADP-ribose as an endogenous regulator of the non-skeletal type ryanodine receptor Ca2+ channel. 
Nature 364, 76–9. 
Miao, J.Y., Kaji, K., Hayashi, H., Araki, S., 1997. Inhibitors of phospholipase promote apoptosis of human endothelial cells. J. Biochem. 121, 
612–8. 
Michan, S., Li, Y., Chou, M.M.-H., Parrella, E., Ge, H., Long, J.M., Allard, J.S., Lewis, K., Miller, M., Xu, W., Mervis, R.F., Chen, J., Guerin, 
K.I., Smith, L.E.H., McBurney, M.W., Sinclair, D.A., Baudry, M., de Cabo, R., Longo, V.D., 2010. SIRT1 Is Essential for Normal 
Cognitive Function and Synaptic Plasticity. J. Neurosci. 30, 9695–9707. 
Michelangeli, F., Ogunbayo, O.A., Wootton, L.L., 2005. A plethora of interacting organellar Ca2+ stores. Curr. Opin. Cell Biol. 17. 
Michikawa, M., Fan, Q.W., Isobe, I., Yanagisawa, K., 2000. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes 
and neurons in culture. J. Neurochem. 74, 1008–16. 
Migaud, M.E., Pederick, R.L., Bailey, V.C., Potter, B.V.L., 1999a. Probing Aplysia californica Adenosine 5‘-Diphosphate Ribosyl Cyclase for 
Substrate Binding Requirements:  Design of Potent Inhibitors. Biochemistry 38, 9105–9114. 
Migaud, M.E., Pederick, R.L., Bailey, V.C., Potter, B.V.L., 1999b. Probing Aplysia californica Adenosine 5‘-Diphosphate Ribosyl Cyclase for 
Substrate Binding Requirements: Design of Potent Inhibitors. Biochemistry 38, 9105–9114. 
Migliore, M., Ferrante, M., Ascoli, G.A., 2005. Signal propagation in oblique dendrites of CA1 pyramidal cells. J. Neurophysiol. 94, 4145–55. 
Miho, Y., Kouroku, Y., Fujita, E., Mukasa, T., Urase, K., Kasahara, T., Isoai, A., Momoi, M.Y., Momoi, T., 1999. bFGF inhibits the activation of 
caspase-3 and apoptosis of P19 embryonal carcinoma cells during neuronal differentiation. doi.org 6, 463–470. 
Miller, J.H., Azmitia, E.C., 1999. Growth inhibitory effects of a mu opioid on cultured cholinergic neurons from fetal rat ventral forebrain, 
brainstem, and spinal cord. Brain Res. Dev. Brain Res. 114, 69–77. 
Miller, M.L., Johnson, G.V.W., 1995. Transglutaminase Cross‐Linking of the τ Protein. J. Neurochem. 65. 
Min, B. Il, Kim, C.J., Rhee, J.S., Akaike, N., 1996. Modulation of glycine-induced chloride current in acutely dissociated rat periaqueductal gray 
neurons by μ-opioid agonist, DAGO. Brain Res. 734, 72–78. 
Minster, R.L., Demirci, F.Y., DeKosky, S.T., Kamboh, M.I., 2009. No association between CALHM1 variation and risk of Alzheimer disease. 
Hum. Mutat. 30, E566–E569. 
Mirzabekov, T.A., Lin, M.-C., Kagan, B.L., 1996. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271. 
Missiaen, L., De Smedt, H., Droogmans, G., Casteels, R., 1992. Ca2+ release induced by inositol 1,4,5-trisphosphate is a steady-state 
phenomenon controlled by luminal Ca2+ in permeabilized cells. Nature 357, 599–602. 
Missiaen, L., De Smedt, H., Parys, J.B., Casteels, R., 1994. Co-activation of inositol trisphosphate-induced Ca2+ release by cytosolic Ca2+ is 
loading-dependent. J. Biol. Chem. 269. 
Missiaen, L., Parys, J.B., De Smedt, H., Sienaert, I., Sipma, H., Vanlingen, S., Maes, K., Kunzelmann, K., Casteels, R., 1998. Inhibition of 
inositol trisphosphate-induced calcium release by cyclic ADP-ribose in A7r5 smooth-muscle cells and in 16HBE14o- bronchial mucosal 
cells. Biochem. J. 489–95. 
Miyoshi, K., Ohyagi, Y., Sakae, N., Motomura, K., Ma, L., Taniwaki, T., Furuya, H., Tabira, T., Kira, J., 2009. Enhancement of Activation of 
Caspases by Presenilin 1 Gene Mutations and its Inhibition by Secretase Inhibitors. J. Alzheimer’s Dis. 16, 551–564. 
Mizuguchi, M., Otsuka, N., Sato, M., Ishii, Y., Kon, S., Yamada, M., Nishina, H., Katada, T., Ikeda, K., 1995. Neuronal localization of CD38 
antigen in the human brain. Brain Res. 697, 235–40. 
Moccia, F., Zuccolo, E., Soda, T., Tanzi, F., Guerra, G., Mapelli, L., Lodola, F., D’Angelo, E., 2015. Stim and Orai proteins in neuronal Ca2+ 
signaling and excitability. Front. Cell. Neurosci. 9, 153. 
Moechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V, Checler, F., Godaux, E., 
Cordell, B., Van Leuven, F., 1999. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor 
protein in brain. J. Biol. Chem. 274, 6483–92. 
Mogami, H., Nakano, K., Tepikin, A. V, Petersen, O.H., 1997. Ca2+ flow via tunnels in polarized cells: recharging of apical Ca2+ stores by focal 
Ca2+ entry through basal membrane patch. Cell 88, 49–55. 
Momeni, H.R., 2011. Role of calpain in apoptosis. Cell J. 13, 65–72. 
Monaco, G., Beckers, M., Ivanova, H., Missiaen, L., Parys, J.B., De Smedt, H., Bultynck, G., 2012a. Profiling of the Bcl-2/Bcl-XL-binding sites 
on type 1 IP3 receptor. Biochem. Biophys. Res. Commun. 428, 31–35. 
Monaco, G., Decrock, E., Akl, H., Ponsaerts, R., Vervliet, T., Luyten, T., De Maeyer, M., Missiaen, L., Distelhorst, C.W., De Smedt, H., Parys, 
J.B., Leybaert, L., Bultynck, G., 2012b. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain 
of Bcl-2 versus Bcl-Xl. Cell Death Differ. 19, 295–309. 
Monaco, G., Decrock, E., Nuyts, K., Wagner II, L.E., Luyten, T., Strelkov, S. V., Missiaen, L., De Borggraeve, W.M., Leybaert, L., Yule, D.I., 
De Smedt, H., Parys, J.B., Bultynck, G., 2013. Alpha-Helical Destabilization of the Bcl-2-BH4-Domain Peptide Abolishes Its Ability to 
Inhibit the IP3 Receptor. PLoS One 8, e73386. 
Monaghan, P., Robertson, D., Amos, T.A., Dyer, M.J., Mason, D.Y., Greaves, M.F., 1992. Ultrastructural localization of bcl-2 protein. J. 
Histochem. Cytochem. 40, 1819–1825. 
Moreno-López, B., González-Forero, D., 2006. Nitric oxide and synaptic dynamics in the adult brain: physiopathological aspects. Rev. Neurosci. 
17, 309–57. 
Moreno-Ortega, A.J., Buendia, I., Mouhid, L., Egea, J., Lucea, S., Ruiz-Nuño, A., López, M.G., Cano-Abad, M.F., 2015. CALHM1 and its 
polymorphism P86L differentially control Ca2+homeostasis, mitogen-activated protein kinase signaling, and cell vulnerability upon 
exposure to amyloid β. Aging Cell 14, 1094–102. 
Moreno-Ortega, A.J., Garcia, A., Ruiz-Nuño, A., Cano-Abad, M., 2011. The mutation P86L-CALHM1, linked to Alzheimer’s disease, alters the 
nuclear calcium signalling. Alzheimer’s Dement. 7, S581. 
Moreno, H., Morfini, G., Buitrago, L., Ujlaki, G., Choi, S., Yu, E., Moreira, J.E., Avila, J., Brady, S.T., Pant, H., Sugimori, M., Llinás, R.R., 
2016. Tau pathology-mediated presynaptic dysfunction. Neuroscience 325, 30–38. 
Morgan, A., Churchill, G., Masgrau, R., Ruas, M., Davis, L., Billington, R., Patel, S., Yamasaki, M., Thomas, J., Genazzani, A., Galione, A., 
2005. Methods in Cyclic ADP-Ribose and NAADP Research. In: Putney, J.W. (Ed.), Calcium Signaling, Second Edition. CRC Press, pp. 
265–334. 
Morgan, A.J.G., Cyclic, A.D.P., 2002. A. Sensitizing Calcium-Induced Calcium Relase, Role of cADPR as an Endogenous Modulator. ribose 
NAADP Struct. Metab. Funct. pp Dordr. Kluwer 167–197. 
Morgan, D., Diamond, D.M., Gottschall, P.E., Ugen, K.E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., 





Alzheimer’s disease. Nature 408. 
Morikawa, H., Khodakhah, K., Williams, J.T., 2003. Two intracellular pathways mediate metabotropic glutamate receptor-induced Ca2+ 
mobilization in dopamine neurons. J. Neurosci. 23, 149–57. 
Morita, K., Kitayama, S., Dohi, T., 1997. Stimulation of cyclic ADP-ribose synthesis by acetylcholine and its role in catecholamine release in 
bovine adrenal chromaffin cells. J. Biol. Chem. 272, 21002–9. 
Morley, S., Kaar, A., Rae, M., 2012. Evoked hippocampal supralinear intracellular calcium responses are absent in 3xTg Alzheimer’s mice. 
Alzheimer’s Dement. 8, P409. 
Morley, S.J., Keogh, M.K., Rae, M.G., 2011. Evidence of altered intracellular calcium handling in week old cultured hippocampal neurones of a 
murine model of Alzheimer’s disease (3xTg AD). Irish J. Med. Sci. 180, S303–S304. 
Morrissette, J., Heisermann, G., Cleary, J., Ruoho, A., Coronado, R., 1993. Cyclic ADP-ribose induced Ca2+ release in rabbit skeletal muscle 
sarcoplasmic reticulum. FEBS Lett. 330, 270–4. 
Mothet, J.P., Fossier, P., Meunier, F.M., Stinnakre, J., Tauc, L., Baux, G., 1998. Cyclic ADP-ribose and calcium-induced calcium release regulate 
neurotransmitter release at a cholinergic synapse of Aplysia. J. Physiol. 507 ( Pt 2, 405–414. 
Muchmore, S.W., Sattler, M., Liang, H., Meadows, R.P., Harlan, J.E., Yoon, H.S., Nettesheim, D., Chang, B.S., Thompson, C.B., Wong, S.-L., 
Ng, S.-C., Fesik, S.W., 1996. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335–341. 
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E.M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., McConlogue, L., 
2000. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity 
without Plaque Formation. J. Neurosci. 20. 
Mulkey, R.M., Malenka, R.C., 1992. Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. 
Neuron 9, 967–75. 
Müller, M., Cheung, K.-H., Foskett, J.K., 2011. Enhanced ROS Generation Mediated by Alzheimer’s Disease Presenilin Regulation of InsP 3 R 
Ca 2+ Signaling. Antioxid. Redox Signal. 14, 1225–1235. 
Muller, U.C., Deller, T., Korte, M., 2017. Not just amyloid: physiological functions of the amyloid precursor protein family. Nat Rev Neurosci 
18, 281–298. 
Müller, U.C., Zheng, H., 2012. Physiological functions of APP family proteins. Cold Spring Harb. Perspect. Med. 2, a006288. 
Murayama, T., Ogawa, Y., 2002. Roles of two ryanodine receptor isoforms coexisting in skeletal muscle. Trends Cardiovasc. Med. 12, 305–11. 
Murphy, M.P., 2009. How mitochondria produce reactive oxygen species. Biochem. J. 417, 1–13. 
Murphy, M.P., LeVine, H., 2010. Alzheimer’s Disease and the Amyloid-β Peptide. J. Alzheimer’s Dis. 19, 311–323. 
Murphy, S.N., Miller, R.J., 1988. A glutamate receptor regulates Ca2+ mobilization in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 85, 
8737–8741. 
Murphy, S.N., Miller, R.J., 1989. Two distinct quisqualate receptors regulate Ca2+ homeostasis in hippocampal neurons in vitro. Mol. Pharmacol. 
35, 671–80. 
Mutel, V., Ellis, G.J., Adam, G., Chaboz, S., Nilly, A., Messer, J., Bleuel, Z., Metzler, V., Malherbe, P., Schlaeger, E.-J., Roughley, B.S., Faull, 
R.L.M., Richards, J.G., 2008. Characterization of [3H]Quisqualate Binding to Recombinant Rat Metabotropic Glutamate 1a and 5a 
Receptors and to Rat and Human Brain Sections. J. Neurochem. 75, 2590–2601. 
Mynlieff, M., 1997. Dissociation of postnatal hippocampal neurons for short term culture. J. Neurosci. Methods 73, 35–44. 
Naber, P.A., Witter, M.P., Lopes Silva, F.H., 2000. Networks of the hippocampal memory system of the rat. The pivotal role of the subiculum. 
Ann. N. Y. Acad. Sci. 911, 392–403. 
Nakamura, T., Barbara, J.G., Nakamura, K., Ross, W.N., 1999. Synergistic release of Ca2+ from IP3-sensitive stores evoked by synaptic 
activation of mGluRs paired with backpropagating action potentials. Neuron 24, 727–737. 
Nakamura, T., Lasser-Ross, N., Nakamura, K., Ross, W.N., 2002. Spatial Segregation and Interaction of Calcium Signalling Mechanisms in Rat 
Hippocampal CA1 Pyramidal Neurons. J. Physiol. 543, 465–480. 
Nakamura, T., Lipton, S.A., 2011. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal 
synaptic damage in neurodegenerative diseases. Cell Death Differ. 18, 1478–1486. 
Nakamura, T., Nakamura, K., Lasser-Ross, N., Barbara, J.G., Sandler, V.M., Ross, W.N., 2000. Inositol 4,5-trisphosphate (IP3)-mediated Ca2+ 
release evoked by metabotropic agonists and backpropagating action potentials in hippocampal CA1 pyramidal neurons. J. Neurosci. Off. 
J. Soc. Neurosci. 20 1, 8365–8376. 
Nakamura, Y., Fukami, K., 2017. Regulation and physiological functions of mammalian phospholipase C. J. Biochem. 161, mvw094. 
Nakamura, Y., Harada, H., Kamasawa, N., Matsui, K., Rothman, J.S., Shigemoto, R., Silver, R.A., DiGregorio, D.A., Takahashi, T., 2015. 
Nanoscale distribution of presynaptic Ca(2+) channels and its impact on vesicular release during development. Neuron 85, 145–58. 
Nakanishi, S., 1992. Molecular diversity of glutamate receptors and implications for brain function. Science 258, 597–603. 
Nam, T.-S., Choi, S.H., Rah, S.-Y., Kim, S.-Y., Jang, W., Im, M.-J., Kwon, H.J., Kim, U.-H., 2006. Discovery of a small-molecule inhibitor for 
kidney ADP-ribosyl cyclase: Implication for intracellular calcium signal mediated by cyclic ADP-ribose. Exp. Mol. Med. 38, 718–26. 
Namazi, M.R., 2003. Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J. 17, 1377–1379. 
Nash, M.S., Saunders, R., Young, K.W., Challiss, R.A., Nahorski, S.R., 2001. Reassessment of the Ca2+ sensing property of a type I 
metabotropic glutamate receptor by simultaneous measurement of inositol 1,4,5-trisphosphate and Ca2+ in single cells. J. Biol. Chem. 
276, 19286–93. 
Näslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., Buxbaum, J.D., 2000. Correlation Between Elevated Levels of 
Amyloid β-Peptide in the Brain and Cognitive Decline. JAMA 283, 1571. 
Nedergaard, M., Ransom, B., Goldman, S.A., 2003. New roles for astrocytes: Redefining the functional architecture of the brain. Trends 
Neurosci. 26. 
Nelson, O., Supnet, C., Liu, H., Bezprozvanny, I., 2010. Familial Alzheimer’s Disease Mutations in Presenilins: Effects on Endoplasmic 
Reticulum Calcium Homeostasis and Correlation with Clinical Phenotypes. J. Alzheimer’s Dis. 21, 781–793. 
Nelson, O., Supnet, C., Tolia, A., Horre, K., De Strooper, B., Bezprozvanny, I., 2011. Mutagenesis Mapping of the Presenilin 1 Calcium Leak 
Conductance Pore. J. Biol. Chem. 286, 22339–22347. 
Nelson, O., Tu, H., Lei, T., Bentahir, M., de Strooper, B., Bezprozvanny, I., 2007. Familial Alzheimer disease–linked mutations specifically 
disrupt Ca2+ leak function of presenilin 1. J. Clin. Invest. 117, 1230–1239. 





Neumann, H., Daly, M.J., 2013. Variant TREM2 as Risk Factor for Alzheimer’s Disease. N. Engl. J. Med. 368, 182–184. 
Nhan, H.S., Chiang, K., Koo, E.H., 2015. The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. 
Acta Neuropathol. 129, 1–19. 
Niswender, C.M., Conn, P.J., 2010. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 
50, 295–322. 
Nitsch, R.M., Deng, A., Wurtman, R.J., Growdon, J.H., 2002. Metabotropic Glutamate Receptor Subtype mGluR1α Stimulates the Secretion of 
the Amyloid β-Protein Precursor Ectodomain. J. Neurochem. 69, 704–712. 
Niu, Y., Su, Z., Zhao, C., Song, B., Zhang, X., Zhao, N., Shen, X., Gong, Y., 2009. Effect of amyloid β on capacitive calcium entry in neural 2a 
cells. Brain Res. Bull. 78, 152–157. 
Noble, W., Hanger, D.P., Miller, C.C.J., Lovestone, S., 2013. The importance of tau phosphorylation for neurodegenerative diseases. Front. 
Neurol. 4, 83. 
Noguchi, N., Takasawa, S., Nata, K., Tohgo, A., Kato, I., Ikehata, F., Yonekura, H., Okamoto, H., 1997. Cyclic ADP-ribose binds to FK506-
binding protein 12.6 to release Ca2+ from islet microsomes. J. Biol. Chem. 272, 3133–6. 
Nomura, A., Shigemoto, R., Nakamura, Y., Okamoto, N., Mizuno, N., Nakanishi, S., 1994. Developmentally regulated postsynaptic localization 
of a metabotropic glutamate receptor in rat rod bipolar cells. Cell 77, 361–369. 
Nordstedt, C., Caporaso, G.L., Thyberg, J., Gandy, S.E., Greengard, P., 1993. Identification of the Alzheimer beta/A4 amyloid precursor protein 
in clathrin-coated vesicles purified from PC12 cells. J. Biol. Chem. 268, 608–12. 
Nunan, J., Small, D.H., 2000. Regulation of APP cleavage by α-, β- and γ-secretases. FEBS Lett. 483. 
Nunez, J., 2008. Primary Culture of Hippocampal Neurons from P0 Newborn Rats. J. Vis. Exp. 3–4. 
Nusser, Z., Mulvihill, E., Streit, P., Somogyi, P., 1994. Subsynaptic segregation of metabotropic and ionotropic glutamate receptors as revealed 
by immunogold localization. Neuroscience 61, 421–427. 
Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B.P., LaFerla, F.M., 2003a. Amyloid deposition precedes tangle formation in a triple transgenic 
model of Alzheimer’s disease. Neurobiol. Aging 24, 1063–70. 
Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P., Akbari, Y., LaFerla, F.M., 2003b. 
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and TanglesIntracellular Aβ and Synaptic Dysfunction. Neuron 39, 409–
421. 
Ogihara, T., Miya, K., Morimoto, S., 1990. Possible participation of calcium-regulating factors in senile dementia in elderly female subjects. 
Gerontology 36 Suppl 1, 25–30. 
Oh, K.-J., Perez, S.E., Lagalwar, S., Vana, L., Binder, L., Mufson, E.J., 2010. Staging of Alzheimer’s pathology in triple transgenic mice: a light 
and electron microscopic analysis. Int. J. Alzheimers. Dis. 2010. 
Ohno, M., Cole, S.L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., Disterhoft, J.F., Vassar, R., 2007. BACE1 gene deletion prevents neuron loss 
and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol. Dis. 26, 134–145. 
Ohno, M., Sametsky, E.A., Younkin, L.H., Oakley, H., Younkin, S.G., Citron, M., Vassar, R., Disterhoft, J.F., 2004. BACE1 deficiency rescues 
memory deficits and cholinergic dysfunction in a mouse model of Alzheimer’s disease. Neuron 41, 27–33. 
Okada, T., Shimizu, S., Wakamori, M., Maeda, A., Kurosaki, T., Takada, N., Imoto, K., Mori, Y., 1998. Molecular cloning and functional 
characterization of a novel receptor-activated TRP Ca2+ channel from mouse brain. J. Biol. Chem. 273, 10279–87. 
Olsson, A., Olofsson, T., Pero, R.W., 1993. Specific binding and uptake of extracellular nicotinamide in human leukemic K-562 cells. Biochem. 
Pharmacol. 45, 1191–200. 
Olton, D.S., Papas, B.C., 1979. Spatial memory and hippocampal function. Neuropsychologia 17, 669–82. 
Oorschot, D.E., 1989. Effect of fluorodeoxyuridine on neurons and non-neuronal cells in cerebral explants. Exp. brain Res. 78, 132–8. 
Orciani, M., Trubiani, O., Guarnieri, S., Ferrero, E., Di Primio, R., 2008. CD38 is constitutively expressed in the nucleus of human hematopoietic 
cells. J. Cell. Biochem. 105, 905–912. 
Osenkowski, P., Ye, W., Wang, R., Wolfe, M.S., Selkoe, D.J., 2008. Direct and Potent Regulation of ?-Secretase by Its Lipid Microenvironment. 
J. Biol. Chem. 283, 22529–22540. 
Ostapchenko, V.G., Beraldo, F.H., Guimarães, A.L.S., Mishra, S., Guzman, M., Fan, J., Martins, V.R., Prado, V.F., Prado, M.A.M., Guimaraes, 
A.L., Mishra, S., Guzman, M., Fan, J., Martins, J.R., Prado, V.F., Prado, M.A.M., 2013. Increased prion protein processing and 
expression of metabotropic glutamate receptor 1 in a mouse model of Alzheimer’s disease. J Neurochem 127, 415–425. 
Otani, S., Ben-Ari, Y., 1991. Metabotropic receptor-mediated long-term potentiation in rat hippocampal slices. Eur. J. Pharmacol. 205, 325–326. 
Otsuka, K., Mizuguchi, M., Aizawa, T., Haga, S., Sato, M., Inoya, H., Namba, Y., Hofbauer, J., Marberger, M., 1994. Immunoreactivity in 
Alzheimer’s neurofibrillary tangles. Brain Pathol 4, 558. 
Ott, M.O., Bullock, S.L., 2001. A gene trap insertion reveals that amyloid precursor protein expression is a very early event in murine 
embryogenesis. Dev. Genes Evol. 211, 355–7. 
Ottersen, O.P., Landsend, A.S., 1997. Organization of glutamate receptors at the synapse. Eur. J. Neurosci. 9, 2219–2224. 
Oules, B., Del Prete, D., Greco, B., Zhang, X., Lauritzen, I., Sevalle, J., Moreno, S., Paterlini-Brechot, P., Trebak, M., Checler, F., Benfenati, F., 
Chami, M., Oulès, B., Del Prete, D., Greco, B., Zhang, X., Lauritzen, I., Sevalle, J., Moreno, S., Paterlini-Bréchot, P., Trebak, M., 
Checler, F., Benfenati, F., Chami, M., Oules, B., Del Prete, D., Greco, B., Zhang, X., Lauritzen, I., Sevalle, J., Moreno, S., Paterlini-
Brechot, P., Trebak, M., Checler, F., Benfenati, F., Chami, M., 2012. Ryanodine Receptor Blockade Reduces Amyloid-  Load and 
Memory Impairments in Tg2576 Mouse Model of Alzheimer Disease. J. Neurosci. 32, 11820–11834. 
Outeiro, T.F., Marques, O., Kazantsev, A., 2008. Therapeutic role of sirtuins in neurodegenerative disease. Biochim. Biophys. Acta - Mol. Basis 
Dis. 1782, 363–369. 
Page, G., Khidir, F.A.L., Pain, S., Barrier, L., Fauconneau, B., Guillard, O., Piriou, A., Hugon, J., 2006. Group I metabotropic glutamate receptors 
activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK 1/2) 
signaling pathways in rat striatal and hippocampal synaptoneurosomes. Neurochem. Int. 49, 413–421. 
Pahl, H.L., Baeuerle, P.A., 1996. Activation of NF-kappa B by ER stress requires both Ca2+ and reactive oxygen intermediates as messengers. 
FEBS Lett. 392, 129–36. 
Palmer, A.E., Jin, C., Reed, J.C., Tsien, R.Y., 2004. Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved 
genetically encoded fluorescent sensor. Proc. Natl. Acad. Sci. 101, 17404–17409. 
Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., Yoo, J., Ho, K.O., Yu, G.-Q., Kreitzer, A., Finkbeiner, S., Noebels, 





Mouse Models of Alzheimer’s Disease. Neuron 55, 697–711. 
Palop, J.J., Jones, B., Kekonius, L., Chin, J., Yu, G.-Q., Raber, J., Masliah, E., Mucke, L., 2003. Neuronal depletion of calcium-dependent 
proteins in the dentate gyrus is tightly linked to Alzheimer’s disease-related cognitive deficits. Proc. Natl. Acad. Sci. 100, 9572–9577. 
Palty, R., Hershfinkel, M., Sekler, I., 2012. Molecular Identity and Functional Properties of the Mitochondrial Na + /Ca 2+ Exchanger. J. Biol. 
Chem. 287, 31650–31657. 
Papadimitriou, J.C., Ioffe, O.R., Castellani, R.J., Simons, J., Drachenberg, C.B., 1996. Shifting of cytoplasmic pattern of bcl-2 expression in 
reactive and preneoplastic lesions to nuclear pattern in their malignant counterparts. Cancer Detect. Prev. 20. 
Paradis, E., Douillard, H., Koutroumanis, M., Goodyer, C., LeBlanc, A., 1996. Amyloid beta peptide of Alzheimer’s disease downregulates Bcl-2 
and upregulates bax expression in human neurons. J. Neurosci. 16, 7533–9. 
Pardossi-Piquard, R., Petit, A., Kawarai, T., Sunyach, C., Alves da Costa, C., Vincent, B., Ring, S., D’Adamio, L., Shen, J., Müller, U., Hyslop, 
P.S.G., Checler, F., 2005. Presenilin-Dependent Transcriptional Control of the Aβ-Degrading Enzyme Neprilysin by Intracellular 
Domains of βAPP and APLP. Neuron 46, 541–554. 
Parekh, A.B., Putney, J.W., 2005. Store-Operated Calcium Channels. Physiol. Rev. 85, 757–810. 
Parihar, M.S., Brewer, G.J., 2007. Simultaneous age-related depolarization of mitochondrial membrane potential and increased mitochondrial 
reactive oxygen species production correlate with age-related glutamate excitotoxicity in rat hippocampal neurons. J. Neurosci. Res. 85, 
1018–32. 
Park, K.-H., Kim, B.-J., Kang, J., Nam, T.-S., Lim, J.M., Kim, H.T., Park, J.K., Kim, Y.G., Chae, S.-W., Kim, U.-H., 2011. Ca2+ Signaling Tools 
Acquired from Prostasomes Are Required for Progesterone-Induced Sperm Motility. Sci. Signal. 4, ra31-ra31. 
Park, L., Wang, G., Moore, J., Girouard, H., Zhou, P., Anrather, J., Iadecola, C., 2014. The key role of transient receptor potential melastatin-2 
channels in amyloid-?-induced neurovascular dysfunction. Nat. Commun. 5, 5318. 
Park, S.A., Shaked, G.M., Bredesen, D.E., Koo, E.H., 2009. Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor 
protein. Biochem. Biophys. Res. Commun. 388, 450–455. 
Park, Y.J., Woo, M., Kieffer, T.J., Hakem, R., Safikhan, N., Yang, F., Ao, Z., Warnock, G.L., Marzban, L., 2014. The role of caspase-8 in 
amyloid-induced beta cell death in human and mouse islets. Diabetologia 57, 765–775. 
Parsadanian, A.S., Elliott, J.L., Snider, W.D., 1995. Multiple Ced-3 and Ced-9 homologues are expressed in the murine nervous system. Soc 
Neurosci Abstr 21. 
Partida-Sánchez, S., Cockayne, D.A., Monard, S., Jacobson, E.L., Oppenheimer, N., Garvy, B., Kusser, K., Goodrich, S., Howard, M., Harmsen,  
a, Randall, T.D., Lund, F.E., 2001. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium 
influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med. 7, 1209–1216. 
Partridge, L.D., Müller, T.H., Swandulla, D., 1994. Calcium-activated non-selective channels in the nervous system. Brain Res. Brain Res. Rev. 
19, 319–25. 
Parys, J.B., 2014. The IP3 Receptor as a Hub for Bcl-2 Family Proteins in Cell Death Control and Beyond. Sci. Signal. 7, pe4-pe4. 
Parys, J.B., de Smedt, H., Missiaen, L., Bootman, M.D., Sienaert, I., Casteels, R., 1995. Rat basophilic leukemia cells as model system for 
inositol 1,4,5-trisphosphate receptor IV, a receptor of the type II family: functional comparison and immunological detection. Cell 
Calcium 17, 239–49. 
Passer, B.J., Pellegrini, L., Vito, P., Ganjei, J.K., D’Adamio, L., 1999. Interaction of Alzheimer’s presenilin-1 and presenilin-2 with Bcl-X(L). A 
potential role in modulating the threshold of cell death. J. Biol. Chem. 274, 24007–13. 
Patterson, R.L., Boehning, D., Snyder, S.H., 2004. Inositol 1,4,5-Trisphosphate Receptors as Signal Integrators. Annu. Rev. Biochem. 73, 437–
465. 
Paula-Lima, A.C., Adasme, T., SanMartín, C., Sebollela, A., Hetz, C., Carrasco, M.A., Ferreira, S.T., Hidalgo, C., 2011. Amyloid β-Peptide 
Oligomers Stimulate RyR-Mediated Ca 2+ Release Inducing Mitochondrial Fragmentation in Hippocampal Neurons and Prevent RyR-
Mediated Dendritic Spine Remodeling Produced by BDNF. Antioxid. Redox Signal. 14, 1209–1223. 
Pawlikowska, L., Cottrell, S.E., Harms, M.B., Li, Y., Rosenberg, P.A., 1996. Extracellular synthesis of cADP-ribose from nicotinamide-adenine 
dinucleotide by rat cortical astrocytes in culture. J. Neurosci. 16, 5372–81. 
Payne, A.J., Kaja, S., Koulen, P., 2015. Regulation of ryanodine receptor-mediated calcium signaling by presenilins. Recept. Clin. Investig. 2, 
e449. 
Pearson, H.A., Peers, C., 2006. Physiological roles for amyloid beta peptides. J. Physiol. 575, 5–10. 
Pekny, M., Pekna, M., 2016. Reactive gliosis in the pathogenesis of CNS diseases. Biochim. Biophys. Acta - Mol. Basis Dis. 1862, 483–491. 
Pellerin, L., Magistretti, P.J., 1994. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to 
glucose utilization. Proc. Natl. Acad. Sci. U. S. A. 91, 10625–9. 
Pellerin, L., Pellegri, G., Bittar, P.G., Charnay, Y., Bouras, C., Martin, J.L., Stella, N., Magistretti, P.J., 1998. Evidence supporting the existence 
of an activity-dependent astrocyte-neuron lactate shuttle. Dev. Neurosci. 20, 291–9. 
Peppiatt, C.M., Collins, T.J., Mackenzie, L., Conway, S.J., Holmes, A.B., Bootman, M.D., Berridge, M.J., Seo, J.T., Roderick, H.L., 2003. 2-
Aminoethoxydiphenyl borate (2-APB) antagonises inositol 1,4,5-trisphosphate-induced calcium release, inhibits calcium pumps and has 
a use-dependent and slowly reversible action on store-operated calcium entry channels. Cell Calcium 34, 97–108. 
Perraud, A.-L., Fleig, A., Dunn, C.A., Bagley, L.A., Launay, P., Schmitz, C., Stokes, A.J., Zhu, Q., Bessman, M.J., Penner, R., Kinet, J.-P., 
Scharenberg, A.M., 2001. No Title. Nature 411, 595–599. 
Perroy, J., Raynaud, F., Homburger, V., Rousset, M.-C., Telley, L., Bockaert, J., Fagni, L., 2008a. Direct Interaction Enables Cross-talk between 
Ionotropic and Group I Metabotropic Glutamate Receptors. J. Biol. Chem. 283, 6799–6805. 
Perroy, J., Raynaud, F., Homburger, V., Rousset, M.-C., Telley, L., Bockaert, J., Fagni, L., 2008b. Direct interaction enables cross-talk between 
ionotropic and group I metabotropic glutamate receptors. J. Biol. Chem. 283. 
Perry, G., Cash, A.D., Smith, M.A., 2002. Alzheimer Disease and Oxidative Stress. J. Biomed. Biotechnol. 2, 120–123. 
Perry, G., Nunomura, A., Raina, A.K., Smith, M.A., 2000. Amyloid-β junkies. Lancet 355, 757. 
Petralia, R.S., Wang, Y.-X., Singh, S., Wu, C., Shi, L., Wei, J., Wenthold, R.J., 1997. A monoclonal antibody shows discrete cellular and 
subcellular localizations of mGluR1α metabotropic glutamate receptors. J. Chem. Neuroanat. 13, 77–93. 
Pfrieger, F.W., 2003. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 60, 1158–1171. 
Pfrieger, F.W., Barres, B.A., 1997. Synaptic efficacy enhanced by glial cells in vitro. Science 277, 1684–7. 





Pierrot, N., Ferrao Santos, S., Feyt, C., Morel, M., Brion, J.-P., Octave, J.-N., 2006. Calcium-mediated transient phosphorylation of tau and 
amyloid precursor protein followed by intraneuronal amyloid-β accumulation. J. Biol. Chem. 281. 
Pierrot, N., Ghisdal, P., Caumont, A.-S., Octave, J.-N., 2004. Intraneuronal amyloid-β1-42 production triggered by sustained increase of cytosolic 
calcium concentration induces neuronal death. J. Neurochem. 88, 1140–1150. 
Pinheiro, P.S., Mulle, C., 2008. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat. Rev. Neurosci. 9, 423–
436. 
Pinton, P., Ferrari, D., Magalhães, P., Schulze-Osthoff, K., Di Virgilio, F., Pozzan, T., Rizzuto, R., 2000. Reduced loading of intracellular Ca(2+) 
stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. J. Cell Biol. 148, 857–62. 
Pinton, P., Giorgi, C., Siviero, R., Zecchini, E., Rizzuto, R., 2008. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of 
apoptosis. Oncogene 27, 6407–6418. 
Pinton, P., Rizzuto, R., 2006. Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ. 13, 1409–1418. 
Pisani, A., Calabresi, P., Centonze, D., Bernardi, G., 1997. Enhancement of NMDA responses by group I metabotropic glutamate receptor 
activation in striatal neurones. Br. J. Pharmacol. 120, 1007–14. 
Pitas, R.E., Boyles, J.K., Lee, S.H., Hui, D., Weisgraber, K.H., 1987. Lipoproteins and their receptors in the central nervous system. 
Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. 
Chem. 262, 14352–60. 
Pollak, N., Niere, M., Ziegler, M., 2007. NAD Kinase Levels Control the NADPH Concentration in Human Cells. J. Biol. Chem. 282, 33562–
33571. 
Pollock, J., Crawford, J.H., Wootton, J.F., Seabrook, G.R., Scott, R.H., 1999. Metabotropic glutamate receptor activation and intracellular cyclic 
ADP-ribose release Ca2+ from the same store in cultured DRG neurones. Cell Calcium 26, 139–148. 
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., Kontula, K., 1995. 
Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein. N. Engl. J. Med. 333, 1242–1248. 
Poon, W.W., Carlos, A.J., Cotman, C.W., Rohn, T.T., 2010. Overexpression of Bcl-2 in APP transgenic mice reduces amyloid pathology. 
Alzheimer’s Dement. 6, S376. 
Poppek, D., Keck, S., Ermak, G., Jung, T., Stolzing, A., Ullrich, O., Davies, K.J.A., Grune, T., 2006. Phosphorylation inhibits turnover of the tau 
protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem. J. 400, 511–520. 
Popugaeva, E., Bezprozvanny, I., 2013. Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease. Front. Mol. 
Neurosci. 6, 29. 
Popugaeva, E., Supnet, C., Bezprozvanny, I., 2012. Presenilins, Deranged Calcium Homeostasis, Synaptic Loss and Dysfunction in Alzheimer’s 
Disease. Messenger 1, 53–62. 
Posse De Chaves, E.I., Vance, D.E., Campenot, R.B., Kiss, R.S., Vance, J.E., 2000. Uptake of lipoproteins for axonal growth of sympathetic 
neurons. J. Biol. Chem. 275, 19883–90. 
Pozzi, D., Ban, J., Iseppon, F., Torre, V., 2017. An improved method for growing neurons: Comparison with standard protocols. J. Neurosci. 
Methods 280, 1–10. 
Prasad, G.S., McRee, D.E., Stura, E.A., Levitt, D.G., Lee, H.C., Stout, C.D., 1996. Crystal structure of Aplysia ADP ribosyl cyclase, a 
homologue of the bifunctional ectozyme CD38. Nat. Struct. Biol. 3, 957–64. 
Price, P.J., Brewer, G.J., 2001. Serum-Free Media for Neural Cell Cultures: Adult and Embryonic. In: Protocols for Neural Cell Culture. Humana 
Press, New Jersey, pp. 255–264. 
Priller, C., Dewachter, I., Vassallo, N., Paluch, S., Pace, C., Kretzschmar, H.A., Van Leuven, F., Herms, J., 2007. Mutant presenilin 1 alters 
synaptic transmission in cultured hippocampal neurons. J. Biol. Chem. 282, 1119–27. 
Prins, D., Michalak, M., 2011. Organellar Calcium Buffers. Cold Spring Harb. Perspect. Biol. 3, a004069–a004069. 
Prybylowski, K., Chang, K., Sans, N., Kan, L., Vicini, S., Wenthold, R.J., 2005. The synaptic localization of NR2B-containing NMDA receptors 
is controlled by interactions with PDZ proteins and AP-2. Neuron 47. 
Puschmann, T.B., Zandén, C., De Pablo, Y., Kirchhoff, F., Pekna, M., Liu, J., Pekny, M., 2013. Bioactive 3D cell culture system minimizes 
cellular stress and maintains the in vivo-like morphological complexity of astroglial cells. Glia 61. 
Putney, J.W., 2003. Capacitative calcium entry in the nervous system. Cell Calcium 34, 339–344. 
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan, M., MacGrogan, D., Rodgers, J.T., Puigserver, P., Sadoshima, 
J., Deng, H., Pedrini, S., Gandy, S., Sauve, A.A., Pasinetti, G.M., 2006. Neuronal SIRT1 activation as a novel mechanism underlying the 
prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281, 21745–54. 
Qin, Z., Zhou, X., Gomez-Smith, M., Pandey, N.R., Lee, K.F.H., Lagace, D.C., Béïque, J.-C., Chen, H.-H., 2012. LIM Domain Only 4 (LMO4) 
Regulates Calcium-Induced Calcium Release and Synaptic Plasticity in the Hippocampus. J. Neurosci. 32. 
Qiu, A., Fennema-Notestine, C., Dale, A.M., Miller, M.I., 2009. Regional shape abnormalities in mild cognitive impairment and Alzheimer’s 
disease. Neuroimage 45, 656–661. 
Quarona, V., Zaccarello, G., Chillemi, A., Brunetti, E., Singh, V.K., Ferrero, E., Funaro, A., Horenstein, A.L., Malavasi, F., 2013. CD38 and 
CD157: A long journey from activation markers to multifunctional molecules. Cytom. Part B - Clin. Cytom. 84, 207–217. 
Querfurth, H.W., Jiang, J., Geiger, J.D., Selkoe, D.J., 1997. Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor 
protein-transfected HEK293 cells. J. Neurochem. 69, 1580–91. 
Querfurth, H.W., LaFerla, F.M., 2010. Alzheimer’s Disease. N. Engl. J. Med. 362, 329–344. 
Querfurth, H.W., Selkoe, D.J., 1994. Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry 33, 4550–61. 
Rae, M.., Irving, A.J., 2003. Metabotropic glutamate receptors (mGluRs) and dynamic endoplasmic reticulum (ER) loading in CA1 pyramidal 
neurons. In: Soc. Neuroscience Abs. (801.6). 
Rae, M.G., Hilton, J., Sharkey, J., 2012. Putative TRP channel antagonists, SKF 96365, flufenamic acid and 2-APB, are non-competitive 
antagonists at recombinant human α1β2γ2 GABAA receptors. Neurochem. Int. 60, 543–554. 
Rae, M.G., Irving, A.J., 2004. Both mGluR1 and mGluR5 mediate Ca2+ release and inward currents in hippocampal CA1 pyramidal neurons. 
Neuropharmacology 46, 1057–1069. 
Rae, M.G., Martin, D.J., Collingridge, G.L., Irving,  a J., 2000. Role of Ca2+ stores in metabotropic L-glutamate receptor-mediated supralinear 
Ca2+ signaling in rat hippocampal neurons. J. Neurosci. 20, 8628–8636. 
Raff, M.C., Fields, K.L., Hakomori, S.I., Mirsky, R., Pruss, R.M., Winter, J., 1979. Cell-type-specific markers for distinguishing and studying 





Rah, S.-Y., Park, K.-H., Han, M.-K., Im, M.-J., Kim, U.-H., 2005. Activation of CD38 by Interleukin-8 Signaling Regulates Intracellular Ca2+ 
Level and Motility of Lymphokine-activated Killer Cells. J. Biol. Chem. 280, 2888–2895. 
Rakovic, S., Galione, A., Ashamu, G.A., Potter, B. V, Terrar, D.A., 1996. A specific cyclic ADP-ribose antagonist inhibits cardiac excitation-
contraction coupling. Curr. Biol. 6, 989–96. 
Rammes, G., Hasenjäger, A., Sroka-Saidi, K., Deussing, J.M., Parsons, C.G., 2011. Therapeutic significance of NR2B-containing NMDA 
receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term 
potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60. 
Rao, S.P., Sikdar, S.K., 2004. Estradiol-induced changes in the activity of hippocampal neurons in network culture are suppressed by co-
incubation with gabapentin. Brain Res. 1022, 126–36. 
Reed, J.M., Squire, L.R., 1997. Impaired recognition memory in patients with lesions limited to the hippocampal formation. Behav. Neurosci. 
111, 667–75. 
Reitz, C., Brickman, A.M., Brown, T.R., Manly, J., DeCarli, C., Small, S.A., Mayeux, R., 2009. Linking Hippocampal Structure and Function to 
Memory Performance in an Aging Population. Arch. Neurol. 66, 1385–92. 
Renner, M., Lacor, P.N.N., Velasco, P.T.T., Xu, J., Contractor, A., Klein, W.L.L., Triller, A., 2010. Deleterious effects of amyloid beta oligomers 
acting as an extracellular scaffold for mGluR5. Neuron 66. 
Renner, M., Specht, C.G., Triller, A., 2008. Molecular dynamics of postsynaptic receptors and scaffold proteins. Curr. Opin. Neurobiol. 18. 
Rensen, P.C., Jong, M.C., van Vark, L.C., van der Boom, H., Hendriks, W.L., van Berkel, T.J., Biessen, E.A., Havekes, L.M., 2000. 
Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J. Biol. Chem. 275, 8564–
71. 
Resende, R., Ferreiro, E., Pereira, C., Resende de Oliveira, C., 2008. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 
1-42: Involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 155, 725–737. 
Resh, M.D., 1998. Fyn, a Src family tyrosine kinase. Int. J. Biochem. Cell Biol. 30, 1159–62. 
Reyes-Harde, M., Empson, R., Potter, B.V.L., Galione, A., Stanton, P.K., 1999a. Evidence of a role for cyclic ADP-ribose in long-term synaptic 
depression in hippocampus. Proc. Natl. Acad. Sci. U. S. A. 96, 4061–6. 
Reyes-Harde, M., Potter, B. V, Galione, A., Stanton, P.K., 1999b. Induction of hippocampal LTD requires nitric-oxide-stimulated PKG activity 
and Ca2+ release from cyclic ADP-ribose-sensitive stores. J. Neurophysiol. 82, 1569–76. 
Ribeiro, S., Gervasoni, D., Soares, E.S., Zhou, Y., Lin, S.-C., Pantoja, J., Lavine, M., Nicolelis, M.A.L., 2004. Long-lasting novelty-induced 
neuronal reverberation during slow-wave sleep in multiple forebrain areas. PLoS Biol. 2, E24. 
Ring, S., Weyer, S.W., Kilian, S.B., Waldron, E., Pietrzik, C.U., Filippov, M.A., Herms, J., Buchholz, C., Eckman, C.B., Korte, M., Wolfer, D.P., 
Muller, U.C., 2007. The Secreted  -Amyloid Precursor Protein Ectodomain APPs  Is Sufficient to Rescue the Anatomical, Behavioral, 
and Electrophysiological Abnormalities of APP-Deficient Mice. J. Neurosci. 27, 7817–7826. 
Rissman, R.A., Poon, W.W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M.P., LaFerla, F.M., Rohn, T.T., Cotman, C.W., 2004. Caspase-
cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121–130. 
Rizzuto, R., Brini, M., Murgia, M., Pozzan, T., 1993. Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by 
neighboring mitochondria. Science 262, 744–7. 
Rizzuto, R., De Stefani, D., Raffaello, A., Mammucari, C., 2012. Mitochondria as sensors and regulators of calcium signalling. Nat. Rev. Mol. 
Cell Biol. 13, 566–578. 
Rizzuto, R., Marchi, S., Bonora, M., Aguiari, P., Bononi, A., De Stefani, D., Giorgi, C., Leo, S., Rimessi, A., Siviero, R., Zecchini, E., Pinton, P., 
2009. Ca2+ transfer from the ER to mitochondria: When, how and why. Biochim. Biophys. Acta - Bioenerg. 1787. 
Roberson, E.D., Halabisky, B., Yoo, J.W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., Palop, J.J., Noebels, J.L., Mucke, 
L., 2011. Amyloid-β/fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of 
alzheimer’s disease. J. Neurosci. 31. 
Roberts, G.W., Gentleman, S.M., Lynch, A., Murray, L., Landon, M., Graham, D.I., 1994. Beta amyloid protein deposition in the brain after 
severe head injury: implications for the pathogenesis of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 57, 419–25. 
Robinson, J.L., Molina-Porcel, L., Corrada, M.M., Raible, K., Lee, E.B., Lee, V.M.-Y., Kawas, C.H., Trojanowski, J.Q., 2014. Perforant path 
synaptic loss correlates with cognitive impairment and Alzheimer’s disease in the oldest-old. Brain 137, 2578–2587. 
Roderick, H.L., Cook, S.J., 2008. Ca2+ signalling checkpoints in cancer: Remodelling Ca 2+ for cancer cell proliferation and survival. Nat. Rev. 
Cancer 8. 
Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C.T., Cheng, R., Hasegawa, H., Chen, F., Shibata, N., 
Lunetta, K.L., Pardossi-Piquard, R., Bohm, C., Wakutani, Y., Cupples, L.A., Cuenco, K.T., Green, R.C., Pinessi, L., Rainero, I., Sorbi, 
S., Bruni, A., Duara, R., Friedland, R.P., Inzelberg, R., Hampe, W., Bujo, H., Song, Y.-Q., Andersen, O.M., Willnow, T.E., Graff-
Radford, N., Petersen, R.C., Dickson, D., Der, S.D., Fraser, P.E., Schmitt-Ulms, G., Younkin, S., Mayeux, R., Farrer, L.A., St George-
Hyslop, P., 2007. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39, 168–
177. 
Rohn, T.T., 2010. The role of caspases in Alzheimer’s disease; potential novel therapeutic opportunities. Apoptosis 15, 1403–1409. 
Rohn, T.T., Rissman, R.A., Davis, M.C., Kim, Y.E., Cotman, C.W., Head, E., 2002. Caspase-9 activation and caspase cleavage of tau in the 
Alzheimer’s disease brain. Neurobiol. Dis. 11, 341–54. 
Rohn, T.T., Vyas, V., Hernandez-Estrada, T., Nichol, K.E., Christie, L.-A., Head, E., 2008. Lack of Pathology in a Triple Transgenic Mouse 
Model of Alzheimer’s Disease after Overexpression of the Anti-Apoptotic Protein Bcl-2. J. Neurosci. 28. 
Rojas, G., Cárdenas, A.M., Fernández-Olivares, P., Shimahara, T., Segura-Aguilar, J., Caviedes, R., Caviedes, P., 2008. Effect of the knockdown 
of amyloid precursor protein on intracellular calcium increases in a neuronal cell line derived from the cerebral cortex of a trisomy 16 
mouse. Exp. Neurol. 209, 234–242. 
Romanello, M., Bicego, M., Pirulli, D., Crovella, S., Moro, L., D’Andrea, P., 2002. Extracellular NAD+: a novel autocrine/paracrine signal in 
osteoblast physiology. Biochem. Biophys. Res. Commun. 299, 424–31. 
Rong, Y.-P., Aromolaran, A.S., Bultynck, G., Zhong, F., Li, X., McColl, K., Matsuyama, S., Herlitze, S., Roderick, H.L., Bootman, M.D., 
Mignery, G.A., Parys, J.B., De Smedt, H., Distelhorst, C.W., 2008. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition 
of apoptotic calcium signals. Mol. Cell 31, 255–65. 
Rong, Y.-P., Bultynck, G., Aromolaran, A.S., Zhong, F., Parys, J.B., De Smedt, H., Mignery, G.A., Roderick, H.L., Bootman, M.D., Distelhorst, 
C.W., 2009. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the 
IP3 receptor. Proc. Natl. Acad. Sci. U. S. A. 106, 14397–402. 





Veliçelebi, G., Stauderman, K.A., 2005. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J. Cell 
Biol. 169. 
Rose, C.R., Konnerth, A., 2001. Stores Not Just for Storage: Intracellular Calcium Release and Synaptic Plasticity. Neuron 31, 519–522. 
Roses, A.D., 1996. Apolipoprotein e alleles as risk factors in Alzheimer’s disease. Annu. Rev. Med. 47, 387–400. 
Roses, A.D., 2006. On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J. 
Alzheimers. Dis. 9, 361–6. 
Roses, A.D., Saunders, A.M., Alberts, M.A., Strittmatter, W.J., Schmechel, D., Gorder, E., Pericak-Vance, M.A., 1995. Apolipoprotein E E4 
allele and risk of dementia. JAMA 273, 374-5; author reply 375-6. 
Rossi, B., Maton, G., Collin, T., 2008. Calcium-permeable presynaptic AMPA receptors in cerebellar molecular layer interneurones. J. Physiol. 
586, 5129–5145. 
Rubio-Moscardo, F., Setó-Salvia, N., Pera, M., Bosch-Morató, M., Plata, C., Belbin, O., Gené, G., Dols-Icardo, O., Ingelsson, M., Helisalmi, S., 
Soininen, H., Hiltunen, M., Giedraitis, V., Lannfelt, L., Frank, A., Bullido, M.J., Combarros, O., Sánchez-Juan, P., Boada, M., Tárraga, 
L., Pastor, P., Pérez-Tur, J., Baquero, M., Molinuevo, J.L., Sánchez-Valle, R., Fuentes-Prior, P., Fortea, J., Blesa, R., Muñoz, F.J., Lleó, 
A., Valverde, M.A., Clarimón, J., 2013. Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer’s 
disease patients alter calcium homeostasis. PLoS One 8, e74203. 
Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., Hockey, A., Montgomery, P., Beyreuther, K., Masters, C.L., 1989. 
Amyloid A4 Protein and Its Precursor in Down’s Syndrome and Alzheimer’s Disease. N. Engl. J. Med. 320, 1446–1452. 
Rush, A.M., Wu, J., Rowan, M.J., Anwyl, R., 2002. Group I metabotropic glutamate receptor (mGluR)-dependent long-term depression mediated 
via p38 mitogen-activated protein kinase is inhibited by previous high-frequency stimulation and activation of mGluRs and protein 
kinase C in the rat dentate gyrus in vitro. J. Neurosci. 22, 6121–8. 
Rybalchenko, V., Hwang, S.-Y., Rybalchenko, N., Koulen, P., 2008. The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine 
receptor single channel activity. Int. J. Biochem. Cell Biol. 40, 84–97. 
Sáez-Valero, J., Angeretti, N., Forloni, G., 2000. Caspase-3 activation by beta-amyloid and prion protein peptides is independent from their 
neurotoxic effect. Neurosci. Lett. 293, 207–10. 
Saido, T.C., Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., 
Sekine-Aizawa, Y., 2000. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to 
biochemical and pathological deposition. Nat. Med. 6, 143–150. 
Saillé, C., Marin, P., Martinou, J.C., Nicole, A., London, J., Ceballos-Picot, I., 1999. Transgenic murine cortical neurons expressing human Bcl-2 
exhibit increased resistance to amyloid beta-peptide neurotoxicity. Neuroscience 92, 1455–63. 
Sajikumar, S., Li, Q., Abraham, W.C., Xiao, Z.C., 2009. Priming of short-term potentiation and synaptic tagging/capture mechanisms by 
ryanodine receptor activation in rat hippocampal CA1. Learn. Mem. 16, 178–86. 
Salido, G.M., Sage, S.O., Rosado, J.A., 2009. Biochemical and functional properties of the store-operated Ca2+ channels. Cell. Signal. 21, 457–
461. 
Salmina, A.B., Komleva, Y.K., Lopatina, O.L., Gorina, Y. V., Malinovskaya, N.A., Pozhilenkova, E.A., Panina, Y.A., Zhukov, E.L., Medvedeva, 
N.N., 2014. CD38 and CD157 Expression: Glial Control of Neurodegeneration and Neuroinflammation. Messenger 3, 78–85. 
Salmina, A.B., Okuneva, O.S., Malinovskaya, N.A., Taranushenko, T.E., Morgun, A. V., Mantorova, N.S., Mikhutkina, S. V., 2008. NAD+-
dependent mechanisms of disturbances of viability of brain cells during the acute period of hypoxic-ischemic perinatal injury. 
Neurochem. J. 2, 215–221. 
Salmina, A.B., Okuneva, O.S., Mikhutkina, S. V., Malinovskaya, N.A., Morgun, A. V., Zykova, L.D., Yudin, G. V., Laletin, D. V., Fursov, M.A., 
Frolova, O. V., Tagaeva, G.A., Bolshakova, E. V., 2011. Perinatal Hypoxic-Ischemic Brain Injury Affects the Glutamatergic Signal 
Transduction Coupled with Neuronal ADP-Ribosyl Cyclase Activity. Bull. Exp. Biol. Med. 150, 583–586. 
Sammels, E., Parys, J.B., Missiaen, L., De Smedt, H., Bultynck, G., 2010. Intracellular Ca2+ storage in health and disease: A dynamic 
equilibrium. Cell Calcium 47, 297–314. 
Sanan, D.A., Weisgraber, K.H., Russell, S.J., Mahley, R.W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., Roses, 
A.D., 1994. Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 
associates more efficiently than apoE3. J. Clin. Invest. 94, 860–869. 
Sandbrink, R., Masters, C.L., Beyreuther, K., 1996. APP gene family. Alternative splicing generates functionally related isoforms. Ann. N. Y. 
Acad. Sci. 777, 281–7. 
Sanderson, K.L., Butler, L., Ingram, V.M., 1997. Aggregates of a beta-amyloid peptide are required to induce calcium currents in neuron-like 
human teratocarcinoma cells: relation to Alzheimer’s disease. Brain Res. 744, 7–14. 
Sannerud, R., Declerck, I., Peric, A., Raemaekers, T., Menendez, G., Zhou, L., Veerle, B., Coen, K., Munck, S., De Strooper, B., Schiavo, G., 
Annaert, W., 2011. ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal 
sorting of BACE1. Proc. Natl. Acad. Sci. 108, E559–E568. 
Sano, Y., Inamura, K., Miyake, A., Mochizuki, S., Yokoi, H., Matsushime, H., Furuichi, K., 2001. Immunocyte Ca2+ influx system mediated by 
LTRPC2 293, 1327–30. 
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, 
C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M., Ashe, K.H., 2005. Tau Suppression in a 
Neurodegenerative Mouse Model Improves Memory Function. Science (80-. ). 309, 476–481. 
Sanz, J.M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L., Di Virgilio, F., 2009. Activation of Microglia by 
Amyloid ? Requires P2X7 Receptor Expression. J. Immunol. 182, 4378–4385. 
Sastre, M., Steiner, H., Fuchs, K., Capell, A., Multhaup, G., Condron, M.M., Teplow, D.B., Haass, C., 2001. Presenilin-dependent γ-secretase 
processing of β-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2, 835–841. 
Satou, T., Cummings, B.J., Cotman, C.W., 1995. Immunoreactivity for Bcl-2 protein within neurons in the Alzheimer’s disease brain increases 
with disease severity. Brain Res. 697, 35–43. 
Saura, C.A., Choi, S.-Y., Beglopoulos, V., Malkani, S., Zhang, D., Rao, B.S.S., Chattarji, S., Kelleher III, R.J., Kandel, E.R., Duff, K., Kirkwood, 
A., Shen, J., 2004. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent 
neurodegeneration. Neuron 42. 
Scanlon, J.M., Brocard, J.B., Stout, A.K., Reynolds, I.J., 2000. Pharmacological investigation of mitochondrial Ca2+ transport in central neurons: 
Studies with CGP-37157, an inhibitor of the mitochondrial Na+ -Ca2+ exchanger. Cell Calcium 28. 
Scemes, E., Giaume, C., 2006. Astrocyte calcium waves: What they are and what they do. Glia 54, 716–725. 






Schellenberg, G., Bird, T., Wijsman, E., Orr, H., Anderson, L., Nemens, E., White, J., Bonnycastle, L., Weber, J., Alonso, M., et,  al., 1992. 
Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science (80-. ). 258, 668–671. 
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T.D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, 
E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., Younkin, S., 1996. Secreted 
amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP 
mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864–70. 
Schiller, J., Schiller, Y., Clapham, D.E., 1998. NMDA receptors amplify calcium influx into dendritic spines during associative pre- and 
postsynaptic activation. Nat. Neurosci. 1, 114–8. 
Schmid, F., Bruhn, S., Weber, K., Mittrücker, H.-W.W., Guse, A.H., 2011. CD38: A NAADP degrading enzyme. FEBS Lett. 585, 3544–3548. 
Schmitt, H., Gozes, I., Littauer, U.Z., 1977. Decrease in levels and rates of synthesis of tubulin and actin in developing rat brain. Brain Res. 121, 
327–42. 
Schneider, I., Reverse, D., Dewachter, I., Ris, L., Caluwaerts, N., Kuiperi, C., Gilis, M., Geerts, H., Kretzschmar, H., Godaux, E., Moechars, D., 
Van Leuven, F., Herms, J., 2001. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the 
threshold for excitotoxicity and facilitating long-term potentiation. J. Biol. Chem. 276, 11539–44. 
Schrader, L.A., Tasker, J.G., 1997. Modulation of multiple potassium currents by metabotropic glutamate receptors in neurons of the 
hypothalamic supraoptic nucleus. J. Neurophysiol. 78, 3428–37. 
Schram, M.T., Trompet, S., Kamper, A.M., De Craen, A.J.M., Hofman, A., Euser, S.M., Breteler, M.M.B., Westendorp, R.G.J., 2007. Serum 
Calcium and Cognitive Function in Old Age. J. Am. Geriatr. Soc. 55, 1786–1792. 
Schuber, F., Lund, F.E., 2004. Structure and enzymology of ADP-ribosyl cyclases: conserved enzymes that produce multiple calcium mobilizing 
metabolites. Curr. Mol. Med. 4, 249–261. 
Schultz, G., Rosenthal, W., 1985. Principles of transmembranous signal transduction in the action of hormones and neurotransmitters. 
Arzneimittelforschung. 35, 1879–85. 
Sclip, A., Antoniou, X., Colombo, A., Camici, G.G., Pozzi, L., Cardinetti, D., Feligioni, M., Veglianese, P., Bahlmann, F.H., Cervo, L., Balducci, 
C., Costa, C., Tozzi, A., Calabresi, P., Forloni, G., Borsello, T., 2011. c-Jun N-terminal kinase regulates soluble Aβ oligomers and 
cognitive impairment in AD mouse model. J. Biol. Chem. 286. 
Scorrano, L., Oakes, S.A., Opferman, J.T., Cheng, E.H., Sorcinelli, M.D., Pozzan, T., Korsmeyer, S.J., 2003. BAX and BAK Regulation of 
Endoplasmic Reticulum Ca2+: A Control Point for Apoptosis. Science (80-. ). 300, 135–139. 
Segal, M.M., Baughman, R.W., Jones, K.A., Huettner, J.E., 1998. Mass cultures and microislands of neurons from postnatal rat brain. In: Banker, 
G. & Goslin, K. (Ed.), Culturing Nerve Cells. The MIT Press, Cambridge, Massachusetts, USA, pp. 339–370. 
Seibenhener, M.L., Wooten, M.W., 2012. Isolation and Culture of Hippocampal Neurons from Prenatal Mice. J. Vis. Exp. 4–9. 
Selkoe, D.J., 2002. Alzheimer’s Disease Is a Synaptic Failure. Science (80-. ). 298, 789–791. 
Selkoe, D.J., Hardy, J., 2016. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608. 
Selkoe, D.J., Schenk, D., 2003. Alzheimer’s Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics, Annual Review of 
Pharmacology and Toxicology. 
Sepulveda, F.J., Parodi, J., Peoples, R.W., Opazo, C., Aguayo, L.G., 2010. Synaptotoxicity of Alzheimer Beta Amyloid Can Be Explained by Its 
Membrane Perforating Property. PLoS One 5, e11820. 
Sergé, A., Fourgeaud, L., Hémar, A., Choquet, D., 2002. Receptor Activation and Homer Differentially Control the Lateral Mobility of 
Metabotropic Glutamate Receptor 5 in the Neuronal Membrane. J. Neurosci. 22. 
Serretti, A., Artioli, P., Quartesan, R., De Ronchi, D., 2005. Genes involved in Alzheimer’s disease, a survey of possible candidates. J. 
Alzheimers. Dis. 7, 331–53. 
Sethi, J.K., Empson, R.M., Bailey, V.C., Potter, B. V, Galione, A., 1997. 7-Deaza-8-bromo-cyclic ADP-ribose, the first membrane-permeant, 
hydrolysis-resistant cyclic ADP-ribose antagonist. J. Biol. Chem. 272, 16358–63. 
Sethi, J.K., Empson, R.M., Galione, A., 1996. Nicotinamide inhibits cyclic ADP-ribose-mediated calcium signalling in sea urchin eggs. Biochem. 
J. 319 ( Pt 2, 613–617. 
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P.H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, 
F., Arastu, M., Li, M., Chollate, S., Brennan, M.S., Quintero-Monzon, O., Scannevin, R.H., Arnold, H.M., Engber, T., Rhodes, K., 
Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R.M., Sandrock, A., 2016. The antibody aducanumab reduces Aβ 
plaques in Alzheimer’s disease. Nature 537, 50–56. 
Seymour-Laurent, K.J., Barish, M.E., 1995. Inositol 1,4,5-trisphosphate and ryanodine receptor distributions and patterns of acetylcholine- and 
caffeine-induced calcium release in cultured mouse hippocampal neurons. J. Neurosci. 15, 2592–608. 
Shaham, S., 2005. Glia–Neuron Interactions in Nervous System Function and Development. In: Current Topics in Developmental Biology. pp. 
39–66. 
Shan, J., Betzenhauser, M.J., Kushnir, A., Reiken, S., Meli, A.C., Wronska, A., Dura, M., Chen, B.-X., Marks, A.R., 2010. Role of chronic 
ryanodine receptor phosphorylation in heart failure and ?-adrenergic receptor blockade in mice. J. Clin. Invest. 120, 4375–4387. 
Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., Sabatini, B.L., 2007. Natural Oligomers of the Alzheimer 
Amyloid-  Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. 
J. Neurosci. 27, 2866–2875. 
Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., 
Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., 2008. Amyloid-β protein dimers isolated directly from Alzheimer’s brains 
impair synaptic plasticity and memory. Nat. Med. 14, 837–842. 
Sharp, A.H., McPherson, P.S., Dawson, T.M., Aoki, C., Campbell, K.P., Snyder, S.H., 1993. Differential immunohistochemical localization of 
inositol 1,4,5-trisphosphate- and ryanodine-sensitive Ca2+ release channels in rat brain. J. Neurosci. 13, 3051–63. 
Shea, T.B., Ekinci, F.J., 1999. Biphasic effect of calcium influx on tau phosphorylation: Involvement of calcium-dependent phosphatase and 
kinase activities. J. Alzheimer’s Dis. 1. 
Shen, J., Kelleher, R.J., III, 2007. The presenilin hypothesis of Alzheimer’s disease: evidence for a loss-of-function pathogenic mechanism. Proc. 
Natl. Acad. Sci. U. S. A. 104, 403–9. 
Shen, W., Slaughter, M.M., 1998. Metabotropic and ionotropic glutamate receptors regulate calcium channel currents in salamander retinal 
ganglion cells. J. Physiol. 510, 815–828. 





Shi, G., Partida-Sánchez, S., Misra, R.S., Tighe, M., Borchers, M.T., Lee, J.J., Simon, M.I., Lund, F.E., 2007. Identification of an alternative Gα q 
-dependent chemokine receptor signal transduction pathway in dendritic cells and granulocytes. J. Exp. Med. 204, 2705–2718. 
Shideman, C.R., Reinardy, J.L., Thayer, S.A., 2009. γ-Secretase activity modulates store-operated Ca2+ entry into rat sensory neurons. Neurosci. 
Lett. 451, 124–128. 
Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P.J., Neki, A., Abe, T., Nakanishi, S., Mizuno, N., 1997. 
Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. Off. J. Soc. 
Neurosci. 17, 7503–7522. 
Shilling, D., Mak, D.-O.D., Kang, D.E., Foskett, J.K., 2012. Lack of evidence for presenilins as endoplasmic reticulum Ca2+ leak channels. J. 
Biol. Chem. 287, 10933–44. 
Shilling, D., Mu, M., Takano, H., Mak, D.D., Abel, T., Coulter, D.A., Foskett, J.K., 2014. Suppression of InsP 3 Receptor-Mediated Ca 2 ϩ 
Signaling Alleviates Mutant Presenilin-Linked Familial Alzheimer ’ s Disease Pathogenesis 34, 6910–6923. 
Shimizu, S., Abt, A., Meucci, O., 2011. Bilaminar co-culture of primary rat cortical neurons and glia. J. Vis. Exp. 2–6. 
Shimohama, S., Fujimoto, S., Sumida, Y., Tanino, H., 1998. Differential Expression of Rat Brain Bcl-2 Family Proteins in Development and 
Aging. Biochem. Biophys. Res. Commun. 252, 92–96. 
Shirasaki, T., Harata, N., Akaike, N., 1994. Metabotropic glutamate response in acutely dissociated hippocampal CAI pyramidal neurones of the 
rat. J. Physiol. 475. 
Shirwany, N.A., Payette, D., Xie, J., Guo, Q., 2007. The amyloid beta ion channel hypothesis of Alzheimer’s disease. Neuropsychiatr. Dis. Treat. 
3, 597–612. 
Shmigol, A., Svichar, N., Kostyuk, P., Verkhratsky, A., 1996. Gradual caffeine-induced Ca2+ release in mouse dorsal root ganglion neurons is 
controlled by cytoplasmic and luminal Ca2+. Neuroscience 73, 1061–7. 
Simakova, O., Arispe, N., 2007. The Cell-Selective Neurotoxicity of the Alzheimer’s A Peptide Is Determined by Surface Phosphatidylserine and 
Cytosolic ATP Levels. Membrane Binding Is Required for A Toxicity. J. Neurosci. 27, 13719–13729. 
Šimić, G., Babić Leko, M., Wray, S., Harrington, C., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., 
Wischik, C., Hof, P.R., 2016. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and 
Possible Neuroprotective Strategies. Biomolecules 6, 6. 
Simpson, P.B., John Challiss, R.A., Nahorski, S.R., 1995. Neuronal Ca2+ stores: activation and function. Trends Neurosci. 18, 299–306. 
Simpson, P.B., Nahorski, S.R., Challiss, R.A., 1996. Agonist-evoked Ca2+ mobilization from stores expressing inositol 1,4,5-trisphosphate 
receptors and ryanodine receptors in cerebellar granule neurones. J. Neurochem. 67, 364–73. 
Singaravelu, K., Deitmer, J.W., 2006. Calcium mobilization by nicotinic acid adenine dinucleotide phosphate (NAADP) in rat astrocytes. Cell 
Calcium 39, 143–153. 
Sisodia, S.S., 1992. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. U. S. A. 89, 6075–9. 
Sitsapesan, R., Williams, A.J., 1995. Cyclic ADP-ribose and related compounds activate sheep skeletal sarcoplasmic reticulum Ca2+ release 
channel. Am. J. Physiol. 268, C1235-40. 
Sleegers, K., Brouwers, N., Bettens, K., Engelborghs, S., van Miegroet, H., De Deyn, P.P., Van Broeckhoven, C., 2009. No association between 
CALHM1 and risk for Alzheimer dementia in a Belgian population. Hum. Mutat. 30, E570–E574. 
Slunt, H.H., Thinakaran, G., Von Koch, C., Lo, A.C., Tanzi, R.E., Sisodia, S.S., 1994. Expression of a ubiquitous, cross-reactive homologue of 
the mouse beta-amyloid precursor protein (APP). J. Biol. Chem. 269, 2637–44. 
Small, S.A., Schobel, S.A., Buxton, R.B., Witter, M.P., Barnes, C.A., 2011. A pathophysiological framework of hippocampal dysfunction in 
ageing and disease. Nat. Rev. Neurosci. 12, 585–601. 
Smith, I.F., Hitt, B., Green, K.N., Oddo, S., LaFerla, F.M., 2005. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of 
Alzheimer’s disease. J. Neurochem. 94, 1711–1718. 
Snell, C.R., Snell, P.H., Richards, C.D., 1984. Degradation of NAD by synaptosomes and its inhibition by nicotinamide mononucleotide: 
implications for the role of NAD as a synaptic modulator. J. Neurochem. 43, 1610–5. 
Snowdon, D.A., 1997. Aging and Alzheimer’s disease: lessons from the Nun Study. Gerontologist 37, 150–6. 
Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Nairn, A.C., Salter, M.W., Lombroso, P.J., Gouras, G.K., Greengard, P., 
2005. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 8, 1051–1058. 
Soares, S., Thompson, M., White, T., Isbell, A., Yamasaki, M., Prakash, Y., Lund, F.E., Galione, A., Chini, E.N., 2007. NAADP as a second 
messenger: neither CD38 nor base-exchange reaction are necessary for in vivo generation of NAADP in myometrial cells. Am. J. 
Physiol. Cell Physiol. 292, C227–C239. 
Sohn, J.-W., Yu, W.-J., Lee, D., Shin, H.-S., Lee, S.-H., Ho, W.-K., 2011. Cyclic ADP Ribose-Dependent Ca2+ Release by Group I Metabotropic 
Glutamate Receptors in Acutely Dissociated Rat Hippocampal Neurons. PLoS One 6, e26625. 
Sohn, J.-W.W., Lee, D., Cho, H., Lim, W., Shin, H.-S.S., Lee, S.-H.H., Ho, W.-K.K., 2007. Receptor-specific inhibition of GABAB-activated K+ 
currents by muscarinic and metabotropic glutamate receptors in immature rat hippocampus. J. Physiol. 580, 411–422. 
Sokol, D.K.K., Maloney, B., Long, J.M.M., Ray, B., Lahiri, D.K.K., 2011. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 
are molecular links. Neurology 76, 1344–1352. 
Sokolov, Y., Kozak, J.A., Kayed, R., Chanturiya, A., Glabe, C., Hall, J.E., 2006. Soluble Amyloid Oligomers Increase Bilayer Conductance by 
Altering Dielectric Structure. J. Gen. Physiol. 128, 637–647. 
Solovyova, N., Fernyhough, P., Glazner, G., Verkhratsky, A., 2002. Xestospongin C empties the ER calcium store but does not inhibit InsP3-
induced Ca2+ release in cultured dorsal root ganglia neurones. Cell Calcium 32, 49–52. 
Sommer, B., Seeburg, P.H., 1992. Glutamate receptor channels: novel properties and new clones. Trends Pharmacol. Sci. 13, 291–296. 
Song, Y.S., Park, H.J., Kim, S.Y., Lee, S.H., Yoo, H.S., Lee, H.S., Lee, M.K., Oh, K.W., Kang, S.-K., Lee, S.E., Hong, J.T., 2004. Protective role 
of Bcl-2 on β-amyloid-induced cell death of differentiated PC12 cells: reduction of NF-κB and p38 MAP kinase activation. Neurosci. 
Res. 49, 69–80. 
Sonnleitner, A., Conti, A., Bertocchini, F., Schindler, H., Sorrentino, V., 1998. Functional properties of the ryanodine receptor type3 (RyR3) 
Ca2+ release channel. EMBO J. 17, 2790–2798. 
Soriano, S., Lu, D.C., Chandra, S., Pietrzik, C.U., Koo, E.H., 2001. The Amyloidogenic Pathway of Amyloid Precursor Protein (APP) Is 
Independent of Its Cleavage by Caspases. J. Biol. Chem. 276, 29045–29050. 
Sorrentino, G., Singh, I.N., Massarelli, R., Kanfer, J.N., 1996. Stimulation of phospholipase C activity by norepinephrine, t-ACPD and bombesin 





Sparagna, G.C., Gunter, K.K., Sheu, S.-S., Gunter, T.E., 1995. Mitochondrial calcium uptake from physiological-type pulses of calcium: A 
description of the rapid uptake mode. J. Biol. Chem. 270. 
Spasic, D., Tolia, A., Dillen, K., Baert, V., De Strooper, B., Vrijens, S., Annaert, W., 2006. Presenilin-1 Maintains a Nine-Transmembrane 
Topology throughout the Secretory Pathway. J. Biol. Chem. 281, 26569–26577. 
Stahl, W.L., 1984. (Na+ + K+)-ATPase: Function, structure, and conformations. Ann. Neurol. 16, S121–S127. 
Standaert, D., 1999. NMDA receptors and nitric oxide synthase. Mol. Psychiatry 4, 13–14. 
Starkus, J., Beck, A., Fleig, A., Penner, R., 2007. Regulation of TRPM2 by Extra- and Intracellular Calcium. J. Gen. Physiol. 130, 427–440. 
States, D.J., Walseth, T.F., Lee, H.C., 1992. Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen 
CD38. Trends Biochem. Sci. 17, 495. 
Staub, C., Vranesic, I., Knöpfel, T., 1992. Responses to Metabotropic Glutamate Receptor Activation in Cerebellar Purkinje Cells: Induction of 
an Inward Current. Eur. J. Neurosci. 4, 832–839. 
Stein, L.R., Imai, S., 2012. The dynamic regulation of NAD metabolism in mitochondria. Trends Endocrinol. Metab. 23, 420–428. 
Stein, T.D., Johnson, J.A., 2002. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated 
with increased levels of transthyretin and the activation of cell survival pathways. J. Neurosci. 22, 7380–8. 
Stéphan, A., Laroche, S., Davis, S., 2001. Generation of Aggregated β-Amyloid in the Rat Hippocampus Impairs Synaptic Transmission and 
Plasticity and Causes Memory Deficits. J. Neurosci. 21. 
Sternfeld, L., Krause, E., Guse, A.H., Schulz, I., 2003. Hormonal control of ADP-ribosyl cyclase activity in pancreatic acinar cells from rats. J. 
Biol. Chem. 278, 33629–33636. 
Sterniczuk, R., Antle, M.C., LaFerla, F.M., Dyck, R.H., 2010a. Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: Part 2. 
Behavioral and cognitive changes. Brain Res. 1348, 149–155. 
Sterniczuk, R., Dyck, R.H., LaFerla, F.M., Antle, M.C., 2010b. Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: Part 1. 
Circadian changes. Brain Res. 1348, 139–148. 
Stevens, L.M., Brown, R.E., 2015. Reference and working memory deficits in the 3xTg-AD mouse between 2 and 15-months of age: A cross-
sectional study. Behav. Brain Res. 278, 496–505. 
Stieren, E., Werchan, W.P., El Ayadi, A., Li, F., Boehning, D., 2010. FAD Mutations in Amyloid Precursor Protein Do Not Directly Perturb 
Intracellular Calcium Homeostasis. PLoS One 5, e11992. 
Stiller, I., Lizak, B., Banhegyi, G., 2014. Physiological Functions of Presenilins; Beyond γ-Secretase. Curr. Pharm. Biotechnol. 15, 1019–1025. 
Stoppelkamp, S., Riedel, G., Platt, B., 2010. Culturing conditions determine neuronal and glial excitability. J. Neurosci. Methods 194, 132–138. 
Stover, K.R., Campbell, M.A., Van Winssen, C.M., Brown, R.E., 2015. Early detection of cognitive deficits in the 3xTg-AD mouse model of 
Alzheimer’s disease. Behav. Brain Res. 289, 29–38. 
Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., Roses, A.D., 1993. Apolipoprotein E: high-
avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. 
U. S. A. 90, 1977–81. 
Stutzmann, G.E., 2007. The pathogenesis of Alzheimers disease is it a lifelong “calciumopathy”? Neuroscientist 13, 546–559. 
Stutzmann, G.E., Caccamo, A., LaFerla, F.M., Parker, I., 2004. Dysregulated IP3 Signaling in Cortical Neurons of Knock-In Mice Expressing an 
Alzheimer’s-Linked Mutation in Presenilin1 Results in Exaggerated Ca2+ Signals and Altered Membrane Excitability. J. Neurosci. 24, 
508–513. 
Stutzmann, G.E., Mattson, M.P., 2011. Endoplasmic Reticulum Ca2+ Handling in Excitable Cells in Health and Disease. Pharmacol. Rev. 63. 
Stutzmann, G.E., Smith, I., Caccamo, A., Oddo, S., Laferla, F.M., Parker, I., 2006. Enhanced ryanodine receptor recruitment contributes to Ca2+ 
disruptions in young, adult, and aged Alzheimer’s disease mice. J. Neurosci. 26, 5180–9. 
Stutzmann, G.E., Smith, I., Caccamo, A., Oddo, S., Parker, I., Laferla, F., 2007. Enhanced Ryanodine-Mediated Calcium Release in Mutant PS1-
Expressing Alzheimer’s Mouse Models. Ann. N. Y. Acad. Sci. 1097, 265–277. 
Su, J.H., Satou, T., Anderson, A.J., Cotman, C.W., 1996. Up-regulation of Bcl-2 is associated with neuronal DNA damage in Alzheimer’s 
disease. Neuroreport 7, 437–40. 
Suh, P.-G., Park, J.-I., Manzoli, L., Cocco, L., Peak, J.C., Katan, M., Fukami, K., Kataoka, T., Yun, S., Ryu, S.H., 2008. Multiple roles of 
phosphoinositide-specific phospholipase C isozymes. BMB Rep. 41, 415–34. 
Sulger, J., Dumais-Huber, C., Zerfass, R., Henn, F.A., Aldenhoff, J.B., 1999. The calcium response of human T lymphocytes is decreased in 
aging but increased in Alzheimer’s dementia. Biol. Psychiatry 45, 737–42. 
Sumoza-Toledo, A., Penner, R., 2011. TRPM2: a multifunctional ion channel for calcium signalling. J. Physiol. 589, 1515–25. 
Sun, D., Bullock, M.R., McGinn, M.J., Zhou, Z., Altememi, N., Hagood, S., Hamm, R., Colello, R.J., 2009. Basic fibroblast growth factor-
enhanced neurogenesis contributes to cognitive recovery in rats following traumatic brain injury. Exp. Neurol. 216, 56–65. 
Sun, L., Adebanjo, O.A., Koval, A., Anandatheerthavarada, H.K., Iqbal, J., Wu, X.Y., Moonga, B.S., Wu, X.B., Biswas, G., Bevis, P.J.R., 
Kumegawa, M., Epstein, S., Huang, C.L.-H., Avadhani, N.G., Abe, E., Zaidi, M., 2002. A novel mechanism for coupling cellular 
intermediary metabolism to cytosolic Ca2+ signaling via CD38/ADP-ribosyl cyclase, a putative intracellular NAD+ sensor. FASEB J. 
16, 302–14. 
Sun, S., Zhang, H., Liu, J., Popugaeva, E., Xu, N.-J., Feske, S., White, C.L.C., Bezprozvanny, I., Xia, W., Tesco, G., al.,  et, 2014. Reduced 
Synaptic STIM2 Expression and Impaired Store-Operated Calcium Entry Cause Destabilization of Mature Spines in Mutant Presenilin 
Mice. Neuron 82, 79–93. 
Supnet, C., Bezprozvanny, I., 2010. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 47, 183–189. 
Supnet, C., Grant, J., Kong, H., Westaway, D., Mayne, M., 2006. Amyloid-beta-(1-42) Increases Ryanodine Receptor-3 Expression and Function 
in Neurons of TgCRND8 Mice. J. Biol. Chem. 281, 38440–38447. 
Supnet, C., Noonan, C., Richard, K., Bradley, J., Mayne, M., 2010. Up-regulation of the type 3 ryanodine receptor is neuroprotective in the 
TgCRND8 mouse model of Alzheimerâ€TMs disease. J. Neurochem. 112, 356–365. 
Suzuki, M., Nagai, Y., Wada, K., Koike, T., 2012. Calcium leak through ryanodine receptor is involved in neuronal death induced by mutant 
huntingtin. Biochem. Biophys. Res. Commun. 429, 18–23. 
Svendsen, C.N., Fawcett, J.W., Bentlage, C., Dunnett, S.B., 1995. Increased survival of rat EGF-generated CNS precursor cells using B27 
supplemented medium. Exp. brain Res. 102, 407–14. 






Svichar, N., Shmigol, A., Verkhratsky, A., Kostyuk, P., 1997b. InsP3-induced Ca2+ release in dorsal root ganglion neurones. Neurosci. Lett. 227, 
107–110. 
Swann, J.W., Brady, R.J., Martin, D.L., 1989. Postnatal development of GABA-mediated synaptic inhibition in rat hippocampus. Neuroscience 
28, 551–61. 
Swiatek, P.J., Lindsell, C.E., del Amo, F.F., Weinmaster, G., Gridley, T., 1994. Notch1 is essential for postimplantation development in mice. 
Genes Dev. 8, 707–19. 
Sze, C.I., Troncoso, J.C., Kawas, C., Mouton, P., Price, D.L., Martin, L.J., 1997. Loss of the presynaptic vesicle protein synaptophysin in 
hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 933–44. 
Szegedi, V., Juhász, G., Budai, D., Penke, B., 2005. Divergent effects of Aβ1-42 on ionotropic glutamate receptor-mediated responses in CA1 
neurons in vivo. Brain Res. 1062. 
Szlufcik, K., Missiaen, L., Parys, J.B., Callewaert, G., De Smedt, H., 2006. Uncoupled IP<inf>3</inf> receptor can function as a Ca2+-leak 
channel: Cell biological and pathological consequences. Biol. Cell 98. 
Takahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H., Beal, M.F., Xu, H., Greengard, P., Gouras, G.K., 2002. 
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 
1869–79. 
Takasawa, S., Akiyama, T., Nata, K., Kuroki, M., Tohgo, A., Noguchi, N., Kobayashi, S., Kato, I., Katada, T., Okamoto, H., 1998. Cyclic ADP-
ribose and inositol 1,4,5-trisphosphate as alternate second messengers for intracellular Ca2+ mobilization in normal and diabetic beta-
cells. J. Biol. Chem. 273, 2497–500. 
Takasawa, S., Tohgo, A., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Yonekura, H., Okamoto, H., 1993. Synthesis and hydrolysis of cyclic 
ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. J. Biol. Chem. 268, 26052–4. 
Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M., Takahashi, Y., Thinakaran, G., Iwatsubo, T., 2003. The role of presenilin 
cofactors in the γ-secretase complex. Nature 422, 438–441. 
Takechi, H., Eilers, J., Konnerth, A., 1998. A new class of synaptic response involving calcium release in dendritic spines. Nature 396, 757–60. 
Tamaru, Y., Nomura, S., Mizuno, N., Shigemoto, R., 2001. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: 
differential location relative to pre-and postsynaptic sites. Neuroscience 106, 481–503. 
Tang, W.-X., Chen, Y.-F., Zou, A.-P., Campbell, W.B., Li, P.-L., 2002. Role of FKBP12.6 in cADPR-induced activation of reconstituted 
ryanodine receptors from arterial smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 282, H1304-10. 
Tanzi, R.E., Bertram, L., 2005. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective. Cell 120, 545–555. 
Tao, R., Sun, H.-Y., Lau, C.-P., Tse, H.-F., Lee, H.-C., Li, G.-R., 2011. Cyclic ADP ribose is a novel regulator of intracellular Ca2+ oscillations 
in human bone marrow mesenchymal stem cells. J. Cell. Mol. Med. 15, 2684–2696. 
Tao, Y., Black, I.B., DiCicco-Bloom, E., 1996. Neurogenesis in neonatal rat brain is regulated by peripheral injection of basic fibroblast growth 
factor (bFGF). J. Comp. Neurol. 376, 653–63. 
Tarasoff-Conway, J.M., Carare, R.O., Osorio, R.S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., 
Frangione, B., Blennow, K., Ménard, J., Zetterberg, H., Wisniewski, T., de Leon, M.J., 2015. Clearance systems in the brain—
implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457–470. 
Tarassishin, L., Yin, Y.I., Bassit, B., Li, Y.-M., 2004. Processing of Notch and amyloid precursor protein by  -secretase is spatially distinct. Proc. 
Natl. Acad. Sci. 101, 17050–17055. 
Terhorst, C., van Agthoven, A., LeClair, K., Snow, P., Reinherz, E., Schlossman, S., 1981. Biochemical studies of the human thymocyte cell-
surface antigens T6, T9 and T10. Cell 23, 771–80. 
Ternaux, J.P., Portalier, P., 1993. Culture of hypoglossal cells, dissociated from foetal and new-born rats. J. Neurosci. Methods 49, 33–47. 
Terry, R.D., 2000. Cell death or synaptic loss in Alzheimer disease. J. Neuropathol. Exp. Neurol. 59. 
Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., Katzman, R., 1991. Physical basis of cognitive 
alterations in alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–580. 
Thakur, A., Wang, X., Siedlak, S.L., Perry, G., Smith, M.A., Zhu, X., 2007. c-Jun phosphorylation in Alzheimer disease. J. Neurosci. Res. 85. 
Thayer, S.A., Perney, T.M., Miller, R.J., 1988. Regulation of calcium homeostasis in sensory neurons by bradykinin. J. Neurosci. 8, 4089–97. 
Thibault, O., Gant, J.C., Landfield, P.W., 2007. Expansion of the calcium hypothesis of brain aging and Alzheimer’s disease: minding the store. 
Aging Cell 6, 307–17. 
Thomas, J.M., Masgrau, R., Churchill, G.C., Galione, A., 2001. Pharmacological characterization of the putative cADP-ribose receptor. Biochem. 
J. 359, 451–7. 
Thomas, J.M., Summerhill, R.J., Fruen, B.R., Churchill, G.C., Galione, A., 2002. Calmodulin dissociation mediates desensitization of the 
cADPR-induced Ca2+ release mechanism. Curr. Biol. 12, 2018–22. 
Thomenius, M.J., Distelhorst, C.W., 2003. Bcl-2 on the endoplasmic reticulum: protecting the mitochondria from a distance. J. Cell Sci. 116, 
4493–4499. 
Thomenius, M.J., Wang, N.S., Reineks, E.Z., Wang, Z., Distelhorst, C.W., 2003. Bcl-2 on the Endoplasmic Reticulum Regulates Bax Activity by 
Binding to BH3-only Proteins. J. Biol. Chem. 278, 6243–6250. 
Thomsen, C., Mulvihill, E.R., Haldeman, B., Pickering, D.S., Hampson, D.R., Suzdak, P.D., 1993. A pharmacological characterization of the 
mGluR1 alpha subtype of the metabotropic glutamate receptor expressed in a cloned baby hamster kidney cell line. Brain Res. 619, 22–8. 
Todd, G.K., Boosalis, C.A., Burzycki, A.A., Steinman, M.Q., Hester, L.D., Shuster, P.W., Patterson, R.L., 2013. Towards Neuronal Organoids: A 
Method for Long-Term Culturing of High-Density Hippocampal Neurons. PLoS One 8, e58996. 
Tomita, T., 2014. Molecular mechanism of intramembrane proteolysis by γ-secretase. J. Biochem. 156, 195–201. 
Tong, B.C.-K., Lee, C.S.-K., Cheng, W.-H., Lai, K.-O., Foskett, J.K., Cheung, K.-H., 2016. Familial Alzheimer’s disease-associated presenilin 1 
mutants promote γ-secretase cleavage of STIM1 to impair store-operated Ca2+ entry. Sci. Signal. 9, ra89. 
Topolnik, L., Chamberland, S., Pelletier, J.-G., Ran, I., Lacaille, J.-C., 2009. Activity-Dependent Compartmentalized Regulation of Dendritic 
Ca2+ Signaling in Hippocampal Interneurons. J. Neurosci. 29, 4658–4663. 
Tortosa, A., López, E., Ferrer, I., 1998. Bcl-2 and Bax protein expression in Alzheimer’s disease. Acta Neuropathol. 95, 407–12. 
Tóth, B., Csanády, L., Toth, B., Csanady, L., 2010. Identification of Direct and Indirect Effectors of the Transient Receptor Potential Melastatin 2 





Townsend, M., Shankar, G.M., Mehta, T., Walsh, D.M., Selkoe, D.J., 2006. Effects of secreted oligomers of amyloid beta-protein on 
hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572, 477–92. 
Tozzi, A., Bengtson, C.P., Longone, P., Carignani, C., Fusco, F.R., Bernardi, G., Mercuri, N.B., 2003. Involvement of transient receptor 
potential-like channels in responses to mGluR-I activation in midbrain dopamine neurons. Eur. J. Neurosci. 18, 2133–45. 
Tozzi, A., Sclip, A., Tantucci, M., de Iure, A., Ghiglieri, V., Costa, C., Di Filippo, M., Borsello, T., Calabresi, P., 2015. Region- and age-
dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer’s disease. 
Neurobiol. Aging 36, 123–133. 
Tracy, T.E., Gan, L., 2017. Acetylated tau in Alzheimer’s disease: An instigator of synaptic dysfunction underlying memory loss. BioEssays 39, 
1600224. 
Trenkner, E., 1992. Cerebellar cells in culture. In: Banker, G. Goslin, L. (Ed.), Culturing Nerve Cells. Massachusetts Institute of Technology, 
USA, pp. 283–330. 
Triller, A., Choquet, D., 2008. New Concepts in Synaptic Biology Derived from Single-Molecule Imaging. Neuron 59. 
Trinchese, F., Fa’, M., Liu, S., Zhang, H., Hidalgo, A., Schmidt, S.D., Yamaguchi, H., Yoshii, N., Mathews, P.M., Nixon, R.A., Arancio, O., 
2008. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J. Clin. Invest. 118. 
Tripathi, A., Schenker, E., Spedding, M., Jay, T.M., 2016. The hippocampal to prefrontal cortex circuit in mice: a promising electrophysiological 
signature in models for psychiatric disorders. Brain Struct. Funct. 221, 2385–2391. 
Tripathy, A., Xu, L., Mann, G., Meissner, G., 1995. Calmodulin activation and inhibition of skeletal muscle Ca2+ release channel (ryanodine 
receptor). Biophys. J. 69, 106–19. 
Trulock, E.P., 1990. Arterial Blood Gases, Clinical Methods: The History, Physical, and Laboratory Examinations. Butterworths. 
Tsai, J.-Y., Wolfe, M.S., Xia, W., 2002. The search for γ-secretase and development of inhibitors. Curr. Med. Chem. 9. 
Tsujimoto, Y., Shimizu, S., Eguchi, Y., Kamiike, W., Matsuda, H., 1997. Bcl-2 and Bcl-xL block apoptosis as well as necrosis: possible 
involvement of common mediators in apoptotic and necrotic signal transduction pathways. Leukemia 11 Suppl 3, 380–2. 
Tu, H., Nelson, O., Bezprozvanny, A., Wang, Z., Lee, S.-F., Hao, Y.-H., Serneels, L., De Strooper, B., Yu, G., Bezprozvanny, I., 2006. 
Presenilins Form ER Ca2+ Leak Channels, a Function Disrupted by Familial Alzheimer’s Disease-Linked Mutations. Cell 126, 981–993. 
Tu, J.C., Xiao, B., Naisbitt, S., Yuan, J.P., Petralia, R.S., Brakeman, P., Doan, A., Aakalu, V.K., Lanahan, A.A., Sheng, M., Worley, P.F., 1999. 
Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23. 
Tyler, S.J., Dawbarn, D., Wilcock, G.K., Allen, S.J., 2002. alpha- and beta-secretase: profound changes in Alzheimer’s disease. Biochem. 
Biophys. Res. Commun. 299, 373–6. 
Tyszkiewicz, J.P., Yan, Z., 2005. β-Amyloid Peptides Impair PKC-Dependent Functions of Metabotropic Glutamate Receptors in Prefrontal 
Cortical Neurons. J. Neurophysiol. 93. 
Ullian, E.M., Sapperstein, S.K., Christopherson, K.S., Barres, B.A., 2001. Control of synapse number by glia. Science 291, 657–61. 
Um, J.W., Kaufman, A.C., Kostylev, M., Heiss, J.K., Stagi, M., Takahashi, H., Kerrisk, M.E., Vortmeyer, A., Wisniewski, T., Koleske, A.J., 
Gunther, E.C., Nygaard, H.B., Strittmatter, S.M., 2013. Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer 
Bound to Cellular Prion Protein. Neuron 79, 887–902. 
Um, J.W., Nygaard, H.B., Heiss, J.K., Kostylev, M.A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E.C., Strittmatter, S.M., 2012. 
Alzheimer amyloid-Î 2 oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15. 
Um, J.W., Strittmatter, S.M., 2013. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion 7, 37–41. 
Unni, V.K., Zakharenko, S.S., Zablow, L., DeCostanzo, A.J., Siegelbaum, S.A., 2004. Calcium Release from Presynaptic Ryanodine-Sensitive 
Stores Is Required for Long-Term Depression at Hippocampal CA3-CA3 Pyramidal Neuron Synapses. J. Neurosci. 24. 
Urra, H., Dufey, E., Lisbona, F., Rojas-Rivera, D., Hetz, C., 2013. When ER stress reaches a dead end. Biochim. Biophys. Acta - Mol. Cell Res. 
1833, 3507–3517. 
Vale, C., Alonso, E., Rubiolo, J.A., Vieytes, M.R., LaFerla, F.M., Giménez-Llort, L., Botana, L.M., 2010. Profile for Amyloid-β and Tau 
Expression in Primary Cortical Cultures from 3xTg-AD Mice. Cell. Mol. Neurobiol. 30, 577–590. 
Valenti, O., Conn, P.J., Marino, M.J., 2002. Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors co-expressed in the 
same neuronal populations. J. Cell. Physiol. 191, 125–137. 
van den Eijnde, S.M., Boshart, L., Baehrecke, E.H., De Zeeuw, C.I., Reutelingsperger, C.P., Vermeij-Keers, C., 1998. Cell surface exposure of 
phosphatidylserine during apoptosis is phylogenetically conserved. Apoptosis 3, 9–16. 
van Groen, T., Miettinen, P., Kadish, I., 2003. The entorhinal cortex of the mouse: organization of the projection to the hippocampal formation. 
Hippocampus 13, 133–49. 
Van Hoesen, G., Pandya, D.N., 1975. Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. I. 
Temporal lobe afferents. Brain Res. 95, 1–24. 
Van Hoesen, G.W., Hyman, B.T., 1990. Hippocampal formation: anatomy and the patterns of pathology in Alzheimer’s disease. Prog. Brain Res. 
83, 445–57. 
Vance, J.E., 2010. Transfer of Cholesterol by the NPC Team. Cell Metab. 12, 105–106. 
Vance, J.E., 2012. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis. Model. Mech. 5. 
Vanlingen, S., Sipma, H., De Smet, P., Callewaert, G., Missiaen, L., De Smedt, H., Parys, J.B., 2001. Modulation of inositol 1,4,5-trisphosphate 
binding to the various inositol 1,4,5-trisphosphate receptor isoforms by thimerosal and cyclic ADP-ribose. Biochem. Pharmacol. 61, 
803–809. 
Vanlingen, S., Sipma, H., Missiaen, L., Smedt, H.D., Smet, P.D., Casteels, R., Parys, J.B., 1999. Modulation of type 1, 2 and 3 inositol 1,4,5-
trisphosphate receptors by cyclic ADP-ribose and thimerosal. Cell Calcium 25, 107–114. 
Varon, S., Adler, R., 1980. Nerve growth factors and control of nerve growth. Curr. Top. Dev. Biol. 16, 207–52. 
Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, 
S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Collins, F., Treanor, J., Rogers, G., 
Citron, M., 1999. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. 
Science 286, 735–41. 
Vassilev, P.M., Mitchel, J., Vassilev, M., Kanazirska, M., Brown, E.M., 1997. Assessment of frequency-dependent alterations in the level of 
extracellular Ca2+ in the synaptic cleft. Biophys. J. 72, 2103–2116. 
Vaughan, M.B., Kaar, A., Mauleon, G., Eddington, D.., Rae, M.G., 2018. Calcium homeostasis is significantly disrupted in dentate gyrus neurons 





pp. 41, C086. 
Veinbergs, I., Jung, M.W., Young, S.J., Van Uden, E., Groves, P.M., Masliah, E., 1998. Altered long-term potentiation in the hippocampus of 
apolipoprotein E-deficient mice. Neurosci. Lett. 249, 71–4. 
Venkatachalam, K., van Rossum, D.B., Patterson, R.L., Ma, H.-T., Gill, D.L., 2002. The cellular and molecular basis of store-operated calcium 
entry. Nat. Cell Biol. 4, E263–E272. 
Verderio, C., Bruzzone, S., Zocchi, E., Fedele, E., Schenk, U., De Flora, A., Matteoli, M., 2001. Evidence of a role for cyclic ADP-ribose in 
calcium signalling and neurotransmitter release in cultured astrocytes. J. Neurochem. 78, 646–57. 
Verderio, C., Coco, S., Pravettoni, E., Bacci, A., Matteoli, M., 1999. Synaptogenesis in hippocampal cultures. Cell. Mol. Life Sci. C. 55, 1448–
1462. 
Verkhratsky, A., Reyes, R.C., Parpura, V., 2013. TRP Channels Coordinate Ion Signalling in Astroglia. In: Reviews of Physiology, Biochemistry 
and Pharmacology. pp. 1–22. 
Verkhratsky, A., Toescu, E.C., 2003. Endoplasmic reticulum Ca 2+ homeostasis and neuronal death. J. Cell. Mol. Med. 7, 351–361. 
Verma, M., Vats, A., Taneja, V., 2015. Toxic species in amyloid disorders: Oligomers or mature fibrils. Ann. Indian Acad. Neurol. 18, 138–45. 
Vervliet, T., Decrock, E., Molgo, J., Sorrentino, V., Missiaen, L., Leybaert, L., De Smedt, H., Kasri, N.N., Parys, J.B., Bultynck, G., 2014. Bcl-2 
binds to and inhibits ryanodine receptors. J. Cell Sci. 127, 2782–2792. 
Vervliet, T., Lemmens, I., Vandermarliere, E., Decrock, E., Ivanova, H., Monaco, G., Sorrentino, V., Nadif Kasri, N., Missiaen, L., Martens, L., 
De Smedt, H., Leybaert, L., Parys, J.B., Tavernier, J., Bultynck, G., 2015a. Ryanodine receptors are targeted by anti-apoptotic Bcl-XL 
involving its BH4 domain and Lys87 from its BH3 domain. Sci. Rep. 5, 9641. 
Vervliet, T., Parys, J.B., Bultynck, G., 2015b. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of 
protein-protein interactions for channel regulation. Biochem. Soc. Trans. 43, 396–404. 
Vervliet, T., Parys, J.B., Bultynck, G., 2016. Bcl-2 proteins and calcium signaling: complexity beneath the surface. Oncogene 35, 5079–5092. 
Vezzani, A., Ravizza, T., Balosso, S., Aronica, E., 2008. Glia as a source of cytokines: Implications for neuronal excitability and survival. 
Epilepsia 49, 24–32. 
Vosler, P.S., Brennan, C.S., Chen, J., 2008. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol. Neurobiol. 
38, 78–100. 
Vyas, S., Javoy-Agid, F., Herrero, M.T., Strada, O., Boissiere, F., Hibner, U., Agid, Y., 1997. Expression of Bcl-2 in adult human brain regions 
with special reference to neurodegenerative disorders. J. Neurochem. 69, 223–31. 
Wagenknecht, T., Radermacher, M., Grassucci, R., Berkowitz, J., Xin, H.-B., Fleischer, S., 1997. Locations of Calmodulin and FK506-binding 
Protein on the Three-dimensional Architecture of the Skeletal Muscle Ryanodine Receptor. J. Biol. Chem. 272, 32463–32471. 
Wagner, G.K., Guse, A.H., Potter, B.V.L., 2005. Rapid Synthetic Route toward Structurally Modified Derivatives of Cyclic Adenosine 5‘-
Diphosphate Ribose. 
Wahrle, S.E., Jiang, H., Parsadanian, M., Hartman, R.E., Bales, K.R., Paul, S.M., Holtzman, D.M., 2005. Deletion of Abca1 increases Abeta 
deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 43236–42. 
Wahrle, S.E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C.L., Bales, K.R., Paul, S.M., 
Holtzman, D.M., 2008. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. 
Clin. Invest. 118, 671–82. 
Wahrle, S.E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J.D., Kowalewski, T., Holtzman, D.M., 2004. ABCA1 is required for 
normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279, 40987–93. 
Wallace, T.L., Johnson, E.M., 1989. Cytosine arabinoside kills postmitotic neurons: evidence that deoxycytidine may have a role in neuronal 
survival that is independent of DNA synthesis. J. Neurosci. 9, 115–24. 
Walseth, T.F., Aarhus, R., Kerr, J.A., Lee, H.C., 1993. Identification of cyclic ADP-ribose-binding proteins by photoaffinity labeling. J. Biol. 
Chem. 268, 26686–91. 
Walseth, T.F., Wong, L., Graeff, R.M., Lee, H.C., 1997. Bioassay for determining endogenous levels of cyclic ADP-ribose. Methods Enzymol. 
280, 287–94. 
Walsh, D.M., Klyubin, I., Fadeeva, J. V, Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., 2002. Naturally secreted oligomers of 
amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416. 
Walter, J., Fluhrer, R., Hartung, B., Willem, M., Kaether, C., Capell, A., Lammich, S., Multhaup, G., Haass, C., 2001. Phosphorylation Regulates 
Intracellular Trafficking of  -Secretase. J. Biol. Chem. 276, 14634–14641. 
Wang, B., Wang, Z., Sun, L., Yang, L., Li, H., Cole, A.L., Rodriguez-Rivera, J., Lu, H.-C., Zheng, H., 2014. The Amyloid Precursor Protein 
Controls Adult Hippocampal Neurogenesis through GABAergic Interneurons. J. Neurosci. 34, 13314–13325. 
Wang, D.-S., Iwata, N., Hama, E., Saido, T.C., Dickson, D.W., 2003. Oxidized neprilysin in aging and Alzheimer’s disease brains. Biochem. 
Biophys. Res. Commun. 310, 236–41. 
Wang, J., Fivecoat, H., Ho, L., Pan, Y., Ling, E., Pasinetti, G.M., 2010. The role of Sirt1: At the crossroad between promotion of longevity and 
protection against Alzheimer’s disease neuropathology. Biochim. Biophys. Acta - Proteins Proteomics 1804, 1690–1694. 
Wang, J.Z., Grundke-Iqbal, I., Iqbal, K., 1996. Restoration of biological activity of Alzheimer abnormally phosphorylated tau by 
dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Res. Mol. Brain Res. 38, 200–8. 
Wang, Q., Walsh, D.M., Rowan, M.J., Selkoe, D.J., Anwyl, R., 2004. Block of Long-Term Potentiation by Naturally Secreted and Synthetic 
Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent 
Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as …. J. Neurosci. 24. 
Wang, X., Liu, P., Zhu, H., Xu, Y., Ma, C., Dai, X., Huang, L., Liu, Y., Zhang, L., Qin, C., 2009. miR-34a, a microRNA up-regulated in a double 
transgenic mouse model of Alzheimer’s disease, inhibits bcl2 translation. Brain Res. Bull. 80, 268–273. 
Wang, Y., Greig, N.H., Yu, Q., Mattson, M.P., 2009. Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses 
NMDA currents in hippocampus slices. Neurobiol. Aging 30, 1061–1068. 
Wang, Y., Wu, J., Rowan, M.J., Anwyl, R., 1996. Ryanodine produces a low frequency stimulation-induced NMDA receptor-independent long-
term potentiation in the rat dentate gyrus in vitro. J. Physiol. 495, 755–767. 
Wang, Y.X., Zheng, Y.M., Mei, Q.B., Wang, Q.S., Collier, M.L., Fleischer, S., Xin, H.B., Kotlikoff, M.I., 2004. FKBP12.6 and cADPR 
regulation of Ca2+ release in smooth muscle cells. Am. J. Physiol. Cell Physiol. 286, C538-546. 
Waung, M.W., Pfeiffer, B.E., Nosyreva, E.D., Ronesi, J.A., Huber, K.M., 2008. Rapid Translation of Arc/Arg3.1 Selectively Mediates mGluR-





Webster, N.J., Ramsden, M., Boyle, J.P., Pearson, H.A., Peers, C., 2006. Amyloid peptides mediate hypoxic increase of L-type Ca2+ channels in 
central neurones. Neurobiol. Aging 27, 439–445. 
Wehrens, X.H.T., Lehnart, S.E., Marks, A.R., 2005a. Intracellular calcium release and cardiac disease. Annu. Rev. Physiol. 67, 69–98. 
Wehrens, X.H.T., Lehnart, S.E., Reiken, S., van der Nagel, R., Morales, R., Sun, J., Cheng, Z., Deng, S.-X., de Windt, L.J., Landry, D.W., Marks, 
A.R., 2005b. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc. 
Natl. Acad. Sci. 102, 9607–9612. 
Wehrens, X.H.T., Lehnart, S.E., Reiken, S., Vest, J.A., Wronska, A., Marks, A.R., 2006. Ryanodine receptor/calcium release channel PKA 
phosphorylation: A critical mediator of heart failure progression. Proc. Natl. Acad. Sci. 103, 511–518. 
Wehrens, X.H.T., Marks, A.R., 2005. Ryanodine receptors : structure, function and dysfunction in clinical disease. Springer. 
Weidemann, A., Eggert, S., Reinhard, F.B.M., Vogel, M., Paliga, K., Baier, G., Masters, C.L., Beyreuther, K., Evin, G., 2002. A novel ε-cleavage 
within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with notch processing. 
Biochemistry 41. 
Weinberger, S.E., Cockrill, B.A., Mandel, J., Weinberger, S.E., Cockrill, B.A., Mandel, J., 2014. 1 – Pulmonary Anatomy and Physiology: The 
Basics. In: Principles of Pulmonary Medicine. pp. 1–19. 
Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., Kirschner, M.W., 1975. A protein factor essential for microtubule assembly. Proc. Natl. Acad. 
Sci. U. S. A. 72, 1858–62. 
Westmark, C.J., 2013. What’s hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders. Mol. 
Psychiatry 18, 425–434. 
Westmark, C.J., Malter, J.S., 2007. FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein. PLoS Biol. 5, e52. 
Westmark, P.R., Westmark, C.J., Jeevananthan, A., Malter, J.S., 2011. Preparation of synaptoneurosomes from mouse cortex using a 
discontinuous percoll-sucrose density gradient. J. Vis. Exp. 
White, C., Li, C., Yang, J., Petrenko, N.B., Madesh, M., Thompson, C.B., Foskett, J.K., 2005. The endoplasmic reticulum gateway to apoptosis 
by Bcl-XL modulation of the InsP3R. Nat. Cell Biol. 7, 1021–1028. 
Wiggin, G.R., Fawcett, J.P., Pawson, T., 2005. Polarity Proteins in Axon Specification and Synaptogenesis. Dev. Cell 8, 803–816. 
Willem, M., Tahirovic, S., Busche, M.A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L.D.B., Moore, S., Daria, A., Hampel, 
H., Müller, V., Giudici, C., Nuscher, B., Wenninger-Weinzierl, A., Kremmer, E., Heneka, M.T., Thal, D.R., Giedraitis, V., Lannfelt, L., 
Müller, U., Livesey, F.J., Meissner, F., Herms, J., Konnerth, A., Marie, H., Haass, C., 2015. η-Secretase processing of APP inhibits 
neuronal activity in the hippocampus. Nature 526, 443–447. 
Williams, T.L., Serpell, L.C., 2011. Membrane and surface interactions of Alzheimer’s Aβ peptide - insights into the mechanism of cytotoxicity. 
FEBS J. 278, 3905–3917. 
Willmott, N., Sethi, J.K., Walseth, T.F., Lee, H.C., White, A.M., Galione, A., 1996. Nitric oxide-induced mobilization of intracellular calcium via 
the cyclic ADP-ribose signaling pathway. J. Biol. Chem. 271, 3699–3705. 
Wilsch, V.W., Behnisch, T., Jäger, T., Reymann, K.G., Balschun, D., 1998. When are class I metabotropic glutamate receptors necessary for 
long-term potentiation? J. Neurosci. 18, 6071–80. 
Wilson, C.A., Doms, R.W., Lee, V.M.-Y., 2003. Distinct Presenilin-Dependent and Presenilin-Independent γ-Secretases Are Responsible for 
Total Cellular Aβ Production. J. Neurosci. Res. 74. 
Wilson, H.L., Galione, A., 1998. Differential regulation of nicotinic acid-adenine dinucleotide phosphate and cADP-ribose production by cAMP 
and cGMP. Biochem. J. 331 ( Pt 3, 837–843. 
Wiltgen, B.J., Royle, G.A., Gray, E.E., Abdipranoto, A., Thangthaeng, N., Jacobs, N., Saab, F., Tonegawa, S., Heinemann, S.F., O’Dell, T.J., 
Fanselow, M.S., Vissel, B., 2010. A Role for Calcium-Permeable AMPA Receptors in Synaptic Plasticity and Learning. PLoS One 5, 
e12818. 
Wisniewski, K.E., Wisniewski, H.M., Wen, G.Y., 1985. Occurrence of neuropathological changes and dementia of Alzheimer’s disease in 
Down’s syndrome. Ann. Neurol. 17, 278–282. 
Wolfe, M.S., 2010. Structure, mechanism and inhibition of gamma-secretase and presenilin-like proteases. Biol. Chem. 391, 839–47. 
Wong, G.T., Manfra, D., Poulet, F.M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J.S., Lee, H.-J.J., Zhang, L., 
Higgins, G.A., Parker, E.M., 2004. Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits γ-Amyloid Peptide Production 
and Alters Lymphopoiesis and Intestinal Cell Differentiation. J. Biol. Chem. 279. 
Wong, H.-K., Sakurai, T., Oyama, F., Kaneko, K., Wada, K., Miyazaki, H., Kurosawa, M., De Strooper, B., Saftig, P., Nukina, N., 2005. β 
subunits of voltage-gated sodium channels are novel substrates of β-site amyloid precursor protein-cleaving enzyme (BACE1) and γ-
secretase. J. Biol. Chem. 280. 
Woodhall, G., Gee, C.E., Robitaille, R., Lacaille, J.-C., 1999. Membrane Potential and Intracellular Ca 2/ Oscillations Activated by mGluRs in 
Hippocampal Stratum Oriens/Alveus Interneurons. 
Woody, S.K., Zhao, L., 2016. Clusterin (APOJ) in Alzheimer’s Disease: An Old Molecule with a New Role. In: Update on Dementia. InTech. 
Woon, E.C.Y., Threadgill, M.D., 2005. Poly(ADP-ribose)polymerase inhibition - where now? Curr. Med. Chem. 12, 2373–92. 
Wu, J., Petralia, R.S., Kurushima, H., Patel, H., Jung, M.-Y., Volk, L., Chowdhury, S., Shepherd, J.D., Dehoff, M., Li, Y., Kuhl, D., Huganir, 
R.L., Price, D.L., Scannevin, R., Troncoso, J.C., Wong, P.C., Worley, P.F., 2011. Arc/Arg3.1 Regulates an Endosomal Pathway 
Essential for Activity-Dependent β-Amyloid Generation. Cell 147. 
Wu, M.M., Buchanan, J., Luik, R.M., Lewis, R.S., 2006. Ca 2+ store depletion causes STIM1 to accumulate in ER regions closely associated with 
the plasma membrane. J. Cell Biol. 174, 803–813. 
Wu, R.L., Barish, M.E., 1999. Modulation of a slowly inactivating potassium current, I(D), by metabotropic glutamate receptor activation in 
cultured hippocampal pyramidal neurons. J. Neurosci. 19, 6825–37. 
Wyss, J.M., van Groen, T., 1989. Development of the hippocampal formation. In: Chan-Palay, V., Köhler, C. (Eds.), Neurology and 
Neurobiology. Alan R. Liss, New York, pp. 1–16. 
Wyss, M.T., Jolivet, R., Buck, A., Magistretti, P.J., Weber, B., 2011. In Vivo Evidence for Lactate as a Neuronal Energy Source. J. Neurosci. 31. 
Xia, D., Watanabe, H., Wu, B., Lee, S.H., Li, Y., Tsvetkov, E., Bolshakov, V.Y., Shen, J., Kelleher, R.J., 2015a. Presenilin-1 Knockin Mice 
Reveal Loss-of-Function Mechanism for Familial Alzheimer’s Disease. Neuron 85, 967–981. 
Xia, D., Watanabe, H., Wu, B., Lee, S.H., Li, Y., Tsvetkov, E., Bolshakov, V.Y., Shen, J., Kelleher, R.J., III, 2015b. Presenilin-1 knockin mice 
reveal loss-of-function mechanism for familial Alzheimer’s disease. Neuron 85, 967–81. 





†, 2004. Synthesis and Biological Evaluation of Novel Membrane-Permeant Cyclic ADP-Ribose Mimics:  N1-[(5‘ ‘-O-
Phosphorylethoxy)methyl]-5‘-O-phosphorylinosine 5‘,5‘ ‘-Cyclicpyrophosphate (cIDPRE) and 8-Substituted Derivatives. 
Xiao, Q., Gil, S.-C., Yan, P., Wang, Y., Han, S., Gonzales, E., Perez, R., Cirrito, J.R., Lee, J.-M., 2012. Role of Phosphatidylinositol Clathrin 
Assembly Lymphoid-Myeloid Leukemia (PICALM) in Intracellular Amyloid Precursor Protein (APP) Processing and Amyloid Plaque 
Pathogenesis. J. Biol. Chem. 287, 21279–21289. 
Xie, C., Markesbery, W.R., Lovell, M. a., 2000. Survival of hippocampal and cortical neurons in a mixture of MEM+ and B27-supplemented 
neurobasal medium. Free Radic. Biol. Med. 28, 665–672. 
Xie, G.-H., Rah, S.-Y., Yi, K.S., Han, M.K., Chae, S.W., Im, M.-J., Kim, U.-H., 2003. Increase of intracellular Ca(2+) during 
ischemia/reperfusion injury of heart is mediated by cyclic ADP-ribose. Biochem. Biophys. Res. Commun. 307, 713–8. 
Xie, Z., Romano, D.M., Tanzi, R.E., 2005. Effects of RNAi-Mediated Silencing of PEN-2, APH-1a, and Nicastrin on Wild-Type vs FAD Mutant 
Forms of Presenilin 1. J. Mol. Neurosci. 25, 067–078. 
Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R.W., Huang, Y., 2006. Profile and Regulation of Apolipoprotein E (ApoE) Expression 
in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus. J. Neurosci. 26, 4985–4994. 
Xu, X., Zeng, W., Popov, S., Berman, D.M., Davignon, I., Yu, K., Yowe, D., Offermanns, S., Muallem, S., Wilkie, T.M., 1999. RGS proteins 
determine signaling specificity of Gq-coupled receptors. J. Biol. Chem. 274, 3549–56. 
Xue, Y., Lee, S., Ha, Y., 2011. Crystal structure of amyloid precursor-like protein 1 and heparin complex suggests a dual role of heparin in E2 
dimerization. Proc. Natl. Acad. Sci. U. S. A. 108, 16229–34. 
Yachnis, A.T., Giovanini, M.A., Eskin, T.A., Reier, P.J., Anderson, D.K., 1998. Developmental Patterns of BCL-2 and BCL-X Polypeptide 
Expression in the Human Spinal Cord. Exp. Neurol. 150, 82–97. 
Yaghmoor, F., Noorsaeed, A., Alsaggaf, S., Aljohani, W., Scholtzova, H., Boutajangout, A., Wisniewski, T., 2014. The Role of TREM2 in 
Alzheimer’s Disease and Other Neurological Disorders. J. Alzheimer’s Dis. Park. 4. 
Yamamoto-Katayama, S., Ariyoshi, M., Ishihara, K., Hirano, T., Jingami, H., Morikawa, K., 2002. Crystallographic studies on human BST-
1/CD157 with ADP-ribosyl cyclase and NAD glycohydrolase activities. J. Mol. Biol. 316, 711–723. 
Yamamoto, M., Kamatsuka, Y., Ohishi, A., Nishida, K., Nagasawa, K., 2013. P2X7 receptors regulate engulfing activity of non-stimulated 
resting astrocytes. Biochem. Biophys. Res. Commun. 439, 90–95. 
Yamamoto, T., Byun, J., Zhai, P., Ikeda, Y., Oka, S., Sadoshima, J., 2014. Nicotinamide Mononucleotide, an Intermediate of NAD+ Synthesis, 
Protects the Heart from Ischemia and Reperfusion. PLoS One 9, e98972. 
Yamasaki-Mann, M., Demuro, A., Parker, I., 2009. cADPR stimulates SERCA activity in Xenopus oocytes. Cell Calcium 45, 293–9. 
Yamasaki, M., Thomas, J.M., Churchill, G.C., Garnham, C., Lewis, A.M., Cancela, J.-M., Patel, S., Galione, A., 2005. Role of NAADP and 
cADPR in the induction and maintenance of agonist-evoked Ca2+ spiking in mouse pancreatic acinar cells. Curr. Biol. 15, 874–878. 
Yamashita, N., Nishiyama, N., Abe, K., Saito, H., Fukuda, J., 1992. Primary culture of postnatal rat hypothalamic neurons in astrocyte-
conditioned medium. Brain Res. 594. 
Yang, J., Vais, H., Gu, W., Foskett, J.K., 2016. Biphasic regulation of InsP 3 receptor gating by dual Ca 2+ release channel BH3-like domains 
mediates Bcl-x L control of cell viability. Proc. Natl. Acad. Sci. 113, E1953–E1962. 
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., Li, R., Shen, Y., 2003. Elevated β-
secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9, 3–4. 
Yang, Y., Cook, D.., 2004. Presenilin-1 deficiency impairs glutamate-evoked intracellular calcium responses in neurons. Neuroscience 124, 501–
505. 
Yao, M., Nguyen, T.-V. V, Pike, C.J., 2005. -Amyloid-Induced Neuronal Apoptosis Involves c-Jun N-Terminal Kinase-Dependent 
Downregulation of Bcl-w. J. Neurosci. 25, 1149–1158. 
Yao, Z., Yang, W., Gao, Z., Jia, P., 2017. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci. Lett. 
647, 133–140. 
Yarza, R., Vela, S., Solas, M., Ramirez, M.J., 2016. c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer?s Disease. 
Front. Pharmacol. 6, 321. 
Yasojima, K., McGeer, E.G., McGeer, P.L., 2001. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer 
disease and normal brain. Brain Res. 919, 115–21. 
Ye, C., Ho-Pao, C.L., Kanazirska, M., Quinn, S., Rogers, K., Seidman, C.E., Seidman, J.G., Brown, E.M., Vassilev, P.M., 1997. Amyloid-beta 
proteins activate Ca(2+)-permeable channels through calcium-sensing receptors. J. Neurosci. Res. 47, 547–54. 
Yeckel, M.F., Berger, T.W., 1990. Feedforward excitation of the hippocampus by afferents from the entorhinal cortex: redefinition of the role of 
the trisynaptic pathway. Proc. Natl. Acad. Sci. U. S. A. 87, 5832–6. 
Yeromin, A. V, Roos, J., Stauderman, K.A., Cahalan, M.D., 2004. A store-operated calcium channel in Drosophila S2 cells. J. Gen. Physiol. 123, 
167–82. 
Yin, R.-H., Yu, J.-T., Tan, L., 2015. The Role of SORL1 in Alzheimer’s Disease. Mol. Neurobiol. 51, 909–918. 
Ying, W., Alano, C.C., Garnier, P., Swanson, R.A., 2005a. NAD+ as a Metabolic Link Between DNA Damage and Cell Death. J. Neurosci. Res. 
79, 216 –223. 
Ying, W., Alano, C.C., Garnier, P., Swanson, R.A., 2005b. NAD+ as a metabolic link between DNA damage and cell death. J. Neurosci. Res. 79, 
216–223. 
Ying, W., Garnier, P., Swanson, R.A., 2003. NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse 
astrocytes. Biochem. Biophys. Res. Commun. 308, 809–13. 
Yoo, A.S., Cheng, I., Chung, S., Grenfell, T.Z., Lee, H., Pack-Chung, E., Handler, M., Shen, J., Xia, W., Tesco, G., Saunders,  a J., Ding, K., 
Frosch, M.P., Tanzi, R.E., Kim, T.W., 2000. Presenilin-mediated modulation of capacitative calcium entry. Neuron 27, 561–572. 
Yoshimura, S., Takagi, Y., Harada, J., Teramoto, T., Thomas, S.S., Waeber, C., Bakowska, J.C., Breakefield, X.O., Moskowitz, M.A., 2001. 
FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proc. Natl. Acad. Sci. U. S. A. 98, 5874–9. 
Yoshimura, Y., Ichinose, T., Yamauchi, T., 2003. Phosphorylation of tau protein to sites found in Alzheimer’s disease brain is catalyzed by 
Ca2+/calmodulin-dependent protein kinase II as demonstrated tandem mass spectrometry. Neurosci. Lett. 353. 
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q., Lee, V.M.-Y., 2007. 
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. Neuron 53, 337–351. 
Youle, R.J., Strasser, A., 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47–59. 





metabotropic glutamate receptors. J. Physiol. 554, 371–385. 
Yu, J.-T., Chang, R.C.-C., Tan, L., 2009. Calcium dysregulation in Alzheimer’s disease: from mechanisms to therapeutic opportunities. Prog. 
Neurobiol. 89, 240–255. 
Yu, S.P., Sensi, S.L., Canzoniero, L.M., Buisson, A., Choi, D.W., 1997. Membrane-delimited modulation of NMDA currents by metabotropic 
glutamate receptor subtypes 1/5 in cultured mouse cortical neurons. J. Physiol. 499 ( Pt 3), 721–32. 
Yuan, Q., Deng, K.-Y., Sun, L., Chi, S., Yang, Z., Wang, J., Xin, H.-B., Wang, X., Ji, G., 2016. Calstabin 2: An important regulator for learning 
and memory in mice. Sci. Rep. 6, 21087. 
Yuan, W., Guo, J., Li, X., Zou, Z., Chen, G., Sun, J., Wang, T., Lu, D., 2009. Hydrogen peroxide induces the activation of the phospholipase C-
gamma1 survival pathway in PC12 cells: protective role in apoptosis. Acta Biochim. Biophys. Sin. (Shanghai). 41, 625–30. 
Yue, J., Wei, W., Lam, C.M.C., Zhao, Y.-J., Dong, M., Zhang, L.-R., Zhang, L.-H., Lee, H.-C., 2009. CD38/cADPR/Ca2+ Pathway Promotes 
Cell Proliferation and Delays Nerve Growth Factor-induced Differentiation in PC12 Cells. J. Biol. Chem. 284, 29335–29342. 
Yuste, J.E., Tarragon, E., Campuzano, C.M., Ros-Bernal, F., 2015. Implications of glial nitric oxide in neurodegenerative diseases. Front. Cell. 
Neurosci. 9, 322. 
Yuste, R., Denk, W., 1995. Dendritic spines as basic functional units of neuronal integration. Nature 375, 682–684. 
Zalk, R., Lehnart, S.E., Marks, A.R., 2007. Modulation of the ryanodine receptor and intracellular calcium, Annual Review of Biochemistry. 
Zhang, C., Wu, B., Beglopoulos, V., Wines-Samuelson, M., Zhang, D., Dragatsis, I., Südhof, T.C., Shen, J., 2009. Presenilins are essential for 
regulating neurotransmitter release. Nature 460, 632–636. 
Zhang, D., Zhang, C., Ho, A., Kirkwood, A., Südhof, T.C., Shen, J., 2010. Inactivation of presenilins causes pre-synaptic impairment prior to 
post-synaptic dysfunction. J. Neurochem. 115, 1215–1221. 
Zhang, H., Liu, J., Sun, S., Pchitskaya, E., Popugaeva, E., Bezprozvanny, I., 2015a. Calcium Signaling, Excitability, and Synaptic Plasticity 
Defects in a Mouse Model of Alzheimer’s Disease. J. Alzheimer’s Dis. 45, 561–580. 
Zhang, H., Wu, L., Pchitskaya, E., Zakharova, O., Saito, T., Saido, T., Bezprozvanny, I., 2015b. Neuronal Store-Operated Calcium Entry and 
Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer’s Disease. J. Neurosci. 35, 13275–13286. 
Zhang, J.-S., Jin, D., Higashida, H., 2005. Acetylcholine stimulates cyclic ADP-ribose formation via M1 muscarinic receptors in rat superior 
cervical ganglion. Biochem. Biophys. Res. Commun. 335, 920–4. 
Zhang, Sun, S., Herreman, A., De Strooper, B., Bezprozvanny, I., 2010. Role of presenilins in neuronal calcium homeostasis. J. Neurosci. 30, 
8566–80. 
Zhang, W., Hu, Y., Newman, E.A., Mulholland, M.W., 2006. Serum-free culture of rat postnatal neurons derived from the dorsal motor nucleus 
of the vagus. J. Neurosci. Methods 150, 1–7. 
Zhang, Y. -w., Wang, R., Liu, Q., Zhang, H., Liao, F.-F., Xu, H., 2007. Presenilin/ -secretase-dependent processing of beta-amyloid precursor 
protein regulates EGF receptor expression. Proc. Natl. Acad. Sci. 104, 10613–10618. 
Zhang, Y., Bhavnani, B.R., 2005. Glutamate-induced apoptosis in primary cortical neurons is inhibited by equine estrogens via down-regulation 
of caspase-3 and prevention of mitochondrial cytochrome c release. BMC Neurosci. 6, 13. 
Zhang, Y., Thompson, R., Zhang, H., Xu, H., 2011. APP processing in Alzheimer’s disease. Mol. Brain 4, 3. 
Zhang, Z., Nadeau, P., Song, W., Donoviel, D., Yuan, M., Bernstein, A., Yankner, B.A., 2000. Presenilins are required for γ-secretase cleavage of 
β-APP and transmembrane cleavage of Notch-1. Nat. Cell Biol. 2. 
Zhao, D., Watson, J.B., Xie, C.-W., 2004. Amyloid β prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor 
phosphorylation during hippocampal long-term potentiation. J. Neurophysiol. 92. 
Zhao, F., Li, P., Chen, S.R.W., Louis, C.F., Fruen, B.R., 2001. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular 
mechanism and isoform selectivity. J. Biol. Chem. 276, 13810–13816. 
Zhao, W., Bianchi, R., Wong, R., 2001. Ca2+ store-dependent and -independent population activity induced by the activation of group I mGluRs 
in the hippocampus. Soc. Neurosci. Abstr. 27, 599. 
Zhao, X.-L., Wang, W.-A., Tan, J.-X., Huang, J.-K., Zhang, X., Zhang, B.-Z., Wang, Y.-H., YangCheng, H.-Y., Zhu, H.-L., Sun, X.-J., Huang, 
F.-D., 2010. Expression of  -Amyloid Induced Age-Dependent Presynaptic and Axonal Changes in Drosophila. J. Neurosci. 30, 1512–
1522. 
Zhao, Y.J., Lam, C.M.C., Lee, H.C., 2012. The Membrane-Bound Enzyme CD38 Exists in Two Opposing Orientations. Sci. Signal. 5, ra67-ra67. 
Zheng, H., Jiang, M., Trumbauer, M.E., Sirinathsinghji, D.J., Hopkins, R., Smith, D.W., Heavens, R.P., Dawson, G.R., Boyce, S., Conner, M.W., 
Stevens, K.A., Slunt, H.H., Sisoda, S.S., Chen, H.Y., Van der Ploeg, L.H., 1995. beta-Amyloid precursor protein-deficient mice show 
reactive gliosis and decreased locomotor activity. Cell 81, 525–31. 
Zheng, L., Cedazo-Minguez, A., Hallbeck, M., Jerhammar, F., Marcusson, J., Terman, A., 2012. Intracellular distribution of amyloid beta peptide 
and its relationship to the lysosomal system. Transl. Neurodegener. 1, 19. 
Zhong, N., Weisgraber, K.H., 2009. Understanding the Association of Apolipoprotein E4 with Alzheimer Disease: Clues from Its Structure. J. 
Biol. Chem. 284, 6027–6031. 
Ziegler, M., 2000. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur. J. Biochem. 267, 1550–1564. 
Zimmerman, A.N., Hülsmann, W.C., 1966. Paradoxical influence of calcium ions on the permeability of the cell membranes of the isolated rat 
heart. Nature 211, 646–7. 
Zingarelli, B., Cuzzocrea, S., Zsengellér, Z., Salzman, A.L., Szabó, C., 1997. Protection against myocardial ischemia and reperfusion injury by 3-
aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc. Res. 36, 205–215. 
Zocchi, E., Carpaneto, A., Cerrano, C., Bavestrello, G., Giovine, M., Bruzzone, S., Guida, L., Franco, L., Usai, C., 2001. The temperature-
signaling cascade in sponges involves a heat-gated cation channel, abscisic acid, and cyclic ADP-ribose. Proc. Natl. Acad. Sci. U. S. A. 
98, 14859–64. 
Zocchi, E., Usai, C., Guida, L., Franco, L., Bruzzone, S., Passalacqua, M., De Flora, A., 1999. Ligand-induced internalization of CD38 results in 
intracellular Ca2+ mobilization: role of NAD+ transport across cell membranes. FASEB J. 13, 273–83. 
Zola-Morgan, S., Squire, L.R., Amaral, D.G., 1986. Human amnesia and the medial temporal region: enduring memory impairment following a 
bilateral lesion limited to field CA1 of the hippocampus. J. Neurosci. 6, 2950–67. 
Zou, W.-Q., Xiao, X., Yuan, J., Puoti, G., Fujioka, H., Wang, X., Richardson, S., Zhou, X., Zou, R., Li, S., Zhu, X., McGeer, P.L., McGeehan, J., 
Kneale, G., Rincon-Limas, D.E., Fernandez-Funez, P., Lee, H.-G., Smith, M.A., Petersen, R.B., Guo, J.-P., 2011. Amyloid-β42 interacts 
mainly with insoluble prion protein in the Alzheimer brain. J. Biol. Chem. 286. 





Sancho, J., Zubiaur, M., 2010. Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with 
signaling complexes containing CD81, Hsc-70 and Lyn. Exp. Cell Res. 316, 2692–2706. 
 
